ࡱ> #  &'()*+} G I K  { xbjbjzz A :g'   6!6!6!Dz'z'z' 0\V3z'AL>B$bFbFGՈY݊D$X6!!ofՈ!!&&bFG9׼׼׼!&bFH6!G׼!׼׼u>MGE)dKulm0lM6!M !!׼!!!!!׼!!!!!!!!!!!!!!!! :   EMBED Word.Picture.8  DEPARTMENT OF HEALTH AND SENIOR SERVICES PO BOX 360 TRENTON, N.J. 08625-0360 www.state.nj.us/health January 2003 Dear Public Employer: The PEOSH Bloodborne Pathogens Standard was published in the New Jersey Register on July6,1993 and applies to all employees with occupational exposure to blood or other potentially infectious materials. In order to assist employers in complying with the standard, the NewJersey Department of Health and Senior Services (NJDHSS) Public Employees Occupational Safety and Health (PEOSH) Program developed an Employer Guide and Model Exposure Control Plan in December 1993. The revised PEOSH Bloodborne Pathogens Standard was adopted on September 4, 2001. The revised standard applies to all public employees with occupational exposures to blood or other potentially infectious materials. The Bloodborne Pathogens Standard (29 CFR 1910.1030(c)) requires that each employer, having an employee(s) with occupational exposure, establish a written Exposure Control Plan (ECP) designed to eliminate or minimize such exposure. The ECP should reflect the new requirements of the revised standard, which include additional definitions (e.g., engineering controls); solicitation of input from non-managerial employees; and maintaining a sharps injury log. To assist you in your efforts to comply with the revised Bloodborne Pathogens Standard, the NJDHSS PEOSH Program has provided you with this revised Bloodborne Pathogens Standard Model Exposure Control Plan and Employer Guide. The Model is written in a clear, concise manner and contains relevant reference materials, samples of all forms needed to fulfill recordkeeping requirements, and other appropriate information. The Model is designed to guide you through the compliance process. Areas in bold type in the Exposure Control Plan (ECP) refer to the new requirements in the revised standard. After your revised ECP is developed and implemented, the plan will help protect employees from occupational exposure to hepatitis B virus (HBV), hepatitisC virus (HCV), human immunodeficiency virus (HIV), as well as other bloodborne pathogens within their workplace. As its title indicates, the Bloodborne Pathogens Standard Model Exposure Control Plan and Employer Guide is intended to serve as an employer compliance guide to the revised Bloodborne Pathogens Standard (Appendix R). A central component of your compliance effort will be the development of an ECP tailored to your worksite. At a minimum, the plan should include the following elements: statement of employer policy designation of employees responsible for implementation of various plan elements determination of employee exposure implementation of various methods of exposure control, including: universal precautions engineering controls and work practices personal protective equipment training hepatitis B vaccination post-exposure evaluation and follow-up housekeeping labeling employer recordkeeping Before proceeding to use this document, you should have read the revised Bloodborne Pathogens Standard found in Appendix R. After you have familiarized yourself with the standard, follow the Model Exposure Control Plan in the order in which it is presented, adding information specific to your worksite wherever indicated. The Model must be completed in its entirety if you wish to be assured that your ECP complies with the revised standard. You will note that in several places within the Model, it will be necessary for you to exercise judgement as to how you will proceed. References to hepatitis C have been added to reflect the U.S. Public Health Service, Centers for Disease Control and Preventions (CDC) recommendation to include blood-testing for hepatitis C antibody (in addition to hepatitis B and HIV blood-testing) following an exposure incident. The Bloodborne Pathogens Standard Model Exposure Control Plan and Employer Guide also contains forms that may be used to comply with recordkeeping requirements of the Standard. Information pamphlets, highlights of the program's requirements, and a resource list are also provided to assist employers with the training provisions of the Standard. Note that PEOSH now offers expanded educational and consultative services. The Model will be available in a usable form on the PEOSH website: www.state.nj.us/health/peoshweb. If you have any questions regarding the revised Model ECP, the revised Bloodborne Pathogens Standard, or need further assistance, please contact the NJDHSS, PEOSH Program, at (609) 984-1863. Sincerely, Eric Beckhusen, Acting Program Manager Public Employees Occupational Safety and Health Program TABLE OF CONTENTS Introduction 2 Policy 3 Program Administration 4 Employee Exposure Determination 5 Effective Dates 6 Exposure Control Plan (ECP) 7 Engineering Controls 8 Personal Protective Equipment (PPE) 9 Training 12 Training Program Elements 14 Hepatitis B Vaccination 15 Post Exposure Evaluation 17 Health Care Professionals 20 Housekeeping 22 Labeling 26 Recordkeeping 27 Medical Records 29 Training Records 30 First Aid Providers 31 APPENDIX SECTION Appendix A Occupations at Risk and Definitions A1 Appendix B Employee Education and Training Record B1 Appendix C Hepatitis B Vaccine Immunization Record C1 Declination Statement C2 Appendix D Exposure Incident Report D1 Appendix E Request for Source Individual Evaluation (Letter and Form) E1 Appendix F Employee Exposure Follow-up Record F1 Appendix G Information on Regulated Medical Waste G1 Appendix H Biohazard Illustration H1 Appendix I Fact Sheet - Personal Protective Equipment Cuts Risks I1 Appendix J Fact Sheet - Reporting Exposure Incidents J1 Appendix K Fact Sheet - Protecting Yourself When Handling Sharps K1 Appendix L Fact Sheet - Hepatitis B Vaccination - - Protection for You L1 Appendix M Fact Sheet - Hepatitis C M1 Appendix N Fact Sheet - Holding the Line on Contamination N1 Appendix O Cleaning Schedule O1 Appendix P Hepatitis B Vaccine Manufacturer Information P1 Appendix Q NJDEP Regulations - Regulated Medical Waste Q1 Appendix R Revised Bloodborne Pathogens Standard 29 CFR 1910.1030 R1 Appendix S Resource List S1 Appendix T Sharps Injury Log T1 Appendix U Sample Forms U1 Acquired Immune Deficiency Syndrome (AIDS), hepatitis B, and hepatitis C warrant serious concern for workers occupationally exposed to blood and certain other body fluids that contain bloodborne pathogens. It is estimated nationally that more than 5.6 million workers in health care and public safety occupations could be potentially exposed. In recognition of these potential hazards, the New Jersey Public Employees Occupational Safety and Health Program has adopted the Occupational Safety and Health Administration (OSHA) regulation [Bloodborne Pathogens 29 Code of Federal Regulations (CFR) 1910.1030] to help protect New Jersey public workers from these health hazards. The major intent of this regulation is to prevent the transmission of bloodborne diseases within potentially exposed workplace occupations. The standard is expected to reduce and prevent employee exposure to the human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and other bloodborne diseases. The Occupational Safety and Health Administration (OSHA) estimates the standard could prevent more than 200 deaths and about 9,000 infections per year from HBV alone. The standard requires that employers follow universal precautions, which means that all blood or other potentially infectious materials must be treated as being infectious for HIV, HBV, and other bloodborne pathogens. (This includes hepatitis C.) Each employer must determine the application of universal precautions by performing an employee exposure evaluation. If employee exposure is recognized, as defined by the standard, then the standard mandates a number of requirements. One of the major requirements is the development of an Exposure Control Plan, which mandates engineering controls, work practices, personal protective equipment, HBV vaccinations and training. The standard also mandates practices and procedures for housekeeping, medical evaluations, hazard communication, and recordkeeping. The _______________________ is committed to provide a safe and healthful work environment for our entire staff. In pursuit of this endeavor, the following Exposure Control Plan (ECP) is provided to eliminate or minimize occupational exposure to bloodborne pathogens in accordance with the PEOSH Bloodborne Pathogens Standard, Title 29 Code of Federal Regulations 1910.1030. The ECP is a key document to assist our facility in implementing and ensuring compliance with the standard, thereby protecting our employees. This ECP includes: I. Employee exposure determination II. The procedures for evaluating the circumstances surrounding an exposure incident, and III. The schedule and method for implementing the specific sections of the standard, including: Methods of compliance Hepatitis B vaccination and post-exposure follow-up Training and communication of hazards to employees Recordkeeping ( ___________________________________ is (are) responsible for the implementation of the ECP. ________________________________ will maintain and update the written ECP at least annually and whenever necessary to include new or modified tasks and procedures. ( Those employees who are reasonably anticipated to have contact with or exposure to blood or other potentially infectious materials are required to comply with the procedures and work practices outlined in this ECP. ( _______________________________ will have the responsibility for written housekeeping protocols and will ensure that effective disinfectants are purchased. ( _______________________________ will be responsible for ensuring that all medical actions required are performed and that appropriate medical records are maintained. ( _______________________________ will be responsible for training, documentation of training, and making the written ECP available to employees, PEOSH and NIOSH representatives. ( _______________________________ will maintain and provide all necessary personal protective equipment (PPE), engineering controls (i.e., sharp containers, self-sheathing needles, etc.), labels and red bags as required by the standard. _______________________________ will ensure that adequate supplies of the aforementioned equipment are available.  I. Employee Exposure Determination  A. As part of the exposure determination section of our ECP, the following is a list of all job classifications at our establishment in which all employees have occupational exposure:   B. The following is a list of job classifications in which some employees at our establishment have occupational exposure. Included are a list of tasks and procedures in which occupational exposure may occur for these individuals.   All exposure determinations for A and B were made without regard to the use of Personal Protective Equipment (PPE).  If needed, additional job classification lists and task sheets for Section A and B are provided in the Appendix Section (see Appendix A-3 and A-4).  II. Effective Dates: The Bloodborne Pathogens Standard was published in the New Jersey Register on July 6, 1993. The standard became operative on October 4, 1993. The dates for completing the different parts of the Standard were: Exposure Control Plan December 3, 1993 Recordkeeping January 6, 1994 Information and Training January 6, 1994 Methods of Compliance February 6, 1994 (Except Universal Precautions) Hepatitis B Vaccination and Post-Exposure February 6, 1994 Evaluation and Follow-Up Labels and Signs February 6, 1994 PEOSH Revised Bloodborne September 4, 2001 Pathogens Standard (Effective Date) Published in New Jersey Register The methods of implementation of these elements of the standard are discussed in the subsequent pages of this Exposure Control Plan. III. Methods of Implementation and Control 1.0 Universal Precautions 1.1 All employees will utilize Universal Precautions. Universal Precautions is an infection control method which requires employees to assume that all human blood and specified human body fluids are infectious for HIV, HBV and other bloodborne pathogens and must be treated accordingly. (This includes hepatitis C.) 2.0 Exposure Control Plan (ECP) 2.1 Employees covered by the Bloodborne Pathogens Standard will receive an explanation of this ECP during their initial training session. It will also be reviewed in their annual refresher training. All employees will have an opportunity to review this Plan at any time during their work shifts by contacting _______________________________. Employees seeking copies of the Plan may contact ______________________. A copy of the Plan will be made available free of charge and within 15 days of the request. 2.2 _________________ will be responsible for reviewing and updating the ECP annually or sooner if necessary to reflect any new or modified tasks and procedures which affect occupational exposure and to reflect new or revised employee positions with occupational exposure. 3.0 Engineering Controls and Work Practices 3.1 Engineering controls and work practice controls will be used to prevent or minimize exposure to bloodborne pathogens. The specific engineering controls and work practices used are listed below: For example, non-glass capillary tubes, sharps with engineered sharps injury protections (SESIPs), needleless systems) ___________________________________________________________________________ ___________________________________________________________________________ Sharps disposal containers are inspected and maintained or replaced by (Name of responsible person or department) every (list frequency) or whenever necessary to prevent overfilling. This facility identifies the need for changes in engineering controls and work practices through Examples: review of PEOSH records, employee interviews, committee activities, etc.___________________________________________________________________________ ______________________________________________________________________________ We evaluate new procedures or new products regularly by (Describe the process, literature reviewed, supplier information, products considered)__________________________________ ______________________________________________________________________________ ______________________________________________________________________________ Both front-line workers and management officials are involved in this process. (Describe how employees will be involved)___________________________________________________ ______________________________________________________________________________ ______________________________________________________________________________ (Name of responsible person or department)____________________________________ will ensure effective implementation of these recommendations. Examples of engineering controls include, but are not limited to: ( self-sheathing needles ( puncture-resistant disposal containers for contaminated sharps ( sharps with engineered sharps injury protections (SESIPs) ( needleless systems Examples of work practice controls include, but are not limited to: ( providing readily accessible hand washing facilities ( washing hands immediately or as soon as feasible after removal of gloves ( at non-fixed sites (i.e., emergency scenes, mobile blood collection sites) which lack hand washing facilities, providing interim hand washing measures, such as antiseptic towelettes and paper towels. Employees can later wash their hands with soap and water as soon as feasible ( washing body parts as soon as possible after skin contact with blood or other potentially infectious materials occurs ( prohibiting the recapping or bending of needles ( shearing or breaking contaminated needles is prohibited ( labeling ( equipment decontamination ( prohibiting eating, drinking, smoking, applying cosmetics or lip balm and handling contact lenses in work area where there is a likelihood of occupational exposure ( prohibiting food and drink from being kept in refrigerators, freezers, shelves, cabinets or on counter tops or bench tops where blood or other potentially infectious materials are present ( requiring that all procedures involving blood or other potentially infectious materials shall be performed in such a manner as to minimize splashing, splattering, and generation of droplets of these substances ( placing specimens of blood or other potentially infectious materials in a container which prevents leakage during collection, handling, processing, storage, transport or shipping ( examining equipment which may become contaminated with blood or other potentially infectious materials prior to servicing or shipping and decontaminating such equipment as necessary. Items will be labeled per the standard if not completely decontaminated 4.0 Personal Protective Equipment (PPE) Personal protective equipment must be used if occupational exposure remains after instituting engineering and work practice controls, or if the controls are not feasible. Training will be provided by _____________________________________ in the use of the appropriate personal protective equipment for employees' specific job classifications and tasks/procedures they will perform. Additional training will be provided, whenever necessary , such as if an employee takes a new position or if new duties are added to their current position. Appropriate personal protective equipment is required for the following tasks; the specific equipment to be used is listed after the task: Task Equipment ________________________________ ________________________________ ________________________________ ________________________________ ________________________________ ________________________________ ________________________________ ________________________________  PPE items include: glovesmasksgownseye protection (splash-proof goggles, safety glasses with side shields)laboratory coatsface shieldsresuscitation bags and mouthpieces  4.2 As a general rule, all employees using PPE must observe the following precautions: ( Wash hands immediately or as soon as feasible after removal of gloves or other personal protective equipment. ( Remove protective equipment before leaving the work area and after a garment becomes contaminated. ( Place used protective equipment in appropriately designated areas or containers being stored, washed, decontaminated, or discarded.  ( _____________________________________________________________________ _____________________________________________________________________ _____________________________________________________________________ _____________________________________________________________________ _____________________________________________________________________ ( Wear appropriate gloves when it can be reasonably anticipated that you may have contact with blood or other potentially infectious materials and when handling or touching contaminated items or surfaces. Replace gloves if torn, punctured, contaminated, or if their ability to function as a barrier is compromised. ( Following any contact of body areas with blood or any other infectious materials, you must wash your hands and any other exposed skin with soap and water as soon as possible. Employees must also flush exposed mucous membranes (eyes, mouth, etc) with water. ( Utility gloves may be decontaminated for reuse if their integrity is not compromised. The decontamination procedure will consist of ______________ _____________________________. ( Discard utility gloves when they show signs of cracking, peeling, tearing, puncturing, or deterioration. ( Never wash or decontaminate disposable gloves for reuse or before disposal. ( Wear appropriate face and eye protection such as a mask with glasses with solid side shields or a chin-length face shield when splashes, sprays, splatters, or droplets of blood or other potentially infectious materials pose a hazard to the eye, nose, or mouth. ( If a garment is penetrated by blood and other potentially infectious materials, the garment(s) must be removed immediately or as soon as feasible. If a pullover scrub (as opposed to scrubs with snap closures) becomes minimally contaminated, employees should be trained to remove the pullover scrub in such a way as to avoid contact with the outer surface; e.g., rolling up the garment as it is pulled toward the head for removal. However, if the amount of blood exposure is such that the blood penetrates the scrub and contaminates the inner surface, not only is it impossible to remove the scrub without exposure to blood, but the penetration itself would constitute exposure. It may be prudent to train employees to cut such a contaminated scrub to aid removal and prevent exposure to the face. Repair and/or replacement of PPE will be at no cost to employees. Refer to Appendix I for additional information on PPE. 5.0 Training 5.1 All employees who have or are reasonably anticipated to have occupational exposure to bloodborne pathogens will receive training conducted by _____________________________. ____________________________________ will provide training on the epidemiology of bloodborne pathogen diseases. OSHA pamphlet Occupational Exposure to Bloodborne Pathogens and Fact Sheets located in the Appendix Section and _______________________ will be used to inform employees of the epidemiology, symptoms, and transmission of bloodborne diseases. In addition, the training program will cover, at a minimum, the following elements: A copy and explanation of the revised standard Epidemiology and symptoms of bloodborne pathogens Modes of transmission Our Exposure Control Plan and how to obtain a copy Methods to recognize exposure tasks and other activities that may involve exposure to blood Use and limitations of Engineering Controls, Work Practices, and PPE PPE - types, use, location, removal, handling, decontamination, and disposal PPE - the basis for selection Hepatitis B Vaccine - offered free of charge. Training will be given prior to vaccination on its safety, effectiveness, benefits, and method of administration (See Appendix P) ( Emergency procedures - for blood and other potentially infectious materials ( Exposure incident procedures ( Post-exposure evaluation and follow-up ( Signs and labels - and/or color coding ( Questions and answer session  An Employee Education and Training Record (see Appendix B) will be completed for each employee upon completion of training. This document will be kept with the employee's records at _________________________________________. Highlights of Training Program Elements  Contents of revised standard Epidemiology of bloodborne diseases Exposure Control Plan Job duties with exposure Types of controls Protective equipment Hepatitis B vaccination program Emergency procedures Post-exposure procedures Signs/labels/(color coding) Question and answer session 6.0 Hepatitis B Vaccination 6.1 _______________________________ will provide information on hepatitis B vaccinations addressing its safety, benefits, efficacy, methods of administration and availability. A general overview of these considerations is given in Appendix L for review. The hepatitis B vaccination series will be made available at no cost within 10 days of initial assignment of employees who have occupational exposure to blood or other potentially infectious materials unless: ( the employee has previously received the series ( antibody testing reveals that the employee is immune ( medical reasons prevent taking the vaccination; or ( the employee chooses not to participate Hepatitis B vaccination will be provided by (list healthcare professional at location)_______________ __________________________________________________________________________________ __________________________________________________________________________________ All employees are strongly encouraged to receive the hepatitis B vaccination series. However, if an employee chooses to decline HB vaccination, then the employee must sign a statement to this effect. Employees who decline may request and obtain the vaccination at a later date at no cost. Documentation of refusal of the HB vaccination (see Appendix C2) will be kept in _____________________________ with the employees other medical records. Appendix C1 is an optional form that may be used to record the employee vaccination series information.  Highlights of Hepatitis B Vaccination Other Requirements  Participation in pre-screening is not a prerequisite for receiving the hepatitis B vaccination Hepatitis B vaccination provided even if employee declines but later accepts vaccine Employee must sign statement when declining HB vaccination Vaccination administered in accordance with United States Public Health Service (USPHS) recommended protocol* HB vaccination booster doses must be available to employees if recommended by USPHS  ________________ * See the Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposure to HBV, HCV, and HIV and Recommendations for Post Exposure Prophlylaxis (June29,2001/50 (RR11); 1-42 at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5o11a1.htm 7.0 Post Exposure Evaluation and Follow-up and Procedures for Reporting, Documenting and Evaluating the Exposure 7.1 Should an exposure incident occur contact _________________________ immediately. Each exposure must be documented by the employee on an Exposure Report Form (see AppendixD). ___________________________ will add any additional information as needed. An immediately available confidential medical evaluation and follow-up will be conducted by _______________________________. The following elements will be performed: ( Document the routes of exposure and how exposure occurred. ( Identify and document the source individual (see Appendix E), unless the employer can establish that identification is infeasible or prohibited by State or local law (See Note#1). ( Obtain consent (See Note #2) and test source individual's blood as soon as possible to determine HIV and HBV infectivity (See footnote) and document the sources blood test results. ( If the source individual is known to be infected with either HIV or HBV (See footnote), testing need not be repeated to determine the known infectivity. ( Provide the exposed employee with the source individuals test results and information about applicable disclosure laws and regulations concerning the source identity and infectious status. ( After obtaining consent, collect exposed employees blood as soon as feasible after the exposure incident and test blood for HBV and HIV serological status. (See footnote) ( If the employee does not give consent for HIV serological testing during the collection of blood for baseline testing, preserve the baseline blood sample for at least 90 days. (See Note #3) Appendix D Exposure Incident Report and Appendix E Request for Source Individual Evaluation and Appendix F Employee Exposure Follow-Up Record (see Note #4) will be provided to the employee so they may bring them along with any additional relevant medical information to the medical evaluation. Original copies of these appendixes will be maintained with the employees medical records. ________________ * Update: The U .S. Public Health Service, Centers for Disease Control and Prevention (CDC) recommend including blood-testing of the source and the exposed individual for the presence of hepatitis C antibody (anti-HCV). See footnote, page 16 and Appendix M. ___________________________________ will review the circumstances of the exposure incident to determine if procedures, protocols and/or training need to be revised.  Highlights of Post Exposure Evaluation and Follow-Up Requirements  Documentation of exposure routes and how exposure incident occurred Identification and documentation of source individuals infectivity, if possible Collection and testing of employees blood for HBV and HIV serological status (employees consent required) (See footnote) Post-exposure prophylaxis when medically indicated Counseling Evaluation of reported illnesses   ___________________ * Update: The U.S. Public Health Service, Centers for Disease Control and Prevention (CDC) recommend including blood-testing of the source and the exposed individual for the presence of hepatitis C antibody (anti-HCV). See footnote, p. 16 and Appendix M. 8.0 Health Care Professionals 8.1 ______________________will ensure that health care professionals responsible for employees HB vaccination and post-exposure evaluation and follow-up be given a copy of the PEOSH Bloodborne Pathogens Standard. _________________________________ will also ensure that the health care professional evaluating an employee after an exposure incident receives the following: ( a description of the employee's job duties relevant to the exposure incident ( route(s) of exposure ( circumstances of exposure ( if possible, results of the source individuals blood test; and ( relevant employee medical records, including vaccination status 8.2 Healthcare Professionals Written Opinion __________________ will provide the employee with a copy of the evaluating healthcare professionals written opinion within 15 days after completion of the evaluation. For HB vaccinations, the healthcare professionals written opinion will be limited to whether the employee requires or has received the HB vaccination. The written opinion for post-exposure evaluation and follow-up will be limited to whether or not the employee has been informed of the results of the medical evaluation and any medical conditions which may require further eva1uation and treatment. All other diagnoses must remain confidential and not be included in the written report to our facility.  8.3 Procedures for Evaluating the Circumstances Surrounding an Exposure Incident (Name of responsible person or department)___________________________________ will review the circumstances of all exposure incidents to determine. engineering controls in use at the time work practices followed a description of the device being used (including type and brand) protective equipment or clothing that was used at the time of the exposure incident (gloves, eye shields, etc.) location of the incident procedure being performed when the incident occurred employees training (Name of responsible person or department)____________________________________ will record all percutaneous injuries from contaminated sharps in the Sharps Injury Log. If it is determined that revisions need to be made, (Name of responsible person or department)_________________________________________ will ensure that appropriate changes are made to this ECP. (Changes may include an evaluation of safer devices, adding employees to the exposure determination list, etc.) 9.0 Housekeeping 9.1 _________________________ has developed and implemented a written schedule for cleaning and decontaminating work surfaces as indicated by the standard. Cleaning Schedule AreaScheduled Cleaning (Day/Time)Cleaners and Disinfectants Used Specific Instructions  ( Decontaminate work surfaces with an appropriate disinfectant after completion of procedures, immediately when overtly contaminated, after any spill of blood or other potentially infectious materials, and at the end of the work shift when surfaces have become contaminated since the last cleaning. ( Remove and replace protective coverings such as plastic wrap and aluminum foil when contaminated. ( Inspect and decontaminate, on a regular basis, reusable receptacles such as bins, pails, and cans that have a likelihood for becoming contaminated. When contamination is visible, clean and decontaminate receptacles immediately, or as soon as feasible. ( Always use mechanical means such as tongs, forceps, or a brush and a dust pan to pick up contaminated broken glassware; never pick up with hands even if gloves are worn. ( Store or process reusable sharps in a way that ensures safe handling. ( Place regulated waste in closable and labeled or color-coded containers. When storing, handling, transporting or shipping, place other regulated waste in containers that are constructed to prevent leakage. ( When discarding contaminated sharps (including safer medical devices), place them in containers that are closable, puncture-resistant, appropriately labeled or color-coded, and leak-proof on the sides and bottom. ( Ensure that the sharps containers are easily accessible to personnel and located as close as feasible to the immediate area where sharps are used or can be reasonably anticipated to be found. Sharps containers also must be kept upright throughout use, replaced routinely, closed when moved, and not allowed to overfill. Never manually open, empty, or clean reusable contaminated sharps disposal containers. Discard all regulated waste according to federal, state, and local regulations, i.e., liquid or semi-liquid blood or other potentially infectious material; items contaminated with blood or other potentially infectious materials that would release these substances in a liquid or semi-liquid state if compressed; items caked with dried blood or other potentially infectious materials and capable of releasing these materials during handling; contaminated sharps; and pathological and microbiological wastes containing blood or other potentially infectious materials. 9.2 Laundry The following contaminated articles will be laundered: ( _________________________________________________________________________ _________________________________________________________________________ _________________________________________________________________________ _________________________________________________________________________ Laundry will be performed by ___________________________________________________ at ________________________________________. The following requirements must be met, with respect to contaminated laundry: Handle contaminated laundry as little as possible and with a minimum of agitation. Use appropriate personal protective equipment when handling contaminated laundry. Place wet contaminated laundry in leak-proof, labeled or color-coded containers before transporting. Bag contaminated laundry at its location of use. Never sort or rinse contaminated laundry in areas of its use. ( *Use red laundry bags or those marked with the biohazard symbol unless universal precautions are in use at the facility and all employees recognize the bags as contaminated and have been trained in handling the bags. ( *All generators of laundry must have determined if the receiving facility uses universal precautions. If universal precautions are not used, then clearly mark laundry sent off-site with orange biohazard labels or use red bags. Leak proof bags must be used when necessary to prevent soak-through or leakage. ( When handling and/or sorting contaminated laundry, utility gloves and other appropriate personal protective equipment (i.e., aprons, mask, eye protection) shall be worn. ( Laundries must have sharps containers readily accessible due to the incidence of needles and sharps being unintentionally mixed with laundry. ( Linen soiled with blood or body fluids should be placed and transported in bags that prevent leakage. If hot water is used, linen should be washed with detergent in water at least 140(F - 160(F for 25 minutes. If low-temperature (<140(F) laundry cycles are used, chemicals suitable for low-temperature washing at proper use concentration should be used. * NOTE: For these items specify below which labeling system, red bags or biohazard labeling, will be used for laundering.  10.0 Laundry 10.1 The following labeling method(s) will be used at our facility: ( _________________________________________________________________________ _________________________________________________________________________ ______________________ will ensure warning labels are affixed or red bags are used as required. Employees are to notify _______________________ if they discover unlabeled regulated waste containers.  11.0 Recordkeeping 11.1 Medical Records Medical records are maintained for each employee with occupational exposure in accordance with 29 CFR 1910.1020, Access to Employee Exposure and Medical Records. _________________________ is responsible for maintenance of the required medical records and they are kept at ______________________________________________________. NOTE: Refer to the Appendix Section for copies of applicable medical record forms. In addition to the requirements of 29 CFR 1910.1020, the medical record will include: ( The name and social security number of employee; ( A copy of the employee's hepatitis B vaccinations and any medical records relative to the employee's ability to receive vaccination; ( A copy of all results of examinations, medical testing, and follow-up procedures as required by the standard; ( A copy of all healthcare professionals written opinion(s) as required by the standard. All employee medical records will be kept confidential and will not be disclosed or reported without the employees express written consent to any person within or outside the workplace except as required by the standard or as may be required by law. Employee medical records shall be confidential and maintained for at least the duration of employment plus 30 years in accordance with 29 CFR 1910.1020. Employee medical record shall be provided upon request of the employee or to anyone having written consent of the employee within 15 working days. 11.2 Training Records Bloodborne pathogen training records will be maintained by ___________________________ at ________________________________ (see Appendix B). The training record shall include: ( the dates of the training sessions; ( the contents or a summary of the training sessions; ( the names and qualifications of persons conducting the training; ( the names and job titles of all persons attending the training sessions. Training records will be maintained for a minimum of three (3) years from the date on which the training occurred. Employee training records will be provided upon request to the employee or the employee's authorized representative within 15 working days. 11.3 Transfer of Records If ____________________________ ceases to do business and there is no successive employer to receive and retain the records for the prescribed period, the employer shall notify the Director of the National Institute for Occupational Safety and Health (NIOSH) at least three (3) months prior to scheduled record disposal and prepare to transmit them to the Director. Highlights of Medical Records  Employee name and social security number Employee hepatitis B vaccination status Medical testing and post-exposure follow-up results Healthcare Professionals written opinion Information provided to the health care professional  Highlights of Training Records  Training dates Training session content or summary Names and qualifications of trainers Names and job titles of all trainees  PEOSH Recordkeeping An exposure incident is evaluated to determine if the case meets PEOSHs Recordkeeping Requirements (29 CFR 1904). This determination and the recording activities are done by (Name of responsible person or department)_______________________________________________________________________________________________. Sharps Injury Log In addition to the 29 CFR 1904 Recordkeeping Requirements, all percu-taneous injuries from contaminated sharps are also recorded in the Sharps Injury Log. All incidences must include at least: the date of the injury the type and brand of the device involved the department or work area where the incident occurred an explanation of how the incident occurred This log is reviewed at least annually as part of the annual evaluation of the program and is maintained for at least five years following the end of the calendar year that they cover. If a copy is requested by anyone, it must have any personal identifiers removed from the report. This section only applies to employees who are designated to render first aid assistance, but this assistance is not their primary work assignment. First aid providers who are in this collateral duty category at this facility are listed below for easy reference and also in Section B of the Employer Exposure Determination on page five. Designated First Aid Providers ( _____________________________________________________________________________ _____________________________________________________________________________ _____________________________________________________________________________ _____________________________________________________________________________ Our facility has decided to: (check box for facilitys specific policy) ( offer hepatitis B vaccination to the first aid provider after a first aid incident ( offer pre-exposure vaccination. In the event of a first aid incident where blood or other potentially infectious materials (OPIM) are present, the employee(s) providing the first aid assistance is (are) instructed to report to __________________________________ before the end of their workshift. ____________________________ will maintain a report (Appendix D can be used) which describes name of the first aider, date, time and description of incident. ____________________________ will ensure that any first aider that desires the vaccine series after an incident involving blood or OPIM will receive it as soon as possible, but no later than twenty four hours after the incident. ____________________________ will train first aid providers on the specifics of the reporting procedures, in addition to all the training required in Section 5.0 Training.  APPENDIX SECTION OCCUPATIONS AT RISK Occupations that may involve risk from occupational exposure to blood or other potentially infectious material: PhysicianMedical TechnologistPhysicians AssistantRegulated Waste HandlerNurseSome laundry and housekeeping employeesPhlebotomistIndustrial Medical Center PersonnelMedical ExaminerLab WorkersEmergency Medical Technician (EM)Life GuardsSupervisor (performing first-aid)FirefightersDentistCorrections OfficersDental HygienistPolice DEFINITIONS Before beginning a discussion of the standard there are several definitions that should be explained which specifically apply to this regulation. These definitions are also included in paragraph (b) of the standard. A. Blood - human blood, human blood components, and products made from human blood. B. Bloodborne Pathogens - pathogenic microorganisms that are present in human blood and can infect and cause disease in humans. These pathogens include, but are not limited to, hepatitis B virus (HBV) and human immunodeficiency virus (HIV). (This includes hepatitis C virus.) C. Contaminated - the presence or the reasonably anticipated presence of blood or other potentially infectious materials on an item or surface. D. Engineering Controls - means controls (e.g., sharps disposal containers, self-sheathing needles, safer medical devices such as sharps with engineered sharps injury protections and needleless systems) that isolate or remove the bloodborne pathogen hazard from the workplace. E. Exposure Incident - a specific eye, mouth, other mucous membrane, non-intact skin, or parenteral contact with blood or other potentially infectious materials that results from the performance of an employees duties. F. Occupational Exposure - reasonably anticipated skin, eye, mucous membrane, or parenteral contact with blood or other potentially infectious materials that may result from the performance of an employees duties. G. Other Potentially Infectious Materials (OPIM) 1. The following human body fluids: a. semen h. amniotic fluid b. vaginal secretions i. Saliva in dental procedures c. cerebrospinal fluid j. any body fluid visibly contaminated d. synovial fluid with blood e. pleural fluid k. all body fluids in situations where it is f. pericardial fluid difficult or impossible to differentiate g. peritoneal fluid between body fluids; 2. Any unfixed tissue or organ (other than intact skin) from a human (living or dead); 3. HIV-containing cells or tissue cultures, organ cultures, and HIV or HBV-containing cultures medium or other solutions; and 4. Blood, organs, or other tissue from experimental animals infected with HIV or HBV. H. Regulated Waste - 1. Liquid or semi-liquid blood or OPIM; 2. Contaminated items that would release blood or OPIM in a liquid or semi-liquid state if compressed; 3. Items that are caked with dried blood or OPIM and are capable of releasing these materials during handling; 4. Contaminated sharps; and 5. Pathological and microbiological wastes containing blood or OPIM. I. Universal Precautions - an approach to infection control whereby all human blood and certain human body fluids are treated as if known to be infectious for HIV, HBV, and other bloodborne pathogens. JOB CLASSIFICATIONS IN WHICH ALL EMPLOYEES HAVE OCCUPATIONAL EXPOSURE TO BLOODBORNE PATHOGENS Below are listed the job classifications in our facility where all employees will have reasonably anticipated exposure to human blood and other potentially infectious materials: Job TitleDepartment/Location JOB CLASSIFICATIONS AND WORK ACTIVITIES IN WHICH SOME EMPLOYEES HAVE OCCUPATIONAL EXPOSURE TO BLOODBORNE PATHOGENS Below are listed the job classifications and work activities in our facility where some employees will have reasonably anticipated exposure to human blood and other potentially infectious materials: Job TitleDepartment/LocationTask Procedure EMPLOYEE EDUCATION & TRAINING RECORD Employee ______________________________________ Date of Hire ______________________________ Job Title _______________________________________ Date Assigned ____________________________ INITIAL TRAINING:SUBJECTDATELOCATIONTRAINEREMPLOYEE SIGNATUREa. The Standardb. Epidemiology & Symptoms of Bloodborne Diseasesc. Modes of Transmissiond. Exposure Control Plane. Recognizing Potential Exposuref. Use & Limitations of Exposure Control Methodsg. Personal Protective Equipment (PPE)h. Selection of PPEi. HBV Immunization Programj. Emergencies involving Blood or Potentially Infectious Materialsk. Exposure Follow-up Proceduresl. Post Exposure Evaluation and Follow-upm. Signs & Labelsn. Opportunity to Ask Questions ADDITIONAL EDUCATION:SUBJECTDATELOCATIONTRAINEREMPLOYEE SIGNATURE ANNUAL RETRAINING:SUBJECTDATELOCATIONTRAINEREMPLOYEE SIGNATURE CONFIDENTIAL HEPATITIS B VACCINE IMMUNICATION RECORD Vaccine is to be administered on: _________________________________________________ Elected dates: First: __________________________________________________________________ One month from elected date: _____________________________________________ Six months from elected date: ______________________________________________ Employee Name: ______________________________________________________________ Date of first dose: ______________________________________________________________ Date of second dose: ___________________________________________________________ Date of third dose: _____________________________________________________________ Antibody test results - pre-vaccine (optional): ________________________________________ Antibody test results - post-vaccine: _______________________________________________ Time interval since last injection: _________________________________________________ Employee Signature: __________________________________________  DECLINATION STATEMENT I understand that due to my occupational exposure to blood or other potentially infectious materials, I may be at risk of acquiring hepatitis B virus (HBV) infection. I have been given the opportunity to be vaccinated with hepatitis B vaccine, at no charge to myself. However, I decline hepatitis B vaccination at this time. I understand that by declining this vaccine, I continue to be at risk of acquiring hepatitis B, a serious disease. If in the future I continue to have occupational exposure to blood or other potentially infectious materials and I want to be vaccinated with hepatitis B vaccine, I can receive the vaccination series at no charge to me. _______________________________ _______________________ Employee Signature Date  Side 1 of 2-sided form EXPOSURE INCIDENT REPORT (Routes and Circumstances of Exposure Incident) Please Print Date Completed _______________________________ Employees Name ______________________________________ SS# ________-________-________ Home Phone __________________________________ Business Phone _________________________ DOB _______________________________ Job Title ________________________________________ Employee Vaccination Status ____________________________________________________________ Date of Exposure _______________________ Time of Exposure ___________________ am ( pm ( Location of Incident (Home, Street, Clinic, etc) Be Specific: ___________________________________ _____________________________________________________________________________________ Nature of Incident (Auto Accident, Trauma, Medical Emergency) Be Specific: _____________________________________________________________________________________ _____________________________________________________________________________________ _____________________________________________________________________________________ Describe what task(s) you were performing when the exposure occurred. Be Specific: _____________________________________________________________________________________ _____________________________________________________________________________________ _____________________________________________________________________________________ Were you wearing personal protective equipment (PPE)? Yes ( No ( If yes, list ____________________________________________________________________________ Did the PPE fail? Yes ( No ( If yes, explain how: ____________________________________________________________________ _____________________________________________________________________________________ _____________________________________________________________________________________ What body fluid(s) were you exposed to (blood or other potentially infectious material)? Be Specific: _____________________________________________________________________________________ _____________________________________________________________________________________ _____________________________________________________________________________________ Continued on back Side 2 of 2-sided form Continued from front What parts of your body became exposed? Be specific: ________________________________________ ______________________________________________________________________________________ Estimate the size of the area of your body that was exposed: _____________________________________ ______________________________________________________________________________________ For how long? _________________________________________________________________________ Did a foreign body (needle, nail, auto part, dental wires, etc.) penetrate your body? Yes ( No ( If yes, what was the object? ______________________________________________________________ Where did it penetrate your body? _________________________________________________________ Was any fluid injected into your body? Yes ( No ( If yes, what fluid?: _______________________________________ How much? ________________ Did you receive medical attention? Yes ( No ( If yes, where? _________________________________________________________________________ When ________________________________________________________________________________ By whom _____________________________________________________________________________ Identification of source individual(s) _______________________________________________________ Name(s) ______________________________________________________________________________ Did you treat the patient directly? Yes ( No ( If yes, what treatment did you provide. Be specific: __________________________________________ _____________________________________________________________________________________ Other pertinent information: _____________________________________________________________ _____________________________________________________________________________________ _____________________________________________________________________________________ _____________________________________________________________________________________ REQUEST FOR SOURCE INDIVIDUAL EVALUATION Dear (Emergency Room Medical Director, Infection Control Practitioner): During a recent transport of a patient to your facility, one of our prehospital care providers was involved in an event which may have resulted in exposure to a Bloodborne Pathogen. I am asking you to perform an evaluation of the source individual who was transported to your facility. Given the circumstances surrounding this event, please determine whether our prehospital care worker is at risk for infection and/or requires medical follow-up. Attached is a Documentation and Identification of Source Individual form which was initiated by the exposed worker. Please complete the source individual section and communicate the findings to the designated medical provider. The evaluation form has been developed to provide confidentially assurances for the patient and the exposed worker concerning the nature of the exposure. Any communication regarding the findings is to be handled at the medical provider level. We understand that information relative to human immunodeficiency virus (HIV) and AIDS has specific protections under the law and cannot be disclosed or released without the written consent of the patient. It is further understood that disclosure obligates persons who receive such information to hold it confidential. Thank you for your assistance in this very important matter. Sincerely, _____________________________  CONFIDENTIAL DOCUMENTATION AND IDENTIFICATION OF SOURCE INDIVIDUAL Name of Exposed Employee ___________________________________________________________ Name and Phone Number of Medical Provider Who Should be Contacted: ___________________________________________________________________________________ Incident Information Date: __________________________________ Name or Medical Record Number of the Individual Who is the Source of the Exposure: ___________________________________________________________________________________ Nature of the Incident ( Contaminated Needlestick Injury ( Blood or Bodyfluid Splash Onto Mucous Membrane or Non-Intact Skin Other: _____________________________________________________________________________ Report of Source Individual Evaluation Chart Review By ____________________________________________ Date: ___________________ Source Individual Unknown - Researched by ______________________________________________ Date: ____________________________ Testing of Source Individuals Blood Consent Obtained ( Refused ( Check One: ( Identification of source individual infeasible or prohibited by state or local law. State why is infeasible. ( Evaluation of the source individual reflected to known exposure to Bloodborne Pathogen. ( Evaluation of the source individual reflected possible exposure to Bloodborne Pathogen and medical follow-up is recommended. Person Completing Report: ____________________________ Date: _______________________ Note: Report the results of the source individuals blood test to the medical provider named above who will inform the exposed employee. Do not report blood test findings to the employer. HIV-related information cannot be released without the written consent of the source individual. CONFIDENTIAL EMPLOYEE EXPOSURE FOLLOW-UP RECORD Employees Name ____________________________ Job Title ______________________________ Occurrence Date _________________________ Reported Date ______________________________ Occurrence Time _____________________ am ( pm ( SOURCE INDIVIDUAL FOLLOW-UP Request Made to ____________________________________________________________________ Date __________________________ Time ___________________ am ( pm ( EMPLOYEE FOLLOW-UP Employees Health File Reviewed by ____________________________ Date: ___________________ Information given on source individuals blood test results Yes ( Not Obtained ( Referred to healthcare professional with required information Name of healthcare professional _______________________________________________________ By Whom __________________________________________ Date _________________________ Blood Sampling/Testing Offered By Whom __________________________________________ Date _________________________ Vaccination Offered/Recommended By Whom __________________________________________ Date _________________________ Counseling Offered By Whom __________________________________________ Date _________________________ Employee Advised of need for further evaluation of medical condition By Whom __________________________________________ Date _________________________  INFORMATION ON REGULATED MEDICAL WASTE The following information is included to assist you in evaluating and contracting for a transport, handling, and disposal company, should you not be equipped to handle your regulated medical waste. Every Prospective Client is Urged to: 1. Request and check references and solicit information on reliability from colleagues who are known clients of vendor(s); 2. Obtain a specific detailed contract for services rendered; 3. Require accurate documentation on transportation practices and date, method and location of ultimate disposal; 4. If at all possible, make a site visit to the vendors base of operation and disposal facilities; and 5. Strictly monitor all aspects of the services provided to you on an ongoing basis. For Additional Information on Regulated Medical Waste, contact: New Jersey Department of Environmental Protection Division of Solid Waste Management Bureau of Resource Recovery and Technical Programs PO Box 414 401 East State Street Trenton, NJ 08625-0414 (609) 984-6620 And/Or New Jersey Department of Health and Senior Services Division of Environmental and Occupational Health Services Public Health Sanitation and Safety Program PO Box 369 3635 Quakerbridge Road Trenton, NJ 08625-0369 (609) 588-3124  Personal Protective Equipment Cuts Risk  Wearing gloves, gowns, masks, and eye protection can significantly reduce health risks for workers exposed to blood and other potentially infectious materials. The new OSHA standard covering bloodborne disease requires employers to provide appropriate personal protective equipment (PPE) and clothing free of charge to employees. Workers who have direct exposure to blood and other potentially infectious materials on their jobs run the risk of contracting bloodborne infections from hepatitis B virus (HBV), human immuno-deficiency virus (HIV) which causes AIDS, and other pathogens. About 8,700 health care workers each year are infected with HBV, and 200 die from the infection. Although the risk of contracting AIDS through occupational exposure is much lower, wearing proper personal protective equipment can greatly reduce potential exposure to all bloodborne infections. SELECTING PPE Person protective clothing and equipment must be suitable. This means the level of protection must fit the expected exposure. For example, gloves would be sufficient for a laboratory technician who is drawing blood, whereas a pathologist conducting an autopsy would need considerably more protective clothing. PPE may include gloves, gowns, laboratory coats, face shields or masks, eye protection, pocket masks, and other protective gear. The gear must be readily accessible to employees and available in appropriate sizes. If an employee is expected to have hand contact with blood or other potentially infectious materials or contaminated surfaces, he or she must wear gloves. Single use gloves cannot be washed or decontaminated for reuse. Utility gloves may be decontaminated if they are not compromised. They should be replaced when they show signs of cracking, peeling, tearing, puncturing, or deteriorating. If employees are allergic to standard gloves, the employer must provide hypoallergenic gloves or similar alternatives. Routine gloving is not required for phlebotomy in voluntary blood donation centers, though it is necessary for all other phlebotomies. In any case, gloves must be available in voluntary blood donation centers for employees who want to use them. Workers in voluntary blood donation centers must use gloves (1) when they have cuts, scratches or other breaks in their skin, (2) while they are in training; and (3) when they believe contamination might occur. Employees should wear eye and mouth protection such as goggles and masks, glasses with solid side shields, and masks or chin-length face shields when splashes, sprays, splatters, or droplets of potentially infectious materials pose a hazard through the eyes, nose or moth. More extensive coverings such as gowns, aprons, surgical caps and hoods, and shoe covers or boots are needed when gross contamination is expected. This often occurs, for example, during orthopedic surgery or autopsies. AVOIDING CONTAMINATION The key is that blood or other infectious materials must not reach an employees work clothes, street cloths, undergarments, skin, eyes, mouth, or other mucous membranes under normal conditions for the duration of exposure. Employers must provide the PPE and ensure that their workers wear it. This means that if a lab coat is considered PPE, it must be supplied by the employer rather than the employee. The employer also must clean or launder clothing and equipment and repair or replace it as necessary. Additional protective measures such as using PPE in animal rooms and decontaminating PPE before laundering are essential in facilities that conduct research on HIV or HBV. EXCEPTION There is one exception to the requirement for protective gear. An employee may choose, temporarily and briefly, under rare and extraordinary circumstances, to forego the equipment. It must be the employees professional judgment that using the protective equipment would prevent the delivery of health case or public safety services or would pose an increased hazard to the safety of the worker or coworker. When one of those excepted situations occurs, employers are to investigate and document the circumstances to determine if there are ways to avoid it in the future. For example, if a firefighters resuscitation device is damaged, perhaps another type of device should be used or the device should be carried in a different manner. Exceptions must be limited- -this is not a blanket exemption. DECONTAMINATING AND DISPOSING OF PPE Employees must remove personal protective clothing and equipment before leaving the work area or when the PPE becomes contaminated. If a garment is penetrated, workers must remove it immediately or as soon as feasible. Used protective clothing and equipment must be placed in designated containers for storage, decontamination, or disposal. OTHER PROTECTIVE PRACTICES If an employees skin or mucous membranes come into contact with blood, he or she is to wash with soap and water and flush eyes with water as soon as feasible. In addition, workers must wash their hands immediately or as soon as feasible after removing protective equipment. If soap and water are not immediately available, employers may provide other handwashing measures such as moist towelettes. Employees still must wash with soap and water as soon as possible. Employees must refrain from eating, drinking, smoking, applying cosmetics or lip balm, and handling contact lenses in areas where they may be exposed to blood or other potentially infectious materials. This is one of a series of fact sheets that discuss various requirements of the Occupational Safety and Health Administrations standard covering exposure to bloodborne pathogens. Single copies of fact sheets are available from OSHA Publications, Room N-3103, 200 Constitution Avenue, N.W., Washington, D.C. 20210 and from OSHA regional offices. . Reporting Exposure Incidents  OSHAs new bloodborne pathogens standard includes provisions for medical follow-up for workers who have an exposure incident. The most obvious exposure incident is a needlestick. But any specific eye, mouth, other mucous membrane, non-intact skin, or parenteral contact with blood or other potentially infectious materials is considered an exposure incident and should be reported to the employer. Exposure incidents can lead to infection from hepatitis B virus (HBV) or human immuno-deficiency virus (HIV) which causes AIDS. Although few cases of AIDS are directly traceable to workplace exposure, every year about 8,700 health care workers contract hepatitis B from occupational exposures. Approximately 200 will die from this bloodborne infection. Some will become carriers, passing the infection on to others. WHY REPORT? Reporting an exposure incident right away permits immediate medical follow-up. Early action is crucial. Immediate intervention can forestall the development of hepatitis B or enable the affected worker to track potential HIV infection. Prompt reporting also can help the worker avoid spreading bloodborne infection to others. Further, it enables the employer to evaluate the circumstances sur-rounding the exposure incident to tray to find ways to prevent such a situation from occurring again. Reporting is also important because part of the follow-up includes testing the blood of the source individual to determine HBV and HIV infectivity if this is unknown and if permission for testing can be obtained. The exposed employee must be informed of the results of these tests.  Employers must tell the employee what to do if an exposure incident occurs. MEDICAL EVALUATION AND FOLLOW-UP Employers must provide free medical evaluation and treatment to employees who experience an exposure incident. They are to refer exposed employees to a licensed health care provider who will counsel the individual about what happened and how to prevent further spread of any potential infection. He or she will prescribe appropriate treatment in line with current U.S. Public Health Service recommendations. The licensed health care provider also will evaluate any reported illness to determine if the symptoms may be related to HIV or HBV development. The first step is to test the blood of the exposed employee. Any employee who wants to participate in the medical evaluation program must agree to have blood drawn. However, the employee has the option to give the blood sample but refuse permission for HIV testing at that time. The employer must maintain the employees blood sample for 90 days in case the employee changes his or her mind about testing- -should symptoms develop that might relate to HIV or HBV infection. The health care provider will counsel the employee based on the test results. If the source individual was HBV positive or in a high risk category, the exposed employee may be given hepatitis B immune globulin and vaccination, as necessary. If there is no information on the source individual or the test is negative, and the employee has not been vaccinated or does not have immunity based on his or her test, he or she may receive the vaccine. Further, the health care provider will discuss any other findings from the tests. The standard requires that the employer make the hepatitis B vaccine available, at no cost to the employee, to all employees who have occupational exposure to blood and other potentially infectious materials. This requirement is in addition to post-exposure testing and treatment responsibilities. WRITTEN OPINION In addition to counseling the employee, the health care provider will provide a written report to the employer. This report simply identifies whether hepatitis B vaccination was recommended for the exposed employee and whether or not the employee received vaccination. The health care provider also must note that the employee has been informed of the results of the evaluation and told of any medical conditions resulting from exposure to blood which require further evaluation or treatment. Any added findings must be kept confidential. CONFIDENTIALITY Medical records must remain confidential. They are not available to the employer. The employee must give specific written consent for anyone to see the records. Records must be maintained for the duration of employment plus 30 years in accordance with OSHAs standard on access to employee exposure and medical records. This is one of a series of fact sheets that discuss various requirements of the Occupational Safety and Health Administrations standard covering exposure to bloodborne pathogens. Single copies of fact sheets are available from OSHA Publications, Room N-3103, 200 Constitution Avenue, N.W., Washington, D.C. 20210 and from OSHA regional offices. Protecting Yourself When Handling Sharps  A needlestick or a cut from a contaminated scalpel can lead to infection from hepatitis B virus (HBV) or human immunodeficiency virus which causes AIDS. Although few cases of AIDS have been documented from occupational exposure, approximately 8,700 health care workers each year contract hepatitis B. About 200 will die as a result. The new OSHA standard covering bloodborne pathogens specifies measures to reduce these risks of infection. PROMPT DISPOSAL The best way to prevent cuts and sticks is to minimize contact with sharps. That means disposing of them immediately after use. Puncture-resistant containers must be available nearby to hold contaminated sharps--either for disposal or, for reusable sharps, later decontaminated for re-use. When reprocessing contaminated reusable sharps, employees must not reach by hand into the holding container. Contaminated sharps must never be sheared or broken. Recapping, bending, or removing needles is permissible only if there is no feasible alternative or if required for a specific medical procedure such as blood gas analysis. If recapping, bending, or removal is necessary, workers must use either a mechanical device or a none-handed technique. If recapping is essential--for example, between multiple injections for the same patient- - the employee must avoid using both hands to recap. Employees must recap with a one-handed scoop technique, using the needle itself to pick up the cap, pushing cap and sharp together against a hard surface to ensure a tight fit. Or they might hold the cap with tongs or forceps to place it on the needle. SHARPS CONTAINERS Containers for used sharps must be puncture resistant. The sides and the bottom must be leakproof. They must be labeled or color coded red to ensure that everyone knows the contents are hazardous. Containers for disposable sharps must have a lid, and they must be maintained upright to keep liquids and the sharps inside. Employees must never reach by hand into containers of contaminated sharps. Containers for reusable sharps could be equipped with wire basket liners for easy removal during reprocessing, or employees could use tongs or forceps to withdraw the contents. Reusable sharps disposal containers may not be opened, emptied, or cleaned manually. Containers need to be located as near to as feasible the area of use. In some cases, they may be placed on carts to prevent access to mentally disturbed or pediatric patients. Containers also should be available wherever sharps may be found, such as in laundries. The containers must be replaced routinely and not be overfilled, which can increase the risk of needlestick or cuts. HANDLING CONTAINERS When employees are ready to discard containers, they should first close the lids. If there is a chance of leakage from the primary container, the employees should use a secondary container that is closable, labeled, or color coded and leak resistant. Careful handing of sharps can prevent injury and reduce the risk of infection. By following these work practices, employees can decrease their chances of contracting bloodborne illness. This is one of a series of fact sheets that discuss various requirements of the Occupational Safety and Health Administrations standard covering exposure to bloodborne pathogens. Single copies of fact sheets are available from OSHA Publications, Room N-3103, 200 Constitution Avenue, N.W., Washington, D.C. 20210 and from OSHA regional offices. Hepatitis B Vaccination -- Protection For You WHAT IS HBV? Hepatitis B virus (HBV) is a potentially life-threatening bloodborne pathogen. Centers for Disease Control estimates there are approximately 280,000 HBV infections each year in the U.S. Approximately 8,700 health care workers each year contract hepatitis B, and about 200 will die as a result. In addition, some who contract HBV will become carriers, passing the disease on to others. Carriers also face a significantly higher risk for other liver ailments which can be fatal including cirrhosis of the liver and primary liver cancer. HBV infection is transmitted through exposure to blood and other infectious body fluids and tissues. Anyone with occupational exposure to blood is at risk of contracting the infection. Employers must provide engineering controls; workers must use work practices and protective clothing and equipment to prevent exposure to potentially infectious materials. However, the best defense against hepatitis B is vaccination. WHO NEEDS VACCINATION? The new OSHA standard covering bloodborne pathogens requires employers to offer the three injection vaccination series free to all employees who are exposed to blood or other potentially infectious materials as part of their job duties. This includes health care workers, emergency responders, morticians, first aid personnel, law enforcement officers, correctional facilities staff, launders, as well as others.  The vaccination must be offered within 10 days of initial assignment to a job where exposure to blood or other potentially infectious materials can be reasonably anticipated. The requirements for vaccinations of those already on the job take effect July 6, 1992. WHAT DOES VACCINATION INVOLVE? The hepatitis B vaccination is a noninfectious, yeast-based vaccine given in three injections in the arm. It is prepared from recombinant yeast cultures, rather than human blood or plasma. Thus, there is no risk of contamination from other bloodborne pathogens nor is there any chance of developing HBV from the vaccine. The second injection should be given one month after the first, and the third injection six months after the initial dose. More than 90 percent of those vaccinated will develop immunity to the hepatitis B virus. To ensure immunity, it is important for individuals to receive all three injections. At this point it is unclear how long the immunity lasts, so booster shots may be required at some point in the future. The vaccine causes no harm to those who are already immune or to those who may be HBV carriers. Although employees may opt to have their blood tested for antibodies to determine need for the vaccine, employers may not make such screening a condition of receiving vaccination nor are employers required to provide prescreening. Each employee should receive counseling from a health care professional when vaccination is offered. This discussion will help an employee determine whether inoculation is necessary. WHAT IF I DECLINE VACCINATION? Workers who decide to decline vaccination must complete a declination form. Employers must keep these forms on file so that they know the vaccination status of everyone who is exposed to blood. At any time after a worker initially declines to receive the vaccine, he or she may opt to take it. WHAT IF I AM EXPOSED BUT HAVE NOT YET BEEN VACCINATED? If a worker experiences an exposure incident, such as a needlestick or a blood splash in the eye, he or she must receive confidential medical evaluation from a licensed health care professional with appropriate follow-up. To the extent possible by law, the employer is to determine the source individual for HBV as well as human immunodeficiency virus (HIV) infectivity. The workers blood will also be screened if he or she agrees.  The health care professional is to follow the guidelines of the U.S. Public Health Service in providing treatment. This would include hepatitisB vaccination. The health care professional must give a written opinion on whether or not vaccination is recommended and whether the employee received it. Only this information is reported to the employer. Employee medical records must remain confidential. HIV or HBV status must NOT be reported to the employer. This is one of a series of fact sheets that discuss various requirements of the Occupational Safety and Health Administrations standard covering exposure to bloodborne pathogens. Single copies of fact sheets are available from OSHA Publications, Room N-3103, 200 Constitution Avenue, N.W., Washington, D.C. 20210 and from OSHA regional offices. Hepatitis C  Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) which is found in the blood of persons who have this disease. The infection is spread by contact with the blood of an infected person. Hepatitis C is serious for some persons, but not for others. A small number of persons die of liver failure shortly after getting hepatitis C. Most persons who get hepatitis C carry the virus for the rest of their lives. Most of these persons have some liver damage but many do not feel sick from the disease. Some persons with liver damage due to hepatitis C may develop cirrhosis (scarring) of the liver and liver failure which may take many years to develop. The hepatitis C virus is involved in most cases of parenterally transmitted non-A, non-B hepatitis in the United States. An estimated 2% to 4% of the HCV infections in the United States occurred among healthcare personnel who were occupationally exposed to blood (needlestick, punctures). There is no vaccine or post-exposure prophylaxis available for HCV, and immune globulin is not recommended after an exposure incident. Blood-testing is now available to test for detection of antibody to HCV (anti-HCV), although screening assays do not distinguish acute, chronic, or resolved infection. The Bloodborne Pathogens Standard requires that post-exposure evaluations, follow-up, and prophylaxis be provided according to the current recommendations of the U.S. Public Health Service (USPHS). The USPHS, Centers for Disease Control and Prevention (CDC) now recommend testing of the source and exposed individual for the presence of anti-HCV antibody after an exposure incident Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposure to HBV, HCV and HIV and Recommendations for Post Prophylaxis (June 29, 20001/50 (RRII); 1-42). The CDC stated that healthcare institutions should consider imple-menting recommended policies and procedures for follow-up for HCV infection after percutaneous or mucosal exposures to blood. At a minimum, such policies can include: (1) baseline testing of the source for anti-HCV; (2) baseline and follow-up testing (e.g., 6 months) for anti-HCV and alanine amino-transferase activity of the person exposed to an anti-HCV sero-positive source; (3) confirmation by supplemental anti-HCV testing of all anti-HCV results reported as repeatedly active by enzyme immuno-assay; (4) recommendation against post-exposure prophylaxis with immune globulin or antiviral agents (e.g., interferon); and (5) education of healthcare personnel about the risk for the prevention of bloodborne infections, including HCV, in occu-pational settings, with information routinely updated to ensure accuracy. Hepatitis C Fact Sheet SIGNS & SYMPTOMSjaundice fatigue dark urineabdominal pain loss of appetite nausea 80% of persons have no sign or symptoms. CAUSEHepatitis C Virus (HCV) LONG-TERM EFFECTSChronic infection: 75-85% of infected persons Chronic liver disease: 70% of chronically infected persons Deaths from chronic liver disease: <3 Leading indication for liver transplant  TRANSMISSIONOccurs when blood or body fluids from an infected person enters the body of a person who is not infected. HCV is spread through sharing needles or works when shooting drugs, through needlesticks or sharps exposure on the job, or from an infected mother to her baby during birth.  Persons at risk for HCV infection might also be at risk for infection with hepatitis B virus (HBV) or HIV. Recommendations for Testing Based on Risk for HCV infection *Anyone who wants to get tested should ask their doctor. RECOMMENDATIONS FOR TESTING BASED ON RISK FOR HCV INFECTIONPERSONSRISK OF INFECTIONTESTING RECOMMENDED?Injecting drug usersHighYesRecipients of clotting factors made before 1987HighYesHemodialysis patientsIntermediateYesRecipients of blood and/or solid organs before 1998IntermediateYesPeople with undiagnosed liver problemsIntermediateYesInfants born to infected mothersIntermediateAfter 12-18 months oldHealthcare/Public safety workersLowOnly after known exposurePeople having sex with multiple partnersLowNo*People having sex with an infected steady partnerLowNo* Hepatitis C Fact Sheet Page 2 PREVENTIONThere is no vaccine to prevent hepatitis C. Do not shoot drugs. If you shoot drugs, stop and get into a treatment program. If you cant stop, never share needles, syringes, water, or works, and get vaccinated against hepatitis A and B. Do not share personal care items that might have blood on them (razors, toothbrushes). If you are a healthcare or public safety worker, always follow routine barrier precautions and safely handle needles and sharps; get vaccinated against hepatitis B. Consider the risks if you are thinking about getting a tattoo or body piercing. You might get infected if the tools have someone elses blood on them or if the artist or piercer does not follow good health practices. HCV can be spread by sex, but this is very rare. If you are having sex with more than one steady sex partner, use condoms* correctly and every time to prevent the spread of sexually transmitted diseases. You should also get vaccinated against hepatitis B. If you are HCV positive, do not donate blood, organs, or tissue.  TREATMENT & MEDICAL MANAGEMENTHCV positive persons should be evaluated by their doctor for liver disease. Interferon and ribavirin are two drugs licensed for the treatment of persons with chronic hepatitis C. Interferon can be taken alone or in combination with ribavirin. Combination therapy is currently the treatment of choice. Combination therapy can get rid of the virus in up to 4 out of 10 persons. Drinking alcohol can make your liver disease worse.  STATISTICS & TRENDSNumber of new infections per year has declined from an average of 240,000 in the 1980s to about 40,000 in 1998. Most infections are due to illegal injection drug use. Transfusion-associated cases occurred prior to blood donor screening; now occurs in less than one per million transfused unit of blood. Estimated 3.9 million (1.8%) Americans have been infected with HCV, of whom 2.7 million are chronically infected.  *The efficacy of latex condoms in preventing infection with HCV is unknown, but their proper use may reduce transmission. Holding the Line on Contamination  Keeping work areas in a clean and sanitary condition reduces employees risk of exposure to bloodborne pathogens. Each year about 8,700 health care workers are infected with hepatitis B virus, and 200 die from contracting hepatitis B through their work. The chance of contracting human immunodeficiency virus (HIV), the bloodborne pathogen which causes AIDS, from occupational exposure is small, yet a good housekeeping program can minimize this risk as well. DECONTAMINATION Every employer whose employees are exposed to blood or other potentially infectious materials must develop a written schedule for cleaning each area where exposures occur. The methods of decontaminating different surfaces must be specified, determined by the type of surface to be cleaned, the soil present and the tasks or procedures that occur in that area. For example, different cleaning and decontam-ination measures would be used for a surgical operatory and a patient room. Similarly, hard surfaced flooring and carpeting require separate cleaning methods. More extensive efforts will be necessary for gross contamination than for minor spattering. Likewise, such varied tasks as laboratory analyses and normal patient care would require different techniques for clean-up. Employees must decontaminate working surfaces and equipment with an appropriate disinfectant after completing procedures involving exposure to blood. Many laboratory procedures are performed on a continual basis throughout a shift. Except as discussed below, it is not necessary to clean and decontaminate between procedures. However, if the employee leaves the area for a period of time, for a break or lunch, then contaminated work surfaces must be cleaned. Employees also must clean (1) when surfaces become obviously contaminated; (2) after any spill of blood or other potentially infectious materials; and (3)at the end of the work shift if contamination might have occurred. Thus, employees need not decontaminate the work area after each patient care procedure, but only after those that actually result in contamination. If surfaces or equipment are draped with protective coverings such as plastic wrap or aluminum foil, these coverings should be removed or replaced if they become obviously contaminated. Reusable receptacles such as bins, pails and cans that are likely to become contaminated must be inspected and decontaminated on a regular basis. If contamination is visible, workers must clean and decontaminate the item immediately, or as soon as feasible. Should glassware that may be potentially con-taminated break, workers need to use mechanical means such as a brush and dustpan or tongs or forceps to pick up the broken glass - never by hand, even when wearing gloves. Before any equipment is serviced or shipped for repairing or cleaning, it must be decontaminated to the extent possible. The equipment must be labeled, indicating which portions are still contaminated. This enables employees and those who service the equipment to take appropriate precautions to prevent exposure. REGULATED WASTE In addition to effective decontamination of work areas, proper handling of regulated waste is essential to prevent unnecessary exposure to blood and other potentially infectious materials. Regulated waste must be handled with great care -- i.e., liquid or semi-liquid blood and other potentially infectious materials, items caked with these materials if compressed, pathological or microbiological wastes containing them and contaminated sharps. Containers used to store regulated waste must be closable and suitable to contain the contents and prevent leakage of fluids. Containers designed for sharps also must be puncture resistant. They must be labeled or color-coded to ensure that employees are aware of the potential hazards. Such containers must be closed before removal to prevent the contents from spilling. If the outside of a container becomes contaminated, it must be placed within a second suitable container. Regulated waste must be disposed of in accordance with applicable state and local laws. LAUNDRY Laundry workers must wear gloves and handle contaminated laundry as little as possible, with a minimum of agitation. Contaminated laundry should be bagged or placed in containers at the location where it is used, but not sorted or rinsed there.  Laundry must be transported within the establishment or to outside laundries in labeled or red color-coded bags. If the facility uses Universal Precautions for handling all soiled laundry, then alternate labeling or color-coding that can be recognized by the employees may be used. If laundry is wet and it might soak through laundry bags, then workers must use bags that prevent leakage to transport it. RESEARCH FACILITIES? More stringent decontamination requirements apply to research laboratories and production facilities that work with concentrated strains of HIV and HBV. This is one of a series of fact sheets that discuss various requirements of the Occupational Safety and Health Administrations standard covering exposure to bloodborne pathogens. Single copies of fact sheets are available from OSHA Publications, Room N-3103, 200 Constitution Avenue, N.W., Washington, D.C. 20210 and from OSHA regional offices. CLEANING SCHEDULE AREASCHEDULED CLEANING (DAY/TIME)CLEANERS & DISINFECTANTS USED SPECIFIC INSTRUCTIONS  RECOMBIVAX HB HEPATITIS B VACCINE (RECOMBINANT) DESCRIPTION RECOMBIVAX HB Hepatitis B Vaccine (Recombinant) is a non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells. A portion of the hepatitis B virus gene, coding for HBsAg, is cloned into yeast, and the vaccine for hepatitis B is produced from cultures of this recombinant yeast strain according to methods developed in the Merck Research Laboratories. The antigen is harvested and purified from fermentation cultures of a recombinant strain of the yeast Saccharomyces cerevisiae containing the gene for the adw subtype of HBsAg. The fermentation process involves growth of Saccharomyces cerevisiae on a complex fermentation medium which consists of an extract of yeast, soy peptone, dextrose, amino acids and mineral salts. The HBsAg protein is released from the yeast cells by cell disruption and purified by a series of physical and chemical methods. The purified protein is treated in phosphate buffer with formaldehyde and then coprecipitated with alum (potassium aluminum sulfate) to form bulk vaccine adjuvanted with amorphous aluminum hydroxyphosphate sulfate. The vaccine contains no detectable yeast DNA but may contain not more than 1% yeast protein. The vaccine produced by the Merck method has been shown to be comparable to the plasma-derived vaccine in terms of animal potency (mouse, monkey, and chimpanzee) and protective efficacy (chimpanzee and human). The vaccine against hepatitis B, prepared from recombinant yeast cultures, is free of association with human blood or blood products. Each lot of hepatitis B vaccine is tested for safety, in mice and guinea pigs, and for sterility. RECOMBIVAX HB is a sterile suspension for intramuscular injection. However, for persons at risk of hemorrhage following intramuscular injection, the vaccine may be administered subcutaneously. (See DOSAGE AND ADMINISTRATION.) RECOMBIVAX HB Hepatitis B Vaccine (Recombinant) is supplied in three formulations. (See HOW SUPPLIED.) Pediatric/Adolescent Formulation (With and Without Preservative), 10 mcg/mL: each 0.5 mL dose contains 5 mcg of hepatitis B surface antigen. Adult Formulation (With and Without Preservative), 10 mcg/mL: each 1 mL dose contains 10 mcg of hepatitis B surface antigen. Dialysis Formulation, (With and Without Preservative), 40 mcg/mL: each 1 mL dose contains 40 mcg of hepatitis B surface antigen. Formulations that contain a preservative include thimersoal, a mercury derivative, at 1:20,000 or 50 mcg/mL. All formulations contain approximately 0.5 mg of aluminum (provided as amorphous aluminum hydroxyphosphate sulfate, previously referred to as aluminum hydroxide) per mL of vaccine. In each formulation, hepatitis B surface antigen is absorbed onto approximately 0.5 mg of aluminum (provided as amorphous aluminum hydroxyphosphate sulfate) per mL of vaccine. The vaccine is of the adw subtype. RECOMBIVAX HB is indicated for vaccination of persons at risk of infection from hepatitis B virus including all known subtypes. RECOMBIVAX HB Dialysis Formulation is indicated for vaccination of adult predialysis and dialysis patients against infection caused by all known subtypes of hepatitis B virus. CLINICAL PHARMACOLOGY Hepatitis B virus is one of several hepatitis viruses that cause a systemic infection, with a major pathology in the liver. These include hepatitis A virus, hepatitis D virus, and hepatitis C and E viruses, previously referred to as non-A, non-B hepatitis viruses. Hepatitis B virus is an important cause of viral hepatitis. There is no specific treatment for this disease. The incubation period for hepatitis B is relatively long; six weeks to six months may elapse between exposure and the onset of clinical symptoms. The prognosis following infection with hepatitis B virus is variable and dependent on at least three factors: (1) Age Infants and younger children usually experience milder initial disease than older persons;1 (2) Dose of Virus The higher the dose, the more likely acute icteric hepatitis B will result;1 and, (3)Severity of associated underlying disease Underlying malignancy or pre-existing hepatic disease predisposes to increased morbidity and mortality.1 Persistence of viral infection (the chronic hepatitis B virus carrier state) occurs in 5-10% of persons following acute hepatitis B, and occurs more frequently after initial anicteric hepatitis B than after initial icteric disease. Consequently, carriers of hepatitis B surface antigen (HBsAg) frequently give no history of having had recognized acute hepatitis. The Centers for Disease Control and Prevention (CDC) estimates that there are more than 300 million chronic carriers worldwide and 1.25 million chronic carriers of hepatitis B virus in the USA.29,30 Chronic carriers represent the largest human reservoir of hepatitis B virus. Serious complications and sequelae of hepatitis B virus infection include massive hepatic necrosis, cirrhosis of the liver, and chronic active hepatitis. More than one million people worldwide die each year of hepatitis B associated acute and chronic liver disease.34 In the United States, hepatitis B-virus-related acute and chronic liver disease causes approximately 4-5000 deaths annually.29,30 Reduced Risk of Hepatocellular Carcinoma Hepatocellular carcinoma is another serious complication of hepatitis B virus infection. Studies have demonstrated the link between chronic hepatitis B infection and hepatocellular carcinoma; 80% of primary liver cancers are caused by hepatitis B virus infection. The CDC has recognized hepatitis B vaccine as the first anti-cancer vaccine because it can prevent primary liver cancer.35 There is also evidence that several diseases other than hepatitis have been associated with hepatitis B virus infection through an immunologic mechanism involving antigen-antibody complexes. Such diseases include a syndrome with rash, urticaria, and arthralgia resembling serum sickness; periarteritis nodosa; membranous glomerulonephritis; and infantile papular acrodermatilis.3,4 Although the vehicles for transmission of the virus are often blood and blood products, viral antigen has also been found in tears, saliva, breast milk, urine, semen and vaginal secretions. Hepatitis B virus is capable of surviving at least a month29 on environmental surfaces exposed to infected body fluids containing hepatitis B virus. Infection may occur when hepatitis B virus, transmitted by infected body fluids, is implanted via mucous surfaces or percutaneously introduced through accidental or deliberate breaks in the skin. Transmission of hepatitis B virus infection is often associated with close interpersonal contact with an infected individual and with crowded living conditions. In such circumstances, transmission by inoculation via routes other than overt percutaneous ones may be quite common.1 Perinatal transmission of hepatitis B infection from infected mother to child, at or shortly after birth, can occur if the mother is a hepatitis B surface antigen (HBsAg) carrier or if the mother has an acute hepatitis B infection in the third trimester. Infection in infancy by the hepatitis B virus usually leads to the chronic carrier state. Without prophylaxis, infants born to women whose sera are positive for both the hepatitis B surface antigen and the e antigen have an 85-90% likelihood of being infected and becoming a chronic carrier.5,6 Well-controlled studies have shown that administration of three 0.5 mL doses of Hepatitis B Immune Globulin (Human) HBIG starting at birth is 75% effective in preventing establishment of the chronic carrier state in these infants during the first year of life.6 However, the protective effect of HBIG is transient. Hepatitis B is endemic throughout the world and is a serious medical problem in population groups at increased risk. Because vaccination limited to high-risk individuals has failed to substantially lower the overall incidence of hepatitis B infection, both the Advisory Committee on Immunization Practices (ACIP) and the Committee on Infectious Diseases of the American Academy of Pediatrics (AAP) have also endorsed universal infant immunization as part of a comprehensive strategy for the control of hepatitis B infection.7,8 In addition, the ACIP also recommends hepatitis B vaccination for all infants and children born after November 21, 1991 and catch-up vaccination of children at high risk of infection (children <11 years of age in households of Pacific Islander ethnicity or of first generation immigrants/refugees from countries with an intermediate or high endemicity of infection).30 These advisory groups further recommend broad-based vaccination of adolescents. The ACIP recommends that all individuals not previously vaccinated with hepatitis B vaccine be vaccinated at 11-12 years of age with the age-appropriate dose of vaccine and that the vaccination schedule take into account the feasibility of delivering three doses of vaccine to this age group. In addition, older unvaccinated adolescents with identified risk factors for hepatitis B virus infection should also be vaccinated.30 Similarly, the AAP recommends that universal immunization of all adolescents should be implemented when resources permit with emphasis on those individuals in high-risk settings.8 A National Institutes of Health Consensus Development Conference Panel on the management of hepatitis C recommends the immunization of all hepatitis C virus (HCV) positive individuals with hepatitis B vaccine.36 (Refer to INDICATIONS AND USAGE). Numerous epidemiological studies have shown that persons who develop anti-HBs following active infection with the hepatitis B virus are protected against the disease on re-exposure to the virus.9 Clinical studies have shown that RECOMBIVAX HB when injected into the deltoid muscle induced protective levels of antibody in 96% of 1,213 health adults who received the recommended 3-dose regimen. Antibody responses varied with age; a protective level of antibody was induced in 98% of 787 young adults 20-29 years of age, 94% of 249 adults 30-39 years of age and in 89% of 177 adults >40 years of age.10 Studies with hepatitis B vaccine derived from plasma have shown that a lower response rate (81%) to vaccine may be obtained if the vaccine is administered as a buttock injection.11 Seroconversion rates and geometric mean antibody titers were measured 1 to 2 months after the third dose. Multiple clinical studies have defined a protective antibody (anti-HBs) level as 1) 10 or more sample ratio units (SRU) as determined by radioimmunoassay or 2) a positive result as determined by enzyme immunoassay.2 Note: 10 SRU is comparable to 10 mIU/mL of antibody.12,13,14,15 RECOMBIVAX HB was shown to be highly immunogenic in clinical studies involving infants, children and adolescents. Three 5 mcg doses of vaccine induced a protective level of antibody in 100% of 92 infants, 99% of 129 children, and in 99% of 112 adolescents10 (see DOSAGE AND ADMINISTRATION). The protective efficacy of three 5 mcg doses of RECOMBIVAX HB has been demonstrated in neonates born of mothers positive for both HBsAg and HBeAg (a core-associated antigenic complex which correlates with high infectivity). In a clinical study of infants who received one dose of HBIG at birth followed by the recommended three-dose regimen of RECOMBIVAX HB, chronic infection had not occurred in 96% of 130 infants after nine months of follow-up.16 The estimated efficacy in prevention of chronic hepatitis B infection was 95% as compared to the infection rate in untreated historical controls.17 Significantly fewer neonates became chronically infected when given one dose of HBIG at birth followed by the recommended three-dose regimen of RECOMBIVAX HB when compared to historical controls who received only a single dose of HBIG.8 Testing for HBsAg and anti-HBs is recommended at 12-15 months of age. If HBsAg is not detectable, and anti-HBs is present, the child has been protected. As demonstrated in the above study, HBIG, when administered simultaneously with RECOMBIVAX HB at separate body sites, did not interfere with the induction of protective antibodies against hepatitis B virus elicited by the vaccine. For adolescents (11 through 15 years of age), the immunogenicity of a two-dose regimen (10 mcg at 0 and 4-6 months) was compared with that of the standard three-dose regimen (5 mcg at 0.1, and 6 months) in an open, randomized, multicenter study. The proportion of adolescents receiving the two-dose regimen who developed a protective level of antibody one month after the last dose (99% of 255 subjects) appears similar to that among adolescents who received the three-dose regimen (98% of 121 subjects). After adolescents (11 through 15 years of age) received the first 10-mcg dose of the two-dose regimen, the proportion who developed a protective level of antibody was approximately 72%.10 In one published study, the seroprotection rates in individuals with chronic HCV infection given the standard regimen of RECOMBIVAC HB was approximately 70%.37 In a second published study of intravenous drug users given an accelerated schedule of RECOMBIVAX HB, infection with HCV did not affect the response to RECOMBIVAX HB.35 As with other hepatitis B vaccines, the duration of the protective effect of RECOMBIVAX HB in healthy vaccines is unknown at present, and the need for booster doses is not yet defined. However, long-term follow-up (5 to 9 years) of approximately 3,000 high-risk vaccines (infants of carrier mothers, male homosexuals, Alaskan Natives) who developed an anti-HBs titer of >10 mIU/mL when given a similar plasma-derived vaccine at intervals of 0, 1, and 6 months showed that no subjects developed clinically apparent hepatitis B infection and that 5 subjects developed antigenemia, even though up to half of the subjects failed to maintain a titer at this level.18-21 Persistence of vaccine-induced immunologic memory among healthy vaccines who responded to a primary course of plasma-derived or recombinant hepatitis B vaccine has been demonstrated by an anamnestic antibody response to a booster dose of RECOMBIVAX HB given 5-12 years later.22 Predialysis and Dialysis Patients Predialysis and dialysis adult patients respond less well to hepatitis B vaccines than do healthy individuals; however, vaccination of adult patients early in the course of their renal disease produces higher seroconversion rates than vaccination after dialysis has been initiated.30 In addition, the responses to these vaccines may be lower if the vaccine is administered as a buttock injection. When 40 mcg of Hepatitis B Vaccine (Recombinant), was administered in the deltoid muscle, 89% of 28 participants developed anti-HBs with 86% achieving levels >10 mIU/mL. However, when the same dosage of this vaccine was administered inappropriately either in the buttock or a combination of buttock and deltoid, 62% of 47 participants developed anti-HBs with 55% achieving levels of >10 mlU/mL.10 A booster dose of revaccination with RECOMBIVAX HB Dialysis Formulation may be considered in predialysis/dialysis patients if the anti-HBs level is less than 10 mlU/mL.23 Reports in the literature describe a more virulent form of hepatitis B associated with superinfections or coinfections by delta virus, an incomplete RNA virus. Delta virus can only infect and cause illness in persons infected with hepatitis B virus since the delta agent requires a coat of HBsAg in order to become infectious. Therefore, persons immune to hepatitis B virus infection should also be immune to delta virus infection.2 Interchangeability of Plasma-Derived and Recombinant Hepatitis B Vaccines Although there have been no clinical studies in which a three-dose vaccine series was initiated with HEPTAVAX-B (Hepatitis B Vaccine) and completed with RECOMBIVAX HB, or vice versa, extensive in vitro and in vivo studies have demonstrated that these two vaccines are immunologically comparable.22,24-28 INDICATIONS AND USAGE RECOMBIVAX HB is indicated for vaccination against infection caused by all known subtypes of hepatitis B virus. RECOMBIVAX HB Dialysis Formulation is indicated for vaccination of adult predialysis and dialysis patients against infection caused by all known subtypes of hepatitis B virus. Vaccination with RECOMBIVAX HB is recommended for: 1) Infants including those born to HBsAg positive mothers (high-risk infants). 2) Children born after November 21, 1991.30 3) Adolescents (see CLINICAL PHARMACOLOGY). 4) Other persons of all ages in areas of high prevalence or those who are or may be at increased risk of infection with hepatitis B virus, such as:30 Health Care Personnel Dentists and oral surgeons. Physicians and surgeons. Nurses. Paramedical personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory personnel handling blood, blood products, and other patient specimens. Dental, medical and nursing students. Selected Patients and patient Contacts Staff in hemodialysis units and hematology/oncology units. Hemodialysis patients and patients with early renal failure before they require hemodialysis. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Sub-populations with a known high incidence of the disease, such as: Alaskan Natives. Pacific Islanders. Refugees from areas where hepatitis B virus infection is endemic. Adoptees from countries where hepatitis B virus infection is endemic. International Travelers Military Personnel Identified as being at increased risk Morticians and Embalmers Blood bank and plasma fractionation workers Persons at Increased Risk of the Disease Due to Their Sexual Practices, such as: Persons who have heterosexual activity with multiple partners. Persons who repeatedly contract sexually transmitted diseases. Homosexual and bisexual adolescent and adult men. Female Prostitutes. Prisoners Injection drug users Neither dosage strength will prevent hepatitis caused by other agents, such as hepatitis A virus, hepatitis C virus, hepatitis E virus or other viruses known to infect the liver. Revaccination See CLINICAL PHARMACOLOGY. Use with Other Vaccines Results from clinical studies indicate that RECOMBIVAX HB can be administered concomitantly with DTP (Diphtheria, Tetanus and whole cell Pertussis), OPV (oral Poliomyelitis vaccine), M-M-R* II (Measles, Mumps, and Rubella Virus Vaccine Live), Liquid PedvaxHIB* [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] or a booster dose of DTaP [Diphtheria, Tetanus, acellular Pertussis], using separate sites and syringes for injectable vaccines. No impairment of immune response to individually tested vaccine antigens was demonstrated. The type, frequency and severity of adverse experiences observed in these studies with RECOMBIVAX HB were similar to those seen when the other vaccines were given alone. In addition, and HBsAg-containing product, COMVAX [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine] was given concomitantly with eIPV (enhanced inactivated Poliovirus vaccine) or VARIVAX [Varicella Virus Vaccine Live (Oka/Merck)], using separate sites and syringes for injectable vaccines. No impairment of immune response to these individually tested vaccine antigens was demonstrated. No serious vaccine-related adverse events were reported. COMVAX has also been administered concomitantly with the primary series of DTaP to a limited number of infants. No serious vaccine-related adverse events were reported.10 Separate sites and syringes should be used for simultaneous administration of injectable viruses. CONTRAINDICATIONS Hypersensitivity to yeast or any component of the vaccine. WARNINGS Patients who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine (see CONTRAINDICATIONS). Because of the long incubation period for hepatitis B, it is possible for unrecognized infection to be present at the time the vaccine is given. The vaccine may not prevent hepatitis B in such patients. PRECAUTIONS General As with any percutaneous vaccine, epinephrine (1:1000) should be available for immediate use should an anaphyslactoid reaction occur. Any serious active infection including febrile illness is reason for delaying use of the vaccine except when in the opinion of the physician, withholding the vaccine entails a greater risk. Caution and appropriate care should be exercised in administering the vaccine to individuals with severely compromised cardiopulmonary status or to others in whom a febrile or systemic reaction could pose a significant risk. Instructions to Healthcare Provider The healthcare provider should determine the current health status and previous vaccination history of the vaccinee. The healthcare provider should question the patient, parent or guardian about reactions to a previous dose of RECOMBIVAX HB or other hepatitis B vaccines. The healthcare provider must record in the patients permanent record: the manufacturer, lot number, date of administration, and the name and address of the person administering the vaccine. Injection of a blood vessel should be avoided. Information for Vaccine Recipients and Parents/Guardians The healthcare provider should provide the vaccine information required to be given with each vaccination to the patient, parent or guardian. The healthcare provider should inform the patient, parent or guardian of the benefits and risks associated with vaccination, as well as the importance of completing the immunization series. For risks associated with vaccination, see WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS. Patients, parents and guardians should be instructed to report any serious adverse reactions to their healthcare provider, who in turn should report such events to the U.S. Department of Health and Human Services through the Vaccine Adverse Event Reporting System (VAERS), 1-800-822-7967.32 The healthcare provider should inform the parent or guardian of the National Vaccine Injury Compensation Program (NVICP), 1-888-338-2382 or  HYPERLINK http://www.hrsa.dhhs.gov/bhpr/vicp http://www.hrsa.dhhs.gov/bhpr/vicp. Drug Interactions There are no known drug interactions. (See INDICATIONS AND USAGE, Use with Other Vaccines.) Carcinogenesis, Mutagenesis, Impairment of Fertility RECOMBIVAX HB has not been evaluated for its carcinogenic or mutagenic potential, or its potential to impair fertility. Pregnancy Pregnancy Category C: Animal reproduction studies have not been conducted with the vaccine. It is also not known whether the vaccine can cause fetal harm with administered to a pregnant woman or can affect reproduction capacity. The vaccine should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether the vaccine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when the vaccine is administered to a nursing woman. Pediatric use RECOMBIVAX HB has been shown to be usually well-tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well; maternally transferred antibodies do not interfere with the active immune response to the vaccine. See DOSAGE AND ADMINISTRATION for recommended pediatric dosage and for recommended dosage for infants born to HBsAg positive mothers. The safety and effectiveness of RECOMBIVAX HB Dialysis Formulation in children have not been established. Geriatric Use Clinical studies of RECOMBIVAX HB did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reports from the clinical literature indicate that hepatitis B vaccines are less immunogenic in adults aged 65 years or older than in younger individuals.33 No overall differences in safety were observed between these subjects and younger subjects. ADVERSE REACTIONS RECOMBIVAX HB and RECOMBIVAX HB Dialysis Formulation are generally well-tolerated. No serious adverse reactions attributable to the vaccine have been reported during the course of clinical trials. No adverse experiences were reported during clinical trials which could be related to changes in the titers of antibodies to yeast. As with any vaccine, there is the possibility that broad use of the vaccine could reveal adverse reactions not observed in clinical trials. In three clinical studies, 434 doses of REOMBIVAX HB, 5 mcg, were administered to 147 healthy infants and children (up to 10 years of age) who were monitored for 5 days after each dose. Injection site reactions and systemic complaints were reported following 0.2% and 10.4% of the injections, respectively. The most frequently reported systemic adverse reaction (>1% injections), in decreasing order of frequency, were irritability, fever (>101oF oral equivalent), diarrhea, fatigue/weakness, diminished appetite, and rhinitis.10 In a study that compared the three-dose regimen (5 mcg) with the two-dose regimen (10 mcg) of RECOMBIVAX HB in adolescents, the overall frequency of adverse reactions was generally similar. In a group of studies, 3,258 doses of RECOMBIVAX HB, 10 mcg, were administered to 1,252 healthy adults who were monitored for 5 days after each dose. Injection site reactions and systemic complaints were reported following 17% and 15% of the injections, respectively. The following adverse reactions were reported: Incidence Equal To or Greater Than 1% of Injections LOCAL REACTION (INJECTION SITE) Injection site reactions consisting principally of soreness, and including pain, tenderness, pruritus, erythema, ecchymosis, swelling, warmth, and nodule formation. BODY AS A WHOLE The most frequent systemic complaints include fatigue/weakness; headache; fever (>100oF); and malaise. DIGESTIVE SYSTEM Nausea and diarrhea RESPIRATORY SYSTEM Pharyngitis and upper respiratory infection Incidence Less Than 1% of Injections BODY AS A WHOLE Sweating; achiness; sensation of warmth; lightheadedness; chills; and flushing DIGESTIVE SYSTEM Vomiting; abnormal pains/cramps; dyspepsia; and diminished appetite RESPIRATORY SYSTEM Rhinitis; influenza; and cough NERVOUS SYSTEM Vertigo/dizziness; and paresthesia INTEGUMENTARY SYSTEM Pruritus; rash (non-specified); angioedema; and urticaria MUSCULOSKELETAL SYSTEM Arthralgia including monoarticular; myalgia; back pain; neck pain; shoulder pain; and neck stiffness HEMICILYMPHATIC SYSTEM Lymphadenopathy PSYCHIATRIC/BEHAVIORAL Insomnia/disturbed sleep SPECIAL SENSES Earache UROGENITAL SYSTEM Dysuria CARDIOVASCULAR SYSTEM Hypotension Marketed Experience The following additional adverse reactions have been reported with use of the marketed vaccine. In many instances, the relationship to the vaccine was unclear. Hypersensitivity Anaphylaxis and symptoms of immediate hypersensitivity reactions including rash, pruritus, urticaria, edema, angioedema, dyspnea, chest discomfort, bronchial spasm, palpitation or symptoms consistent with a hypotensive episode have been reported within the first few hours after vaccination. An apparent hypersensitivity syndrome (serum-sickness-like) of delayed onset have been reported days to weeks after vaccination, including: arthralgia/arthritis (usually transient), fever, and dermatologic reactions such as urticaria, erythema multiforme, ecchymoses and erythema nodosum (see WARNINGS and PRECAUTIONS). Digestive System Elevation of liver enzymes; constipation Nervous System Guillain-Barre Syndrome; multiple sclerosis; exacerbation of multiple sclerosis; myelitis including transverse myelitis; seizure; febrile seizure; peripheral neuropathy including Bells Palsy; radiculopathy; herpes zoster; migraine; muscle weakness; hypesthesia; encephalitis Integumentary System Stevens-Johnson Syndrome; alopecia; petechiae Musculoskeletal System Arthritis Hematologic Increased erythrocytes sedimentation rate; thrombocytopenia Immune System Systemic lupus erythematosus (SLE); lupus-like syndrome; vasculitis Psychiatric/Behavioral Irritability; agitation; somnolence Special Senses Optic neuritis; tinnitus; conjunctivitis; visual disturbances Cardiovascular System Syncope; tachycardia The following adverse reaction has been reported with another Hepatitis B Vaccine (Recombinant) but not with RECOMBIVAX HB; keratitis. Patients, parents and guardians should be instructed to report any serious adverse reactions to their healthcare provider, who in turn should report such events to the U.S. Department of Health and Human Services through the Vaccine Adverse Event Reporting System (VAERS), 1-800-822-7967.32 DOSAGE AND ADMINISTRATION Do not inject intravenously or intradermally. RECOMBIVAX HB Hepatitis B Vaccine (Recombinant) DIALYSIS FORMULATION [(40 mcg/mL) (WITH AND WITHOUT PRESERVATIVE)] IS INTENDED ONLY FOR ADULT PREDIALYSIS/DIALYSIS PATIENTS. RECOMBIVAX HB Hepatitis B Vaccine (Recombinant) PEDIATRIC/ADOLESCENT (WITH AND WITHOUT PRESERVATIVE) and ADULT FORMULATIONS (WITH AND WITHOUT PRESERVATIVE) ARE NOT INTENDED FOR USE IN PREDIALYSIS/DIALSYSIS PATIENTS. RECOMBIVAX HB Hepatitis B Vaccine (Recombinant) PEDIATRIC/ADOLESCENT FORMULATION (WITHOUT PRESERVATIVE) IS AVAILABLE FOR USE IN INDIVIDUALS FOR WHOM A THIMEROSAL-FREE VACCINE MAY BE DESIRED.31 Three-Dose Regimen The vaccination regimen for each population consists of 3 doses of vaccine given according to the following schedule: First dose: at elected date Second dose: 1 month later Third dose: 6 months after the first dose For infants born of mothers who are HBsAg positive or mothers of unknown HBsAg status, treatment recommendations are described in the subsection titled: Guidelines For Treatment of Infants Born of HBsAG Positive Mothers or Mothers of Unknown HBsAG Status. Two-Dose Regimen Adolescents (11 through 15 years of age) An alternate two-dose regimen is available for routine vaccination of adolescents (11 through 15 years of age). The regimen consists of two doses of vaccine (10 mcg) given according to the following schedule: First injection: at elected date Second injection: 4-6 months later Table 1 summarizes the dose and formulation of RECOMBIVAX HB for specific populations, regardless of the risk of infection with hepatitis B virus. Table 1 GroupDose/Regimen**FormulationColor CodeInfants, Children and Adolescents 0-18 years of age5 mcg (0.5 mL) 3 x 5 mcgPediatric/ AdolescentYellowAdolescents* 11 through 15 years of age10 mcg (1.0 mL) 2 x 10 mcgAdultGreenAdults >20 years of age10 mcg (1.0 mL) 3 x 10 mcgAdultGreenPredialysis and Dialysis Patients40 mcg (1.0 mL) 3 x 40 mcgDialysisBlue ** If the suggested formulation is not available, the appropriate dosage can be achieved from another formulation provided that the total volume of vaccine administered does not exceed 1 mL (see text above regarding use of the formulation without preservative). However, the Dialysis Formulation may be used only for adult predialysis/dialysis patients. * Adolescents (11 through 15 years of age) may receive either regimen, the 3 x 5 mcg (Pediatric/Adolescent Formulation) or the 2 x 10 mcg (Adult Formulation). ( See also recommendations for revaccination of predialysis and dialysis patients in DOSAGE AND ADMINISTRATION, Revaccination. RECOMBIVAX HB is for intramuscular injection. The deltoid muscle is the preferred site for intramuscular injection in adults. Data suggest that injections given in the buttocks frequently are given into fatty tissue instead of into muscle. Such injections have resulted in a lower seroconversion rate than was expected. The anterolateral thigh is the recommended site for intramuscular injection in infants and young children. For persons at risk of hemorrhage following intramuscular injection, RECOMBIVAX HB may be administered subcutaneously. However, when other aluminum-absorbed vaccines have been administered subcutaneously, an increased incidence of local reactions including subcutaneous nodules has been observed. Therefore, subcutaneous administration should be used only in persons (e.g. hemophiliacs) who are at risk of hemorrhage following intramuscular injections. The vaccine should be used as supplied; no dilution or reconstitution is necessary. The full recommended dose of the vaccine should be used. For All Formulations Without Preservative: Once the single-dose vial has been penetrated, the withdrawn vaccine should be used promptly, and the vial must be discarded. For All Formulations With and Without Preservative: Shake well before use. Thorough agitation at the time of administration is necessary to maintain suspension of the vaccine. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. After thorough agitation, the vaccine is a slightly opaque, white suspension. For Vials With and Without Preservative: Withdraw the recommended dose from the vial using a sterile needle and syringe free of preservatives, antiseptics, and detergents. It is important to use a separate sterile syringe and needle for each individual patient to prevent transmission of hepatitis and other infectious agents from one person to another. Needles should be disposed of properly and should not be recapped. Injection must be accomplished with a needle long enough to ensure intramuscular deposition of the vaccine. Guidelines For Treatment of Infants Born of HBsAg Positive Mothers or Mothers of Unknown HBsAg Status Each infant should receive three 5 mcg doses of RECOMBIVAX HB irrespective of the mothers HBsAg status (see Table 1). The ACIP recommends that if the mother is determined to be HBsAg positive within 7 days of delivery, the infant also should be given a dose of HBIG (0.5 mL) immediately. The first dose of RECOMBIVAX HB may be given at the same time as HBIG, but it should be administered in the opposite anterolateral thigh.7 Revaccination The duration of the protective effect of RECOMBIVAX HB in healthy vaccines is unknown at present and the need for booster doses is not yet defined (see CLINICAL PHARMACOLOGY). A booster dose or revaccination with RECOMBIVAX HB Dialysis Formulation (blue color code) may be considered in predialysis/dialysis patients if the anti-HBs level is less than 10 mlU/mL 1 to 2 months after the third dose.23 The ACIP recommends that the need for booster doses of vaccine should be assessed by annual antibody testing and a booster dose given when antibody levels decline to <10 mlU/mL.30 Known or Presumed Exposure to HBsAg There are no prospective studies directly testing the efficacy of a combination of HBIG and RECOMBIVAX HB in preventing clinical hepatitis B following percutaneous, ocular or mucous membrane exposure to hepatitis B virus. However, since most persons with such exposures (e.g., health-care workers) are candidates for RECOMBIVAX HB and since combined HBIG plus vaccine is more efficacious than HBIG alone in perinatal exposures, the following guidelines are recommended for persons who have been exposed to hepatitis B virus such as through (1) percutaneous (needlestick), ocular, mucous membrane exposure to blood known or presumed to contain HBsAg, (2) human bites by known presumed HBsAg carriers, that penetrate the skin, or (3)following intimate sexual contact with known or presumed HBsAg carriers. HBIG (0.06 mL/kg) should be given intramuscularly as soon as possible after exposure and within 24 hours if possible. RECOMBIVAX HB (see dosage recommendation) should be given intramuscularly at a separate site within 7 days of exposure and second and third doses given one and six months, respectively, after the first dose. HOW SUPPLIED PEDIATRIC/ADOLESCENT FORMULATION (PRESERVATIVE-FREE) No. 4980 RECOMBIVAX HB for use in infants, children, and adolescents is supplied as 5 mcg/0.5 mL of HBsAg in a 0.5 mL single-dose vial, color coded with a yellow cap and stripe on the vial labels and cartons and an orange banner on the vial labels and cartons stating Preservative Free, NDC 0006-4980-00. No. 4981 RECOMBIVAX HB for use in infants, children and adolescents is supplied as 5 mcg/0.5 mL of HBsAg in a 0.5 mL single-dose vial, in a box of 10 single-dose vials, color coded with a yellow cap and stripe on the vials labels and cartons and an orange banner on the vial labels and cartons stating Preservative Free. NDC 0006-4981-00. No. 4994 RECOMBIVAX HB for use in infants, children, and adolescents is supplied as 5 mcg/0.5 mL of HBsAg in a 0.5 mL pre-filled single-dose Luer-Lok** syringe in a box of 10 pre-filled single-dose syringes, color coded with a yellow plunger rod and stripe on the syringe labels and cartons and an orange banner on the syringe labels and cartons stating Preservative Free, NDC 0006-4994-41. PEDIATRIC/ADOLESCENT FORMULATION No. 4769 RECOMBIVAX HB for use in infants, children, and adolescents is supplied as 5 mcg/0.5 mL of HBsAg in a 0.5 mL single-dose vial, color coded with a yellow cap and stripe on the vial labels and cartons, NDC0006-4769-00. No. 4876 RECOMBIVAX HB for use in infants, children, and adolescents is supplied as 5 mcg/0.5 mL of HBsAg in a 0.5 mL single-dose vial, in a box of 10 single-dose vials, color coded with a yellow cap and stripe on the vial labels and cartons, NDC 0006-4876-00. ADULT FORMULATION (PRESERVATIVE FREE) No. 4995 RECOMBIVAX HB for use in adults and adolescents (11 through 15 years of age) is supplied as 10 mcg/mL of HBsAg in a 1 mL single-dose vial, color coded with a green cap and stripe on the vial labels and cartons and an orange banner on the vial labels and cartons stating Preservative Free, NDC 0006-4995-00. No. 4995 RECOMBIVAX HB for use in adults and adolescents (11 through 15 years of age) is supplied as 10 mcg/mL of HBsAg in a 1 mL single-dose vial, in a box of 10 single-dose vials, color coded with a green cap and stripe on the vial labels and cartons and an orange banner on the vial labels and cartons stating Preservative Free, NCD 0006-4995-41. ADULT FORMULATION No. 4775 RECOMBIVAX HB for use in adults and adolescents (11 through 15 years of age) is supplied as 10mcg/mL of HBsAg in a 1 mL single-dose vial, color coded with a green cap and stripe on the vial labels and cartons, NDC 0006-4775-00. No. 4773 RECOMBIVAX HB for use in adults and adolescents (11 through 15 years of age) is supplied as 10mcg/mL of HBsAg in a 3 mL multiple-dose vial, color coded with a green cap and stripe on the vial labels and cartons, NDC 0006-4773-00. No. 4872 RECOMBIVAX HB for use in adults and adolescents (11 through 15 years of age) is supplied as 10mcg/mL of HBsAg in a 1 mL single-dose vial, in a box of 10 single-dose vials, color coded with a green cap and stripe on the vial labels and cartons, NDC 0006-4872-00. No. 4873 RECOMBIVAX HB for use in adults and adolescents (11 through 15 years of age) is supplied as 10mcg/mL of HBsAg in a 3 mL multiple-dose vial, in a box of 10 multi-dose vials, color coded with a green cap and stripe on the vial labels and cartons, NDC 0006-4873-00. DIALYSIS FORMULATION (PRESERVATIVE FREE) No. 4992 RECOMBIVAX HB Dialysis Formulation is supplied as 40 mcg/mL of HBsAg in a 1 mL single-dose vial, color coded with a blue cap and stripe on the vial labels and cartons and an orange banner on the vial labels and cartons stating Preservative Free, NDC 0006-4992-00. DIALYSIS FORMULATION No. 4776 RECOMBIVAX HB Dialysis Formulation is supplied as 40 mcg/mL of HBsAg in a 1 mL single-dose vial, color coded with a blue cap and stripe on the vial labels and cartons, NDC 0006-4776-00. Storage Store vials and syringes at 2-8oC (36-46oF). Storage above or below the recommended temperature may reduce potency. Do not freeze since freezing destroys potency. REFERENCES 1. Robinson, W.S.: Hepatitis B Virus and the Delta Virus, in Principles and Practice of Infectious Diseases, G.L. Mandell; R.G. Douglas; J.E. Bennett (eds), vol. 2, New York, John Wiley & Sons, 1985, pp. 1002-1029. 2. Recommendation of the Immunization Practices Advisory Committee (ACIP): Protection against viral hepatitis, MMWR 39(RR-2): 5-22, Feb. 9, 1990. 3. Balisteri, W.F.: Viral Hepatitis, Unique aspects of infection during childhood, Consultant 24(4): 131-153 passlm, April 1984. 4. Robinson, W.S.: Hepatitis B Virus and Hepatitis Delta Virus in Principles and Practice of Infectious Diseases, G.L. Mandell, R.G. Douglas, and J.E. Bennett (eds), Churchill Livingstone, 1204-1231, 1990. 5. Stevens, C.E.; Toy, P.T.; Tong, M.J.; Taylor, P.E.; Vyas, G.N.; Nair, P.V.; Gudavalli, M.; Krugman, S.: Perinatal hepatitis B virus transmission in the United States, JAMA 253(12): 1740-1745, 1985. 6. Beasley, R.P.; Hwang, L.; Stevens, C.E.; Lin, C.; Hsieh, F.; Wang, K.; Sun, T.; Szmuness, W.; Efficacy of Hepatitis B Immune Globulin for prevention of Perinatal Transmission of the Hepatitis B Virus Carrier State: Final Report of a Randomized Double-Blind, Placebo-Controlled Trail, Hepatology 3: 135-141, 1983. 7. Recommendations of the Immunization Practices Advisory Committee (ACIP): Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination, MMWR 40(RR-13): 1-25, November 22, 1991 8. Universal Hepatitis B Immunization, Committee on Infectious Diseases, Pediatrics 89(4): 795-800, 1992. 9. Melnick, J.L.: Historical aspects of hepatitis B vaccine in Hepatitis B Vaccine Inserm Symposium No. 18, P. Maupas and P. Guesry (eds), Elsevier/North-Holland Biomedical Press, p. 23-31, 1981. 10. Data on file at Merck Research Laboratories. 11. Centers for Disease Control, Suboptimal response to hepatitis B vaccine given by injection in to the buttock. MMWR 34(8): 105-113, March 1, 1985. 12. Hadler, S.C., et al.: Long-term Immunogenicity and Efficacy of Hepatitis B Vaccine in Homosexual Men, NEJM 315(4): 209-214 (1986). 13. Szmuness, W.; Stevens, C.E.; Horley, H.J., et al.: Hepatitis B Vaccine, Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States, NEJM 303: 833-841, 1980. 14. Francis, D.P.; Hadler, S.C.; Thompson, S.E., et al.: The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control Multi-center Efficacy Trial among Homosexual Men. Ann. Int. Med. 97: 362-366, 1982. 15. Szmuness, W.; Stevens, C.E.; Horley, H.J., et al.: Hepatitis B vaccine in medical staff of hemodialysis units. Efficacy and subtype cross-protection, NEJM 307: 1481-1486, 1982. 16. Stevens, C.E.; Taylor, P.E.; Tong, M.J., et al.: Prevention of perinatal hepatitis B virus infection with hepatitis B immune globulin and hepatitis B vaccine. IN: Zuckerman, A.J. (ed.), Viral Hepatitis and Liver Diseases, Alan R. Liss, 1988, pp. 982-983. 17. Stevens, C.E.; Taylor, P.E.; Tong, M.J., et al.; Yeast-Recombinant Hepatitis B Vaccine, Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission, JAMA 257(19): 2612-2616, 1987. 18. Wainwright, R.B.; McMahon, B.J.; Bulkow, L.R., et al.: Duration of Immunogenicity and efficacy of hepatitisB vaccine in a Yupik Eskimo population, Preliminary Results of an 8-Year Study in Viral Hepatitis and Liver Disease, F.B. Hollinger, S.M. Lemon, and H. Margolis (eds), Williams & Wilkins, 762-766 1990. 19. Hadler, S.C.; Coleman, P.J.; OMalley, P., et al.: Evaluation of Long-Term Protection by Hepatitis B Vaccine for Seven to Nine Years in Homosexual Men in Viral Hepatitis and Liver Disease, F.B. Hollinger, S.M. Lemon, and H. Margolis (eds), Williams & Wilkins, 766-768, 1990. 20. Tong, M.J.; Stevens, C.E.; Taylor, P.E., et al.: Prevention of hepatitis B infection in infants born to HBsAg positive HBsAg carrier mothers in the United States. An Update, 1989, Progress in Hepatitis B Immunization, P. Coursaget and M.J. Tong (eds), Colloque INSERM/John Libbey Eurotext Ltd., Vol. 194, 339-345, 1990. 21. Hwang, L-Y.; Lee, C-Y.; and Beasley, R.P.: Five-Year Follow-up of HBV Vaccination with Plasma-derived Vaccine in Neonates: Evaluation of Immunogenicity and Efficacy Against Perinatal Transmission in Viral Hepatitis and Liver Disease, F.B. Hollinger, S.M. Lemon, and H. Margolis (eds), Williams & Wilkins, 759-761, 1980. 22. West, D.J.; Calandra, G.B.: Vaccine induced immunologic memory for hepatitis B surface antigen; implications for policy on booster vaccination, Vaccine, 14(11):1019-1027, 1996. 23. Recommendations of the Immunization Practices Advisory Committee (ACIP): Update on Hepatitis B Prevention. MMWR 36(23): 353-366, June 19, 1987. 24. Emini, E.A.; Ellis, R.W.; Miller, W.J.; McAleer, W.J.; Scolnick, E.M. and Gerety, R.J.: Production and immunological analysis of recombinant hepatitis B vaccine, J. of Infection, 13(Sup. A): 3-9, 1986. 25. Brown, S.E.; Stanley, C.; Howard, C.R.; Zuckerman, A.J.; Steward, M.W.: Antibody responses to recombinant and plasma derived hepatitis B vaccine, Brit. Med. J., 292:159-161, 1986. 26. Yamamoto, S.; Kuroki, T.; Kurai, K.; Lino, S.: Comparison of results for Phase I studies with recombinant and plasma-derived hepatitis B vaccines, and controlled study comparing intramuscular and subcutaneous injections of recombinant hepatitis B vaccine, J. of Infection, 13(Sup. A): 53-60, 1986. 27. Jilg, W.; Schmidt, M.; Zoulek, G.; Lorbeer, B.; Wilske, B.; Deinhardt, F.; Clinical evaluation of a recombinant hepatitis B vaccine, Lancet, 1174-1175, Nov. 24, 1984. 28. Schalm, S.W.; Heytink, R.A.; Kruining, H.; Bakker-Bendik, M.: Immunogenicity of recombinant yeast hepatitis B vaccine, Neth, J. Med. 29-28, 1986. 29. Centers for Disease Control: Epidemiology and prevention of vaccine-preventative diseases, W. Atkinson, L. Furphy, J. Gantt, M. Mayfield, G. Phyne (eds), chapter 9. 30. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Hepatitis B virus infection: a comprehensive strategy to eliminate transmission in the United States, 1996 update, MMWR (draft January 13, 1996). 31. Thimerosal in Vaccines: A Joint Statement of the American Academy of Pediatrics and the Public Health Service, MMWR 48(26): 563-565, July 09, 1999. 32. Vaccine Adverse Event Reporting System United States. MMWR 39(41): 730-733, October 19, 1990. 33. Zajac, B. A., West, D. J. McAleer, W. J. and Scolnick, E.M.: Overview of Clinical Studies with Hepatitis B Vaccine Made by Recombinant DNA, J. of Infection, 13 (Sup. A): 39-45, July 1986. 34. WHO Bulletin, Expanded Program on Immunization, Hepatitis B Vaccine - Making Global Progress. October, 1996. 35. Centers for Disease Control and Prevention, Federal Register, February 23, 1999. 64(35): 9044-9045. 36. National Institutes of Health, National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C, Hepatology. 26(Suppl. 1): 2S-10S. 1997. 37. Wiedmann, M.; Liebert, U.G.; Oesen. U.; Porst, H.; Wiese, M.; Schroader, S.; Halm, U.; Mossner, J.; Barr, F.; Decreased Immunogencity of recombiant hepatitis B vaccine in chronic hepatitis C, Hepatology, 31: 230-234, 2000. 38. Minniti, F.; Baldo, V.; Trivello, R.; Bricolo, R.; Di Furia, L.; Renzulli, G.; Chiaramonie, M.; Response to HBV vaccine in relation to anti-HCV and anti-HBc positivity: a study in intravenous drug addicts. Vaccine, 17: 3083-3085, 1999.  Syringes of RECOMBIVAX HB are also manufactured by: Evans Vaccines Ltd. Gaskill Road, Speke, Liverpool L24 9GR, England Issued July 2002 Printed in USA PRESCRIBING INFORMATION Engerix-B Hepatitis B Vaccine (Recombinant) DESCRIPTION Engerix-B [Hepatitis B Vaccine (Recombinant)] is a noninfectious recombinant DNA hepatitis B vaccine developed and manufactured by SmithKline Beecham Biologicals. It contains purified surface antigen of the virus obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus. The surface antigen expressed in Saccharomyces cerevisiae cells is purified by several physicochemical steps and formulated as a suspension of the antigen adsorbed on aluminum hydroxide. The procedures used to manufacture Engerix-B result in a product that contains no more than 5% yeast protein. No substances of human origin are used in its manufacture. Engerix-B is supplied as a sterile suspension for intramuscular administration. The vaccine is ready for use without reconstitution; it must be shaken before administration since a fine white deposit with a clear colorless supernatant may form on storage. Pediatric/Adolescent Each 0.5 mL of vaccine consists of 10 mcg of hepatitis B surface antigen adsorbed on 0.25 mg aluminum as aluminum hydroxide. The pediatric/adolescent vaccine is formulated without preservatives. The pediatric formulation contains a trace amount of thimerosal (<0.5 mcg mercury) from the manufacturing process, sodium chloride (9 mg/mL) and phosphate buffers (disodium phosphate dihydrate, 0.98 mg/mL; sodium dihydrogen phosphate dihydrate, 0.71 mg/mL). Adult Each 1 mL adult dose consists of 20 mcg of hepatitis B surface antigen adsorbed on 0.5 mg aluminum as aluminum hydroxide. The adult vaccine is formulated without preservatives. The adult formulation contains a trace amount of thimerosal (<1.0 mcg mercury) from the manufacturing process, sodium chloride (9 mg/mL) and phosphate buffers (disodium phosphate dihydrate, 0.98 mg/mL; sodium dihydrogen phosphate dihydrate, 0.71 mg/mL). CLINICAL PHARMACOLOGY Several hepatitis viruses are known to cause a systemic infection resulting in major pathologic changes in the liver (e.g., A,B,C,D,E,G). The estimated lifetime risk of HBV infection in the United States varies from almost.100% for the highest-risk groups to less than 20% for the population as a whole.1 Hepatitis B Infection Can have serious consequences including acute massive hepatic necrosis, chronic active hepatitis and cirrhosis of the liver. Up to 90% of neonates and 6 to 10% of adults who are infected in the United States will become hepatitis B virus carriers.1 It has been estimated that 200 to 300 million people in the world today are persistently infected with hepatitis B virus.1 The Centers for Disease Control (CDC) estimates that there are approximately 1 to 1.25 million chronic carriers of hepatitis B virus in the United States.1 Those patients who become chronic carriers can infect others and are at increased risk of developing primary hepatocellular carcinoma. Among other factors, infection with hepatitis B may be the single most important factor for development of this carcinoma.1.2 Reduced Risk of Hepatocellular Carcinoma: According to the CDC, the hepatitis B vaccine is recognized as the first anti-cancer vaccine because it can prevent primary liver cancer.3 A clear link has been demonstrated between chronic hepatitis B infection and the occurrence of hepatocellular carcinoma. In a Taiwanese study, the institution of universal childhood immunization against hepatitis B virus has been shown to decrease the incidence of hepatocellular carcinoma among children.4 In a Korean study in adult males, vaccination against hepatitis B virus has been shown to decrease the incidence of, and risk of, developing hepatocellular carcinoma in adults.5 Considering the serious consequences of infection, immunization should be considered for all persons at potential risk of exposure to the hepatitis B virus. Mothers infected with hepatitis B virus can infect their infants at, or shortly after, birth if they are carriers of the HBsAg antigen or develop an active infection during the third trimester of pregnancy. Infected infants usually become chronic carriers. Therefore, screening of pregnant women for hepatitis B is recommended.1 Because a vaccination strategy limited to high-risk individuals has failed to substantially lower the overall incidence of hepatitis B infection, the Advisory Committee on Immunization Practices (ACIP) recommends vaccination of all persons from birth to age 18.6 The Committee on Infectious Diseases of the American Academy of Pediatrics (AAP) has also endorsed universal infant immunization as part of a comprehensive strategy for the control of hepatitis B infection.7 The AAP, American Academy of Family Physicians (AAFP) and American Medical Association (AMA) also recommend routine vaccination of adolescents 11 to 12 years of age who have not been vaccinated previously.8 The AAP further recommends that providers administer hepatitis B vaccine to all previously unvaccinated adolescents.9 (See INDICATIONS AND USAGE.) There is no specific treatment for acute hepatitis B infection. However, those who develop anti-HBs antibodies after active infection are usually protected against subsequent infection. Antibody titers >10 mIU/mL against HBsAg are recognized as conferring protection against hepatitis B.1 Seroconversion is defined as antibody titers >1 mIU/mL. Protective Efficacy: Protective efficacy with Engerix-B [Hepatitis B Vaccine (Recombinant)] has been demonstrated in a clinical trial in neonates at high risk of hepatitis B infection.10,11 Fifty-eight neonates born of mothers who were both HBsAg and HBeAg positive were given Engerix-B (10 mcg at 0, 1 and 2 months) without concomitant hepatitis B immune globulin. Two infants became chronic carriers in the 12-month follow-up period after initial inoculation. Assuming an expected carrier rate of 70%, the protective efficacy rate against the chronic carrier state, during the first 12 months of life was 95%. Immunogenicity in Neonates: Immunization with 10 mcg at 0, 1 and 6 months of age produced seroconversion in 100% of infants by month 7 with a GMT of 713 mIU/mL (N=52), and the seroprotection rate was 97%. Clinical trials indicate that administration of hepatitis B immune globulin at birth does not alter the response to Engenx-B [Hepatitis B Vaccine (Reconmbinant)]. Immunization with 10 mcg at 0, 1 and 2 months of age produced a seroprotection rate of 96% in infants by month 4, with a GMT among seroconverters of 210 mIU/mL (N=311); an additional dose at month 12 produced a GMT among seroconverters of 2,941 mIU/mL at month 13 (N=126). Immunogenicity in Pediatric Patients: In clinical trials with 242 children ages 6 months to, and including, 10 years given 10 mcg at months 0, 1 and 6, the seroprotection rate was 98% 1 to 2 months after the third dose; the GMT of seroconverters was 4,023 mIU/mL. In a separate clinical trial including both children and adolescent aged 5 to 16 years, 10 mcg of Engerix-B was administered at 0, 1, and 6 months (N=181) or 0, 12, and 24 months (N=161). Immediately before the third dose of vaccine, seroprotection was achieved in 92.3% of subjects vaccinated on the 0, 1, 6-month schedule and 88.8% of subjects on the 0, 12, 24-month schedule (117.9 mIU/mL vs. 162.1 mIU/mL, respectively, p=0.18). One month following the third dose, seroprotection was achieved in 99.5% of children vaccinated on the 0, 1, 6-month schedule compared to 98.1% of those on the 0, 12, 24-month schedule. GMTs were higher (p=0.02) for children receiving vaccine on the 0, 1, 6-month schedule compared to those on the 0, 12, 24-month schedule (5,687.4 mIU/mL vs. 3,158.7 mIU/mL, respectively). The clinical relevance of this finding is unknown. Immunogenicity in Adolescents: In clinical trials with healthy adolescent subjects 11 through 19 years of age, immunization with 10 mcg using a 0, 1, 6-month schedule produced a seroprotection rate of 97% at month 8 (N=119) with a GMT of 1,989 mIU/mL (N=118, 95% confidence intervals=1,318-3,020). Immunization with 20 mcg using a 0, 1, 6-month schedule produced a seroprotection rate of 99% at month 8 (N=122) with a GMT of 7,672 mIU/mL (N=122, 95% confidence intervals=5,248-10,965). Immunogenicity in Healthy Adults and Adolescents: Clinical trials in healthy adult and adolescent subjects have shown that following a course of three doses of 20 mcg Engerix-B [Hepatitis B Vaccine (Recombinant)] given according to the ACIP recommended schedule of injections at months 0, 1 and 6, the seroprotection (antibody titers >10 mIU/mL) rate for all individuals was 79% at month 6 and 96% at month 7; the geometric mean antibody titer (GMT) for seroconverters at month 7 was 2,204 mIU/mL. On an alternate schedule (injections at months 0, 1 and 2) designed for certain populations (e.g., neonates born of hepatitis B infected mothers, individuals who have or might have been recently exposed to the virus, and certain travelers to high-risk areas. See INDICATIONS AND USAGE.), 99% of all individuals were seroprotected at month 3 and remained protected through month 12. On the alternate schedule, an additional dose at 12 months produced a GMT for seroconverters at month 13 of 9,163 mIU/mL. Immunogenicity in Older Subjects: Among older subjects given 20 mcg at months 0, 1 and 6, the seroprotection rate 1 month after the third dose was 88%. However, as with other hepatitis B. vaccines, in adults over 40 years of age, Engerix-B vaccine produced anti-HBs titers that were lower than those in younger adults (GMT among seroconverters 1 month after the third 20 mcg dose with a 0, 1, 6-month schedule: 610 mIU/mL for individuals over 40 years of age, N=50). Immunogenicity in Subjects with Chronic Hepatitis C: In a clinical trial of subjects with chronic hepatitis C, 31 subjects received Engerix-B on the usual 0, 1, 6-month schedule. All subjects responded with seroprotective titers. The GMT of anti-HBs was 1,260 mIU/mL (95% CI:709-2237). Hemodialysis Patients: Hemodialysis patients given hepatitis B vaccines respond with lower titers,12 which remain at protective levels for shorter durations than in normal subjects. In a study in which patients on chronic hemodialysis (mean time on dialysis was 24 months; N=562) received 40 mcg of the plasma-derived vaccine at months 0, 1 and 6, approximately 50% of patients achieved antibody titers >10 mIU/mL.12 Since a fourth dose of Engerix-B [Hepatitis B Vaccine (Recombinant)] given to healthy adults at month 12 following the 0, 1, 2-month schedule resulted in a substantial increase in the GMT (see above), a four-dose regimen was studied in hemodialysis patients. In a clinical trial of adults who had been on hemodialysis for a mean of 56 month (N=43), 67% of patients were seroprotected 2 months after the last dose of 40 mcg of Engerix-B (two x 20 mcg) given on a 0, 1, 2, 6-month schedule; the GMT among seroconverters was 93 mIU/mL. Interchangeability with Other Hepatitis B Vaccines: Recombinant DNA vaccines are produced in yeast by expression of a hepatitis B virus gene sequence that codes for the hepatitis B surface antigen. Like plasma-derived vaccine, the yeast-derived vaccines are protein particles visible by electron microscopy and have hepatitis B surface antigen epitopes as determined by monoclonal antibody analyses. Yeast-derived vaccines have been shown by in vitro analyses to induce antibodies (anti-HBs) which are immunologically comparable by epitope specificity and binding affinity to antibodies induced by plasma-derived vaccine.13 In cross absorption studies, no differences were detected in the spectra of antibodies induced in man to plasma-derived or to yeast-derived hepatitis B vaccines.13 Additionally, patients immunized approximately 3 years previously with plasma-derived vaccine and whose antibody titers were <100 mIU/mL (GMT: 35 mIU/mL; range: 9-94) were given a 20 mcg dose of Engerix-B [Hepatitis B Vaccine (Recombinant)]. All patients, including two who had not responded to the plasma-derived vaccine, showed a response to Engerix-B (GMT: 5,069 mIU/mL; range: 624-15,019). There have been no clinical studies in which a three-dose vaccine series was initiated with a plasma-derived hepatitis B vaccine and completed with Engerix-B, or vice versa. However, because the in vitro and in vivo studies described above indicate the comparability of the antibody produced in response to plasma-derived vaccine and Engerix-B, it should be possible to interchange the use of Engerix-B and plasma-derived vaccines (but see CONTRAINDICATIONS). A controlled study (N=48) demonstrated that completion of a course of immunization with one dose of Engerix-B (20 mcg, month 6) following two doses of Recombivax HB* (10 mcg, months 0 and 1) produced a similar GMT (4,077 mIU/mL) to immunization with three doses of Recombivax HB (10 mcg, months 0, 1 and 6; 2,654 mIU/mL). Thus, Engerix-B can be used to complete a vaccination course initiated with Recombivax HB.14 Other Clinical Studies: In one study,15 four of 244 (1.6%) adults (homosexual men) at high risk of contracting hepatitis B virus became infected during the period prior to completion of three doses of Engerix-B (20 mcg at 0, 1, 6 months). No additional patients became infected during the 18-month follow-up period after completion of the immunization course. INDICATIONS AND USAGE Engerix-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) do s not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by Engerix-B vaccination. Engerix-B will not prevent hepatitis caused by other agents, such as hepatitis A, C and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus,1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Health Care Personnel: Dentists and oral surgeons. Dental, medical and nursing students. Physicians, surgeons and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood-bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle-cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations with a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals with Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitisC. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices,1,16 such as: Persons with more than one sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity. Use with Other Vaccines: The Immunization Practices Advisory Committee states that, in general, simultaneous administration of certain live and inactivated pediatric vaccines has not resulted in impaired antibody responses or increased rates of adverse reactions.17 Separate sites and syringes should be used for simultaneous administration of injectable vaccines. CONTRAINDICATIONS Hypersensitivity to yeast or any other component of the vaccine .is a contraindication for use of the vaccine. Patients experiencing hypersensitivity after Engerix-B [Hepatitis B Vaccine (Recombinant)] injection should not receive further injections of Engerix-B. WARNINGS Hepatitis B has a long incubation period. Hepatitis B vaccination may not prevent hepatitis B infection in individuals who had an unrecognized hepatitis B infection at the time of vaccine administration. Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers. PRECAUTIONS General As with other vaccines, although a moderate or severe febrile illness is sufficient reason to postpone vaccination, minor illnesses such as mild upper respiratory infections with or without low-grade fever are not contraindications.17 Prior to immunization, the patient's medical history should be reviewed. The physician should review the patient's immunization history for possible vaccine sensitivity, previous vaccination-related adverse reactions and occurrence of any adverse-event-related symptoms and/or signs, in order to determine the existence of any contraindication to immunization with Engerix-B and to allow at assessment of benefits and risks. Epinephrine injection (1:1000) and other appropriate agents used for the control of immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur. A separate sterile syringe and needle or a sterile disposable unit should be used for each individual patient to prevent transmission of hepatitis or other infectious agents from one person to another. Needles should be disposed of properly and should not be recapped. Special care should be taken to prevent injection into a blood vessel. As with any vaccine administered to immunosuppressed persons or persons receiving immunosuppressive therapy, the expected immune response may not be obtained. For individuals receiving immunosuppressive therapy, deferral of vaccination for at least 3 months after therapy may be considered.l Multiple Sclerosis: Although no causal relationship has been established, rare instances of exacerbation of multiple sclerosis have been reported following administration of hepatitis B vaccines and other vaccines. In persons with multiple sclerosis, the benefit of immunization for prevention of hepatitis B infection and sequelae must be weighed against the risk of exacerbation of the disease. Information for the Patient Patients, parents or guardians should be informed of the potential benefits and risks of the vaccine, and of the importance of completing the immunization series. As with any vaccine, it is important when a subject returns for the next dose in a series that he/she be questioned concerning occurrence of any symptoms and/or signs of an adverse reaction after a previous dose of the same vaccine. Patients, parents or guardians should be told to report severe or unusual adverse reactions to their healthcare provider. The parent or guardian should be given the Vaccine Information Materials, which are required by the National Childhood Vaccine Injury Act of 1986 to be given prior to immunization. Drug Interactions For information regarding simultaneous administration with, other vaccines, refer to INDICATIONS AND USAGE. Carcinogenesis, Mutagenesis, Impairment of Fertility Engerix-B [Hepatitis B Vaccine (Recombinant)] has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility. Pregnancy Pregnancy Category C: Animal reproduction studies have not been conducted with Engerix-B. It is also not known whether Engerix-B can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Engerix-B should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether Engerix-B is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Engerix-B is administered to a nursing woman. Pediatric Use Engerix-B has been shown to be well tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well; maternally transferred antibodies do not interfere with the active immune response to the vaccine. (See CLINICAL PHARMACOLOGY for seroconversion rates and titers in neonates and children. See DOSAGE AND ADMINISTRATION for recommended pediatric dosage and for recommended dosage for infants born of HBsAg-positive mothers.) ADVERSE REACTIONS Engerix-B [Hepatitis B Vaccine (Recombinant)] is generally well tolerated. As with any vaccine, however, it is possible that expanded commercial use of the vaccine could reveal rare adverse reactions. Ten double-blind studies involving 2,252 subjects showed no significant difference in the frequency or severity of adverse experiences between Engerix-B and plasma-derived vaccines. In 36 clinical studies a total of 13,495 doses of Engerix-B were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers, and healthy neonates. All subjects were monitored for 4 days post-administration. Frequency of adverse experiences tended to decrease with successive doses of Engerix-B. Using a symptom checklist, the most frequently reported adverse reactions were injection site soreness (22%) and fatigue (14%). Other reactions are listed below. Incidence 1% to 10% of Injections Local reactions at injection site: Induration; erythema; swelling. Body as a whole: Fever (>37.5C). Nervous system: Headache; dizziness. Parent or guardian completed forms for children and neonate. Neonatal checklist did not include headache, fatigue or dizziness. Incidence <1 % of Injections Local reactions at injection site: Pain; pruritus; ecchymosis. Body as a whole: Sweating; malaise; chills; weakness; flushing; tingling. Cardiovascular system: Hypotension. Respiratory system: Influenza-like symptoms; upper respiratory tract illnesses. Gastrointestinal system: Nausea; anorexia; abdominal pain/cramps; vomiting; constipation; diarrhea. Lymphatic system: Lymphadenopathy. Musculoskeletal system: Pain/stiffness in arm, shoulder or neck; arthralgia; myalgia; back pain. Skin and appendages: Rash; urticaria; petechiae; pruritus; erythema. Nervous system: Somnolence; insomnia; irritability; agitation. Additional adverse experiences have been reported with the commercial use of Engerix-B. Those listed below are to serve as alerting information to physicians. Hypersensitivity: Anaphylaxis; erythema multiforme including Stevens-Johnson syndrome; angioedema; arthritis. An apparent hypersensitivity syndrome (serum-sickness-like) of delayed onset has been reported days to weeks after vaccination, including: arthralgia/arthritis (usually transient), fever and dermatologic reactions such as urticaria, erythema multiforme, ecchymoses and erythema nodosum (see CONTRAINDICATIONS). Cardiovascular system: Tachycardia/palpitations. Respiratory system: Bronchospasm including asthma-like symptoms. Gastrointestinal system: Abnormal liver function tests; dyspepsia. Nervous system: Migraine; syncope; paresis; neuropathy including hypoesthesia, paresthesia, Guillain-Barr syndrome and Bell's palsy, transverse myelitis; optic neuritis; multiple sclerosis; seizures. Hematologic: Thrombocytopenia. Skin and appendages: Eczema; purpura; herpes zoster; erythema nodosum; alopecia. Special senses: Conjunctivitis; keratitis; visual disturbances; vertigo; tinnitus; earache. Reporting Adverse Events The National Childhood Vaccine Injury Act requires that the manufacturer and lot number of the vaccine administered be recorded by the healthcare provider in the vaccine recipient's permanent medical record, along with the date of administration of the vaccine and the name, address and title of the person administering the vaccine.18 The Act further requires the healthcare provider to report to the U.S. Department of Health and Human Services via VAERS the occurrence following immunization of any event set forth in the Vaccine Injury Table including: anaphylaxis or anaphylactic shock within 4 hours, encephalopathy or encephalitis within 72 hours, or any sequelae thereof (including death).18,19 In addition, any event considered a contraindication to further doses should be reported. The VAERS toll-free number is 1-800-822-7967. DOSAGE AND ADMINISTRATION Injection: Engerix-B [Hepatitis B Vaccine (Recombinant)] should be administered by intramuscular injection. Do not inject intravenously or intradermally. In adults, the injection should be given in the deltoid region but it may be preferable to inject in the anterolateral thigh in neonates and infants, who have smaller deltoid muscles. Engerix-B should not be administered in the gluteal region; such injections may result in suboptimal response. The attending physician should determine final selection of the injection site and needle size, depending upon the patient's age and the size of the target muscle. A 1-inch 23-gauge needle is sufficient to penetrate the anterolateral thigh in infants younger than 12 months of age. A 5/8-inch 25-gauge needle may be used to administer the vaccine in the deltoid region of toddlers and children up to, and including, 10 years of age. The 1-inch 23-gauge needle is appropriate for use in older children and adults.17 Engerix-B may be administered subcutaneously to persons at risk of hemorrhage (e.g., hemophiliacs). However, hepatitis B vaccines administered subcutaneously are known to result in lower GMTs. Additionally, when other aluminum-adsorbed vaccines have been administered subcutaneously, an increased incidence of local reactions including subcutaneous nodules has been observed. Therefore, subcutaneous administration should be used only in persons who are at risk of hemorrhage with intramuscular injections. Preparation for Administration: Shake well before withdrawal and use. Parenteral drug products should be inspected visually for particulate matter or discoloration prior to administration. With thorough agitation, Engerix-B [Hepatitis B Vaccine (Recombinant)] is a slightly turbid white suspension. Discard if it appears otherwise. The vaccine should be used as supplied; no dilution is necessary. The full recommended dose of the vaccine should be used. Any vaccine remaining in a single-dose vial should be discarded. Dosage Schedules: The usual immunization regimen (see Table 1) consists of three doses of vaccine given according to the following schedule: 1st dose: at elected date; 2nd dose: 1 month later; 3rd dose: 6 months after first dose. Table 1. Recommended dosage and administration schedule GroupDoseScheduleInfants born of: HBsAg-negative mothers HBsAg-positive mothers 10 mcg/0.5 mL 10 mcg/0.5 mL 0, 1, 6 months 0, 1, 6 monthsChildren: Birth through 10 years of age 10 mcg/0.5 mL 0, 1, 6 monthsAdolescents: 11 through 19 years of age 10 mcg/0.5 mL 0, 1, 6 monthsAdults (>19 years)20 mcg/1.0 mL0, 1, 6 monthsAdult hemodialysis40 mcg/2.0 mLa0, 1, 2, 6 monthsa Two x 20 mcg in one or two injections. For hemodialysis patients, in whom vaccine-induced protection is less complete and may persist only as long as antibody levels remain above 10 mIU/mL, the need for booster doses should be assessed by annual antibody testing. 40 mcg (tw x 20 mcg) booster doses with Engerix-B should be given when antibody levels decline below 10 mIU/mL.1 Data show individuals given a booster with Engerix-B achieve high antibody titers. (See CLINICAL PHARMACOLOGY.) There are alternate dosing and administration schedules which may be used for specific populations (see Table 2 and accompanying explanations). Table 2. Alternate dosage and administration schedules GroupDoseScheduleInfants born of: HBsAg-positive mothers 10 mcg/0.5 mL 0, 1, 2, 12 monthsbChildren: Birth through 10 years of age 5 through 10 years of age 10 mcg/0.5 mL 10 mcg/0.5 mL 0, 1, 2, 12 monthsb 0, 12, 24 monthscAdolescents: 11 through 16 years of age 11 through 19 years of age 11 through 16 years of age 10 mcg/0.5 mL 20 mcg/1.0 mL 20 mcg/1.0 mL 0, 12, 24 monthsc 0, 1, 6 months 0, 1, 2, 12 monthsbAdults (>19 years)20 mcg/1.0 mL0, 1, 2, 12 monthsbb This schedule is designed for certain populations (e.g., neonates born of hepatitis B infected mothers, others who have or might have been recently exposed to the virus, certain travelers to high-risk areas. See INDICATIONS AN USAGE.). On this alternate schedule, an additional dose at 12 months is recommended for prolonged maintenance of protective titers. c For children and adolescents for whom an extended administration schedule is acceptable based on risk of exposure. booster vaccinations: Whenever administration of a booster dose is appropriate, the dose of Engerix-B is 10 mcg for children 10 years of age and under; 20 mcg for adolescents 11 through 19 years of age and 20 mcg for adults. Studies have demonstrated a substantial increase in antibody titers after Engerix-B [Hepatitis B Vaccine (Recombinant)] booster vaccination following an initial course with both plasma- and yeast-derived vaccines. (See CLINICAL PHARMACOLOGY.) See previous section for discussion on booster vaccination for adult hemodialysis patients. Known or presumed exposure to hepatitis B virus: Unprotected individuals with known or presumed exposure to the hepatitis B virus (e.g., neonates born of infected mothers, others experiencing percutaneous or permucosal exposure) should be given hepatitis B immune globulin (HBIG) in addition to Engerix-B [Hepatitis B Vaccine (Recombinant)] in accordance with ACIP recommendations1 and with the package insert for HBIG. Engerix.-B [Hepatitis B Vaccine (Recombinant)] can be given on either dosing schedule (see above). STORAGE Store refrigerated 2 and 8C (36 and 46P). Do not freeze; discard if product has been frozen. Do not dilute to administer. HOW SUPPLIED Engerix-B [Hepatitis B Vaccine (Recombinant)] is supplied as a slightly turbid white suspension in vials and prefilled Tip-Lok syringes. Adult Dose 20 mcg/mL in Single-Dose Vials in packages of 1 and 25 vials. NDC 58160-857-01 (package of 1) NDC 58160-857-16 (package of 25) 20 mcg/mL in Single-Dose Prefilled Disposable Tip-Lok Syringes with 1-inch 23-gauge needles. NDC 58160-857-35 (package of 5) NDC 58160-857-26 (package of 25) Pediatric/Adolescent Doses 10 mcg/0.5 mL in Single-Dose Vials in packages of 1 and 10 vials. NDC 58160-856-01 (package of 1) NDC 58160-856-11 (package of 10) 10 mcg/0.5 mL in Single-Dose Prefilled Disposable Tip-Lok Syringes (packaged without needles) NDC 58160-856-46 (package of 5) NDC 58160 856-50 (package of 25) 10 mcg/0.5 mL in Single-Dose Prefilled Disposable Tip-Lok Syringes with 1-inch 25-gauge SafetyGlide needles. NDC 58160-856-56 (package of 25) 10 mcg/0.5 mL in Single-Dose Prefilled Disposable Tip-Lok Syringes with 1-inch 23-gauge SafetyGlideTM needles. NDC 58160-856-58 (package of 25) 10 mcg/0.5 mL in Single-Dose Prefilled Disposable Tip-Lok Syringes with 5/8-inch 25-gauge SafetyGlideTM needles. NDC 58160-856-57 (package of 25) REFERENCES 1. Centers for Disease Control and Prevention: Epidemiology and prevention of vaccine-preventable diseases. Atkinson, W., et al. (eds). 6th ed. 2000:207-229. 2.Beasley R.P., et al.: Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 3:135-141, 1983. 3.Centers for Disease Control and Prevention. Federal Register, Feb. 23, 1999,64(35):9044-9045. 4.Chang M.H., Chen C.J., Lai M.S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N.Engl.J:Med. 1997;336(26):1855-1859. 5.Lee M.S., Kim D.H., et al. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: A cohort study in Korea. Int. J: Epidemiol. 1998;27:316-319. 6.Centers for Disease Control and Prevention: Effectiveness of Seventh Grade School Entry Vaccination Requirement--Statewide and Orange County, Florida, 1997-1998. MMWR. 1998;47(34):714. 7.Committee on Infectious Diseases: Universal hepatitis B immunization. Pediatrics. 89(4):795-800, 1992. 8.Centers for Disease Control: Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. MMR. 45(No. RR-13), 1996. 9.American Academy of Pediatrics: Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. Pediatrics. 1997;99(No.3):479-488. 10.Andre F.E., and Safary A.: Clinical experience with a yeast-derived hepatitis B vaccine. In Zuckerman A.J. (ed): Viral hepatitis and liver disease, Alan R. Liss, Inc., 1988, pp. 1025-1030. 11.Poovorawan Y., et al.: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA. 261(22):3278-3281, June 9, 1989. 12.Stevens C.E., et al.: Hepatitis B vaccine in patients receiving hemodialysis. N. Engl. J. Med. 311:496-501, 1984. 13.Hauser P., et al.: Immunological properties of recombinant HBsAg produced in yeast. Postgrad. Med. J: 63 (Suppl. 2):83-91,.1987. 14.Bush L.M.,Moonsammy G.I., Boscia J.A. Evaluation of initiating. a hepatitis B vaccination schedule with one vaccine and completing it with a other. Vaccine. 1991:9(11):807-809. 15.Goilav C., et al.: Immunization of homosexual men with a recombinant DNA vaccine against hepatitis B: immunogenicity and protection. In Zuckerman, A.J. (ed): Viral hepatitis and liver disease, Alan R. Liss, Inc., 1988, pp.1057-1058. 16.Centers for Disease Control and Prevention. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR. 1998;47(RR-1):102. 17.Centers for Disease Control and Prevention: General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1994;43(RR-1):1-38. 18.Centers for Disease Control. National Childhood Vaccine Injury Act: Requirements for permanent vaccination records and for reporting of selected events after vaccination. MMWR. 1988;Vol. 37 (No. 13):197-200. 19.National Vaccine Injury Compensation Program: Revision of the vaccine injury table. Federal Register. Wednesday, February 8, 1995;Vol. 60 (No. 26):7694. ___________________ * yeast-derived, Hepatitis B Vaccine, MSD. U.S. License No. 1090 Manufactured by SmithKline Beecham Biologicals Rixensart, Belgium Distributed by SmithKline Beecham Pharmaceuticals Philadelphia, PA 19101 DATE OF ISSUANCE NOV. 2001 SmithKline Beecham, 2001 Rx Only Engerix-B and Tip-Lok are registered trademarks of SmithKline. SafetyGlide is a trademark of Becton, Dickinson and Company. EB:L33 REGULATED MEDICAL WASTE GENERATOR FACT SHEET THE NEW JERSEY REGULATED MEDICAL WASTE PROGRAM IS A COMPREHENSIVE MANAGEMENT SYSTEM THAT PROVIDES FOR THE PROPER AND SAFE TRACKING, ON-SITE CONTROL, COLLECTION AND DISPOSAL OF MEDICAL WASTES BY USING A SPECIAL TRACKING FORM TOGETHER WITH SPECIFIC PACKAGING, MARKING, LABELING, REPORTING AND OTHER REQUIREMENTS. BACKGROUNDA comprehensive, cradle-to-grave, regulated medical waste (RMW) management program was developed by the New Jersey Department of Environmental Protection (NJDEP) under NewJersey's Comprehensive Regulated Medical Waste Management Act (N.J.S.A. 13:1 E-48 et seq.), with the assistance of the Department of Health and Senior Services (DOHSS). Procedures for the proper processing, transportation and ultimate disposal of RMW are listed in the New Jersey Administrative Code, Title 7, Chapter 26, Subchapter 3A, (N.J.A.C. 7:26-3A). Guidelines for general procedures in other medical situations may be found in the DOHSS Hospital Licensure Manual, Section 306 and in the Occupational Safety and Health Administration Instruction (CPL 2-2.44). The Regulated Medical Waste Fact sheets are a publication of the Division of Solid and Hazardous Waste (DSHW), Bureau of Resource Recovery and Technical Programs. These fact sheets are designed only as an information guide, to be read in conjunction with the NewJersey RMW regulations. All persons are responsible for compliance with the RMW Regulations at N.J.A.C. 7:26-3A et seq. COPIES OF REGULATIONS & FORMSCopies of the New Jersey Comprehensive Regulated Medical Waste Management Act E-48.1 etseq.), the New Jersey medical waste regulations (N.J.A.C. 7:26-3A) are available from the publishing firm West Group, 610 Opperman Drive, PO Box 64526, St. Paul, MN 55164-0526, telephone - 1-800-808-9378, Fax -1-800-562-2329. The RMW regulations are found at pages 26-121 through 26-152. As an alternative to purchasing the regulations from the publishing firm, access to an unofficial version of the regulations is made available from the Department's web site at http://www.state.nj.us/dep/dshw/resource/index.htm#Rules. New Jersey RMW tracking forms, reporting forms and technical assistance with regulatory interpretations may be obtained from the NJDEP, DSHW, Bureau of Resource Recovery and Technical Programs, PO Box 414, Trenton, NJ 08625-0414 or by calling (609) 984-6620 during normal business hours. WHAT IS REGULATED MEDICAL WASTE? (N.J.A.C.7:26-3A.6)RMW is defined as any solid waste, generated in the diagnosis, treatment (e.g., provision of medical services), or immunization of human beings or animals, in research pertaining thereto or in the production or testing of biologicals, that is not excluded or exempted under N.J.A.C. 7:26-3A.6(b) and that is listed or meets any waste characterization criteria described in the table at N.J.A.C. 7:26-3A.6(a). Refer to the rule for excluded wastes (N.J.A.C. 7:26-3A.6(b)). "Treated RMW" means RMW that has been treated to substantially reduce or eliminate its potential for causing disease, but has not yet been destroyed (N.J.A.C. 7:26-3A.5). "Destroyed RMW" means RMW that is no longer generally recognizable as RMW because all components of the waste have been ruined, torn apart, or mutilated to produce unrecognizable and unusable pieces smaller than three-quarters of an inch, except that all sharps must be smaller than one-half inch. It does not mean compaction or encapsulation except through: 1. Processes such as thermal treatment or melting, during which treatment and destruction occur; 2. Processes such as shredding, grinding, tearing, or breaking, during which only destruction takes place; or 3. Processes that melt plastics and fully encapsulate metallic or other sharps and seals waste completely in a container that will not be penetrated by undestroyed sharps. NEW JERSEY DEPARTMENT OF ENVIRONMENTAL PROTECTION - DIVISION OF SOLID & HAZARDOUS WASTE MEDICAL WASTE TECHNICAL ASSISTANCE - (609) 984-6620 RMW Generator Fact Sheet Page 1 of 5 REGULATED MEDICAL WASTE TABLE -WASTE CLASS & DESCRIPTION 1. Cultures & StocksCultures and stocks of infectious agents and associated biologicals, including: cultures from medical and pathological laboratories; cultures and stocks of infectious agents from research and industrial laboratories; wastes from the production of biologicals; discarded live and attenuated vaccines; and culture dishes and devices used to transfer, inoculate, and mix cultures. 2. Pathological WastesHuman pathological wastes, including tissues, organs and body parts and body fluids that are removed during surgery or autopsy, or other medical procedures, and specimens of body fluids and their containers. * (* Regulated body fluids means liquids emanating or derived from humans and limited to blood; dialysate; amniotic; cerebrospinal, synovial, pleural, peritoneal and pericardial fluids; and semen and vaginal secretions (N.J.A.C. 7:26-3-A.5)) 3. Human Blood & Blood Products Liquid waste human blood; blood; items saturated and/or dripping with human blood; or items that were saturated and/or dripping with human blood that are now caked with (dried human blood; including serum, plasma, and other blood components, and their containers, which were used or intended for use in either patient care, testing and laboratory analysis or the development of pharmaceuticals. Intravenous bags, soft plastic pipettes and plastic blood vials are also included in this category. 4. SharpsSharps that were used in animal or human patient care or treatment or in medical research, or industrial laboratories, including sharp or potentially sharp if broken items such as, but not limited to hypodermic needles, all syringes to which a needle can be attached (with or without the attached needle) and their components, including those from manufacturing research, manufacturing and marketing, pasteur pipettes, scalpel blades, blood vials, carpules, needles with attached tubing, and culture dishes (regardless of presence of infectious agents). Also included are other types of broken or unbroken glassware that were in contact with infectious agents, such as used slides and cover slips. 5. Animal WasteContaminated animal carcasses, body parts, and bedding of animals that were known to have been exposed to infectious agents during research (including research in veterinary hospitals), production of biologicals, or testing of pharmaceuticals. 6. Isolation WastesBiological waste and discarded materials contaminated with blood, excretion, exudates, or secretions from humans who are isolated to protect others from certain highly communicable diseases, or isolated animals known to be infected with highly communicable diseases. 7. Unused SharpsThe following unused, discarded, sharps that were intended to be used: hypodermic needles, suture needles, syringes, and scalpel blades. N.J.A.C. 7:26-3A.6(b)4 excludes residues from treatment and destruction processes once RMW has been both treated and destroyed. RMW that is treated but not destroyed, or destroyed but not treated, is still considered RMW. WHO IS A MEDICAL WASTE GENERATOR? (N.J.A.C. 7:26-3A.5)"Generator" means any person, by site, whose act or process produces RMW as defined in N.J.A.C. 7:26-3A.6) or whose act first causes a RMW to become subject to regulation. Noncontiguous properties owned or operated by the same person are separate sites and in the case where more than one person (for example, doctors with separate medial practices) are located in the same building and office, each individual business entity is a separate generator for the purposes of this subchapter. However, households utilizing home self-care exclusively are not generators. USE OF THE NJDEP RMW TRACKING FORMThe New Jersey medical waste regulations require all medical waste generators, transporters, intermediate handlers and destination facilities to track RMW, no matter how small the amount generated. Each generator shipping RMW off-site is responsible for initiating the New Jersey RMW Tracking Form. Each person in the chain of custody (handling process) of RMW assumes the responsibility for getting the waste to the proper destination facility for treatment, destruction or disposal.NEW JERSEY DEPARTMENT OF ENVIRONMENTAL PROTECTION - DIVISION OF SOLID & HAZARDOUS WASTE MEDICAL WASTE TECHNICAL ASSISTANCE - (609) 984-6620 RMW Generator Fact Sheet Page 2 of 5 CLASSIFICATION OF WASTEPortions of the New Jersey RMW Tracking Form must be completed by the RMW generators, transporters, intermediate handlers and by destination or disposal facilities (N.J.A.C. 7:26-3A.19,3A.31 and 3A.39). REGISTRATION AND FEESIn addition, RMW generated in New Jersey but transported for disposal to another state, which prints and requires use of its own tracking form, must also be reported on that state's tracking form (N.J.A.C. 7:26-3A.19(a)).  SEGREGATION OF WASTE (N.J.A.C. 7:26-3A.10) GENERATOR REQUIREMENTS Assistance with waste classification can be obtained from NJDEP's Bureau of Resource Recovery and Technical Programs at (609) 984-6620 or the DOHSS, Division of Environmental and Occupational Health Services at (609) 588-3124. All medical waste generators, no matter how small the amount produced, with the exception of home self-care medical waste, must register with the NJDEP and pay the appropriate fees (N.J.A.C. 7:26- 3A.8(a)). For information on medical waste generator registration call (609)984-3448. Generators must segregate RMW intended for transport off-site, to the extent practicable, prior to placement in containers. * Generators must segregate RMW into: 1. Sharps (Classes 4 and 7 as defined at N.J.A.C. 7:26-3A.6(a)) including sharps containing residual fluids; 2. Fluids (quantities greater than 20 cubic centimeters); and 3. 0ther RMW. * If waste other than RMW is placed in the same container(s) as RMW then the generator must package, label and mark the container and its entire contents according to the RMW rule requirements at N.J.A.C. 7:26-3A.11, 3A.14 and 3A.15. STORAGE (N.J.A.C. 7:26-3A.12Any person who stores RMW prior to treatment or disposal on-site or for transport off-site must: 1. Store the RMW in a manner and location that maintains the integrity of the packaging and provides protection from the elements; 2. Maintain the RMW in a nonputrescent state using refrigeration if necessary; 3. Lock any outdoor storage areas containing RMW to prevent unauthorized access; 4. Limit access to on-site storage areas only to authorized employees; 5. Store the RMW in a manner that provides protection from animals and does not provide a breeding place or a food source for insects and rodents; 6. Dispose of RMW immediately if it becomes putrescent; and 7. Store RMW for no longer than one year. PACKAGING (N.J.A.C. 7:26-3A.11)Generators must ensure that all RMW is placed in containers * that are: 1. Rigid; 2. Leak-resistant; 3. Impervious to moisture; 4. Sufficiently strong to prevent tearing or bursting under normal conditions of use and handling; 5. Sealed to prevent leakage during transport; 6. Puncture resistant for packaging sharps and sharps with residual fluids; and 7. Break-resistant and tightly lidded or stoppered for packaging fluids (quantities greater than 20 cubic centimeters). 8. Solid waste that is not managed as RMW shall not be packaged for shipment inside a RMW container or in containers attached to, or part of an RMW container. * Oversized RMW need not be placed in containers (N.J.A.C. 7:26-3A.11(d)). NEW JERSEY DEPARTMENT OF ENVIRONMENTAL PROTECTION - DIVISION OF SOLID & HAZARDOUS WASTE MEDICAL WASTE TECHNICAL ASSISTANCE - (609) 984-6620 RMW Generator Fact Sheet Page 3 of 5 TRANSPORTATION OF RMW Generators must use only medical waste transporters that are registered with the Division of Solid and Hazardous Waste, NJDEP and who possess a Certificate of Public Convenience and Necessity (N.J.A.C. 7:26-3A.27) from the NJDEP (609) 292-7081 (N.J.A.C. 7:26-3A.16(d)). * * Exemptions: N.J.A.C. 7:26-3A.17(a): Generators of less than 3 cubic feet (50 pounds) of RMW per month that transport only their own RMW to another generator for storage or disposal are exempt from transporter registration requirements provided: (1) the RMW is transported by the generator or authorized employee in a vehicle with a gross weight of less than 8,000 pounds, owned by the generator or an authorized employee; (2) the original generation point and the storage point or disposal facility are located in NewJersey; and (3) the generator completes a New Jersey Tracking Form in accordance with (N.J.A.C. 7:26-3A.19(e)). LABELING AND MARKINGTransporters may not accept any shipment of RMW from a generator unless the outer surface of the container is properly labeled and marked in accordance with N.J.A.C. 7:26-3A.14 and 3A.15 (N.J.A.C. 7:26-3A.28(a)). Labeling refers to the designation of the contents as "medical waste" or "infectious waste". Labeling means each generator must, prior to offering for transport off-site, label each container of untreated RMW with a water-resistant label affixed to or printed on the outside of the container. The label shall include the words "Medical Waste", or "Infectious Waste", or display the universal biohazard symbol. Containers of treated medical waste or red plastic bags used as inner packaging are not required to be labeled (N.J.A.C. 7:26-3A.14(a)1). Marking refers to the use of a name and address. Treated RMW is required to be marked (N.J.A.C. 3A.14(a)2). Marking means the generator, including an intermediate handler must mark the outermost surface of the outer container of RMW prepared for shipment with a water-resistant identification tag containing the generator's or intermediate handler's name and address, the transporter's name and NJDEP solid waste registration number, date of shipment, and identification of the contents as RMW (N.J.A.C. 7:26-3A.15(a)1). TRACKING FORMEach New Jersey RMW Tracking Form contains 6 copies to be distributed as follows: (N.J.A.C. 7:26-3A.19)  Copy 6 Generator Copy - retained by generator Copy 3,4 & 5 Transporter Copy - retained by transporter Copy 2 Destination Facility Copy - retained by destination facility owner/operator Copy 1 Generator Copy - mailed by destination facility back to generator  a. The Generator completes items 1 through 15, including signing the certification at Item 15; b. The Transporter verifies the quantity, notes any discrepancies in Item 23, and completes and signs item 16: c. The Generator removes copy 6 and keeps it; and d. The Transporter retains copies 3, 4 and 5 and delivers the waste to the approved destination facility. RESPONSIBILITIESGenerators must complete the generator portion of the tracking form and sign the certification. A licensed medical waste transporter may complete the generator section of the tracking form but it is the generator who is ultimately responsible for ensuring the information is accurate. All RMW that is shipped off the site of generation must be accompanied by a properly completed tracking form. Certification should be completed at the time that the RMW is picked up by the licensed transporter (N.J.A.C. 7:26-3A.19). RECORDKEEPINGRetain a copy of each tracking form for at least three years from the date the waste was accepted by the initial transporter unless the Department specifically requires an additional retention period (N.J.A.C. 7:26-3A.21 (a)1). NEW JERSEY DEPARTMENT OF ENVIRONMENTAL PROTECTION - DIVISION OF SOLID & HAZARDOUS WASTE MEDICAL WASTE TECHNICAL ASSISTANCE - (609) 984-6620 RMW Generator Fact Sheet Page 4 of 5RECEIPT OF DESTINATIONIf a copy of the completed tracking form is not received from the destination facility within 35 days of acceptance of waste by the initial transporter, contact the transporter or facility to determine the status of the tracked waste (N.J.A.C. 7:26-3A.22(a)). EXCEPTION REPORTIf a signed copy of the tracking form is not received from the destination facility within 45 days of acceptance of the waste by the transporter, the generator must submit a Generator Exception Report (N.J.A.C. 7:26-3A.22(b)) to:  NJDEP Division of Enforcement Field Operations Bureau of Inspections and Investigations PO Box 407 Trenton, New Jersey 08625-0407 The Exception Report must be postmarked on or before the 46th day and include: 1. A legible copy of the original tracking form for which the generator does not have confirmation; 2. A cover letter signed by the generator explaining the efforts taken and the results to locate the RMW. A copy of the Exception Report must be kept for at least 3 years from the date of the report. ANNUAL REPORTSAll generators of RMW must complete and submit an Annual Generator Report (forms are provided by the NJDEP) to the Department for the period of June 22 through June 21 of each calendar year by July 21 of each calendar year (N.J.A.C. 7:26-3A.21 (d)) unless the Department specifically changes the reporting or filing date. GENERATOR WITH ON-SITE INCINERATORS OPERATING LOGGenerators of RMW with on-site incinerators must keep a Generator On-Site Incinerator Operating Log at their facility that includes: date, duration and quantity (in pounds) of the incineration cycle, the quantity of ash generated and transported off site, including dates of transport and identification of the transporter and disposal facility (N.J.A.C. 7:26-3A.25(a)). OPERATORS WITH ON-SITE INCINERATORS THAT ACCEPT RMW FROM OTHER GENERATORS Generators of RMW with on-site incinerators that accept RMW from other generators must maintain information on: the date of waste acceptance and the origin and quantity of the RMW. Generators must also register with the NJDEP and declare intent to operate on a commercial or non-commercial basis. Additional information on registration as a disposal facility may be obtained by calling (609)984-6620 (N.J.A.C. 7:26-3A.25(b)). GENERATORS ON-SITE REPORTS (N.J.A.C. 7:26-3A.26) Generators of RMW with on-site incinerators must submit annual on-site incinerator reports on or before July 30 of each calendar year covering the period of July 1 through June 30. The report shall be submitted to the NJDEP at the following address:  New Jersey Department of Environmental Protection Division of Solid and Hazardous Waste Bureau of Resource Recovery and Technical Programs PO Box 414 Trenton, NJ 08625-0414 Phone (609) 984-6620 NEW JERSEY DEPARTMENT OF ENVIRONMENTAL PROTECTION - DIVISION OF SOLID & HAZARDOUS WASTE MEDICAL WASTE TECHNICAL ASSISTANCE - (609) 984-6620 RMW Generator Fact Sheet Page 5 of 5REGULATED MEDICAL WASTE Q & A GENERATOR FACT SHEET THE NEW JERSEY REGULATED MEDICAL WASTE PROGRAM IS A COMPREHENSIVE MANAGEMENT SYSTEM THAT PROVIDES FOR THE PROPER AND SAFE TRACKING, ON-SITE CONTROL, COLLECTION AND DISPOSAL OF MEDICAL WASTES BY USING A SPECIAL TRACKING FORM TOGETHER WITH SPECIFIC PACKAGING, MARKING, LABELING, REPORTING AND OTHER REQUIREMENTS. THE REGULATED MEDICAL WASTE FACT SHEETS ARE A PUBLICATION OF THE DIVISION OF SOLID AND HAZARDOUS WASTE (DSHW), BUREAU OF RESOURCE RECOVERY AND TECHNICAL PROGRAMS. THESE FACT SHEETS ARE DESIGNED ONLY AS AN INFORMATION GUIDE, TO BE READ IN CONJUNCTION WITH THE NEW JERSEY RMW REGULATIONS. ALL PERSONS ARE RESPONSIBLE FOR COMPLIANCE WITH THE RMW REGULATIONS AT N.J.A.C. 7:26-2a ET SEQ. COMMON QUESTIONS AND ANSWERS ABOUT NEW JERSEYS MEDICAL WASTE REGULATIONS Q1. Are regulated medical waste (RMW) generators required to dispose of (have a registered transporter pick up) their waste monthly or at definite time periods? A. No, the medical waste regulations do not require generators to dispose of their waste monthly or provide specific time frames for the disposal of RMW. However, all RMW must be disposed of at least once per year. (N.J.A.C. 7:26-3A.12.(b)) Q2. Are carpules generated at a dentists office considered RMW? A. Yes, carpules are RMW (N.J.A.C. 7:26-3A.6(a)). They are classified as Class 4 - Sharps. They must be handled with the other sharps such as syringes (with or without the attached needle), needles, endo files, burrs, etc. generated at a dentists office. Q3. What are the regulated body fluids? A. Regulated body fluids are liquids emanating or derived from humans and are limited to blood, cerebro-spinal, synovial, pleural, peritoneal, pericardial fluids, semen, vaginal secretions, dialysate solution and amniotic fluid. Saliva and urine are not regulated body fluids. Q4. What is isolation waste Class6? Is waste generated while treating a patient with AIDS (Acquired Immune Deficiency Syndrome) considered to be isolation waste? A. Isolation waste is defined as Any biological waste and discarded materials contaminated with blood, excretion, exudates or secretions from humans who are isolated to protect others from certain highly communicable diseases (such as lassa fever or smallpox, etc.) or animals known to be infected with highly communicable diseases (N.J.A.C. 7:26-3A.6(a)). The infectious agents causing these diseases are listed in Level 4 of the Centers for Disease Controls (CDCs) Document Classification of Etiologic Agents on the Basis of Hazard. The CDC guidelines do not list the AIDS virus, therefore waste generated while treating a patient with AIDS is not an isolation waste Class 6. A list of infectious agents included in Class 6 is available from the Bureau of Resource Recovery and Technical Programs (Bureau). Q5. Are intravenous (IV) bags, tubes and needles that had only saline or nutrient medium in them considered regulated medical waste (RMW)? A. The IV bags and needles are always considered RMW pursuant to N.J.A.C. 3A.6(a). however, if the tubing that had only saline or nutrient medium in it is separated from the IV bag and the needle, then the tubing alone is not considered RMW. Q6. Are paper towels or latex gloves containing a drop (or a few drops) of blood or other regulated body fluid considered RMW? A. No, paper towels or gloves that are not saturated with blood or a regulated body fluid and are not either dripping and soaked in or have dried or caked after having been saturated with such fluids are not RMW. Q7. Are orthodontic wires, brackets and bonding material considered RMW? A. Orthodontic wires, brackets and bonding material are generally not considered RMW as they do not meet the definition of RMW. These items would only meet the definition for Class 4 RMW and have to be managed as RMW, if they became saturated and/or dripping with blood or regulated body fluids, or were saturated and/or dripping and are now dried and caked with blood or regulated body fluids (N.J.A.C. 7:26-3A.6(a)). Additionally, in certain very rare circumstances, orthodontic wires or other oral appliances would be regulated as Class 6 - Isolation Wastes, if they were removed for some reason from a patient with any of the serious diseases listed at CDC Level 4. NEW JERSEY DEPARTMENT OF ENVIRONMENTAL PROTECTION - DIVISION OF SOLID & HAZARDOUS WASTE MEDICAL WASTE TECHNICAL ASSISTANCE - (609) 984-6620 RMW Q & A Generator Fact Sheet Page 1 of 4 Q8. Are strep test cards, discs and slides considered RMW? A. If strep test cards, discs and slides are medical diagnostic test systems that contain and biologicals, such as animal antibodies or products of their metabolism, they would be considered RMW Class 1 - Cultures and Stocks and would be subject to all RMW regulations (N.J.A.C. 7:26-3A.6(a)). However, if they are medical diagnostic test systems that consist of non-biological reagents, they would not be considered RMW. Swabs that are used to inoculate a culture are considered RMW Class 1 - Cultures and Stocks. Q9. Are animal blood and vaccine vials considered RMW? A. Blood vials that have been used in animal care are considered RMW Class 4 - Sharps and must be handled as such. Animal vaccine vials that have contained agents that have the potential to cause disease in humans are considered RMW Class 4 - Sharps (N.J.A.C. 7:26-3A.6(a)). Vaccine vials that have contained agents infectious only to non-humans are not considered RMW. Q10. Are barium enema bags con-sidered RMW? A. No barium enema bags are generally not considered RMW, as they do not meet the definition of RMW found at N.J.A.C. 7:26-3A.6. These items would only be considered RMW if they are saturated and/or dripping with blood or are now caked with dried human blood or regulated body fluids. Additionally, in certain very rare circumstances these items would be regulated as Class 6 - Isolation Wastes, if they were generated from a patient with any of the serious diseases listed at CDC Level 4. Q11. When is my annual generator report (AGR) due? Must I request it be mailed to me? A. Generators are responsible for submitting a completed annual report to NJDEP by July 21 of each calendar year (N.J.A.C. 7:26-3A.21.d). The AGR form is mailed to all registered generators. However, if you fail to receive a form you may request one by calling (609) 984-6620. Q12. If for some reason the NJDEP did not receive an AGR from a generator by the due date and requests the AGR from the generator; however, the generator did submit the report and has documentation to prove that, what should the generator do to respond to such request? A. The generator should submit a copy of the completed AGR from its records. Q13. If I have more than one office, must I register each location with the Department? A. Yes, each location that generates RMW must be registered with the NJDEP (N.J.A.C. 7:26-3A.5) unless a location is a temporary location operating less than 15 days per year (N.J.A.C. 7:26-3A.17(e)). Call (609) 984-3448 for a registration packet. Q14. If generators treat and destroy their own RMW by methods such as treating with chlorine bleach and grinding, are they considered to be a destination facility? Do they have to be registered as a destination facility? A. Yes, generators that both treat and destroy their own RMW on site are considered destination facilities and they must be registered as such with the NJDEP. This includes all facilities that accept RMW from other registered generators for treatment and destruction. Registration forms are available by calling (609) 984-6620. Q15. Where can a generator obtain medical waste tracking forms? Is there a fee for them? How many forms can be ordered at one time? A. A generator/transporter can obtain the medical waste tracking forms, free of charge from the NJDEP, Bureau of Resource Recovery and Technical Programs, PO Box 414, Trenton, NJ 08625-0414 or by calling (609) 984-6620 during normal business hours. Q16. Is a generator required to submit copies of tracking forms to the NJDEP? A. No, generators are not required to submit copies of tracking forms to the NJDEP. The copies of these forms must be retained at the generators office for at least three years from the date the waste was generated/ accepted by the initial medical waste transporter unless the NJDEP specifically requires an additional retention period. The New Jersey Department of Health and Senior Services (DOHSS) inspectors during their compliance inspections check these records. A. No, generators, such as hospitals cannot transport another generators RMW without possessing the permits listed at N.J.A.C. 7:26-3A.27. These requirements include: a. Registering as an RMW trans-porter in accordance with N.J.A.C. 7:26-3A.8; b. Registering as a solid waste transporter, and c. Obtaining a certificate of public convenience and necessity issued by the Division of Solid and Hazardous Waste. NEW JERSEY DEPARTMENT OF ENVIRONMENTAL PROTECTION - DIVISION OF SOLID & HAZARDOUS WASTE MEDICAL WASTE TECHNICAL ASSISTANCE - (609) 984-6620 RMW Generator Fact Sheet Page 2 of 4 Q18. What should I do if I do not receive Copy 1 of the Medical Waste Tracking Form from the destination facility? A. If you do not receive a completed Copy 1 of the tracking form with a handwritten signature of the owner/ operator within 35 days of initial transport off site, you should contact the destination facility and attempt to determine the status of the tracked waste. If, within 45 days of initial transport off site you still do not receive Copy 1 of the tracking form you must submit an exception report to: NJDEP, Bureau of Solid Waste Compliance and Enforcement, PO Box 407, Trenton, NJ 08525-0407 (N.J.A.C. 7:26-3A.22(b)). Q19. If I have more than one office, may I take the RMW to one site for storage, consolidation or disposal? A. Yes, if a generator generates less than 50 lbs. per month and transports its waste in a vehicle weighing less than 8,000 lbs. (N.J.A.C. 7:26-3A.17) but a RMW tracking form must still be used to transport the RMW from one site to another. Please note that generators which accept RMW for storage or consolidation must be registered as a collection facility and generators which accept RMW for disposal must be registered as RMW destination facility. Q20. May mail services be used to transport RMW? A. Yes, the U.S. Postal Service can be used to transport RMW Class 4 - Sharps and Class 7 - Unused Sharps for disposal. The RMW must be sent registered for certified mail, return receipt requested. The generator must retain the original receipt and the returned registered or certified mail receipt and attach them to the generator copy of the tracking form. The generator must sign the certification section of the tracking form by hand; sign the transporter section indicating the transporter is the U.S. Postal Service and note the date the shipment was mailed; and ensure that the tracking form accompanies the RMW while in transit (N.J.A.C. 7:26-3A.17(b)). Q21. How do I dispose of RMW that is derived from radioactive medical materials? A. Such waste may be returned to the supplier of the original radioactive medical materials using a registered RMW transporter and completing a RMW form as described in N.J.A.C. 7:26-3A.19(h). Q22. May I recycle RMW? A. Yes, certain materials that are reused or recycled in accordance with all applicable Federal, State and local laws and regulations for the handling and managing of such materials, are not considered RMW if the generator first treats the materials and, for sharps, destroys them prior to shipping off site (N.J.A.C. 7;26-3A.6(b)). Q23. What is the proper way to mark and label packages of RMW? A. See Figure 1 on page 4 (N.J.A.C. 7:26.3A.14 and 15). Q24. If I am in compliance with the NJDEPs medical waste regulations, can I assume that I am in compliance with OSHAs regulations? A. No, the Federal Occupational Safety and Health Administration (OSHA) has separate regulations with which you must comply for a broader range of patient contact issues; materials and wastes produced at your business other than RMW. You may contact OSHA at (609) 757-5181. NEW JERSEY DEPARTMENT OF ENVIRONMENTAL PROTECTION - DIVISION OF SOLID & HAZARDOUS WASTE MEDICAL WASTE TECHNICAL ASSISTANCE - (609) 984-6620 RMW Q & A Generator Fact Sheet Page 3 of 4 Telephone Numbers for Regulatory and Technical Assistance: NJDEP Medical Waste Technical Assistance (609) 984-6620 Medical Waste Registration: ! Generators (609) 984-3448 ! Transporter Registration (609) 292-7081 ! Facilities (609) 984-6620 Bureau of Solid Waste Compliance And Enforcement (Transporters & Facilities) (609) 584-4180 U.S. Department of Labor Occupational Safety and Health Administration (OSHA) (609) 757-5181 Figure 1 New Jersey Department of Health And Senior Services Division of Environmental and Occupational Health (Consumer and Environmental Health Services) (Generator Inspections) (609) 588-3124 REPORT ALL INCIDENTS CONCERNING RELEASES OF RMW BY CALLING THE NJDEP 24-HOUR EMERGENCY HOTLINE AT (609) 292-7172 NEW JERSEY DEPARTMENT OF ENVIRONMENTAL PROTECTION - DIVISION OF SOLID & HAZARDOUS WASTE MEDICAL WASTE TECHNICAL ASSISTANCE - (609) 984-6620 RMW Q & A Generator Fact Sheet Page 4 of 4  Regulations (Standards - 29 CFR) Bloodborne pathogens. - 1910.1030 ( OSHA Regulations (Standards - 29 CFR) - Table of Contents Standard Number: 1910.1030- Standard Title: Bloodborne pathogens. SubPart Number: Z SubPart Title: Toxic and Hazardous Substances Interpretation(s) (a) Scope and Application. This section applies to all occupational exposure to blood or other potentially infectious materials as defined by paragraph (b) of this section. (b) Definitions. For purposes of this section, the following shall apply: Assistant Secretary means the Assistant Secretary of Labor for Occupational Safety and Health, or designated representative. Blood means human blood, human blood components, and products made from human blood. Bloodborne Pathogens means pathogenic microorganisms that are present in human blood and can cause disease in humans. These pathogens include, but are not limited to, hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Clinical Laboratory means a workplace where diagnostic or other screening procedures are performed on blood or other potentially infectious materials. Contaminated means the presence or the reasonably anticipated presence of blood or other potentially infectious materials on an item or surface. Contaminated Laundry means laundry which has been soiled with blood or other potentially infectious materials or may contain sharps. Contaminated Sharps means any contaminated object that can penetrate the skin including, but not limited to, needles, scalpels, broken glass, broken capillary tubes, and exposed ends of dental wires. Decontamination means the use of physical or chemical means to remove, inactivate, or destroy bloodborne pathogens on a surface or item to the point where they are no longer capable of transmitting infectious particles and the surface or item is rendered safe for handling, use, or disposal. Director means the Director of the National Institute for Occupational Safety and Health, U.S. Department of Health and Human Services, or designated representative. Engineering Controls means controls (e.g., sharps disposal containers, self-sheathing needles, safer medical devices, such as sharps with engineered sharps injury protections and needleless systems) that isolate or remove the bloodborne pathogens hazard from the workplace. Exposure Incident means a specific eye, mouth, other mucous membrane, non-intact skin, or parenteral contact with blood or other potentially infectious materials that results from the performance of an employee's duties. Handwashing Facilities means a facility providing an adequate supply of running potable water, soap and single use towels or hot air drying machines. Licensed Healthcare Professional is a person whose legally permitted scope of practice allows him or her to independently perform the activities required by paragraph (f) Hepatitis B Vaccination and Post-exposure Evaluation and Follow-up. HBV means hepatitis B virus. HIV means human immunodeficiency virus. Needleless systems means a device that does not use needles for: (1) The collection of bodily fluids or withdrawal of body fluids after initial venous or arterial access is established; (2) The administration of medication or fluids; or (3) Any other procedure involving the potential for occupational exposure to bloodborne pathogens due to percutaneous injuries from contaminated sharps. Occupational Exposure means reasonably anticipated skin, eye, mucous membrane, or parenteral contact with blood or other potentially infectious materials that may result from the performance of an employee's duties. Other Potentially Infectious Materials means (1) The following human body fluids: semen, vaginal secretions, cerebrospinal fluid, synovial fluid, pleural fluid, pericardial fluid, peritoneal fluid, amniotic fluid, saliva in dental procedures, any body fluid that is visibly contaminated with blood, and all body fluids in situations where it is difficult or impossible to differentiate between body fluids; (2) Any unfixed tissue or organ (other than intact skin) from a human (living or dead); and (3) HIV-containing cell or tissue cultures, organ cultures, and HIV- or HBV-containing culture medium or other solutions; and blood, organs, or other tissues from experimental animals infected with HIV or HBV. Parenteral means piercing mucous membranes or the skin barrier through such events as needlesticks, human bites, cuts, and abrasions. Personal Protective Equipment is specialized clothing or equipment worn by an employee for protection against a hazard. General work clothes (e.g., uniforms, pants, shirts or blouses) not intended to function as protection against a hazard are not considered to be personal protective equipment. Production Facility means a facility engaged in industrial-scale, large-volume or high concentration production of HIV or HBV. Regulated Waste means liquid or semi-liquid blood or other potentially infectious materials; contaminated items that would release blood or other potentially infectious materials in a liquid or semi-liquid state if compressed; items that are caked with dried blood or other potentially infectious materials and are capable of releasing these materials during handling; contaminated sharps; and pathological and microbiological wastes containing blood or other potentially infectious materials. Research Laboratory means a laboratory producing or using research-Iaboratory-scale amounts of HIV or HBV. Research laboratories may produce high concentrations of HIV or HBV but not in the volume found in production facilities. Sharps with engineered sharps injury protections means a nonneedle sharp or a needle device used for withdrawing body fluids, accessing a vein or artery, or administering medications or other fluids, with a built-in safety feature or mechanism that effectively reduces the risk of an exposure incident. Source Individual means any individual, living or dead, whose blood or other potentially infectious materials may be a source of occupational exposure to the employee. Examples include, but are not limited to, hospital and clinic patients; clients in institutions for the developmentally disabled; trauma victims; clients of drug and alcohol treatment facilities; residents of hospices and nursing homes; human remains; and individuals who donate or sell blood or blood components. Sterilize means the use of a physical or chemical procedure to destroy all microbial life including highly resistant bacterial endospores. Universal Precautions is an approach to infection control. According to the concept of Universal Precautions, all human blood and certain human body fluids are treated as if known to be infectious for HIV, HBV, and other bloodborne pathogens. Work Practice Controls means controls that reduce the likelihood of exposure by altering the manner in which a task is performed (e.g., prohibiting recapping of needles by a two-handed technique). (c) Exposure Control -- (c)(1) Exposure Control Plan. (c)(1)(i) Each employer having an employee(s) with occupational exposure as defined by paragraph (b) of this section shall establish a written Exposure Control Plan designed to eliminate or minimize employee exposure. (c)(1)(ii) The Exposure Control Plan shall contain at least the following elements: (c)(1)(ii)(A) The exposure determination required by paragraph (c)(2), ..1910.1030(c)(1)(ii)(B) (c)(1)(ii)(B) The schedule and method of implementation for paragraphs (d) Methods of Compliance, (e)HIV and HBV Research Laboratories and Production Facilities, (f) Hepatitis B Vaccination and Post- Exposure Evaluation and Follow-up, (g) Communication of Hazards to Employees, and (h) Recordkeeping, of this standard, and (c)(1)(ii)(C) The procedure for the evaluation of circumstances surrounding exposure incidents as required by paragraph (f)(3)(i) of this standard. (c)(1)(iii) Each employer shall ensure that a copy of the Exposure Control Plan is accessible to employees in accordance with 29 CFR 1910.1020(e). (c)(1)(iv) The Exposure Control Plan shall be reviewed and updated at least annually and whenever necessary to reflect new or modified tasks and procedures which affect occupational exposure and to reflect new or revised employee positions with occupational exposure. The review and update of such plans shall also: (c)(1)(iv)(A) Reflect changes in technology that eliminate or reduce exposure to bloodborne pathogens; and (c)(1)(iv)(B) Document annually consideration and implementation of appropriate commercially available and effective safer medical devices designed to eliminate or minimize occupational exposure. (c)(1)(v) An employer, who is required to establish an Exposure Control Plan shall solicit input from non-managerial employees responsible for direct patient care who are potentially exposed to injuries from contaminated sharps in the identification, evaluation, and selection of effective engineering and work practice controls and shall document the solicitation in the Exposure Control Plan. (c)(2) Exposure Determination. (c)(2)(i) Each employer who has an employee(s) with occupational exposure as defined by paragraph (b) of this section shall prepare an exposure determination. This exposure determination shall contain the following: (c)(2)(i)(A) A list of all job classifications in which all employees in those job classifications have occupational exposure; ..1910.1030(c)(2)(i)(B ) (c)(2)(i)(B) A list of job classifications in which some employees have occupational exposure, and (c)(2)(i)(C) A list of all tasks and procedures or groups of closely related task and procedures in which occupational exposure occurs and that are performed by employees in job classifications listed in accordance with the provisions of paragraph (c)(2)(i)(B) of this standard. (c)(2)(ii) This exposure determination shall be made without regard to the use of personal protective equipment. (d) Methods of Compliance -- (d)(1) General. Universal precautions shall be observed to prevent contact with blood or other potentially infectious materials. Under circumstances in which differentiation between body fluid types is difficult or impossible, all body fluids shall be considered potentially infectious materials. (d)(2) Engineering and Work Practice Controls. (d)(2)(i) Engineering and work practice controls shall be used to eliminate or minimize employee exposure. Where occupational exposure remains after institution of these controls, personal protective equipment shall also be used. ..1910.1030(d) (2)(ii) (d)(2)(ii) Engineering controls shall be examined and maintained or replaced on a regular schedule to ensure their effectiveness. (d)(2)(iii) Employers shall provide handwashing facilities which are readily accessible to employees. (d)(2)(iv) When provision of handwashing facilities is not feasible, the employer shall provide either an appropriate antiseptic hand cleanser in conjunction with clean cloth/paper towels or antiseptic towelettes. When antiseptic hand cleansers or towelettes are used, hands shall be washed with soap and running water as soon as feasible. (d)(2)(v) Employers shall ensure that employees wash their hands immediately or as soon as feasible after removal of gloves or other personal protective equipment. (d)(2)(vi) Employers shall ensure that employees wash hands and any other skin with soap and water, or flush mucous membranes with water immediately or as soon as feasible following contact of such body areas with blood or other potentially infectious materials. (d)(2)(vii) Contaminated needles and other contaminated sharps shall not be bent, recapped, or removed except as noted in paragraphs (d)(2)(vii)(A) and (d)(2)(vii)(B) below. Shearing or breaking of contaminated needles is prohibited. ..1910.1030(d) (2)(vii)(A) (d)(2)(vii)(A) Contaminated needles and other contaminated sharps shall not be bent, recapped or removed unless the employer can demonstrate that no alternative is feasible or that such action is required by a specific medical or dental procedure. (d)(2)(vii)(B) Such bending, recapping or needle removal must be accomplished through the use of a mechanical device or a one-handed technique. (d)(2)(viii) Immediately or as soon as possible after use, contaminated reusable sharps shall be placed in appropriate containers until properly reprocessed. These containers shall be: (d)(2)(viii)(A) Puncture resistant; (d)(2)(viii)(B) Labeled or color-coded in accordance with this standard; (d)(2)(viii)(C) Leakproof on the sides and bottom; and (d)(2)(viii)(D) In accordance with the requirements set forth in paragraph (d)(4)(ii)(E) for reusable sharps. (d)(2)(ix) Eating, drinking, smoking, applying cosmetics or lip balm, and handling contact lenses are prohibited in work areas where there is a reasonable likelihood of occupational exposure. (d)(2)(x) Food and drink shall not be kept in refrigerators, freezers, shelves, cabinets or on countertops or benchtops where blood or other potentially infectious materials are present. ..1910.1030(d)(2)(xi) (d)(2)(xi) All procedures involving blood or other potentially infectious materials shall be performed in such a manner as to minimize splashing, spraying, spattering, and generation of droplets of these substances. (d)(2)(xii) Mouth pipetting/suctioning of blood or other potentially infectious materials is prohibited. (d)(2)(xiii) Specimens of blood or other potentially infectious materials shall be placed in a container which prevents leakage during collection, handling, processing, storage, transport, or shipping. (d)(2)(xiii)(A) The container for storage, transport, or shipping shall be labeled or color-coded according to paragraph (g)(1)(i) and closed prior to being stored, transported, or shipped. When a facility utilizes Universal Precautions in the handling of all specimens, the labeling/color-coding of specimens is not necessary provided containers are recognizable as containing specimens. This exemption only applies while such specimens/containers remain within the facility. Labeling or color-coding in accordance with paragraph (g)(1)(i) is required when such specimens/containers leave the facility. (d)(2)(xiii)(B) If outside contamination of the primary container occurs, the primary container shall be placed within a second container which prevents leakage during handling, processing, storage, transport, or shipping and is labeled or color-coded according to the requirements of this standard. ..1910.1030(d)(2)(xiii)(C) (d)(2)(xiii)(C) If the specimen could puncture the primary container, the primary container shall be placed within a secondary container which is puncture-resistant in addition to the above characteristics. (d)(2)(xiv) Equipment which may become contaminated with blood or other potentially infectious materials shall be examined prior to servicing or shipping and shall be decontaminated as necessary, unless the employer can demonstrate that decontamination of such equipment or portions of such equipment is not feasible. (d)(2)(xiv)(A) A readily observable label in accordance with paragraph (g)(1)(i)(H) shall be attached to the equipment stating which portions remain contaminated. (d)(2)(xiv)(B) The employer shall ensure that this information is conveyed to all affected employees, the servicing representative, and/or the manufacturer, as appropriate, prior to handling, servicing, or shipping so that appropriate precautions will be taken. (d)(3) Personal Protective Equipment -.- {d){3)(i) Provision. When there is occupational exposure, the employer shall provide, at no cost to the employee, appropriate personal protective equipment such as, but not limited to, gloves, gowns, laboratory coats, face shields or masks and eye protection, and mouthpieces, resuscitation bags, pocket masks, or other ventilation devices. Personal protective equipment will be considered "appropriate" only if it does not permit blood or other potentially infectious materials to pass through to or reach the employee's work clothes, street clothes, undergarments, skin, eyes, mouth, or other mucous membranes under normal conditions of use and for the duration of time which the protective equipment will be used. (d)(3)(ii) Use. The employer shall ensure that the employee uses appropriate personal protective equipment unless the employer shows that the employee temporarily and briefly declined to use personal protective equipment when, under rare and extraordinary circumstances, it was the employee's professional judgment that in the specific instance its use would have prevented the delivery of health care or public safety services or would have posed an increased hazard to the safety of the worker or co-worker. When the employee makes this judgement, the circumstances shall be investigated and documented in order to determine whether changes can be instituted to prevent such occurrences in the future. (d)(3)(iii) Accessibility. The employer shall ensure that appropriate personal protective equipment in the appropriate sizes is readily accessible at the worksite or is issued to employees. Hypoallergenic gloves, glove liners, powderless gloves, or other similar alternatives shall be readily accessible to those employees who are allergic to the gloves normally provided. (d)(3)(iv) Cleaning, Laundering, and Disposal. The employer shall clean, launder, and dispose of: personal protective equipment required by paragraphs (d) and (e) of this standard, at no cost to the employee. ..1910.1030(d)(3)(v) (d)(3)(v) Repair and Replacement. The employer shall repair or replace personal protective equipment as needed to maintain its effectiveness, at no cost to the employee. (d)(3)(vi) If a garment(s) is penetrated by blood or other potentially infectious materials, the garment(s) shall be removed immediately or as soon as feasible. (d)(3)(vii) All personal protective equipment shall be removed prior to leaving the work area. (d)(3)(viii) When personal protective equipment is removed it shall be placed in an appropriately designated area or container for storage, washing, decontamination or disposal. (d)(3)(ix) Gloves. Gloves shall be worn when it can be reasonably anticipated that the employee may have hand contact with blood, other potentially infectious materials, mucous membranes, and non-intact skin; when performing vascular access procedures except as specified in paragraph (d)(3)(ix)(D); and when handling or touching contaminated items or surfaces. (d)(3)(ix)(A) Disposable (single use) gloves such as surgical or examination gloves, shall be replaced as soon as practical when contaminated or as soon as feasible if they are torn, punctured, or when their ability to function as a barrier is compromised. ..1910.1030(d)(3)(ix)(B) (d)(3)(ix)(B) Disposable (single use) gloves shall not be washed or decontaminated for re-use. (d)(3)(ix)(C) Utility gloves may be decontaminated for re-use if the integrity of the glove is not compromised. However, they must be discarded if they are cracked, peeling, torn, punctured, or exhibit other signs of deterioration or when their ability to function as a barrier is compromised. (d)(3)(ix)(D) If an employer in a volunteer blood donation center judges that routine gloving for all phlebotomies is not necessary then the employer shall: (d)(3)(ix)(D)(1) Periodically reevaluate this policy; (d)(3)(ix)(D)(2) Make gloves available to all employees who wish to use them for phlebotomy; (d)(3)(ix)(D)(3) Not discourage the use of gloves for phlebotomy; and (d)(3)(ix)(D)(4) Require that gloves be used for phlebotomy in the following circumstances: (d)(3)(ix)(D)(4)(i) When the employee has cuts, scratches, or other breaks in his or her skin; (d)(3)(ix)(D)(4)(ii) When the employee judges that hand contamination with blood may occur, for example, when performing phlebotomy on an uncooperative source individual; and (d)(3)(ix)(D)(4)(iii) When the employee is receiving training in phlebotomy. ..1910.1030(d)(3)(x) (d)(3)(x) Masks, Eye Protection, and Face Shields. Masks in combination with eye protection devices, such as goggles or glasses with solid side shields, or chin-Iength face shields, shall be worn whenever splashes, spray, spatter, or droplets of blood or other potentially infectious materials may be generated and eye, nose, or mouth contamination can be reasonably anticipated. (d)(3)(xi) Gowns, Aprons, and Other Protective Body Clothing . Appropriate protective clothing such as, but not limited to, gowns, aprons, lab coats, clinic jackets, or similar outer garments shall be worn in occupational exposure situations. The type and characteristics will depend upon the task and degree of exposure anticipated. (d)(3)(xii) Surgical caps or hoods and/or shoe covers or boots shall be worn in instances when gross contamination can reasonably be anticipated (e.g., autopsies, orthopedic surgery). (d)(4) Housekeeping -- (d)(4)(i) General. Employers shall ensure that the worksite is maintained in a clean and sanitary condition. The employer shall determine and implement an appropriate written schedule for cleaning and method of decontamination based upon the location within the facility, type of surface to be cleaned, type of soil present, and tasks or procedures being performed in the area. (d)(4)(ii) All equipment and environmental and working surfaces shall be cleaned and decontaminated after contact with blood or other potentially infectious materials. ..1910.1030(d)(4)(ii)(A) (d)(4)(ii)(A) Contaminated work surfaces shall be decontaminated with an appropriate disinfectant after completion of procedures; immediately or as soon as feasible when surfaces are overtly contaminated or after any spill of blood or other potentially infectious materials; and at the end of the work shift if the surface may have become contaminated since the last cleaning. (d)(4)(ii)(B) Protective coverings, such as plastic wrap, aluminum foil, or imperviously-backed absorbent paper used to cover equipment and environmental surfaces, shall be removed and replaced as soon as feasible when they become overtly contaminated or at the end of the workshift if they may have become contaminated during the shift. (d)(4)(ii)(C) All bins, pails, cans, and similar receptacles intended for reuse which have a reasonable likelihood for becoming contaminated with blood or other potentially infectious materials shall be inspected and decontaminated on a regularly scheduled basis and cleaned and decontaminated immediately or as soon as feasible upon visible contamination. (d)(4)(ii)(D) Broken glassware which may be contaminated shall not be picked up directly with the hands. It shall be cleaned up using mechanical means, such as a brush and dust pan, tongs, or forceps. (d)(4)(ii)(E) Reusable sharps that are contaminated with blood or other potentially infectious materials shall not be stored or processed in a manner that requires employees to reach by hand into the containers where these sharps have been placed. (d)(4)(iii) Regulated Waste -- ..1910.1030(d)(4)(iii)(A) (d)(4)(iii)(A) Contaminated Sharp's Discarding and Containment. (d)(4)(iii)(A)(1) Contaminated sharps shall be discarded immediately or as soon as feasible in containers that are: (d)(4)(iii)(A)(1)(i) Closable; (d)(4)(iii)(A)(1)(ii) Puncture resistant; (d)(4)(iii)(A)(1)(iii) Leakproof on sides and bottom; and (d)(4)(iii)(A)(1)(iv) Labeled or color-coded in accordance with paragraph (g)(1)(i) of this standard. (d)(4)(iii)(A)(2) During use, containers for contaminated sharps shall be: (d)(4)(iii)(A)(2)(i) Easily accessible to personnel and located as close as is feasible to the immediate area where sharps are used or can be reasonably anticipated to be found (e.g., laundries); (d)(4)(iii)(A)(2)(ii) Maintained upright throughout use; and (d)(4)(iii)(A)(2)(iii) Replaced routinely and not be allowed to overfill. (d)(4)(iii)(A)(3) When moving containers of contaminated sharps from the area of use, the containers shall be: (d)(4)(iii)(A)(3)(i) Closed immediately prior to removal or replacement to prevent spillage or protrusion .of contents during handling, storage, transport, or shipping; (d)(4)(iii)(A)(3)(ii) Placed in a secondary container if leakage is possible. The second container shall be: (d)(4)(iii)(A)(3)(ii)(A) Closable; (d)(4)(iii)(A)(3)(ii)(B) Constructed to contain all contents and prevent leakage during handling, storage, transport, or shipping; and (d)(4)(iii)(A)(3)(ii)(C) Labeled or color-coded according to paragraph (g)(1)(i) of this standard. (d)(4)(iii)(A)(4) Reusable containers shall not be opened, emptied, or cleaned manually or in any other manner which would expose employees to the risk of percutaneous injury. (d)(4)(iii)(B) Other Regulated Waste Containment -- (d)(4)(iii)(B)(J) Regulated waste shall be placed in containers which are: (d)(4)(iii)(B)(1)(i) Closable; (d)(4)(iii)(B)(1)(ii) Constructed to contain all contents and prevent leakage of fluids during handling, storage, transport or shipping; (d)(4)(iii)(B)(1)(iii) Labeled or color-coded in accordance with paragraph (g)(1)(i) this standard; and (d)(4)(iii)(B)(1)(iv) Closed prior to removal to prevent spillage or protrusion of contents during handling, storage, transport, or shipping. (d)(4)(iii)(B)(2) If outside contamination of the regulated waste container occurs, it shall be placed in a second container. The second container shall be: (d)(4)(iii)(B)(2)(i) Closable; (d)(4)(iii)(B)(2)(ii) Constructed to contain all contents and prevent leakage of fluids during handling, storage, transport or shipping; (d)(4)(iii)(B)(2)(iii) Labeled or color-coded in accordance with paragraph (g)(1)(i) of this standard; and (d)(4)(iii)(B)(2)(iv) Closed prior to removal to prevent spillage or protrusion of contents during handling, storage, transport, or shipping. (d)(4)(iii)(C) Disposal of all regulated waste shall be in accordance with applicable regulations of the United States, States and Territories, and political subdivisions of States and Territories. ..1910.1030(d)(4)(iv) (d)(4)(iv) Laundry. (d)(4)(iv)(A) Contaminated laundry shall be handled as little as possible with a minimum of agitation. (d)(4)(iv)(A)(1) Contaminated laundry shall be bagged or containerized at the location where it was used and shall not be sorted or rinsed in the location of use. (d)(4)(iv)(A)(2) Contaminated laundry shall be placed and transported in bags or containers labeled or color-coded in accordance with paragraph (g)(1)(i) of this standard. When a facility utilizes Universal Precautions in the handling of all soiled laundry, alternative labeling or color- coding is sufficient if it: permits all employees to recognize the containers as requiring compliance with Universal Precautions. (d)(4)(iv)(A)(3) Whenever contaminated laundry is wet and presents a reasonable likelihood of soak-through of or leakage from the bag or container, the laundry shall be placed and transported in bags or containers which prevent soak-through and/or leakage of fluids to the exterior. (d)(4)(iv)(B) The employer shall ensure that employees who have contact with contaminated laundry wear protective gloves and other appropriate personal protective equipment. ..1910.1030(d)(4)(iv)(C) (d)(4)(iv)(C) When a facility ships contaminated laundry off-site to a second facility which does not utilize Universal Precautions in the handling of all laundry, the facility generating the contaminated laundry must place such laundry in bags or containers which are labeled or color-coded in accordance with paragraph (g)(1)(i). (e) HIV and HBV Research Laboratories and Production Facilities. (e)(1) This paragraph applies to research laboratories and production facilities engaged in the culture, production, concentration, experimentation, and manipulation of HIV and HBV. It does not apply to clinical or diagnostic laboratories engaged solely in the analysis of blood, tissues, or organs. These requirements apply in addition to the other requirements of the standard. (e)(2) Research laboratories and production facilities shall meet the following criteria: (e)(2)(i) Standard Microbiological Practices. All regulated waste shall either be incinerated or decontaminated by a method such as autoclaving known to effectively destroy bloodborne pathogens. (e)(2)(ii) Special Practices. (e)(2)(ii)(A) Laboratory doors shall be kept closed when work involving HIV or HBV is in progress. ..1910.1030(e)(2)(ii)(B) (e)(2)(ii)(B) Contaminated materials that are to be decontaminated at a site away from the work area shall be placed in a durable, leakproof, labeled or color-coded container that is closed before being removed from the work area. (e)(2)(ii)(C) Access to the work area shall be limited to authorized persons. Written policies and procedures shall be established whereby only persons who have been advised of the potential biohazard, who meet any specific entry requirements, and who comply with all entry and exit procedures shall be allowed to enter the work areas and animal rooms. (e)(2)(ii)(D) When other potentially infectious materials or infected animals are present in the work area or containment module, a hazard warning sign incorporating the universal biohazard symbol shall be posted on all access doors. The hazard warning sign shall comply with paragraph (g)(1)(ii) of this standard. (e)(2)(ii)(E) All activities involving other potentially infectious materials shall be conducted in biological safety cabinets or other physical-containment devices within the containment module. No work with these other potentially infectious materials shall be conducted on the open bench. (e)(2)(ii)(F) Laboratory coats, gowns, smocks, uniforms, or other appropriate protective clothing shall be used in the work area and animal rooms. Protective clothing shall not be worn outside of the work area and shall be decontaminated before being laundered. ..1910.1030(e)(2)(ii)(G) (e)(2)(ii)(G) Special care shall be taken to avoid skin contact with other potentially infectious materials. Gloves shall be worn when handling infected animals and when making hand contact with other potentially infectious materials is unavoidable. (e)(2)(ii)(H) Before disposal all waste from work areas and from animal rooms shall either be incinerated or decontaminated by a method such as autoclaving known to effectively destroy bloodborne pathogens. (e)(2)(ii)(I) Vacuum lines shall be protected with liquid disinfectant traps and high-efficiency particulate air (HEPA) filters or filters of equivalent or superior efficiency and which are checked routinely and maintained or replaced as necessary. (e)(2)(ii)(J) Hypodermic needles and syringes shall be used only for parenteral injection and aspiration of fluids from laboratory animals and diaphragm bottles. Only needle-locking syringes or disposable syringe-needle units (i.e., the needle is integral to the syringe) shall be used for the injection or aspiration of other potentially infectious materials. Extreme caution shall be used when handling needles and syringes. A needle shall not be bent, sheared, replaced in the sheath or guard, or removed from the syringe following use. The needle and syringe shall be promptly placed in a puncture-resistant container and autoclaved or decontaminated before reuse or disposal. (e)(2)(ii)(K) All spills shall be immediately contained and cleaned up by appropriate professional staff or others properly trained and equipped to work with potentially concentrated infectious materials. ..1910.1030(e)(2)(ii)(L) (e)(2)(ii)(L) A spill or accident that results in an exposure incident shall be immediately reported to the laboratory director or other responsible person. (e)(2)(ii)(M) A biosafety manual shall be prepared or adopted and periodically reviewed and updated at least annually or more often if necessary. Personnel shall be advised of potential hazards, shall be required to read instructions on practices and procedures, and shall be required to follow them. (e)(2)(iii) Containment Equipment. (e)(2)(iii)(A) Certified biological safety cabinets (Class I, II, or III) or other appropriate combinations of personal protection or physical containment devices, such as special protective clothing, respirators, centrifuge safety cups, sealed centrifuge rotors, and containment caging for animals, shall be used for all activities with other potentially infectious materials that pose a threat of exposure to droplets, splashes, spills, or aerosols. (e)(2)(iii)(B) Biological safety cabinets shall be certified when installed, whenever they are moved and at least annually. (e)(3) HIV and HBV research laboratories shall meet the following criteria: ..1910.1030(e)(3)(i) (e)(3)(i) Each laboratory shall contain a facility for hand washing and an eye wash facility which is readily available within the work area. (e)(3)(ii) An autoclave for decontamination of regulated waste shall be available. (e)(4) HIV and HBV production facilities shall meet the following criteria: (e)(4)(i) The work areas shall be separated from areas that are open to unrestricted traffic flow within the building. Passage through two sets of doors shall be the basic requirement for entry into the work area from access corridors or other contiguous areas. Physical separation of the high-containment work area from access corridors or other areas or activities may also be provided by a double-doored clothes-change room (showers may be included), airlock, or other access facility that requires passing through two sets of doors before entering the work area. (e)(4)(ii) The surfaces of doors, walls, floors and ceilings in the work area shall be water resistant so that they can be easily cleaned. Penetrations in these surfaces shall be sealed or capable of being sealed to facilitate decontamination. ..1910.1030(e)(4)(iii) (e)(4)(iii) Each work area shall contain a sink for washing hands and a readily available eye wash facility. The sink shall be foot, elbow, or automatically operated and shall be located near the exit door of the work area. (e)(4)(iv) Access doors to the work area or containment module shall be self-closing. (e)(4)(v) An autoclave for decontamination of regulated waste shall be available within or as near as possible to the work area. (e)(4)(vi) A ducted exhaust-air ventilation system shall be provided. This system shall create directional airflow that draws air into the work area through the entry area. The exhaust air shall not be recirculated to any other area of the building, shall be discharged to the outside, and shall be dispersed away from occupied areas and air intakes. The proper direction of the airflow shall be verified (i.e., into the work area). (e)(5) Training Requirements. Additional training requirements for employees in HIV and HBV research laboratories and HIV and HBV production facilities are specified in paragraph (g)(2)(ix). (f) Hepatitis B Vaccination and Post-exposure Evaluation and Follow-up -- ..1910..1030(f)(1) (f)(1)(i) The employer shall make available the hepatitis B vaccine and vaccination series to all employees who have occupational exposure, and post-exposure evaluation and follow-up to all employees who have had an exposure incident. (f)(1)(ii) The employer shall ensure that all medical evaluations and procedures including the hepatitis B vaccine and vaccination series and post-exposure evaluation and follow-up, including prophylaxis, are: (f)(1)(ii)(A) Made available at no cost to the employee; (f)(1)(ii)(B) Made available to the employee at a reasonable time and place; (f)(1)(ii)(C) Performed by or under the supervision of a licensed physician or by or under the supervision of another licensed healthcare professional; and (f)(1)(ii)(D) Provided according to recommendations of the U.S. Public Health Service current at the time these evaluations and procedures take place, except as specified by this paragraph (f). (f)(1)(iii) The employer shall ensure that all laboratory tests are conducted by an accredited laboratory at no cost to the employee. ..1910.1030(f)(2) (f)(2) Hepatitis B Vaccination. (f)(2)(i) Hepatitis B vaccination shall be made available after the employee has received the training required in paragraph (g)(2)(vii)(I) and within 10 working days of initial assignment to all employees who have occupational exposure unless the employee has previously received the complete hepatitis B vaccination series, antibody testing has revealed that the employee is immune, or the vaccine is contraindicated for medical reasons. (f)(2)(ii) The employer shall not make participation in a prescreening program a prerequisite for receiving hepatitis B vaccination. (f)(2)(iii) If the employee initially declines hepatitis B vaccination but at a later date while still covered under the standard decides to accept the vaccination, the employer shall make available hepatitis B vaccination at that time. (f)(2)(iv) The employer shall assure that employees who decline to accept hepatitis B vaccination offered by the employer sign the statement in Appendix A. (f)(2)(v) If a routine booster dose(s) of hepatitis B vaccine is recommended by the U.S. Public Health Service at a future date, such booster dose(s) shall be made available in accordance with section (f)(1)(ii). (f)(3) Post-exposure Evaluation and Follow-up. Following a report of an exposure incident, the employer shall make immediately available to the exposed employee a confidential medical evaluation and follow-up, including at least the following elements: (f)(3)(i) Documentation of the route(s) of exposure, and the circumstances under which the exposure incident occurred; ..1910.1030(f)(3)(ii) (f)(3)(ii) Identification and documentation of the source individual, unless the employer can establish that identification is infeasible or prohibited by state or local law; (f)(3)(ii)(A) The source individual's blood shall be tested as soon as feasible and after consent is obtained in order to determine HBV and HIV infectivity. If consent is not obtained, the employer shall establish that legally required consent cannot be obtained. When the source individual's consent is not required by law, the source individual's blood, if available, shall be tested and the results documented. (f)(3)(ii)(B) When the source individual is already known to be infected with HBV or HIV, testing for the source individual's known HBV or HIV status need not be repeated. (f)(3)(ii)(C) Results of the source individual's testing shall be made available to the exposed employee, and the employee shall be informed of applicable laws and regulations concerning disclosure of the identity and infectious status of the source individual. (f)(3)(iii) Collection and testing of blood for HBV and HIV serological status; (f)(3)(iii)(A) The exposed employee's blood shall be collected as soon as feasible and tested after consent is obtained. ..1910.1030(f)(3)(iii)(B) (f)(3)(iii)(B) If the employee consents to baseline blood collection, but does not give consent at that time for HIV serologic testing, the sample shall be preserved for at least 90 days. If, within 90 days of the exposure incident, the employee elects to have the baseline sample tested, such testing shall be done as soon as feasible. (f)(3)(iv) Post-exposure prophylaxis, when medically indicated, as recommended by the U.S. Public Health Service; (f)(3)(v) Counseling; and (f)(3)(vi) Evaluation of reported illnesses. (f)(4) Information Provided to the Healthcare Professional. (f)(4)(i) The employer shall ensure that the healthcare professional responsible for the employee's Hepatitis B vaccination is provided a copy of this regulation. (f)(4)(ii) The employer shall ensure that the healthcare professional evaluating an employee after an exposure incident is provided the following information: (f)(4)(ii)(A) A copy of this regulation; (f)(4)(ii)(B) A description of the exposed employee's duties as they relate to the exposure incident; (f)(4)(ii)(C) Documentation of the route(s) of exposure and circumstances under which exposure occurred; ..1910.1030(f)(4)(ii)(D) (f)(4)(ii)(D) Results of the source individual's blood testing, if available; and (f)(4)(ii)(E) All medical records relevant to the appropriate treatment of the employee including vaccination status which are the employer's responsibility to maintain. (f)(5) Healthcare Professional's Written Opinion. The employer shall obtain and provide the employee with a copy of the evaluating healthcare professional's written opinion within 15 days of the completion of the evaluation. (f)(5)(i) The healthcare professional's written opinion for Hepatitis B vaccination shall be limited to whether Hepatitis B vaccination is indicated for an employee, and if the employee has received such vaccination. (f)(5)(ii) The healthcare professional's written opinion for post-exposure evaluation and follow-up shall be limited to the following information: (f)(5)(ii)(A) That the employee has been informed of the results of the evaluation; and (f)(5)(ii)(B) That the employee has been told about any medical conditions resulting from exposure to blood or other potentially infectious materials which require further evaluation or treatment. ..1910.1030(f)(5)(iii) (f)(5)(iii) All other findings or diagnoses shall remain confidential and shall not be included in the written report. (f)(6) Medical Recordkeeping. Medical records required by this standard shall be maintained in accordance with paragraph (h)(1) of this section. (g) Communication of Hazards to Employees -- (g)(1) Labels and Signs -- (g)(1)(i) Labels. (g)(1)(i)(A) Warning labels shall be affixed to containers of regulated waste, refrigerators and freezers containing blood or other potentially infectious material; and other containers used to store, transport or ship blood or other potentially infectious materials, except as provided in paragraph (g)(1)(i)(E), (F) and (G). (g)(1)(i)(B)  Labels required by this section shall include the following legend: (g)(1)(i)(C) These labels shall be fluorescent orange or orange-red or predominantly so, with lettering and symbols in a contrasting color. (g)(1)(i)(D) Labels shall be affixed as close as feasible to the container by string, wire, adhesive, or other method that prevents their loss or unintentional removal. ..1910.1030(g)(1)(i)(E) (g)(1)(i)(E) Red bags or red containers may be substituted for labels. (g)(1)(i)(F) Containers of blood, blood components, or blood products that are labeled as to their contents and have been released for transfusion or other clinical use are exempted from the labeling requirements of paragraph (g). (g)(1)(i)(G) Individual containers of blood or other potentially infectious materials that are placed in a labeled container during storage, transport, shipment or disposal are exempted from the labeling requirement. (g)(1)(i)(H) Labels required for contaminated equipment shall be in accordance with this paragraph and shall also state which portions of the equipment remain contaminated. (g)(1)(i)(I) Regulated waste that has been decontaminated need not be labeled or color-coded. (g)(1)(ii) Signs. (g)(1)(ii)(A)  The employer shall post signs at the entrance to work areas specified in paragraph (e), HIV and HBV Research Laboratory and Production Facilities, which shall bear the following legend: (Name of the Infectious Agent) (Special requirements for entering the area) (Name, telephone number of the laboratory director or other responsible person.) ..1910.1030(g)(1)(ii)(B) (g)(1)(ii)(B) These signs shall be fluorescent orange-red or predominantly so, with lettering and symbols in a contrasting color. (g)(2) Information and Trarining. (g)(2)(i) Employers shall ensure that all employees with occupational exposure participate in a training program which must be provided at no cost to the employee and during working hours. (g)(2)(ii) Training shall be provided as follows: (g)(2)(ii)(A) At the time of initial assignment to tasks where occupational exposure may take place; (g)(2)(ii)(B) Within 90 days after the effective date of the standard; and (g)(2)(ii)(C) At least annually thereafter. (g)(2)(iii) For employees who have received training on bloodborne pathogens in the year preceding the effective date of the standard, only training with respect to the provisions of the standard which were not included need be provided. (g)(2)(iv) Annual training for all employees shall be provided within one year of their previous training. ..1910.1030(g)(2)(v) (g)(2)(v) Employers shall provide additional training when changes such as modification of tasks or procedures or institution of new tasks or procedures affect the employee's occupational exposure. The additional training may be limited to addressing the new exposures created. (g)(2)(vi) Material appropriate in content and vocabulary to educational level, literacy, and language of employees shall be used. (g)(2)(vii) The training program shall contain at a minimum the following elements: (g)(2)(vii)(A) An accessible copy of the regulatory text of this standard and an explanation of its contents; (g)(2)(vii)(B) A general explanation of the epidemiology and symptoms of bloodborne diseases; (g)(2)(vii)(C) An explanation of the modes of transmission of bloodborne pathogens; (g)(2)(vii)(D) An explanation of the employer's exposure control plan and the means by which the employee can obtain a copy of the written plan; (g)(2)(vii)(E) An explanation of the appropriate methods for recognizing tasks and other activities that may involve exposure to blood and other potentially infectious materials; ..1910.1030(g)(2)(vii)(F) (g)(2)(vii)(F) An explanation of the use and limitations of methods that will prevent or reduce exposure including appropriate engineering controls, work practices, and personal protective equipment; (g)(2)(vii)(G) Information on the types, proper use, location, removal, handling, decontamination and disposal of personal protective equipment; (g)(2)(vii)(H) An explanation of the basis for selection of personal protective equipment; (g)(2)(vii)(I) Information on the hepatitis B vaccine, including information on its efficacy, safety, method of administration, the benefits of being vaccinated, and that the vaccine and vaccination will be offered free of charge; (g)(2)(vii)(J) Information on the appropriate actions to take and persons to contact in an emergency involving blood or other potentially infectious materials; (g)(2)(vii)(K) An explanation of the procedure to follow if an exposure incident occurs, including the method of reporting the incident and the medical follow-up that will be made available; (g)(2)(vii)(L) Information on the post-exposure evaluation and follow-up that the employer is required to provide for the employee following an exposure incident; ..1910.1030(g)(2)(vii)(M) (g)(2)(vii)(M) An explanation of the signs and labels and/or color coding required by paragraph (g)(1); and (g)(2)(vii)(N) An opportunity for interactive questions and answers with the person conducting the training session. (g)(2)(viii) The person conducting the training shall be knowledgeable in the subject matter covered by the elements contained in the training program as it relates to the workplace that the training will address. (g)(2)(ix) Additional Initial Training for Employees in HIV and HBV Laboratories and Production Facilities. Employees in HIV or HBV research laboratories and HIV or HBV production facilities shall receive the following initial training in addition to the above training requirements. (g)(2)(ix)(A) The employer shall assure that employees demonstrate proficiency in standard microbiological practices and techniques and in the practices and operations specific to the facility before being allowed to work with HIV or HBV. (g)(2)(ix)(B) The employer shall assure that employees have prior experience in the handling of human pathogens or tissue cultures before working with HIV or HBV. ..1910.1030(g)(2)(ix)(C) (g)(2)(ix)(C) The employer shall provide a training program to employees who have no prior experience in handling human pathogens. Initial work activities shall not include the handling of infectious agents. A progression of work activities shall be assigned as techniques are learned and proficiency is developed. The employer shall assure that employees participate in work activities involving infectious agents only after proficiency has been demonstrated. (h) Recordkeeping -- (h)(1) Medical Records. (h)(1)(i) The employer shall establish and maintain an accurate record for each employee with occupational exposure, in accordance with 29 CFR 1910.1020. (h)(1)(ii) This record shall include: (h)(1)(ii)(A) The name and social security number of the employee; (h)(1)(ii)(B) A copy of the employee's hepatitis B vaccination status including the dates of all the hepatitis B vaccinations and any medical records relative to the employee's ability to receive vaccination as required by paragraph (f)(2); (h)(1)(ii)(C) A copy of all results of examinations, medical testing, and follow-up procedures as required by paragraph (f)(3); (h)(1)(ii)(D) The employer's copy of the healthcare professional's written opinion as required by paragraph (f)(5); and .,1910.1030(h)(1)(ii)(E) (h)(1)(ii)(E) A copy of the information provided to the healthcare professional as required by paragraphs (f)(4)(ii)(B)(C) and (D). (h)(1)(iii) Confidentiality. The employer shall ensure that employee medical records required by paragraph (h)(1) are: (h)(1)(iii)(A) Kept confidential; and (h)(1)(iii)(B) Not disclosed or reported without the employee's express written consent to any person within or outside the workplace except as required by this section or as may be required by law. (h)(1)(iv) The employer shall maintain the records required by paragraph (h) for at least the duration of employment plus 30 years in accordance with 29 CFR 1910.1020. (h)(2) Training Records. (h)(2)(i) Training records shall include the following information: (h)(2)(i)(A) The dates of the training sessions; (h)(2)(i)(B) The contents or a summary of the training sessions; (h)(2)(i)(C) The names and qualifications of persons conducting the training; and ..1910.1030(h)(2)(i)(D) (h)(2)(i)(D) The names and job titles of all persons attending the training sessions. (h)(2)(ii) Training records shall be maintained for 3 years from the date on which the training occurred. (h)(3) Availability. (h)(3)(i) The employer shall ensure that all records required to be maintained by this section shall be made available upon request to the Assistant Secretary and the Director for examination and copying. (h)(3)(ii) Employee training records required by this paragraph shall be provided upon request for examination and copying to employees, to employee representatives, to the Director, and to the Assistant Secretary. (h)(3)(iii) Employee medical records required by this paragraph shall be provided upon request for examination and copying to the subject employee, to anyone having written consent of the subject employee, to the Director, and to the Assistant Secretary in accordance with 29 CFR 1910.1020. ..1910.1030(h)(4) (h)(4) Transfer of Records. (h)(4)(i) The employer shall comply with the requirements involving transfer of records set forth in 29CFR 1910.1020(h). (h)(4)(ii) If the employer ceases to do business and there is no successor employer to receive and retain the records for the prescribed period, the employer shall notify the Director, at least three months prior to their disposal and transmit them to the Director, if required by the Director to do so, within that three month period. (h)(5) Sharps injury log. (h)(5)(i) The employer shall establish and maintain a sharps injury log for the recording of percutaneous injuries from contaminated sharps. The information in the sharps injury log shall be recorded and maintained in such manner as to protect the confidentiality of the injured employee. The sharps injury log shall contain, at a minimum: (h)(5)(i)(A) The type and brand of device involved in the incident, (h)(5)(i)(B) The department or work area where the exposure incident occurred, and (h)(5)(i)(C) An explanation of how the incident occurred. (h)(5)(ii) The requirement to establish and maintain a sharps injury log shall apply to any employer who is required to maintain a log of occupational injuries and illnesses under 29 CFR 1904. (h)(5)(iii) The sharps injury log shall be maintained for the period required by 29 CFR 1904.6. (i) Dates -- (i)(1) Effective Date. The standard shall become effective on March 6, 1992. (i)(2) The Exposure Control Plan required by paragraph (c) of this section shall be completed on or before May 5, 1992. (i)(3) Paragraph (g)(2) Information and Training and (h) Recordkeeping shall take effect on or before June 4, 1992. (i)(4) Paragraphs (d)(2) Engineering and Work Practice Controls, (d)(3) Personal Protective Equipment, (d)(4) Housekeeping, (e) HIV and HBV Research Laboratories and Production Facilities, (f) Hepatitis B Vaccination and Post-Exposure Evaluation and Follow-up, and (g)(1) Labels and Signs, shall take effect July 6, 1992. [56 FR 64004, Dec. 06, 1991, as amended at 57 FR 12717, April 13, 1992; 57 FR 29206, July 1, 1992; 61 FR 5507, Feb. 13, 1996; 66 FR 5325 Jan., 18, 2001] ( OSHA Regulations (Standards - 29 CFR) - Table of Contents WEB SITE RESOURCE LIST New Jersey Department of Health and New Jersey Department of Labor Senior Services Public Employees Occupational Safety Public Employees Occupational Safety and Health Program And Health Program PO Box 386 PO Box 360, 7th Floor Trenton, NJ 08625-0386 Trenton, NJ 08625-0360 (609) 292-0767 (609) 984-1863 (800) 624-1644 http://www.state.nj.us/health/eoh/peoshweb http://www.state.nj.us/labor/lsse/lspeosh.html Effective Engineering Controls CDC Guidelines and Recommendations Vaccine Safety NOTE: This appendix contains web sites that can be used for the purposes of information and research. The examples of effective engineering controls in this appendix do not include all those on the market, but are simply representative of the devices available. PEOSH does not approve, endorse, register, or certify medical devices. Inclusion in this list does not indicate PEOSH approval, endorsement, registration, or certification. The final determination of compliance with PEOSHs standards takes into account all factors pertaining to the use of such devices at a particular worksite. Effective Engineering Controls ECRI Available: http://healthcare.ecri.org ECRI, designated as an Evidence-based Practice Center by the Agency for Health Care Policy and Research, is a nonprofit international health services research organization. Food and Drug Administration (FDA) Safety Alerts Available: http://www.fda.gov/cdrh/safety.html Link page for Safety Alerts and Advisories that warn of the risk of injuries from medical devices. International Health Care Worker Safety Center, University of Virginia Available: http://www.people.virginia.edu/~epinet/products.html Features a list of safety devices with manufacturers and specific project names. National Institute for Occupational Safety and Health (NIOSH) Sharps Disposal Containers Available: http://www.cdc.gov/niosh/sharps1.html Features information on selecting, evaluating, and using sharps disposal containers. Occupational Safety and Health Administration (OSHA) Glass Capillary Tubes: Joint Safety Advisory About Potential Risks Available: http://www.osha-sic.gov/OshDoc/Interp_data/I19990222.html Describes safer alternatives to conventional glass capillary tubes. Occupational Safety and Health Administration (OSHA) Needlestick Injuries Available: http://www.osha-slc.gov/SLTC/needlestick/index.html Features recent news, recognition, evaluation, controls, compliance, and links to information on effective engineering controls. Safety Sharp Device Contracts Available: http://www.va.gov/vasafety/osh-issues/needlesafety/safetysharpcontracts.htm Features safety sharp devices on contract with the US Department of Veterans Affairs (VA). SHARPS Injury Control Program Available: http://www.dhs.ca.gov/ohb/sharps/default.htm Established by Senate Bill 2005 to study sharps injuries in hospitals, skilled nursing facilities, and home health agencies in California. Features a Beta version of Safety Enhanced Device Database Listing by Manufacturer. Training for Development of Innovative Control Technologies (TDICT) Project Available: http://www.tdict.org/criteria.html Features Safety Feature Evaluation Forms for specific devices. US DEPARTMENT OF HEALTH & HUMAN SERVICES (HHS): CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) GUIDELINES AND RECOMMENDATIONS CDC Prevention Guidelines Database Available: http://aepo-xdv-www.epo.cdc.gov/wonder/PrevGuid/PrevGuid.shtml Provides access to the CDC Prevention Guidelines Database, which is a compilation of all of the official guidelines and recommendations published by the CDC for the prevention of diseases, disabilities, and injuries. Information on how to find a specific CDC Prevention Guideline. Morbidity and Mortality Weekly Report (MMWR) Available: http://www2.cdc.gov/mmwr/mmwr.html Provides access to the MMWR, a series which is prepared by the CDC. Contains comprehensive information on policy statements for prevention and treatment that are within the CDCs scope of responsibility, for example, recommendations from the Advisory Committee on Immunization Practice (ACIP). The following are CDC guidelines and recommendations on HIV, Hepatitis B, and Hepatitis C: Guideline for Infection Control in Health Care Personnel, 1998. Available: http://www.cdc.gov/ncidod/hip/GUIDE/InfectControl98.pdf Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. Publication date 10/16/1998. Available: http://www.cdc.gov/epo/mmwr/preview/mmwrhtml/00055154.htm Public Health Service Guidelines for the Management of Health-Care Worker Exposures to HIV and Recommendations for Postexposure Prophylaxis. Publication date 5/15/1998. Available: http://www.cdc.gov/eop/mmwr/preview/mmwrhtml/00052722.htm Appendix - First-Line Drugs for HIV Postexposure Prophylaxis (PEP). Publication date 5/15/1998. Available: http://www.cdc.gov/epo/mmwr/preview/mmwrhtml/00052801.htm Immunization of Health-Care Workers: Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). Publication date 12/26/1997. (Provides recommendations for Hepatitis B). Available: http://www.cdc.gov/epo/mmwr/preview/mmwrhtml/00050577.htm Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. Publication date June 29, 2001. Available: http://www.cdc.gov/mmwr/PDF/rr/rr5011.pdf VACCINE SAFETY Centers for Disease Control and Prevention (CDC) Available: http://www.cdc.gov/nip/vacsafe/ The National Immunization Program (NIP) of the CDC features information on vaccine safety. Food and Drug Administration (FDA) Available: http://www.fda.gov/fdac/features/095_vacc.html and http://www.fda.gov/cber/vaers/vaers.htm The first site features information on how the FDA ensures vaccine safety. The second site features information on the Vaccine Adverse Event Reporting System (VAERS), a cooperative program for vaccine safety of the FDA and CDC. Immunization Action Coalition (IAC) Available: http://www.immunize.org/ The IAC is a nonprofit organization working to increase immunization rates and prevent disease. Features Vaccine Information Statements, free print materials, and other hepatitis and immunization sites. Infectious Diseases Society of America (IDSA) Available: http://www.idosociety.org/vaccine/index.html The Vaccine Initiative is a project of the IDSA and the Pediatric Infectious Diseases Society. Features information on vaccination and vaccination-related issues. Institute for Vaccine Safety, Johns Hopkins School of Public Health Available: http://www.vaccinesafety.edu/ The purpose of the Institute is to obtain and distribute information on the safety of recommended immunizations. National Institutes of Health (NIH) Available: http://www.niaid.nih.gov/publications/vaccine/undvacc.htm Features a 40 page brochure Understanding Vaccines. World Health Organization (WHO) Available: http://www.who.int/gpv-safety/ Features a vaccine safety home page which offers links to vaccine safety-related information. Centers for Disease Control Morbidity and Mortality Weekly Report: Updated U.S. Public Health Services Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. June 29, 2001, Vol.50, No. RR-11  HYPERLINK http://www.cdc.gov/mmwr/PDF/rr/rr5011.pdf http://www.cdc.gov/mmwr/PDF/rr/rr5011.pdf Establishment/Facility Name: _________________________________________________________________________________ Sample Sharps Injury Log Year 2____ DateCase/ Report No. Type of Device (e.g., syringe, suture needle) Brand Name of DeviceWork Area were injury occurred (e.g., Geriatrics, Lab)Brief description of how the incident occurred (i.e., procedure being done, action being performed (disposal, injection, etc.), body part injured) 29 CFR 1910.1030, OSHAs Bloodborne Pathogens Standard, in paragraph (h)(5), requires an employer to establish and maintain a Sharps Injury Log for recording all percutaneous injuries in a facility occurring from contaminated sharps. The purpose of the Log is to aid in the evaluation of devices being used in healthcare and other facilities and to identify problem devices or procedures requiring additional attention or review. This log must be kept in addition to the injury and illness log required by 29 CFR 1904. The Sharps Injury Log should Include all sharps injuries occurring in a calendar year. The log must be retained for five years following the end of the year to which it relates. The Log must be kept in a manner that preserves the confidentiality of the affected employee. QUESTIONNAIRE FOR EVALUATING SHARPS DISPOSAL CONTAINER PERFORMANCE INSTRUCTIONS: Product evaluators should inspect and operate containers to be evaluated in side-by-side comparisons. Representative sharps (syringes, IV sets, blades, biopsy needles, pipettes, etc.) should be used to test candidate products. Actual use conditions should be simulated, if possible. Prior to inserting test sharps, attempt to reopen sealed containers and attempt to spill or remove contents from unsealed containers if this is a functional requirement. Evaluation facilitators should provide product manufacturer literature and visual instructions and should demonstrate proper operation of each of the containers. Use of this guideline requires knowledge that the ideal product may not exist and that this evaluation tool was based on common product designs available at the time. PLEASE CIRCLE YOUR RESPONSE FUNCTIONALITY agree disagree Container is stable when placed on horizontal surface and when used as described in the product labeling for use in trays, holders, or enclosures 1 2 3 4 5 Container provides for puncture, leak, and impact resistance 1 2 3 4 5 Container, labels, warming devices, and brackets are durable 1 2 3 4 5 Container is autoclavable, if necessary 1 2 3 4 5 Container is available in various sizes and capacities 1 2 3 4 5 Container is available with auxiliary safety features (e.g., restricted access to sharps in the container), if required 1 2 3 4 5 Closure mechanism will not allow needlestick injury 1 2 3 4 5 Closure mechanism provides secure seal 1 2 3 4 5 Design minimizes needle-tip flipback 1 2 3 4 5 Design promotes clinical performance (e.g., will not compromise sterile field or increase injury or infection control hazards) 1 2 3 4 5 Design resists easy reopening after sealing for final disposal or autoclaving 1 2 3 4 5 Inlet design defeats waste removal when open 1 2 3 4 5 Inlet design prevents spillage of contents (physical or liquid) while sharps disposal container is in use in the intended upright position 1 2 3 4 5 Containers designed to be reopenable have removable lids design with tight closure that facilities ease of removal with grip safety and conduct 1 2 3 4 5 Mounting brackets are rugged and designed for ease of service and documentation 1 2 3 4 5 ACCESSIBILITY agree disagree Container available in various opening sizes and shapes 1 2 3 4 5 Containers are supplied in sufficient quantity 1 2 3 4 5 Container has an entanglement-free opening/access way 1 2 3 4 5 Container opening/access way and current fill status visible to user prior to placing sharps into container 1 2 3 4 5 Internal design/molding of container does not impede ease of use 1 2 3 4 5 Handles, if present, located above full-fill level 1 2 3 4 5 Handles, if present, facilitate safe vertical transport and are located away from opening/access way and potentially soiled surfaces 1 2 3 4 5 Fixed locations place container within arms reach of point of waste generation 1 2 3 4 5 Fixed locations allow for installation of the container below horizontal vision level 1 2 3 4 5 If necessary, in high patient or visitor traffic areas, container should provide for security against tampering 1 2 3 4 5 VISIBILITY agree disagree Color or warming label implies danger 1 2 3 4 5 A warning indicator (i.e., color or warming label) is readily visible to the user prior to user placing sharps into container 1 2 3 4 5 Overfill level provided and current fill status is readily visible to the user prior to use placing sharps into container 1 2 3 4 5 Sharps disposal container complies with OSHA requirements 1 2 3 4 5 Disposal opening/access way is visible prior to user placing sharps into container 1 2 3 4 5 Security, mounting, aesthetic, and safety features do not distort visibility of the opening/access way or fill status indicator 1 2 3 4 5 ACCOMMODATION agree disagree No sharp edges in construction or materials 1 2 3 4 5 Safety features do not impede free access 1 2 3 4 5 Promotes patient and user satisfaction (i.e., aesthetic to extent possible) 1 2 3 4 5 Is simple to operate 1 2 3 4 5 Any emissions from final disposal comply with pollution regulations 1 2 3 4 5 Easy to assemble, if required 1 2 3 4 5 Components of containers that require assembly are easy to store prior to use 1 2 3 4 5 Use allows one handed disposal 1 2 3 4 5 Product available in special designs for environments with specific needs (e.g., laboratories, emergency rooms, emergency medical services, pediatrics, correctional facilities) 1 2 3 4 5 Mounting system durable, secure, safe, cleanable, and, where appropriate, lockable 1 2 3 4 5 Mounting systems allow height adjustments 1 2 3 4 5 Design promotes task confidence 1 2 3 4 5 Cost effectiveness 1 2 3 4 5 OTHER COMMENTS What design or performance requirements are missing from the product you evaluated that are really needed to safely or more comfortably conduct your job or sharps related task? Additional Evaluator Concerns and Comments: This product selection questionnaire was developed by the Centers for Disease Control and Preventions National Institute for Occupational Safety and Health in conjunction with NIOSH Educational Resource Centers; The John Hopkins University, Baltimore; the University of Texas, Houston; the University of California, Berkeley; and the Mount Sinai School of Medicine, New York City. ECRIs Needlestick-Prevention Device Evaluation Form Device: ________________________________________________________________________________________ Supplies/Trade Name: ___________________________________________________________________________ Applications: ___________________________________________________________________________________ Reviewer: ___________________________________________________________ Date: _____________________ For each question circle the appropriate response for the needlestick-prevention (NPD) device being evaluated. Healthcare Worker Safety 1. A. Does the NPD prevent needlesticks during use (i.e., before disposal)? Yes No B. Does it do so after use (i.e., does the safety mechanism remain activated through disposal of the NPD)? Yes No 2. A. Does NPD provide protection one of the following ways: Either intrinsically or automatically? (Answer No if a specific action by the user is required to activate the safety mechanism.) Yes No B. If No, is the mechanism activated in one of the following ways: either by one-handled technique or by a two-handed technique accomplished as part of the usual procedure? Yes No 3. During the use of NPD do users hands remain behind the needle until activation of the safety mechanism is complete? Yes No 4. Is the safety mechanism reliable when activated properly? Yes No 5. Does the NPD minimize the risk of user exposure to the patients blood? Yes No Patient Safety and Comfort 6. Does the NPD minimize the risk of infection to the patient (e.g., through cross-contamination)? Yes No 7. Can the NPD be used without causing more patient discomfort than a conventional device? Yes No 8. For IV NPDs: Does the NPD attach comfortably (i.e., without causing patient discomfort at the catheter port or IV tubing? Yes No Ease of use and Training 9. Is NPD Operation obvious? That is can the device be used properly without extensive training? Yes No 10. Can the NPD be used by a left-handed person as easily as by a right-handed person? Yes No 11. Is the technique required for using the NPD the same as that for using a conventional device? Yes No 12. Is it easy to identify the type and size of the product from the packaging? Yes No 13. For Intravenous (IV) catheters and blood collection needle sets: Does the NPD provide a visible blood flashback during initial insertion? Yes No 14. Please rate the ease of using this NPD Exc. Good Fair Poor 15. Please rate the quality of the in-service training Exc. Good Fair Poor Compatibility 16. Is the NPD compatible with devices (e.g., blood collection tubes) from a variety of suppliers? Yes No 17. For IV NPDs: A. Is the NPD compatible with intralipid solutions? Yes No B. Does the NPD attach securely at the catheter port? Yes No C. Does the NPD attach securely or lock at a Y-site (e.g., for piggybacking)? Yes No 18. Is the NPD easy to dispose of in sharps containers of all sizes (if required)? Yes No 19. Does using the NPD instead of a conventional device result in only a modest (if any) increase in sharps container waste volume? (Answer No if the NPD will increase waste volume significantly) Yes No Overall 20. Would you recommend using this device? Yes No Comments (e.g., describe problems, list incompatibilities) Source: Reprinted with permission of ECRI, Plymouth Meeting, Pennsylvania 1998 ECRI NPD Cost Calculation Worksheet* WORKSHEETSAMPLE DATAPROTECTIVE SYSTEM __________________________________ NPD (supplier/trade name) __________________________________ A. Price per device A= $ __________ B. Uses per year B= ____________ C. Uses per device C= ____________ D. Quantity used per year (B ( C) D= ____________ E. NPD cost per year (A x D) E= $ _________ Additional component _________________________________ F. Price per device F= $ _________ G. Uses per year G= ____________ H. Uses per device H= ____________ I. Quantity used per year (G ( H) I= ____________ J. NPD cost per year (F x I) J= $ _________ K. Annual protective system cost (E ( J) K= $ _________ CONVENTIONAL SYSTEM _________________________________ Conventional device _________________________________ L. Price per device L= $ __________ M. Uses per year M= ____________ N. Uses per device N= ____________ O. Quantity used per year (M ( N) O= ____________ P. NPD cost per year (L x O) P= $ _________ Additional component _________________________________ Q. Price per device Q= $ __________ R. Uses per year R= ____________ S. Uses per device S= ____________ T. Quantity used per year (R ( S) T= ____________ U. NPD cost per year (Q x T) U= $ _________ V. Annual conventional system cost (P ( U) V= $ _________ RELATED DISPOSAL COSTS Additional sharps containers W. Disposal volume of each NPD W= ____________ X. Disposal volume of each conventional device X= ____________ Y. Sharps container volume Y= ____________ Z. Number of additional sharps containers per year (W x Z= ____________ AA. Price per sharps container AA= $ _________ AB. Annual additional sharps containers cost (Z x AA) AB= $ _________ AC. Other additional disposal costs AC= $ _________ AD. Total annual increase in disposal costs (AB + AC) AD= $ _________ NSI Cost AE. Number of NSIs per year with conventional device AE= $ _________ AF. Projected NSIs per year with NPD (50% x AE) AF= $ _________ AG. Cost of each NSI AG= $ _________ AH. Annual NSI cost savings (AG x [AE - AF]) AH= $ _________ AI. MISCELLANEOUS COSTS AI= $ _________ AJ. NET PROTECTIVE SYSTEM COSTS (K+AD+AI-AH) AH= $ _________ AK. ANNUAL INCREASE IN EXPENDITURES (AJ-V) AK= $ _________Protective blood collection tube holder XYZ Medical Pro Hold A= $4.00 B= 130,000 C= 300 D= 433 E= $1,732 XYZ Medical ProHold Companion 1 Qt Sharps Container F= $3.50 G= Dispose of 130,000 needles H= NA (see next entry) I= 32** J= $112 K= $1,844 Blood collection tube holder XYZ Medical Tube Holder L= $0.15 M= 130,000 N= 300 O= 433 P= $65 Conventional 1 qt sharps container Q= $2.13 R= Dispose of 130,000 needles S= NA (see next entry) T= 32** U= $68.16 V= $133.16 W= 14 cm3 (tube holder only) X= 12 cm3 (tube holder only) Y= 1 qt (=943cm3) Z= 1 (assumes 100% packing efficiency) AA+ $3.50 AB= $3.50 AC= None AD= $3.50 AE= 6 AF= 3 AG= $540 AH= $1,620 AI= None AJ= $227.50 Annual increase in expenditures = $94.34*The figures obtained by completing this worksheet should be used for comparison purposes only. These figures will not reflect the actual costs and cost savings associated with implementing the alternative under consideration, and they cannot reflect the true value of using an NPD in terms of staff safety and the economic impact on NSIs that result in seroconversion. **Calculated by multiplying the estimated volume of one needle (0.23 cm3) by the number of needles per year (130,000) and then dividing by the volume of one sharps container (1 qt = 943 cm3). Note that this analysis assume 100% packing efficiency.Source: Reprinted with permission of ECRI, Plymouth Meeting, Pennsylvania 1998 ECRI  Guidelines for the Use of Safety Feature Evaluation Sheets Coordinator: Determine which products are to be evaluated and provide at least four or more test samples for each individual evaluating the product. (Each evaluator should have enough samples to disassemble and examine the design thoroughly.) Set up a testing station for each type of device which allows testers to evaluate products in a simulated patient procedure. Provide training dummies (injection pads, oranges, etc.) as necessary. Provide visual instructions and demonstrate proper use of each device. Review the instructions and rating system with each evaluator. Encourage each evaluator to comment on the sheets and prioritize the questions at the end of the evaluation. This will provide a useful decision making tool and will help alert you to specific areas of concern which may not have been covered by the questionnaire. Evaluators: Re-enact all steps of intended or possible procedures performed with the device being tested. Attempt to misuse the device and circumvent or disable the safety feature. Answer each question, including the short answer section at the end. If you do not understand a question, please write comments directly on the sheets. NOTE: The utility of these criteria is for initial screening of devices and NOT for clinical assessment/pilot testing. Certain assumptions have been made in the development of these forms based on information about currently available products. We recognize the likelihood that the ideal product may not exist. TDICT welcomes your comments on the use of these tools. Source: Reprinted with permission of Training for Development of Innovative Control Technology Project June Fisher, M.D. June 1993, revised August 1998 Trauma Foundation, Bldg #1, Room #300 San Francisco General Hospital 1001 Potrero Avenue San Francisco, CA 94110 Safety Feature Evaluation Form SAFETY SYRINGES Date: ____________ Department: _________________________ Occupation: _________________ Product: ____________________________________ Number of times used: __________________ Please circle the most appropriate answer for each question. Not applicable (N/A) may be used if the question does not apply to this particular product. agree disagree DURING USE: 1. The safety feature can be activated using a one-handed technique 1 2 3 4 5 N/A 2. The safety feature does not obstruct vision of the tip of the sharp 1 2 3 4 5 N/A 3. Use of this product requires you to use the safety feature 1 2 3 4 5 N/A 4. This product does not require more time to use than a non-safety device 1 2 3 4 5 N/A 5. The safety feature works well with a wide variety of hand sizes 1 2 3 4 5 N/A 6. The device is easy to handle while wearing gloves 1 2 3 4 5 N/A 7. This device does not interfere with uses that do not require a needle 1 2 3 4 5 N/A 8. This device offers a good view of any aspirated fluid 1 2 3 4 5 N/A 9. This device will work with all required syringe and needle sizes 1 2 3 4 5 N/A 10. This device provides a better alternative to traditional recapping 1 2 3 4 5 N/A AFTER USE: 11. There is a clear and unmistakable change (audible or visible) that occurs when the safety feature is activated 1 2 3 4 5 N/A 12. The safety feature operates reliably 1 2 3 4 5 N/A 13. The exposed sharp is permanently blunted or covered after use and prior to disposal 1 2 3 4 5 N/A 14. This device is no more difficult to process after use than non-safety devices 1 2 3 4 5 N/A TRAINING: 15. The user does not need extensive training for correct operation 1 2 3 4 5 N/A 16. The design of the device suggests proper use 1 2 3 4 5 N/A 17. It is not easy to skip a crucial step in proper use of the device 1 2 3 4 5 N/A Of the above questions, which three are the most important to your safety when using this product? Are there other questions which you feel should be asked regarding the safety/utility of this product? Source: Reprinted with permission of Training for Development of Innovative Control Technology Project June Fisher, M.D. June 1993, revised August 1998 Safety Feature Evaluation Form I.V. ACCESS DEVICES Date: ____________ Department: _________________________ Occupation: ________________________ Product: ____________________________________ Number of times used: _________________________ Please circle the most appropriate answer for each question. Not applicable (N/A) may be used if the question does not apply to this particular product. agree disagree 1. The safety feature can be activated using a one-handed technique 1 2 3 4 5 N/A 2. The safety feature does not interfere with normal use of this product 1 2 3 4 5 N/A 3. Use of this product requires you to use the safety feature 1 2 3 4 5 N/A 4. This product does not require more time to use than a non-safety device 1 2 3 4 5 N/A 5. The safety feature works well with a wide variety of hand sizes 1 2 3 4 5 N/A 6. The device allows for rapid visualization of flashback in the catheter or chamber 1 2 3 4 5 N/A 7. Use of this product does not increase the number of sticks to the patient 1 2 3 4 5 N/A 8. The product stops the flow of blood after the needle is removed from the catheter (or after the butterfly is inserted) and just prior to line connections or hep-lock capping 1 2 3 4 5 N/A 9. A clear and unmistakable change (either audible or visible) occurs when the safety feature is activated 1 2 3 4 5 N/A 10. The safety feature operates reliably 1 2 3 4 5 N/A 11. The exposed sharp is blunted or covered after use and prior to disposal 1 2 3 4 5 N/A 12. The product does not need extensive training to be operated correctly 1 2 3 4 5 N/A Of the above questions, which three are the most important to your safety when using this product? Are there other questions which you feel should be asked regarding the safety/utility of this product? Source: Reprinted with permission of Training for Development of Innovative Control Technology Project June Fisher, M.D. June 1993, revised August 1998 Safety Feature Evaluation Form SHARPS DISPOSAL CONTAINERS Date: ____________ Department: _________________________ Occupation: ________________________ Product: ____________________________________ Number of times used: _________________________ Please circle the most appropriate answer for each question. Not applicable (N/A) may be used if the question does not apply to this particular product. agree disagree 1. The containers shape, its markings, or its color, imply danger 1 2 3 4 5 N/A 2. The implied warning of danger can be seen from the angle at which people commonly view it (very short people, people in wheel chairs, children, etc) 1 2 3 4 5 N/A 3. The implied warning can be universally understood by visitors, children, and patients 1 2 3 4 5 N/A 4. The containers purpose is self-explanatory and easily understood by a worker who may be pressed for time or unfamiliar with the hospital setting 1 2 3 4 5 N/A 5. The container can accept sharps from any direction desired 1 2 3 4 5 N/A 6. The container can accept all sizes and shapes of sharps 1 2 3 4 5 N/A 7. The container allows single handed operation. (Only the hand holding the sharp should be near the container opening) 1 2 3 4 5 N/A 8. It is difficult to reach in and remove a sharp 1 2 3 4 5 N/A 9. Sharps can go into the container without getting caught on the opening 1 2 3 4 5 N/A 10. Sharps can go into the container without getting caught on any molded shapes in the interior 1 2 3 4 5 N/A 11. The container is puncture resistant 1 2 3 4 5 N/A 12. When the container is dropped or turned upside down (even before it is permanently closed) sharps stay inside 1 2 3 4 5 N/A 13. The user can determine easily, from various viewing angles, when the container is full 1 2 3 4 5 N/A 14. When the container is to be used free-standing (no mounting bracket), it is stable and unlikely to tip over 1 2 3 4 5 N/A 15. It is safe to close the container. (Sharps should not protrude into the path of hands attempting to close the container) 1 2 3 4 5 N/A 16. The container closes securely. (e.g. if the closure requires glue, it may not work if the surfaces are soiled or wet.) 1 2 3 4 5 N/A 17. The product has handles which allow you to safely transport a full container 1 2 3 4 5 N/A 18. The product does not require extensive training to operate correctly 1 2 3 4 5 N/A Of the above questions, which three are the most important to your safety when using this product? Are there other questions which you feel should be asked regarding the safety/utility of this product? Source: Reprinted with permission of Training for Development of Innovative Control Technology Project June Fisher, M.D. June 1993, revised August 1998 Safety Feature Evaluation Form I.V. CONNECTORS Date: ____________ Department: _________________________ Occupation: ___________________________ Product: ____________________________________ Number of times used: ____________________________ Please circle the most appropriate answer for each question. Not applicable (N/A) may be used if the question does not apply to this particular product. agree disagree 1. Use of this connector eliminates the need for exposed needles in connections 1 2 3 4 5 N/A 2. The safety feature does not interfere with normal use of this product 1 2 3 4 5 N/A 3. Use of this product requires you to use the safety feature 1 2 3 4 5 N/A 4. This product does not require more time to use than a non-safety device 1 2 3 4 5 N/A 5. The safety feature works well with a wide variety of hand sizes 1 2 3 4 5 N/A 6. The safety feature allows you to collect blood directly into a vacuum tube, eliminating the need for needles 1 2 3 4 5 N/A 7. The connector can be secured (locked) to Y-sites, hep-locks, and central lines 1 2 3 4 5 N/A 8. A clear and unmistakable change (either audible or visible) occurs when the safety feature is activated 1 2 3 4 5 N/A 9. The safety feature operates reliably 1 2 3 4 5 N/A 10. The exposed sharp is blunted or covered after use and prior to disposal 1 2 3 4 5 N/A 11. The product does not need extensive training to be operated correctly 1 2 3 4 5 N/A Of the above questions, which three are the most important to your safety when using this product? Are there other questions which you feel should be asked regarding the safety/utility of this product? Source: Reprinted with permission of Training for Development of Innovative Control Technology Project June Fisher, M.D. June 1993, revised August 1998 Safety Feature Evaluation Form VACUUM TUBE BLOOD COLLECTION SYSTEMS Date: ____________ Department: _________________________ Occupation: ___________________________ Product: ____________________________________ Number of times used: ____________________________ Please circle the most appropriate answer for each question. Not applicable (N/A) may be used if the question does not apply to this particular product. agree disagree 1. The safety feature can be activated using a one-handed technique 1 2 3 4 5 N/A 2. The safety feature does not interfere with normal use of this product 1 2 3 4 5 N/A 3. Use of this product requires you to use the safety feature 1 2 3 4 5 N/A 4. This product does not require more time to use than a non-safety device 1 2 3 4 5 N/A 5. The safety feature works well with a wide variety of hand sizes 1 2 3 4 5 N/A 6. The safety feature works with a butterfly 1 2 3 4 5 N/A 7. A clear and unmistakable change (either audible or visible) occurs when the safety feature is activated 1 2 3 4 5 N/A 8. The safety feature operates reliably 1 2 3 4 5 N/A 9. The exposed sharp is blunted or covered after use and prior to disposal 1 2 3 4 5 N/A 10. The inner vacuum tube needle (rubber sleeved needle) does not present a danger of exposure 1 2 3 4 5 N/A 11. The product does not need extensive training to be operated correctly 1 2 3 4 5 N/A Of the above questions, which three are the most important to your safety when using this product? Are there other questions which you feel should be asked regarding the safety/utility of this product? Source: Reprinted with permission of Training for Development of Innovative Control Technology Project June Fisher, M.D. June 1993, revised August 1998 Safety Feature Evaluation Form E. R. SHARPS DISPOSAL CONTAINERS Date: ____________ Department: _________________________ Occupation: ________________________ Product: ____________________________________ Number of times used: _________________________ Please circle the most appropriate answer for each question. Not applicable (N/A) may be used if the question does not apply to this particular product. agree disagree 1. The containers shape, its markings, or its color, imply danger which can be understood by visitors, children, and patients 1 2 3 4 5 N/A 2. The implied warning of danger can be seen from the angle at which people commonly view it (very short people, people in wheel chairs, children, etc) 1 2 3 4 5 N/A 3. The container can be placed in a location that is easily accessible during emergency procedures 1 2 3 4 5 N/A 4. The containers purpose is self-explanatory and easily understood by a worker who may be pressed for time or unfamiliar with the hospital setting 1 2 3 4 5 N/A 5. The container can accept sharps from any direction desired 1 2 3 4 5 N/A 6. The container can accept all sizes and shapes of sharps 1 2 3 4 5 N/A 7. The container is temporarily closable, and will not spill contents (even after being dropped down a flight of stairs) 1 2 3 4 5 N/A 8. The container allows single handed operation. (Only the hand holding the sharp should be near the container opening) 1 2 3 4 5 N/A 9. It is difficult to reach in and remove a sharp 1 2 3 4 5 N/A 10. Sharps can go into the container without getting caught on the opening or any molded shapes in the interior 1 2 3 4 5 N/A 11. The container can be placed within arms reach 1 2 3 4 5 N/A 12. The container is puncture resistant 1 2 3 4 5 N/A 13. When the container is dropped or turned upside down (even before it is permanently closed) sharps stay inside 1 2 3 4 5 N/A 14. The user can determine easily, from various viewing angles, when the container is full 1 2 3 4 5 N/A 15. When the container is to be used free-standing (no mounting bracket), it is stable and unlikely to tip over 1 2 3 4 5 N/A 16. The container is large enough to accept all sizes and shapes of sharps, including 50 ml preloaded syringes 1 2 3 4 5 N/A 17. It is safe to close the container. (Sharps should not protrude into the path of hands attempting to close the container) 1 2 3 4 5 N/A 18. The container closes securely under all circumstances 1 2 3 4 5 N/A 19. The product has handles which allow you to safely transport a full container 1 2 3 4 5 N/A 20. The product does not require extensive training to operate correctly 1 2 3 4 5 N/A Of the above questions, which three are the most important to your safety when using this product? Are there other questions which you feel should be asked regarding the safety/utility of this product? Source: Reprinted with permission of Training for Development of Innovative Control Technology Project June Fisher, M.D. June 1993, revised August 1998 Safety Feature Evaluation Form SAFETY DENTAL SYRINGES Date: ____________ Department: _________________________ Occupation: ________________________ Product: ____________________________________ Number of times used: _________________________ Please circle the most appropriate answer for each question. Not applicable (N/A) may be used if the question does not apply to this particular product. agree disagree 1. The safety feature can be activated using a one-handed technique 1 2 3 4 5 N/A 2. The safety feature does not obstruct vision of the tip of the sharp and the intraoral injection site 1 2 3 4 5 N/A 3. Use of this product requires you to use the safety feature 1 2 3 4 5 N/A 4. This product does not require more time to use than a non-safety device 1 2 3 4 5 N/A 5. The safety feature works well with a wide variety of hand sizes 1 2 3 4 5 N/A 6. The device is easy to handle while wearing gloves 1 2 3 4 5 N/A 7. The device is easy to handle when wet 1 2 3 4 5 N/A 8. This device accepts standard anesthetic carpules and does not hinder carpule changing 1 2 3 4 5 N/A 9. The safety feature does not restrict visibility of carpule contents intraorally 1 2 3 4 5 N/A 10. This device accepts standard dental needles of all common lengths and gauges, and does not interfere with needle changing 1 2 3 4 5 N/A 11. The device provides a better alternative to traditional recapping 1 2 3 4 5 N/A 12. Sterilization of this device is as easy as a standard dental syringe 1 2 3 4 5 N/A 13. For syringes with integral needles only: The needle on this syringe will not break while bending and repositioning in the tissue 1 2 3 4 5 N/A 14. This device is no more difficult to break down after use for sterilization than a standard dental syringe 1 2 3 4 5 N/A 15. The safety feature operates reliably 1 2 3 4 5 N/A 16. The exposed sharp is permanently blunted or covered after use and prior to disposal 1 2 3 4 5 N/A 17. There is a clear and unmistakable change (either visible or audible) that occurs when the safety feature is activated 1 2 3 4 5 N/A 18. The user does not need extensive training to operate the product correctly 1 2 3 4 5 N/A 19. The design of the device allows for easy removal of the needle from the syringe 1 2 3 4 5 N/A 20. The design of the device allows for easy removal of the carpule from the syringe 1 2 3 4 5 N/A Source: Reprinted with permission of Training for Development of Innovative Control Technology Project June Fisher, M.D. June 1993, revised August 1998 Safety Feature Evaluation Form HOME USE SHARPS DISPOSAL CONTAINERS Date: ____________ Department: _________________________ Occupation: ___________________________ Product: ____________________________________ Number of times used: ____________________________ Please circle the most appropriate answer for each question. Not applicable (N/A) may be used if the question does not apply to this particular product. agree disagree The container is puncture resistant 1 2 3 4 5 N/A The container is stable 1 2 3 4 5 N/A There is a handle which is robust, comfortable to carry, and compact 1 2 3 4 5 N/A The container allows single handed use 1 2 3 4 5 N/A The user can access the container from any direction 1 2 3 4 5 N/A It is possible to drop sharps into the container vertically 1 2 3 4 5 N/A Minimal or no force is required to put sharps into the container 1 2 3 4 5 N/A The container opens and closes easily 1 2 3 4 5 N/A Container closure maintains integrity after repeated use 1 2 3 4 5 N/A The box accommodates a range of sharps, including 12 cc syringe, butterfly and lancet 1 2 3 4 5 N/A The size of the container is appropriate to its use 1 2 3 4 5 N/A No one (including a child) can access the contents of the container to retrieve a sharp 1 2 3 4 5 N/A Needle/tubing do not get caught on the opening or interior shape 1 2 3 4 5 N/A There is a temporary lock for transport which is secure but reversible 1 2 3 4 5 N/A There is a permanent lock for final disposal which is not reversible 1 2 3 4 5 N/A There is an absorbent lining to collect excess fluid 1 2 3 4 5 N/A The user can determine the fill level visually 1 2 3 4 5 N/A There is a signal when the box is 2/3 full 1 2 3 4 5 N/A The container is appropriately labeled 1 2 3 4 5 N/A Biohazard of container contents is apparent 1 2 3 4 5 N/A The box is not threatening to patients 1 2 3 4 5 N/A Use of this container in no way compromises infection control practices 1 2 3 4 5 N/A Of the above questions, which three are the most important to your safety when using this product? Are there other questions which you feel should be asked regarding the safety/utility of this product? Source: Reprinted with permission of Training for Development of Innovative Control Technology Project June Fisher, M.D. June 1993, revised August 1998  A USER-BASED PERFORMANCE STANDARD: for the design, evaluation, and selection of medical devices This Performance Standard was developed by the TDICT Project, in conjunction with line healthcare workers and the HIV Office of the Centers for Disease Control. It steps back from device specific criteria to look at overall procedures and the fundamental standards which must be met by all products, in all phases of use. Download a pdf version of this document. Performance Standard vs. Selection Criteria Generalized/GenericDevice Specific ApplicationsBased on ProcedureBased on DeviceEncompasses Product Life CyclePoint of Use Only MAJOR CATEGORIES I. PATIENT SAFETY & QUALITY OF CARE Is the proposed solution of equal or greater effectiveness? Will the device improve patient well-being? (Quality Assurance) Does the device increase time needed for given procedure? Is the device FDA approved? Is it Class I, II, or III? Does the device expose the patient to harmful elements? (Latex, X-rays, Chemicals, Extreme Light or Heat, etc.) Does proper use of the device involve unnecessary invasions into the patients body? II. USER SAFETY Does use of the device require excessive re-training? Can most of the re-training be done in a lab or simulated setting? Do new users experience a steep learning curve? Does the level of expertise of the user affect the learning curve? (Novice vs. Expert user?) Does the use of the device change the existing procedure significantly? Is the device intrinsically more simple, as opposed to more complex, than the device it will replace? Does the device require an action which is counter to prevailing procedures? (Is the correct use of the device intuitive?) Does the device increase time needed for the given procedure? Is the product self-contained as opposed to an assembly of different parts? Does the product need to be disassembled-assembled prior to disposal? Does the device fit well in the hand of the user as opposed to being cumbersome? Who uses the given product? Where and how will failure occur? Can product be easily misused, used differently, co-opted for alternate use? What are the scenarios for common, uncommon, and inappropriate use? If a safety feature exists on the device, is it passively activated? (Effective without user interaction/interference) Are the safety cues for the safety feature evident at all times? (Are clicks audible, visual markings noticeable, tactile sensations noticeable through gloves?) III. USER FIT AND SATISFACTION Will use of the device require excessive re-training? Can most of the re-training be done in a lab setting? Do new users experience a steep learning curve? Does the level of expertise of the user affect the learning curve? (Novice vs. Expert user?) Does the use of the device change the existing procedure significantly? Is the device intrinsically more simple as opposed to complex? Does the device require an action which is counter to prevailing procedures? (Is the correct use of the device intuitive?) Does the device increase time needed for given procedure? Is product self-contained as opposed to an assembly of different parts? Does product need to be disassembled-assembled prior to disposal? Does the device fit well in the hand of the user as opposed to being cumbersome? Is the packaging of the device easy to open? Does the packaging clearly indicate its contents? Does the packaging clearly indicate the correct procedures for use of the device? Are recycling or disposal directions clear on the packaging or product? Where and how will failure occur? Can product be easily misused, used differently, co-opted for alternate use? What are the scenarios for common, uncommon, and inappropriate use? IV. PATIENT FIT AND SATISFACTION Will the device improve patient well-being? (Quality Assurance) Is the proposed solution of equal or greater effectiveness? Does the device increase time needed for given procedure? Does the device expose the patient to harmful elements? (Latex, X-rays, Chemicals, Extreme Light or Heat, etc.) Does proper use of the device involve unnecessary invasions into the patients body? V. PRODUCT LIFE-CYCLE What environmental factors must be considered in product evaluation? What is the product life-cycle? Are recycling or disposal directions clear on the packaging or product? Is product self-contained as opposed to an assembly of different parts? Is the packaging excessive or cumbersome? Does the device, or its packaging, present any new storage problems? Does the device incorporate materials that are non-recyclable in places where recyclable materials would be just as effective? VI. ADMINISTRATIVE FIT AND SATISFACTION Does the cost of the product correlate closely with other similar devices on the market? Is the cost prohibitive to widespread use of the product? Does the cost of the product appear to be correlated to the expense of production? Will implementation of the device require excessive re-training? Can most of the re-training be done in a lab setting? Does the level of expertise of the user affect the learning curve? Novice vs. Expert user? Does the use of the device change the existing procedure significantly? Is the proposed solution of equal or greater effectiveness? Where is the product used? What environmental factors must be considered in product evaluation? What is the product life-cycle? Are recycling or disposal directions clear on the packaging or product? Does the device, or its packaging, present any new inventory problems? Is the device FDA approved? Is it Class I, II, or III? How does the device affect patient well-being? (Quality Assurance) Who uses the given product? Where and how will failure occur? How might product be misused, used differently, co-opted for alternate use? What are the scenarios for common, uncommon, and inappropriate use? Does the device offer a distinct advantage to the institution using it? TDICT METHODSEVALUATION TOOLSPERFORMANCE STANDARDCURRENT WORKRELATED SITES TDICT Project Trauma Foundation Bldg. #1, Rm. #300 San Francisco General Hospital 1001 Potrero Ave  HYPERLINK "mailto:info@tdict.org" info@tdict.org ** Luer-Lok is a trademark of Becton Dickinson & Company     PAGE  PAGE 1 INTRODUCTION PAGE 2 POLICY PAGE 3 PROGRAM ADMINISTRATION PAGE 4 EMPLOYEE EXPOSURE DETERMINATION PAGE 5 EFFECTIVE DATES PAGE 6 EXPOSURE CONTROL PLAN PAGE 7 ENGINEERING CONTROLS PAGE 8 PERSONAL PROTECTIVE EQUIPMENT PAGE 9 PAGE 10 PAGE 11 TRAINING PAGE 12 PAGE 13 TRAINING PROGRAM ELEMENTS PAGE 14 HEPATITIS B VACCINATION PAGE 15 PAGE 16 POST EXPOSURE EVALUATION PAGE 17 PAGE 18 PAGE 19 HEALTH CARE PROFESSIONALS PAGE 20 PAGE 21 HOUSEKEEPING PAGE 22 PAGE 23 PAGE 24 PAGE 25 LABELING PAGE 26 RECORDKEEPING PAGE 27 PAGE 28 MEDICAL RECORDS PAGE 29 TRAINING RECORDS PAGE 30 FIRST AID PROVIDERS PAGE 31 PAGE 32 APPENDIX A APAGE 4 APPENDIX A APPENDIX B BPAGE 1 APPENDIX B APPENDIX C CPAGE 1 APPENDIX C CPAGE 2 APPENDIX C APPENDIX D DPAGE 1 APPENDIX D APPENDIX D DPAGE 2 APPENDIX Q APPENDIX E LETTER EPAGE 2 APPENDIX E FORM APPENDIX F FPAGE 1 APPENDIX G GPAGE 1 APPENDIX H HPAGE 1 APPENDIX I IPAGE 1 APPENDIX I IPAGE 2 APPENDIX J JPAGE 2 APPENDIX K KPAGE 1 APPENDIX L LPAGE 2 APPENDIX M APPENDIX M MPAGE 3 APPENDIX N NPAGE 2 APPENDIX O OPAGE 1 APPENDIX P PPAGE 15 APPENDIX Q QPAGE 2 QPAGE 9 QPAGE 6 APPENDIX Q APPENDIX R RPAGE 1 RPAGE 27 APPENDIX S SPAGE 1 APPENDIX U UPAGE 16 JAMES E. MCGREEVEY Governor CLIFTON R. LACY, M.D. Commissioner 2 Note to Employer: The names or job titles of the Program Administrators can be used to simplify compliance. In a small facility the responsibilities for the program may be held by one individual. In this case these items can be combined. Note to Employer: You are not required to complete both sections that follow; you may only complete the section that applies. Note to Employer: Examples of category B would include custodians who occasionally clean contaminated equipment and laundries where some workers are assigned the task of handling contaminated laundry. Facilities are also required to notify contract employers (i.e., plumber, etc.) of potential contact with blood or other potentially infectious materials so they can take appropriate precautions. Refer to Appendix A for definition of occupational exposure. Note to Employer: Good Samaritan acts which result in exposure to blood or other potentially infectious materials from assisting a fellow employee (i.e., assisting a coworker with nosebleed, giving CPR or first aid) are not included in the Bloodborne Pathogens Standard. PEOSH, however, encourages employers to offer Post-Exposure Evaluation and Follow-up in such cases. Note to Employer: The employer should decide how to make PPE "readily accessible" for employees use. Specify in writing what will be issued, how, when and who will provide the PPE. For large facilities which might have numerous tasks present, a summary of the tasks and required PPE can be used. The important part to remember is that it is imperative that employees wear appropriate protective body coverings such as gowns, aprons, caps, and boots when occupational exposure is anticipated. The type and characteristics will depend upon the task and degree of exposure anticipated. Note to Employer: Employers with first aid responders are reminded to have quick access to kits having impervious gloves, resuscitation bags or mouthpieces, eye protection, aprons, disinfectant towelettes for hand washing, and red bags or biohazard-labeled bags. Note to Employer: Designate areas or containers which are to be used and their location. Note to Employer: The training materials, such as overheads, pictures, work sheets, pamphlets, etc., can be made a part of the ECP. Note to Employer: To ensure that employees are aware of the importance of the hepatitis B vaccination, it is necessary to thoroughly discuss the efficacy, safety, methods of administration, benefits of the vaccination, the fact that it is given at no cost, and during work hours. Antibody Testing after the Hepatitis B Vaccination The CDC stated in their latest report* that health-care personnel (HCP) (e.g., employees, students attending clinicians, public safety workers or volunteers) who have contact with patients or blood and are at ongoing risk for percutaneous injuries should be tested 1-2 months after completion of the 3-dose vaccination series for antibodies for hepatitis B surface antigen (anti-HBs). The PEOSH Bloodborne Pathogens Standard (29 CFR 1910.1030) requires that the most recent CDC guidelines be followed regarding the hepatitis B vaccine and post-exposure follow-up. Therefore, employers of New Jersey public safety workers (e.g., EMTs, police, firefighters, corrections officers) and other public employees covered under the PEOSH Bloodborne Pathogens Standard must determine if their employees are at ongoing risk for percutaneous injuries. If so, then the employer is required to offer blood testing to those employees 1-2 months after completion of the 3-dose vaccination series for antibodies for hepatitis B surface antigen (anti-HBs). (If the employee does not respond to the primary vaccine, consult the CDC report* for additional recommendations.) The employer does not have to offer antibody testing to those employees who have been previously vaccinated. Note to Employer: Note #1 New Jersey Law (N.J.S.A. 26-5C et. seq.) and Regulation (N.J.A.C. 8:57-2) requires information about AIDS and HIV to be kept confidential. While the law requires reporting of positive HIV results to the State Health Department, the law strictly limits disclosure of HIV-related information. When disclosure of HIV-related information is authorized by a signed release, the person who has been given the information MUST keep it confidential. Redisclosure may occur ONLY with another authorized signed release. Note #2 If, during this time, the exposed employee elects to have the baseline sample tested, testing shall be done as soon as feasible. Note #3 Appendixes D, E, and F are optional forms which have been provided to assist employers with gathering information that is required by the standard. If an employer chooses not to use these forms, this information must still be provided and recorded in accordance with the Standard: Also note that HIV Confidential Case Report form and/or the AIDS Adult Confidential Case Report form, as well as, the HIV Testing Policy information applicable to New Jersey public sector employers can be obtained by contacting: The New Jersey State Department of Health and Senior Services Data Analysis Unit PO Box 363 Trenton, New Jersey 08625-0363 (609) 984-6204 Note #4 Following an exposure incident, prompt medical evaluation and prophylaxis is imperative. Timeliness is, therefore, an important factor in effective medical treatment For Health Care Providers and Health Care Professionals there is a 24-hour Hotline where clinicians can obtain post-exposure prophylaxis treatment guidelines. For staff that has been exposed, the Hotline also provides counseling on treatment issues. The Toll-free number is: 1-888-448-4911, 24 hours a day, 7 days a week, on call staff can always be reached. The internet address is: www.ucsf.edu/hivcntr Once you access the Internet go onto the PEPline (Post-exposure prophylaxis) Note to Employer: If the employer is also the health care professional, the employer must ensure that the results of the employee's post-exposure evaluation remain confidential from his/her co-workers. Note to Employer: Include a housekeeping schedule and method of decontamination above. Include location of cleanup and decontamination supplies. A list of approved sterilants can be obtained from the Environmental Protection Agency (EPA), Antimicrobial Division at: http://www.epa.gov/oppad001/chemregindex.htm or e-mail: liem.david@epa.gov. A preformatted schedule sheet (Appendix O) is provided in the Appendix Section of this kit if additional space is required. Note to Employer: To further assist employers in developing a written housekeeping schedule, the following procedures are provided as examples. To ensure a complete working document, it is recommended that the written task be as specific as possible. Note to Employer: Disposable protective clothing can be used to eliminate or greatly reduce the need for laundering. Note to Employer: The employer must specify which warning methods are used and communicate this information to all employees. The standard requires that fluorescent orange or orange-red warning labels be attached to: (1) containers of regulated waste; (2) refrigerators and freezers containing blood and other potentially infectious materials; (3) sharps disposal containers; (4) laundry bags and containers; (5} contaminated equipment for repair (portion contaminated); and (6) other containers used to store, transport, or ship blood or other potentially infectious materials. These labels are not required when: (1) red bags or red containers are used; (2) containers of blood, blood components, or blood products are labeled as to their contents and have been released for transfusion or other clinical use; and (3) individual containers of blood or other potentially infectious materials are placed in a labeled container during storage, transport, shipment or disposal. The warning label must be fluorescent orange or orange-red, contain the biohazard symbol and the word BIOHAZARD (See Appendix H) in a contrasting color, and be attached to each object by string, wire, adhesive, or other method to prevent loss or unintentional removal of the label. Note to Employer: Examples of employees who may meet the above criteria include: ( Security Guards, Coaches, Bus Drivers, DPW/DOT, Office Workers, Industrial Plant Personnel, who are designated and trained to perform first aid. Examples of employees who do not meet the criteria and must be offered the hepatitis B vaccination series include: ( Personnel who provide first aid at a first aid station, clinic, emergency response or public safety personnel, who are expected to render first aid in the normal course of their work (i.e., EMS personnel, police, firefighters). This is not an all-inclusive list, nor does it imply that every employee in these job titles are covered. Also, as a reminder, good samaritan acts are still not covered by the Standard BIOHAZARD  EMBED CorelDraw.Graphic.7   EMBED Word.Picture.8  U.S. Department of Labor Occupational Safety and Health Administration  EMBED Word.Picture.8  U.S. Department of Labor Occupational Safety and Health Administration  EMBED Word.Picture.8  U.S. Department of Labor Occupational Safety and Health Administration  EMBED Word.Picture.8  U.S. Department of Labor Occupational Safety and Health Administration  EMBED Word.Picture.8   EMBED Word.Picture.8  U.S. Department of Labor Occupational Safety and Health Administration MERCK & CO., INC. Whitehouse Station, NJ 08889, USA 7994325  EMBED Word.Picture.8   EMBED Word.Picture.8  Manuf. and Dist. by: MERCK & CO., INC., Whitehouse Station, NJ 08889, USA Occupational Safety & Health Administration U.S. Department of Labor APPENDIX T T1  EMBED Word.Picture.8   EMBED Word.Picture.8   EMBED Word.Picture.8   EMBED Word.Picture.8   EMBED Word.Picture.8   EMBED Word.Picture.8   EMBED Word.Picture.8   EMBED Word.Picture.8   EMBED Word.Picture.8  GjklmK y P 2 ཱm_YSMG@G9 h5CJ h6CJ hCJ hCJ hCJ hCJhB*CJOJQJph'jhB*CJUmHnHphu/jhB*CJOJQJUmHnHphuhB*CJOJQJphhB*CJphh@B*CJphhjhUmHnHu jd< hUVmHnHuj hUmHnHuhmHnHujhUGRk 2 3  @@1$d1$d  !H$xa$$a$$a$$a$2 .{qr =#]()y*{*****++,,,,---d.e.. ///////00"1#1%1(1*1+1J1L1M1112,jh5CJOJQJUhmHnHu jqhCJh5CJOJQJhhCJOJQJh5CJOJQJ hCJ!jhCJUhmHnHu h5CJ h6CJ hCJ7:0NWp()d & F hT@@T&1$^Tgd & F hT@@T91$^Tgd & F hT@@T+1$^Tgd & F h@@1$^gd @@1$)78 3ZrEQn &J1$  &Jd1$$1$a$ @@91$ @@1$-.?@r!j9q&c T&@J1$ &J &J1$= Y y =#>#[(\(]())w*x*****Z+[+ B@1$$1$a$1$ T#@J1$ T&@J1$[+q++++++,,--c.d. / ///!1"1$1$ @1$^`a$1$ & F h1$^gd & F h+1$^gd & F h1$^gd$1%1&1'1(1L1N122 22222233z3{3}3~3444 8@@81$^8`$ v8@@81$^8`a$ $ v8@@1$a$1$2 2 2 2M2R222233z3{3|3~3444404b5c5E66H7s7y7778888<</<<o=>Q>{>>>>$?w???@@N@@@AABBjBB CJCCCսգսսսսս hCJh56CJOJQJh6>*CJOJQJh56>*CJOJQJ h@hh5CJOJQJhCJOJQJ)jhCJOJQJUhmHnHu>4444041455/505P5Q5|5}555566 6$ z8@@@1$a$$ z8@@@81$^8a$$ z8@@@81$^8a$$ z8@@@v1$^v`a$ $ z8@@@1$a$1$ 6D6E6r6666F7G7H7s7t7788:<0<<$ 8@@81$^8`a$ v@$ 8@@81$^8`a$d$1$$ z8@@@v1$^v`a$ $ z8@@@1$a$<p==>>?@@AiABjBBKCLC1$$ 8@@8x1$^8`a$$ 8@@81$^8`a$$ 8@@81$^8`a$$ & F h@1$^a$gd$ & F h@x1$^a$gdLCCCCCCC/D0DGDHDDDDDEE0F #b@@@b1$]^b` #b@@@b1$]^b` #8T@@@@@T1$^T` #b@@@b1$^b` #8T@@@T1$^T`CCCCCCCCCCC0D2D3D4DDDDDDDDDEEEE1F3F4F5FFFFFFFFFG G!G"G,G.G/G0GMGOGPGQGGGGGHHHHIIIIFJHJIJJJOKrKtK#N$N4NDOEOFOLO,jh5CJOJQJUhmHnHuh5CJOJQJ hCJhCJOJQJh jqhCJL0F1FFFFFGG+G,GJGKGLGMGG ^@@@b1$]^b`1$1$ hb@@@b1$]^b` h#b@@@@b1$]^b` #b@@@b1$]^b`GHIFJIKJKsKtKLLMM#N$N4NwN 8@@1$    AA1$ v#^@@ #8^@@@81$^8`1$ ^@@@b1$]^b` ^@@@b1$]^b` ^@@@b1$]^b`wNNN@OAOBOCODOFOGO\O]OdOjO & F hVx$1$If^V`gd & F h$1$If^`gd #^1$1$ 8@@1$ LOMOOPP[P\P^P_P`PPPPP6Q8Q9QQQQQQ1S3S4S5SpTrTsTtTvUyUzU{U2V4V5V6VVVVVVVVVVVVVWWWW[[[[````````aah6CJOJQJ jhCJOJQJ jqhCJ hCJh)jhCJOJQJUhmHnHuhCJOJQJh5CJOJQJCjOkOqOOOOO6Jkd' $$Ifl4C0# `4 latf4 & F hVx$1$If^V`gd & F h$1$If^`gdEkd$$Ifl0# 4 latOOOOOO|631$Ekd $$Ifl0# 4 lat & F hVx$1$If^V`gd & F h$1$If^`gdJkd $$Ifl4B0# 4 latf4OPPP[P\PPP6QQQQQ RURRR0S #^@@@^<<1$^^`1$$ #^@@@b]^b`a$$ #^@@@b1$]^b`a$ #^@@@1$  #8^@@@@1$0S1SoTpTvUwUV1V2VVVVVWWYY$ #^@@@b1$]^b`a$$ #^@@@^1$]^^`a$$ #^@@@b1$]^b`a$ #^@@@b1$^b`Y"[#[e[f[[[[[^^K^i & F h1$]^gd1$$ #8@@@@81$^8`a$ #8@@@@81$^8` #^@@@b1$^b` #^@@@b1$^b$ & F h#^ @@@ 1$^ a$gd$ #^@@@b1$^b`a$ K^L^~^^^^^^'_(_m_n_____````` #^@@@b1$]^b`$ & F h1$]^a$gd & F h1$]^gd 1$]^`a+a,aWaXaza|a}a~abbcbdbebfbbbbbb & F hp @p1$^pgd1$$ #8b@@@@81$^8`a$ #^@@@b1$^b` #^@@@b1$]^b`aaa*a+a,a.a/a0aVaWaXaZa[a\axaza{aafbbbbbccccccceeeeeeeeef f!f"fVfXfYfZffff颗 h@hCJOJQJh5CJOJQJhCJOJQJ)jhCJOJQJUhmHnHu,jh5CJOJQJUhmHnHu hCJh5CJOJQJhCJOJQJh jqhCJ2bbbbbbcccc/c0cPcQcfcgcccccccccc1$  @1$ & F hp @p1$^pgd p @@1$^ccceeeffUfVffff@gggahbhWiXiii $ ^@@<a$1$ #^1$ #^1$ $ ^@@a$ 8^@@@@81$^8`fff@ggiiijjjkkkkkkkllJmnnnn;o=o>o?oooooppppNqPqQqRq潨|v|pgpgpgpgpg jqhCJ hCJ hCJh5CJOJQJ,jh5CJOJQJUhmHnHuhCJOJQJ)jhCJOJQJUhmHnHuhCJOJQJhCJOJQJ)jhCJOJQJUhmHnHuh h>*@ h@h6>*@(iiiiijjjjdjejjjjjekfkkkkk  @1$ p @@b1$]b^ & F hp @bp1$]b^pgd1$kklllKmLmOnPnnn:o;oooppMqNqr ^@@@b1$]^b` 8^@@@@81$^8`1$ h@h^h`$ 8^@@@@81$^8`a$rrrrssuuuuuuu'u*v+vvvv v1$$ h^@@@@h1$^h`a$$ 8^@@@@81$^8`a$ ^@@@b1$^b` ^@@@b1$]^b`Rqrrrrrrrr'u)v+vvvvvwwwxxxxxxyyyyD{F{G{H{{{{{{{{{{{{{||uh5CJOJQJ,jh5CJOJQJUhmHnHuhCJOJQJ)jhCJOJQJUhmHnHuhCJOJQJ hCJ)jhCJOJQJUhmHnHuhOJQJh jqhCJ hCJhCJOJQJ.vvvwwwwawbwww0x1xdxexpxqxxxxxx  @1$  @b1$]b^ p @@b1$]b^ & F hp @bp1$]b^pgd1$xyyyyC{D{{{{|U|V|||0}1}} $ ^@@a$ #8^@@@@1$ #^@@@b1$^b` ^@@@b1$^b`  v#^@@@ #8^@@@@1$1$$ h@h1$^h`a$||||~~126)*^_tvāŁ!UTU\hj!w"$%&$&'(ӇՇևׇ !"伵 hCJ h56h56>*h5CJOJQJ)jhCJOJQJUhmHnHu h5hCJOJQJh jqhCJE}}~~1345G_*_t & F h#^@@1$^gd & F h^@@1$^gd  v#^@@@ #8^@@@@1$1$ $ ^@@a$UVWij!4?L_`v$If $$1$Ifa$  v#8^ #8^1$1$ $ ^@@a$vwxyz{ldddd$1$IfkdA!$$Ifl\) 7DR&    04 la{|}~jbbbb$1$Ifkd"$$Iflp\) 7DR&    04 lajbbbb$1$Ifkd"$$Iflp\) 7DR&    04 lajggggggQQ #^@@@b1$]^b`1$kdx#$$Iflp\) 7DR&    04 la !"#$҇Ӈˉ̉ij1$ p1$]^p & F h  1$]^ gd$1$a$ #^@@@b1$]^b`"̉ΉωЉ!I3uwxySUVW<>?@ϔєҔӔ<BǖɖuwxM)jhCJOJQJUhmHnHu jhCJOJQJ jhCJOJQJh5CJOJQJh jqhCJ hCJhCJOJQJB9ӎ !tHI 1$]^ & F h1$]^gd1$ #8^< #8^<<1$  #8^ #8^1$I34rstuRS;<Δϔ7 #^b1$]^b`1$ & F h1$]^gd 1$]^ & F h]^gd78Ȗɖ]uv$ #8^8^8`a$ #8^<<1$ #8^1$  8^ 8^1$1$$ #bb1$^b`a$$ #^b1$^b`a$vwyz{MNMN$ #8^1$a$$ #J^~ @F1$^F`a$$ #J^F1$^F`a$ v8#J^F^F` $ #J^1$a$1$ܚޚߚgijkۛݛޛߛ8dp579:;`bcdߟ-Mޢʣˣ̣ͣУtuvwιίιί)jhCJOJQJUhmHnHuhCJOJQJ)jhCJOJQJUhmHnHuhCJOJQJ hCJ h5h jqhCJ hCJhCJOJQJ:ܚfgڛۛ7856ѝҝghi #^1$^`1$$ #J^F1$^F`a$ v8#J^F^F`$ #8^1$a$ #[pp1$]^p` #[pp1$]^p`67_`ޟߟ,-1$ #F^F1$^F`a$$ 8#F^F^F`a$ #Tpp1$^p` #8^1$ v8#^^` #^1$^`12LMޢߢ 45ij  @b1$]b^ p @@b1$]b^ & F hp @bp1$]b^pgd1$ v8#F^F^F` #F^F1$^F`ʣˣͣΣϣУ()NOtuwxy p @@b1$]b^1$ v8#J^F^F`  @1$ & F hp @bp1$]b^pgdyzΥϥ"NOlmn$ #J^1$^`a$$ & F h#^@@2 n1$^2 `na$gd$ #^@@n1$^`na$$ #^n1$^`na$1$wz|C̥ѥǧѧlpstuɫ̫ͫΫ234EH\]ͯ2>"s/4E̴̾ynh5CJOJQJ hCJ)jhCJOJQJUhmHnHuh jqhCJ hCJ jhCJOJQJhCJOJQJh56>*CJOJQJh5CJOJQJ hCJh5>*CJOJQJhCJOJQJh5CJOJQJ+©4Ԫ$%opȫɫ.$ #8T1$^`a$ #^<<1$ #8^1$$ #J^1$^`a$./0124EFGH\]ͯίد$ & F(($1$Ifa$gd$ & F(($1$Ifa$gd$1$a$ $1$a$1$"I4$ & F(($1$Ifa$gdEkds$$$Ifl0*V%,4 la$ & F(($1$Ifa$gd$ & F(($1$Ifa$gdEkd$$$Ifl0*V%,4 la"JKX|}z4Ekd%$$Ifl0*V%,4 la$ & F(($1$Ifa$gd$ & F(($1$Ifa$gdEkd$$$Ifl0*V%,4 la$ & F(($1$Ifa$gd}ɰze$ & F (($1$Ifa$gd$ & F(($1$Ifa$gdEkdo%$$Ifl0*V%,4 la$ & F(($1$Ifa$gd$ & F(($1$Ifa$gdɰʰI4$ & F(($1$Ifa$gdEkd&$$Ifl0*V%,4 la$ & F!(($1$Ifa$gd$ & F(($1$Ifa$gdEkd%$$Ifl0*V%,4 la)01z4Ekd&$$Ifl0*V%,4 la$ & F&(($1$Ifa$gd$ & F(($1$Ifa$gdEkdk&$$Ifl0*V%,4 la$ & F"(($1$Ifa$gd12>?no/0 @A_$ #8$ @@@@81$^8`a$$ #881$]^8`a$$1$a$$1$a$'g|-̼ϼA`!"w{_`rs$':;mrsx|ῸῸῸ梙h56CJ h5CJh56CJ hCJ h5CJ hCJ hCJh56CJ hCJ h5CJ h5hhCJOJQJh5CJOJQJ9_ط:|ݹ޹ b v#8$ @@@@`^``$ #8$ @@@@81$^8`a$bc-]?@AK_$ v#8$ @@@@($If^`a$ v#8$ @@@@^`$ v#8$ @@@@a$$ v#8$ @@@@a$ v#8$ @@@@ v#8$ @@@@`^`` _`abuu v#8$ @@@@$If^`nkd'$$Iflp0Z`'V04 labcdeuu v#8$ @@@@$If^`nkd'$$Iflp0Z`'V04 laefghuu v#8$ @@@@$If^`nkdo($$Iflp0Z`'V04 lahijkuu v#8$ @@@@$If^`nkd($$Iflp0Z`'V04 laklmnuu v#8$ @@@@$If^`nkd)$$Iflp0Z`'V04 lanopquu v#8$ @@@@$If^`nkd*$$Iflp0Z`'V04 laqrstuu v#8$ @@@@$If^`nkd*$$Iflp0Z`'V04 latuvwuu v#8$ @@@@$If^`nkd&+$$Iflp0Z`'V04 lawxyzuu v#8$ @@@@$If^`nkd+$$Iflp0Z`'V04 laz{|}uu v#8$ @@@@$If^`nkd<,$$Iflp0Z`'V04 la}~uu v#8$ @@@@$If^`nkd,$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkdR-$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkd-$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkdh.$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkd.$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkd~/$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkd 0$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkd0$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkd1$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkd1$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkd52$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkd2$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkdK3$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkd3$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkda4$$Iflp0Z`'V04 lauu v#8$ @@@@$If^`nkd4$$Iflp0Z`'V04 la׽"#$qqq``J v#8$ @@@@^`$ v#8$ @@@@a$$ v#8$ @@@@a$ v#8$ @@@@nkdw5$$Iflp0Z`'V04 la Okd6$$IflpFZ> "'   0    4 la$ v#8$ @@@@($If^`a$ v#8$ @@@@ !"bkd6$$IflpFZ> "'   0    4 la v#8$ @@@@$If^`"#$%&}bbb v#8$ @@@@$If^`kdB7$$IflpFZ> "'   0    4 la&'()*}bbb v#8$ @@@@$If^`kd7$$IflpFZ> "'   0    4 la*+,-.}bbb v#8$ @@@@$If^`kd<8$$IflpFZ> "'   0    4 la./012}bbb v#8$ @@@@$If^`kd8$$IflpFZ> "'   0    4 la23456}bbb v#8$ @@@@$If^`kd69$$IflpFZ> "'   0    4 la6789:}bbb v#8$ @@@@$If^`kd9$$IflpFZ> "'   0    4 la:;<=>}bbb v#8$ @@@@$If^`kd0:$$IflpFZ> "'   0    4 la>?@AB}bbb v#8$ @@@@$If^`kd:$$IflpFZ> "'   0    4 laBCDEF}bbb v#8$ @@@@$If^`kd*;$$IflpFZ> "'   0    4 laFGHIJ}bbb v#8$ @@@@$If^`kd;$$IflpFZ> "'   0    4 laJKLMN}bbb v#8$ @@@@$If^`kd$<$$IflpFZ> "'   0    4 laNOPQR}bbb v#8$ @@@@$If^`kd<$$IflpFZ> "'   0    4 laRSTUV}bbb v#8$ @@@@$If^`kd=$$IflpFZ> "'   0    4 laVWXYZ}bbb v#8$ @@@@$If^`kd=$$IflpFZ> "'   0    4 laZ[\]^}bbb v#8$ @@@@$If^`kd>$$IflpFZ> "'   0    4 la^_`ab}bbb v#8$ @@@@$If^`kd>$$IflpFZ> "'   0    4 labcdef}bbb v#8$ @@@@$If^`kd?$$IflpFZ> "'   0    4 lafghij}bbb v#8$ @@@@$If^`kd?$$IflpFZ> "'   0    4 lajklmn}bbb v#8$ @@@@$If^`kd @$$IflpFZ> "'   0    4 lanopqr}bbb v#8$ @@@@$If^`kd@$$IflpFZ> "'   0    4 larstuv}bbb v#8$ @@@@$If^`kdA$$IflpFZ> "'   0    4 lavwxyz}bbb v#8$ @@@@$If^`kdA$$IflpFZ> "'   0    4 laz{|}~}bbb v#8$ @@@@$If^`kdB$$IflpFZ> "'   0    4 la~}o^M< v8@@^`$ v#8$ @@@@a$$ v#8$ @@@@a$ v#8$ @@@@kd}B$$IflpFZ> "'   0    4 la_`rs{_==!$ v#8$ @@@@<<$If^`a$\kdB$$Ifl4''04 lalf4 v#8$ @@@@(($If^` v8@@^` v8@@x^`7kdC$$Iflr :' 8 T F  04 lal!$ v#8$ @@@@<<$If^`a$ v#8$ @@@@<<$If^` v8V@@<<$If^`Y@' v8V@@<$If^` v8V@@<$If^`kdFD$$Iflr :' 8TF 04 lal:kdE$$Iflr :' 8TF 04 lal v#8$ @@@@(($If^`  v#8$ @@@@<<$If^` v8V@@<<$If^`)*Y> v#8$ @@@@<<$If^` v8V@@<<$If^`kdE$$Iflr :' 8TF 04 lal*+,-.:kdgF$$Iflr :' 8TF 04 lal v#8$ @@@@<<$If^`.PQRST v#8$ @@@@<<$If^` v8V@@<<$If^`TUvY@' v8V@@<$If^` v8V@@<$If^`kdG$$Iflr :' 8TF 04 lal:kdG$$Iflr :' 8TF 04 lal v#8$ @@@@(($If^` v#8$ @@@@(($If^` v8V@@<$If^` v8V@@<$If^`Y> v#8$ @@@@<<$If^` v8V@@<<$If^`kdzH$$Iflr :' 8TF 04 lal:kd+I$$Iflr :' 8TF 04 lal v#8$ @@@@<<$If^` v#8$ @@@@<<$If^` v8V@@<<$If^`7Y@' v8V@@<$If^` v8V@@<$If^`kdI$$Iflr :' 8TF 04 lal789:;<:kdJ$$Iflr :' 8TF 04 lal v#8$ @@@@(($If^`<]^_`a v#8$ @@@@<<$If^` v8V@@<<$If^`abY@' v8V@@<$If^` v8V@@<$If^`kd>K$$Iflr :' 8TF 04 lal:kdK$$Iflr :' 8TF 04 lal v#8$ @@@@(($If^` v#8$ @@@@<<$If^` v8V@@<<$If^`Y> v#8$ @@@@<<$If^` v8V@@<<$If^`kdL$$Iflr :' 8TF 04 lal:kdQM$$Iflr :' 8TF 04 lal v#8$ @@@@<<$If^`uSSSSS!$ v#8$ @@@@<<$If^`a$\kdN$$Ifl4''04 lalf4 v#8$ @@@@(($If^` v#8$ @@@@ Y> v#8$ @@@@<<$If^` v8V@@<<$If^`kdN$$Iflr :' 8 T F  04 lal:kdNO$$Iflr :' 8TF 04 lal v#8$ @@@@<<$If^` !"#$ v#8$ @@@@<<$If^` v8V@@<<$If^`$%&':YKK, v#8$ @@@@(($If^` v#8$ @@@@kd P$$Iflr :' 8TF 04 lal:;CHQYl!$ v#8$ @@@@<<$If^`a$\kdP$$Ifl4''04 lalf4lmnoY> v#8$ @@@@<<$If^` v8V@@<<$If^`kdKQ$$Iflr :' 8 T F  04 lalopqrs:kd R$$Iflr :' 8TF 04 lal v#8$ @@@@<<$If^`stuvwx v#8$ @@@@<<$If^` v8V@@<<$If^`xyz{|YKKK. v#8$ @@@@x$If^` v#8$ @@@@kdR$$Iflr :' 8TF 04 lal g`$$ v8$ @@@@hh$If]h^h`a$ $ v8$ @@@@hh$If]h^h`a$!$ v#8$ @@@@hh$If]h^h`a$$ v#8$ @@@@$If^`a$ v#8$ @@@@$If^` RSNOYZ[\ $ v8$ @@@@h$If]h^`a$ $ v8$ @@@@hh$If]h^h`a$uuuuuWW$ v#8$ @@@@$If^`a$ v#8$ @@@@]kdzS$$IfTl&&04 laT$ v#8$ @@@@$If^`a$ W $%&*+ {|}_`ao۳h56CJ h6CJ hCJ hCJ jqhCJ h5 h5CJ h56h hCJ hCJ hCJ h5CJCWXYg$ v#8$ @@@@h$If^h`a$ v8VV$If]V^V` v#8$ @@@@VV$If]V^V` v#8$ @@@@VV$If]V^V`! v#8$ @@@@ZZdp$If]Z^Z`MMMMM3$ v#8$ @@@@$d %d &d 'd N O P Q a$$ v#8$ @@@@a$ v#8$ @@@@_kdS$$IfTl|04 laTMNXY:$ v8h$ @@@@$d %d &d 'd N O P Q ^`a$3$ v#8$ @@@@$d %d &d 'd N O P Q a$ pijlm9$ v8h$ @@@$d %d &d 'd N O P Q ^`a$:$ v8h$ !6$@@@@$d %d &d 'd N O P Q ^`a$ ,-OO<$ v8hN !6$@@@@@$d %d &d 'd N O P Q ^`a$:$ v8h$ !6$@@@@$d %d &d 'd N O P Q ^`a$9$ v8h$ @@@$d %d &d 'd N O P Q ^`a$45HJJJ:$ v8h$ !6$@@@@$d %d &d 'd N O P Q ^`a$<$ v8hN !6$@@@@@$d %d &d 'd N O P Q ^`a$=$ v8h$ !6$@@@@dh$d %d &d 'd N O P Q ^`a$Q0 v#8$ @@@@$d %d &d 'd N O P Q $ v8h$ !6$@@@@Zdh]Z^`a$$ v8h$ !6$@@@@Zdh]Z^`a$=$ v8h$ !6$@@@@dh$d %d &d 'd N O P Q ^`a$>QRmn:$ v8h$ @@@@$d %d &d 'd N O P Q ^`a$:$ v8h$ @@@@$d %d &d 'd N O P Q ^`a$[N:$ v8h$ 6$@@@@$d %d &d 'd N O P Q ^`a$:$ v8h$ !6$@@@@$d %d &d 'd N O P Q ^`a$:$ v8h$ x@@@@$d %d &d 'd N O P Q ^`a$[\?@QR:$ v8h$ x@@@@$d %d &d 'd N O P Q ^`a$:$ v8h$ @@@@$d %d &d 'd N O P Q ^`a$<=EK=$ v8h$ !6$@@@@dh$d %d &d 'd N O P Q ^`a$:$ v8h$ !6$@@@@$d %d &d 'd N O P Q ^`a$:$ v8h$ @@@@$d %d &d 'd N O P Q ^`a$ v8$If]^`$ v8$If]^`a$$ v8h$ !6$@@@@V]V^`a$$ v8h$ !6$@@@@Zdh]Z^`a$/0<=>]^!$ v8h$ !6$@@@@V$If]V^`a$ v8 $If]^` v8$If]^` ^_`aQ3$ v#8$ @@@@$d %d &d 'd N O P Q a$$ v8h$ !6$@@@@V]V^`a$]kdnT$$IfTl    0    4 laTaoC^^^^^:$ v8$ @@@@$d %d &d 'd N O P Q ^`a$3$ v#8$ @@@@$d %d &d 'd N O P Q a$3$ v8$ @@@@$d %d &d 'd N O P Q a$ b,./0 di$\]bcefyz(),i; w<=*] h5CJ h5CJh56CJ h5 jqhCJ hCJ h56hP0 ab<$ v8$ @@@@$d %d &d 'd N O P Q ^`a$:$ v8$ @@@@$d %d &d 'd N O P Q ^`a$?fgN:$ v8 @@@@$d %d &d 'd N O P Q ^`a$:$ v8$ !6$@@@@$d %d &d 'd N O P Q ^`a$:$ v8$ @@@@$d %d &d 'd N O P Q ^`a$gP9$ v8$ @@@$d %d &d 'd N O P Q ^`a$:$ v8$ !6$@@@@$d %d &d 'd N O P Q ^`a$:$ v8:@@@@$d %d &d 'd N O P Q ^`a$, bcRR:$ v8$ 6$@@@@$d %d &d 'd N O P Q ^`a$9$ v8$ @@@$d %d &d 'd N O P Q ^`a$9$ v8@@@n$d %d &d 'd N O P Q ^`na$c"#l47$ v#8$ @@@@$$d %d &d 'd IfN O P Q a$$ v8h$ !6$@@@@V]V^`a$:$ v8$ 6$@@@@$d %d &d 'd N O P Q ^`a$:$ v8$ 6$@@@@$d %d &d 'd N O P Q ^`a$opPPPP?$ v8$ @@@@$$d %d &d 'd IfN O P Q ^`a$7$ v#8$ @@@@$$d %d &d 'd IfN O P Q a$7$ v8$ @@@@$$d %d &d 'd IfN O P Q a$ pdeyz?$ v8$ !6$@@@@$$d %d &d 'd IfN O P Q ^`a$?$ v8$ @@@@$$d %d &d 'd IfN O P Q ^`a$ *+jB?$ v8:@@@@$$d %d &d 'd IfN O P Q ^`a$?$ v8$ !6$@@@@$$d %d &d 'd IfN O P Q ^`a$?$ v8$ B@@@$$d %d &d 'd IfN O P Q ^`a$jkD?$ v8$ !6$@@@@$$d %d &d 'd IfN O P Q ^`a$=$ v8@@@n$$d %d &d 'd IfN O P Q ^`na$=$ v8$ @@@$$d %d &d 'd IfN O P Q ^`a$<=D=$ v8@@@n$$d %d &d 'd IfN O P Q ^`na$=$ v8$ @@@$$d %d &d 'd IfN O P Q ^`a$?$ v8:@@@@$$d %d &d 'd IfN O P Q ^`a$C=$ v8$ @@@$$d %d &d 'd IfN O P Q ^`a$?$ v8:@@@@$$d %d &d 'd IfN O P Q ^`a$?$ v8$ !6$@@@@$$d %d &d 'd IfN O P Q ^`a$ C?$ v8:@@@@$$d %d &d 'd IfN O P Q ^`a$?$ v8$ !6$@@@@$$d %d &d 'd IfN O P Q ^`a$=$ v8@@@n$$d %d &d 'd IfN O P Q ^`na$ uvD?$ v8$ !6$@@@@$$d %d &d 'd IfN O P Q ^`a$=$ v8@@@n$$d %d &d 'd IfN O P Q ^`na$=$ v8$ @@@$$d %d &d 'd IfN O P Q ^`a$vD=$ v8@@@n$$d %d &d 'd IfN O P Q ^`na$=$ v8$ @@@$$d %d &d 'd IfN O P Q ^`a$?$ v8:@@@@$$d %d &d 'd IfN O P Q ^`a$<fI,$ v8h$ !6$@@@@V]V^`a$$ v8h$ !6$@@@@V]V^`a$YkdT$$Ifl'8(04 la?$ v8$ 6$@@@@$$d %d &d 'd IfN O P Q ^`a$<=>+,\]^_ vT !6$@@@V]V vT !6$@@@] vT !6$@@@V]V^`$ v8h$ !6$@@@@V]V^`a$_,=>GH~):;>$ v8b !6$@@@V]V^`a$ v8b !6$@@@V]V^`]@G:;=>gh%,56P \ ^ { |   I!ACp^wxy_oᄊﰩ賓ٓ!jh@UhmHnHu h6 h6@ hCJh@CJh5@CJ h5@ h@ h5 h5CJ(jhUhmHnHuh h6CJ hCJ9>Rfg%& v8hbP@AV]V^`$ v8bP@AV]V^`a$'$ v8bP@AV0&#$/0$1$]V^`a$&$ v8bP@AV0&#$/0$]V^`a$5QR() v8hbP@AV]V^`  \ ^ {     '$ v8bP@AV0&#$/0$1$]V^`a$ v8hbP@AV&d P ]V^` v8hbP@AV]V^`    !BCpqOPde v8hbP@AV]V^`wxy_o8!9!##$ v8hbP@AVx]V^`'$ v8bP@AV0&#$/0$1$]V^`a$ v8hbP@AV]V^` v8hbP@AV&d P ]V^`o8!9!q!u!#$J%!(4(5(2))M+N+|+}++R/i/25262"7$7B7n88[:*</<====PHQHSHTH`HkHlHmHqHֶzhCJOJQJhOJQJh5CJOJQJhCJ OJQJ)jhCJ OJQJUhmHnHujhUhmHnHu!jh@UhmHnHu h5CJ( h6@ h5 h5@ h@h h@+$$J%K%&&!(5(2)3)))))M+N+ v8hbP@AV&d P ]V^` v8hbP@AVx]V^` v8hbP@AV]V^`N+i+|+++G,H,--d.e.Q/R/i/j/ 1225262z3{35 v8hbP@AV]V^`'$ v8bP@AV0&#$/0$1$]V^`a$5 5i6j6#7C7D7m8n888Z:*<+<,<-<.</<==== v8hbP@AV&d P ]V^` v8hbP@AV]V^`==;@<@BBCEEEEFFGGzzzzzz v8hbP@@@AV|]V^`| v8bP@AVh]V^h` v8hbP@AV]V^` v8hbP@AV]V^`'$ v8bP@AV!0&#$/0$1$]V^`a$GGGPHQHRHSH`HkHlH v8hbP@AV$If]V^` v8hbP@AV&d P ]V^` v8hbP@AV]V^` v8hbP@@@AV|]V^`| lHmHnHoHpHqHHHuuuuuR" & F# hv8 bP@AVd$If]V^gd v8hbP@AV$If]V^`nkdZU$$Ifl0`'6 04 laqHHHHHHHHHHHHII%I&IIIII KKKKK4L5LfLgLhLLLLLLLLLL9M:M;MuMvMwMMMMNNN6N7N8NtNuNvN{N|N}N~NNNʵh5CJOJQJhCJ OJQJ)jhCJ OJQJUhmHnHuhCJOJQJhhOJQJhCJOJQJhCJOJQJh5CJOJQJ>HHHHHHHH v8hbP@AV$If]V^` & F# v8hbP@AV$If]Vgd & F# v8bP@AVd$If]Vgd" & F# hv8 bP@AV $If]V^ gdHHHHH|aFF v8hbP@AV$If]V^` v8hbP@AV$If]V^`kd V$$Ifl4FP`'`6 0    4 laf4HHHIpQ v8hbP@AVd$If]V^` v8hbP@AVd$If]V^`okdV$$Ifl40`' 6 04 laf4IIII&IUIuuuR" & F# hv8 bP@AV<$If]V^gd v8hbP@AV$If]V^`nkdW$$Ifl 0`'6 04 laUIIIIII3lkd(X$$Ifl0`'6 04 la v8hbP@AV$If]V^`  & F$ hv8 bP@AV<$If]V^gd" & F# hv8 bP@AV $If]V^ gdIIII[J K K  & F% hv8 bP@AV<$If]V^gd" & F# hv8 bP@AV<$If]V^gd v8hbP@AV$If]V^` KKKK{K|KKKw\\\>\$ v8hbP@AV$If]V^`a$ v8hbP@AV$If]V^` v8hbP@AV$If]V^`lkdX$$Ifl0`'6 04 laKKKKKKKK LL+LuZZZZZZZZ v8hbP@AV$If]V^`lkdVY$$Ifl0`'6 04 la v8hbP@AVP$If]V^` +L5L6L>LFLPLXLeLfL$ v8hbP@AV$If]V^`a$ v8hbP@AV$If]V^`fLgLhLiL~L?$$$ v8hbP@AV$If]V^`kdY$$If/4ֈ~ ^&`'`$ F04 /af4~LLLL v8hbP@AV$If]V^`$ v8hbP@AV$If]V^`a$LLLLL?$$$ v8hbP@AV$If]V^`kd [$$If/4ֈ~ ^&`' $ F04 /af4LLLL v8hbP@AV$If]V^`$ v8hbP@AV$If]V^`a$LLLLL?$$$ v8hbP@AV$If]V^`kd\$$If/4ֈ~ ^&`' $ F04 /af4LLLL v8hbP@AV$If]V^`$ v8hbP@AV$If]V^`a$LLLL'M?$$$ v8hbP@AV$If]V^`kd]$$If/4ֈ~ ^&`' $ F04 /af4'M4M8M9M v8hbP@AV$If]V^`$ v8hbP@AV$If]V^`a$9M:M;MljLLLL$ v8hbP@AV$If]V^`a$kd#i$$Ifl\ '    04 la>l?l@lAlBlCljLLLL$ v8hbP@AV$If]V^`a$kdi$$Ifl\ '    04 laClDlElFlGlHljLLLL$ v8hbP@AV$If]V^`a$kdj$$Ifl\ '    04 laHlIlJlKlLlMljLLLL$ v8hbP@AV$If]V^`a$kdj$$Ifl\ '    04 laMlNlOlPlQlRljLLLL$ v8hbP@AV$If]V^`a$kdk$$Ifl\ '    04 laRlSlTlUlVlWljLLLL$ v8hbP@AV$If]V^`a$kd{k$$Ifl\ '    04 laWlXlYlZl[l\ljLLLL$ v8hbP@AV$If]V^`a$kdk$$Ifl\ '    04 la\l]l^l_l`laljLLLL$ v8hbP@AV$If]V^`a$kdkl$$Ifl\ '    04 laalblcldlelfljLLLL$ v8hbP@AV$If]V^`a$kdl$$Ifl\ '    04 laflglhliljlkljLLLL$ v8hbP@AV$If]V^`a$kd[m$$Ifl\ '    04 laklllmlnlolpljLLLL$ v8hbP@AV$If]V^`a$kdm$$Ifl\ '    04 laplqlrlsltluljLLLL$ v8hbP@AV$If]V^`a$kdKn$$Ifl\ '    04 laulvlwlzllllljPCAAAA $$d N a$$ v8hbP@AV]V^`a$kdn$$Ifl\ '    04 lakwlylzllllllnn-oEottuGuuuvxx@yAyWy7|8|||6}7}9}hmǀɀGLMux{vxՉ؉&)M维窟h6CJOJQJhCJH*OJQJhCJOJQJ h6@ h@ h5 h6 hH* h5CJh5CJH* h5CJhjhUhmHnHu hCJ:lNnOrr9sttuuv@yAyWybz8}9}Mv|G h@@^` h@ h@x$ h@a$ $ h@xa$MN!%  WYӖřǙZ\IJ$&ΠѠEFfkӦԦħlp!#n0238=Dī(JJLMccŻŻŶŶ h6 hH* h5hh5CJOJQJh6CJOJQJh>*CJOJQJhCJOJQJhCJH*OJQJHG ߖΜѠço#$nج \M h*@@*^*` h@@x^` h@@^`Mc?`cв\t & F, h*@@gd & F)gd & F(gd h*@@*^*` h*@@ & F'gdc\C. $ENǽϽV![ru#-.BCD]m.<%3|~.4589J[oϾ h>* h0Jj;ohUjhU h5CJ hH*h56>*CJh56CJh h6ItƳCŴ. $K$ h@a$ h@ 8h@^` & F+gd h*@@  !h*@@ & F*gdDENǽϽV-Vu#-] $$$ h@a$$ h@a$ $ h@xa$]m.<%3.J[o2 $ h@xxa$ $ h@xa$$ h@a$2C:Q $6>T`t'0GR^*9xOSmnj  <=oc jhCJ hCJH* h>*CJ hCJ h6H* h5CJ hH*h h6N2C:Q $6>T`t' $ h@xa$$ h@a$0GR^*9x,-.RSmI! $ h@xxa$ $ h@xa$$ h@a$!l & $<<$Ifa$$a$$ h@a$ $$$ h@a$ $$$ h@xa$$3=Hh`ZODO $<$Ifa$ $<$Ifa$$If<$Ifkd* h5CJh h6 hH*:sXy_g1C4':Nw  i q    #  $$$ hB@x^`a$ $$$ h@a$$ h@a$    RKj9[Xv Q!$ hB@#x^#`a$Q!!"u#$s$4%%&&'((((())))8)9):);) 0^`0$ hB@#x&d P ^#`a$$ hB@#x^#`a$;)S)T)`))))X,Y,Z-[-p-7/8/>/001h5i56 688>@@AA1$p-8/>/017282G3H333`4a4d5g5i5566R7S78899::;;<<====P>Q>>>>>D?I???@AyCCDD+F,FGGGGIIKKMMNNOOPPPPQQFRGRQRSRT Th>*OJQJh6OJQJhH*OJQJh5CJOJQJh56CJOJQJhOJQJNAfBgBxCyCDDGGIIMMOOPPkTlTWWZZ\\]]^'_(_1$ TlTT)V1VVVWWXXYYYYYY_ZhZZZB[K[[[[[(\1\n\{\|\~\\\\\J]S]]^ ^__(_1_G`H`W``````bbeAef7ff;gZgggggggghhhhhiijjHk[kYlh56CJOJQJh5CJOJQJhH*OJQJh6OJQJhOJQJQ(___V`W`````bbeeffffYgZggggghhhhhh !1$1$hiiGkHk[kdlelolmmmnnqqrrerfrssuu9u@wAwwwd1$Ylblelolmmmnnnppqqrssssu9uw xvxx:yCyyyyy(z1zoz~zzz {{<{I{J{S{})}~~~~}~̀ 3BLMYZ[]ށ;KǼ hCJh6CJOJQJhCJOJQJhH*OJQJh5OJQJh5CJOJQJhOJQJh6OJQJHw xuxvxx9y:ynzoz;{<{}})}}}̀3[݁ށ; h@h1$^h`$a$1$Kar-<nĄ  ͆+Co~9EYm "oq݋n#ߍRTV_Sct(*NhCJOJQJh5CJOJQJh5CJOJQJhH*OJQJh56CJOJQJh56OJQJh5OJQJh6OJQJhOJQJ<a-mڄ+o9Y "mnUVR$1$a$1$RSbcMNlkds$$IflF }6 0    4 la (($1$If<1$ ĕܕݕ  ($1$If ($1$If$1$If $1$If d($If #BCQRaoc[[[Q ($1$If$1$If $1$If d($Ifkdt$$IflF }6 0    4 laabooc[[[Q ($1$If$1$If $1$If d($Ifkd*CJ hCJh5>*CJ h>*CJh5>*CJOJQJh5>*@CJh>*@CJh@CJh5>*CJh hCJh59CJ;ķϷ678BPVܿhEkd|$$Ifl0'( 4 laEkd{$$Ifl0'( 4 la $$1$Ifa$ ܿݿ޿ZEkd|$$Ifl0'( 4 la $$1$Ifa$Jkdd|$$Ifl4 0'( 4 laf4 $$Ifa$ ihU$P$1$If^`Pa$Ekd[}$$Ifl0'( 4 laEkd }$$Ifl0'( 4 la $$1$Ifa$ i9:R5kd~$$Ifl4'8(4 laf4 $$1$Ifa$$$$d1$IfNa$Ekd}$$Ifl0'( 4 la$P$1$If^`Pa$ 8:;tuy   cdeúֺֺúֺֺֺֺ h5CJh6>*CJ h6CJ hCJh5>*CJh5>*@CJh@CJh5>*CJ h>*CJ hCJ h5CJhh5>*CJ>:tu \lkdN~$$Ifl0((X 04 la $$1$Ifa$$ d$Ifa$$ h$1$Ifa$ !$a$ x$ h$1$Ifa$lkd~$$Ifl0((X 04 la $$1$Ifa$ xx $$1$Ifa$$ h$1$Ifa$lkdn$$Ifl0((X 04 laxx $$1$Ifa$$ h$1$Ifa$lkd$$Ifl0((X 04 laxx $$1$Ifa$$ h$1$Ifa$lkd$$Ifl0((X 04 laxx $$1$Ifa$$ h$1$Ifa$lkd$$Ifl0((X 04 laxx $$1$Ifa$$ h$1$Ifa$lkd$$Ifl0((X 04 lacde*\kd΂$$Ifl4((04 laf4 $$1$Ifa$lkd>$$Ifl0((X 04 laen|lkdV$$Ifl0((X 04 la $$1$Ifa$ oyPXvwxS[lmnpPY\]^_ȸh5>*CJOJQJ h5CJhh5>*CJOJQJh5>*CJ h>*CJ hCJh5>*@CJh@CJh5>*CJh5>*CJ h>*CJ hCJ87kt $$1$Ifa$$$$d1$IfNa$lkd$$Ifl0((X 04 lavwxKEkd $$Ifl0'( 4 la $$1$Ifa$$1$a$\kd$$Ifl4((04 laf4lmnop $$1$Ifa$Ekd[$$Ifl0'( 4 la $$1$Ifa$ \]hEkd$$Ifl0'( 4 la $$1$Ifa$Ekd$$Ifl0'( 4 la]^_ QEkd$$Ifl0'( 4 la$ VV$1$If^V`a$ $$1$Ifa$EkdH$$Ifl0'( 4 laX[#$  \]^_wrzǺкǺккАuǺh5>*OJQJh5>*CJ h>*CJ hCJh5>*@CJOJQJh@CJ h>*CJ hCJh5>*CJOJQJh5>*CJh5>*CJOJQJh5>*CJOJQJh6>*CJ h6CJ hCJ.$aEkd-$$Ifl0'( 4 la $$1$Ifa$5kd$$Ifl4'8(4 laf4$ hh$1$If^h`a$  \\]$1$If $$1$Ifa$Ekd|$$Ifl0'( 4 la$ VV$1$If^V`a$ ]^_j~.$ VV$1$If^V`a$ $$1$Ifa$Ekdˇ$$Ifl0'( 4 la ?shUUJ $$1$Ifa$$$$d1$IfNa$Ekdi$$Ifl0'( 4 la $$1$Ifa$Ekd$$Ifl0'( 4 la<=r[[$ VV$1$If^V`a$Ekd $$Ifl0'( 4 la $$1$Ifa$$1$a$5kdƈ$$Ifl4'8(4 laf4 z;Ilp#+<=>JKRS()*+38@RSTU]EM_`ano̶٭٭ h5CJh5>*CJh5>*CJOJQJh6>*CJ h6CJ hCJh5>*CJOJQJh5>*CJOJQJ h>*CJ hCJA=>KS()*+RShEkd$$Ifl0'( 4 la $$1$Ifa$Ekd\$$Ifl0'( 4 la STU_`aohEkdI$$Ifl0'( 4 la $$1$Ifa$Ekd$$Ifl0'( 4 lao+OhS_[\]mn`hvwxOWjmno  !ӿ淮ِٖٖh5>*CJ h>*CJ hCJh5>*CJh5>*@CJOJQJh>*@CJh@CJh5>*CJOJQJ h>*CJ hCJh5>*CJOJQJh5>*CJOJQJ h>*CJ hCJ2 GUEkd$$Ifl0'( 4 la$ B $1$Ifa$ $$1$Ifa$Ekd$$Ifl0'( 4 la K[\]nvw $$1$Ifa$Ekd6$$Ifl0'( 4 la$ dd$1$If^d`a$ wxjklmnohU$$$d1$IfNa$Ekdԋ$$Ifl0'( 4 la $$1$Ifa$Ekd$$Ifl0'( 4 la !"-9=>?IPXGkdx$$Iflz0'( 4 la $$1$Ifa$5kd1$$Ifl4'8(4 laf4 $$1$Ifa$$$$d1$IfNa$ !"89$,=>?P"26789HIJY9A)1BCD$,=>?[\r'()*opqr?@A󼵼h5>*CJ h>*CJ hCJ h5CJ h6CJ h>*CJ hCJh5>*CJOJQJh5>*CJh5>*CJOJQJDP6789Al$ d$1$Ifa$ d$1$IfEkdˌ$$Ifl0'( 4 la $$1$Ifa$ }k`II$ VV$1$If^V`a$ $$1$Ifa$Ekdi$$Ifl0'( 4 la$1$IfEkd$$Ifl0'( 4 laHIJYTII $$1$Ifa$Ekd$$Ifl0'( 4 la$1$IfEkd$$Ifl0'( 4 la$ VV$1$If^V`a$BCD[hh``$1$IfEkd$$Ifl0'( 4 laEkdV$$Ifl0'( 4 la $$1$Ifa$ hx=>?K[qr(Ekd$$Ifl0'( 4 la $$1$Ifa$$1$If ()*opqr hXXXX d$1$If^Ekd$$Ifl0'( 4 la $$1$Ifa$EkdC$$Ifl0'( 4 la $:;<=>?@Atti $$1$Ifa$$$$d1$IfNa$Ekd$$Ifl0'( 4 la$ d$1$Ifa$$ d$1$If^a$ d$1$If^  '(+,-wmm ^` $^`a$ $^`a$$d$d&dNPa$$ v8hbP@AV]V^`a$d5kd>$$Ifl4'8(4 laf4  '(,2#+4SD L -     ) K$#+8@08/7¸ h>*CJ hCJh>*CJOJQJhCJOJQJh5>*CJOJQJ h>*CJ hCJh59CJh569CJ OJQJ h6CJ hCJ ?  56MN' (     * + LM $^`a$ ^`I}%&)*9: ^` $^`a$$$d1$Na$$P$d1$Na$  !!b"c"""""W# vh@h^h` ^`0"8"""`###$$$~&&&'''((++++,,,,. .".[.y.../L00011?1B1G1^2v22344 44444444 hCJhCJhmHnHujhCJU!jhCJUhmHnHuh5CJOJQJ h>*CJ hCJhCJOJQJh>*CJOJQJ?W#X#Y#Z#[#\#]#^#_#`###$$$$&&''($ v@^`a$$$d1$Na$$P$d1$Na$ $^`a$ v@^`(()j*k*++++,,,,..\.]...//2030405060708090 v@^`90:0;0<0=0>0?0@0A0B0C0D0E0F0G0H0I0J0K0L0001$ v@^`a$$$d1$Na$$P$d1$Na$ v@^`11@1A1B1H1k1z1{11111111122"222N2]2w2$ v@^`a$$ v@^`a$ v@^`w2x222222222222222233#373d3|3333$ v@^`a$$ v@^`a$3333333333333333333333333333$ v@^`a$3333334444 4y4444444 5 &d P de1$1$ & #$/0$$$d1$Na$$P$d1$Na$$ v@^`a$$ v@^`a$4445 5!5"5[5\5^5o5y5555555555555666666 7t7|77788N9]999h:~:3;D;X<c<==>(>> ???|@@@@@@@@žоооŴЭ hCJh56CJ h5CJhCJOJQJ h5CJh5CJOJQJ hCJ j thhhOJQJh5CJ$OJQJh5CJ OJQJ> 5\5]5^5z5555555$ @<<$1$Ifa$d&d 1$P  & F-d1$^gd & F-d1$^gd & F-1$^gd1$d&d 1$P  h@x 555566666t7u7778uuuuuuuuuuu h@h1$^h` @d1$^`ikdɞ$$Ifl$ $   04 lalp  88N9O999h:i:2;3;X<Y<==>>>>??|@}@@@@@$$ h@h1$^h` h@h1$^h`@ A AQBRB+C,CEEzF{FGG&H'HJJJJ/L0LNNNN$$ h@h1$^h`  h@h^h` h@h1$^h`@ A AQBSBiB+CTCEEzFFGG&H8HJ,JJ1K/LCLN NNNOO^P_PcPdPuPwPzPPPPPvQQQQR.R=RvSS TTTTTUUNV\VWWXXXXXXYYYYYYZ6Z7Z8ZEZZZ[[*\ h6CJhCJOJQJ h5CJh5CJOJQJhh56CJ hCJPNOO^P_PcPyPzPPPPPuQvQQQQQRR.R/R=RuSvS$$ h@h1$^h`  h@h^h` h@h1$^h`vSS T TTTTTUUUMVNV\VWWWXXXXXXYYY$ v8h@h^h`a$ h@h1$^h`YZZ7Z8ZEZZZZ[[[)\*\.\I\J\Q\u]v]}]]]]^^^^^ h@h1$^h`*\.\7\:\E\G\J\Q\\\v]}]]]^^^^,_8___``aabbccccdd.e/enYnZnjn+o7okpzpqqrr>rCrMrYruu#uwwwLyWy|yz4z5z?zXzzh hCJh56CJ h5CJZ^+_,_8____```aaabbcccccddd.e/enYnZnjn*o+o7ojpkpzpqqqrrrBr h@h1$^h`$$ h@h1$^h`BrCrMruuuwwwKyLyWyzz4z5z?zzzz{{{{{{$$ h@h1$^h` h@h1$^h`zz{{{{||| ~~'(6R`ac1?@B;ÅՆ$/ΉcqŌ,/`bhh56CJ hCJ h5CJZ{||| ~ ~~ '(6QRc$$ h@h1$^h` h@h1$^h`01BԆՆ$$ h@h1$^h` v8h@>^`> h@h1$^h`#$/͉ΉbcqŌ, v8h@h^h` h@h1$^h`$$ h@h1$^h` /abtِؐ'(?c$$ h@h1$^h` $$ h@1$ h@h1$^h` h@1$bqrtِ   (78:=?dstvxzܑ̑͑ݑߑ)*,-/ߒ /0257kl{|~ݓ   +,.h h56 h5 h6CJ hCJh56CJ h5CJScdz̑͑ߑ/ߒ 7kl~ܓݓ v8h@h^h` h@h1$^h`5  ̖@AVabx$$ v8h@h^h`$$ h@$$ h@h1$^h` h@h1$^h`.0235  ̖>PQSTVbqrtvxXghjlmn34CDFIKh56CJOJQJh5CJOJQJhCJOJQJ hCJ h5CJh56CJOxWXn34K01@ v8h@h^h` h@h1$^h` 8h@h^h`0@#%&44EٞΠPQXϣ֣+5Z uxڧۧ&=>LEF_`n\j,-;'(6ҰӰhh56CJOJQJ h6CJhCJOJQJh5CJOJQJh56CJ hCJ h5CJJ@%&434E؞ٞ$$ v8h@h^h`$$$$ h@h1$^h` h@h1$^h`Π PQXΣϣ֣*+5tu$ v8h@h^h`a$ h@h1$^h`wxڧۧ&=>LEF_`n[\j,-$ v8h@h^h`a$ v8h@h^h` h@h1$^h`-;'(6ҰӰʱZ[itu$ v8h@h^h`a$ h@h1$^h`ʱ[ituAVWa;<CùιкѺݺ AHaKOPcnQ\%3`nLM[ab h6CJ h5CJh5CJOJQJh56CJ hCJhCJOJQJQ@AVWa;<C¹ùιкѺݺ v8h@h^h` h@h1$^h`ݺ  @AHOPcdnPQ\$% h@h1$^h`$ v8h@h^h`a$%3_`nLM[$ v8h@h^h`a$ h@h1$^h`b szr| Sa \kDEP BCM*^_jN\,-99=LhCJOJQJh56CJh5CJOJQJh h5CJ hCJR rszqr| RSa h@h1$^h`  [\kDEP $$$ v8h@h^h`a$ h@h1$^h` BCM*$ v8h@h^h`a$ h@h1$^h`$$$$ h@h1$^h`^_jMN\,-9$$ h@h1$^h` h@h1$^h`$ v8h@h^h`a$89=hip89:;Hst h@h1$^h`LOVWdfip;HtIV*CDRFT34>LW'6!jhCJUhmHnHujhUmHnHuh5CJOJQJ hCJ h6CJh56CJ h5CJHtHIV h@h1$^h`$$ h@h1$^h`)*CDREFT$$ h@h1$^h`$$  h@] h@h1$^h`34>KLW&'6L h@h1$^h`6M\z jySb[uv[h23>P_ABP   "";J h6CJh56CJhCJOJQJh5CJOJQJ h5CJ hCJQLM\yz  ijyRSb$$ h@h1$^h`$$$$ 8h@h^h` h@h1$^h`Z[uvZ[h23>$$ h@h1$^h`$ 8h@h^h`a$ 8h@h^h` h@h1$^h`>PQ_ABP $ v8h@h^h`a$ h@h1$^h`$$ h@h1$^h`$$$ v8h@h^h`a$    "$$ v8h@h^h`$$ h@$$ h@h1$^h` h@h1$^h`":;JBCP$ v8h@h^h`a$ h@h1$^h`CPKVvGHS  R_ 0gn:;W^78stuh5CJOJQJ j thCJ h6CJh5CJOJQJhCJOJQJh56CJ h5CJ hCJGJKVuv$$ h@h1$^h` v8h@h^h` h@h1$^h`GHS  QR_ 8h@h^h`$ v8h@h^h`a$ h@h1$^h` fgnVW^67$$ h@h1$^h`$$ h@h1$^h`7stuvw B a    |||||||$$ bAA& #$*$/ ,p@ P !$*$$ ,p@ P !$*$a$$ v@^`a$ h@h1$^h`d1$ h@x$dNuvwo q 2         !   /m˽oaP@@h>*B* CJOJQJph!h5>*B* CJOJQJphhB*CJOJQJph!h5>*B*CJOJQJphhB*CJOJQJphh5B*CJOJQJphh5B*CJOJQJphh5B*H*OJQJphh5B*OJQJphhB*phhB*CJOJQJphh5B*CJOJQJphh89CJ hCJ 2 3 R u    eE$$ ,p@ P !$x*$ ,p@ P !$x*$$ ,p@ P !$*$a$$$ ,p@ P !$*$a$ $$$ ,p@ P !$*$a$ $$ pAA*$$$ bAA& #$*$/  "   0lmLM ,p@ P !$*$$ ,p@ P !$*$$$ ,p@ P !$*$$$ ,p@ P !$x*$mM OZ*Sa  #&^PұҠұҁn^h5B*CJOJQJph$h56>*B* CJOJQJph!h56B*CJOJQJphhB*CJOJQJph!h5>*B*CJOJQJphh>*B*CJOJQJph!h5>*B* CJOJQJphhB*CJOJQJphh>*B* CJOJQJphh5B*CJOJQJph$M NOYZx*H`a$ ,p@ P !$*$$$ ,p@ P !$*$ ,p@ P !$*$ %&SE]^MN ,p@ P !$*$#\^LN=>? 68FGH.\]a˜zl\K\K\l!h5>*B* CJOJQJphh5B*CJOJQJphhB*CJOJQJph!h5>*B*CJOJQJph!h5>*B*CJOJQJph!h5>*B* CJOJQJphhB*CJOJQJphh6B*CJOJQJphh5B*CJOJQJph$h56>*B* CJOJQJph!h56B*CJOJQJph>?@78GHy#n o   !! ,p@ P !$*$$$ ,p@ P !$*$ao    !!!"""n###$9$W$$$$%%%%%#&$&%&'&(&*&±žˆ|qfh5CJOJQJh5CJOJQJh0JCJOJQJ*jahB*CJOJQJUph$jhB*CJOJQJUph!h56B*CJOJQJphhB*CJOJQJphh5B*CJOJQJphhB*CJOJQJph!h5>*B* CJOJQJph!!!""""m#n### $$.$X$$$%&&&'&(&)&*&&& @@ ,p@ P !$*$*&+&&&&&'''='T'U'''((E(F()()a++...g4v4888:::>$>?@@OBәӸކ{pp{p{p{fphCJOJQJh5CJOJQJh5CJOJQJhCJOJQJ h6h(jh5OJQJUhmHnHuhCJOJQJhOJQJh5OJQJhCJ OJQJh5CJOJQJh5CJOJQJ,jh5CJOJQJUhmHnHu&&&&&&&&&&&' '''='U'''  !`'@@$If$ !`'@@$Ifa$$ `'@@$Ifa$$ `'@@x$Ifa$ `'@@$If `'@@x$If   &@@x1$'''''''F::::: `'@@$Ifkd~$$IflֈvTHP!T3 p04 la'''''''8kd8$$IflHֈvTHP!T3 p04 la `'@@$If'''''''8kd$$IflHֈvTHP!T3 p04 la `'@@$If''''''(8kd$$IflHֈvTHP!T3 p04 la `'@@$If(((((((8kdr$$IflHֈvTHP!T3 p04 la `'@@$If(( ( ( ( ( (8kd0$$IflHֈvTHP!T3 p04 la `'@@$If ((((((( `'@@$If(((((((D88888 `'@@$Ifkd$$IflHֈvTHP!T3 p04 la(((((((8kd$$IflHֈvTHP!T3 p04 la `'@@$If( (!("(#($(%(8kdj$$IflHֈvTHP!T3 p04 la `'@@$If%(&('((()(*(+(8kd($$IflHֈvTHP!T3 p04 la `'@@$If+(,(-(.(/(0(1(8kd$$IflHֈvTHP!T3 p04 la `'@@$If1(2(3(4(5(6(7(8kd$$IflHֈvTHP!T3 p04 la `'@@$If7(8(9(:(;(<(=( `'@@$If=(>(?(@(A(B(C(D88888 `'@@$Ifkdb$$IflHֈvTHP!T3 p04 laC(D(E(F(`+a+81// `'@@kd $$IflHֈvTHP!T3 p04 la `'@@$Ifa++++...../[///.0`000$1b11 `'X !(#$%@JBBBB]^ %@Jxx]^$ @]^a$ @]^ $ @^a$112L22213q33 4f4g4u4445@555 %@Jxx]^$ `'hX !(#$%@JBBBB]^a$ `'hX !(#$%@JBBBB]^ `'X !(#$%@JBBBB]^56?666)777888 8P888(9^999S: %@Jxx]^$ @]^a$ `'hX !(#$%@JBBBB]^ `'X !(#$%@JBBBB]^S::::::;i;;;;V<<<=<====>>$>%> %@Jxx]^$ @]^a$ `'X !(#$%@JBBBB]^%>>>>>>>>? ? ? ? ? ???@@@@&AAA `'V((]V^ `'Z]Z^ `'h@Z]Z^ `'h@*]*^AOBBB*CCCDlDD'EEEE=F~~~ `'8%R&@@@J@(]^ `'8F%R&@@@J@(]^ `'8%R&@@@J@]^ `'8%R&@@J@]^$ `'V((]V^a$ `'V((]V^OBBB=FWF'G3GGGGGNIIkJyJJJLL'M/MdMMMMMfNNN6OmOOOq}}}}B~T~v~~~~~~~wwww `'8F@@@^ `'D%R&J@<(]^ `' J "#$&@JBBBBB]^$ `'8F@@@^a$ !`' 8FJ "#$&@@@JBBBBB<]^ `'hJ "#$&@JBBBBB<]^ ~ lmnvzfI `'hJ "#$&@JBBBBBx<]^ &@J<<]^% `'8F@@@P$d &d N P ]^# `'8F@@@$d &d N P ]^ `'8F@@@]^ `'8F@@@]^ `'8F@@@]^v̀rÁBRijklmԄ# `'hJ "#$&@JBBBBB<&d P ]^ `'hJ "#$&@JBBBBB<]^ԄՄքׄ؄لڄۄ܄DVx `'8F@@@^ `'D%R&J@<(]^ `' J "#$&@JBBBBB]^$ `'8F@@@^a$ !`' 8FJ "#$&@@@JBBBBB<]^" 0kkW &@J<<]^% `'8F@@@P$d &d N P ]^# `'8F@@@$d &d N P ]^ `'8F@@@]^ `'8F@@@]^ `'8F@@@]^ `'8F@@@^0ه%~ψ Y_يڊۊ>?@A# `'hJ "#$&@JBBBBB<&d P ]^ `'hJ "#$&@JBBBBB<]^ `'hJ "#$&@JBBBBBx<]^AB+Ml `'D%R&J@<(]^ `' J "#$&@JBBBBB]^$ `'8F@@@^a$ !`' 8FJ "#$&@@@JBBBBB<]^ `'hJ "#$&@JBBBBB<]^LFqT `'hJ "#$&@JBBBBB<<]^ `'hJ "#$&@JBBBBB<]^ &@J<]^% `'8F@@@P$d &d N P ]^ `'8F@@@xx]^ `'8F@@@]^ `'8F@@@^Ў+yA֐(^%xs]۔] `'hJ "#$&@JBBBBB<]^ו6XYӗxc `'D%R&J@<(]^ `' J "#$&@JBBBBB]^$ `'8F@@@^a$ !`' 8FJ "#$&@@@JBBBBB<]^# `'hJ "#$&@JBBBBB<&d P ]^ `'hJ "#$&@JBBBBB<]^ *+-.KS0̡ߢstIHI9:ʸʸ| h>*CJ hCJ h5CJ h5CJjlhU hCJ h5hhCJOJQJh5CJOJQJ h5CJ hCJ!jhCJUhmHnHu hCJ h:CJh5:CJh5:CJ0+,-wZ `'hJ "#$&@JBBBBB<<]^ &@J<]^% `'8F@@@P$d &d N P ]^ `'8F@@@xx]^ `'8F@@@]^ `'8F@@@^ `'D%R&J@<(]^5]S͛5#wΝ%bߞe}ҟcŠ `'hJ "#$&@JBBBBB<]^Š()*+,-./0̡x `' J "#$&@JBBBBB]^$ `'8F@@@^a$ !`' 8FJ "#$&@@@JBBBBB<]^ `'hJ "#$&@JBBBBB<]^# `'hJ "#$&@JBBBBB<&d P ]^ ̡u֢עآ|# `'8F@@@$d &d N P ]^ `'8F@@@]^ `'8F@@@]^ `'8F@@@]^ `'8F@@@^ `'D%R&J@<(]^ آrsۣ.c?sb `'hJ "#$&@JBBBBB<]^ `'hJ "#$&@JBBBBBx<]^ &@J<<]^% `'8F@@@P$d &d N P ]^ɦn§D~%{ީߩGHI !`' 8FJ "#$&@@@JBBBBB<]^# `'hJ "#$&@JBBBBB<&d P ]^ `'hJ "#$&@JBBBBB<]^Iê  HI! `' J "#$&@JBBBBB(($If]^$ `' J "#$&@JBBBBB]^a$ `' J "#$&@JBBBBB]^$ `'8F@@@^a$)9mm! `' J "#$&@JBBBBB(($If]^pkd-$$IfTl0XZ 04 laT9:Ykmm! `' J "#$&@JBBBBB(($If]^pkdݝ$$IfTl0XZ 04 laT:klm}~Xg´!6C%tuv  HIJLMOPRSUV\]^`aghǿ̶̯ۨےےےےۈۈ h0Jjh0JUjhU hCJh0JCJ hCJH* h5>*hChSm0JhSmhSm>* hSm>*jhSm>*U h5h h5CJ hCJ h5CJ h5CJ hCJ2klm~rYY== !`'  J "#$&@@@JBBBBB]^ `' J "#$&@JBBBBB]^$ `' J "#$&@JBBBBB]^a$pkd$$IfTl0XZ 04 laT ZWXhio# & F/ #h`'  J "#$&@@JBBBBB]^gd `' J "#$&@@JBBBBB]^# & F. #h`'  J "#$&@@JBBBBB]^gdֱ"hղD´ô `' J "#$&@@JBBBBB]^# & F/ #h`'  J "#$&@@JBBBBB]^gd&$$ & F/ #h`'  J "#$&@@JBBBBB]^gdô1aFCַ5ϸ> `' J "#$&@@JBBBBB]^# & F0 #h`'  J "#$&@@JBBBBB]^gd"\̺!78}-WDE# & F2 #h`'  J "#$&@@JBBBBB]^gd `' J "#$&@@JBBBBB]^# & F1 #h`'  J "#$&@@JBBBBB]^gdEؽ+lGK )K#$" `' J "#$&@@JBBBBB&dP]^# & F3 #h`'  J "#$&@@JBBBBB]^gd$%+3>DPYafnt{#$ `' J "#$&@@JBBBBB<$If]^a$!$ `' J "#$&@@JBBBBB$If]^a$#$ `' J "#$&@@JBBBBB<$If]^a$ `' J "#$&@@JBBBBB]^ tukd=$$IfTl  rz n  t2&&,&&0  4 lap2&&,&&TuvHIKLNOQRTU^&`#$ `' J "#$&@JBBBBB]^$ `' J "#$&@@JBBBBB]^a$ `' J "#$&@@JBBBBB]^^_`klmnopq~&`#$ &dPh]h hh]h`h&`#$hijkq~  ()*012346KLMSTUVWŹŨŹŹŨŹŹŨŹŹŨŹŹŨŹŹŨŹŹŨŹ!hSm0JCJOJQJmHnHuh0JCJOJQJjh0JCJOJQJUh5CJOJQJh h0Jjh0JUh0JmHnHuB()456KLWXYwx&`#$ hh]h`h&`#$ &dPWYwxy  !"#%>?@FGIJKMNTU!hSm0JCJOJQJmHnHuh0JCJOJQJjh0JCJOJQJUh5CJOJQJhM  $Zh]Z`ha$ &dP&`#$ hh]h`h&`#$#$%>?KLMYZ[ghi&`#$ &dP hh]h`h&`#$UWXY[\bcefgi  "h5CJOJQJhh0JCJOJQJjh0JCJOJQJU!hSm0JCJOJQJmHnHuM  '() &dP&`#$ hh]h`h&`#$"#%&')9:;ABDEFHYZ[abdefh|}~θθh5CJOJQJh5CJOJQJhh0JCJOJQJ!hSm0JCJOJQJmHnHujh0JCJOJQJUH)9:FGHYZfgh|}&`#$ hh]h`h&`#$ &dP!" &dPh]h&`#$ !#.0;=>?EFGHIKVXcefgmnopqs~h5CJOJQJ!hSm0JCJOJQJmHnHujh0JCJOJQJUh0JCJOJQJh5CJOJQJhI"#./0;<=IJKVWXcdeqrs~h]h&`#$ &dP&`#$ &dPh]h +-./56789;FHIJPQRSTVacdeklmnoq|~h5CJOJQJh!hSm0JCJOJQJmHnHujh0JCJOJQJUh0JCJOJQJM +,-9:;FGHTUVabcopq|}~ &dPh]h&`#$h]h&`#$ &dP!"#)*+,-/01789:;=HJUWXY_`abcefgmnpqrtճ!h0JCJOJQJmHnHu!hSm0JCJOJQJmHnHujh0JCJOJQJUh0JCJOJQJh5CJOJQJhF !-./;<=HIJUVWcderst&`#$ &dPh]ht$a$h]h&`#$ &dPεεysfh5@CJOJQJ hCJh6B*CJOJ QJ phh6B*CJOJQJphhB*CJOJQJphhB*CJOJQJphhB*CJOJQJphh5CJOJQJh!hSm0JCJOJQJmHnHuh0JCJOJQJjh0JCJOJQJU%bdu13DUVXij`t 234<[c=>?㸩 hCJh>*CJOJQJhCJOJQJh56@CJOJQJh5@CJOJQJ h5h56@CJOJQJhCJOJQJh5@CJOJQJhh@CJOJQJ2cd23WX)* 23$ @@^`a$$a$3=>0>ast$% !1$^$ T@@T^T`a$$ @@^`a$$$ @@^`a$?FGu|#$%;I  !!#45%defghnopq͵ببببب~ؒ~풨 jqhCJh5CJOJQJhCJOJQJh@CJOJQJh5@CJOJQJh5>*CJ OJQJh5CJ OJQJh5CJOJQJh h6CJhCJOJQJ hCJh56CJOJQJ."#demnU$1$a$$ h@@|1$^`|a$$a$$ T@@T^T`a$1$^UV=>Z[t$%>lm$a$$ T@@T^T`a$$ @@^`a$$1$a$9:;<>?VWXY[  !"#%kmn  j@hUj-hUjhUjhUjhUhOJQJjhU+j{@ hOJQJUVhmHnHujxhU jX@ hUVmHnHujhUhhCJ OJ QJ 3m  %STfE_`k &dP @ @$ "Ba$$a$  RTf^_`kmpqrɹjbjGhU+j:=@ hOJQJUVhmHnHuhCJOJQJh5CJOJQJhB*phh5B*ph h5 h5CJ hCJjhUjShU+j@ hOJQJUVhmHnHujhU hCJ h5CJhOJQJh&klmpq;<XYuvwx `' J "#$&@JBBBBB]^$a$ 789:<=TUVWYZqrstwxjGBhUj=hUj7hUj2hUjG-hUj(hUj"hUjhUjhU+j:=@ hOJQJUVhmHnHuh0H0PPP&P/R <0/ =!h"h#h$% DpK 00PPP&P/R <0/ =!"#h$% DpK 00PPP&P/R <0/ =!"#$% DpG00P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpH0PPP&P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpD0P.P.P/R <0/ =!8"8#$% DpK0PPP&P/R <0/ =!8"8#$%0 DpK0PPP&P/R <0/ =!8"8#$%0 DpK00PPP&P/R <0/ =!8"8#$% Dp>0PP&P/R <0/ =!8"8#$% >0PP&P/R <0/ =!8"8#$% >0PP&P/R <0/ =!8"8#$% K00PPP&P/R <0/ =!8"8#$% DpK00PPP&P/R <0/ =!8"8#$% Dp>0PP&P/R <0/ =!8"8#$% K00PPP&P/R <0/ =!8"8#$% Dp>0PP&P/R <0/ =!8"8#$% K00PPP&P/R <0/ =!8"8#$% Dp>0PP&P/R <0/ =!8"8#$% K00PPP&P/R <0/ =!8"8#$% DpK00PPP&P/R <0/ =!8"8#$% DpK00PPP&P/R <0/ =!8"8#$% DpK00PPP&P/R <0/ =!8"8#$% DpR 000PPP&P/R <0/ =!8"8#$% P hDpO00PPP&P/R <0/ =!8"8#$% P hDpO00PPP&P/R <0/ =!8"8#$% P hDpO00PPP&P/R <0/ =!8"8#$% P hDpN 000PPP&P/R <0/ =!8"8#$% hDpO00PPP&P/R <0/ =!8"8#$% P hDpR 000PPP&P/R <0/ =!8"8#$% P hDp>0PP&P/R <0/ =!8"8#$% h>0PP&P/R <0/ =!8"8#$% hO00PPP&P/R <0/ =!8"8#$8% P DpK00PPP&P/R <0/ =!8"8#$% hDpK00PPP&P/R <0/ =!8"8#$% hDpR 000PPP&P/R <0/ =!8"8#$% P hDpO00PPP &P/R <0/ =!8"8#$% P hDp K00PPP&P/R <0/ =!8"8#$% hDp>0PP&P/R <0/ =!8"8#$% hA 00PP&P/R <0/ =!8"8#$% hH 0 00PP&P/R <0/ =!8"8#$% P D 0 00PP&P/R <0/ =!8"8#$% hD 0 00PP&P/R <0/ =!8"8#$% hO00PPP&P/R <0/ =!8"8#$% P DpH 0 00PP&P/R <0/ =!8"8#$% P D 0 00PP&P/R <0/ =!8"8#$% O00PPP&P/R <0/ =!8"8#$% P DpD 0 00PP&P/R <0/ =!8"8#$% A 00PP&P/R <0/ =!8"8#$% H 0 00PP&P/R <0/ =!8"8#$% P hN 000PPP&P/R <0/ =!8"8#$% hDpN 000PPP&P/R <0/ =!8"8#$% hDp=....()()))()()00P/R 8$<0/ =!-"-#$% Dp0....()()))()()0/R 8$<0/ =!-"-#$% 3....()()))()() 00/R 8$<0/ =!-"-#$8% D....()()))()()00P&P0/R 8$<0= /!8"8#$% DpG....()()))()() 000P&P0/R 8$<0= /!8"8#$% DpD....()()))()() 000P&P/R 8$<0/ =!8"8#$8% Dp4....()()))()()0&P/R 8$<0/ =!8"8#$8% 4....()()))()()0&P/R 8$<0/ =!8"8#$8% 4....()()))()()0&P/R 8$<0/ =!8"8#$8% 4....()()))()()0&P/R 8$<0/ =!8"8#$8% 4....()()))()()0&P/R 8$<0/ =!8"8#$8% 4....()()))()()0&P/R 8$<0/ =!8"8#$8% 4....()()))()()0&P/R 8$<0/ =!8"8#$8% 4....()()))()()0&P/R 8$<0/ =!8"8#$8% 4....()()))()()0&P/R 8$<0/ =!8"8#$8% 4....()()))()()0&P/R 8$<0/ =!8"8#$8% 4....()()))()()0&P/R 8$<0/ =!8"8#$8% 4....()()))()()0&P/R 8$<0/ =!8"8#$8% 4....()()))()()0&P/R 8$<0/ =!8"8#$8% `!%BYzL.(I>?H@%x{xWG@p )PJKq(%KqEjP(}ϯޛg=;4iDFL8o{J L}S[)6wOFoǏ7*,ZSrh}ɭ%M h)L )_H^&9udc^K . '^Fr!7 -DBpaw =缎%K,Y]J*(]j :d妍 &[/sl|gd~vD: ijg$K$GjW$D p;E9[yPO帥t륗FH/MtRAJ '^a?"LH/>Ewo~+,Ҟc%^%MѤn2NOZh~W{\6 qH5{vr<pjm9Vt5mpw Fcέ9>'zű6Xv[hmVzȠլx@{񓎰s:vAtE"nᐡ!0QLlEygkЮ0@ Ř7':U}:Q-.LTv*q }8.BU 5G4ҵ3mz6z6#ڂ(8f5qzq 'XJíV B7Í d6ٛRҜ• ;wpY+\Oޚnn1Wś+Z#+k3N4TpE99x+Į8{6zk'w8+k8N6+z@GBDS/^T'7 ԆsWet!Ί>gq/qt[d>dv|&x )kפ&8Qs(] 2~I_YieDNZ\r׾'6D^X_yo]ĹЅI WIһI.U>wN%ECey=}r_9{s.$uE% sS.m\ara";l}Km̲2ѶP-};—&v\j)  p ϖ:gϪI%mzj 1Vwtd`.Gmt1k)|r9=p W0gNYJO5\$ 1RY p`g^[Z?b w5|ZMjUp|B!|t>GsTU*HI)&4\rH$$_ג@2Yb1Y&*E$ AOIl˔{ 3%e؜`z`kQ\`Ni,&= rZ7x)vD8?}[O~2;-$CďH)%U4&ґ[H?n##`Ye#dp{mWn%b!bċ33!#NZHzi,Y{ U$V R qYFK | Ƽl9tG-}Q"CU_]Uqr1|H>r|i)p' WGO^O < $L2 ߬DB_ܖXs^ PQ&EUXTCLQx `_N+s* oHߜ決jWޥZ* *iJΦY9ZU XƦ-o݀ciLrK5!|Ĩ  ?s?S]<{`ƻsz+w]BO1[x6n64Z3i0\?=Ҥ\AcqZcwgiS}8e8.Gm:;`i@m/-H <\l+-z6<X< < <Nu .]AtMHߙy6Lw&F{'u-]Uz[5cбCwE|him{|>@ˁ G9u{F-f_Y>q]^`>|yS].{obzc\&{s` X/ݿmB_I '8lĴMK'S] /Rޱ?݄ゴp\jqUz[|O K3<`15`;vp&C 3 5XwR8` :j@>۴={^k$w3yU#pb-Ě )cn8/x%́M+v]tU>Na|ŒD^P:!.o*."ٸ|>fkZKBpI~.rv?&+b2/ TP)~{*HW\[wvҟ'Znp[ि`w- . 1L27f? 14E߳1woY7[NU¯TTů:P9`ڒ4RUfAT2:håea0ˢ ,fYMna¯8YJoTpG}5KxIj=*`5 XU *`M$Tԇ {'xI6 YW>]Χt1_:fqRYl@~ Ml.wm5ϵҶ60|.ɿO~G9'\bKnK )HiWCʹRuꮷrC%}+iVJCX @uMIrJL.r~w8ۊw(~lu]Mx VYO<2pOK-,#.7AIz}!\`bt5M4PGP;E55j0䐑H>:#Yi!})ħGY 8Yi<秞jP D[Pd`s!d*~ h\ Պ],ȈȈ+:̌.ҝJ"_b&T yW*Bd?)dktq Q>/I2*+ץߐfh?s'e+_D&yʫ/B5 UwFJNT]^3qx***o#:Kii)bⰖOZJs hOv$GԍoQ7v8/ׁ .~菄]`R:[<=yye9l؉?3*.0 {_A>JO #QU~jrd éOC4 IlS|@ժ盷2`I^V]l$$$Uй"++3q2f/]ʏ4gNoVަ;yzFGMs[}M4iRҨ-Ձw{QQBeasxmX=̖r_IGMQ Uyg6'!ԦqS}g f$p~2mGZ}|֎Sv=`Z K:@4KWHJ qՀ k_{ۿO{'k[w/I}3G7O}pK z s1k#scϗn]$-}s1ǧ#.*F=FO)=ܨKqMT-5lȕxVX>h;6޿Źq8;ęetIprHUW#nl||iSߖF^-epW;sXt7gCWjZ8eY3KGUh)$ǨLyxv۴{CoP% 9sxULm7[&E^ko +kKxx͉i鐏rj% +IN%mtN /UӡUSINa::R#{MԳѳu4Véڏk{* (V!RH iɅ g3~g ̮f>;1oxppoǜ\=rj]Js%LF8\K/ l+=߼u?ecc䴦ŒIn*VXZRH9)lTdQk?[e-Y-aZ*i!~ZsZd5$6M"3of==q&k{[/jt9ZO7hIݧzXc)Mg56\Gr|)RgOz僧z-4L8 ?Iq9圆a͖rv zxCy펳l-=FA٫%JSM ke'O{rW _=>}]ٛSwpt;[B}oNL@>Ql}VWYy)lRH6s^r NFφ_=NipF#iI2cRB$@OHo ՠ:bFuC4׷:YFi|ɭ4U@ӂ[X-nq'k8lI ߅C!~uyunֱ QG00`7':=ت%x9wi&v}inteъp5Ŵ -!xŵ8孝G[vqy.vC B ͉Nǧ_g}XggX; ךK~P_] =~R DH\[Y "ޚt d&ddd1d9ۣ 2ze fD7?o~B{AIM*GOmYZ ۘޣNBa<޺=Noĥ~za~B x7'uTWqWsWq̂̆̕ζP<ֱX< ́ wo3{L#=Ik{S:cͬ,b&kYj&2;kfՖXdKc S)a! e_|xEaY0tb VMZLc6EE%tF@1}lpd71 zc8`b}CGS\ -Vh2̀:.a0#@E}wB0;2cgx1:xnD)8g@dD;36`cf30BEV!}M3kc^g Y<;N154Yp 0&mCx: |' e IXt= üt*F%srL1"r,9Zl,6H"#ݱ<2XNydFq43ςLtn鳰jαrҖ%igM:,PaIYLSb&Ot׳"f&g9f%X Fsa0h9AY|05ouXlիB c3tP;Y-v' ouEfP[Elb?5|[- G˶9 B Rp seǺȇIO\h3m &)RbTS. D:KKd2Cso݋bl~&D뱻ysb3wJ,yWR29;٢ٓX z \ qGT†DKcA Ca Οw8!C<6W qG$\` ܢ?JbO`RK0 6D8(nS n/y xЋ,àwWS zX`DVRw"(5b)0~Gj,rUW06væfқ} 1}%zUC1Rd]tcp {0yqlI Ű0lԈ6m ۄMs2f5ag1<ڤq3(f9V]UȰ=MjhmL3(s, Mg(LS7 <Ðm Fy{940S`v,n^̱>ۍ, v!hB?\`@aVY"aF046|:@Ḯ>`Nr8 n'H#)bs%: lzkfKXSjTX`EL+$LnS,REJd]Y]όT0+eq'Sa*51Z9Yj dXrJD`#>sga|u&>g ϱ)0lgʺ:pL:AâB zuXk1;m7E4<,1 4>3,Vw?0`سYvyx ;- #Zݛ?~χ̆)w=2ϰ3a4̤T30CY303ì5i0+l2f0YFvΤmG52G`+F+0Gs9fHo sëF`fPV/G&׶`m-FرAYf4CY541w؁Xw pn`i0gl7vX'pn#;L5eֻSՔQϡ~vm4͆BϿks5=a?gNj(j9 cOo񳷋/)4Ie. 08{] y _8̴jb?nxtiq}IUUU#6sNhn#c۶ 3uֿ]afVFؤðjjc'dDy{}wܞFL( ~)+$L\a쉓 '^#`8 {XVPrCoV3{ؠ,sO5457WD:}^Yϕ4RҲnWP( _m,*J>_b2bMN4̤O4Wy_qwO=~C>\^/yxlj;p$F{jӥׯ^/5׳re%O|kQuMɓS*~\Q[{/,ˊB )>izß޻uG: pH`95!*y9mVNʽK;~3@7 za{5Knw6è2lv2VScRV.:9Μ;=Ɏ8*A25Ec/p1>zpˊǝ/l-mA 9 (DR209^a>:KIm^ҺSgOJ@>ah/)D=3֖zRbbiL HLGH0% oN,:5l}3Е>#F ~`Ϯu19utUD:5jh׫?7ɒ_~vDE z Ï:r449ab|^Ju>3SMΤJ l A_~*2CiԮ&iU/j8juܚ0Imp$bQ⁳bn4)cĔHeTE FA~W➡cOߞgVGmwJfWK ]o,|߄E zL ņ9_rC:*^Ym;JYFO]hPXC:Yo}mLO+i-绨B+siY [*$ X@c$+ٿJx}_~);~gܣsCf L^q149bv+3iߗ|o~`;ɋA+ć88eёCꚵL~sӬ&-1RU]Tj<|W^ d?Ɲ;y<|RSg;vBi#DUu?SB E5!0 u:ٲvK;:R/{[[X1;أ_E5c+ʗmw)6LR1X^֙«tcoDjs=]s:&E̐~#ޛ_tk-w8ܡNzeB517'_^n.)"IQe]{ZtGёs-Hx(e壇\8_txl\Q^YY7׊E zNKX-J1ѐ|ö?):=(De$dfD>qdڔ4h=ӥ,ɔB9F.:I|u>ӕdm#An }U" UWÄ7rpFG$E'ŘME-gQ*ጉZN2bTM8`@h<5u0 DQ߈~#_=G1_@&V@v`K-2#LcV7.ܲC9fWNfi](k,;}x긙+?zm_k2IQ{6Xf}}9ò׭XM͎+Z'weH) {?^if6wEbŅI)r- =\^_i]IWK9 aSq0ؼ-׬nv#+?\o ͜hYV)ԩ)0q`3gp:=d][zFkbeul-\*\ny^ah1MQEh/ M=2㉟s>tܖ{j/,aww@d |ۖm/cɑ)Ff[kRZ/"*l _6jԪ?>3{TQ6hV5y#>m2Gω4[>GR_AQ =2]R>io;L'9s’o.]rhR r޸^. [IjRIOn}Za]afJ=;dYd_Ocheah i$@PJ{Gؼr{xcLOGٶGFhM~WK9^zzf˻;vorF7h$ZS0Ѩi&fN:vԨ1wus/{XCbM0؞C]: ϩk.DaW__Wl˝0}q_Az=\(&00ƿe{;e ۀ]4)(HUDhAآ&毘(4Cł5B56,XJSΠW{yr>eLN ^~#F=Qܢ..+iڇB慘 ;aFxyJ9]uPy3FUAz.Gw)v,{Z?Cd v*xc?" MƆ=*jxB?ԮSuJEC:YN2}`T|a޵7o5LG2ł ^;gϤ~FeO%-´G&o-y"{>:6AHKa>ULÈ_,=|ew˜˅7LӆsnIxع-fJy{ $aiD|%3NNɠ ϳA<<1CCP11&ق1 HeݚOoO$^8zֆc=5nhhhz%O>Oe( 3N grqY,#f.eܷR-$υng]9r;c#g xͶG ̟O%- ^qOf\>廔W5qMp:^2|Z8+fwBN< }lgjFA}E68~L3[3NI20fPfFf- ‚oO`Jǵ}k <~V^f ,yo APhGv`s(q况2 o<,lӑ0}gN ðŌUJkBdҏ? (m;N+" MA7f>ȥ00 mC!cҢe v]wqࣆ6ts8"3~sBccKZ[S]};1ܹPeA_߰ p??vZ}3+[J[[p8\Ph''g9 E>j_Xf҈y WTOL&7ΛzP^RTWYb5uބpz%j tjD{뺿(/72;s31iyg-f 7_9T?{wB*k\)v )_( n[Nt,e/{ d_'&~S|RQNq!Q_/[b2vul?9/Lx:FM0xh_~Y]'wqH\FYWi$wic͑;$4ФԷYu2:(4*0zXT\ƹd?p׶ԋ%" MA84j,g:yuP~~^Ԣ0Z;J@"&=#?JSJEwtg +d#"6D5nEv-/<Ζqjnrso ow3>]1k^.dX['۵W>]kƙllq71Y4O--i/"p쥇*7,LA&*h|.xȐ0d=Bcc5rd TF`#)AJ2a.3լk=O9huA|7,o{u6vOYnfL4l@T =ٖ/""\"v:sDÂtd4Yte3a s\9w/8reË5cݶvX(| h]9/.=rb*n!9ҘQ.Y#g@杴iû\p]xLa}I2'<.h2Ǐ!`;ֽ2ۧS%56uS^^,NF9,8FՒn?f6f 80l\8%rsp~ʆzŨ4t8oҺHCCCc ? ?X.\'Wn5h[ˮ8 M =rz%rW6KQ bb(l,搘2Ȫ5=_*QZ)=k8ÚtW;g\5ĽIc'SVWWW=Smgೄ54[q M0iye`/444=fZN&PK lMA5s1:K89STܻ`qȫvnH [\|6su$~i>5r̭ua[ZEPLn䈸Krd,⻙TL^S F_Zihhz&)g;AP5fAYh@(@kxQCwg6:#-@o[j3NS8!70*ǩ6RX/-P*/ ]{m2m|ͳ6ʫ-P#d`N@EE/9٢[ʹx6:%xڻp8 .ܜ. xSP-|^Fnɖ/> 0 ۏؾ2j@xD@lz+W8vL|d` v**&SZb㚛MҪ!B׺8ofaI {JJT@N(uP`׍:0Y Yidd$nPV7޵s3S1(4z3"8bo'Onu9*im Ξ}FdX7A" M!=:mS,K$X0۶g߱.1@Dlhƽkda)85=V)ujh2U萑& #0"kV;E+~TVk:p2% х><,NSSȷ]pfV? h:С`[q3)憋Qi\&[8轫wkA" Mρ0V ˔BQqEuy}Qq>:1!,Hwsrd܅1FDtttxYL]/Voʽ[x;(?;3[a٥- E "*"XN47JDXb1b%MPcAD" "tvm3 R擛?Μrsw<ޣ"!ǔԊmDEWZϐjK?iS-813tI\jrc~:+efaEa\ 6:Q.*t^=\=Ԥnm]>Fg4zZ𑋕#"x':I]좋(BQ53{NԈA\L|neY@gr̤J|ɮU~"]hIK̆g53"&{P;!{|05^tf1b $J1XqeAJK׈jVqǝ)1BM9Bϻ%,|{Cߑ64q`]v9jx,Q?:DKjP(`,UbiIy>c֢<#aeaqUU_瞮N J9 i_ 4fVChHjB9YT,VgF@\H?ѥ3Rb/v:Y#o,LXb7ϲۓ2䊁}Hs8hسSŹw|M6aÌ!JBbX鲋]I|h"%$|AеwM;nV|yRe~䅋"eo`2PNUOrE##Lp*]k MlhT,+Ke\Nx!}Ҡj4Da L>+y5NJ-84`Qq`stqKerZӷw;<o_>[ OI Z&ɢP( l WkiPe;9(ߑdt.Yx>XڟCA_2|8A'T&SݥµJu@q\*W)$)B䣗ξs}m=qe6۲+Ulv z`ҍpHd&{SQ~2ePZ?D~@NN?p-=vNԴ̇NǬݶn_q4mb%[U_$P֪M-W[فR-0۫6zvgyk4诩l>[8d+fl;rm Qi.vFcVVO Q6wt !L:~شy77x|>~MZ_Xeχ /N8E!`*:ʔmT3?&-Edv:Yؼ*+ݛxPK+iP Vn4ƨBh_Z[+jQg4"t`ɣt[PXc$A$0XQ%t=5^R`}F n߼VK{{%\DO wq,yXli$TҞ*,ಙ>>VfRJ$(<ɫq,m-FhKE6f,;}r.ȭ< 0N!$I@XFXb2,x&jeZ΂N$ o,qTTqk\r CP>| rD|n&˼FTl& gBT;Zr>Լ 5bwj, HO_fM4V2Jj At p!)FM 4S0ubv_Gw`t֭3~3-zXjɲUJrz9(ʭq(P| 54|']`?ATxz*TK++-~M.KŤNN^U 3_wn& ֩QGL@^6{k]В6xڑC%2V/.lLz4?9%A Atw+ݧ#46V$u ,3yBdHh}޶cQgs杸RIXl'G f0w|ꬦ2p=!lD t:q K 1 ]dQ#x%wRy 4&拨IQa#Ln0n8IQ3N;E%8&ڴ\NFg:~dlbmna8ݜ:JQZ0ILlldMmG +l@§Rbta, PJg2^jgi.~^iY ~|I;uh@1lzhȔOItY#BTs򣢇[fm(Zȑc"nmθ~M60!:!62:F. _Pp4N^di09]v CC%MTqeQ7[>޾1y J&#?o3S,^;D&?r/G qbu$|pM$'JRo~ VR8/n 5Rkx͋Yd0 H獵e?3h:gf2|XqdR2n<ϓ;2veُLLMZ%ѳ1AƋ+6}zypدK*ZͱW+4i+ :i]Vq.Z $EUUVߺSP0SssBY}{^9x5nbpX+[VU_ ~OʫL՛G]Y^r؜-|ęx̨]۾ٳWEu} kgBg2 ;ÝGS.ߛ{h77{+|Vʦ)4 :w1fWKWN O<ӺUfQNiL_wtkvq&EQ9vB}%W|@Rƌjk>:Y'YoZ6`s_sYyʹLj;H3OE *U8uu:-hofׯ0-ʾx8P4˗&?]]0(@TE.xMEBR *Z"* 5q䄈 TjMuMQ./?5/U*e⩟Μ0vg:AzI}G}|ӧOs1D8uG޳n-uik/{9"l|o0e2FmX~C2&qqwqV֜m[v"YO#O jXBɳ?%x`[[KS s1a RjjujXqȉ3{z |;[A!JF2゜ע&2a^<Ko-0X72Bdb߮cLy,&qFdԫrQN\;3*|LO>|SK>qTpX37R޼*F䛒 $|ڔA:y7=Hכ'|ruA 0 pYhd]~\=7&l-bִyDqyZy<Аv[eI:otxlGKpqqL'6$E)4MV$^1h`jg>|E}>@ Y7lր3L%w^wBܙj؀ /ݟt3IJ`}* eN&Ivݧ;]TE˫gwaQ]i;.W o HhTbD&%6阵̴ftdb~:mIz4&]A.*"* Emw;g~rɟyuw=½6[468{;f$Dw5u@[Gwos{bJJD\bɉ"O`IiYZrXШOLrp@cfĨԢ ? itX«Gu͸)8r4r1)&Vm4b `2tF uAĤ;"RS &?X8dٮ'jk[WSG*d -;d$&opN:dN7k]<>5-ED٬%`w/L@n,,lRl B@W?96,5.X9`4qRDx;~_}SRJ%IL#CPByj4J*ޤRk9 1cyZ[]홡Q ޾^T_XW]s;M d?3榮N/'B|TTB;? Fxo0x%Vob-!9B&74\,b4:yM2c?NiukϼaᅤI)}nv!7P7͵&hD{wٻg,\y:)>mov+d^qW/ zu|JbQv{cTuuBOCc#F `߄K~y;rSbuiƜSNZt4!"jάNʨinEp_n}xc^*wd3"TYg0Fc HeQ$2Pנ7.\(A;.5rC鉉Į.sFf2h"^pXmMG>~0y0?B")= iY9QǠIkiE#a^~io}M[ZRk -2!T"$ *Y@Aj&+cbuƿ|eų].QP,ju;+!&n0fzO'rD|s I^eg/ȜP}"*(9Ғ8:rKC^><6PnWke{Å{)+Soz.6nȇ[~>xvna@8פ2z)07Q.K>~,\[X+Ov|ϯ)P|û̷HSՋw1jRsd_~QX:kڄ1crsܒQu&*,LIiӅ%i*5ܜ}4f{M יFr]4a S}kLJK%Et3 TB%.*Ta0`xBEIUw@EȠ;eSTfdZgx1(|JXBa#DBpT2J⥥mݽWjuCkw[+= r#p raqSpnlhm6-SiZWΙBN4< 2R@ 8.B讂…K['΍C _xysytajcLY,JNXdHYQ@!"&QьjŪq)",*J5ժ&LΪt垎is|U@Q!$cw.(Gb[6M?_j* R(TT$-<~&@j+0Bѱu]"F ,  y}Lzn "D)"0f0;U1 P|Fi_do*O8P:]Tz)*,'0SQ RFTS~^cв2^~띛2 69AGe  pFQe6קOܗņшg9Qdw{]`݂IV@r].YVx,CXV ˲(Q& $$'DFw6ח8qWWmV9Z\xz;ş,nDg] oη 5 o??9fS}DA)(ۆ"V5.!{ `UcijM7c0>qᏗ}t޾KggKVb*/e*ek(3֮~5BGED:}IĤvǩ3?(`*'KJr_ִK.=wDL|_Ԭ */iFV *={llLZ3DoƢ>ep IDATnl2ƫU\ysgt9N/7w@ d,`u5\u mlt|a [.ٰbR0 `-7j]ٹ6(1\.oR)KJ2$bVR& tҨy-(.w{~:p #LcPJ>ÒSdER3 7GD5\mڽAίjԽv& CRSjMCgyzo=ٿ5L%D`Mb4`zzbbs4XEB(At0Tf*,7&_O479pg73L0Qs[79&|Y Gj.4wZqnFXR]~_1ܡ1=5e~fԗv&ٺnFJ%33u#ff͜?v|\np9]72xBXOO}KA SӞ_h-yTuu=:v88Ľws 3r=5wf=S]nG߬{9_|m(S&ަW_z7}弯׬ܕ~CgZ#Ezt?zTً+Ko4Qs) ڶ9cgǎM]{:V ^L9\A7n7_=56<:!wdd-=kM:hPqw4i::&WspOcGJo"0ϖ- sr܈*+*ԟo>|u (LCB>|J4 -}%n=m^lٞ{_z7?nwB4Z0 Ӳ5mh@ {H|F9B(~h}~?M#oї!ѻڞu>U^#ΩOI9]Qҵ5Z\ h4vPg_>CtnX.Nvy[X*qv&fLg\,[}i^=}/ AVʏOxr/࿹~sL4v˴xQQeGDlLtȗ_3~LHGDѭ~4䤤#WTz-<[ZӨiF]O~5|笹k[VU{ R -ZrC, QLn;bzOF6;K (\{cz]׳OiK)=~s}5uֲEjY{kNR'~vl}K[қ֞O;/x ̦ؑv۳g { 7HiqQr9tU|s>cr#c+.m9=Fg͝oX)fe./ ,J7<1AC:pc09}@Xtek9ԷB23ۨS;ԓ3ˀL1%!4ISVOVԺ>xjW` !dX=Ζ;fSzUya??ZW'7jTkc.#LjerMg:@iR;e}?~Wґ~ $8ݽVN]lХ]B2fY]%TJI@='M3vRPvaGD)!^<3eQng}e3/|2H }vXCYNpkhv<ʫu!{:ڨ>ywuzmȽA%r'znМWߛwμH0Χy@]$v//PJ;vVZ兓s&PX3;{W![-&m/YاG׼;g)"GVhq9{]& a' CH9rmBUH.#0|A"cTYuAԨ7o^~ Ť徑ſ2v9Y;>:¶6q :5/mޒ>q5%ul[#i͋O}*t³{i:)8ÙivH)-eRj;A*&Ir\(-n{2TzF!чҽC䄬k89v;x{h9hլzR^uv;v\\LTiyVNG7KoY9/Nߥ$m 'wr8b[pٛ^힚8}5eURR=ﭟ_/<E[zh4;WgCM C1{7XeUuiYYzR'&OP A"Û1ABc#˫KjĘF?gZz/8 n]qʐ6OL?ʸ3)aB] ᩪ Y00]wv_ǐss U4'6op1 og_o &mp(Jn)\.7TBj TI4vv%h|1!(:SI`nw:a.-="iV:i>#HVQ@#6tƜvVEF]vw6WMiNM(y)RJ1N)i F3-*!&F>r;W:C2 ($H1B(.-$H ӢHtMP1ajJ% bU|.3@ܲ 4ĴiqPp.!EF HC*`TX\RiTH5FBJ)ED:cBHK$PJ@ "HTJ( p!@VT*0 kTE)!J*D""@S L;Lm4 v[!j49)o%_:S~,7 =c+z_}R^,)#%).)i6'}֎Cy!'o䪻o~ԞvnHJM6 VG}L;OC{vo /3*Pb@e_VP| eJ)|uFad(j/m{~e˼&+i /sC֍?AW \qnwG۲w1/o [qU<5߾aE*#'$WFbE|ݥqp/Ӂ`H5O@pO\*:њ op`#sMPLI)R%5 L:A7MtRɅ (T*%S 6J(98"T 82T:R@9dC2 -" h"R dDKIjQJT@At*8BS0I]((D6. 0 ($#LJR"(Pep"@.D01M%EB$TcJrb`+`RC&) 0S]W vR*,BP\Hr\Q%W$: HDJ&P MI cLG$Jchb "$C2@rIl@n*PRQ mnJNXRc4{e$"JRJ4RqޕQ]s>A X -B0@dEBHYR1E!" 0&&d /* d"iK3Hh4{{9$1 &NU\{nw"΅dD&`c ŵ,y/gfLZ}ѐ clu_>m?ZvLv֬&޹ju;>E/#Lhz.-DCC*Al592c`o>XzYgWGMMc>'mj*8xm㹳o<ŻdJcw&5~q;"z)!䤒ApaPR8d2yGhCh` OAҌ( ǙϤSJ]cIVuQ*8. .@?:#iVIl`@I&8K%.E6 t*[SJQ+Ҋ8"/1-J' DkX+0pd\ll:4۝Қѹd|?_Uսow JR[!yb,}_{( J{)00ԖG XTTB %` AbC 0kb3cTJkX$`}.8,))ƚAq.%%eŜgLgkn~{c YQ W=??TW>k6ēZڪճ'4sh%Xsb?پoud1sϽn934GFA}d{+r٪g/(t{aͪm{?x[݇"?![޴uƆ3]po^K O]o&ndx8*@̛yioqߺE3H)cg :;'L~Y|_RLW%;H{ 斍2lA22[k /KpΝs1!%8HQʚr Κx)|eDdsPXL0Z{Z$ @ƹ(`^Z{BJFJ;#qaT<3\( H`a! Zs1:I嬳s8 V&1 )8 ca*t|G1$M!i?ŵN1NșHK$TY;P 0ktw R.&T.sDaa QEV~|G8rDlgWP[]B*㧊u'IIl™΂ؚ(F\,19LHyZ( G'Y!JKIN >dq(4iGAF2\YL'Iġb&1JYfKBn?0ё w62eܐ.{gemmFO;cO'0^A}SkGǾ'T_]\״[[|ǣs9 &7Mn[S`xَSU_va`Ngڦl&[J+2okOIK ywgݻ9_sՋC*L?ׅhKzwOh++G=aڔE^jz7h26.n Fywnܶm-;NndG~vz@?#dj銁B=][ĥ6Oꇦꖎ!k5-44a;_S;sRa7]7r~z@'Nk]vS'OܺP3Ks=w^ңJʊ^oxxqME]A_rܘl?}W]*u'/}t¤G#NҞيZ=? R.bMfOꃵW3`VZy\.i`mdz{6ts,jyk+?b.g3fΨye+-2ƇKP)M5Ռ2.[Y%@Pq4kb>Uql9_8w p ' ~R|f[-bgjfy)sϘyU/^uRUzf0>L6UW[?oo{`'tvv׎2q_͓Xsnwkii7a 8HIb\kvٴޤ~*u&1u_tIL<1MGqTX-Mu?$ SN<+nV/?}3\s٘af67@@åLS4Ms/v]\nfiij ji$."( (0 vsGwoԏ_3ϼsf9}yNAI %e:uUju̷MҭkD 3v{ t֣fً:!@\l>I8F[O^>M7{wa}BG4?!<08sTF5n0u^ی0VhϳF9I;>;E;hlj6+yrpUJOr(J&" z/Ѣ(ZvI(AoDI*7MBF\fc@0eX$GȖLM("a[?k&XBG]+-qVpO$R'Ef\: 5ZkQ]XSnffkШ`-Kzծ lwoV!w{/ĉ}} g4bh6ho葰`~r<Ýl¿"Ӆ:{WOyb:rBa¼ճ|s&2,A[~@TN>] qR)+Z p p/J!a\xy/F:sfNԃy^<=L}&z})Akv%K[%ugMٽacPC O;o@װw,yZ@1 @vQޘ l'Ea (2OgG~F ݮZa]ma E ^Ƽڧ/LNִo1UȕjOOV+"08^Rtk*o (4< I 6 Ǐ:R-.L;"ecwۮ^eі'Τ<&rp,;vFmE+yE%r#'9{aV5L?c o1}:^XSeF^0a9$DQE 'p0"yA@0)y?Zam_ʾ5>TOmu*PP'w%\EqֻJu?z̋CQT!wջ $$.CByςh`p$ )]{AE[Bb8GPT{ C;s!dݦo%(jo61.'>(۾\RԀi|8~;j|ng%>I6tk>"f٬XT}z9.ڽqRUY]~ڐfSmś:xvZOcBDU4uJ( x@kcFs|՜k>?kַ-VΧfv5h&͜fwmu_haJ[5[y9WJEk䤟0}p 꼴ʴx*j~ʐ^Wٲa Nx}ЁqFٮ=MT*fΜ}5/?z^}`h+qVv"*]8wBX|Zw9K£8)wT-*͗P祬, 蓔\TR!--q1sC}>QQqQQ2l_OrmLǯkzUYU?IxW4z^2^si&vm05xf;v½{w 39?ck|t,Ӯӡi$Q/,͠7ip^'l8KKQkqr$%&R(@\E79S /I4;kg}EΞk2aY7M7])k׬ҷ_hX%N؃d= vڪRy9&G(rR]]6+TI.UzVa!#HkԚ (JbHΝi\Yo;:j{3gΙL$^ )$!Wi!WX6.^. X@AE AJh$H!6-SOIB:/V~ZwfϬ >z4&2*%- !hvW7XXE\_ 6ެ+myf|g FZA=J#;V|$1*L\111f777;"W[9Uꝗ]wG.Rp17" #^?X@TvI:,9k iׯ]5 2C2lU\wMv:Yfґ;*Qs/Vb_n_yͲ;=j[d i]3{^=~;Ř><}݅E#"c+s·^Efpzʘ}Mu`s\|)Ĥ>cF33}!9.1`P ȄlݺO?xϟi[;/Ұnr Z*q$I߼lpvvvbr*Eђ$q˩(x5D/ynBsuI}_XqlBB{9I^Y%L1X""!(004:"R[_풊JK%q]dyɋ+%U[_vG&`T;~î(P׉+z\iWNfۼD^٭W@`zkM=  BiͭsEJ/Sɠj*p˾.QjCuY=~`m{dƍ8S@k)q^A{mMrTMwhAǘ"B8?dnWvޟ.{ 0!@MT&Ĕ楻1^ڸ.j+n߻wE/~D^67Akyď^*+qz.s;~Eє8p:7OfE7Z .096Rv~8Wߝ )b@ֽ ԭpYc:C!yo޾g6XSa)Mՠԟ3 7b(7O>Z 7CLaZj*+s9ܾ 4a H"ih[<1sݱo]I /V2%N[\ 2zC72=؃9":)B|Uŭ._Yb1fVchht]1IG)z7O;vp\>tt'<9c?(sRWV>u?.[g+|ӌԴiN%8<.GlۑQA+%={Iby^e*X%7?d ɉsf=h^w)me!IЪMowxDW@ &""+XuN!MA%Q,Df0bT:^lVοOVT[:vVi!StZ;wp{V”:!JqÏ?}ėH`=7?jߐŨ8x@hw3%@Q_yisΖKd"ؾyҿ۵]_飼E􎊜1i%<~ҍ#+zXm ɧD29(fA(9D!fΘ> cٜafFu=M$RUU# odx$BC/햠{%BѴNcUJ 0B! 0M!v=LiyYNww A\å8SpeQhqK]lLG_^Pz5T'>j)綫dhMJϸ^Rw4C9Nʆ|Үtho2bv~}uqe,(.GmP &X6&2Ksq%'Xzx˾ME r|jJZ>mbbcnSXVE;t>RT)W_ X_.O_so*SbJ@QoMܓwӃ20H [h;lİ<&-) VGI^F#f4QR[UU._\p-!)D bUKLM; (Um+.ꀦ8 ǩaA I}OجH')\R_Woj(EwSrG+۟,;cvg^x4ghEFu}.SFyD#3# IDATe7(J׎8.=#5.>`h!Ehtxh⅋^Ν;GwX%% ^yD DBP_:`@QS£oUv`Bi.oE eϾ퇯V{$Ǭ1v~} T‚#l2ZM.Tse^YñFP˒ΠHJ:HБh=i$Fo ~<XŢ--82‡^YW7M0; dD͝7,曡7sew}JY-/x.&%_9niw~&M|C*vϗ8iΝ4 G&\eeQQPcq@_.'-kvF\"*P3~N- ;6!ɳ[||noJKzGD(_2*LZ%"Yj Wj*Jr3+YuC1 t:]8zP(hV]Ǧ鵪Ȩa@[ Ш^aeUJh[ c}`UeM#""Iւ+AC+Bft\ Yƌ8>_zh C#F6z.8ҁU*|oyQB A~Qp4ڝSj>RSo\NZl{K[l04_+9vRĤ$͚6S.$ƪNĩ#dY6\mҫQ|ԇ^L@Prx)4y+Z$9Fё?ݵ3ҏR@(C?CoZ9'rz')Ȋ[;/~1(!0_ּ7>!ԊU !?nhG料+}X@R2X_`!Ro?w)ҝ ) g pY"*^N@{R>2R$_WjuU֗;EKi[1BН`$͙SYmEyGQL޳T  UZ`AD ^ H"bCE:HI$J f%[g?6J@xߞ93sfsVE+g܄6SS]U"óEEܔ uDQdڴ{w~v1bU͖[)9w `:sΌ͛֞xIlXbԤ?c#nrǨRa#<^zBYa^s@qxmS:ɠj:o $s'7Y EPB6bY Ww QQNΛ5,'LѨA@MMM58;ʗ_k`qf\KgrtHQwR uDܕucsO]xk)<9W?~EeѼ_y|fF#Y5>:M3diyk?iFԔ hZad~\lVh 0lB}u]o`#MDp@SXiAv7n>RGsʢm,zf:++ ߻S\]n Pp=>)>J;dUu(jۭ]fZÚHgFX,#r7g͘R\QzƥtT !8 Rm3]=vش&$%f|Nv}Ct_OvիWfʼnxxYfblUO4xp]4x|>\ڞ")A@hk;O0e@dc KO_ݻ:mFNwr.yKJm޴_jʱX앍S{ 0D_W?]«s=!]IW-]DQl|©#B$m1zr {зUy,.Wb`18 | :%$AECiy"sJHYMD E[6 F@3ɓ"&CMk&=+GzszM.H/(jhvROvbK'R -DAdKWF uvB?,XT!/>̂Y^YRT]\1ꇽV"S7.gCad5urm!qNd|+=z>]d`` paB>E6hqEIB5L[]b(2\{'VoqO\=`>IG6+C1_LM")sKȹ.k&;aFiiZjݿAɧ|tܘIٕEW6}b`ѽ;eaSҮ$2d[m Ek>{ɰ[W ۆãFJN~ڠ+k6&e9_0jGڶ6+J{۳Vqa*[xiC}˶sugA@=Xs%G&gn@`pVv^?x`wC Mѳ'NO{=akJF*C'a ^2/ٗ[OMVߛXxFXfj^;4HU |5ڴ䵷{hKnQP,rU&젋bEym HVWZu+杢{qbPo\YR]ө NzEm弍~*#LLtV׈N ]Bhtk^A šɹ7zkވ"ԝ6{`(7+3;fB[p{eL<*3EYmkEQݔP2ص}n"[j1/ҝ )+k|`q(ylNʄ[E2$fP ᠾ| T2{iuф9EE ͺ|([D^AYPǫKQT 0 c#FG-K9re\!jՋ3АE7-u2'?lܵOҘvEkV/"` $M4F- ݢ† +]lDij!r'w)&=JI<=<}.$QPz: #V&bﺆ:bŲM#@k3 &SZDl:/;UAG~ƒW<";OktUۗ; T]t(}F|M{P.-NMM8Au*"8[ė~|#}-᯿8=?s+ƀSu],IH9#th(@e> ޮљNƝW.+~}oܺ){: t PT 'r?Ҋ ] Y ,x^Ϻ pM*x23Ql~s牎GH@CõƵ6UdnN)-y"h}bXwrN+MTjh 9]Hp ?{+zw %fyT}TPYrm. z?sưI#FNJɺGZCkH;A/w9m{7Q7 'H|.fݒ ڲ͘y_߾v9bnQ}#<|ul#ANQ|)rºz(CM޺I>2ubćgr!<( <͐]`]X#;َw)F k//d@nyM:?1NJ (z'Q݇4ݽy$bX F/200<#cq^ɣa!hsD OPz!剱= *0.sgQ6\hd0PYeFG93vfx2WMg+(I]W徥]簫c6N .i(@X*H܃^~y惲c̣(<^w=[$Kl#|ېA6a$`X؁sd. BH̵W|H>dHi{?Z`ˋ_jLWU~UWS_2g>%;y[PKT0SGӬMMQ^ց  / k]'#~7\ Σ'<ÌMLL.hj>t Olh=>fXptxb+a)cɤ?LNDK&`1UN^p͛_e6:0?qb֦-[L/`R9y)XUP"bHw_2za"c`#YyHY:2ٖۮgpx߾zQ!!:(3bkvEI]_i3iu |!a]zn\63^411L1sܶ@|0j}8#k<ù.6B PUBE8):[5;;nZnvaSgs qeJ_1iڇ?1 !,r^cΙw1$$P0Z`#GhqaL? ;{}ϯ>i&(5C E*V_lݱULW1ǎ9=?V*C[V7~W]c޸dk~a7o{-0m i((B<+̿񢉉e`N]2nQ[_9w5ظ5>޳XIL, T*' l 82=Hp(PS[؆C-rљ?j-gW#EHog鱞} d(_3cY΍}|싌d̛/Cгkf,]mϼ;g Aiv# 1w.ẛI[nѭ"_VBO޻a霛|WاjΧ_*$$LܵUU3(L64dtYy$ HŦ񢉉e>cO-rݰSWj͝_%~3w`Mv>!B 9A tĩi#먯Ըo"I,UOgĔ9\^߹k7r m6wĉ~)pf1%rQx0 $䤑lbaM>Xy;&O$uVTML8Ʋi=5}G~9qU9-.i޸g΁gϤ$lrVND޲[hBQ/j\_411LHvwn(9bG}K'!w,}X>u#ŵ}}'%3fsi. g:E;*K]J6sXyjҼm !0"![(b|=)UW(HF@d'gpba}7M~7nt7v  RaڢmcDkwU/iӻ_ &bn9z`Vyou=-ľ{ O}o7_411|tu4IR/*t}_ x=EU'Ot? 2Q}ɘTnYY=ET[nYkNupgklז{$Ϸ}8!{_T}:$d;tΪ@" xZ]l oŔB>d;fϠesÊPaBemnH[96'e(,彝(2I IDAT7*rdyES!QËBqvKdp$Ȉ!޳׭|'e~Ǚb UU#߾sգ;ύ&&&htWM,Ȑ v(+RZpg4M1v{8/uiMS <L !x2 d94M3 k_L9@E^ߠ$yy9YpO4u !04cLPduMQPGkG8t*0IC5!XIXWII-V'A`BXJ! Ugf̚' Iw@&brH@p@$*j)$ m*IHx*tC5RUي55e%JIraXpI!v(BIzZeT"fs8Si=q׊G{svtORx"m@(T?A2>8/MD2)햱 OrVQTxIP0T^^"2A#(%n#Y2g7ҿ9Y1uqdtaw4Hu%9/IQ9,c)fInK) \"v )\` zBI  )Y'"<E3:5 ):4ːyC/D]촉ɹ D=}^o}|EAFHCf-))iDIu04hn|s,#F͢$]Nєn<}]B*!c:=RQTO gECEQ,iX(" b>ߐ.X\UQ(pvQ4GuQrZLFclwp(`,$! i`4ֈzAEMLL.3V֗^96m|^D!(sAt9FC@$#3x04MAAl_aXȰ4`w˶zh%iC嶎͵A   `Ƨ:[$0&i TV! 0BEAYU&2gnE")i靷_`g'm e)9* Fx,de$DZ>2iQHc-ƓEeEH!MU)ehMQ̜&EX{97gnmm-((ضoJ%bK??|/⶞7xULk-MGhfI mxN>EE"#" 55@/$RMװ$<!(TZQP8D|vawk# IЗH 2e)]׍u2[v|GEy޿9eS;w4N Dhwfwt;Vf0)Q(2)vعSIEc˨"4 - @ǘe`(LfuLU0X"Hdgy<6͐ѻxQ.\NēBܽP~<771|Jb' N)ol <Ñx ?4+Oxց! 6&>f6I&3&[;GU6'1g۱c>0660! I ݷCLm}Cz׏_?!0yli޺5c{Ndrlx@UWU[)O"zU"S.1+zXbgO<=6WZVu⥘o+G{}'.P=<6{] US֩eJW:yS5d7o\д}ǣT(/NRWAphl"Jy]xWj O0zrQyL2 M[ e1A{->@UwߵJ3::ZUYt慃/)gpĂ |eι}wkVma+C!R[d2ɷ|ELO'@`|KԌ#p468tYYA$߾Pm9ƖE˅` 4g)˜lǟW-}[t‹-ٺb_b(@G`ذ^ݱ >5[,07 ۦieu ;>N@?97k,`TLui;;qSF+jMi*R苣YZ)D.t⾖ơiRmU OU #n\rOvy^ZY([fZ,k&W^ak9%勢9J9 O7Ֆ:,ThM* Hj6 O]8LI*q`(G=wuqXQɔsFM*|ݒ7T_c.#e{Б R0hM-ȗ*F*/tXE3#4 H$[\7_DpZZc2`u"ΠNT7A>*Tl0ʬ w @1=xpBjndĕ3Xa;`-r$BP[m6SQ(}iJou{l{^R).P ]Iӥgr,~KHr\\Qk5j&ߨ3Zj6m @  @ǰ%eA/|FSc Ǣ -߽gd0}Zs9IA܈LU:;rc{?yu $%OcC׫o0TYYqzsgcϫuk7z9j>1e7ZI]3}4C#|$CjZZZZhrZw4Jek{n \Rp/yAAආ#k :lf1L ]O&Uv56 ȍyfژLG|?AXB@XXyRȻB[t>îgX ME٧MFP(\`(E !&̴\Z b  =AE >[Ը\BP2歄 ;\q\sAק3 Dv!B"Zzp k{}D"K,'!M&yO>)Wr5"sQ<ɦJ: j ~k2ISD(-R&ѐRT9vaa~~^l.+*.6jokۇY: yx \XQScAP(I9\0WTT p칛{>'yRqԴml$Fy|C£`"{|+7y44_nm6[ݜvE:q 4A0I0 |f@CqA\3,Ap sqYq9Yzt:?l\dXD51͏ٰ?X,;8N_ڏPt:kR+k@)~ɟ~bm ڜ+mB k5!׳Lenv\7R4͸`Aa q OtMNfǣidefbsrlbr2sM @%ӻ|ĝچ{bgTsK%@0|/fݷ59եE?I"p^ZZwNye^0s9pLG&'MÓE{[CfV3vXrba/6mN\*I^۬Cݏ7;k**. hA0IѦ@ b`F*Ylʟ/NLFJ3 */,p/]yzo &  b&{sZ]Lٸb6f(嘵)$j+,չBA y᥃U|\6k BeƱ+#G?r:<˙2in"Rom=-{,CӞ_9HB|h{ޝ[y|L*Vk&@ph$q~s߾v, 65oiR2mn;{FD]ZW)4MdxdгeϛԮ] b| 2Kp>&'&tz{el`6)37M8*éx"򄎜hSd 3Vdsn鄐?BGQJfGg.O%P_d$Ho,1,'! DLԜ>~c:YZ#\&f^+)A0v\_vFGmKpEu%B(ASEEu6Cxdl\dXD%~!\ou&|HJ) xyd>n)Q|ɟzL+f k=6:Nu]T^l,>6kX"sυ1:7h^:E:{fm-"t0 {\o66jsz˚Y''gw s`Ith<zbW& w'ݜ*]aӧL}(]KTțC{ b4)ejC7UPdD("E/w_{wFu=e[,ے%|ǎC8\v arLB3P)t)ahz@a!%+ Il'mY!ɺClL&ico+踻jI .*\dhsMSP(usrl{>?sn+IEGQñ r!=ՍMzCG)kőszwT[PCQ70 "H?쥁)N$woo{uCIt4PjJ:.ƒ_~yd؝b_x1O1$D_hX"yBdL;8+?"K# @td‚ B$+lgyYůyɧU(mmm 25DgBQ}B䫍}]媢gH)fdrUIYmo,b؉@qBΌ:sHȝW\wS"jឆ٩45mNKHAo&Hg#,MU4XRY7{wW;uT/{5Wg.К+[> !ʨ,˿_~OV[# 4RrKϝ?kPb5UU_sng4F$$9rsO=cǏ˖4qlEaa2JZ)͗K FjzNDΓTS4xarjB&Q"ݻ_۽+Leyp_`|Us羴k4 Bwr$梡e+7㓽3]/ }GPGN$G5_}>C~AqAt2PAKK9^o(lbyoNOWGk&?ܱ 5f5ԯTR9yW ϻ {?* 0Glin6YL$TZsۖT*MFPRxl(-]ZZo(fa>#"iԹ>-E`l664ȣVZ ˒۱!v> ]vD]<<ֺj5eoِˤBwѝ; uUw^rKi8ںd ϸ~noJjfgU]4`^T+$+*2DTd͹yX図YLѸR$S^ ._'T8pНkW)<birri8 G"Z2el|s&띎%gj)TĢ=vJl X2kl?4u[-Fa4ɘ}lvA|FD4ܺQr sP]Ddq1h0P(R&[IDATXGcIיDLIp\!d+Y~l%NsA@)"lP8 Z0yibEX,.1l šHBph)'Nnj=90b(*`dL,=4Jr߻Qt:+#_47CeE. IpZfO&̓I}qQ6 jQ\G~>zP]DA\@uAA" TAd 2EA" AuAA栺  sP]DA9$D\&*e&d3b=gѕe3k} = AJWZeyJoG!ȼjsn Ifhuϛӯsծ]DQJ8!"1̵*xBa6p(&%ל~cZog{w}KIENDB`n۽*WᛦS4PNG  IHDRNgAMAPLTEٟ pHYs%%rB@IDATx?D b >hH|L 8H 'ER*>JD(Q>Br@BsZgos尴80Z&j7 o' $P>C-@*$9[=C K LG|+2ԌM+٢bV7|vɼoJXt>AN:ZEwQEG]O ;JL7 ƺd _>7QS0=̕媖jՑ*]U6xȆ:"{YSӓyQ?$"\J%<ԹO{L%,T*[JS}#j3$h$0L:Vqђ n [MNr ~פܸ CvF%i"L *G;EIFMNh}w#a=MSQ~?&~G5s#.^6ʧݎJg4MT4q;Ah4]Mn;1⸸>~I> h:I|?<0^/Caa~IENDB`nd7:PNG  IHDR_a?^gAMA pHYs-1[IDATxQ@]S$(@TePP!Qf]3ϴYw|zƹde ĤxxzRUf~cJ#[b!$ܪ/R=(;Qt׳Q?P27k | uKw ;3i~q!eBGti=RhI#N>^&B頶u[aWFc*!L%qkV"DԱ]}Bԁu D^>WԄig,|k7zRYD1ząLKrMOR޾AS}%o0wPa+Aw,1u hޣIENDB`n0!:Ɉ۾+|^PNG  IHDR1DBgAMAPLTEٟ pHYs.#.#x?v IDATx}͏I_P=HӻA -@bhC{}nKkrrMOE C 09x"&SYE SNIH{T>$3~{"Kh_>J=;܇{itl>ͦ4f4k^-{\_~UQ4/~[,zqwjoa σ>=܉-ҳ^ >׳5h6f ӮtV<^ l~/ +ث9ZP :Q{-I85S_ne/g5Y8ip2%viip-ODq= uGӫ<и/yǥۃj[oשvYpxZ^=AdӪ';}.t 3x^Jn]디̠ ޢFw-fޝZJs|M;6[ EX9N=s;4ILƧW ܵ[,ffƎ?ǭ.]4gZk;;zjp5fKYUm ߛP3%uܢ$Eh6}B$Gfr22${vS8,rr4{Ml\V3Xgt'c[Bւo&ޜO1}h?ٚRD)E1gsSMR7 WM7 dӒzޱ&ƽx!Ϋϫ q +&垏F#rsm fͣ"fzn6=_vuG/5I)~ᜈP$wKFƸQ@FsrE VDwr(C&&䟏^KLz_A{K}A [~ fY?>>ϮdfAM<%Yޤ4Җ8 rY'd|YŮmc0|=!Atc&Oh-<A|]#4a(Fÿc@a)]JCN ΧpCx)ryr1̺ۂE/IZs c`ٴрsCNT)yeF#Պ Ii^^%L=ԱRTDh;ymp/Ek7|Ɯ57NE*c6gX=on}>$~xwIM  LM1&kLA|3r\18㎣4(,g䳄uC-1PxRXqh(pFyϚM:ѪK鞢0z$пc ~CAUkY{. ajc' rދ=;^n ֛s5M[ hN~f̮;W 7qób6&%yI-q FL@D7tF<nNkΥye#)rN!j.>{i"r,!+(v~S F b̅2wAV;Fϫi)^+,uU2QM%YZBl<8MP'~G .Mg7ٵ:{& k[HN3+q;f!^3aX#7)j!t`v;p&3b*.te0՘@=[yY\ 75ׂB2bYO#ץ5;џ(,NƔ]pSTt=cVQ391W)~OdU'Ej /L:]gRGw2[7kpnصcʐ$٢' Nw *.KwE,O47BnCT֔L_oq=wRKnVlxeW'SĽc}،;$7Vf>I'g=c,|+|xKo`|rq3Nف6Ύuդн",hNQWv`{.t*dՖͰGzM=ke1[זJSZO̼wKvw^SJbSKs2,.ڹl6fil= ?5&EAQ|_?.]PNdTK NY)L$;ug fhS2^*/A>mhK%="'|9!8/ً[ܛ\(6v1,VwMem:Ϟnr׳3V>-.ώt=sZFZl{\RaHq:7G0U c~ ٛt>iŔ+V)]TlL..ٽl9e JKD"g6eqcP7WheÇmcl 䪷auK[j-Iy~ ǝ GX8̜ԛHgRY!g9+Uo]t3fF7nߩ0idD):1[ϐ% nKw*k\xSEtgl*. $\ N3\Mw3bk7:sU Bܱ ǒe\K̢wiCBIAFdjjM^nI9h;uG< 7#[Lᯗz#(kq:`76Kީk޼KpX 3\7xnlieߩ:>+m_ȹ>H;6tR]:9p 1YlՏ *۲L& j+]d=BzN/ eCxeAܗ7F)5XfRtˠAr ##䔥/;S2@ u0 Ji2! wՠ[|l\qSkѰfޗPVqg@י@JCo&ܖ , q9ߥ 9tԚco9`;'&R%bQ0%A5R6}91>]+- qjʝ-spmxm#nfZ ݃OXxT51jw9ln j&z;aF1VTqYf x:} [(&Ν7I@5BEG%9/㾾o-8k kٽaeoԖv2?bjp_Yʿ9u]g@TwCekI\6{|C!QƽPJ]fi4BJ].]Bäs`ϵeJ R۸FKhPdQ l7E& Ł{qu~ǣ>dvwk介ҁ$ay`}BTFY4QP޴}ө9`hi85{oncGF_VW.. -r(KZoꝥ]YCgVp+ [b} q\lg7_m}{FR{+mbo7ϣ2jepm/AWÖv&~ϣ7YEY~V6+)S _l*[Zeͫ,^N0?EaF/VtpYsgEQ&6m[EJy"R .04b堍{?׬5"ym\?KpE9 [X˹,(X/߭h=DXV[!ly+$B>s>y-uw)ҝq~.iuץ2I|hx̷F,y*{[r97AQar,a{/h7dAOR^wU%kE7-J:T|\lR."+c%2} ncK <׾uZ]Qi{_9{Q^r}$0W,4#k 5|F?ZvԧķVi}+\^r?'qQ4($Fe mHF~{s$$l4EX5Nf5QVHoQ+ u;l񒁉h`G3Wo>륔'yD+[9 OL'tFɻ<,,h5;[M[5d: Uw8yؒ1 wxP{ŋB;=/xD#C7Œ8n22O&-+nc5% ܿKuMS$4W7ڻlמEѰ\`@Afe,z31xp.w筠քF?݄blIyVWv1rֽnm<|qk6ψhϹ%|[pvŲ%Z,2OpibW %H۫x^,IؚWg%kz8 ;춑'iƽ#3w7N6]ɉ!A }8- [5ҝm!ʝ-s'R? ijTbѻѵ%=P{vzK';-;ycK)ݭrKC*S$(ɉ oϡp)e6p?e>対f-:vq%q1^ f-A] wynm bk>zRYg} Q~gQ6:sEvBkdmK!w;P^$:U#Mpo3׮4--"۰|XyXhϬ"tHHVT3nTrA^ǧқ-;ǰem]Wؽa&[˂V_L)RO nv,{As=(q(mD34t6_]e/2EZZݟbi9aKĊipTOǧ+yz ȿ@ԍpe/{I%ݡPʖ.{qfEc_<4jPWvݶ\_&c7@-=78E|4lGFˎ z/pSrG9QN)wV;p+ F: ]}y7M5!>;l}k(fdHv-yj=ZO?4(ETO}7B-0k Wf:SջQa4з K+ع̸%NXIA0Mp:Vq21P]Tp~'Ai9z{Rs@=l-9Ŏv_jy_޵8uOѫ;T@-"n\2U,N=ͭ~T0xGpZG*@X9tu|S&ǁ3+l@>Pf0̩TȽSVܨzBD| !(aߧ[g w͉&-A d(oyҜq*+} ([ij\uP~Ӌ|ٍ<-23)5mafA][΃r'_ 76@UȠ>r1i{ȵn58`pdOTÎ*55Ȉ-vi$і YО9|č=y34 rݖ]z]E<Ɓ(v,Ͻ{;|)AoJ}HlK<"D7gMxl.]ܵԆ!+HKUw$%-^Rƽ\i8C_k{;NhH r@cb~|wT>ŭW-]4ܘԗpDZyܟ9cK6jPG.ڤ9aV*-D-1i2@ =o%!ARC-Z98x:\c~-INR-R~E r#a|&#lYi!w7i 9c6wժq^ixld'†Ȅ+@1ے )GVKw Nm9瑽~Ie2}3wow-kJ;ڄ̨YO%Y;6x&bcth*xrxv}$\1y7~{sL:پcN]=nsIo˭-%ͨZi\̓E61Lkn{sVP4Wխ`4$(dr^Z-Q1Vn熙pK|ڇ'GH=b%8/fT?c/˔ds8Mooߺl`ϏVgf'zӲp 8bAd?'O'O'\޻/ֺ΄@Z L$i]~=':{:~hVV1 8`-qyIKOG#Dkjs3kasW~ a_}Rm1r$vw.Vp<^lqGO/HWbT*M[ַ~JDE+rSyTFt}Rv /5yqPHT(U$KHļ;~滭&";sBЊs$S[.7 ~bbљ S\+ZNp%Kw|[wWR,Tx,IwG]DoVZ(ʾpP9$ox٧['J%x?)X9\ser̓N5^4(hrr`13ӹLMy>>g gGD8%)?W(r7Uhvo; []Bw#a*y"4&v>}5|XFo[?ހG?RW%Ml@J&J33: o#$Mp7liF+btjִ=3`!尳EyEP^gU!wp7 X1VpKG,?Vp DuiY^{Yw7kS_фޙ?Ūh7}Xؿ\bgNFN204{-ݛDR= ٪u'$nevOzQF.*Vcһ7Ȓ{ 9)>z|c|Ӈ%[;w3;;d VA,Zq*2m9E'Z3L%̜`ρfEؤߤo_cS-^;<vx+Z:cxCr)q{߻F -:O!ޱ]:paw1UCg@W&g!&]KL.]Td>mk_^O=ѣΏIiG9y?`?v] ?R7i,m}9v[ GUrޚPR<@jc2)o?40L2Z:Ee [G1KYs~E{b&n2(MºEyWq`Xo"n;DrHީ_mC)Y^h[d2vudA^ Á?!6hA:Qa ojJή7p?Z XşBŁnC=>{{? UA*JR*FߔK=;#b4,`$S]m}uܚ$|R7qZ+3zB1Isa}ڛc[H~u!gz75G]iKBeo-_ ߄hFWu|N(-r !hd^R|,v l膆 06_ Z'yvB=/C&1?/]58GO+}3w̎@i*7gs 3^=LM O8o;[e7Ug; dzѰ ס>zNv^֞ó\׸Bq;J9u䨄s}΍2so˖Hk='!癌 k۬o{}Ir>\& >GFv\QMnȼFJrn}PP&lr1Ǧ/ް'w% sC7ly{|gYNlKMJ~ytf&E%pÍy ?efEUڜt7ހ0W|hpsi!#Osϔ4H1nݒD$m9vr£znso$rHe,I$.:]o ^lw1n̪ٕt鮁ヘRCy%>9dϛ5f}Bw do-j8\:=<s# wW?>-MP @~.zѺ tTw!0j= %"MУ+9> 818Q!7s}xjFV4q! nndlI.eC}k.,xF[uߞC Gq3wY쑼8Ѭ,Q5RWԍƆ yg Eݥ𠼻&a=q)<[5ox(rĪEւ JUI9~R+p濂[3'ã'Y{gq yS i nnrgǠ7_,緈o/$߹zڽ4k?tT\gs˭nSM8h!M_Ϳr'fM=w] ߞ0&&-}*Uq|tz7IȿG`,aQ$iۯ;eC D1WCY,ն|(h5lsZ9TMcɚCM)2r#˖s0\ y}\[PQPUx(b/s/}~򙅷4PŻhs".,$s$tbHqi:d1$BH8 8mJ*:ث㽩Y9^L;nǮSlS Z_ ' _p:V0q}FL3nQ07(s(J*h1$"8:Jx;NQN)߉pS%pR>'i!OD8.*?@'3MNn"!#閖7!fKb}$}T)0dh %2myR-kqQ^.qxbduWtXG:R?HSۮF efw;Uue t99tM[I5}@#<T^HwǨ;_GUJ!ef~u%\b_Ñ+ćnz>:4*\rZ7V9yL$LYUy6S •[r%S>4#wW-ׄ/D˵}rjH`ee}sbf·i:w9ћ3b䱀sM2&WW҇~Kynk5 n?=;}$TGq/N ̟U5?1YWQgKމxVV {% yڢg0$pߝw:~jClԄePGqZwxmU s94b&t&#bUpv3ڇT'^g#u\EOJbqN0ӕo,zʄ:r tԩ@-@lMREAym-nrHԜ'TN}ח4Z'x6/?B8:鱬s7דD:kԎziKmmzRUdʠɲtJU8jxQ$*jKa[呒Tͫ`Z*+mC'On;|ڡ9fsK%+6{> ENwZxhi9Mcۏqx,sӓHD+7ƌs{CPr@YjU/l./;>)ے7g2S܇ޖkUhVr=CQ•]l*f+?"D3?*&.5LѷVESE"Wd=9Ȗ^|:##P 5|`lB |%Zس)rh}4wX9M3\2,*Ό$Zul!'/߾{[-6ꁽ2b`rnq%+rہA0l=x'M1s`WF'gƯ+1F`O[HdVEޮOب$D׆?3ǩ5< 6j\4usՐFIǒ9IZgePL ILdbXRuLD`5Q_& vgCgD#ihE`*֎ʴ|$ñg,l73l|j.8peŻEYyۛkf&h䬎Vj)<u!mOXél?\|0nLRk. |3lB37viĞM8?|؛.ֶ-QA[8y˫.xcDE4F@&F#y e9s7fQPQ oI#.sne"7:* W@cJ!NːoNs1jOSC`f|J똁5J"U{kfRLE)§y_R?z6U:5uO^ն0Z5ECI 픝c&Սi3njjdК6ځRH[] C7\1Z v%u`4CL'33熩z#97JOB.Zv6CM1P7 _|L4km@'Hl_͢éTY:wð2wˈ=J`u&1L0L9RIF]_ϼЦU@^wEWxSh2mJ `{AwUhg>l2_gQ2fHJR &D|Ƞ4;rǀi6{Ќ{B<ۓҡ{lZ8 H:f4cܝ1=ꄇ!01zg9cy8 FM(qSp7c˻`>>uI.S7[xz=OP<pMWfxL7UG0ݒshֳ莃}8ؔ{*Ui@ɻ8q:=7~ħa_tw`P%eоEivCI,:С'լZ3ōr=!-v^P?wMWwΔ[S&REtԔ_ f HNZL]H&PRb(&'Ո$)"aeׂ/kŧ I &K(3t`< 3C 7xm $@Ӌ={@эHOߨvgی1* q^R0a(?q b[](,[e7+q =azѤ^x2yӗ} U~F+]t;!PMĸے0ƍ \$n={ m?$5M˹sVj Hȡ]_vھ<:[qڻUY|Iӕ7OBNO/AIߑ-Qroh2}$mə%O׿2kici)p`@-'W|2^ -()yf1?k^8.}$ 6p\NuhZw`F]]Jl^ |51Q/8:|\ZiEngث&آ%<ϥ-ꏷkk?XkN'*4%K0*!0<\8KP Psm1^v%Gm1)4Ƙ6 \=zq`Jd=$IZH=q G"ZGouj-sn 3}ӏ eޣI7j3K ;d)J/FVu}܃0„4e(Urd$=;k &"'_VNL|ZE]_E|r3zzjԢ9T R{b_},5!Tiٯ$ xQqkS@JL@tk#փK3kHV ɚ V9Pk.ڦ%/sM=h%9\\Z8N͉~4YN%uʫnY-^ɈS=)g w9k@HM?rהLF%ȶ =#'1?T)-:7.j|ٰ,^ᆇPs@usil" -*,)01X^6 ųXWM7]  a֚Q@r[Pf; V4^y& "'9OrXl,4Q._wtQ\$ }E{n: k_j7j~-&~Yʻg3 q\1t`8CZ؍0:-N(Av+L]+F}00EEgS꺃zi(k9 p΢ Y;&n'V+JMƆWw}hCt@-ص6OKL2FHfD''+2iN`1:gĢ111F Z_T/1:h564lMd|D*O2g+ @sیfUVQo1m]:ChkގeX-"6Wqv`}~ n~P Wh=B"&ʿ_{y.]5z>ĥukȬ FojRѲ`5*[dB&5Oߕ$ED5Not~|\ V ;aۿ0Q4פ/ʦ "xu> C^b)tlgXo3L/HCFr9loh&<>YF7'ܸH0z/ nȚc0m Ω@UwѸ7xDU1~gKyw \ׇ!9Oӆ,>GBdo/N ֋Ef}JHe0yʳ#myUς-ʅ:vֱ+k5ʸ3H|{雷Ƶ! ^5%jA[L,Q{TCfe2&KT.i-RJTlڙtȣ*_>M?7lzq_?ͱ7%\[fsםH&K@U%?`'+2BRn(@\ljH c_z jϙ{ßUo&s瘩B󃻨8G@5'E*)'p兓?gLj =[O=͒Iln]̵C0NFrL:;ٻ(<HB\&!G Eu]E:3;^Aw\><cF@@@$$$t;ݽU^UWwWu&?^UWw{g͕1酢%0; MGeEP?2䈟5 pp 1o֠Q9vU+QSϜk܁ľC]QE LK0#D!Eh9b, d-<3g ߷zZo{daUKsHI2.?C|F&LK0y-Dc '`]З{Q(7fJ.(x1m} E@^huIH#̎>-cN׵ٽMXڳD`ŒdPo}&!ȂiY20ƶWh >Omq’94dX~(ihfaLḘ;y|y&X.~{ WMH35g\%9#o$}Rg(OeU]4_4&leMӠ!lJmuh6Q=- 69H#@07Ѿb;]p<,P%W~U_?z6p{>ٴwϞ-@v]M%3&1PY&nT[[[[>L]@_/=x9q ԉ͟83Si(9pvJ̼j)D5ӻ_p%cȈS inҞDO}5N::<[$LȾh.=@o<ġ/-d GYz|ٺ>5d gxe: vn/નxiKȊedvVU( |q'|bo}][ɮBmOt(>SWȻ.Y7anĈNZòm>Ѧt.i!se*?'9f]*H%>b?wV"˔OAܲg'HmCk߳kJ쑻8(t)DjG;=/pp_Bȩ ]y?ٲls>[o{Ty2(wXQcD7 /yt3W k.H :"T0.m2ZbEBW7is h~CtuҦ28VP>Od,}K>pϡsxpgrf>sLD TQ.ub E5mlqHc'n!c+ijlNOJ5t%#} t w>-旯cLSt&I7[9R/$R^~V^CWyk9`n;L__l婿$~BLK;?}`D"$"HNqj?70J[d}[2,bLظqӔޗ{>2D͍p.DtVok i]ˉ>u IDATϡsE~m|G} 6'@ѢbEWVQbueN(k`1ٛtFɧ,>}#P:nS^"_X\ Sv|aMEKWMweBp/GU[ /kZK!gW4\q099KwbpQXD߸/'pP> % IMO=mkOdfh8&'KY22 >\zH`[rE pi-pb#+( Yr O0RܴL&qÞ}dL:w#{ "@,2} sKϏfK62x$'"K0e$lpk!; =Pz!єv +ɛ~! fg\uNs`u"$m,e:f*ad(O*W[ $\ˮݤgɛ=J_|B4I,drO}A܍w=<*h|5)hVy2ыM>2 \FBM6:`0D&b(!O[!rW"_圤bDQ9!,19 M E 9a9Au9EiCsP>)(-s |+`'$֟y#/Ycܣ4JBr%+Rd$ V/(xVJ;㏞(7ㄥelv~R EE5l\M5F&CDLfBʕe2сP蠈H `', FBpbWJbM8Rtte2lf Voa(_}gs hJ5QMv*3Y2 DDGVG </ r31- $txh X/` a ]"y<>{@AΓEv!w]>?y$`P]w#aYqrJ{eJg0.͈.!A.ҟ="O,Bc{%3T82`O#w8Ix|7epD]1 <_uS}/I!C%%#ޣ W x:^c5cDYlΝS[x,\0J0aȏ (qu8N:*&*1>.6eA+woޗ#Onun+`M˹\h׻Obll6~<k;t)X&|^J& &Wx v*:Ħ'qȪX3\c B.P6+`q7֓{n$\yyUN⠴*S,4"J@bv %,4 LaJVQ7-)Dg@FeRwP4;?HkQ@I\"`.\ !SeFQMղ+C)& UbЙޡ d,<'TuOd F#rdմ\a (CN+foQF F!b u~O:ѺvA'`1PZ:;En`= !DDaQvod C,MdS(0[軮8kjyQJWܓǨxI&OR"'dh <( h; I05kbNquRqO5Y/f4wl9@lI''n~_ ,DLd{R&I35ktYچerD"4‹11bJ(^)g:de˽zdf| ƿ&"zU,\6i OQ̗9Y/pPxPD ,BȑGLNO>n{H&oֶ/A>fe &*۫&3RxN/{_aK+"z4v%|N,"Mf7H'O҄H")?&-+=ۚ⬫6me2+|؏gPaf:5̗$!" })w0tqYg'͓? 0't($sB_EK-ߌ+ EM(HިreK!>{@M;|N_؁V\!kf9,Ga,[sEgOiȜ]{|T՝ݙ$$#! EV-إ*vٮѭ]|Z>ZVjbQ" $y2I&yc9s$?pc̜9/E?̀5wȩAWcĸ\}qѪN6{BYƬ<ۄm n) c(Dl!W=sazja*ۄ c(Dl[Γ$T<|~qR"#w\)r4pQ&̸8<Y 1F~FuImw,6 n%˓!}녂(w҉;+sƮ,1LK臉EP‹n>z7kEHڇIBTbq=ޠ=*PW-1S7)2}j.n.af ^llBr嗺)[m~n_|~48M^~t!fE2w+f|i~sB E m_SHb0]d?=~? P)D~؀ŏ5(>"V 3F)%T'>9HpF2}-ED?&qQ%l]nR9Rd ՔgeQ-9! [J؉d߁ ȳ"DJƃһNN"GMu/a,+WH]%p吟@U#n=`Mr SsD8o*YZ~) mλQggOݖSXjX [gfxzcR!%9{ٜ0ZE<´F\}@5 aNasGgjpwۋq`Wv)t/C:LxM uVsXoZvx#Mx ۦrMO[@3%3 һy!R"$/j'%b*=5P`}!~yGgLm39$ގ^63r3}}ϡUGξSd쳭A4Gekv@);d $|] :pBsa/۔鎯6CN4$u_0ovBp8߀vs'dßR=zy>|mp1nr d)hN^kpkK 6%2oF֛1;܅;vqMw! k=a'uQ8?oGį1 ]S)kĶ ݸSpD7LČDZC-OFO} ~zLڛT60Dm1XWc [b1U_^۩XȤ.um7H3fW*J"cGnm\7 )ax{c*Kw}Xqȕh[w,6MɍNS$nH 2Ⱦ 5H,~0#2TpvyŔDs%WtpJi釞cG]B}M*?PхyVm]}5-:/Ua3. Xc t?!+D1i8v]B*QIptU [Yлzx띌:˺Qr[k E*?{F! ?tUxT(2aKpX{LzvBA상05@Դ˨}ŸC⸴JMadT Hg60R`YI$dchoKoÎwK۶޳؍0YxU@6G2IyhFt!2"¹B].gsQr**jl! ¬@ 9lG 3 a`<F{*8$6bvbСysq~H h3th.&FIG @d iL$!AFYR?]cEⴝm-$u9dqUl&hLWW7sSƴd4QF T34:&&xf-f* N4q?#cr]ci'F N SK+O B 2RBOLOHa Y?0 E߇' 0, ՗x2E4x" QXKΞ9H%Bs->= eQ 4А0|O7nK5^NQhP+v0?5g}&jD#PExDhb{xkGW;Feeg'Մr~ˆE11M==9!g `23Sf06 (Z0LFwS (B.&" 7(gVj@Rh%J}1pla_r„NAzޯ,Ւ/.!L\F8m\ \nKuˬ2 y TPޘPiMU,*s.on;9}͂86`lRffĻ3h~̬2~ Í2_N<s3S?i IDAT |sJaoUe,CLJWg?ae8Vngw۬q&>uY aDJ?+ad|B9axe--'^%`Ƴإ:(z1- sz wO gsk'z[[~ۮ]P,MJ^k)EL7Sjmq/[8}y 3\;F* dYB;|U"2*ZƳO5{k`]h1prT65%;ܑ݁Y'!ދ}çRJaoNr NNG}5YtxQz $eŌ= jj gMniL"ً u͸Ԛ+*i޽Y8\T5#}2,tlhA9˫k); B٠i3Y"foQ*Υ&L2l]]O o5L&JCa^?[ö\J䗮BI)\ʄYTMM8 OXmpə)킉$ B N} 0܂$$YR>iT"$3F ͙NX]Ԛ8+7c?n"pdˉ5,jk{1y3a'Ű S$HTD.)"7^a y 2w^Y"!*??f[@RN/"iXFLw<5`eq7b@Ce'[9/?d),} M4+pE#N{cIH/VcV#cƌ@؂, Q %4 60,\=(ڏd/Rzo"$0"#o!=79Y =4* cf?eh%zksn_5]FLƮ\N|XS]17zsFi/~+ՠCL-CdSc +#"K[ -|Ld+K~fwcB#xjp)e5;Ǜa‹5):~3|rkѡ?h@gFJ3)OHJQFmѴ &7J)*I+z؈^2ߢGMx{7rIZ$q|Ǧ)ad7v~ _lQ vTn% S\e12G0Tv̪SR<5/N@f x_e^u9kTٞpRȫJ)-䓸3 KP]$ 5]8/ﳥܔ{NvVGETdZK0^~̇oʾjG[E&Im%ȹS8ʭ 6xu­f[NY)uR[(g!Faar)6i=ҌnF9[`?HOS]swMµ-%RվQtyO*vQ &R|%XhK$> ]igF[ j%[)Y*׭;]_Iq/~Ԝ0iw5~h/꜖b\ R[~Dq++Ϛ3:բun\ O0*ߎlK\]QJ s ]e>jTBPr+#;϶~]9{7Fɹ^umryj賋,\bAf_\o<zbƩuU3e"O|B/!ZIy|B_UjoQURO&-+V*٤brL=KAR YtvC$\8W٫ڃ wCo)qcT)ⱁH'"9^JҒ,0`IWEbqȤKS|jU_9Xu^WSgoYFly{- >5"ܒrt$m9|TWRfȕKKe/wC kGyTwxC`H輫t !U1܅hNklrsdtb%ow`ߡM7X4aNmMMέs Z9^G&l$&X uĩszT- suVW ̘O%duЛǨ0`#&} 6 gJF^zB&Ú9Sf(Kbs(oK8k2F<3&,zSȞ; <çfeAdWl)6MRe X#0,G70(Ľ=%ڛh!K`⌛}1I1DÈvYBϊ j IMq{j~FwY|#>i.6_f49nKjNarv8pxwUP>ct_ڂu >aKd٧m0CEU$0f8ĖC4Tm!~U6s {kċ?*]@#ȧ9?zlqP'0Nbvw颀e۵&X`hA-t1cQ ԪQqN6|+wLJ()77Wo»~ca3|^2IRt!`RZ>OU]n^Dd]? |T2+lfKK 莫7FPSKAi2]yr:n\K Ӝ$c^vC=h?,׾8Fr۫3'ikrucr%j# ӡL`Gt,㕛:Pne= !rC3ze$3uɼ@1rj>L=YE`R7ײUb,<[pƾa_ך~qVnݟNx#ֿPsguUUuum}sO^?-҂\rHfOK)wQPp8 ɤ+x={h fi!nr@ZqF HyC 3xuٮJ1^{xK܄XE:=c|̴1:^Se+k{"{@d w2Jb pVC|C " 9t1`cT^\w!҄~e Hڳ̷?h+^J'ԭ%!aw !IDc|IMz.zf(&:ߗJK:A1PdLf5]шԕ(dn'&-nAd ZvF .ɡw V62!'cBZ!ҵ$RL.ۥqpyҪb 5VRʑ:ӜGO^FJd+%Gm6½%nۃRa"eO-msS`"se֍5-M~%N3}?el>;ͫ"0vv_O8?m> 6""0^^G{[mx1(0n0$>s گQ<囤i**:~߿empdC̾hO㿚ߜva7-)mf[^Lqu?>В̷xf(Q|#3X2:UqZi_ ld:Wʯ|ߒrA 1(cͼqjte/cϓZB3Z1̥}@>TM&T$0i`S鉒R^F3Nu?%ǓfEh\3'((t>?s\=Q)$ꂚ01XOLM,I,܉ubz+Ö)scɏLyc5cM S(vI~|~`"0H̪Rrg UfWTHǾ=7N VA*㩇c??A^nyU GL,9DI9 F޴OSvӢ~ɠ٥V@C>)=;:[4y Q9> K7ɖp[͖Οr|tKWE_:y9ϛv4 ܣXD O3nt*D7bHmcBf/+LT8k^Ym復[1 U3lRE!Xd]s_z}O/.l\/T2~6߽2xh_tO?Zp fF C1l2o^`xG`*cj$Æȝ8y֢#wyf̃j=YW'o2míM=3g<룗z ݁\3ЅHMK%k :G.ڹƓ R[(>Юjunʬ}I)Lu7BU PS20?Myw.KToSo-LjVnLâͪX+@xyK[o} o+f攂+ Qx2 S`D`XhGn,?ث75t{Go@~8V8 ><2SY`<\6ۉz 0Wȗ{5^fwǞNW۹׺AC,4]B79ag/hڽ=v3R.Z+lcjmE A>㊧29ezKϯW5{^ӹ#6΍9Vo9`u]k &%0֑Yڝ 46RR*qHT`ѤR7j9>Xyiл}ӷZJ]Y]=e~ѡ7Ԓ4vS&jnJ|#Kgp*+IINWO* GiAzZ3Gsi?`Kh@ `B`]#;$Fϝ:)\b`_#M^e @;<됦ˬqԪ.xqcs ْᤡ833UbC IJtj({E!H."H*Wu#\4o:I IDATC_#L\%! 1 A\C$"_|+EiDU3UU IXB; BڍcJt 3mnGpavhPZDF@oB0+PKR?^eJIOn޻W{ϹΩ q{pM#e 4Br5Wf%F}d'8U(ޓ+R9嘽=p-Q$Q@]̍TV]e:S51/{vL{_t#Wʨ7fvt4B)ߥdHkle6s~4 T-r())!!WlKHCO;VLH8L-ثDZZֵ{'UBug4R4xGٸJ̃$ ~ DyFtlG=| {} tvM+Gc}Fw?K4VWq Z^l]ՇRd0 Av{! tICֲ2cF18-UUܴ+/nQՖz@ʷ\gY!ͼ>A:yr^Q [f3RrR!Ym.6\rkWw#jfQU9qj#wȴ ;,ffenOH!,熑u,Ak DNNBI]7L5Uo8݀՞lXҋ0_!Ƚ* o h8˜Ó! ~ؾ3MRXNo1q,5گvZalQ0Gt[(FarV.`_?Q.Zk>1l B|}z(DX%'H?ƃmXniI,mF[7ͫȝlgWX\YoKKP|3~*kD&aB[ErQ#ܲ浥ɿQkdڗZW2t-i~ԁMηU' $7W{Q偪 KPӵZ醖!MK׷l={jpzWI@_aw= q<\¤?m={$TRx!C* &QA׊8coWR1g;#klضՍlx9Ţ3uwW!(;N`em mrPa堽%єoꢒ6%a%#]: dAtB!z8(\1pn'#7ux:)kQYRHf cF<8k@duRBbUDA:a'uGE8Pj 'ĮSK٭FĿ c _׈.2 gfjh'F$7iJk.BD6K] #:]I-TT>JcQCn a.ʨd4c|u9m&K56D".*IA#BXk#QmT7KF}N5 A4حfgeUmʲ|#rQgG y >mtwSdp ԧRÃ!VE0Y:oU򞏝_ V_ShJ)8U>=z2x;bDuJJnڰLSy[A&ī,&0W*"IKuTV)V&%tFr ERU+_h()w/ aXgQ6x O2x]D;yJC/|chBI·G7ȏt6L/I8csen%]jpZkfCu 6T0?-0&/DKd.*̍Vtj\F qh \a|Uݘl F5Ή쐴zLZ)$RZ>&@}&wCnR[A(1tbtl$$]*+StcxӖ@gx Lt庌}B]`$PKa؛",i1\6>T݌K8.W@` )W(O`TI)x~h=]>b>Dĩ!q@ȱRמ~xj1\&BUu1H Fv ܭK -]i\8~˾ gVâ" W5H!yKSr _W`Ή=vjt-?u\&WF܊Raw/ˆQC^YL&&d--DVBQI%m;!;+z_as6 j7d -ne3ԯK_/ pOruuZ3Q5$evǾ6 aY˦+2;چvb ,7ꅩ7B' q(xG?#bcMx(lbpZH]nxa!C!pB!nxnzd ߔq`&T еJR)?*c$*h4!Dp<(TÒ+IVO'kHSxԙLՏ^׆ hgfU90 zV:)>{Ugk+xh|WjftE7͟5a\O4wegV35{-,ps= f/۔s[^(_wfsu==0(j*Y@1akŝAF4 vCwhj“g6yuKZֳ  {VB`6w:eKkÓ' pl0ae1+QZnGLj1$IDNq=;)]rT)83y{oC…yGK1 :Y8hdlo('vRʚw2FLP%$yLɀN{H0E>]=O4Ȋ{8ZՇIp=zV@9懥?+΂УNdHw@Iɇla> gU8nd@eqc8I)LIyB<@*ڧm[W7}j_@ 0lγ> rkA㖟n_1raBoaۿҩEnBs4nS#N.)A_yT6`^qD +i!?`%c K0ݰw܅wf#&?ryݍ_~Bv.D`D,1?aKVX낯L(M=ؼS~cqZE(u*]pUj'C pVa83+iO,梛 7'(u1Tl7#v.D,ٛ:RJ[U> ر|lSB-fz kcx%w |)jV X\X@۷f܅X oTBrSsvM*9,zhڮO SϬrfY'?(`KW<޺f'7k )3G3Z{e]E6AQQ45sYiQjf̗Ӭvomϲ[Zdb " Y8_ 3(?t9gfyy|&G?*j-x8;AUS c 8 mV{RZhnoT@IG!BQaBT* VXckb%>eAcF!jQ8{2R{BY'VqcGe̔Z!ޣ Dͦ+%_"mȥ2 h_`Ef# 몷m(-# pW[cY=m%z?๞/#zq8|ks8TccLw n54PUQnRWTD?ٮ̗墾!1}5d;YO> mAٛY>PUE02ҍzYH1{ dhOMN/\ zvu4_ʾwZJ:M(_VR*2?a9T:1]{`ב2mUD04`YE+'n&ϾPcʮ"oSµR`DbwD4ANS~V1SϦYV2TL,Y]gK&/uUgӬpΟ_"aE|Pv@ՠI_1ѳiV8 %6Uֹn>7s-[=rKZq :LEMf:u[7enijI5 *U7T03t'WץΜ57/cƁ1H <VZG V>UG|p#,v>t #1T'kf[2\-MnԹHnh͐ ш>f0145L. J:Ĉ:Br8HbCك٩f + ; 8+*qT XeÀ&a{zp̴p47uARu̱%ᱺ$l{$ x9 wab*pk(mY޹n{UvhI= C/:f.z&I.@MJVU]CX±t#4gT6<4n'su勏KEɦqT.z`w k4 $)']yr'wRu$ϲgalS6慳npSo_1_sJZ/˛aLH,4jo ؟ "c@5VQ\`$Bn]p^ m>->2CʈOuO,[rpז$ a,O5?Jf_s{k@IΩr:S&(-'0P?W˸\"U0q*(̈?f—cVB*%%7'EkA^jCÉ /z閞\ۿGld2(0޶ ;Igq|XkN&&cUOLʬCۮ8(^yot*ơNļH{j1f@_$/=p $.)shiV?T(||xT29⺁aSM1+% NnїK7?xu;aċHi|<]OO[$z. wdꣀO\kc]8%mOV܆0&kxǂ4B`|fy۞X-@;wz`=w ӳ]?q~7'=O `˲:u_ (]ϲ Sk\{gzBdcv5 lӔoS,]N:SS[YgR!wv2~Ctzg2#VĝЅ>ׅw@gq~g|6\ έaԵO5J]dD8|S Y~U$PQ2ݟP1;D,=Ce-O2UԤXM n7:*޳ Ngx*xmѳe&m:)< .HoYI8NQ}1]_@&68^`b[WG/#ېE?mh8Y0@eD̤|te(k.H-7)4=U yc 4x UzUN-/ӹvVݴ'3h.en=Q56/3?-ŜU7&Fhd<>Βbsr&vXI@ _MnmQ٭dm7l/[]|6^o*E-X"wNG:\Js"UͿ\k3w_>''\\4[?I0:}*!fGg3D 此7*= 2UW + ~aO},zmy/rǠ5 )evCV'̀Ə6-ZK{DaݽKV*sٺ3Y90LYߞ:0 Mj:PMl2^kg)U!a_,~In&KbfSF&yx'CkE`T sGbOZ_G4I$ pCLw `y" 0m\݀?*I*nJZ\ս9]ݭ@fX0<)nfF)5kA)քKi YYqW= xsW>P +Ěˀ"rAnb=rzn4Ќ-V#0:a{yA 'En9IIjt Ph"ېn&qjOU@#t+0 U11CP~*/n74vFgzO9xbiӳ3 .A>QV7(g3N]{pr̝bAtSZvPMъPX.n 7*At/8DK"OfbuWOӆ#lJ/G?:0wz6{:?{y̾G(Ҕ$JBKJ(VmCPK(jZD@*QQBK*iRIDRjcw흙;u^5ڻkvs~읻;s9s_`<u_Ay Xo`"`̀yh/a/ ۾ 5Fn~ڱکG^9xޓs W.N+ϽhdΝW~ w{%5{f7'u;|-7>w}8wT ']N3Ͽs1? /S)ܼQ?z?Ud(]ȅs~N<7oW.bxϼ:t[/]oU6-7_pM^ >p9ɻ;9K۳f5Mg/뾌yY* }+xhnoGO=AOX?p/mN:w9Xw+/ZC{`olsh|aދGoC>:IwLsCsʅ=0/}R}J^,? %`-w8 2<0n{_yuurg @hR>ڤ /=t?Zwʗo\4}Z ُ}|0?d_zQ7t\DY\'M[G?pojwv8׍TKȴ]ћލ _?4`jI zs}wIf<{s_{쯟LZ ]bd],Z;{ttݖe}f;0zR4^Xƛw#-xhLM6# LѤ{^Yp3UsZ50O:Yipsy/6m]u ZJ6,қ1'q‹?D9gin7y;5wi۠k^7GN*b}Yƃ  VᘡVw`Ӟ8u}WKABRyjJT/?ֹyS=0m^…O<۽YV`hdx9ǧNbw0lнLz敹f%7t֎5Va簺3l-L3?̈́<ҡ(:Qzd7Pnn9+k10`Խ,HaE{V8n;N.0S 88N.0S 88N.0S 88N.0S 88N.0S 88N.0S 88N.0S 88N.0S 88N.0S 88N.0S 88N.0S 88N.0S 8]gtv?}{z+\ `{}Ju?wʡGW oc^3,Wt6⥠y<-J2o;d87JY҄iG"i*3*y*٘eV0X+SK_z.,zXXDTZ:,J*hXCеRgڧ}s 1*Ojf u(EF}? ٰ UsYvX=6iaeŎ1 c RSDKƟ޷5M6֫^:iQbf#NbŌ_3}ZfLDD@,qN[UIrB?*ץ& $$딫$,õge ̲#D}ynrť#~} *# d0;іlN;<`.(U6e 3q7vB&XʐsQ5 &ۮP"Qط&OB֋Hy(=ع^JBC6ú]7&4DY^.I47x2z]kƈPm WYkT"nz)(N2@6Pyϴ=꩚3g>Ke #Slh-++hDX񃱚A2taBMs_k5 G޾`nF ZɽEr F[T.9jC²l`Br<.5s*D 8~3eD &΍Fzկ(uA"M֮֨W73!64EeergC KL \?TGɨQ_z0\a+zmJH-W0"؄Ū+KDe/NJc"CH^ # B(O2^ez2ܟJ)d=OikmTk,foPIdV7&N7/챚DT+^z"jG_^?:2kA+ 6 o~&kA'$Bd%R>*م_~Ft)KLN/WO)^( ReV[90&ǨR~Z*ɥ,|mVqԚ{ԗ̛*0Tou0Z֎fCMQb)a[ JtdR 8,4"lN(*VLf= IS= BT%ABY♠R/ m)>SAA Obn:ICX ǻbz;,-]q%9aXIsefȆ5"m9M ` ʕQ~ !A 5hYBњyZf:مqbsb4 O j  VI0'Yrc0 si7(#0xv1YwYkl;KUfiNQt?ڱJVebVR-`` jkA0 DY#)TKBIP#kml$_ҌږxrC kYaf%"c4AMV-a  (@` ȒJLشF k(ƂS㕉ZΙX~\u{N-s{}<#cca( b'O[$$x@EO@B@x@BH@8ʆld03<=~KU5R!~?O[:K)i*p}2}F)!6§( _sbL;'mYKj1 L+'Q 1( &Zt^̧Z:H2bH/=syc*7ɤTP%J$F$wĦ~qd(y{L|啸[ņti6tovUgw(~?{)# H\?O(LQ'_bFpʦ]?I[>DBp?`VX;bƆ\LN\,x{]Dd :(>$$!PV.Q ͦ&{0" Lbb֒dMK {9M]Jl AgN&`?C!<ޔr%Pbmq>kK}77/ի(*8HvFo"4ݥVkߏ|ƬդV)9FFheRvCɦץ9X6&O QF6Ix#4L6~&I"AR<_}O>K'S5#"߁c~} !ҁEz[1&2CWjdgU?m.4aȫWu{&xo`Y0W)M~Diq@J wZťUQiM$`L3o$ɝ?t$OYjH,ZEzUܪ3̇Nu}mĶM50?5ɢ Ĕ:!MsH,_MZmII3A!%Z?#/N^7C7 6V[݊:7zIs=}B. W#kg*XA^$%6*Y>Jwbc<9E2Y$0CX#tMOx/vtV{g7&AHXmX9Nl ق9mrv*8 PP4rtϬtsXvxhV!V ~b'3ܳf_0{g/ vf(9. ZݮUgly`j3j p" f{έjCo^@Tp)A!|gv^DjEp4e0R4] (c5]h92?8d?O~FOXI$ƪf]G-5h_0{ (9TU)Y.Gu[+J"(+!%mKt3Ѡ;V |Lu2¢JPRRE$f[sS4*ye7VU$͛M;h|-> n 6^|r֋;}ZLmԦneZ輔xT8̞CJ`6D/Cu,n ԅrp;Ύf,neKӤk*3jȊnjT9 U 7Rb@J {HU+sVkp)CP3ze }+-+K|JDn%L%̡iYR[[|= fR֨rj,7#Zɏ=ੰ#m24g &8kD\+o V0;OD-{s5JEDTD KU~o`(lBV s)ζ7Sz$dKˇ͘U g Z&l- 6tss8"̞ (!uKsd:nhZ?F7\1y/}uo&%ەMEwܸ{`g?$kh)b֏[R7I{uck0$ls9rR2,iN8Qg6OlYĚ(6?LBdP2GHs_[[+7>UQ2?"[5A 8k(@?7ns^j&*ԝds礁nv5q^A $ P;$>&Q\Ihiԡa7Pvݩ2)ph=> 30^d0oR.YMb5R(%F͵xnj|S_':@44) 65DDL؝wK H.2k%kj#`qѶ<4[8ZUaPqY@.;-iy]M0YcÒ:4{DJʢ7q&hLҹ"TQJߝmjh=>wn\'5qИR !$e&V0(hZPvg׶D=gRzer~nľ`&@[WT`4NrHQS55 xMq+3}fjZ Mi:S׶'sVt:A[ՄIyjy2.q@I {-1-j ()$ QQ{xur[!%9+c|oC=b_TJPj"B{)m\f2!l1Fw-f IDATQ8rQ9Hi`1D3 ? f7` V88i7(`Ĥg n+[3wZ}z[eQjغLLUU_$E՝[Ws :yza|̡MmӂX(ioz#RF-ei%"Ek+H6iL2Iffa:<6x '3ؿ]U}BB0[fW+ѩop$*LUEXf&!Yr^N Tg!dkWvHV`">+.Qp\;-@r T`1-Y(6dsu6/n!( DTQx? GflU9|mv.$A8~fzYγŐ葁n؃콶Y J=_εɪ0^"#O}hϿyǻG.^-7:qkC&4*5JPU-I9Q闩aV\c_c7'ؘۣ0'"1D׶2Ñ`3<Ay}]NN>=Ucz1ߧq %z &%!%6,s`S*ͥv~DDC.RIã<>>_5kõZ;瀏,z֭`iRTԪTBTaIE~o so/u]EzCQ_xosY5*@I$5MTM}{76=[͝Ԣ^͢qA&sF_jfc `%=_>sTmT+MzK!b)(YϹKE5Is_4Ckx*y7çHnBvsDıI"RVi JGx D82ТB S>q""fkM91$Ԍ%Ud7/CbP5YZcXLPUD|h &YKĖ 3$ĺޚȡOYNuSԏad()+(A4DxCbeĠyx5`W4! @PaD~IAJv$zzi~%zXNЦ|q|Ij3Hc j/S$K E%PpT9KqgY&ѻSy7  Sτ|=g'C;Z:,@apD+PLOdDEhe˿b4) .EъDR߽Nđ`7{$EUι; :聲rUЈLq|ף=jj P]$k_׮M"O%Fp*)?}NOUR; Nrs~h %z9:!~"B&gpgMUe\9Dwf`J8KF޼ICxF L %^-Q% Ñ` J΃zڙ)iziٽ~>gY%+<ťsGiZT9ipڥ|1TU<;晆ar7/ݿn}SOgNߨX+eDD:+@P&f]%u]$LYq`N/"TP,>z?Gy@@`Q() I٭b]K\fHۡz' _iQ*fjbGIگ(*JHw;}}}M'rk9M,^qȎ"dVop.CQD BY$& M+3]|Eʛ;$L SdN!6aHO=9B Ў6+hLNL?#m6fM!LB|d{| |0QՠĈJ㿩߾j1(O-F6%iCȴC2m{'W⯻߾ۣ_%ݤ哓>w .EfS {w4 D~ኆa=Rau{擴&UJ H0ȨW ٘(O y319&޾ qeCg\J$C|VFtF77xJs& iN czdo룻#$jfkwFWRÊF&0ļAQTzR[q'nsl-vZ7z)Hg<6d Srw?/Gy0\nbKLEM+t̮]*ۗEQW˨z2kg/١p|#Ғ UV8 W)p/U?&e("M;ˤ ;~q1x.0oZh4;'`aA5ew|_,CB߂{ot#$-,Ԧӕ@6?a>ĨZ&~9N&wۂӧht±~WVDd|.m=}\? Z[yfA5J&6C0y;쥺02aJLuJmatkd̹ n{w763bh"lhծjoQ\ZTlmG{hoR%QLhs:o*aS }S`i5㊑,O'Iwyf7\Rrt,hSgDj۵;v ~t# J%(cuҟ\Y?U$`IB3t=nxrBo}ARO5O#rJg ٽ1끌hrvaYH5SU6]7<[! f/v~qǵߓ#<H4H5rT "/2F& _ }v0y>Kh$"e^+0N)`h;vib5,сʠc=T 6VZ,S*g|+Ҙo:{ִ8@n{I q?a[UM[1B!īH0w}/y?UXXڝXc;ٍmUfN̶.˞7Y_ଉm;y*jĪKC/\=iW",PB{w`2!|D;Osyv{{q3I6ƙ50I4 aY\WQ\k/]YEA̅n$;a&̤{{^E֝8@>ԩSG #Z˧4NTUHZ#k)YƑ]?MR[8Μ Κ kLY D{v *!'?ZI&J1ive q؝gVw4;wCCɗxUAʎa+0 (b8RUf)!.8iB61 eYSY=0aWhc4 |q FV|iU;W~ACQ@U Y ib )R+:O;R)(p:usL'nq7]&B0<6c# ܀EQhf76=qzk 0 &R{9RycP[d 2lncdMB@PTڞrΎ^>#3Z!pUay qx_-^y/Ԧ^5G#(טO1 \0s ̂rYeK3ZGH-lk۷dRjLeEv( 2v{Ǵ>v_S+澨X"j ʬT}Ĉݟ 6| # zJm,јxӴDu"@G(ڮ5?[;@ep6eHQTJ+cp"OE@ZPUهX鬩ӽL_l/Ovb 萜iABas[k\OL*d7ި񏛣_zSy9'3b f/h\AFʍ-s/<|BUkhwP5M03e挙9ipi>V/hKz|(**BړPďFz&5U+U^yZWۯ݇Φv  B@],{9UPkӎsG6B.`^2d%UY9KvTWx 7vW8.ُ^0@bbȮ  gU@VecORL HVY L7.倒 *±U2Y_ƅݭ:;;gnăJ# ;`\^,ISR8*+( )*TP?2]lDRlޱY Z7kѬ(֞K=} H6vA4@St2A2ϴG:xc|L Tk|Y1ȶc''s"O nTCh|`]d3Xܣ~{YsW)oגA[$"c\u$y-Ly*"(G߱8cji,HIA'oLRx4VfoڙU @H[=BU1HޮJ SDCo]=^LRGN; 312"c=`OՍ˃%$A%'$PA5 TSj+?p?ş vB2R/:l%2+*F ,I}~U6ntٻ*.[ Rw1lszRƕA;nWʹ'a>tm$]_I*.+ b}զ^\OmQ{~Q"VΙU[0d @x sw_(nkXHU#"sx렪rnq|0@OKZ4~1o{~zl;^ MU Z)E PQ* T*U"$M)yUZ5 ٺd8qlxls/TgJ{~{=kC;0*^U}`ev!ʸBݑI{f' @Ȃ :P W\͂f_-x~)E%HJ?Qbso$!X=!-APPD+WW1V\%WR(nut+UQՊ^=vQ !ع"Pu}=bla H(\ˈrgU<PDmҙMX 斊K#`B E1Q d+H$W !Z{g)2g{a484TqflB8X0`A)o\LH\H[ #^]bO5ET-:`>*G7~" S^ jqeV!إk sK?_N /Ss-FZpuUTny7j"2&")8PA Ei0 ..W|#0vh AALcjy1i-g4Pql|ZK; *P'>xg^`cO7^] .`v$٣O}IT9bE@EHcvn>,!,o^3vH.=quɰ鿆UUYTP;׉F]Fd ăp>Ģ aXH_OͲ~vN,ֆX 2Ʌmm~9p] vAiQcFQˠd'굓zɕm]v6. a{<~IxrP$i "}+(@[=7l$h7WRmh؎Ž#L2EU$7Ty+CPH$ uK`8 HuX H Q2BHq56Njk3O{KKkhS;4R{kV@HM{~8,&)uN|ǟ&MLv ;:wfrY4ilC \!9_\#Mć9w;.>ͼ1~;~4rXE4쎢.NIA4*K"@͚ fhWfR,}5Cn-l7zx<$2("1>K )/" a^<+iH@e)+PT܈ a@ŀJZm" L_+W8FPTXmIGX]dţAPT!4N)cK(\zy⸽И۸{o*>v|2GwMX)J}3DϽ TEO%7Z4x`+6fG0*:ER̹Z@憈v6/R' ͌#m K]#*|h@ bx%2u빇/{(r8{UЇ#-|kW& r=hງdtG)Ƽ0I~Қ#74}{#]&!bP RuOcG0ێH6& 7͂E^;5@^Ш=ׇPA֨.̎93`c]lXTM! Jh=]WWrZ+*" ؖ/ Z;WKϫy/\&sΜǙ414`(T ^"EREx(*-i%icRbfLr&s{{udd2@|ywkDϐ[f5k',ߔ"t8h* ot}Ip4SZ,ϊfPTpK^]~HBl؄8hc{-5`iaf<>8AW-"onL lp$CE cG(I:08qmPI75>tI{b/83bH.dGv>|{gjA0:aQG8?:v;M!T$EDlƇgcY3M>dmRבxA%6Ӷ)Vi*!C;wce#!w`d.H3zpCw^A d~k[uş1pKЀuoKalILj7b'_|$]Sbݍy[-H$HBV1!0g6$rEv߿<e؃T QL #Д"+@J$j{zF : P밒:0ŌZg/CcZu 1&C%u* hH 0t=i,wK |쯬y++ꗃk[A*g7Gj_k ,>IqDߪYgwlíTQŬVC J}@X֘GRĂ"ڮH {!4;Ml%(!:cthn?2X;SŶ9'>6XS#>twצ6$PI !p7w4}木):Jy>Y,77_+:. M5E/?p-M2fiJaF?6Zb_͟)diR% Il1v$UFRzة4M3-UoHֿ07Q2G6E3+{$ h OZ$aaNGNuO팜ҐYcw"'L TPuy>ך._ 4 $JPԌK鷹ÒqzA!fc `㒣"6 \}U.ߍ "sHx_w10fi,X@:,5g6yUuaq&#}tƔQ ȢR ֶ]5/f`Ns!I^)NW& Fg'^\PX1inxwD?Ə7Uj `8;24H=gîzm/\%E=܀kpD, z( [ppB0#)JcF]bE6א\)T@%qXW+) jFMTpNںⅭj9!"!77;z[yŽF!33q@vZ^նm89Ս{3ܓeT!,B5&١Ks|ճ[G3 )w+k1ީzt|.ޓ >8-wvQ I@-8+Ӑ׺I8d0C@Ӏfjᦗnzݡ7PԜ @?֝3mF4=H{}/ʱ/;ނ>;x«/'2iܼ]7@ee`͝M_>SՌU?][!&ĕ1*X #;q?"ɳ6O0K1ЃU6uښҞmC!řk;bOA`C'@N FEpQ7?)wT0%$4g` >V"-Nf"y>2O.R`ѽzwU]0 .ߎwk/XΩM@/.dNxg/|Bwuz!~fCرN_IgO\d*\6Ƙ:~ А4xĽQ(Pf񤿦>T(e5wGE$ tdހ$`/HO/-)W@? ȇ/}m$W\wuYyn# #Æ \<\dD=<ԵE4}1az,3>\-`",H$򭞂o`x,(*hS8n뙙UTmlػu֧$i')wSbĬ1)jc!ǮR&"P̢vNU-}+ybqP s=::qF};f3W)˔@Z[k:[k}s-NDi"M  mA$?> x @BQyB(UTĹxl9sn{ﵾ{B%e*Uy;{wYac#3km7,?>QYFMF*E pbC僀Pƅ@-h& P(c[Ќy΍tiqrK* 0R'!HN"H_?d@I#ځý~Un ;<IErql\px=cqUKh{cc->w;JХ-ȧ]f<)*$ē!**ఀOlS)bf)w'WWVvRYf3#„?*v37vξ=6hA4FJ׮x;e_8T|_ZWXXRa 7%ĬE2DB,OUiddN@ 2ot^s&. 5ϸL1 W8@Yv#gJn_|Pfn?]n 5 ?ٔK'i9՜iqS.ϕ\E?cL,F4f!#=6)晞QG8qZ5@{+Vf+fVv LR`)vx<0}JŠVe 9Sh!.AH2Gs)Yridߑ($)ٟ]~4pHٙ[K[ojԣnδܨ=;/M~k!w0z+SX/KXDƢ$2I{!AB${tkF f,sǦՙcr!ƧG7oR|-&I=hH1UU0:q{4/MFӝA%oFLP)%*f*ɹNKip~)5A8Y.Z JG-ihX7犛 Am[e8YG~)EL#QΧ~b7/w{~$H8N`Pe(^;qce4&V**2DmJAԖ.3[~^RtF UdQ"(ͥ*v0Q@a 1w_9T,J3+,VHt>LA]&0ЩuJg]{7W{ _=pW)h<|c+Z G<m?̮awk3oM:sC3W޹nkADI"*Pc+u1 OzBBV H dfBt.xwŞOf=p$F֍qD?^/v",vWF1XGf]DE;-D 2hSNLv1$=9ء{՗EˠWJ2K`4`qD LDhB ]Y1z& L.xpէ>˕3:oxtHo5>Eo㝋Sѡ'kǏ]9F9LW REZl=װV)IJ|}ݳnmgUޙ;Qx b *kQ@'T6g=]?f/-D|%!6QnRX9S #\r℠ %}ZWĕYDϯ2yutlVlo ']hkwӭ @,61ٿ'$]$P}G]GA@9{TFKN~&R,#E%0G 2(&* ft=mͦl3EvFx* s5%A&:'(⑒:Dܵ4Z=RT0c3n*9טBP}xi듯#@dx建ڣD0o {}z Q",LhXn;14EܵG] .+*nIeŤ 2 JZI^{dѳrm8D;'M1BQݗ-X 4@0x0~M߼iqȰd)! 0P;%B5إs]-q-qaz`FNxafP#nְձ[].إb=>ԜQU@ҔDVGO8 fx{1.% sS77ʹQwn@.XXfQ׳s';IPTh}aсIirGA*&N|fIٻz~ gCE,9eVMb'JA , &l8<,CF1dYIHQr<{:YJ9Z$SUS4S,;BW"E۱#ϭ|^s4OI IDATric(ԃFZ;"7ճ6 =W zmV."kJ6y HBIKGWG˫OmY[ܳۿ)MF#)FDQRY,G iPRQd48 J(}os'~۱ns;ezCOv۝9i}\~]YvU"5֭:VTU;wb&(^R{Y yK@6)":膮,;/^9[!GoZE7$#,qDv"0 p͑+~P(*HX 7~k#vy&T׮ǽ~,uƣ,H;^{ڞwƬQ瓾 K.Y{UQMUMxkTeڻ9|'W͵N&3u-TV(b D  x}ʿز|/d ]VGMG Ad$2U,Ah>@EDwځ{Mf`mNVd+nWÇ?irSNko }[gi.e5>?!`m-e#rA=-?^QQݎ\SQ-= ɭ'5Lt(N%*ڔbzKBKPGmsߝu h-".JaBGzRϷNe'WԦM@|0難=I]s6n^{fZV4*Y:8~,hN-.[SV!zo‹k'Z;b8dDq@zR1j" q; nx37OK. S3т*P1T"A,;W'dV5?BX ɷIӒZu695*B+z~q\,yΥA{qk0,mh:\e< ItB4>> @ Bpaݴ$z'ITUIA.w_097va* !.t JQ J'%EY[-r1ҺT5q ^nJaNGM?'ٺ\7X_LR+'^-d?fW:lڧ8R &hFkH$ IŚٗ_Ú+U~<,ufZKxz䩗5=DTaw+d]~lyP9ECo 7#M|M.QwS0,[UL C*)(JR WFE2pɍܸ, Ju-AVW;+$0g@7* 9 " KXig8|xb|iMK-탙4v˂}1xuxcs[1nd(eLNM {*o]||U4}6*#]j<!͛e"f:VOK[ATh6B4$$,%WB uUb)ZTW*rm6i3k/Ώ!p5A\N]y1^˫zУI譆Rvm^F^y3\Щ[ݧq&µ{;У|=b"@K_=9\v2Sr*4Rue{nv9lƧSs0۪] WNF1ªŠᨵ'bj!֣T eMBJ. ‘\`ʷ3As^]HBv%=sU_bTC2 ڜJ^gY˕8Ar^$_\rv*TZdto_kn_*ȅ\Nյ7,BDI思:6D:6"iPȚ+Tc]sa\3Ɏ*~N[!%ԯ1;lpذ?fcVu;.NKS aY/O-Af6Y'%412v` fYf8y#{ǯMάVa{\W^<ʰPsz\vN%{[&+W 4AP.#)pqŹKP82gʱ ~!*]t' Jo͢EiwBQgnj~vgHbʯloJ`MC6+r/BkpMc&`*k*6b 1ogob-]'o/hK5ʐwZ <ޟ5gۿQ9 CJ.F"P\@؈rZuz6gAN9g8>V+}XՃ..bj+Aqͭ_/uA%Q堣e8cc_B i!RۺU坙պo͟b9^|Ku*CbN^5{=WZ;'nN~>gqF+b&QU#R1,\9.$u ФK,ډsG7_/&9r=6I1aҀo?Zz^؄0:tO&W$;c<0ϵ347pBasays9;FMˇ:1n9ܮ_2,!u(:xy{:yܜ >kԗuS(/pE(Q9]s@)BxovpZgRFC=x$vS_RIrsWܼZN+y`g*'u!xܺ` F@7|4[ϖNO9{sB[ Mٜ&scYIۨf]\rr6C{V]< B>V)Ys{i;?K8aF,36`&+2ez0)2P-Fٝ'{*=[L 9ѧ[IW޹N $1E+p~}/On[*yΉk">'e{X*}GЇ5w ?z`0Y.(Xv2(W?7zgL6\ryCE2SK܆rɥ:o 00'k #}}>4^'uu%oL7 /]$a6\Sj ]m! 1.- c+Kv=x(Q].Jky-hZ0dUuہ[W!-ҡH3YeU-xx VBbF0\e8#VR_9cƶxlAH1K*2u_xS |TkZ)LbQH,DZNׂl+9qu;<3Ke9y_^R~1卽f61|>CAxTXۗs!"0a+YV\ˑV3$hV;oql5](4++T$-!'i[mFjX}~u:ucP 뿪"AEZ-U:L[9)ˈ/vu8KRedudEn\̃u9QoA4Y&s}gt{+nf}j+L+:}J~sˡ %"nUU##*nM_^nK<f6|͜I eVXNӪD竝(I4nMz|omb2)6vʊ)Ut紾,&;.9Mň,oaFm YpfYBpq^BNc=+Փ @X(I_-zybჍYtf <./VۡFF8`ktØyPudCZlaSnϾUGWkrP[[ˤ DŽuSO1Yř JY$&`I]wI>e4V۞epݸ|U`όwV i=+۱Ȫ{3!JWPۢՖnHF!'%H|n 7\̬x؋sˍ̇PR.>ܗq>'^{ZridT1Ќ,aRu𘀭}ee791:M|9PQ]z$J: 1闊 @iOǯ7zwڊ6,DXyS1-v,E)/W4(zu1/PI}2뷼d_֮0sAyC\(ӿP VbV =ID%y*ih"0* j hl4I}#^0yH $ T&]i~tz& "e^Y>۸;R2H@qg~7%0aD.X՜˯,"ogF* 1<[י^]5H ̣ &`^:~Bo:E:ӓy-+Ic" gNSMf" *L2DE¼i$ze)ǠRH#C"N#ӕ[(żY,Q/ѮOAULUhL2hێ6FOF[%M&%AAD |>{2ȷˠlMOz5Oz<,:T1QÝWn֎&y04y1py5_|hKnbɭ*}&) M_ƘIswO\v3ϐ&w]1T׵L$dj{]r:Y55ד ȫDjJ7wH"8ws${E1H2n'uVJX.:%Ѭ;Ep:۟"S"Zڙpp&Bi-#֐0&eگ'V7fiBSQ%CEו bQ$IE'0zѝ`;CqYESRʣr3FG ;ԪՅf!1JxyVi-d$q%gƫz姎iEE=Tǡ{JIV.\O,yyKA-^L-4ubI.ADU,O ;oeYVM'3{>,/5xw^aekؤ1nbrh;s$;itqLNQ/;R3 fbD:ğ 0u>R?دbD(0ӮT}nWOf4O"^*J'b)JQTP0TR^#L[D팠&joRGDt͟/z%ܭo>o\8iyMdM/نٙLQB83XkxQzNQ rub^XHhTFGJ V*JhF] jW? 9sqE'QW_;aIܾɑC YSybXՊiٛvl *i+FRRP>|.Qߣ[Ve`u\$;۽M\xlvo{z8WSM cH'_VvT Iw ]U<;[Evx'S-8H !P0U $"u6s:`~U)4ꠊn2$IfG~co}u 9tj!9)L#2SF~DXU!h1[7kQDI=G9m7{~O[\ٲVaϊ#jAVdxeyI% y٠Ƞ,,Y:v)d_:v|y 塕H^Do G"qBa=5De IDAT읈<.گ,=ol7oyx%@<'ֺ0ST햿uVk{ww^wd7v߬-Uh]=:łQ)uF_ӯI(SYJ d7ұqz0L?+'ۘUا|T Of;]ds) C؊U ^IUV7%f¨9|^<'ihQ,ώU/b")9`KC% MTd_#""n4;gUMF_JD9kt s^ںE(OMDԙADlR $w#FjA(8ʯVتjS5:LgM6[DrE9DR$ ΩAE^U޲4FN&{WC??I ࠝ4[pvi^uVweɬ(:RGK DR5 =&>+TdoXe5>d#@e`>%?b|{^1zMM|ljWc}'=n{7^4\Z%~e%byښn7Ea6Yلՙ%K$%%!IJPanr]?LYt⑍S6Yi\&dpsq0ioQPPn$&>v#&#Ke)AcyKuX\ypR>BaDjEݹM:v*M.U4uSQejzje"4-T {VbUj/`ᵕ!"FWT}qNMto.85E&EdR lP bv丮{S==w^$RHD]8@ˈI8yGs! (aqbV$ۢ)Q9:u^yl7QWߟ g(+ 5ecY&C@ZFwE4BLs> GcMS^>\Om땟 bdN@IebOk.J7XpR{ P7G럾rc~ޒԁF&JEᯮ]~`8!jTZ8ş.ޤhٛfv)\ZHj-"SEhXAЩ֦h$a.gV%(LE+**fWwLD_OE4ʈ-!(]p08i lU,浳Z"$dxŒ%߼r崛)K1QHVb2b_i:'|8%hDB#%$q|κo{{ӥX-ζnR)³P):ݻK5hGhj. sAu,WR {捦V"CN ?e ﭢ W_Yjo>X41eCS/i%MB5ԯF/v#2/>ux ])Y(x"$FWoQ=*ťR̈G/g 1նY z/>;8%`.j 2Y_DWwGsOGW|wxڪQ J==bIRmUg?MMDi~i"۹U1*p*ez'"Y' ?^mEWъӗ.7={|uaۺvsY6RkDD"tFhԦlAAY~A*!= ۺx鹋clWe龹s@!&H($4 Bpx!q׏)E帽fKx&ze8Qx7GGϞz/ZVFU*@=#^wG~gڭ5f=WZQC/u&Kvy%!tOHB3ʏ#{hee:Ǭuj= 'D8͹WnGE  (|3¨1̕LW=`=#d};oͶ>];BY"==nl\P:q d4q|_u9e^W"L{%F*DϾԣpѕHQK)WB۾ g VIQ;kVż&jP 1fn>d*tq+uȅI鈟c/(|iHH)[eNM.'[{!T@qbxroc~jͦe':fYb$9(Fiʴ]&)?vQYn&m)tMv;Քy ˵g$#͚jY<,'*0j9p$h/: ׶=+n9{o@ qQB'(B7{ ExͭN;iq\J#~T_Z359d1cTD r1mʔ_(lFƼ֤NdwU!ɩulH fҤD$\)AlO=(Ed@dDv!iT> A"0= UAO<)? L7&}Pͧ ]}P@%D"?Sk:$= LD7}z1SM6J5;5R>“w{wedM9JC)_{a5NlLOZwUtI W'5‰;>}{3@-a^$Vc*sՐaޙH?{[ck{G*R?W1>X kѴDW3 ei_FnWhn[ˍ6CՕuyBr[ uIt E`DW]IahamY:Pme܃;sjw%Y%bτ`LIH$I˄&@ .ML-ЖHWI::1Mã$i11~[sw=?Jl imKg=ޫOj=3FWU)BĨz\yOeg{IEĸк"9Tz#1b4W&t\ZƮةb HlSL[szR4F|oWOil'A4oUVLE9+y+&m3h_w bU4MR<`2)eFgDشXHb$N*8sg*)ٴըTf>SIM*.&׫1bUGHbD"NGzVPTGe(jRC9ߙo8r*`MlOuVmWw%)WQWўTxI%NRDbK4曊VW%x[ s"fViwxb; Y bT!. ysb&hbx#oyPDٺ^B5֩)%Ԃx"x"AHj%""6rsi)3wsƥxr,:HΨ|֑q:gQ-cݚNֵƆ['QI k2HmlD.Q|0y!?ˢOS֋SMq$>Hd">{KG5l[y-XQQުA"-ʼn[+k]a&l}5X>̑3r/L.k]w$E@Zn2&kb,"^D4֚ħTˤ]S>[gͫ7Dry1oRVF>թWhTQ7$/ %_T6|jsIbY לË֦ƧW|N*&u\MѩidԨ ƦR?KA0cNPUb!W:ΉmiE8%*r$UdEt&e4ѵ bR#Ũ>O!jhrDs/}wgzGQGbS.J.ŔDT4gD^Ĉ8'jbȩHlbIUk\._N+h_`ƞ^S*ƩcUis']zV*8,H$.ĚtΎ* ^1FT~s $*Y"yiw71ĸ9W8!]iy5V,j5d;G%Ҹ{hG*io*>uR1O+ؘ4'zE.gM61^#WŊ3qL.ըxF=bT6o$'>~iG`q5N5H"Y 7x&[ȶj67j/F1Ũ1{@4s|t8.)A ,9@P ' D DI3 Gb۾Cq}]-L`9NZDzFTsY!A0o?(!$$@-fAL,k_1o: &g j & @` j & @` j & @` j & @` j & @` j xcvuĭ*L|Lwہ#Ҟ8BU;c 5Os)W]0(gW(;5.>u%|;߶;-8 @蒍5~8 f5Dj=`IWMʮ,AH!j4'{j]Jxϫ7z)7qї/eo׽=m's2Vߺi%T ws7pVssy;ӯ:_O,~o{'o{y;|/x垕ԝC,q`ƃ:ٰl[,Wz}pÀ{ŕ<[o5һhOcY|n7Pz~mCw^vgŪ:wj y_+o?ıOÌ "gZ~㡊j ;o 7h"kw64oh\#I?}c,ty/]pPؔg;X>9O}k[y`}@Ϗ>lM;i{|;,ڞ _[ H6"K6\K5.`&M".&_-u o.mfnhnx D- @xp%Càv[T; jufKQ:}JS E̸qnM,<_͝V?@7(y ~/1xqU5e1o޼8źè$`Sp°Y .?Ģ ;8ra~`=2A͜V]7z]qBxpOyi}H+5`$`F;nBiWa L_o}GZq@S^`b&藍Z~ \us 8_x)fdWj&7k8QKvR6y@ 2i+Vb{8o#u@ESvv!ځ?a%f վ,wSTGʣ"tƑf ~@s2HLaxf&L};g^}O>tf9`nXE :<`.ӣ+7Gz_Uȭaj\xV#pTS릎3B 3ƴͦyurpX'oot{a] |镥=3~.},<~+mv zKr-a}kJN_|x;&<^Җ^ޖ^5PDDAuq\apQgÈ2 2xgaY`JYZ*ZzmӒ^6mx6Wlԕ?{y$yy9}߃VMk?ȡ Ɍ&cόl!A =02B0~F gv'gӧOAx ./Լfݢ9rCX9?xp<.BГX/mZoP @x_h IDATϽ .fm^G6 wfE t 3 ێ4Wk A ީw)lNf(]Vr̺ޱx@^JZZZZAD(a=? q`]ޑtPp|Nd+@!ٽǽДT3&l Yv3 Pѡ@Ah~C[^::S :qiԁfS@Op~Аc:/CRFf9g3`h(%S߅l)MN[S?6Z IB{V= vtKDSgGI[Z26]64`7vG(NxRzGj=}Pڄ;" p[{URd[en.O`EfD!NH}J~񄷒;_p}WJ] }8\оiz@8}ط#3_%|!gدK;a- 8'U0@9b`|e~O玃c+IeR!0NQ2?`hspXHg5 G, t)T N!vӁ9,0Nx ~rg # !0Z d_1y.e-=h+tgpF ُ8fK@3:Mfh[7SsW&Å9߂*({vGhkʅɁ2\38ǞxH>Ī% pl Lx0YA*&y 8lג0pxZi(&  5r$"[WAy1'ت)*`oY31(>7? Hk?u ntb& )+mkajZ^(IRxS*D/0@Ð?HtϐƐ(.Vi},d.TJR:I2yf$I!H*zJ.H|5g$I9:"I \ɿ{^AHI=tM7("DXK޶>a]mҤM 3zskq{,U*aƐCfմD8&<~˽U'"0G1`F\iD iJHr޸2c2̱fBQ%Ny{ z # > d?)@x} W(^wlNR+9Lz\/IRok֎N{aZp᭠ۙ[;^~5?;ϑ__ǑLpuDkl0-zO;jzC)???Ծew!e{c15qZK6s -zswӘz*V^_m*¥gc[lQ~Կ'l PM^ofՃK;gn_ e s\0ՖsOGM+<:k0`љ0@1ύR̖:}|̒3B0~fV%`-(|`a5GT֜v8hrw61KѲL_M(]Gu*΅Sm %yLo1~}P>YƖ7t}8NW|P / W2F~ވ&yBZS 2ha-ޔ:OУse/ojF<<{V$NijOWZ<$ .L498 WhPE,uZ #@B0> #@B0> #@B0> #Q3z 84ڳE M!%G6 X."RStkmx02{8" `$OA+aa}?*g2_WE0A3nPP>-fc: huBO)jcN&BUw԰{!8lH%/|X!'"d@JX!JbCz&(.Y<:9^U`=\@y ֨AC|=֖:^qaD4hD' }mGdd[.Cfr'AYghL/gL7sg!Ҳ(<61 n̂vֶI?LHG:#ʃ@돳Yz %Aw > e_gAd-^ *Ct4rQZL@`nCM@C h-@ ߲[" r)R,G: WКwȮ}UpH P#oTV :\M 6l҂!nRpAqolfDzXDh v6z`va*Ikӆ5@o… #rDNJuM䑴RwFF4ɺ<g|TUߝItBHz E$@Hy>((~,E* R,-!@! I)2IL80j{IS@R'_-Z֯gNYEpgga v\vU3+_\@A0wwHϦY*p%k%Sw%$QVkY6 tjbr} +tNC +|lGV~ +~sul9@x4Àmydr`öO M/иOs*%u- P(/ۮveS'xCE{Oua C 8p 2?kgL^ ~귢[| gKz%jV-VRP w4P "lˏK".تUuYB0fqș]fߗyqŷ ̉\[Z8DNM.<rU6d`L 8S^>.޸BP[^~p =sin\dtp{8W8CIN^sbG暾Jy-$,-vo[4POE5x|B]z=5nAq"a4@\L0˅`׈B4>vbj<3躋zAyZ]huI &?c94UY8p$~_%s>8f©펥m*} 8jDՍj,IK$pꚳÁs׏E&@Z{,~pȚ2H)<7aG8AwwYF6ڡO>s t+ӐtN>*^лwrügLQu9; WMswNlT? _]y_K] ti:NĠ]e_!S֖̉H3˔aʨ//,xĹQΞ;mm>Ʋmv/MU+6x׭حÁ78mHrxD9f@?Vx'_^|NemΓ5L-|{EY#@:>U]LajAvWY2ml59J!PULUs<7=եͱ i ^(&@]&$G;"F!2c[!ľ)  ˇ|6S!U"ˊ3T[EdS~ ]yU=pàkՃ|(RTmojq4|eBτX?h_돺ФaBBx4:sJ޽kdƱ;};&k7 OsZmƊw|^ޙd?Rw/{#ίܕG5j;u]FF-nu ݋?pae`:%wks7ʗ|򨨨6Y8Ԛ7.w 8/p9@M;Xd+^m.cئl[(ui@w=-o=v"՛5xq@τ]vH?gz`[8@A%G\'9qA5ric~7蒴+ʰ6~'~3 p&ݙ?v&ucL!x M#/x_qM} շy[b t^zD;R@qF(0ٞa^wk20#^HY{* \RSEQR"(ߺsOFD 7-ςD_݃L (ʣ\>6]8xMUUˬDZqE|cڷ,l`"-ջqD)9RkvwmmxpF2G_] Yiݕ:XᣁTX ]+ &yNmr[/z5d=O ]? `>5ueA݋C6̏t9yj띯M6~?FHzШ'p,Ϻ7:l5L Y1INeДl6GtQoGޖn.[{&26ոSоԠ S\cEM@P5\EubT>]9Se`$JSg.C :VSnh.* ޯ|Xgbںq/uT `uғѬQ; DkL@;X7)V 3z[Ǥ(HȜ6H8[X6~ -XX4N;oqz%?p$,/oӦ3D \|Uf-i&ϐ-$Y(Jܛ F/ϵ,eN0\:xKH_c Fli2?X4 ~(%G}ܻEě*_o+_vz0-:BZTYGlwgT5W_ռG||o><^Zw2N6LV$ c" XSMWX ;4>";t^7 rLG!oƫ8rͱgťXpc'ZF8T7L[>vŸδN|/e 3)czX. ~:~+R?sȟv+u J}y(57r2ⓏW$̟4rE_Q(0h%wz)ǩ;GÖ[W^?<>bߞLV/a5Pv]E)*rq]QUDeT/ (K@X# $$!B0dfN?NX}D<էSӧkz,v0$*/lύ,V=1.,tZ$p鬘L*|gֽM`n41@9=xaJ5E'89Yq<3%C[_LK"]D{w~ɩ.N3f )J~ l0oK.såuo+Pv DN`ͼ8gp=`_~8k#a:sdG]`g'Ǵo;̿Rp"[PZ`Q|1by|@B };DYYmx4J,SgHTuNzO kV_kR}c IDATFvt!`0']~?V 5;=٩Uqm:̅~Ocݧ]1w _1)-{>K2QSy&jo-tNY#j<ڀ`4{f(R#Y:t/+ _؞=}rF͗_( "o=؇_DA` ĤO Y-9F 1!O Z_ؕ'Β7y/~)xguOI~~[%Pe3-X 1R2T#2)xF,+2ɪw5%LN$ㆷȨߘ%*?g HvꎮyY&,/%2I:GE[}@V-\ ͜2*AoHMQZ.)zhjo#:첳hg:`q8;F`m%kO=NV^n0zGQre] f97`$P񾙊 4kⶦ&-3pBʴ,[wIR7>[0z#zX4UM`y^^hQWb_@W~k4܆%-n ޱ.!i>.S)wD HϯJyZKzY<#24:mPPVZֵ} LM\݆r ,ӯ7xWNX?E3zr~&"| p3P:uc0ř[=kS}//_6^UII խ KJ)OGEE8Rv1nbV}Sv{=AÔa;d[ϩORI.w#G~UexHĆ8^gx-ތc}X5ݒsfҰax6 FSg=HhJ (b-V0IbhЌR}lvIwun0o3t\[v?߸2'KYl}`Ei10na!X zw13T7yAۿOkoǭ8;-‘X>!ў@ 9p6mq#!Sgtw#gfRqH^|/@'B^Xd'վ]..U/h{k/&`'-/ |ZNq}lF .=BG|YQ^UեBBw.>bl}% si;|6"'>-ĈU_pbJ_XT+֦9DrxLa7IoM8Omcw`0l"J|(k@o19*!47;3y"PynY%Fbf<4wEkL=!dwՏQ?xPhgyW$kǛ4/djbYZ KWֲYl jma8W,-(b.ѫ'r4kΝz·!PؽJtt} `;_vBrC.|+53Tt}{$覌+cz8qJF0ri,c 8emOuX:3 z,{Sh[6s7r5B`0tkO$ pWq59\PmҖm-OSӇE孿MOYŒbo`)Q>ܺBPRNf畄s> {t8W)u7tj Z^C`ؓ_f"Kc&`f!E/d1B Ju5YnߞիMzi^CM-[mN[ԫƭIzE ܙb%֤#u٠xdNw\sՍ Aa]ƋM׫=8Uu͉NMC7R Ԫy^;(h A{.>D{N婵^+=ׄY=RR5X njVa{tiI X4ܫŮ]>迀1mtjǛ 8&'Q'^w`PF|2}N;Ve{]QUrH)=J >&BgC!enIh躱3smoDx/ݗviͺs??5܇@ාeL+q{k^OD?l=wĆє擒vډu\:gEכYjbc*:Xe^N~[T"5×3rGSl;vE Mpe_ [@{7OM)N^}F{V٫zvL\rօTS߫NsKb;jG'q5Π;xCTh`XprJ⁶5(׮[gs:uSMC_pittDlLG QZܼ"nkُޗY$ W{gAū)yDIo%byP.g/k"'Pv5ֿFbӊd;R0bMsbDXc BCk`0 E(HN})_Ih,Uf.5()NNڶ^sq*q7K ܭJ?H&SfԲ j&^$r<3U 5FACwYG7Z`ԋ 8 Hì);. A\h)ap܅"qvr v*,ʞ{Ti0\ǡE42zϿReS^ũ~5RN'ϦRu]̤#;c骵t9So5ހlO .Z:T)߀FnhԍTѩT41N!a , ЪaZd;fۚ9#i^I3t8erJ#~;H#?ëEAR]%MLp4 \>^?r.́ׯ&>Z/pa?ilCԍ"*0- Cf^Г༴)e>)QZr1Ge+I ce5+ûVtrAfp>nֈn7pºXJ*"[ٵ!𫳃 JW1\=/lt1n &W3xTG誽Y؝ }A:OҜqms8 drLVii:\o,> <ʇFA;*]/?:iPfXj] y=ɯ1:dN3*9~O(%D}L-J[q+%n衧2 '>eы'Ok<)!,A^~#>؎rMro2/ݱ] fY@VE8nOS4pȓ+q]s:>({_5]?Nu $C.y; (*E2#wMYVըƸ6o9VS2W?%"H#vB25^",V@q`;ʄ0'f1j@(Z#⿩'[v.]H+N(0oF+p/Pkglvt](콕 ^!xD, 0`z8~ @eYvH|OjpkMPG8-ɡ|T@;t[@}[}p9Zܕ`vؽD<)'-l)i> zu:feJI`!~gFImdWPT5fRuKvOd2" dpa9<!wx j?+鏙hybtr.)sr3ӓj.'(DL% e)tg4e٪}nW^8O)3iN3?Y*p|X x-biWm/(ymk!ǍQz^PXU)Tz#BbN]\- Oo|?!N2Qv. Yyw~Z:]+/ddcln)RM^{ kj*a <P #agem\.hlEyZ%T k%2J+2Rm1h4U* 1WVZw"_*0-^Qkij=D>WyXq?!6rCz#Ǣ3!LRo'*z-8wQKg/jb\Ȣ^s4Xʈ+G~GP!61p\H쒧w<ZYal%H>v瞓/$2R̩HM4@j}|ʘo={~ I}_g<,TƯv q0˘8{Bh6FdFBm]*Pfgcl裉 C1\d-0؊n3t۲kvnB$+AY>-]ӆ19?:rz{,PfCI%/MD\ibՙO%G}Ikd6ނE=˸ӆ PrIz;&z=(p .Dw!v#xf>)ܒp3Kyvב7{7@uj BQu1 MBe"8 '_fš1s*F%}_C'; r2% i֡l=;V H]FgU5C)8VyIsf@,~ *z1Ҩ LV9dw`m wj76NX=E?RrDbH!ߗMq5N\9,@=L(n" .ؔ12' ڃ7@5~թ8,J/? kA{n<+ڙ.7B޶B): Uh|JYru[k;3d|#\||a;g|H9pΊ4pob,'H:#NnlVJ)LcʾaUWYRR7yR)GeUb, /fŏ];eSUx1V_56=˽} vO>)qw\ //9=+H$Vyn{<>GoPJ^~E܁Ę.V74'+5Oa*Ъa^lܰfۯ}Ou5VHԒ>@ܭguWcs٠FS޴Kろ9Mpd'>y,A t>x:Z@o/o*ʛ4`x.kL|=?x1O!@mNk63/tjz[/kfJ, #?w$M sqLs{<W{BHl@cbѮؽ5Q1 ORϲÞcBr M<]:_z~8O~t 4;U`^ V]yYcg/ ` p_1xJsw<8iI AO)$6S_f.#cp8ޙnM{)qPKAB!d蟖z0z앢U`^ l>WۑQb]ᒤþ|dq3jyy!V-]R#r$ Έ("VT J{1ߠ=T'{ J;h;(va2oETԡ < ^bL9Պ.OƜ2V}Rrc qC͋҈i%fJV*0/ ]{I=١w\QmR$Q:;c6lo% nFQ1iv9vpvsSn&R :YC6o;りZ0ݥKwGvh~WD!Ozp]"臓 Ҫۏϒ*L҉Sq~lsErMd*JC71/Wmu`7!G וGY|lb"}ޢkqSȈf({R)}Gpj>e3.%Mֺ* 9 / KfH(jN;Zrv=W|BW=moPJ);.c9gl`=VbHbI B5vc7XcE% ""*h@EKQ3e̢~߿v3g OEP$0G4<>̟ʡҲ.ӻW?)O?kZXQJϷN]tS^R>En26H)D<f[{cހU%x)RJF@jȡ J)43hZ"&-b{,R>{^axJ[\朧}OGZ:IDAT +)!4t1iiT7(\ո9==Q n>26"P561~fb2W[ty3)Tsw35)g狒1F9y۳fHglCzMÑF4~x㥯i8J3c;+?+&~@^jaLm`K!\t?"6Xo-[%Zo [lKSwoyɟoyq_l96t}1- m8\`ݥC4{N?KCϚT<:#2n7q.jT $փtCt2 )QW#LdgWc1Y[~LܿΦ[=Tt˫s]7t8N]",_!yXw\x};ìJ3Y~ktϒ>ci/>&)V(rseV,MkN'hf#4)@EzB+2iH4mI|Wq&ɍti0*B{C5,f8 /[^Z}AjP =+saڣ_L84Z[;W9}B}~g|Ol u멤Fd|xxi+ӻdTө|b_\sfb'6< }ow;) 1~,'6U-%v(cM_Bg82exT=}|4liߟ]ȸSB2eĊ3V@(5iݢ/4@^MWF0 L ~5@ditV崊>vM}SPѩVlM-%LaAVzu4ýeټiD VKE++{lX̢\f\jBcxXȔ+tOjYಂ!"DFT .Z C{h_AgZLsq/r&]&_a)>eJa$c$>y&Uؽ5`@S~O?JֻtiyymX,eRU cWX5B9Tޅ_5zdGda s[k5F u RrrZ<НүZ`lV LEV_,mВ'ј}jv|_e.ԮOrg]e L.* bNIt`ErLHL, 7@ܚ BY C5JAxɰ1%CQ$%,),i6};gL-`9\g >KI`q"ZmlDrLwkEEe鵀9*[?ҏJ ^RB!8g9N(NP:"2NȱT$YbZX򋖆yvv\FѸt۟f]5Ά#[kuyreE*(:gPP! D dR P()#Eb8XDP$: ;yqOo!% G_MzpʍZ8NBxF ,S۟;]hΤNC$:ٽ>p7Ui&1 ̻sӺSI?-PVdi[Yګ/\.1&v͛703,ՓbI}7JSQL~@Hz 5 6M:;unQ#LTGyD Z*La&*i҄J`&*I[FI ^S4@KLF%i'd*dz^r#XUAoĶ_@OpRQuKj906v&8jrri?Xw<'d6ԏÕ2fa~J>TJbY^E> &*d$M^#170a{s^XXoTAXA0"$ HRba`ԕ&/'vow8908< SxHfNB͜H~Ӕơ]<{y<<>F:vhӑ&iD{8U3><83u9>ʃ^kt~eϕY\Gg=A{q@\MPzVrJ׭zt W*W+1$ȵ ת6>O @Zwy4{'γs0Rz/H .kŗ[?&.T*bz8ԋ yA*o-Ȑ9M2pQ%0~60+LG?Qf+}Tr3ܵ,3JBT@D.ļﱟ_p>~"ܟV{x]x5?@5zeK3H#a|vc1rvQtF$kP 9[̔XJ(x3yAXf>PNx`n,62Fp^2,xIXޤK 쭴u2G"n-[_mPUe=.nz~/Y3e Ա b;_C_gRT9}Dž7†;*\BZ*73>-`s5T.5Ǐ_ Ѧ;Dn\\CrWˑEt +@gNjS Q/_:/ْe< {WM#vwG+ix f@lR˲|!eB*xkO 4߀#Dv<s>)KYY>s!.u_}#jl.QjF Fz驦LZo\<=dJg,zz]FȽ`RV!ª-  0~hCX¡[]햵Փfz &߉ܧIt.m狃Ʊ㯷Rz ޮu[V|q׭$;J wO%Q>zcn={\oun5< juxJrϟ;}v NP;hSaH=;'Je{nsL2^Iew_}{m7~Z2ƥ9}ypbRJݰsOb8a<ӭXy߆,Xצ󋩮e7܁0I!v2*ei /1"Mxty}0)xy}1_<Άtʆ-3WS]Ȣ'l+cA 80߶X]!dÆ7ppd6~~|iUC;d^\ǡSFJo NҞ4/jKyfO*N>Rڕ&ɡXuq/z/]5NmX+ϫ?+Xu@RFVʛyox=ҤuYuqy_K &vk܍;WIGu&$Glo;8W&h;FTÑMW؝ g잩ɦ%G̃}O g󡙼$%nߌ)DD>i-j*w J_%hJݕy!0IU74Dsv3wUQ2%QAu@ :N eá YW.~9' 2:5`0a2 FE 7pWΡERIE>UhVLO?_%.0}VSl_e<C<TStzrQf}99^;C+2kLv#?[WHMxIͦ%oalDζ,\cZ%*lk$0=*Cw8 \16KV$$?pLrf⫽=;+ڄ Ya\;obfoz{ssn*-`vւyݒmiZw3E|ZA3_d . l))x!Wɵ8 Ijdst)"p:1~PYe*h8]uXC1*HO0K pPsk&ZwP_ {0sPXʣjs%j #}KOa67Ҍ"mS($d] :i;lqctI|Ug5ʘ*GfX>dv˭ ,\'o IbYguRe1odPO Tkl:Ln͎s =>o`Lx 9Pƨ,b﯍VpG1(;TyXED^pYʰWSDhC 1S@4 ՜P[Ӈ"E6 .",3?Bh[ mG^ ('0o1ݰ@9 }/a :CT\]KW'B F$0B B *H`PA# !TF$0B B *H`PA# !TF$0B B *H`PA# !TF$0B B *H`PA# !TF$0B B *H`PA# !TF$0B B *H`PA# !TF$0B B *H`PA# !TF$0B B *H`PA# !TF$0B B */o~IENDB`Dd u >B  S A? b=Y߽cUlps9DnY߽cUlps9PNG  IHDRVdagAMA pHYsgggcud IDATxo\u93Ht\E}鏠c#N"q"1\ _/  >( 8FI'mEޗ-qw$EIwfeYIY&fK|?O읙s//g抻J;""""""" 9"""""""c΅hs!"""""""?\9"""""""c΅hs!"""""""xE}9pkZ/7M\*n#""":;]@˰٥d{}[2$zw4~%"""?\L}#ae^I@!&KV}s4yKDDD4g\[DDDDg|Q`@(UVT-)rp\h/Ye`-("fEģcWǣ;p"""{ "49@u{{O]v{^(榓󎛈hnQ;qy VjH 2VE}%ڊ;p"""a΅O\@=yK1wnm壃,9Z/qm q G-vw!*OԳ'ߏvKo~;~yyc BDDDtzs!""QG4|;ycy]7sZWL͕{p_=4 \hJ">nّ=BJ{NQnp-ŭ۽wJi%]gG_Ciqw 0[y|Ѵ"QDf">0۞LtDDDDg9"""k^.Yp=Eᵈ[[_AcTq<@2½oOG{\n[>{:~ɬ?|-t"ji܉ YM|"""DDD,I-Ih7#1.E>q4! )UжJcmf(VB_V|?O;`B|0~e0xʥ^"?S^9 (*wnz1ՂH(9I0\gV3车a1hͼDDD1BDDFUǒ9 Hs8w㧗E>-%VvߟE0%nMT*Gbً9_o> n[ojYH @¢7qn"hw7Bou/*_h i.-{ݯCw&9d=S@|ID|@'yRwM \MUg *kmrf)7D"PJ)k"}/94K.zi[ 7FcnZLDDĵEDDt/yz|͡"wA ۪[iRn%`AΥ!dA×yQ䋈ySUR"OxʝDDt2SSdɆѥRTw_qۆȊE0ښճt*?zlppu~zbw裒4Vky櫍zW WraJ9?`lYEbHc,":Ȫs} ܽV|GxO{.ε:l4%3Aԋ~ ww~7?:""xVO^ RQenU *@3,4YE0 _갠4[ ЎZ8|-5:swt)Ds1]nDOXO=WŒʂxJ'`J^EE00 ښK/aWEK*-+GW?_s i cK<]6rtxW{P//H(Ųh掇qUaV Ab\ Td8B KM AbUr*n\:DDD\n\%qwTYec4TݞdJWK݂h 'K QO)eR(H(^f""9"" JHO7j5-"!o=WW&b-&ML~3դfk|ҡnUղ\r uv[fs_s,E5gЙ^[bqĽY˾:?q5y@;u|qR+pQ QZŋJ)֞''|Urmj߼Ni^T]nM'Lx`+1`iDua%EyE5\OVFZD9wou9r,)}cS$lSՈ6p!hK M6h־}iZ]1s9} ERԊ((yw. |]mr.EJIEQEZDQExIX%O7g篆pɡIo+kLfd" :Kzfm9>9]ޜ<QUBD`"{hx41V-*nkcpzg!Ϯ55HRo-%Ԅ {fBPWU ȋ? *,;aADD +&'jAaaFp#/E񚆧D?]%6zxHUȳaD\e'5rzKŗ<%ΦYV :0φ9p;u6(%ēG7y3؊YL [tO{<-DQEc.QEVBztݽ@#׫PgjU{b Zń!BT,u  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~    % !" -./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry/ F,5dK$@ Data GWordDocument.A ObjectPool1 &dK,5dK_1013245318 F&dK&dK1TableCompObjhObjInfo [$@$NormalmH <A@<Default Paragraph Font  l,b$Nu/(Swd@ @(  H  C A" \?B S  ?u t@gd@GTimes New Roman5Symbol3& Arial"hB&B&!r0NJDHSSNJDHSS  !"#$%&'()*,  FMicrosoft Word Picture MSWordDocWord.Picture.89qObjectPool &dK&dKWordDocument,SummaryInformation( ~ DocumentSummaryInformation8       !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { |  q bjbjt+t+ AA] ggg{}}}}}}$l`BgE"ggg{_{{{g {g{{{{{ !qq {  jUmHN N!%!"&!#$$$%nNu/(Swd@PNG  IHDRVdagAMA pHYsgggN& IDATxo%Uڧp3y@B  ? ADF$A7DD螶=nս=mgZo:uTչ껗އ`1s rIjd f1% HJHJ1c5c1ܞh(8*'|UfB5c1<c1,O9%H6  rdDYfc1k.cz&J]R&rn>:bH.-@Jj[c1bc1_jIC @E % 31+ ݶ L *Ec1bc1w @I@x=%)!i4j+c1c1D 1.SeWZH+1#If!Շ1cXs1c݈ɐkdܔ!cQ ДgVv1c^+c1gsND$Uk$LdbS""Ħ ֫ *x1cC>c1ܙٞ*C@R^8;No{ώ7MChutmx1c>c1Z\jRV<}m'Cbyxsq <{g3/6WW?:@BI\c1bc1g\;E!K %jٓ9pZU| | |)JrWu׫Jc1[[d1Ƙ"5@H=" HY#qrȨC |W$mHR6c>c1܉DJ4~<U8*ȎdfeH9B2?81c6c1$L0DY\_|ѽ%^@@=/xx[x:wj1c -2cno:yu!B' w{)=&>6`)f\o@U'A[sY G=gמf1ac̽&[9E&Wav` $j ,l6w;ů:n>j|gu qnkٽ{gє3ho`kӾTdG 1b/ \^8}#L WML=O=@DAi)P`[Eb|CMFh5e@@RDR$Jrzr!NW-! I Q.ZF]0)p{=Ŧ[an13z]@K||\b1b1^3rS|)Iq؍x։L# L.UpiԢ9n?68YD zn^%͢Rp, t".Gq`sCONϾGV䏨o~Q6E*$ՒMw $NOG>cKd" ƣXZ?LE}kl5w2!j,Kmx#~F44^\rFi^|9=OcIXs1s?`$40&}w? .e9-G 9ID"^3Hn~U$ Źh@ Vr1] 0 UBDu@wċa8yI!@E%"$䅀Pl#T2j]y<ԑ!dmAjbxLJ;(S+j Qm֝X3G9%4R84>Z:{c1k.c3)vNjΦ-vȩm*I)fsm5\HY׬7Ûd͘ [UZJz ,@G L`;p JMlv$Nʧ<}Qk^7J0 tY/>CAJ@mx'cEAޔcBe(d)dm"֗뽽F0׈v!b9 'ƷBwDRNֹKCsLjFUOViRb{TbY+E/.cKc1v5\fgm췓͑E`M.ZF,zv_5G.hU!t TI0T\[P_߾xjqOO(_Hb>u)dsPRm*2IuݐyR倮2sЉ (/߾&'NAZel+ˎ3gTLn5~D{ZԎ >L.>/%OãYd̲ͮ=E3af~Iw]7j}1Ƙ}.c'yCPl#j,Oi* થ$쭔t r)FٿX[C^M\4D˳gHUP)Yt (Q@t!7PEMHa֘7))UB1Yt=[6T,@&$RMw,0΂  Dtw4Dcb@IJZ>J,"N`#KZiiDJF*Zql (ul5жm.c!Xs1s/Y25Y m&e7ԅ$]sۇj>@̟t>xP@!Hdɶ ,TTAPPN%^c(j`D)]t_^*q$`aqM u2SI-W. KJqi-G2**EwZhWȱmʸnTwj3+mX\++A\+vbڥ}b*YVP{,M>5M:cyxXs1s?,Ph]P[RA@f-)UL@[\,)s<.ghsOQ^.:_D‹a7Ti倬`'E5mP)!Z$ jxq!;$ry"6MjF,yM}E?t Bd|m>6˜ٶ\aZy [ZxlfV&V6[ZZRAfBKzLI}wԗ}֮zLz3v(T(>QTqU.ɫm)lI$Q7Wo>+Ȋ',a<Las+W׿ʔ3r裔VBv~ևjZ=d-+@kP&q4vLT"7gu\&mH(lN&x-OD?̌蔭ȯHViPPsuS3&MdJbDDUm1Ƙ5c1¶nJ5k+t"Us:נ]SYY@j3bw7h. *1-4.S]˲1p119Tװ "F-ίm)hz^IDXrKKŇ9I8߃?gco?O?16ZqrE^Bg` R/AD)(}Z`+˶e#rD}gpb+JJbR r86SQf69X-V=HٚSkd@2$An!" ٵ@xV|Q5g?b) aUٶilƆuLEKÍ 65[y'&".[ɛj*O 6EU鱭hgٺyb p QG{0QPGR Ӌo1!'D@d"[Ӄ_[f43B ,H9=z U X Ϳn9"0+"f#)ݔRPg` vvy4uHUmR ;p f@ʵ7$"nkp/7_kVzL]KKHuA0TkPaC######<5 XC gf6uSl=,Ɩ+R_֞b+ɄO $v}^Fm*DyIOo"hCw1;UIh6JgP'$1%K%0;RBR% 7+efAu&lvxt2`4bOb6 M/ 8;@@DIٷx蕈OI׋A+tgd鶳}efFykRz?F[ 5XYu`p8:}EGdrh2Uh*Zi[ R5 YM{%:./0BDqni::={' CB cMzFFFFFFx#####/2w]$2x;f {!a% +be$uH 2nYN6i/imp!28l<9}&_$k)P:IDVQQШAF諗%A3A?fǯ%Z r`vc}RЬĜ/IMNNްboo[m[6y!FK08{a5 ]g֍ۉ0fE#####/$9#M+\0XPHMJ7| m(Z=M}|5w@;CLz|uncK;FD++!&~xb @RfE(fdڑp->|am럆RSEdw!聽^g_JOKJ dH65ي/2eddddĨ= C`JmL{=8V@_jvc.Z񮻎6P5ahDԝsD1P a[ΏMpmy4Lb"$wt%oçedƨWEEؤJT\}]K0\j ")P2S5my)2۸sc1'>0FZvb-agKk뎢bᖋt 6YJ.KِkL~ܮcȋsJj*VfZ|W$T#A7EaUJu4&".}_Yp"1jM3A"Hg;+ZqT7hͲPep!'=E"UJWd4\\?ؤnmZCA[ 8AK+D"凗]۠nt6}L[[xú;t R@Q0-4'>gS&oCR]&ɏCK..LSc>-fK?9=~N 7&f:ka|xLj"8p|Zh/|/wu A )w{ۿ0( Bu}(%ۻ@)exivmi]Q:_<-4+v#AjTݣCZ= Փb-j#X"fwc6}܃2䖆mP~YS ʰzva\@"LFFͯ ;1܅B |N߭ws}Yj-@ہmNo]%A.'jPC7Ǖr%t ͇RYr͌dx5(avSJazr\ϹsM"|{ fӥOv\uy#w(@rrˮݜ »Т<:~N 0~XcE`:? _1߅z"-8XФ~Ph(̊MW(ɣa^'ŧTm]Y{ym !="*{`X|~GAΞ*#\"SWA &=x:7S]]Kʵo庡iV/4嗄{@ͪ^~nՃ(Z~9֪9n@*8UYII Fs7'_[kWDI,س(L wD#Sz/IAM ZdXQrX|Xĵ6AkoZL"Xs?TH,zLs)ޓ{i.O;Iܸqya@%bb9ACx\"%pWF޺C dWDDGUJ)5ȆNpH:[.Qޣ$1Y`?1EݤkG% C Gfa}Xzi.5IG۱J_uWDs IDAT<`3ƂW_b{S?R߀%z[ Qlk̾%%6JM"Iع&UgjMND{ɝ] \A̅ayD&PUYʩ^a5\DQ2<\44/"RMd۟Ƀ83D_/ qJ 8%/.sG?qMoH/uˁ w󠪪:ۂHl/W/A^NĀZ5͖:%Ƿ0r$)|qNR̦ ܂*<5 lC ُ\*~JmpSs1m3jvtttt< #nDfޠ Q3BImlKh(Bӗ- PG?lzTh 0n0I:epX~E`RD8>q;ƵWV(q#4*8ܷGG/d*b?#7U( 0(cNTi}-,s9hK춻9$ѷ-?1t(I=$Ӡ=HH DP-)SPoKy3p (}3K;]GAc8C@#\+2 FR0p4!cH& ">0좞}teB Z΂݊{dp~FVLgJh! >R],BD,EHcu1^lfuZq4$"@[/ XpYaS=OqUtby޹ǖ!¾Egol'wqUW:,΀Ӥ[/;X–vjKGGGGdzLttttt<\ .v;Y!"@@J--6I$<8pW2,l=b4KŇ%c:>yͪT/ޯBJlDDtNX#‹w @̀D'~d"a¾@@J@SL&{"{kYtVp0qRElzd/&m+ :Oo'oUKrM uC2*ۤY ,Bܣ`Bpw!nyV&TGF9^' rEX*u$z Cd6Qҭgm+$A9U9=ާs:\s*KMrx|sMHT @z bj.4!GXNJtp|ϣkY2?s U') ezLnKlާG'$;luՔH/J9"䫫 ':Txv4]^ETǟ ?Tz=j H1} S ȁ^s:pcf۔.z[((A6i8J(/\ LsSe/7= KLCG%x퇋U)veH =Q욛+ywߵRl"HxOןK1r_H5EiEbJTŅdbI:bMI.G ;"qțկ;s 7J"MPA\<8[^xʐSPU |ۺ\VFhor+_UfHght8|Ȑr@`8z ҇U}KNNK sLFܳP(ZA% R<<`:}MDgO(؜i0mG#@MĄ)!)`l8<|-ٷȢ?@R]="i.O'm-"c#&4MHmåB"'H@1o,SF8p_e]u0ChZ@l /toRE. mpi+ 2XpJM$0zkځf݃yoOsi|5Ϛ;v-Rw9l#Y* ?_Ru̥Q&!:y%`K[ 7r3Od'tVZ @Yׂ\](Zj;r`6{}mݿKc8(1Uw\ drD $W͐0Rʾt\8Kv{CR*z|rAd ; Xoni]LwXz;E'ayuAwraO_4THFwh5dy]9jRo8(~`oaW|{!':]):pE%,&Ifk凨pYhj<զE괔!B% Mfۑ˜K+iHb=DJXo`6}*Fl~crǓ 쉇kOfE ~ j B!0_OM-m!JVj;"%iOk.=====) .B%`9vݦNKrwI40Giid`2C8#CxږC۲mوia͠"&5r.VYYt~R)6>~Gh jtXr ՇG/8 i`D3j 惒a'ޮϭ}RgiKu o1>GӆE;zOJK.cXuIj&nGϒDMs D&L؍ixT=ALɮ.ZxrJ \l:<ߤaɩ`h76n.kF1*"] .( +3 yWcQLBW  DH (qMۇICs& -bȹ%"xuofy@pTi9%Zb9Ũڋ9v@$4"ts8!6 % tER "͘Ξ/82i{D@ɟTΪ^5*Yf|1=====_\zͥ3^4, :ɗ2P%3n{% uK74~6b jy?5P(|L],WZ F սv;5`kvٶ nA ?;y`Olj0 co a R2YSbt!]Jv_~  /߭[Ym 1܆PC3gPZL'/EJ^.v+tS76=%Hݤ^= ݞ߿ B[^?R w\lh\P% 4j$ (Z4 Ɠo2t?_zXu􈰝xtR  Jfs5?4n!ar fN+npIP6t1U?GGG2mQ(E&;mI.mq%cbOPAmAOQj32gN^T hyJ-O0 V7VV_?J]======czͥ3Vg=ܐ[Lgϕvi-aP&/_#0NB^Eq&מ1ۮVi`"7F(:UF@DÀ h,7ۡ۬%t _/ RRrj"V7F㿄#$Pd5?ۍЀ" ǔ68GDtӈ;['}Wxr:\$):A@)fP}z{(; :C9TE =6.߹fh `gTpu:@"0|5SŬ;[zI (f)Y&ӿȭ#q!ٝO\J LRzi3 NvDMK rx "F}b/WB.L^HɀJS2BtoDrl MaN@4Żh1p!UGT$j ;"2ݠA -u/{G 7qr-EJ~WT twD|15xR)L^m/';ܶ&BR 5HOWk;'':% ͗/ gg?}/¬"Yҍ9:XSDQLLn:@X>|W8RMm~ÓHnGmaS{ 2(4RZzKɕ 6mx?A#h{q| hB2#vNn=QI>4 ܢYy9lեvSJEԷu8Q85PMk;'jǓm RZ6{8$3&j4LGf*"0J>M7UTۢؐ@H+6GF `4z!i*e|v1یNYiW ė`~xT'qyX?X'-"DHG'NO Ni7 \R_0G cI"y$m(_׏!X_,ms)ӿoxzZ)pO`6&l~q#V'oe======_`zͥ3PmuoU`֖FaUk O",}xc코X~Зz> fIZ!1(H [Ξϥy sDx3Tض u5)AAǣW7.aU M^.I5L~k2 :|rnFn0SUl|܇;JǽYNe;ٮ 1U/u>$ ;ۉc%o$'B  ]^s֮> r$ KwU{uIkԘc|U9NLȋi=Ȭ3XZM{ I ޳<98Ah?vI9n@&2!o=I > 2x(S#X,)@ME IOH-1'_}`/"!t ]w Ԝfv *Dr%JggaSN@uXe,ћqq*.32^N(S xzp-ZHϦ66-l6-ԁWՂD.FJH }0=y%u᝼/m|*ۑ[a/HY+H6B") wVFiv9ج%֮y)0f Ѡ}flGO>a;ۧpraQa>ő*NgJ(=s&b9fHEqJL+"[hO&l*sɐJ_Oz'92YJqe*336y$" g'%ɤ HLoCd!mtUlQ&vj)eS hn򮊷TY!BFmUhr¡ϱ⽣ [7˽u^v`5Q{h3;h-T ڑ$jK3]A/jw 7 ƴv 9X/Tlh}x4,^ 3B9Wz:mPQQZoBD L:*T'4U3|ygRֻp N̮aq_wQ1<ܕ(>msvÄ. T7" +4kDb%3+=țСT䦡O$+jo622222x1\꽟$^4 UYwk#=idddddQsb|Vp;|.%['-5avQ$8YRl9rLe)T8ˋDB놩l:_|JP+k65X~rCX0)o?B0 +΀]fJwX3l]r YB%t@)UWW4Dv>%PdzˋˏM|P?N=@b0D#32tj̗/J n.'0h %w+/"Z6qa*KJ&zݦ&&)ifNGo0K4,T+*֫''/lHl֜|z]ӻ碦Xm7?[LuPBR?(̥t8_|t cW@ZwKCSymЬ|L&VGlA-/<]uzQǏ>L%m$u{ m](qx nJX?>RV IDAT1F-3xV20k9"An{RL(2j.#####_'.O|nԝ!`ls O p -r>X  `jg)i"g?]^ ͕Gʹr;?c/|ٚ{2\t |wv]B@1( :ЪPMAm?}|W 3nӷۿ))#J4_}# :v(rZy;C`;0 ͥ%Ԇl2p= n֛0bH ( ާyMfKib!"yF|~U']iC3*SU,,v~bŒXF=RހKVC(HoCT( %]tT0tcC~!=+u$$.><t4au-L?Dd&sۺ]H3J*3'cj:LkIcIê&F=*2Ngo\]L1 7PXor2Q uoHӓ2RowJjC!@V-fc:OݖF-"G =ԅz멮1Fedddd nNnKX-*Xگػخ>vK-?$Pa !~8vb'T$O0IW`@UF0VKzO{^ ι-Y qU9lMǣ5'fo-^^_4׾蚞4A[,/sEJIW)/E$@)`]ޭqdHI}&./w\۞Q}Rs b!_6]^IvϻvP VCps b|@2>q|u%Xir2 56R/[O@HFtU ɯe.\覠R mr;cj˘I |QpPӷfcf<ޱ\|)uh]ೋ2 p,4b^`y^ꚧW/^5L {Y 9? zDINT<]DŽnpIRCJfZjϏaQ[Tv"( Z:=}g #Fa\F1ba[LB- a gc_v,TAL`瑔 E꺈B~Vt\;l.<~ݴc|dzI礣?h֑V¬~ dl2k4jւx\^^8eqH-.Oo[ L{qUɯ+`lC9KtJEPCo@C k)<,oQ LE`-Бϭf%ЬOchp 5H[#w!VzT`3]lꐻmL[;@`-fzbdL:;==0u Q3V&ps+rJdA~ -_"]\l~!׎^ B<#Z@fX}㕡)h\9[6\l~~x揈0cbv(9!jKPh$&3l6< ?;<|l$'J!xlđb$𚼠m3,׊q)j7A<.m~Ƥ@rI )% ؒ|;nq4bĈ#Fa1r.#F1~A|lZ;!@MEűqrЁu5jf {2IDGÎ`dW}דAau}}ÊU` d@7BdT1R Sd j E jz1tNiM}`$Z .-“Kf},"ݙM=a⾃_0YDYPer>չogTz0^]J3d-ڍ YA ~ޙ팏nvLuᒥ^1V;cLzR,!G/?H*{ܗ>IDOޝ̴5 {'o"2K_ĽO~2v2Uy1?r&f2()֢Dxop|WUed(dA>qIKu]2DmY8&S;<|p8/8|:S̢K=7L;0!(u ZHH!ZB57N-U;JOCYC]F1eĈ#F|I9#FqO+--ޥ՗>_r CTԐhU h"c<8}?Ĵ(}g-si"P go}|~ ^@cPީ8(" "goN2R YAA)% fڊdw¿138U> 1bbh95 5U<|JӳM:T%2Y^Ouo;n.kS,gܞJn bqkns #4WԊl!ecIeVٸnSG˯7a22gH4q;go[ cX2 q*g.72-RޞdҡzZɹ \J݅^SpV(ӄzoͣzD3&pyV}cV'&G!H"i`DTh<bOM0 r倨Eg0Cy¡͈< |Mdi$Q?b57)fe"]n #F1Kȹ1bĈ/;Ύdś<]ꃚRd.}ᾢ*PK~WT5/u"=*6RvNBu9`hv%!9 Jekj)f#s#Q:%P\<⎪qĞPIF0p7P(RH(Kbt]"U+& v[M& b.cs-ЮfVS6v wɏdAMpNwpg{G2cw&wVe'!w9ˇ}DAY}p0'.LC6k%KbjH:1fWe",A!&JW/YJRLݰZ`I"roL1e&BRNBkId#]B쒗 6IJ0zD& be'{RM s >Z1WW${сD8@kHL0 G x2[P!EjX /+fKHg/F*$N _2O2('7ͮduy){ůhҲ8'az~uvr~O`ERUyn@f@89!,CjeuUkGBZ ]^x>ǝMea黂03'Cj[ܧ|wI\?뷐Sw.OpOQdkPHz9`M`v*Oaye%n~!JpP:HD wpRL99Yuh-T ;'5{^{cB:2a̠[q?tI 8m!Y" J BmܹFfPbq{jHoR{sVD`:m=la+EqAd&Y$#s>Ji)SIlVzu^K58{[6jnM 8e$5jԨOP2jԨQ~G}7w\DMt0b>I9;)$NHL+}X٘=`Pqq2*h ~ɭV؝G/ Fgק `~J#H3Sj D?˓{cèn<D dQ ~G-^{+;T]KFX $%iaq%ӐpG63OoW}vԨQF5z.F5a6,|2=iO< k`$Audwy`V'WO-LdQ(%"/.9d.SLݦ\eq/L F\1=~Rc|tanow{mm(*x$%3fnqYTo=j]{uWSxXǎW'fchle; "p/&vzv/ Ӏ CE 2ܻ_}.֏ݼw؎S9#½_?˰{ >P$"1_( eZO2Z'mMEĦmGh SB6D)`X|v>=;#Jev" G12jԨQ>A˨QFÐt;6 V`Q"+ԧR8t`@0Vo,ҙdZѕNP  TZAÙ ,Җߧ-'|S/=a{ MQxk./wHpǣGteP{xAX`B!24HIp[1Yjtf6D3rݜ=! @-b 0} E PPġ4ϾTaNw4Gժ!G6 =ʉxPkpî H'D__~D6089,LL5lcqߜ>y 4fK#{̿8J҆|T E2bM(znh) j9p5jԨQFeԨQFn=ۥ}pkҬ(-}=hٹr :C3BjH{PcxUc_~}d6k&毬Xn5mgO~<mJڟiYw~ & p_ޮsEM"×#v`ԽnXhB X>Mb*>Luu2g~ڸLycĤ ۃ\uAN #]D D倒" "ܦ3`VPIe"efo;w050?"xzZqbp]̿(o6:'VX 20.xmVQ+|-Sl a Ƚ'/ޢM˜xqxfv:qk6Uvao6=&W t.7J̵1 .//@;Ѷ *- NM'REЗ.VmXc9Z|z|}yݰ,? =jԨQF}=QFK=hAì42+j}43]|xPa5ۅP.L6'3lhϑ6_=wKQa⯊n󫛧E46$&PxKuk%{ <+ q'fB}# .J댻] XE 5 UaVf}Q7A{w=)8tXoccuKtP-S;0(\$5 e'3/^O"-i@fQ_6bѦUn=!F..}I)pC@lQ!::}sQf E$A Na#2 ՟QT4P7DnebL(`fi.t&(.з^fGnh=)ݐYA#_x~X (W`{i7A.6̬e"pL s8NTQ7뿷'Xο jߏME,N_o7L 2;F 5@a9 a]6kGB ;c4NY,&;j5qr=>Odb˛ 8 K}HgQF5蹌5jԨ{}XJkFB2XjqftvMG7(hhd_eQA8{b?\$$d? 0!O: IDAT3A(d222Q0\azfntk{g /K(Z.0zZDFܚuʎECo d TI#v5Vd  v 2Ur;~Eж>b D`_81{&ZCJ q^'Vڤ6&MZ/x@`>]3NP(cxA)C ~bQ "H"5ϜyamĭC.cK&z@ BA+-{5Xu 3d0vDPA0FvYK'JE QSL "qKd3'?RTEfkA.c/`vH7M;xz m r12*7Z@c1e&>"H1ur랆2iC :"yK m"'άTg)z\7jԨQF}=QFhKA %?4 z>euhA}1Ԁof`;-QS!T!X;H3ŷa,afH|h9nk >zxCih-m SpNalїbBMt=5qzjT#:4q vY J[Yܧn2_|wQvPB2WH6m%7B-[-t^ Q :dl`H5m5]W}D/PjLڙ_^^<3 @ZbѳDp L8"zY֊۰[3˾M"Q0͊+|Gm ۏ?=xB J {N\le4p| ȳRX6n7 GI%q?aXEqYAzv i]❌g)fұݳh0]gV:^7ft^tTf@0[8 Dxf}f%r97l!bb;Űc֛2RfvC#.3`.f *i͓DfaB$N5Iu Y- }օlXœG'oJ@K:é*G軌5jԨ߳FeԨQ\bO٢ύ_ VjiA^?+-ŀ+#n?,V t>D7NF;YAޭ>h+4 %0,ZC0v})+V`oF6{EiIdcѪP! A;|~iwBV'oyKe| \|҆;qwי-€t=?NG`$dg?lſc2؟: ]<6|DFn#0-v߁*!+CW3gP': 7OTMP+H!bH! ib.Z"Õ>S*jwns+CVֈI5&Iֈ ;eH/IUNY/46]wٳ7r&jtPIp2v!V%'a`Y{`T+T`!fšX dǏ @2>?7_Sb؅zeH"+ ]nOE%UKb# DGM3 ?l˻ N&Z~G\lsn?魷8u5aVҺZA]ŏWZbG'ozy'WGvCQF{蹌5jԗDp۲!uа56մvmKaH!DRnQf@Wf[ށ 3Tm븽Ph _1'm)wb6 /֋Q@yQ5 _NvpfRI756/ Xlaz]=i^`Z-f3Wjj.[.2ܥ~W2"T;(;BVJ`6}0ZJӾ\6 1/3Z2G$-`@Am(fpKܰXr<~.Edl,ċMzg-K(ȁU0Z}# <EfX\5y؁CYj -r"K6fX΍ܿc 7JUZ67cBF) % ~`۴qyBT9aiu%"duq*{ZWmRBHi#8#8r.Gq_<p[cB~U2tVOaZ%_#3Co*֧ tdSk74Tԙ/("CfQ2܆ARJ,ǓƳf:}^ '*i 3 gE@4$~ Y^7%3Lwe i?oM Ik(%3 춟^6Fb JT,g Wa =׈K2+㿸~X/'_\{=g%"0RTܼ ED.ax9H {n# "BʁrRV,khU=LL 5MfzX%U@ "T[#K!. ϶/mrvSazw6[b4GqV8uksl&G٫U#`$:XAj.anlL_MD4iFO6oH7CidIFK&bHR{i_+|F)ʘ^] ($N:j=d]OQrL^V& G!+wuЦ40;O~{.gZ )CpiMCJ pIOȽqZO auN̆ؠbFGHvB6@5xu]MKa.I3 3^(&Xv[K'[ fSc'Nr)H)Y,I@ \%tJ^&n뙮 AHV[[ J`>ScP(f 1ȗJ(F_a[nidDx]TL/@NB0SbAX_iLkbQJ8C-4@(M}@P)T2xcA u8J5ŹvpzAd\^ τִF<Nst(J&oGhaEH6:%$F85%MZm߁_2#!\[05\)5O)Y5(݃(KU6rb~Č%nh8P9D$N,b"hB{Zq'L=5BV󬇥?{jOR_ v9#8?0GqCDU! >18>KT"jͳ6ſ$4TgMD1c;1'vy|7)F*nHM3a0I l a#s/__gCE#jVjI2md>{e{nd r`]"pF̡t8Nr&yJFf<rg]~fȇ_P2<>2'8ȅ`da;O)V%44taX,.w!6GQ Y}PJrɲ0Gb6Yѹ.X>dx훃kckZUP)G7Th>PwZ-FD1lQP3<G$} !f)N76jeJHC`*K#w5 $ET_ڡn܌b+\@Bi>{q~TD!um@vn0>yg}xoOi<\d";Zi rL F*FuS.-j~#& }b]z>É0gdD=2f;Dx곮9䫈MuhZ>j[- bEld@tac\~#9+~ν_u U9Ilfg#`eGY0!vW{Hbaou A ST<$ez@2`),[r0F5jԨߟFeԨQ^޺}n;7rԛŽJFs՗?f dcߗl'3B R l7?Ma|(l>X ($cq.0pJdr4QLD7 '8 '%fb`$mldcb$T x,47w+ 20hTS ,XpPh8+Q}ܡB3)̞7MԌx-E@(ҫjYv|=3q&s24 y =K" R7xSt4f?Δ.f dM̺q2:\"2 w8Ր1^i{r: аcX1Xf43Uo=|TG47??;gYtNJP3P3ASK/FdŒ 0|5f z8s`%>SNkw=r3!k6Fl@<jIR. 3K1hZ%3)ܩgD*fıXfH6a0,?,tAR5FWO]92$,kWz~e-wԨQFk\F5%QK@~;& wgAհG-$ "9P6o!fzC UGHAzJbN$zw5h_}9ZLefdN@z nT`-CqW*sp`T 6L$8 c&]dupBϤtt @}JND H]o(!LFʚ€oJAcs"\YgJH_fBZ4sC  Y6MMXcv(>$2 *@ "h*& ͳԆ!;4_k:*4h" hѾ2G)-23 2jKS@A"q *&E"╌0Vd5qIvm96s%Pc9  F׀j"up,LC}vXvM>8%Kv Ht3p!X}'@ -NO VMTm}?>Vz914/ߑfi`NNYv|ov<|[j64+=6@6}J~ha|ex逛*fsIՏK uD?K<ӬN֌wΡlqEMѼk>`U7" z\X.*dgܯ7?AZ[ͽ7"E碿K]B+m߭f׻x -Fӳٷ7^C.W /"r=EL e 8QX+̼@hB𛴐&i{x.]m/a>£H gHn>G!V8ɮ2&J&)j͗_QcatbqƟV[v}oYٻ'+]Yx^}Ȥif"E 7JC],[LZW!..{ۓ6Fo5jԨQ~;˨QF$Yo0/Ȁyv}E7@*fS7Eu*& ITB4>˷&4p<yOYHAVP;j&=pdL zMQ={wO7މS~ 5fb2% i?}SJSRo >]ʝD jD,kAI*ǵJQ]l|5:-BA8hWuN!$pc" y*fv? ;:!GF |]bq-;b kcGJ Cb]"a7WƽW0t>{sw Tݾ`I-ΗowyFܗNmiqDQtZer%bpJRQ,DҀ{ƥ= i Ơ>FJ:c@s 8B \^ Q_nՍ7L IDAT5jԨQ+˨QF$3!2<=Qs?&ّP$hfAVϕA$=*B ̬@V@Ұ=V gg8ϻ`#I 'Y*Y=-L(SD_t$2Nb\t)}!2;qq|n4r2=\m?iV`HQ.40,of HI;\cg3&HpA;vOf#%K64vE't~Nofg\?ERoD6]܋6 C ~D.V2 =5Z2t E\:oVzo=ox_9/2 2[{.4׏Z}[_tU׌vYkC:!`:ui}5aY^1N$@AGŹ?5ʜL'õ!D<5j>)`'&441NnͰTaLҥ9٘|yT>]ۼ6v͆>GF2ʪZ{[etaxGHd=Jf@ e$/$11iקvsᜲݝE<'wUu^Vʙ>I%qhK-8On/{o|h\1{[ _l~@^!gH@^.? T ̀V-+D q!+mX͒j-TBfgf J@D;hРA5x. QH"s ba&*;dCStfKSxsiݢ{ 7PO4}'ټABEihu Oy2?}\w@nq 'nx!b /毬6# s搣MX$_ WO@ݕ3wH.DHa fa+ڏD@`ҺG/No2L*SMŘKO@AMo<y7z/Wow#t&n2>sqVn`$XPuMyTW H/fnuLLN~_؅7ϒ fPD덱igawz{w̒Nk/p v$ԭ"gŦ P혾>O=F dDGm# 1B\z"CyʱVtPMr>Ƛ(4FGM7J;Pm)AɁ7C=K.VXD9 h wGh vz.W X ah (RHOWK9\3KEOUN̈Q/u 4hР_eРA>"Yl;Qfnfԉ4buabvWrFJ0C!B;dXm>Ttp2/wXcыR uL!Yyٱ//}_z~X 7M?'@I:D@:Z3a6*J>Uf&eP :j%pMct=5MS2g裂f_tSS8?g>R>9[@X/?Zx9YmirS$ysxQӁJeDHpdE-4K*P$RGcTP+3h_=ܥ_o^zr֞ͧXbfRx2FͻӷXpd. ^k"8Rऄl/~YOۇnGt9yi~iZ`%+$l(pZ|kk3q|b9w5-{ҀI'7?{,!go~7會u! Z@ڍӗŢI2o d {K(BΌf9_u)E)^'KU 4hЯs4hР$B@>_8r`6H􍋋wKTJ*TOi !$svxv"X.^Z ,hR H2pݾ7=}-N&v0ubal_0?@Xv*@@ 'LG63܀8A$N!"V&[Ju}8Kn}|46P藫fe] f@o ggIH1p:;6M2=RE;4];IPԺ" iFkZmkT ԜK 0/) r*KRN(fGEZDlF|w9df$)6ςB"yAaLn2. J0u_"JCdWG캔C IO nT%IZW :=*VQ;{(DF:%G&Js+_nvD8O &dN%XBo7(6ÅQ\!^U8ԲuUKVE_9ŝQX|/i$b" 2 4hР_M2hРA_ L&x XRUkC댁;Sj2~tsP>D-*#zt򧹐:߸ܽKzf,Iu1 u6)2RftGf't`{́vpÑcx:y+{nir`֐RDY#@#ƀ:,u|1\jtYd_J~>z]vaLġmzvIBtExlDZCc-"0O3: =ʧju0 *ܔ;P-/QnKm;GӒR /9#95m QܮsuCG jh3}АvHGR?ߏ$wuϹ[=%QxIDY5&5)/(K)@ ؎C"==?<|gg D$[H3]tUtO900 2DB0۰ S6NMؿ82YkEe&Yn7nii6 [~5vd` B%Pk1]ı@/ml 4:a 7{4)Ht>T:m;::KɴӴݻ<QFIj\F5U$i&$qY?@ =^"c5TfNiY rXWO0Yl\=t33'wys6A`]2j[>Yw7w#XH@}CRhr6+eہ`Nfn#1 qk,:?ܾΧ!Kv?:@XK.Sh['O̧Bf^niFjh Ui}_1?9%X}ùޮqz#@zS ~[j餻 m֛d0K 9f}#i@sf'FE !Vbniίtg1zu yd/^3i wPd1@av7qhԨQF}=QF ,G|X_3"v><72畏LXw0hHY*)7910>~ b܋Vv u}`bH$RFZXw0L~?^L Q28`f.@ʣ3ObX|=`'70EzL[I N#D%Z+2lܤ`=߾=^! TE KVsQ;8v~rT}cTQӧC&<9ŝt3qѭO%+j2tX|b~(ݰ06,s=_ K\t{clHpcz yM?ޡH'?r8,(@T t-q*g2"/n]`&pivE\7oDTl)e X_dRݝG?gWS?8$ /Z 00+wa j@'b!]nr i}Z=f܁Fh&&?2=|IzL:$z_@ fUjU jپׇ`__a {9k`f$SP]5?@1Wm$%2j}yU+9G5j's5jԨ'x ޒWXF؅"|:|sq1ǑwHuNxנ sj{? =.[4N"q\>3~p}/!HX^svpûAvTLyE2;Ӽ 2WϠ)ٓKՈL3&.ܟ c̬VB{bjys3gQOnHgKZBK l~$/#_M./  (D ﯖ[hG1QRr)2~ $'3ܯpn{_*' 4E&RҕY2=Ҍ58yNUI@m)7m)%^ͽvϡl P-gbc a|`0~]׌6 Gwca4J{ :Oe0D@®3*5.tw: zT=M'P1$p*5=PSӿW  պ5y^H qDEYa7P/KJI?w,{LJ SteNǍq~g4}yGB!ŖGkj`zy/o'K8s(l^n^-dҝHPa(ģo)1Kp^cq D a+b`r5jԨQFeԨQ~xE"9t#ta-HZqz%"tj@tHoaZgv;/ t(`8B#ۯq*ìy}ZmArLC2̼W6p/6?o IHl/~\ur| .[t0)\g4k\`ofKrRJ}n` .e"Ők@,ˆpBLRpt920wKݥP:1̅I/<"$ ?Yhtzqnb-/z {oL$y,xkֽOQ$$#4q~AC|][dY][U_fA.ĉ" <1vcGătץaS3ر4TMwMgWu_E)>d)Y#JO?Ef,E B8mÃ?6L(Bv_{;>F$…`A^: +@HD:, 6 #=Vr?N9Lur ȀO[j}2"1j猀m7A2_<AXZH[zcs6$Qs<;4Prp?" N.Dӄ6?HGu옞~~ýB|=Ύ^;.VzBew04$I_島|VL)hxZA#n 'K-RHM03_ Z߃8-''J#&Pm^PכGQÆ #AaV+;,.8+O;֫ǹhuxrB_"*Q//F}%dȯHSnfjk5ؘ +^Oc3Zj~3a[gPwCNDGGY 4"B XӪCˈ#F11bĈoZdZ>Tfp|D m-h&pGJ8a@T'<Jy( IDATH{|}RZkdo@ Ė8Y,?@`:Ea0Ira ; q ._j PRV#VO_,eG? (ӳ?)CCgX]||cEF^uͅ@Tpw.D g' !?D]CCz*R ø/=(UPlS:QJu(IG+I|a}Bda~(ԁYjPSMHEd[`P34ΐ F/?]-6B>!ؘ_5ك#CQ3f w¢UjACi8S k1G0  IPm,2' ̝n:tlĀ2Tnw'݀I4VX6a,Lc HlʇNh\@eUhhYP/"K7`(G{^=,\ʕ{A3 Ӽ\ug_#F11\F1k]%8^*z")T>TP=wk %:-r?s PC18$qf".uvR }Hʕ!2C]25 =bbk*춂=bFRt!WuV@Vmy"T+P3{,~Vb wՂ=C#wB)" p@jA=ZWrZ2n#0`[D`}I!Oa"ZMC@n3!q2cԓ +1b]}1PtJ0[JJvFWs4ֻg :aB!k,b ق\l{%ؚݠ1l&?wmJ, 3"'52٭$Kaxqv2fI:j֝9݆F V;p#!z@(qlTssr{%'K \._WI{ȭܭ2(CpB`;#T?1Z yܘ*g1?zA`0Te>Nj|׏7FJAx Z_~[Fs\~"4LnJXy'B#|t@L-79#,k"ﴶcw0;3q.S5\=n?M]J^$;‹9@SJ ]nK&nh[j\>8X;Ӥ<}^9X!ǨEDWԷK,oAa>|H+IwZ.VZ AniQm8pvDI̊`fz@ јdVO@dEt!!nܷڇ"#`X,g&SD$JF*fQŻ]}+MV& "z׏r`d6q):ЂpTLޒ+u݃Yj/s|l#F1b`\F1kΪʝ@py~vJp"jEc964|5lAJ OS h0n65EQ//E~2H+E`x%SY4Wo9j6+JM{ѷ}lEPt7?۪ Ԑ "~9FH4 gYΏѥVTg7̒1pDA,ϾejmJ&djn!@QOJl֫_! %d)'7EoGe QфrHZ~Oj s GN%`7_ 1/E9R$ޙQ]=|3#0"<׏ r=XU%Km{٥^_/+)(!Dk'8fn.^G M*0ViLb pz˺s %@;P䴲vk{[e;*fK1bĈ_FeĈ#ϧ6@-9նԀau{oF9^WN\=y:}pgD8CkԂ܀03q7o36rAFF Dk(Suc;uG_[^]ʁ58$`L@1JRSX.ELdf{D |b7Kn ]r]w}_Èr!Mj񨬙;?ξMC8[U)4!Czu't#|W5Rp`_N6eh"Lñ,t{H+PSO+_6]NȨ"o׹3Xx'8?(Mh6+8=}1TuA}AZ g<`H7W h@O^3}^S_:j:l2{nJ?;&$2RrOn!IHZ"n $[`0FQjz({D펇Pz,i]ZIF?ABxG$ ѹǀ쾝X!EM/2Mm5yBQmn } \F1bs1bĈ?2 yfԼX!{EN!naS9!J-BnL/aɳ}68?0J)ȠgsLLYc݄3D`>% ֕<H򘶞tI+o5Thmsy>4ULb}h驐tedJK$l+F[[n-(c*9QNOP uWH4lqpP1wP g<Po6jURjPo6[jjӶ@`=Д }>N#wJPQ6jHRz 7t]-=k5 9XJ4!1{,GҤ<8'%Xju * ENCT YC֙ЬHHO'Q>94HU5`=n+R3#F1b#2bĈ_al&9h0$6҈aZRAκ]i$6I#7@CK;%ˋ6Ј_Ǘ RmhD2Z@_Sԁ7竟w5E 3L!֤+S;5ugL]{ZZ%) ְ6˶!_j4.B_} )'8xD.X.}vbu񑳚tr3-/ހ`a@"/Cn`X$U] DM;T !"3 dЌpC롫d(iAwyy Aj ,jZtuǸ,c>vDSKj(r`|1x .IJidQ}+Ow`nњwP0h+mҢ7#F1bs1bĈ?*p2#ɒX6QdɲqqlPNgWt~8% [@- r75JluCN=F԰!q r= 3KCqjZ$cB6i48|`y\E}6@T*|odT_ُJ0SnJM3tHa@8>zA:$z !J`Bh*N/vc(#O,-~6XC*4BzmV8w[uҐAU{ލ]N <>?a`} 8q)jv(ξ%r6O:HH _+c:q%y|>8ft{L ITшȌ )Wͻ*b%M(S_Oslո%ϕ좪tC!:Jl6?5CXtH ,bj<5}-T (SJapwKDj2D8;9Ws{f;KR e[d!qK9JԼ!pdIBP  ̐ܝ{N Wb]OMI|זyH$OuVcs@mM_zUR2) Ȋbj8=:Bxe v]oowFogNў/g5dbyZSSN2],xU <DzۣHef;Vv,fˈt VI 56gfx!o֞jpWyO|=qtX|y$1L7m5͈ID*X|&aĽYw;Li[ ߷w,wQF5wq2jԨQ/13ZS<}%~ ܶ eL&6㍆9nxmEjx{h2i+  ئ|"\HnP|,$H'LZC%3!Ypgs(wCKtG)X.X>cg -&LfhTcWI[38]߇ y8,de@fs =[!ZS:I T`8ttHF WG$=OZ}8d.⛮a^LQ@&׫/0MU$v~*@;9m3(Y;(vDRaߗI Dl>@@ s{ '&&u~8''m-]gn"l͗hi1HE$3vy6գ棤YCD"`cHȒM 0:GTZ}1;{)9$u>OO6>X5h 6V5jԨIeԨQ^P NfPiu @v"zhрȽՂ2WfR%CP[v50GrG+Ì$-[.`?7Cͥݐva&Pq|3aZFX_Wu֥v^V| Mh֬P‰]`~z:VR ־tX]<O:&WYgp>0?S¢V`'.32/op|#azl>l T"m[u- tqwwU46l]'Ɍu6x@boAm@V3YC}澓n24|QlF~q4e۫~fusoEEܟa7VϤUɌVxiH*u]*߼Jh:~ہ}OPX,)e|ZuW]d yCs 4*̱X uB7wC8 IlZ摻K"]TxƭV٬ ԫ֠-6cl-hu1iƢ*kN 6{M@͌)58\G2bsĴfzOIɍZtjԨQF5\F5Wg6<#W^<횀R00s J=㠱U[v7^?mOמfRL{e3ozwQjE?7A_^|חX,_fǻ^^2r"u. !&uf"ڌ`$2WWY&NoHҼɓǑX^([׏i@^ ?(NKT0XWL.mK;Vן;L\8X9?SB@_Pvn]ȋO~ZiyJ Hd)5sC{o߿>]o>=8)fh2,!ޕiLZAcV!LDk ?uHlnu_;` 0l6;bXfI7{}۳է`y'_gWW vnl(7 n\)u\(`4LXK[$J7{w.@H8#Ŏmb3p20- ѶN)03w>wԀ#Ը\## ނ^r[$;v;ˀJTL`# T:H`2L<8wLReAOzYٜ\hv53ɝt #nVDRLl!eLJ;d<ϺnOi>a~3^֗3Ih1pg iv{70 DŽBs` ʺϮ5I(jyX‰fQF5q2jԨQ/8hbID}of돌(I{+Ğ"בyDv )H'2R ٳǍВ,:TKM&"c&v9>p*t]gGpBTd8tHk' \&t; fhE5 >{g#uU>VG}q!!)vlqH!PH`G!_&owwuutݳܪóᮇQO9f ?Z/77ɼBvfW׊}镨h{\n~zwvW?{TQ/2`ަH=Iٹm6f;avq2 sdxH^];#etf98M?Lݘ T%~@ag%'5*Ѷkd@5:r 9IԺ~ w6q:J#ǿ;]yD;plo~ژ{n“3Pww3\)@eО?x n`1CD::`G"\|CyfDh 1@/+9h-6DQILFΤSpe+ߧJI7P8p?5+d'@w\Y5hRMC %tXU0K9a-al A`>ǣ&^J7?QTCa/HGW yg;շXq @ fxH~x{_$ƨnHkaé$^;O#8tF u7 Vo cD4K#14H4T@N x|0Zs,*̕뺛f#dH;RmY6)I_fSξ  w~3䬝p#XKk2I N*NTt9N+iLt$'ѐm["3!#Pk_J*aP &ajGiC[%ǹԙG?g#{r\{ߡmYx^G T7_v}q#/9"HV߈Ir|L@g@- gf{z?L-ـcf{N*qzy "Aey #'!Vrq}c=6'dJ, /eR*0.K|_+[%fm1"V:B <&\e'7;ƨ6@BU K ?_/.|\G)@@㿼9asj=q7T"b:%]xLMnr/1UR vyni4"y;_o,׿Q-ľ9nB5$3ˇ6LO)dOGv4tY&Blk=:dJfkO3qp}M.I&MhL4iq֣ !U2Hd=q%a$k֓hS+2_T@Ce,`3A!yU$I B˰h2Gj,vؙIJܺ{#b_D~u)'G\3bC3SqLxڐ&bpe9ĉt$PLpG6ue<a'Bљ0!"QA|)XTE-eܹ[S < oc+s3M6DCΖ K1tfǻȊr_Q\)9 D w'q]E)HNBAt7=hMx⠍YnG:cKqlOIC94`DQ38:-mP E iy<2 ž-nMZۥBߟvtˆ"xRI nL4$hhAsĹ;ȍ(iddL*5Rw lt1ev!-1G{֡Os^th !%} 9c#CŠcv&M4iҤASeҤI[=d8=sKکԍ9xQ $m *-S;o {ذ"$lW"QhD{@6& #D$: w^?]JnH6g>}KEABcT nt͐xp8ovXYNjj ǀ0gCZ?8[ry7-ca. 1'Cű1i]韤;/cMJb.>{h<6D*fL cԖ:Dw~} -,YT鰢c9rZ{`9ZPv,ݎXi_lhגVGBHtx|?1 *V!dqJV"}ws9 qm&2ZԚ 0/?іfC%ֺ[I @6my|;^`ajDjva|Ez1l0f/mѧ; X03r2\oxeo>n f!p>ϛXИ#xTf?hQ=Bw^1?&M4i&uҤI&}w1 D!y+_uO7l*?ƶ;,B5f@YCf]{W#uUܪꩮ1"lc!DA% -, <3U=Suދs3nW{{= ͔d$%\>_>atJUERP<+ƀ~z7?`~+PbNHߘvLCN͜0^~yy n( yO!p>0WZgBnlΖOJ`!-3t%j"GGfNc=P4Mzzc"^<2> W3wx#Dk}|;16Zv+6f6ħyav Vۊ0(,)E15Hib(de6Y C,+ !N8>y:Vrf "rg0Y&M|Qַ Pֲh>Q> 6KrR OV?\*8dL{5 CݮNd^[==wimV1.;B+iy:-?I\ё)h\_ɨ0lW 1_[[oi)@37Y(4 wkp{94^Fd \ȬPN4^'^\=P3q{P6IebH12:`9NtuW]/ l|$L+&?rP,WuCvƽ˧ B$zv6DZwS(ڍf&H &vF4@u܁xn]_dUFl5E8L4CA:Ie87V[HYj=`tTͮy@%eO sa3`T6lW㝻Ѯ .ZvYF!z,Gp{\~yٸ`"b#qKHrBn@jS<_yT֠E`Е4@ {qzl rq$LD`1 s#䎍f/6]Iͮl2'z6f|x.w9!$7+/^\}e6c=M[{悤ems fԁ=7M eJ$I5[nf"/gvj_QNm!f-W2„9arcjB+P;z]+wR$:I^C*lVЄ-GvvOy؜w._܇L T&[,9G+qtADg6%qw}gg{5Aβc'PaPF IYnU-;)ڪ) 9H$AH>pA e4!dC0l$@VE2kÞ8K{ŏɍp\8 ( lcܚzm,kA]jEKr19FxN(D80{)(w aGG )̮̾~s3x4vTdeTƭ}vrlLW v0[z`/g`Ab}HJUo>Q+[nr &5aa@zT`yd4F&ܛhMQ%dlÌw m uDI79ӻ- yQkuJ^nueFP˔c=c7{e=f_ 8C€$6 7 =1޺EHQ9Tz~yEs="O9rZGFX$& c2Q{d,{#{ ' 0aV{~kl[mBrVt qƳۓ%`"m !s ,2݇ALp1ֻC7Z 㑥pXɀB0պY$x`erprgfkߋ!wm0M1n6 >n^+OU;iJX9#,4Iڋ>a2$"/.omutK|c6rtQOxI6M3tŧN斪M)]AMg-fӟ8B|R$ !5/ij/]q bj>3N:"i7WމrEهGDa1D V!|ۡèf߮niyAcs̭{ո&.//QIN֊wG80A"ld4jqzӬ LHy9\Qv⩶2{p2ŋ0OS Tx'0Z=c=5`Ϲ{hɦ7I`G'ɱa4]!Dl(m8Igʼimӳ¸(&c/& (-)Yݛmg7eK҅2Ha:ǷǙ-0@Z^fF6CΒr;U@5$;է⬯@7߻jӌHe $8Pхd6_D"PNl?#h?F0K% (8zWs*æ)"Vdcǃ R!~;\aδoZ|(--}&8)k+ij jۍ05w1\nzȼ46f^Melk/>0L EIx2%IQ t o$_ &Ӱf4kFstυuW^-ܕeQ]hq$HnN ":Pc^,jkT 3$SV/~ 3hG]o{4G+Lb|C1>Hݬ %X}RЀQcAgmiCbuu\,Qe@$JAfmg4 AyF] IlXF$`Ȭ6[ uZ(\C%L2=2/+Ν%BG E`ҲqSA7hwW/ 5`-G囒2򔜫͖EG-lw?Adf @*yh"ˣW8 JaZQch6^I2ǣ"hmlҤI&Mz4y.&MUU/0rt] _ȀIN}V IDATZ8 x=6F4FjFsv^詌`r$B:f@HxYLKCrA斆VʎHM4cN; ǩ4t r a'n q(l I#AӐaefRs`Ni 7 Ki}$]$2# n`Vagޭn Bw[o$D綀f!ȧe,)qh ⷥ Q&Z*ڛL#sքUW Za)EA !"]w#<'BrH A:CuCd0/Zgfʣ#+hdvfPQVHd(J҆d~V#8P0&)U)ZȌ.(Iȡ soq[Qi^L,PJfn{I;`7٭=&)F~F f9 )AO̟P` uxhԊh,mke,Vtg5{e\]3 5NNvcd$(PvGoqRnѤI&Mzm4y.&MRq1 P5CpJZ8-iDŽ+IWҐ=`rvSP2v]]_Ʊ!b)$P4m̈́l~; Q"̣֍9[qgq(,*T`RߛDž w[$,o[9U.,S|hy~wu*jn2i`A ՏQEg (;5oe7mDo[!a_,9\9]N923on>iN[:{WY3DҀEΕ&\MDovY_2FH:^o~Q7[7_ԸP<&H@%]py/#!j4T3/-m>6m?8ՐlhŻ:z*u5Q$PBttɔ 3s; 7Bn y2J*[fDZ,#SJZ7@vl !IA֋>_]}ҮGw@g$V"\/Yْx)y{JFdf4$"fZF@srhL̎544:C:{ܶ7?C(B=}`|0;A><,UnkHz̧^ѤI&Mz4y.&MJlvLFDqg3WdB;:N=+ $-~Rz>p/jk1I~{i9}ŝDKH&8K5 ʖk$Z"z &T77ƫf0%KHm?6O `(CuՒvW W3_VFqJf̀% bK]m7|~Ȳ9OwW*0uۦn]{Q a޵T? Zf sTfQrp W0-IϚ: ^$I@&@Ch} %?.}/_|Ԛ=Ŕ0"̏2̔ E}3QӿJ50ӔGb>8mfAl>7Gp"'5tk~p*^NG0ˆemt'˿i7zBP?fhHG9'?Xf3 ӹ˛Ib͓e}W_\~ ͏lWu[)HDJ$8cH$H$cf)|8&~~ EAQ]Ug3ǃZtݺRu-8P 0B4l0jkLHj ]$)Ž? N9ybt RQh@A-4MݙBEK}HЦk,wd Acei5at2 覼3[&4_@(+fS nH ch_1l}Uwh&M"(e(7џ_GN>GJ*|L0afb6mheL#i9R;ӽ["@:0QI\] A3 9UH?mY<:ɤJєuD+^vuh"!V70@C~31 0 6$4U4*nݹ`efDkkt6D0MX>@H[Uk^5꡽^{GF^{GV:;b&(N#bG_ۗ'J),:`]0AnAaƊj"P_B<`!0 Nt5 4Q pn@z a۵EjFh6H~k ܱzk7B)7oT0pw5,H:)EnE4n _clt!TUhIItf:qF(s$1sMF:syy4snMzcr$l96?@fqo0QʳnJy}79{=b2VqLGA(@8pz*Gnϯ+^YLg'^qwx\=A4p'Oi "ì6 fK%=JuݳRC ORs A,f%#ՈTpKޱ;l..~ID|V.а\Rp7D0ԍpuҭdh$2rՓB2ee&3%sqt~2tGZ>Hg8A!<^{^{n\k>0,R&Mmkq~:YW,$aV2nVmhB$fӗgM)ҕ]@r0vTJͱZ^ +?TYQlDz״śf A)5%Lj9iX-߉qt8pu O#1~`{Q3[ٟ"2\^ۗ{ӼP;#`r3nkכ3ZIH?o~ovt`E<uW6ˁ߬eJ ~g 8"a~y‰ۋ˟kIJg0Z+pPw,M!3T/I,//~p8M9Nvȓ_}?G541lų[)s(\B2:_?3AkQ,7\8ǯGBoCn+"StHaz1ˋH5 noNhY+*1kjXL'_2ٽOH˜鐋T fB"#1gJ2s]Jwf҆xQ L-*ơn mHl ÞE( HLC!!ugт4Z<@ 0Vҍ]LYű\jMpPv,byw|ךO^{^{\k>zawa@&a ׄXXܶ`4L宋^8`D@aɫ:vJ{}[)$"@ "QdOOƑ3'H%l[j///ƃ Ra(s *hr!!:t|7l x[|hir,0HtY Mt9a9Pa PX]yɈ [ qb#IL'Q3I: []. j`2}E<#~_Rk׫w@$,-Q0;솼In}qBD`2\E^D 461oR@mCҥIv=:}RT7woEE#Pfp ̸]@BJ_PB{C U"Y!&H• ;%z]P2,9%=4l^'hl oȲ(H "rV8Ӏ)m| tyf"o78;{D$ uD6f<\-ޘξJ恆GDfjPH0 @is|TB 6&.k`Wj~ HrP?K-$7'[u TPڎ-V'J Y$ (1qnHnջn`  -%N[vs4?t =&k\5̟7x#K0Vm$bpo:\ژmk'=l)$bfО3]  j qfu@Bw~G!d`61aqAlcFZ 2Vᰪrgv6'p Hw8rC^\~_/ÞO^]_%* HFg''fIEuGTȡ˫/!n>@X3}0C\G:Vm*NN_lg'_N<[~aCJ&ޮo`:}9'ÃK)/wu=]Wu}έ× " !8^yBB8#[$ U]uދ}۲鮇{={XW"caW-`lߋ13b%` $ B26f(3a̿˄%(I!;4Xr}G$2ឩH$)RHdCR &L0ĹL0akEͤdO3_FN0 9 Ac7`o AȂΙb ofhc9COAEHx0%c $ XS{~}9轲 f{A]M,#< k"6 Va=fg`,ba82@}vai|2#%'ƨ0&;%(+m+鑚Rl؆^ oa.~]YUV}CR&+d( Q( ohZ&%hwN[{rCl>`nWQ)\y;\x1+ c A1#"Z160fvp'0k#k*INfw,3&XCR;L 0]mÍTPD1/B%2D$ ƺ7 msCȠBaӇZ-k܏ `QV`rQaF $^ s֡f"XlP$ Bjb vEBۀROe`vu  ?˯(]n:+5qB.^&3),cn_ Xp=pPyB Cy0a„ ^L˄ &Έ]f,QOiYDŽppf5TcC^#67Wd?T!{˗!V5Q2֜Q߉ " =$[-I89m謵#iksal:=0||OON/aO)nY<}Zi)ڋ[Oiא 00w/oKQ`UV!HT 19:mV"dR X49X<4> 5b:Bz.duHBk8r 9\5C vXuuC/>`at'w-`!K,I: JbR88xߎq-\[pxG<{/䊌=C\$ oͬ+"D'ZPu !d/h0CG18pY\0Yf;P sb}#дSS >K$=xXAb[ rIJɚVNxxeO~d< |AW'ǿE]Hgm1!zqEb&L0aks0a„x!@xbNJ1&_w,"qQIc>qPP8@ɠzݯ*ɬX" Ck~$@=0gx2jA) ٥" 6oZ!hbv`Nܵe||ܩLDr 4pZ,i(QX8,S +M _>Ԛ-H.= YԉRJ@bC-pd<m W?;;+B8x. X]_`VlurZ/2TXoBح鷠,P f \ RF@yTǢhA帵D]c  Z{B9;<jR^\~*)ё1wD2C뀶x3f-NN޽gJE]V,`ZlEӴfGӿ._> EXZ}X @ rTxh=h'LYLڽU^]8ϻmvUx2uVR#pu~ 'o &_QciU"Pl;VjUXT;n5MiV7a„ &֘8 &Lx}̗}-߿iRrGUc2,rsWwYp}ѳpT Y$yao@DD~rLhVr|(X''<-|RƸɀ F@&l\i4AL"xl4g2i8;]Q8(w/>`"KKF]]+GM "\WGrO[;:[s錭3"⛆g`ח[@4<{~lu{Tk@`tke-Cਐ q瞢6t(NS6k f@\ v(z`x\J˟/ޕV fu95X'?N{' f$M c.݆ ۫μ̀G?ʝV3ϠG R0"m8yݔ{fceȞ `% /0xAR>59=0 !5<4eV_.?:r oX|֡;+^K3=Yt }%"N" &Lb\&L0ţi`ʊݫGYSh IDAT$dnҥ՛O?.qZKGv}CT(@N f8+WoIe?\<9aW5X3Gyty6 6 )" ]# Qr"Ox^D(̬PpU ́bܚ? }8>8=>ѓkQ0R ♞A8>~ 0La',0Co<{چ 6tR . <]VfT} R3 Wڋf[ t DC ,2OF h 2ww` +ES̞]xQhd@ уaZ3$cD,0"2FW[;:YW{4YD33oAZ!1ˢ<<Cgю`C9l/^}Kn20/N߱U{H~ ,S4IO|x&(͏4Yy[== VJOAɂ,wGmNxI $`힞wf簸zzda-tUuݖN =^u)ܘݨ|2ҍܻ1+Oοiv? &y]Őj57~|riX d(\!˨QFz4z.F|潟 T1)p {0,B=E꜄*V8cj5Rfߔ )U,Jf\?'!^J :%wӨP)D# Q2%CT I](O 'k)J@5H0lФ ̉ꗛwUu%Ա˰!W`]O\ R9ZR3e,g@V fWc/k|bK :(B (@ p65G\JA,wl| "))"i7jS+8/V.k9K`r V"N0V-@8|@zϺޓzP]JD"Xb2_||oqU{%IDdB)4tD5n2UמrqJNQ뫏S2tO"Z~%8ŷ[fдr;..y6*$cx7,fG:\?ަGi[\Q'TmPu {Suܭ8n F+ ~E$Yg']o(2н ukgW5jԨQ ˨QF=z@TD n'Ѭ}F\]^?{3R*` ч^I7v-;``CAzD)`D֥?o=(fEAZp@,H@P)%P,)Kh>Da=W~=%p$+-̠(R2积KNo?.a M'"3vHSI0:6P8?{3{w ,.0$2].]E ͢(S8*gHBV˟M&^(mkND!Giv 3ڴHsku+ax+ₚ&pCC:NgD/݋A\^>.p|R>UUN,߉|_rnV+|x 都#H@@u)&DQґCj- a Lڀ.kk{͈_,R0F5jFeԨQS nsAM7~VWܻeZ~,&O/S5]Eq8wI 1Ԛ ty܋@8j$CӣRhCRf6tJiB4tv$FQC@6l0IEv*h=|h1T<VfPM&jbgJ81;;װz&$Apjo8$OY$#_]>ZL0`gEp0*컴(2%p7O'0diD1Z'WK- Ɠ/y\K]6C@&#B,@B UVp[Ц9_GFq$[`뛛8WL%ջe!:\/{C[Wƹt-SqA(89>x,l8'$^llrГB%yӃ6;:# *@,jЏ̉a xpZ7) ,*$'&Q<nm|Uv=ϴ8=*ZW5  0xV!TѾ۵GÏF5蹌5js*t}lg7=&n^£*w }idDi@L9ci6F"!b0該A8a(m]gυT*a`(hF*ք͡G*F`Ӈd0.(5Ȋ!u-B؀R'{x䶻mdHFotv#+o6N^3Ei v(IbS( ٸ,[tadr嗁y Ű/+ uQ%Z'D H 3Q 0j R88F[)R47P3 ʜ<,C:R>"D<,b }@I&`D3ȄY)%uEr V" Tq{"rX5,p>+<}-HLn*"nLu mVٶ$A@2uT)R[Bhn`(Va+o lk0@^ @~輰'9&-.:`ZmPJ 0"ޕ4QCPSN{^m;FC\- +6v=/YͿ= [RWj_g4A}j~_6jԨQ_˨QF=jjX?o78?6'cP7[_ "pku KViQ ]QsX\)뎰+ 6v9\ edKB)p,M֘ & B/YRTs)"B6]w1DJ')1{k> `v yc8_|;y ^)JX2RG% Plp NryOw"a3gj́E5n7H !Jۗa  & 5xc\YQ>$@45o̹m//H}z+m\ D`<<? 9-G=tS}Z J(,hv/=3#=7ރ-UmNxh拳? yƻj*8=/Ww jqΘߠg$%y[ RNW cu H gy];O?K2[(?lpʻN^Q`JB5V`QGD$j(N&K>L:zW?H_$!=t^ɻG CFB%"^ %J7Sexj^2w oLEdDC׆UK1 qȏ5jԨZ2jԨQϭBi& "%k0c"ٙ(8xU:ˁӭ0."LT<k+5d{_$>a֞庪k}磿^;|@"R0\,Ġ+B-?) Ľ#6y@Wbߙ:{ovUܹ7!2RFS]Uti:#"̤b Pxd!$: p% #CUZF(?5- yrrwzS~UN "k/.ދAt78yVI9τg˳gFȒ_W9: %"Vrz)zV*&ӯrH󳷋f5OZ gL&H8"FN*F*䬔Sˏ;A rvm EN܎Qus;mn%ets6 -Q⷇+>2dH祿|HȍX5ߎ0 R&-τ3$yaf fEjtMcU+}Na: |M1or;q4?/>/8?׮B8֑Ch6msҙ2ޚ$nE%Z$D22B5c6{~xGZ7D緪ljo!(* ֬]Ie#F8Wߙ w)(j> #(ph~{{hpPa@xs=c=u`Ϲ{|Aq?Dk=7R qf- bC8܃*@CnNϵJ rwW-r7?  EݫPC=Ȳ!$*S;'#Cd*s\_ #%I֊Z16mru)pxZBY¾r \\}ʮ"Tنܴzu,مvvzn+.<B GH`B[p H x2uPw6#8!&l]DËJV8ˢ Z:flg͇@/DB/=qk-wfV!RȱN=D@TC(N= p|</܍~: MtWQ9 CΗq| Ёݤ1_ph`60NK ~J bHɯӈ[bkwBV8 wW*ݜ&A'{Ğsc=|` d%f^s k͢W]l^/?TAgN)"cwh@;g |V8_uxS32[tȘd(NBj_"ڛWp0sF :t 7C{; R3";<`(ڮ?=}雂U(p(n`PcY'"kwfV;8պRPt>gt["i`6_Vl 2닷̰8y%bwKP5yqSk J8!P > S$% w@؉~?|pH&Нe7pߩcLj581#lh{@5}7;9J25 LZ/4DĨO,0wUmL[ޡiA)XLg*pZf2<Ŵ6B7BG!<8NXLyõo-b֫}m>Lt,HC3ЂNj5 ( q#!=YqDxz',7mojбb6PN[kXW !ݷC+#pGD.(=OKnC GaFRB ~+{= ={uZDG˺E,̔-hq\aBC-X)+_ ^"L6}agDBO_/h";"<(f6;PD0`1^g*c3Bߤ@i @.ȋ+YxH<2t:qTi"۰Cb07E0W[7RcDEO!bq;IOfgE ,W?r|m[s2~9> DQx.2stbY9á}D,HdMÿ,N m ` ${R{BRS$Œi6A;x"P5$;WywO>E_9Sgٌ\};T,#7f_V9'? **k2n֫aq9X<6"[ ֍Q;T1?u0upGf:&@ +|5_1?۝p,ni~w!m0=G] )GםeTCfl7uLV٨럩va6y "b /~ D=C`h.P@{Ct$}͋ns6bfw["}p -TT>%{ksc="s{Wf0D EͰzZ ^VEhsn(;(}`$I'IhYs#b*tg-"E.r¡ښ];UTG!0`8)͠HFJvs+.i>R 0"q^}-yCKt! MIJb ov'm?!=6}푺3v5`@FXN%nǷO/A՛O֫mۖI+p!Ji;1])av亮cZ{=ácAȈ8"H[Ii$4a„ ^!L˄ &t٪ /@r>/)l~m&BqCJk@30[D-\.>7O?)0 V&[GB!(z곩ibӽ5.湧i4Ao  s(hLTF@ [BLܓkSܻE#5 7 C4<2Y%ip'?ٻg.-N>*J^Y}&[N`30|t~ס?87OP/Jy }?$܋ZS f艫G[<;Cd yNt)ܸGK;_i?Bznt3WpxS:\PHgfwwWfM)2;dVhM=Pǩ\DVc],9vO6?+7K}Rr„ &c\&L0W9_h2vg \8ȮPİ֓_q$ȈЎvh 95O|Z0AHQ‰8f. HQ`j9?wm(܂"5T!u< 2d47 vy RiS+@Y|-^Qۊjs+ܤ -oCL`X0)"ճB5˒D5Bzf9~.\3ɻ5j[U =JٽD}5t"%8U Y Jg >B{@Up CBeC"{H(V$*"ǩ`Ħ8Hlpi2 ӕ,ȃjBTUcAGtxi-*wRDS0khK<*P͟_^~yx A)Ζ6fpk.aE56IdLjefS61fr}i_`8L˾FEC ,#h,U]+qm0Kla͇EiD4S㕱쀎 zlw_+~ 7day:{zY/7G֬sJ2F31Ͽ?M IPn͜#Y2qPYvՊӟLe#-\9|;:}G+..|eí{89n%$dFm/NnwWvprztIܻAcsHVe~ vpbk&>HC֛OZJAտ7FTo>oǻ' "Pk%8/~f\Њxq0#&QlHq~gv71P& kfG E|rAT+yO/}axBFP@@ _^VglbPxz43^QY20ƣAV/D@TP+>PM1tIʝ/OM? ݵ6/ {w9t!r1s@|3^XψF$TtId:o@xʁU%nBSff2'BP"ġQL/I6};#=Xy)כy.] ȚI0dwAtODf@13 a=ê  hqbv2^n?ۏ,Uu\xB"8qHNP $"@x)Bl[ g^y{`x9j=sf4}Rת~Qhj%\9l!^zTc3qhڜVFٻl`ٛ^@gK PhL2ӌ6 0&~vutvqX<]N0:,5%UoXM2}m#?,RW}5q9œ9 BDi*Ѕ̰%ND EF|j\F5yo/M6I dMK)d`>{5 K | NTCj ۅ>{e3KC2d@z?Y˂ޟ}g?)B0l8%9K)1ĽTE&:Dj.@Fiit~lElkG<1в| hw 2Ҫ%);Q70Gl&)7Q8 d烃ye. ÎZ({5@$CvQ2Pu{1 YA0$V2R{6>1vifXiCpcR!~whxrmSJ$CKyLF/-[ B0C"2ϧ xPPPxi!`/O.ߴ j=mS!A x?]A j++/'Nv;˃WsP-5s[!'?J=>Da{C++xlwc%ؔ\9J2Yȳ߈) f!Q5PTV0S 4 tI0P( 7'4d^ j)#*bX|N:'1z4ƲǸ> 6Hu9.Fj\F5W\3j Q}iɏ 4x{MV)SDhd I gU>4dw+g4Jܔ0\\G@wIz$k]RJ[*Oۙ-n ۝kԞ}%4XiIn<={}2$CN1:۵bqEi/=-)ozffiaHHa-7j&{SJHDc&a&$NO\x,i5~yjof_&pf` 3T'gDRv%#M Ir};پ3D|񥿐:r+S텡y!?^z雑X^.ݮBpbo3_4˪vpYcbX cgEЈRhh{YNVnVcwRJ C#3׏pg g)xwNZ?>mVJ$ԚA@O׶ޢmVĆ7ɬ('@~WMؕM۳g'yJ 3`涕!Gjnb`)tAE9?s@6o4@/F3j+f\M`  V\Rd05 $7=nŒ"( , ZXP-z\%L4=QFzN5z.F*|6< #$LdsH&ؙ}t_~lm`T!zGXaKBCeoyE ):z"0_?N_$5sM|u|^ eKXfk|>Ӯ;WUL:!py _ 7u(Fl7on`@pq/%^8ڋw|PuWWA>9tP$RhJGYV+<9xZK5۔F*ݼu ~x>6W Ojo?( ;Ҧ?fl%epC\%jLӐ ܖ1YO(A?cZ{$Z{[S~Ll Hl+Joϟ~S0 '/~ZLXgpu  5bNvst+Q}jNu5Ӕ%)X9QNPnpw~<2#oJ.lGg® y8rR/#W y͇\Ԟ]J"n"+X_N3欔i:#YV҈DzZiW)]:!)F#bX.:Kn.q>4=]Wh ]0,eRbeG3dkVaCnP"٫C@6tB?_.1T}uAÐ:Q' CPY;;^y4:Lb&5u`{eEItdciS8Nz I"ERHbdj0PT ʻzDcun=c*{k0uqPly?|ؐ矼z6EQD+2vhR4Af.b$QB YzĎt=ItQ>l4Jg":H%qیS2cLef:HpM;XeHCf!lϠy$VbBJ\ q/lJED m$YN%HԵBiqF4>=b35!"fZ0Fr#laPv+ճӚF{< XÌ@aDڴtF6 =f6{¶Te9WB0+= Db ╈5p- G}j{sQX &Nofx -*f-0WcPTq\'Mvr^GΣPhIU|,52ЄY&݇h¸@vX^&uqyZ/;yZL3cZU[Ͼ?ܺhfژZE|5Rn̼yDaPiGWQP)H@s"Vw|;ϦN%ATTnyB04Xwե۱?^#༝WI-9ÀR@DXyx{quq˷*4#Y!pX|#9<>籐lb3!gHCIfwYLL%:W[a)3ىȍ89ѡ1{If, sG<$.Vqǧ1˫05-kc=㷁={E_4{#P+ӧ?n `0P6rѴt١Eb ^m)=Nq]5AYM0m{@L'5ͩǧ$fF8x808r|pvyp[fN)YOjF ~'Zrm٭QDEW#qy)PX7O.ޯl~( PGKcu\^|[d#,CĒl<20ِZ "{IFdQEs[n4 p QU򾀽^Y@Qbۑ0&Z*mp%O7bX~$%@rDbhƩtN]N?m_v6bx7e<7OvG(wGtyF/o݋WL3Ӥ,4 ,Bw.v_ΗAg.8t]B z[PAٝBI:nˤ : 'Qc ż<|/UUJIƐ, ӜPkJ=Bm2/x:R03JahYyW$+8ꨣtuQGO_'Y9K#`3,Ʈuy#!zʁX=Hw(B.OזsY=F2(tCܷfO f]݋9 6 0\-WOK95H:CuaamHLpZ7H4Z~fP떥V,%pX~LGT*P& l}soMEI;zY@_x3~B44?N~2L$UtXB갉:\+@$"y  {h_h!r6E "#6b1N=G^0tJZ]ݯhQ!A ==,&B]m}Ep˷]-?2rkō iVv-fF984vAuE,CĐ7`۫!"J ku,OMOk,fQ`~/3Bhz䊢 ރYiҊ"y{؃grv% 0\1b9g@BSSqx9ymE.%EjQnPh/eI+ye5ZXoI!#0cZa t[ ,HR*xnvdOFQ U@A;r(yR [BnnU0i}:M^kQ $gmTH!뜯۟G`:)u**G~~? $ 0po8!z|Q}"@a"DaΘNY`K Ckr4&h@UD72.v-0 0"Tac%]-ߛ}4$vD"2/40GMxD%ڿh$${zK)- DP髹=.`3&uZWdC%cX5'L*ujd-oͣ:ꨣtuQG0 􉪦'4PhԙЮ/~tOճj?bk fFҐz|O4sl|2 9^$r$IdHx rx'._,Er_q\*c&΀ ji{6B9T@Ш(Bcp7O'Ydn6zDQz(\V TI5ؖ^GXE<)HnẂr[\%R^4R;䛫էPX" BNX~1hjhƻs亮Z{/$gdS X6d]( bCG XXJ8 ]d2dwWNUd !zC`fHv>kk0L @Pœau`POϲMP&&4?idHaRհvLW Dj%Sg `?z>  8S528xƢwLWg7@Cw"ryn"`8\xS!WA;48Vl*$dVo!M<ܚiRόa[{ {{/ 3+PRtZH׸Ӹ<=ҡkHM#EPO#ObJM{3+I%uOjb um<-H3MgIdb4KPv]Qt//(<0~ZM0%ሙZZ6L#ƚnj}}i;|VPҜ@=5lV[}]\ja?1򑰚$ƽa\dӡwE0SI4> Ͻ& {$L ݬ8H  ZLJF󆉑{a%^V⒭PNU@spC89x 0:4 iXc֣9>mmuJl!EƽImBFitK@qCJP0LwamLS!/G pmeКiZaՀ1)YïYmecV[rA"QאG="w>!G{$wLhQm8k{-WDB)+ȐHy`Ȗ<'?>Tf;O`&2= Od^g$j.qYx>f@Q*XWō IY ]Ypr];4TW"fݹ}n/vjC۞V[msmxtBvS3g6u26N"6/@V,5%&dVʬM7NK$|zKTm\)ɔRGgth̃!g)/wf=>B- yYkRϻwS[DT rN2$06璒P!snB_7,8]5ֻweKnrfLq|8}N-,~J_-HtVU!nW~p>|wCw(B7!Wӧ?2젙]F7 (DDs)uh#=r MI3t!G\ڻS/04mfAlAw-4a_@lwDYfis&EԽ j 実S] AP h-x:w^wtkֲtDM(J_JWO(d H3Wj ]r#y "9px~r'//-,ҏT Wū^Yi~Ƭ7z%#hf3Іk^J1e5X}Pv5X`=ޯ.j( ǝ[Ϙ6fVjO۞V[m7PX,/n<& Rc4H\8 lF,k V'2QKQv|V|^R;=s^~X蕳'f YCx|<N7KCtL_AK! `?z3+)E4rVZQ拼%Fx ~"nb)Vx} {^<V8Do%dS!idӆdK©4 p$ :et> #j_lH+d4Sp`##Q+4f \0Ffx1q'B4NNu`#n%f$gwj(ZHknm YALJK\k>^Q^`&y]rX.I#H;\?D?zcIXw,-h ܋I}z;i.rʄ.+hw/Y5X|G:,DOh$VZ#,4S2sv~O@聏A,.o #\U-b`xu{ 9G! ($-zWA!lqcK--aFtDPM 2 zS(ux2c{@ht|XyBGc5?$,?R0A Cj\ 4g%iQw3#x(lKHxkg~8 $84dkbE=w "0Up*"qy DA@͌? ~~"qXx$zQ@|#b]߽rH"U) 5O%9%&UHuة8$@TIBL 'Oơ_SՒN+{ 4hX2hРAPjāKejSA0 z{H "09,o<{=y}Z^e %ZT&JUdN^, tʑ &h'y `.UKhPt*ת= F#.EU[wcűzlUϛ%ǤҨ![#VDc{Req:{GEa1˞ER@@"8%XBD$Fdf7ç36?mJ9eO$#+iubWJ?$b$2 wVc\N&vkj PA PQ:4ةj jб]o16蘤^@8A'N шAG"'$(A/(ǢMV-o6G(SKGb>xT/p4i|lqT:gw42` t{VMZ+t :V<ƀkp,r<',TvQHΘXZ/poL_Mp4hР?eРA?B:d!M s" TWy[ޝcU\*ڋV?W?ܣt`0EC1 h*1ԅ&'E" 'CjGDnY#@jtt2b~bt^lj.&h: b0!vujE'WkS`C{`*(su?,zuqD1 j\{f#;meܴ@`Nx=cQNюXZU*d׿jDP+t' ]ws{`o !PH"'&`1|1{bahDE HUD[kB9agʒٸ\p8 hDtǏI*]\CV=—~L$iˋ0RFy7n>ut 0~z=4G"*RpgFIM]L3=&*Ji bBbWf&"|TX"8}`6q528^؟@]'}"SF>J,UpdA62 _^|fBŗWFM$ZHdQGP1=}O؝c]䐨e C%n _V(p4ա|v.ž`Vp~sntz,gg)DAu"$ jɎ HV`E)$ V/w|A؀ųũ"Nme;ǝM&WPMNjdhV M nvGbzZ[y~@?& t-fӿVS)jШj;?Ϻv&X n7ydI_z3DF[z1wUgE(C uڠ @\$:(k n2< K€ !"b"r*W60}[|p.z/Q2u"*D 3TG]f&Ƙ@&NG@„?,`2H 6h11 )/ NT' !p^Agͨz&^ZYTҰ}@jwdNQa8TׇT R@*k@D##eeРAm1|o$64L!F3Vg;?^+2`Yc.3[#& ,}`2f-eVm:YEɾ&5J0+SZl™ 8.U"j!2cilOf'V$Rbzuc2A#*AVgKyC< eVd.`'ʽ-\/.^hNJh]PN3I0 ,jɲڡE4kl6`1=h{}6(iRe9#q;40| 7\T%YĽwP$uiFZfEKNtBɘSI# mh `<lsE3(@qԀ=4@Ӌn~c Ad0tJo})"6N]v%aЕ& :?YnOfOaBl?:{ȸ(L<+@ *!b,AC4dE,ZcKF-i5A*f8#t 6VoS|| ␹+~}ÈAj^Аŷ3>qB2;E*2?` NjhiJS@lw/k~݇rȊvw4׿\N<he{_v"F#gyQ3I}`PdIrZ/S 7We#4Ic #EhbDf3FS0sh¦L޼^?G`Ck6^TF جv.ռ#I ,BF;K$!$0?qj It2{"JDM'JG^nk/K<cHK7 #B=`VJʝp~B l;UJ"U ]gi /PCQjhGuQG}tuQG}5\84<$_qz KFU<;ņ~ͿC Pn.}E0~7ٶ̨'@\~83As?##ѧ\uX @dʜO]'"͝q@$VN+AF jtkyhEe`aU`0܉'vzS`7pZB4Hʤ9;i͞I:v8GN #-dܦt#c쭬pSXgX.~)b_?t4_|LlWSdGgD%%ͿE> 9n/5s `2G853}Wz`jNe:ʼnqJ+=p$bVRr$fFliʒYZ~ id,#? ˋwPf;y#wH W  8KZ#[Q3ByЩe%(#~>q-cefQ" Xο#9 *N:* |Ͽz% -VL,dƐ2՘r6_ ~솚윪r*촯evmHdƟ5.~)t{@s@ 2m<)>!_}C4ƀ$W˿fyu::Koi.I j؟wBvSo. /f'AnZ9ݠ">-ןϴ|\q&M|SLY2)L)rHEm;0EYzj/rp$j@8>V&e+T)WԌ6P/].D o D$Xm?*)s[ ^Mdds=tg//Q.3|xW tjv{u~PhBq*\@]"hƒ@"e,Io('[KRB\BBa'N,l>TMQsDux3gzb%e+FpN\x9Q5VXp3=ɥ͵x6"J py+fw]4^# `RkNydڼBH| !y|:z/=3$Vnzr> F d dcL[L_`2~YrL7 M]gqw'.,!'8xxTԊ{|q4x`>יm.5% %>{NxL! H9trH5@0А~*1?{AWLDO!U;6#dCd!"on@b4zx~j7`U=1I>u*YSnBWQK`b2zAHaI=Mmf]14AuLΞ?A1(jϴ%j@2a:}9&[,>W& $@-*@Y>LH&wk pQ<ȇM;xuC鬃rCPOinϞ(ȕxq)*pvvIM'| ! "F+#gN,&gcGWU-Wwg`2|Ax" 姳#6 R\qc@vؕ>r>zOg侒QQ [h08?ɞN)p )D뎛#U  Bmq!=%D}jc*6F\ &(>8;38nfz--w엢u*G˛(Ԡ`2G}X=);HƏih,+x{Ac),.]E\dZА 77V&&ZdJQ cۃѣ|P(T+;(qfDVš+Bcj8֫{ыI0':)P PKu9q&gsZ,E֫ϠEu81z"Lmr^Jt3P蘌^Q\[܇Q;}wDwjuLƷս&aCϔ$ ٫gN7whÐ")* >/)գ{gg?)dZ\|b@yR#x"j[X|i CA !xׇّjכ@oii_":zZ,ܰt%lV1'1S"-b4[Aﴡ|5պ],S" Z 3؃OABd~^2lK{P:ԡ령P:]F+. s?6`j:WVA¥lZ n;Z/`ʖ !hѲDId`T21Z 4D4%Z}vvn[Uۖ P-ώ`%xZ/V_A !"(@Vtt2B|q8eP H5`S/vDg4}Y}P`8}Hqo p:``2&h IDATTIdUĠ+OH)|3ٻ$]-fI%Qߟ3݀}(+M}>?Xz=2)<{^T@%e6JmAz0 P)v$,OQ8am@JS,./E1E}ME׏,;8q6m  a20"VT#Yv,~jf(R1"%fa2?t[̦Tu f"NJwD\]+a .=PƀC/}ERC #1:<[j@a"̓ 㮜gAWoTm$ :?oe<6n[Akˇ_WC *Y3E{V!NVrBOR]^Q_קRDT2֫OWNJZ.E3RBpǕ`zts~,]ls{ jp:5$.u&)Bn\{^Cf@=k/uCPOY4CPzq#"IkHhhT|Z;j@bBN KՋ}5SdJ"lB7|K`e!"]cC-X,?NE:OgW;RTq;&[Q 'Dk`Lǯ@O+YEUqF?܄jy''2wH*x$u]ᗍ֡g{~NrCg{قP >u&m6 XD*ԤUU&H@"+f7!8s@U%Xk}^3h쁱&ͤ=okNuGٯ)>M^_n> akI-N[bIBL"#$"1^e&2UZT?;<0R7OU 7kqQN,ƣDk!<%<3uuy7) *&k}CX@VՇb 7S ܪ ʆd;K|ChyR*1Զ`>\ʊϩ-*ؖ6}ɰ}@ByH*7`z{ϼ{HoNI 3}?K;/}~-f@g9C@e@$7&%NޕCDeǤ@'\K*.BEh]Vj).n'D$ nqaQ"t] B ruQWqoZfo3SnuZ-[$DptJV[IԎuvCVK, w7i#gii6A]Y"N malEQ5z4XJ~&[f"s(nܹS[23%,5LpNNnp5@u>ܒf myÙf fvU,f[ٸ>v: {YJ/cA3DZ|f _L微_?ya-LЇKBf$EkIO]kؽqth42Lx'8`m}DCb^RyG%I3V0e0dmpbكC4H`x83̅ zx%=ZG"h/GuQ/风:ꨗ\mVYU2@ k9-/2d1ռk#A||yHYvqW/EyYv<;[Ĕ z\>WfW#¡I gK^~29ex#U׫&73I^ ()Dhc9{#sҍ lޠ !˜Nбtݔgdá<^mެ|_5_>C.K 8,.:Us-q:yUX 'J74!Αc3Iwk%WA%A;,2%jYYW\L_#OE16v ) }v]winwϿ81Tǵ/PaE6(@Bzv:: _?27 źͺB}|'D_h5O<F$LJ;32_%c({kPw2ͬFn_p?g-b].Tkh猘7~+eQDkCp +H!MYϿIz`5*q^Nl<ެ9;dﺑ>u dTD3@X_!b{D_$vcn`i7(fƃ4,}Y1y6Z*فubP h¬DMwRrZ̐= |mk `a {x'1%,bAYjo~muݰQQC R,VB̐TIsp N-˸0VggDΦSR)g7̇@Ȋ⛐bߕm2#L7c9{q*?X$6ET6mAb1r7ת]r̈2O:rjK3Dؼ?jg)4ǪAX.ސnJRRl f+ОC:1[kbIݚueܘ1qfF5$'sOQX \.dϧ!n0{PD҇d]]1_[vicl4@ûV<rѧF{3 ۰=VfRli!! i4 s\2籟 f<ɣ?8b}k>~wviT16,3p4#]f+Jc ۧ`Cz/32˃JfWjj0꭪F3PV; DIՈ$x1X{ƎmL&6|,RT\|zDݯ7HؒwGFp{ mD̀yHhȦ@Q qSB܀Z?.;$`6Fo&"%Q1I! ?_#/"$n쁤2hG娣:s9ꨣz5DU(M2eԙtJdmxdۈ"ltAOy$$|m18w]fZ TN!H~@>6&ez( X,%Q<£7?z^f%`yVFnQ7 @c>}tb8Um0 s,}Mt'C%mDPr=Z~c{/x? ,];늯wHiF"E*i"HLjo{I!@ `/㌧qC ̈Ey^}CɎOu'I3HsuXa?Ʃ1-Py7| ٫}>7pvfqJz|\qhFMCo8ߚRQ)x D`yzkbZkYA<^ 5X@X-]/o;pZ?w D!qmЅy+tDCȼ5<%̶ 2BK2#{?ţamLN{O^ՌK GcvL#@Ó';h~#azHf;/YugmsK΍`X.?L^ B>;ptRz1+@CE;W'?B@v(vQJQR2E8][^q`|8%;ze@a}aجVFj{ !LG &avzZFf6f@  d~..wwW &8w艮w>:蠃rtA?:BٲHŤEXCGj,HEŦSD% .팡&j~PPD_ξq/gG急c(zDtn{yZO 󳿓^-pEly۶0@VWUO/~=6ʡM= 7.N"H2:gQdj/J}+))Id(D.r:^hg8r6˹8 u[^\>@FBZ?T ˥5II<_]k!jLQFf4#g%vǩ:u|^|!g50.ӢRϿ]p6{i/VwDq/wH_KUGr) ݰ?O4rHc6CtW͇Gn1;y 1Og?hKen_\SP;y[mU/IШPpНP by82n ls *0Z *롥 =XEI(4Axn^=#ƃAd,b׍'Cc6y)!-, fHwzP*&wLL͠ k^{,~X>Qe]:蠃:x.tA_Z 5Nw>n~}Wkq'ʨ7ikQf2l2PozH F 5hde$3>lmS-ŭ%A+9r13crj>iLЀVGu, 2D$v;LSH7ڂV.-8 -ͤqXOfib"ŏU+st *̙OߠuFI=P7#/m"!\ VnshqLyHBcnM?Db>{=Q:V!LehW.x}HtA}Yu\:蠃-AuBۗfhҥV(Cű\|=g?~JU\WM  {Fl@۽wH9!Tfa09{8LNjU,*3GׅB bvt&}c G?nn>{iVQ-R+Z*$)Ɇ~ܚo6#aӗ"tG5AHGzZLMFZc$n&=/X|Zan݇! a}PGt^Stb 5jE֞/TfaP|D.6`ů ̣} wCC/ܺI D)Q=P>1Y;'uQA Ϯ8I]N&?qۂ1y缮އ0'IלySjq*瘍T@\Ϩ}4FJS7&ӿ/~ZdBpha6gO+rXmU3zꂟN'D/d 8J4\nјFL_[?H8T:s<:/Z}#1!zcso2@L }v#c( )KU•޲ݹZ{ov JHyO<>Ȥ[32lhɾK 茖A:&t.jEQmwWX(ne fyE P 0"x1Yw3h tڢ[;@ f|wsi۔a.8T$cϼ Hv17 IDAT($2E/v w#7 &g4Ii8ϳG؁ @MA&k.oɱ몮3]!ƆP<Ha^_ x.CؘǸEU0R?ᜫVv(jzѴ4jsUi/%𒕻ATׅX^EhYH݇m2o>݇SUaC8ֽ{< jPblȘ!an40POC ceGgq{:}s+u zrp\{wT)Rʤ[LlJ|ק1+e}ҡm_Htj1M}1bĈFeĈ#uԎݤEVB mTQ#dhmV߹Ѱ 27-VץD#@$w^ /㧲-K4,WnWɽ;?{#tBD-Fn׊:΄]h$R-qkQdmjٟ0Ct1[)Ym{]fhJ3 `ӧ5ã}fUA rI7eRRE#.V?W竏zЬeʚI؛`|? M?PsYtj"iDIܔQ ~- zve3[>;*S~/ }M=yj%P:GY| ^q\=쉮Oz3< +8oуVx@l)*!٢| ƶ}Y"QH3o"?.FxUFO2*;y fjQ㩙}{J{]eI6G&fo?DVNޜLJE*|zpleR91-ZZ`AW .axnom4VF4\TãE 7a>۱TQI* \9.Hפ݉>o=ZUlh1bĈFeĈ#]pPs<}-֏ZBDP}d0&i˸23,kSihH޻U#7,EHuTqM||^ã],D̾H狳5Ԉ0y[4S@o6R;2RB|qb"`>(rةV𓶏}F2>qxe`&BAj HڋӿtcZQ709h l2B7Pp1NbUa8XKVOISUe5ϟ' )駋iɇ[jv_$<=}1`By)"Q::(RK+GGG+G^ 360s>Xlj&To]}LeL* zqa-o9'tA߸4'\%\ʛ+8\cAB2|2ʛLVWoWt}z0~Ɲ$NnTl';bӇӀ}*433b沔89bV|{rB vlNǑr?ZRC<88I,h5bw}h2;ͳl,01bĈg#2bĈ*n>3لu͎zšLQUAJ7ُ.̚-17A{L%9X,i:V~CГʌ1bĈgˈ#F<[R8 .}NMaNV{-EٟٛfNtDWS$L4_N/pxRlץJ2Np\,ýd)n:O'AV?Z#jc:ZjĩXztyCd{g>Oⱚ'N3TQ;>\"׀kauN?~=S}7$Ϗ?yf6kT.J@RAfMy/ d^I@on:% [~\&FGIRNqzC3%RϾuoxiTR, XAlt3{r7|۫V0Պ!qYGrj!DYg q\YhhAv^U]P>q~qz ^#OXNQbpN-.y@zƥplC҈*|ׂ8{NlZѳʅv*R;;),o0}Z`&I.{0;|HiSKlEINQM[pТ!kimܘ=aG1bijs1bĈgn㷆1-QLw6~tu]T Y.4 :܃*K߆D9XTBZ5" As'!$la|6U:iM.O;L|p^b7kj7J'.$[zgžMtMS[҈5LO0"@]V! ϾzF>A FzX eo >u tJMs_TLϖ)L_$)m򿄛o2uT10Clb6''[AWj-)1V@$p~_5өF) K'3k4H! f#n.݄S-%kA [oHO*xaDl@ÐU?D`+@MkяHIb` ӕ1 KM;&_|wG쬞}i2/ ` l YdV,,- < iYTg*FdVM۸qj"nͮ{yWbzٿUS>-;[ w'9<\~_Ѧl Iݭ\48@ak-Aznh!>!q}m䊩1?D sd}@HvN2BtЏuw^>cƌ30s.3f̘$4umn_Z PdvqӘY l*# d"nw٨i2to쮣{}͹z~ ߡp >(¥Zo_֝d-nƲ< ^^HFEF4躥&_[_NKh2R'.ѽ$.2de\\G8<Ο~+F_I~ 9YL2dBiB xG@g@R%@@dLpX VG-~܍<<3GGoE< SЇMCRMRNXQ4ы][ 5j=n~t ["Oŵ['ٕhc_359M$ {h4 5mDM>mdJљXl/6~.W4@rc sraS}^IH2nH,r {kqu2,bx7@N?`88x+|/@aZ?=@~%^\|ރ3f̘15̹̘1ck%_,; -}i2bIUIyy[}+LJG^"H<:yW-f[{wE`d;4}LK(u7w$w68>S,I.k6\ukQ#QzUʂъՔ1g%12½H~>|F< 4UEU0+ LF$SAǫ7?9;{b@V'oCa)󑪐̩w p~rvL$0V j) Rɀ#+?g3C*H2!0t[Wj&xpvc pXH%@f"yRUJK C^X&Ծ=Nn2c~NI BT uO)d p恵eⶪ/(o XOK#@_ C d]gs+q_ 82=:+d? =H6 M%b37NOܣb+qo=ݢTdDyD>7&#n5Ь"6V&t0r|M df"o6a6$V)Kg˧돭H&9@ V__E1q; $ KȬJ$ ƾ SQpaVrMlɋ bt:X_5g-s+uq b,h [sM'ye Of˴nƥhV+cIKC:靈!B@ވ:JB-p v7A$Z-@JNh"r?Oa4u.I hv=#FK3f̘̹̘1ck*''Z  AZMW<E0 a/c?%zkrѾ0b>2;ŸD솼Hr S8 g<%(+X7s0[ku{Ɍ>[b~^5~#6ET(? &!lr4nNBEOr{n9a= <>~g}ԹCnapyGGo)c쨇l1QtjZgt (i[ `uGRfsaC NOTB%h;mNk %n!HDBnψK`$q#SGwِ] ̭ׄdn">pqa[Arv5fYmD'<n&܎Ctk s8:: v+~ǒl7qEOE 6dȈB"ɗ3;v]Dt ،c] {ؔ t O#:biã_w;Ğ`CإZ0[hPZwMYn9X6Bz䎪*R^+eۺ2jaܻ%%?9yzK?܁I8?}g^KVn .=Xq~N*ߤbJ宙 )bu]Ŭeyy`w.Sk#v zXKO"Gu gLb$5>""qv^{LڌBl@zL<3!";qz0ܣ1 I(󅷫5بJb;vJU$G/]vy̝1fKu*W;;ܺN2MEJpqLvqG NKVY;'QS_ۆ1|B} "DbKvZ8r(-#Jݐ0 .oai]ʙ`kІ Qk~ad-_랿lSAT;;75!6[MˍGq/\Ѽv޸S IDATba#W/:FZ+ '$fbi$i+@3e Wΰ ڵt<[xNd? ك՗O~F!%ZJjn@"KT%Xl t= ,s_`e}qd ,i#@Ck5h{YQ0X_cz}活ezM͇NܸQP I4A`|n~ƀVр_n‹_bmx5o|ŽESKRDZWpLV)*21őQ!Z$$o><5+t\H箤֞QSSLߤ28s3Jgh3@c8/ {w 8<3h!:ыБB%-^s@4sD7!)C *g n3\\5Y:;~Q7[wHr &LĹL0a3t L-3^s( >.B'_'*>DX0 ͥ6seV#vv}CA,EDc%ʜu\XOBKo]~\vi ,ec Σ]89)I6G 8;{{bl>`fw4pS#2HN63z{|| #g$ac_V],}̘Ub skUJ'[[ W$2fǿde+"cqH>̋󳟴\"Z}8G6h!TvD]gp;NO~1͝ !fts[4*anڍjأ߻L 8\~!ώߦm~t;C܌ξ㊛FGؠv}KV1c:m|XZ͘^ ܌ ˢ:Z=n3$ 0@ V_qR%m-I={vBISrhȋ 9x~n~75M2 &Lx1q.&LFf+4 jV_?=ڦDee[?O DЊtIf̀^9V#Ǯ¬??X7O>=P>,@HYifCꯕ HT=vMsg`!<De/jAsM[Jj Y aJѯa=.P&H՗S#Dd:ߺ^35"JyY~s8>ߴO5F7۰Xy NYy2pxW<O~ټweĘmZ=& 3^`jȥ_={՚t# ̞GCyoڎ5~z|O,Z=$2Z} &Hȅn* d-V߄/oÿ9clw0-&Lc\&L0 \}= e3}{/67Aj\" Z&%)Z(;]gh*֘V2OdrS'^mEJ@ʍiWe+ Ѝ{[%M]{fu9gbX#6A:@I(藣o UC+Uփy.$QTf2pɀy/M `)@V&#@,"NP\!yi+,ë5f.`Aml5( K7^ 1f19SYːSYb%(b^()A%W+;#1) {g‚d{# ವ =#T5&-rfTdo(%%_m50psQ10ذsS怭 J$/&m= WlCpYfOWb[ҘqsNtE,$#*,šy aAKoȭXYT')3nPDNz?[yӔχuv0a„ &e„ ^qff&"fŤ 0jE:6F>rpեW&)WmGr3W^k[=#o0oޏng:,S$QbЀ ٳ[G{F6+ёARw>8aT[0Uy-)ZIC"@E3>d$I * VRz:@ð1$b(IHĄZW:#Yٽ1o{Cagoh#Gq N=cC$1:efZ뒒w EUv q@FbN"g^%L &LUĹL0aW r–[ijf6S)4'Ut1 >ZB h=4Sn 0/J@h<dKI6WM/DY;5M6;u i ]]lz_E9:>y kHKa@ xFJà~2VU#]m V{$JW};h*{3*֡.nWv}8D`yo'Ӷտe%H۔t}9;=;`U!Bn]:3]uVH}4ZuTVߎn?R-Vcz}Y $L"~Du\/'iPaUpyIab̨uѪډ1A6IPFod^;;Зa`Y0?V,Alg:z{FnSBnEw.jF}Aek81 d3GwWiJdB`>g?4 UuR=IgPdTjQ /B;^䓮tg_ &Ljc\&L09ع੯UfFżrC2 (dzxDw{VA|uW.Hg<Y[*Gg?ܴX,Yw}%|Y )9[̯43(,m==wU%'0c@s 岳r[. z]}}ju3(j!@`mb' L3 OS3[H1 @5ԓysRT&)R'GUUڝ]uR ffv{_h1+ND둁?* }?CfՈxv ɄUEC?3d&=ӻdu`zj mH1/CI3W5ڜ]ڲlZXmK|:iT$cPih0l5Ω4US~l{h Bܟ ezɇ6V6yeO)S a39ظw%hrXsd#! qwm5/3A_Vnq0HL7B ԱU}d&L0+s0a„`xI ( $,~ߐ#FG%?Bx͘[tWMԅ!>ԑww}hdEo.ۥ1.?Z.C+w٭7:DעXFm J~}t$`zø(~&+K؍tWoōG||,,#]):קjHZ=Ն}W Y*#PO6&+L6J4@P%pp24_ސ]<~y 8\~'D޺| 6{{z 6S#î$$&@ao4?2o9 /Bp9#3՜`Dbx8Q$% KdAT(pP`O8vj K9G!p~$6N;KBtl웖խU^D`jj]b͜ ,Ht84:jaAwJ׼Vek Xw_ @F`;_u@fvkiWvD'l%a=wF>IIzs-C-մh'AϦg"kZOa.&L 2a„ 3ά4,` %0KZ~6ȁM%b݌z`иE s(![r]\жL}YjH 4VY곕j 0$ߝ0B  s/N \ JݐnA'mSN3qL(T3Ne`sSf $34_ZLd3D<;$ rZ19/mNO ,gǟpz6퓣:@XJJ7*ýKlW7 nNN?"lJQ8`w%e\Z"T80DLJ[/scYu|h+PmP/-um$V237!ĥ+k&7Ҩ}P 3ОpOa=8x]P-`2йX-Gm6뚒ܩ\Иa"`;eʬǂt(zK7%qRS5Yo2!"Hdg6k`{ֲ':a„ ~-L˄ &<qn^w.@*/jԈZ+Q1.nTM3x5+4%82J|<؊6oY'w観!5$Z&gPxI,%'{^ s^+Wn O`}F gMOŘQj1 J0'Q!A5f͚Zpz]БY@t|Ɨd /vH-ߺzo73W{sr$DCD 7@0 hf'iw>vշq"6nuU_WK[ 4*ǫɓ"{&i8;g pfVJ>rqqoItVayXt2> Őad1C te8XX7W?19:Z"E2o-"'1b?SedNeLӗu/HCB #ES`+aNJ,r2w@0-1FZ% dPR-C͝bd"ͭ%z Y;Őc d5ZaV^Rً҅.Qxb;'$gJT9\' qz|)Ԟ(#p*6Q[NIlꀚp%wZy&R7㈎ z2 hK"S[.Եgu[ꊜϡb}[ȼ5O~P^0]McBBf42Zg<2!dd^k0){-1cƌ7>W1cƌ_!|փ)hژ0`"1t] R-3g@Asb'ɬM{W?s('C@8SD.&Z:{TfijϨZ@Q '%jXgCC./zg͟ 8-8obZz}H[B$NN^tPWJͱ2#)ĥ46KDzNʌzh~iyeQpi4' 'W#6G0`D'^WLb4iU B@X,^D].-5]`໫Xw-ʅ;Cf_~[en<8}9Qja[B' *v0y3e0by+5e0^gwL6JckW[5!yF [heL$ؓ#{3@C)"°?]@Jܑ"hNXb t pMhSqT(&$dȻn;^S(]\` D F4L 8]L@==}#@PJf0ЛMIC8m4ƽ$C>ϋ=W#x{s}zMr}NDyG' D *!¡Ã])w6yIZ3]l6ﵳ:-s0(iVI I X_nVP+*ME2_8zŽ˧Ӥp< ,%DEV$ M>jr 2VO_ZmQ S+Iܐp-^qOu%ћ}Ů$LPS}.QGTDӍrp}bZɡۛc%P2;^;9}꣪,fEtN6W? CL7H*Hš#˛` ptk#g>]}ilY& wf̘1c/feƌ3Ƹۢ=W&#Ϣ:RړTݕoAW5蓿|w#dr:mH1nP7:Vf~+>p4'퐣)mRWX!.d.B{[$UDdR=AB_d `@X6e,! !!3UU]y^<YՌ CTJ8]gr40B0~姠_o EqA (N|BAށ矏 \Ub {=0K^VoP '_ǻo$s'_V =Fǂ(!F(Z slf宔ݻ?]@Ib_ͅ//PW& ;H ʐp$^xy-{FX (ΈH >vŞJ OG%>l9_XDx`pTFDB}&0.YjvMa6Ei"i0CALrn0`fꓯ|5뀻bzkND (7zGe2D4}DM ( P|\e}p%Epl:\x+ b. ax(.u膋 2Pk(4_5&ZN[DK ]v{VF*7M> bwc̚5kևF2k֬YXM 4S%(pX-j>/^8,4 .r{:Na,? 5bٱafm0A|䏀j%֫g*Ht>]%V$&ްy۾<}5Ԋpo>m JΏCn(0A&jŠSE|=J''_r~[ʱwh'!&8V~/R6;0<:~8u d{vde"wDHU]6xw=OO_C4ihŨb1Z~ܬߐn&P5O# DtDqqk׷?Ts`Ľ!h còBJ U/l{3TGYbCrPZvVwT`8 '#5-c1$ыr d9"ɻZhݓ۫Ƃ{ȁ<Ì>S4Hw6/O {fpu'_aYAArɹו+#Xsi=–`+E+`8" ؿw`7pT,&C!,W|Y?Fh| b}edqna\ OE|8ygq6\f͚5ãs5k֬?=~G!Q8b{Nbu;˸:$Cg#ha_I  ] fCEs #r 2!+L e#σcNcBP"V`F.ȵ 7 l =q|ArZ#! $(˴ jm& [QN?G;|~1ڂP6YޡYS$* +܅{+R8B:\j~J,'@jpx"nv/r*0 =* _._/nfasctI>d_]IZƳDx$wcjG.e8RQV *<"ΣF8 0BBPPVhh 0X,@!Kcڑp18orya9e"r+G $B<'@Cp} MZ W߳C[tv'N:G #@d(pzWs9jB﮶oX;y=.c0'G&+HR,W,;ƾ? d ,IP"zawj`~K%z8L͚5k֬fe֬Y>zi/~K; Ad1b oCkavu8p% Ѳ6}AN ¶6Jգ.~C/DMIw7 HK!(c K?bN7¼JBkd= M \&"¬NLQ6oM~\p[rC*{x<'dP SDB{)Ĵ"lcወI| f%"Θ! Kq$ғl hI_CTr4u^ӎ90"u Q0E~~xlJz$qyN.4λmRRy5|\ZPBU=J`4 cPj+0]RI5J(ep,^$>=Te(E^l5=i7R"Б{@F,_|1$(@RNGnuÊe7aœOX}x)Oo~P(Gp)D|iKKv$GT:9A0F&% ~=vE dI,QJ{?hXҁވ:| Q ?=ټv})!#p!rWWZ}.zz[ۃ7 xD/`ۡԌ Mﱟiſ͚5k֬=Yfp(`پ'3F(Z+-jC6 ZpRH>SF;]J 0SMoT4Hf E575"ғpRFRP ˵l8@a~7 ڠk gCL0ZƠ!o c(0n?$s}^̂[T(-( i;-pM,fG( *p (JrT Yyo{á2Dְާ\̡7HbuRBl֟y2 cX5îaLѳœP oοx ^JQpіK[ʓ#rbHO#MFsm5}f?ݭXEz9=Z;а#, 5D)wtУQGLˋxOkSJR)g7Kyى5k֬Yo4{.f͚ᐱrB b:6":4GT;`U'{ײ#ٕU܈Ȫ,7̀ bмnK0' $$h&|AcW#\Yqދ>7hLX27'BYs4sr6&1F#^2uf/Ck=$+Ը`8GNT#Ғ` I OY%^(Ǽgƒ(2(! u*2i>3/\H>1qJ\DO`f̔f=:p965Ԕ{bノFeZA+c8A+8hU@qT=PPfsԁL0GIt҈$38J5` ш'ÔD73,WM3єF{K[K4N;1S`-%EM$[sIa2`ΨZFĩQr`}%9YB7zkUTbr̂43V+kiLAʭ:e4&V„ !9R#2H%A|ʩ%(2$+c-/XSkY 3_ C#63&x?L &v=MϥժLJ&FY r>USȵL <.pW88ՄV0KX1C0W`p΁Ip30a|!U2JrfzfL%6JXp2Cb+*!ã, J{xޔaQm#JԒʓTheHRMfMDZi7~xVjWzV{%6[=fwO2sy%u#iŲD*ֿzJ I&1;!61"l0z֓#XŁɡ~"U,g{ܝV"c!W t*)襴l7+ `{=Q8=p}{25*%(", 7CKL^\|q~cit15|?rPRA0ЍyC: zܹzʸT RQ$Zҗ^ Wy6$0ĈofE h'ůFsg-pJZ9&G!bC mz2a`Q[=i|v8/pwl3Ť9`7[$o>7c*ۢ/e rH\j8FF B'g{wzA)^\όh ,BBj$hne1XF BÓQ)8mHF9*jb %@S}65`>FbA~n.ޘYCbZf4'ٯ?K^P9D%@fM̠ArކE"Ҏ1{а= q`dLKݳ@xit#WkhW,댕uS]#[[<zݍMY)6 ;z†:@Dm"<NCI7S>vSϝ0J:q'ҺGO҈58A 4_DW$W2Nq;CҞ$ h{k=uk#%B#;ʥg%e;Ot\uS&G=O]b2V˅a)) ɪyg=zxUfowu IHֻ_~o"Ix|waUw .XU[nJG= ~i"(s+NS`yLHЪi;a%]^|qz y<<.,ZU0=~ԑ#a;Uj\Ў|zy7Ro(q8p|GPn{ƃg=~ Gӄ֬ m96J7: VSI9x-0-[YhGבDʢkJԼ2,`N}pg䍧O6klK =RKl\C!篾Mu-!!`j%&H#6|XG!s|N`ljwA,e7a4fD3('3LvPcl2K8=ycjd5FC-35lF9[>S5bfͮ3Z.MDqW^,7o./?&(ྫྷ MЙ=ivD 3x\A'ȗ ]eO hfTҬGUg44f4v"ӢL/?-@Bk@7ʬ\]~xv6'{hk:'E&VUM'gV4TnQ\z3bl@bapqggo6ӷ>%12;R,$AY*1%07 Igf'0a`^A:}4B9U4 JvՋcIf{+Ō;ρc@_sLIJN~[餡Z 16?!vi"248+pwF>xZyeQnvWݐp L#gRm#JE8*AƖ2UIL$&31IXpp89~3sM|y&2 JY0h[#Ќ'4prxXgGFn̨R0ؒ({P KG$ vz DKFTi+}vn׈ĺx `@B=m4QU#3T0L_5y2%G|z0CHۨ}ANrx?c{VےK JܒC6J3p77Gc}Le䤋g؋Oy}k5|iʑYB/}rߦQezbeX4awwZf_`+Er5ԃy}:ݞkyQG.I%mF1chBs{_N(%Z'jc<5aSO'qs}}e6vJ''o -xwy ]:|߭3c"$^"ZN8"L%GyBDd,; R;3=3]}[=BO] m5nT>0_Z*Τ#Ictoػ='\ ϲOA MC~WHh FH=@`Vey4U]( 7ן} ۋg!I m?@&kjA^*SMQ'PC^?21FV sRKȢAJC4P8s WTڅzЊ#B̯>/a1R68P2 V(~][j ; ̖tIJ{L.KnﰜEΑG15埑'Kh#]~jd).# eOZ>.m$g#0u\!xGY>mHmoF̜viH̗3E[`ie8G%J4Xoj^)V. MPjncj"xbW4a„ _Wp20a„ Ha`HJd&[O!_fR_j8$-w8_'-OߋVҀ4v,C1|ߊ(/S+[YZCΘQNt[3Vؑ6܂1dv5B@Ãqlӷէ!ĄʐF33#:t$x=R/跘/wL- ­%bsG?KW)@ۙgzQ M"ju8;|zyAiq Hb'xe#Y\}_{ogmpCAu$0}; `JH/UC5h*32@?nx!wKwxh;v梁foJdc2dɻA8_Ǚty4Χ+h=[؝pӔ|ge H?57nM^FP"zee8q ] &""utJGqPfDRBh(ީm|ux0>u χ>N 8miPJe4/3Sfւ^MCC$x}4MplN᠕98 @*GlLTHΣ[Y@Ꮎ)TSV$=i0"aЁ0ED@:D:j:$x 1$^Κ^FF'8k0}0WqŽbDqi]8g4hܕ]4c>;CV=vq#\1DK8[URsǺ˾o_mQBC^`]QC`eAӔ&ADufJ dxAD45:,2ʶCI.F7x]HU-dqPޡ$;OaI0:uFS"EaPpj 'ʖ~Tۭx4@FVx!㪿p}־8iܯ{Sρ`l6uXߎ4d*sR2 4!2zM%dHHBRtK{[Ʌ0..>/V" 3r3!iQHi~{l„ &8 &LxuPɂq dM<_]ݏ$]=3;;=ݻk ' Ď AŠC,HĘy%B31_=}poUNîwvuGG`r~9‹ܨ({T0]ncol@An?yI$" RB=<Ub%PH0f;0T355ҭ- "Q4̰^ó'EN)h!""{LHJ$QrAYRVxD& YiF/οWIV3bPы#<7 FChn-_FKgpl|񀚗gxouxkh.76Ms0+Vsz0*:%h쌠zɸ;iUGKc!7Z4T`]6ߍrXMCaw+LgC@yR2xխf!2 ω({++?' vuuyՓ hrWU4"06n|Ti`Ep워p\gW 9T2A , {H Q/)ģ_ {*NJ ʺ1^ڬ]7 M0a„_L˄ &&`k!|_ 9K)TPܙҲyݭ;?\;PƈRZ D먓Q 0`Sjm;@w@l +I~U{z kҧZSIx<( _5BV`ЩST=TG`8ܚv(YH^6 AUrR[QB8v0 Ao V+܊ $QЏ\,K ./>>={qz r+<ѻ|jl L&U8rJP`(}mz*`>^cw PSffP2j =4_l0#Fig݃ahe ()mMI\D>Øv>>$;x0DS0M/p ht@(X9F+9g -qڱg022,oXJGҳba`PTF&ēKNd'*JQ/Wu0 ;j 2@d*jx(ɤ_s!:#xm@8+d fŷr~#O@)8[věC*~Dޔ(OCʋ@ 0zQ)κ0Ǐ~\J6ʹ Xלh &LĹL0akƏڮ".!T0z`YO|T.kAJ,w5UewS:\KD6k^kl!b\F>#Bfl -C%\Ы\j&& &Pnu}t~J C'W?>9CKrVo t\JU@P&)o,]n^jVg46hD;!X^R /Q^1+T3u:'GV> @<Z?*2p"g o.~BGBOԽZ7$>搤V\Vf'b}-\4w$s$AUFQdkʹC"yޚ*(Dnv%xUqJ {|v2 ڢriڡGDPAd{zVx`%w$.+ѥ4\D9!,ow7wW$jw}!KAg*ϧ&0a„ 1q.&L$ Q;J?&C8+q5nG 6Dxn+G0S5,'|?Ð `f q/|hց!}xJT3j6Att8)\n?gIW?O$6?[|FĎvNJKqœ(~ HJ4@M+C)`v9|`4":&Rܗl_IBy,#|٫}Xd: W C /qlv_}||ҙ d ϑ"D@"UL^[vllV.O7Ǖ$A˙G$qHZ}$'cZpg~VbJFd~eXUIuhG5_W;M}v7'40HDg9ϥI(K~|1l@} }IA}=$")^څ=G (bX,JLffA7;r4BSR0_4/z#;bw;Zt FG00a„ 7&e„ ^00nL]33ZA O:Y{@Isߪ!8,R̟Jsa5ACTDY2!cx4ݟLjh(͢ȜQ3ff885Xf^wrDYUȒ;-VQJhֆ1kPhH,ʹ"D*$۞ܦY/Q!ժ˫M5F!/$$Et >C>Cھ#GES('Y_r[*H !(Bos% Ju7VPD;a%J])9vH*v+$Un{fw a7" $xBB""DB d Hx!dvmϸ=<|_۞ٕٗ:Ҵމξ4w͢Aj^?<6qfa`f TOBEW% U8^}Vyd)%x\wEN 8 N>P<K@C%܆kw1Sfef礥DPI4)DȌofTv ZՏ3AJ0 AZ'6Fbj.%1[PO[5pF$ǜ;W/5@I$@Esl.s<9Gɇ@f<ΞM)8>UcItUj2m#1}51l2lfS˄ &L8 &LxݐasaNtR0" )bHL3pJ? -)}$BYݑ(2RqaR pktu7+ocl8R[ 4~('axv;RV֓P6:!6L=;!<=1J:Rysޚ% @9Kv:cLd"H~y|z&,-xcv~|ΐQSTod SuP0`y]ٺy[ ss Uy 89smLgI0O7a*,0 +U#H<ͧ^E5%%F7m"5[hOfO3ӽ+ns42XUgP5*j{f:Hk0U\FL;o} Dl8?X.?&ȫ7i)u DRxf^h{0a„72a„ Zgǭw_^]Lnp\1fE݇ը (|^|dBJywl]4;vеp̻2JRX} uǥYnT IDAT`v<R*443%LYk!4K"3qj8DevfG߿nɿWTcv>g/U%VәG GɷEd2)o`[ +p%U9>p|A OCnd-A4"k,C|(QQ?R`cY7/Jw,#C?4gB7zA%e߄ &Lx0A0a„l1/Ck)%%tNOrk)Wra{QZl_lM5!fFP P'?ꬱc~pv$9Q[4(GQ}LAH͉ ڕ{=H721{\~uu8fM0Z K/9Gy+{?-+^9vo5%IIz7f>@|@/sz6X.HqP!c&;B8`M!ې@N[Z-H9:uɍA@pYoOqZ,xZ}]x6ɸk[P^zD2_!450h#+a`P1>bc+$Q#3n?6p_24I@q]H.|X]{ gd )>X JaPx:<H3FzᎌK2R=y{wH%[}3R dJSSИe;*gR+Y+?uO*oK-žshstq-x~i?nlOUkgѲxUk#>(li$h -~" "O8lax9_c3 N^@$9Tٍ ḯ;mk&L0 ĹL0aksy7#!@۵̆[-S& PH6 _D QX<64ޠzsLOl -&k+!2$k+(}s mwDD@N>k3X1Jב(Ah4! C Et>3w>J Щ32aޫWҢ/ ֎^'# xVy.XRHaj1엇 .RCRv}qY5,99D61FL2ޅ7bg˔^$>n67u*>\}6=NOV\=v-$y\ra46/ V){hcT )AC-f }Yf@xW@eߕlT @lVUH<>nB:J+;a„ o6&e„ ^#٪Idqx3G2SE5)J)ah7 eRs b@#l~E%rEH4vKChc*Y`"=u\B4a/"'şsCu/(4Ë Ѷhu?M){t| H3Zմ?E|9j#"\|dH0e_^[ib$!.>?L9P@ʹ \.~뛟VCq&jqootkb;B3'^e,;7YY3;s#ziye- 50bگ(PVoR݁C_L`hAߌUxU]_u9"Jg#{4EYmZ>0d`k*M"R+ٶLkrJ{ϲk) ]jsV -2)Ft%xڽ0蕫NXIefnJd F]f6ߴ*懥?Xvg`0 &Ujc$z$>ʘđ ~j„ &|0'L0 />Vz4 Y۠m791 X={fs:5.h^9$缌A8G*[q` }w dmG8"HT hHFvSnE11]z˒1PȡPC7#A,ؑǩ p yFsi! A{N[ Àl`24N43gŮYvTÒny;8qT'kr3zf|VVk 1 VQ+mᄼآ/_N!0׆^^FpA Z{e.!"Z&Fj-{bfRJV5k I.LC4"PR>#ǗSL0a„7e„ 0ȕ{B`)"bZ^B aW q*" F0=`N~*,NFD8}d/ԫ5bNdOft2:hސ|{3Zw8n}FEc H+=#ڑV뿫Gf &%Aykff0\.> afdR¥lqoJQsTzb/Ej[w8f ]}N^fpֽ-̙$ !_i1sR}RnJVFvn%d6ـ< UF*!Elk[wf[pwIa#YlYRcx[0Gx^z} .LC .CsP.+3%#Ѭ&'ZRd@8H`7B2CdJbBxJmCAɅLvGD=+w„ 8 &LxCۿ=jgvIݩuPȧm±ym'swISsè7HG/A U(HMmquW‰"/H{y2%rg7JVKw@]S)f50`wERIfGbk܂РA'"hLsE޼zQ1U$1rd` jpdhX.."xnY`(0%!7RatR\)ϥSر"̅o6k^ufؘz1 v"H8 9mV4gbmĕ1լ"i}k0sxu$o2>M&vih=$Eμ'lQa)!9 ۟Cd1߆CdP Y}bi߲NVyTۊF?aS =d)e„ 8 &Lxcc#H fl Kk3iĩTSOpvswiou6d ,%\οk/~9vBL?9[Wvy, Qo=8p14̔(vR &MAQۆ!}$=5źnWwB+(b#fB8v:TD eB.A3ACH eb(8 Ԍ%L<# *(܇G1NAF@؞Ir,͆C##Q..X Y(<[~4P'u\eҒpfN1.zF0h[ x5P b}8[3Qb:pG)jdܣߤ,}jR>w ģS kWFVP%i`rCb?"eY.fdϞ\}PEm׽cz .0Je|?u, ]> |8*)׺ >+(D6 #E)p7㏇*;L0aWq„ dף+8էׅ@R5΄@QmJYפk c1 0@b,}~d7xIٮe.>GV`l(t⎈n:>V0]-E :ݽ>ۏ4 OI0vGkؗP`(L_|yg otrq]U O:#e-|{ q[ʺ Iudqd!8pv[Sť0[rY폎ţc\xEyᎋ/9 *ʊaFfΘb4dy<)+xnpk[&1ׁѹa;c):ӗ Ѓ/)h,` -(: (@P;A~ VU554cPkZh4ɋ}Ar] 2=&L0aW e„ , >ؕ= ςؕG:J䭷|";j[cw15xDy'ka]-IA& @P{QҳEmX_|:)Ò}A<(տdfei/vv u\Grz~;w7?:zj!d-thJ<;ml ,?82*5gOz};NK#:>S4H4 Fs))nW!@uRODa%HbA%"?G .Jp:K'b:05{oO`' Mb ` 6l7w5=dW{_d}efUu7h 1!$Ջ1@c1 ,z볫*{XU=5tEIUݕetGg `K~ș;>5# {!@*%e[ͼr??;J8?hg"ƣϮ.>1`LK5J ~=|u`D8dn/>Gi4m7j]vO7e.难 |3Ds Ҕ PJzVwT Bʫ_4ϞD$2In6h}Zjz]~{qwa{y5cƌ3:3fx@?ϩ+HaR<8RP@ץ\xxAMD [. zK%J=$;îZd't[w|En`& Y(!3ks,xy N"PJZx|sZ!,!̭ g{ Rvev+l((a9{)W!u ͢"¢r TY?"۵v=BTٱҶwy?036ᩏ,D@ 85b^z5VN E/Ɋ8S1wE0#RRt}~b[cǥ4K;Kj@W? NE` joq]86#Tj-=MO"Vm*2r.8YshȬdz=M:bۛ -^k~\U>z@ۂ)[})|(Y)h~K>UA0ؐFm\̵̘1c[Y2cƌo#`V?fX6*BEk?zkJyl?{lɁBқrqkR@ͤi=rhqƦ}1S2b{]d{G>usc6?!1^D, -%ySpi' 'Yf6_ ɄI}v팗!cSlj0)$ve?95[vD'W,mۨG=駶)hF%4ch j[7}nO( z/Ipfr{ſUC{>oDj+vׄ4!LpF,d*ͬ\?AG߈1 ɓ?IS-߉:]7EHˋ opkCaIIV\RYf5P03ZYe=Ͱw/^f0GK ctPw"`\J-耸5$ ui̲73f̘1feƌ3F@^^Da/el CHm@Ie[G9Mx,}NМCۄ lp!P; *:D45S4b&FfůS=/Nc`0F.RGlSV/V+CgdB%76`|%m xb,~y=[$Ա6J+9^ TN q+S''SL_$y+̶P/6bR^&nR>|/|"q&I񹅑W6cfNuU/9;,/mˡF<;p!] gexUuސp&o vOӞ0e @ҫMkJ2$HxbP@bB.z"i|E o@&a[}9HXŵmک ,`hr$if@L =4k̬I"$<Ҝu-bl5Iq׃ݸO2w\=cƌ3feƌ3V(U_}8=}A>اDnC!ƦG`+z1͙ͼ|PDom$Ri) Hɛ.̌Ep"=Hfk59.XbbB憦 RA˙%6jAR&!Hw;Z@%€D41FTHPEžE͛h9Tr l{iBDjBƊT=\Ϡ`ύE=RL&ɜJ/ ucҖxʶ1&M(!}Re~ZcTIM`(ݝ9{ t5+֮x+#e)$ݖkٮg? 6a=/2D,nEo>% I1Z T]i2='읚gbZz`MӋ.)2Hh,#'}CYnA# /0v IDATQ5Ԥ!RiJ!3-3!f b^K3#޴i̤#JF MZ$: nBN̔LFkܐLؓP e˞rpjv,&2H]Siуp1cƌ32cƌo+Wm_ߥ/MPV<"pOװ{U{w]Bz'Hqv6-Wvx#@F[(+` 0X^vC͋K kRsBٺát__L[Ɣ#ɶNyZK><%k9P UGp0U˟[J$G&5]n)Pf ^|Q7&5N;ӽW~{5KɋIUSS KV@&j\e7ȫC6NK!/CF:DZJcYciZ",&/ZnlA$lJZsk- Mf~j3{c vmwfjjWݸv̙|mf)/0vPML6I.>5X~S,@yA)ɢ c@7lxp.)^nL3f̘`\f̘1DŎxP |-MCAl XWAو B06LLd1&sH"'Kս wԲ0[G1]|2VT|td>yG?pIeG])Whvsys3LM>wY#@*@D&>,0I)!e/>zCh߅:xԚC !2øOgg{u᪵i>&^I8 md B,Ǔ +2Ȋ!H"yIkU{&)K,d{jH}NĮ* P>%ph"}CV//?b.\۾asO,/R*Q'|]i[jwk&@- G Ļ2]{w)nfYioUyafU:PBWccɷj}Ie6D^-n>;2*ڨ8&ОrR51kD-}~T Gc8 k%Xfdh lfIjDޝ_}L)&Ykge DM~P_2P`\†Ƅ:}C29~-jusg 5aG7@zv/.#7hYɕ !HVC@_\|\FDD?tsh֬Y^w͞ˬYf`v@d4&B/~1,,fBώ9Ue`L>;'ك[ܽ>&aqVT$\½{/(T(t7Rvn *q8m!wk`m`WHτ']҆+MXtM.VƠ/Ha'kfV2LZ445=;hrWkvmͩ'7~f͚5kks5k֬S )QcjhvR I8DbD>vpRbmu|222N>%kt %"!*|)֨%ݒ-c}$цTps{sS.@r0p@[պ_`g?9]f`3PK%룣-oƛETst6VjhG| "&Ș@=75 {@qY$ێ2F@@G.!v$%S!V~@>4 IV>4-uAg(P"+NO!%Рј4p#cZ` ofn!b5߬cW-b}H(ip󈇃2G#Vn8e@n} I  2Aa$..a(H=oQF'5^ cmyɺ$ ¯ujrJJY&{+Iw۵%`zhdi݊D ^"2\Q *Y=-e#1Hi&dczY@ˈC~(fgM kG#=ӬYfs5k֬Zn'*qrZ{$$S!@;WW7`H )1 P8BO ^wƇu m@‘b)!r4cPϓtj yaDQ9V K =p:cx+1U)xzM/uR"9xeoN NJas^Xw`TΤ KA$ "Vw7.CifEf8_r; (~ biJmFf$ҐKEfD7) 4>wxgIQoǂAw6v&k7Aq! R$t7ƳO*RV+v\*ZeÉ DBݟkK))dBXFâJVm1Aj[|A:\Z)i9:F4bͳ0}0eȀKYM7ty $^FD2xfzPl>T?8/>^w~վK[)z:-_ xU1uc<<2./i(1}4w6\f͚55̚5k*uӅ^%BH!I "aFdfJ/2/" pDLU0Vl𰆟c~J2E@H_Ǝ!9-sOo^}x|v, :.>^.(m6z玨j8։3DƊvaoN3*o>=ZH 'C4H)7=VB4ذ4w!fBMurtwwiTݤLRp`P[BRmd2DE F e4$J<>ZΔi51tBZ$;#!"ZZx 1;`~pI1'h1Lf$Zi2H֝ _|5] Z {}]C|pOUyo|z:dʩ/2t(?/g3e֬Y^_͞ˬYf6GcբB2[AT RBd;hYnn$oP/31HZ" U`'b!vX G{lד6Zb=p.ڎ`H! *Dޒ{}VWnC@\]F>t* kp@RHĂf{)x{5"ف.Ke۲1+: *}lIAP6a0+%$46!AArj0r00EjT,0wc:^ !Hl['6IdȖ*D aJd` -GŶCCT'*L5;$DWCR#p+BػIҫzν_dVU׳g0`Ă<$`d$F K6~tWw3_dVۃ̬PUeV_D8'_L0RxzlSӳegCx;ݒ3mAVuQ* 2S[`Q)A9gLXuƣFzd!K_!JB%cܑmVb/05~@Y-NOKZa6,@"Bx4A'nѤP]Xs7WXbsˊ+VxQB`:fȬ~}%, H9B8P&mWznC|dV-jԓ0w<uyBMك$mOaF2Xp 9D9vA ˏaG! ebJ5 1mj^-`\|uC#B͓VFHG2:4֤hvBKRèRL-U=˵.C^PǰJm27g$R d&+f D!vM/ܹւ'S<}])HoMx12ڸ"P7 t22:R6)Ht >؟E4l|HU&J\%؊Hpp@rre˜\2ؐ_a"R`)O+G ok orgf„$j L6`7Cu ".(( -;1eOh pA-$Vd Pւ1W_~#0Q_ElO8X!ZE+VXb\VXEŸ[R$xYB!,:3V/ KF>&v)B@bLz?6kzXt6?x =uZ"K17q4J>XsLU˓dUUp U4ɞs%1J^@,)yCC7c󰺓Ri4xEW`cT" i2Q:dNN~o""&rj7lpt 2jTpX ={ZQ~LVROC"zHbH R9s2qzrcTnB)֔o .>*}DɎ^7y~Uo} - ҫ̠w~|R^W,˃+%Qs`QyC@eEJJ>A)c|]pleZjEAm7ڣL>{/|s~^To2k}ytuįnoˀ*r03#Fx͓e%0I0UCށ6F+O4eb~f}3/>VDp܄ūjHD|-0ZbŊw+bŊ,L@> %0*ipͮ$K;@P#G%4 nśWɽ t4'im`Ƽi',%FjKY5y=ϊVfn}7߷`|g2s3=,q3s)VCて3" w@YsG2 h (#F`FȌW7?0./&͐2i|&lUTXH%if\U1#,BR$}SY"bb`V`f}.ɧߝ9)i2gef}3k:?|yryڶGK|E:MBiޞ,W2t2;XGgO >g炊l险,uHR3qyjc}&`nK5shh@diOVJbO}'[gH_OCŻ 94!gp3F1uˡ Po~y >!yruqws32fQ9i\2i=͑ L!;(%*WhCVYH [E+VXc\VXů͆!(a܈F$$v_FN"eȶ /~},OGhK4Z. 3PxxCKW}Y"T<{߈~ ﴔt}=/`..22-3g0p{yvt_#V*G69KF 4d8?G4UC$2Q]4b!aGȎ&XByH\]|$- 3ǔY5hiK.jYp{N2 )3 G\ZK>㕞K6=#|jhmhEѾ)rCDd} GٟA9cyM$uo 7z>7L P'+$;fVyh/0sQ2Ĉ40keJk[ǙbI ^^r~M4=qUQx,1 ÎJPwz?&T| Z{ \j2WeŊ+Vˊ+Ve$T#CP#B7:Hpys瀅pdž6b7S~?NbNp{^^)9<Mw// Dpt O {S >S6pSF I!7zƍn|Mekh뛏Cw-o~ =|Em0/p9eOVu4px,1`Tw xs/i"0 Xf2fp)t)hR-m"JFZ%E0V" D:Ţ4R6IR{2@u\\˄ʹ7s1n{Ua[]#{Kl3H=;HtFEG,E:o_dyLL[o#%:R=V]Ed[,s$J%)q$_$n×&=1J-';*IB "vu?m>x8ֻ DCL ږeђiCe@D1=aMDݰ/$PT3ჄMO^︺sb_h ek-m!'kŊ+VX9+VxGQ Q 2mJޏ6k]G†~[}niM#}3-S4nq //L25+WW y:Nv5^޼'o ۟Eԗ_i{W#YvUZ܈=O@B bx,c ! ȴ 䦻sάg/Ȭn]vR>dqCfuאnb9jH&\[ꚼWW?y/Q&m{6 |?+=;o@u?djN8zdZI(FGΕ~wvt Ёdͻc-]Nv Љ?$SHNE37>BSqnOfac T-LYđﲹD5T5v(C*vnڦAn4c?ш9PEu߂7tG܄v/ҁ\Y bgS`ey՝.?:|-hC:H2e!IzlLN8^u ;%9zA6hD&:nGi- =͓?wlc$+]o9C(bv) Wiz?_o"#2- ܞ}'&X` sY`N0Ev 0z0?S|1g^_XDPI۹Z{# W?T3 IDATٶ#>pM.[qk* nvH(@Dzmvϒh WɗmPƮG.޴?J bt `l叞<3 ۛo~Sq~z]fccPg2wkxw0tF1Յ g}G^BrY^J31 6d^so*O۵mΊH7 tklA2U"+^¤aoV2YԋТC0Y4}bx*N칕q:Xa'p4Q]Rؖ}õ𑞬D,Hh[a#I\JtJB~nTɅe{{U8|$H0 @&D"!=ˈcg>͉~f\` ]D,a<ĭU% W#2Fq !P,X`¹,X` " #-p> ͼ9J qv/o ;eg B':CUm2Cg`P`bP5tCkB l7 al`m o@zZ5zykjӮ4}z]'_get:իL_K'=Kwy$/ֿ}Af*fZ3Z@v lptnXA[o (=Hm&2wDb00%fn"27REUb%̊&&^Ĺws.Np܇Ό`}tj<ӄ -%’, HuP&~^i\̭g"`xn{{vbʞV&}؟O}cQZL\q],G.e`z9qzOyKFQj*[gomJ 7cKЃĢ83.ξZрjEWe~|OBNr ,XX8 ,x=53[%+\L{IEhɝ' JocL}v:@dqyk} Ã>VȀsl6Z`m)8ϨPҠ]KD̈Y @ E靖͈uȣ=})2l4wavш徣Am[Q̕^"W4؉gl]%1g}MkbskG ,X+a`)RT[fG(U\7փpq a+*=,ݏ%L "6U̪%φM65p{50zw{"i$v$dIra\]l;#'_lqPoe I}Ck띇^gg݈WX#_zc)Gp#@WR\x]%pvmZ&J{T&-NNmbM4i4j#Ɖ?oI|b>q<@&Dn&mp~ַFG~+]HJg;$#$Gx"L}e) ݪ=FFz`%[29txwcUkw_1=&|[pq?s*%G*]{ѬP`N&R4'h+U3D#8NCЧ ! 8|{s~>x蜉֮+w!\,X`Ƃ +&yD@#Bb-9ϊYJ=`„;y"NtyTc6qۺI"ɑr/쮮D&u qi]J$D<ݲr%!;f+fm`{oMi(z-[fZ_MӈN Ss?l6hWޔCL2:P}Dd:&y~ç_B0iM 2pv'_4=ЍL(>H5D ,`"#F;iEOx}NiFN}>@½8I.I9b*U5'HdC)\ݡѴm̧ǙSZBڿVCՂ ,xͰp. ,Xڢ @Rx-! ]Й9ch V n C c.]6?Zitz߿1&#B9w?I'a;#x !s߭S$% H&L }o?=l`4w<wۥZyn-*9C$ib''1k7 xv~>}ZFqZ@ ܟqrg\B99dUӨF#u4bshDDLlS] h 8:{.g~/V!0 &(Ogjz9"HQuq@$0`h]j6YƁ[X$߽'dhF Y*y#LJRf zll?0cmt ziԌ:Ę`Σ@b,I&1wܾl3Mgc47ӆe$`:2fC'?7[$0$ׁ|z;dLLA92pe-fn,n#%oCg#ozvv&L0ab\&L0a6N >{Vr ,>v˼*l#ZfT)'L>Ǿq/#}!>9Ю.K5p}qg?Rsd}ɐm`.=h0,0!__)%ޚWf`zm.-;aQ|ej`5ע.3d=p}}de5FKKT!!Xh0/bS4NTDTպGL%֩[/sEmŪ;JLdH B_^}H jN߭a`r8<``C"4WpZS5̔2u{Cր}}bnGOm &L8 &Lޢ2 {+úO?vT^WfRwMQږL)D>+ !'BK`UeDڬX!W2 =Ksg!痿98|Gϯ?1If-3)*Dcް&t_Ϳm~-_U6?FhGOᰬ7“@JDȳ^/ZH0 '@۷1J$֗@T.qL3rE$.g0/BHg Ȋ;ȿ XWs/w.~W?^aPkzG|=@*͢CyHq`FwE?]5 %/1{-DA ž HSYiC*]4ڔ)xp̤Vc]S9K$%Q3E,%5O!r4SIb e(ˏ:䮔h+3b `PC,;nZv ;oj6YiS''o|\/2`6Hu|u$bQas[2>87N-ޢ^Of݇ ( 3a9{Fz?@O i r?0^BJtA& x%ㄘ損7FGfoӣèckCݛ~ a eLXZۂvLc3qVܾY6'G2a!a*'><D ssﲭHcQˉe7 F`jv= QSN=^5WkgwXߵi„ &ĹL0a3}`,HD"InhiLeOI;N$y%mhs`c0j&4!ǁ5,~AaGádN'RfBDVjZ 4EZE:2|o =eY/7+NiA|fY3JX"IfxfWQ?Ҽ ¹vY6AwI!5A<8hC*%YTDYߍè@V\fsl2;t( ƽ{zl z_psiT,ȀKє5=Jb8`Vg!eJ/t%JD5!q` o 33)Z[I7+Q_'ȢS$@{%1W#蛀pyKtQ>eAP1R5e?;}OS'TvsI!Eΐ'1D۪Ya8O^ҩ4T "No\T!U )Pwߙr+rV=gk9d,q b$H=Ýg'?KPdّ= @ &1$9(;HZg&LZm9i32p 1(2zN!DYL\ ^U% *H:/Pˀ#v$ 2a„ ^2a„ k5d0BɾN5$()5(LݴIԘvE;g`6!A!7`sk}'HGPʣ.?,) ٛlțkВ_ivvo! q`V⋗SR$3D2{ k^ ;f'gkgr8:z3q2sDZfhFz"?ݏdU6/ GJA#O !!P$#2鏙Lwal 殇\uu>-&Fp$8dRS]ADEK AR!~χzW1 W) \\<< mh:̕t CUc,)a03I};y -y;mgaM|2Qٞi縟Ɲ4ӣg!ύfzvjeJURvYq""qNSA+ vR$}e7UeV6pN?b@3+2 wWڤz]_>1 ('evd_~\hѢEoeѢEt+i3vWշтrBf.=[ l,< %=`-v}yfφ&yT-$(EIlR6uan''S{?|";c^0 E&$Nξ60.7RK)0aci/fnk @f$Nav9#comU;3_w9T@Zdzx·W2!L q]4D2rMuN k2RGK^pʛm/k3݅&{JO.* bxD@896KyAk"4uHزlMgf8[EREN9:w>({9 & NPg䓿#&ǵH?t~Oi(>)tCPHݒm>}J{ʶXB+ff<<ڽ\-Zh,Zh*Aʄh d|܉@'@Z(A8׮~i ;̄_gcDzu?Cx d&݂Pw+S{$:qGm.|[x;u.ͱ%6\]t}gg=}L8O?xz;ϧ9 2\YMs"B{>~/ )C՗ Ү%Iel&''8Uy(9UvSP_rh$\VvAȨb#bm>%BS^qI" w(gF2= 1ڝҝGRQ&&dwxM1ձs bF]Q &`ʜG6y98ƺa0Xc+ X1ƪ |?4b}b6CK8:j%(u$JF(hcf&myp2jd]qOb }-X 0S10=|/Sh@aCxĞif-I %t!ȶTMu{Dxҍoo1ABcKn1,yhM`{N_z-Z ,Zh+yO>ezT_ IDAT0P,ܲK"* МJx0_760Ӗ9R ɝ֪{(ʌQ$wA3idiV6&qv,OP,mpmWf?VAaghGFJfM2?nE =p7Rm507{O͚EO&4bsRPvxry 8 8r4 Y9X%W?qf0l3d&\HЛx{*@ O~~t1 hLqn_-Zh,Zht܇$k$lJly>N^]h=A4 g707mv4.#LA*'1)lg&' x}}E̚ fqAAB49?u2{IAQ% /@%6]'|2޾E {5lC{iI *niMGN>ޑn+~#J@4WI|<00Ufw8ٝ?<1{D@͗>qߎebjy26TREqX@}Hmy "QtHN! m+RInn͟_^9zonF} 0R^%| Ĩ%ھ!GN-F{߃=ȒVhca`ua5C;",LR% 6x=p˾9MgXgQŝVՍ%9b鷮kq1?+ywZ̙E-zx.-ZFk&xʤ8?Gsi|!?*gtO=`dيs `F" nN&Bf@v89J׃6E'>$WyŠl: f߸i6s=Eq=xnop~뇿}߭h#Si6?ӓ?O W0f[H}; Y-ڠ0lzzyU[WHŲ1'gEoqG݄핉W>.w*⯀'3˼pV M*1wB,j'7TzY'&-^^]4 V >QfV/G13 m)fG3sMж zϾ|?N& ]2Ho%xP%SOdZOx@}<`~zvoVh$6>ފVt7hf *C<05ҳ,<,`p}*P@+"@26ɐ?U}] f5B֣~C{6r'f65\]v3&$g}-ZhѢWx.-Z^8"ITC؛Dq #pdzHYt {Ffẙ 7m&̈ZvXOxҠԻs"Xf<*I:9[iU#1Gȗf- ?V _@O74ҠW( <𗠱L%L@sGP[H+ߋ܈@e?_Qaz lm$eH*f~$*VUVuq,#RXcH HcDV$h{ދsnwAtxcz(ݷoskϪrK͕T4mdg{pj$Gx[G k[ "R&Y 0Dd6C<ۓ[gddRif]5\Ped4m_[KzFfCyN{&9_`pw!_8oJA{5å>f[7@CYP#6RWg^ -͐)I@ lZ}/^|1 Y1AP[EͼeBy$̉M%B^2ģ՛OaʗJ-&e hHn2O~l+,4]_?M!7a=)Pid7Yh#lF\^K8^]l6,(=iȄ`n!ZV kd V2_H LRe6 wT dcB8XZ$j|ZĭVvchww$aQp4iҤI&eҤI^Qus`k%|>ˈbAXۃY= :0VceQaG50>IBVX95zvok3f$u?K;ORv >sXM4Zlp0k+g'սq ||w(s@a6P*ΞS7{68[$ӳ Hkc]aDVIsj7 psz|vsKٙ}iLI azOIgd3va0IXDtBغVc Z.5Jr|MQ%D1'&Z4ǵ6gzfjuRb6S#jb| :0Y 2 g̙4\`|lI7k쀯E`e_;|N^H  Qpy 'O޹8ĉT53DzN4iҤI_L4iҫ+I/i:M@}lFDIe#RqB5U 3h9D;vA/d ̠l'j"4g=hS)"+VCn^;Yz{w1;Q1[TJQoM+Fi#Q 0sZd=<`yqx ʓK?:` Hܴa4\`C U۔d _~icjuImϕxJ|92qyQOz r{?df dE%ȡȝi73t7s%,*B4pmr?M)Xo^^?%IY i) #9٠uϥ|fs7l#?>\H^P02a-C 959 A "wB'2>i)iPZ)BѓwĹePzrpxKu {N~}Ah3}A@]/-z%u ]+6D_Y@^ {^>wCJC0:!, qqIbǿwr t΋# X!gƝ`Q&Eҳ2EMCC SL `]$QIBf`Vٵ&M4i+s4iҤW[v<-!I & 2lwOZx!9 VJPsuR,RS2-v8 Qކ~WX}m ECިaH}|pvR( IZK)pd!IBAK2ﵝX VԎxvFS'.v2{[M@ 4blq|lwGKGPzfz^bsk!igIc*8=h.JƭY%.*!ZyH!53#]ŭFlN>qsXP/׷X~L,J)o>nN?_W`Xg#*u~(]9ƕ>e_x[ n;(h+jBjg-D8YqH y˕6+ՏNF@@1/}.CV~2iҤI~&eҤI^Qes5; Z{o ʬmYfjz$ɮ9FdvuMeV!6F^ XDz #aH Vz+룻*3޽{US=Lϰ,?2+>_V8JSM8ydg#z11RVґ Б1dd#r ,1Xw$|`4oCg$eQ#wi;*̬ @ΖQ78fKnޔ:8`[&hC(}1ZMsl^L~^q _ k Vo~s( "AVE]RL]uK'(Rpv'OSKȣF[Jփ$EyܙHQL͉C|\2P!2yZZgYK^/7{5ll ѧ^hF3uCӪ&~hȘ.Uͮ}"䇤]?wu:DBBƠ<['8=~i9/mGn~1$bJ@y =&+V=cƌ3f32cƌo4*As(hG$ddN\8-V;3Z d_ʋ^^~P 1O29 +=ͯ’D͹lZnw қC h Lo֘^>2_J:;Q5kyDߣBX̪d$iTESdD\R-uWu\Vs13 ;8ӄ/z0GӁ$Yy¯FAi9p$DOI?vzKKdŘM痛?*Jbxnx(3L4B bŶ]FTSs@fn/R(nFDҺ'쌪M#iʘa{FM/!9C}aH 1(s޺}qtwx/lI˽_m~3$=g=Ų25QxjgJfY)[sJ׆iж(3h,SY*t(4w.J $z'W7)QcTxz.6{X6&h"_>k͘1cƌ732cƌo(ZL1 sDסD0Ln8t씽QJS${h t=P#d= fh8 0vd] ΔKr0#j$IQZ MC%@h:F[Pj'To @B;:w=~Ts@S%ƂvI Ua:D8; Ee5}iT+VN8ӫRNN.#*bgK_ RJ0\@X2NBkb硼:l;23 ׭\8 Pp5f%NI3 AނW}Y3) 2#zX45;ֈ]Ơ:!3A2逺RSqL3 PIHg BI$$̂tg+79S]f̘1c32cƌo*Ɛ$R/ld:9Q7/>ДᑈDICF4ʈGJlUڼNyix)V0ыI@*`!wOzFnn-AU$##ʿѾu`C`&z" #H@'pU$66O:[=M2s^q`>L$oA!=2VG{mG#J(BSԚj[ݜ탷M;U"]S8;p镕b&L0aI2a„ 8Qf_RT~+MbEtq_kT?}yOY}J5AGd72 shtZ|4b'J@57_.}x9&(nMI!:{|WF}YFc'uլ:elv檦Xf~S)aɪDgU~5`-MlU$6>gwjmȁp4\ye(g8}}[zf,&`?^j 'J ^W袔yR 1>`Qkb6~f'Gm7(.JB> p̾ؠAfhHl6@C׿6I1 ItƷ *֯tH߃b?nfU $N:yf@`k[F$,0PUx4TVjS&"#3ө<& % kb88.M&L01&˄ &x HcE`wpă^)vO~ n_1[ IMP2>ѾbFvVV _F]1n¥u$ QrC]<=2b(Jݑ~rRl%k2'}Hs *MU2En|I%yclW?k)~߽vdVIJ}[j &L0`\&L0$$O7Wz3U^Uglj H DU_Fh3%%,3E@GHm!J+Gi?FbO]UWC֪V˫_.?MB8v/0rښ8#Pi*\0F tB&dHi:"GT $̤ cW#Zc5gIf:lFPBASmm 52ÑVǔUp;hf+b{`mSL=U GP()ώưPt b0flF}m 0pV_]aN5 qWHUvVWZʭ ցMOЫۥ>|b>cjS}D$=!r_,Tr9,73ۊj>=n۹v23!2d&ǭnh3KX&AGw$b }"E}?z8Jc] Q{[Z%U},r۶H+gC}je~sW10.&L0[4a„ ,:cA\SĐOB js|: x` NO> 6B(3uѫd f"Y?(R! iV Brkڕ^x}x~oŚZ!o]=ay}xըuZ@NMDUd76ZIH+G D3P:魐o-~D80tL+ͬvIQiޭ'^]b#mZ&L0aĹL0a;+GI|egz~$9w_U `!8bG DlV,?O!EqBBlQLwU{;,{3Iv͢Z{Jw~l 88 4d;7R!ЎO 0c {r-ZvF]]D)ج׫ %-:rv|!dV$[u7 gb6w`@d!lRAHn*V5h2m3כ7Y5BQSK)hCG /.Rp4hX=ͯ+wXLgy+f&yP[]Eeס܎!Zqz%s 'Vz<뮻9ڨ' 3cbqZƑ4Eߒ+3 a!LI|bγ5څdh#1Eu=AB:W[,fnٶZ{TAt2Cכoo%bl vW&%O0a„O!&e„ >:!a [QTր}?F AF/__C=T.01R`Hgj3sJ,O/@X" [ 090e 4\^}wyNĢ)SC1D󳿮q\˓(Hbfܒ`P<0 !+9i4fR: aãdRjWЊKϐPԜ Y֭O~P "u)iMћS-D` NIMY0kjC@DSh17/JTG+S$MYHoOkդG2I)Qd$GHzW7@Jќ@D ٬{R Ҋ^rkYk!ku`D&ʞ&IϷX,5B2rqںˏ+kЦՎPgڰnq -*s@P\ag ЖG8ImKF|kY 6,@r)"FJO+!ύ'2T/7WoyA\4{+g`4_&L0'&e„ &~C: Ac%`e BYtG!5 F;N@mo87IGw^?cj :!L0@c"L^w?9ux*#Hf^ m=ƯEiVPrUHqfIDJgo{ܴC&L0ӎs0a„O+i>!U-hc}6gsP0F؛@XL(Z,ìVNS-ޮqnȊGwvo HyM+P|F /X_}G֛鈘Ip4f:i4FDtN.SQ*̩)y{x#HOgP N[I # JG4Ȼӿ*.EmV]5C #FJJVIW٫f/Z-<%k]@сO?IiԾh (>DΖo^.Yl|>ԂZGV+P+D|63-O'{8am˽|L;W*%3{I@ξZ+k!*``M~|Ag03D-A}bdN=xB-'m[^snKK%#:᷆;/R(q vH۵NFcsO-_v;quG)9 4a„ &2a„ ^ŏi, `KrՏ?yAC~ <DZss<=U$d”ϛfQodm$­k]ID(ń- mm =6mţ?,#ECcL,1Oߍ蠋wi=8].2tcf~if^ā!`uhk D=&?[a"5&&f`ԫNr̗*&&e„ >h0w.Lu3uK ` cs狿GO+B6QZ7,m(}Z]ծ7dVlB84Z-;ty(d6ifb6y:b57%`$bmb )HǙGPGL$@Lu Z2_W ]F`hO)Q$IvC+luyzna۬* %3e NB۫ӷ@3&q':'8?~ 9¸̀ڡٮa 26R8[(vh[jMC⫵ș;PZHڎsfa|8O]Mo$u=Wp{k `/l'PD!Yfga$ V> ^5!޽'٤ƀ٨΂$dWի &,eR R ?v(׵GipPZld-ޤ+xɽΚ$ % YJT;և"fd+^I vP!P*'2GcPϢJMFwq_IG\\pX)%5)ij,X` ` O1" VElc w'BPyFS&N y"-P!!"i{/6_ZPfJ!=|f-VBjšA [XMnz*qL f cDzm: hm̝p/AdJEO2V7Yǚcga@'r.,ms 5.DRB8W6=` :WF8|>&%D`$!$J8Fo+Wь@#๸άnwkp"Z>~[s51}n8 W3G !sj?-.Q6;2RX[BP-:Ttx,bv8_,f{Y߰FnHdߴuf)F3IV> IDATD'SﻞUt(3!s4R pnzr{ ,X`o¹,X`>J2†a* j` Ō*,,I8 > @lŋo%īTLȶ\^ nn"Z,n٬Z $_H#3^p}OcZOpm8΄2+/ͿyiO C T 8HE\\O<=0,wI[@PHNYKH 8HAxDMYJt,JJcrؽk.H@)ih^^k JCzz2[@ۿ=9CVN[[A$ ZIVY'& 9@O(k J4^U:I7Ha~sdŋo;^"'LM°l1IȜQsȷڇ?ɋGqH5Ů --Lʂ ,p. ,Xa~=3*brɀu WĄa=뻇"dbZǹgxd=b{`ɞF2UNzqsyV<ټؙJ(H4z@`G`ZACqg a˟ɰپKݓ)V%ɀdL_#|vk.h,iK Ky'8~#v9$Ԩ sLsU~VRL&<^Kd@ɶzڑQ s (ACAYHn>4+>ֹK07 aБU8r5G };x jB(zy5~oK ' lp^F9y uzy >L;:qDP58"6fJ'6ő( Fm #$2hZyNNO ]kF4Y)ٹM|l◀re.c-lr'?`n(D1Y!sm0IA'Tlvx ΛCYRJ?J޽Ov,X`sY`~CC_ϧn2Fp))))sPABЛ8;}#2/ؓb#ۆ3)`oagۯK NGܤHN*%*Jnq`<p'G9bwAoaUq$3h9t Q^_^ݰkL23[r@M *4S{S(IL"*22}o@͇q a#2D=O|S[j;?22ۮ07dԢXm~@V_]~}l0%֊3dRz2Ɗq<3>t{!҃͊bUblo~{d./taNv?}Y#IMϟןCgg{Q m}#kvt,}~f{n;$z+N{%mz>W5 Jdғ8YSBR!I#=BSm ,X8 , 68)y`XI^!uYYQ Xu11)Ԋٷrqq"P<3oo?,|3>W Sh('j"X2ÆeM n~pNf8:w5=dW{_deuUeU!!Xa0Bh@FZV/b0 04S]=,b8VwuVd睏h^]$Mɭ. ^ó@=wpIr$d؊NKoSM@_mjћ4lRЀbC@H#rtߟ%˨4(#SVrHR!3ʼe8+ |,d ,XKsY`/779櫠ݒC>`f9vm)_W֜)τ*NN607Fbs/{aDVDjNxJ65Hp ȣ(|K( u‡?ɀ95U)(w&C)tX/l!+PxJA05/.c\# f-q} D ֘+iRn4) CG=(%\GKBz<|N=M_p{< MhS<*^S\3,RC W=xQ":uw 3G.9 $̬)O}x^7{l5m2povg_ޔ9_`EiyCv\]|s@:h#lvxLAkW}ʗkJzBm0̃$4c{4Gjo뢄N@ N[uQt_ ,Xb\,X`=D4٘,`r}&Gݐ;lwA-amxmU[I1 nOfvGb71IbD`GV`Dk-"k;3YSٙJ\\vgN2N-|T0'j:D*c 'hʾ5G@ 8S"\)m_7h[WW23JmP~h< 3ŁU3 э͏"a.HtlR{fԚ))Q:DS/Fy%D*?xi[.'J}˼L# jt7!M6QIPspr\g$Z  @LZ!ϓ/6bL{\ڕ,y5L7Ԭz”iY%G ..9g@lz3zp2 =)+5X|U.)$"_J>ݾ92GakDKaj(aj_"3a3R3`NH;/k9YE^;-ij oY` O,˂ ,g@&pu@>%R66"wSwf fidH%X30hVmˋ7vG#vP1k;=3#w,XE22#ld~pFC؜~G!%dLp@3*|媰vfiNY `FAOu^Ij^^!1ZhPBdD5F8; !Re[V&jԋD3X <vх'ݎ̣}IV?BĮ)bR` (Z;sGL$=g)f: 5"y 5D&i弐4;jVK|྅\; 0feoĄ< '@Pdz+7l0vb,P䆃RV$O]=38Q]%\jHx:' <'4"`(FQwC=J5e_PޟEL~x2<;bn毺ܽEC>)Ag`j &eq;4oG:%d0mADz⓬Sn i :e@DiӰw'=Y.ȕKTNA6S2f^ LYzLyvilۣ| A)AcM ,X3`\,X`A!_?9N$vbU!yd7L3a!v&G6P*&؜}]86s@$YNMmR&zrmv|0<}i{dcG;-W|;h.-|QJ-df$@&ѭ#{Gir.6J nan~2 =us*{e^w+,FʄyP$ڄfRKSfr#΁'$E ԽQqDLFCB#9 e&dqIP7y&DdI4@!6[>V M*%)&F;zfg5,s\_0(d <&Y.Aߘ=H;3.B$(Kj z r 8edx|^bsX@G H! pG B.e̍IE0ZbF4."ZtLctXvyEMAe?37DCL C`IPɉ ؁oy6k<48:kii :3{/''N 13_-X:leMx4Ej-EfkdfR;+ֲS:s3SSNM.MiXqc痟&-37?ɡmP)5kNg̘1cƌ̹̘1cƌ>BO50)Ѽ*tٚ`ؤ(Լ5`fՇpCf&2qz]pZ2,/6qDbH hT;jq&N}dM8[aN_?8C&NwuY-)!"lדRŚ QF vwy]"I/\κsVv{*}>hv(ZasI_nx֌L[gPnNL)S=2qhT]?S> dFK*]9f) r\fb?=ʥo&+H$,`$Ә= ^m˞@[Mq~ oR%TG I4LgnFw;]uafp=6,?qfRri$JT$teh6Wp#5)7#8Rr n.>[36+ =Vnn#Ӓ]q$i+{ۖnό3f?s1cƌo,s[`z'wdff;LE9YL MxDM)3q08Q) ("՛)0G iؘNOAj$׭cy$hI"r'h4%X 6nChIZ@5$|OA7DCƤ٧^vZ$cHw*Fiʝ;Х'/\ 7y_ JfzA&-O o}q};Br $ b~\H'77Nl@lM9vI)5 !rP ܲ\^\|Xt7U_EU݆x"G0 d2KEHS A/_eܾf 'M:(<0KdU:M(OomlVRقJt~ |QeƷd~]Ql*f+KjQvW:Sn;w)%곖:z/bM|1DQedIlu$[N0LBH[J [ z&\f̘1c32cƌ3&LBtG%'UK%^T@DTdߥ^Kd4!6igMoZD(]C6k'wS}̠@haLQ\9UE@cQE %ʳ.ouTCtH[EG2PTdD%TL{?#yh~Oz/]4E~81zUtVgo!u yZ3߼LМldgOA[ Lw쫏TQ} ;*M"A7 ̖eY•A{un{{vO Ud)ܙ='a@ @:D/]>9=q<=3lYfEUY;V h^V nnJc3i~Gߔq,\^ c{[\:_?X@ Q@) q\4Nw\iR:4. uJֵG` {0R3f̘32cƌ3AƊ" w3qd@nݣ IDATH?GqfBcҦG'oGaͯИ]ByWcP8r qѳ%`ofg%Z*Vꅛ;ؓO?-}gộ!]e5[h,FX>ܟ}ԔfJn7njogŽD}15Xi߁N!WCa!.3 zv \¾vxn.,Oj4,e4D,{D¶duپA&M@贤epY6Ab@q@ "aF dgвRmyęܼmx|ۣ{_yiꞄ5S$DӀ_Cd^]rx]_dRt[J,@"b]tVnt6PbKڐyO>/3ڎn[SQJ*goF+4r j뛏0O_KGfPoYb;K :͘8 ">tұ% -WO~sv.m8 ={z`lK$`Ӓ$Gcqs X˾3ȗ&~<3ZveDrQ'o u<49PXTɸg@:ll;g:<%Θ1cƌfeƌ3)*QŎ VʨVa#}UJpQ2X^ oWT!cYlx6Ξ@23%O.BCHv]յ9kg$@( ;AXF!$)䁮"ճILo%c~ ]Bu<pC+#$IsPy܃[#=He9OVJI<w۴abWWđRwNH%KhR`>_2_]4`P̉[ْQڅ2b}X*CFA3BJN6Cݲ:knrm:!P7|vKSDC+!IE]g2k{l۶Bd~=ow0]V]<ɞTcDoRsKjMbFUjҳhKq{I܂2W0'b ꈖ=z_ -in4l$_Ҥ7r1^ضL(ѹDCQFljp0a„ _2a„ )vbL!`d^|z<zb :`Ft3DWN 3,Bj232:-P'qh^ A2YhF{"U •՛VX^mfL8H)pEHRǜ[rO&zA p[OVOKm֗G q>/tX!W*hf G)"P++5(* 2tPrg`ppSutӕfuIeP!x`(DVG)p`D,G܏i+y}\/-2hD22kB3CIE[u~h„ &|!L˄ &` Vh$s8,2ܼ]HDWsZh{zo`$@!jA03B,pm/6h38f3wu9M@&u?xI,G ^ ([(,`1n;MLPi=3Ew.=?&~//U*k; , 0] ATx{W=Amfcر b>,Wo{b%LY{nDu.]* BHžGtPn.>kM@4[0WjkgpE !x~CD# b΢"~ 0blͰS8F)foUBK!aprdarÎ=EcPBr3D6G ~wqF&bV˜'[2a„ &|&e„ ^SՒ_[yŐEh ckVAr "A7ҫbhh/Mf-?"'j"0Ps"<ú[5ьaH4Z̰^k8N o XZ01*R"bke ܉S_NՐtd.(H`px jP(8"f,|`aU$ WЈcu'‘0OW\k^o~l89~,b!ݑk'KRW\{rq|v?Zn,)5~`N:!xߗ*h_8^ Gυ k6S~r\}u>,IFJH<Ά@^|has:͔fޙ-=J X`Bo9f]1HKrZqYVOz1 M\.b-hI|900k;|8Ðo{z֌Bd@LWy$ZlxX3Bt'= %NCA .DGͬ8(&G)Fl[iK|E<.D* c#$P ^n>ǫJd##!5N߁/ȅi z3+!cwќFYnV!GSaQJ]P)`DDIʥb ʔ% "ˈY(C1GAeR^6< ǫ ]jq=mr~vJqz :53a Q%3D,f+xpd>`Ve"y0a„ 2a„ +HHM#V˯JJܳxʸ9;~:0$r#1XAH{;Hv82V%Y ayU@_BK7  ,'C\&@r=7Еoc!=Q̀ W?/+MD ,&G!d~C!$@cq𧁣Оa.(w$p,,raD Ӊ3LBUo,%҂A.zZg A^3#uJ bX HM< v{->)vjA, ǚ400RECWn܏" 7^Cy'cP)OjK> 1HR[n?bAbə4#:ObDώ%l#hqA6}P(P /:bE3K zee//;Ä &L0q.&L:YmJ|_o/u+g`P?-ChI, ~ڍoD" X~%@::]IdY=Ec`,n4 "$#ٖil3m_@UY9VfD;,^DfeVQJ9(ME(g&Ԟ=cDzlPDRM@0X8h X7X}f 0'J 0!$2T:tG!*}WB4dŃQH8zρgۭ9"UiI#m䄒 ]SD2 \`I ͗׺RӨkI#*4Jr4Rp3%,P-jGfϰ1ˉ)|46U> tk{.b9Y xgt93w XpSntF)[lpxj£p}u/(PfNV,Vj qq'3kj $BUL"E..>OJI0bI&fkXa[98q:_3f̘b\f̘1C@mBH7 qyvO t%cD rPtJxOgm ) k Sy"[C5ƺ !g[&Ş:>$  O,(øi?2K%&D.~K-PckZܤF,@Ae42X<#<#4ܯ}*.8>TNNT)R.SQLe6(‘Pt:SSP\T4_ )+MaP␞3YkdF 0=Z6%'!oy$XF ~%x T0I2SMo+<8p,D$E!esl'G^%qcR2x8hsbCChR3VD ׁ]QYTƒ`-#[u2c xTE-3*n6;c(E4[6cƌ3f;feƌ3>PqȄA‚R<aav`Yݽ!UFh!NCmADDcd񁅩&xa!bvա-È< B+o^Ak+b+8x;ΑfDT79$[,(xC\ 2}d#P fC#% j'Gv@0B iaV"ڨ.=J$GY>g2YY )6-= B+&nV#;?)[E&5! :fw339$檒!%y7O*oV02%9)Aʶ,&($ |) 6(YjS̄z3-j*B|Ul'pR-kxW`C-bT521/;W'2^BVyz-ʰJ^֥IZ3f̘ab\f̘1EΓ9['厓?"!M2!5O!FG"0j2n2=dD daG'$8dnE5 &Į¢lE@H`U˵xMgavҰyzB5BX%7dYȬn~fMoQ'G(N{G]JƮd2[䒜F>+Kl g,3>F8ڭ8O62!YKfQՖgILm,yY.i 3WՏ %' "knpr @o^JT:ߣx6}u{qt-h{fvx7fy a*jCr8%QDI22?+㻔2$e4CDEn*f̘1cƌw̹̘1c蟸'aUrWٵBsீGo.1h/z4 dF ga> ) )]9} w'j֧1J ,`WgX$ptdmyV ܠ?xgߓBXd3c(*B =ieSR/~TW!shjs)7hV-TKۻ}Ҩ􊺛&]RBiMH(}\+R{8ztF 0;`@y{yav "wxu :,uXő̚B"H+@xف <0sK" ?@ +.RUlm1C1k6U`Q--GAhS^ݓOno@(,]soь3fx7̜ˌ3f|xzC E;Ɓ`(xzF¥OlWPz8eF(8E'>B`ANI.2\_^G_?Hٽ^oXГqg{$iD#d2-<%]Qc-lx?Bn=œ5`=e cޙsy7DI2nm{<.'u_ȸv =~}3ƉSm"iRjLe7WBkfmMj32\e6lǣ+b[4}3W؅hª~bbBhHڜJf/36bץ 3wznBA E&11Fͦ6_e$vZiߢ$~ńK x ++C e"jVx"5 nZ~'[ mrO4c8m>S׊g`e[.Fil32KRfl#3&Ӕ2l=.)xW*I 2ru5>,Lnfb%Rl 5ס5 ^\}9ٻ#Ri|_/!Dd Xٱ^IbfO<fIw 4/l~4,o;膕pg6,RMlioC5.G*tLWuVcLdBllj[K6eRL(%r3ˬHuI!$\$(Pz*klraċ)W;x|E',04΢b촠}4N RQW@wx13Lq1ԂG8x"tAg0z'3Ժ"_1<%Q=TROLoϤ.X P(p5wcKsG*iƌ3f93fxC1T18V / NNe@ umCgWW?͂XDdQFmւ 'wpXͷ2l:IEY^<VSE <ڔpiﬞy"3 6td DX{z%) r x֘iW5yavmW?Qn;2,Ql*K%J#I.nr@_\m(lѨ-ąR`e۸5s@&z˟,h dـŘΐpf4ɏ.0M\VY_k,fb--)8!]\X.cyܒ ǜ?E!R‰1|\,cҢi|[!@̓p3V=*˃D/+O˳ hٲ69,W cE{f̘1cc\f̘1Mb1$7X-٭J\E\zzqPL8 &wf܍YP;`SG%es)68  SmfWǘL7aH9;Aؖf|QKew2ݢ/w!]}U0[-ؐ!(TL%0$tbbuVZ6ڌQ)S2q3Z=~)mBr8]qC{(d]t18hVR O IdkCOٻߡ]\|9ʛɇb6fl\y'!<{tĶ%ܗgŠ1yz+U.D!pt'{{5Vmn~b-[GjpŞ2B^]BU\Yؓ5^hnBf/ء ,+f: D]B X!A]xLZ=z&]{78:kƌ3fy93fxS1FFm(:ã3RdZgg'@ޑԺY1,%+doDCL6Y9&Psj.8=ʔiii!`:!,u1 v625C @!ֈq,LfyfqZ06h/4f XM9Lޔ6wtI[Va_(n-6y'f3*5#\!pAp0_=qX+`ki@ g~@4v=> O7)\gAf&+"HP;6X.wBVؽpryE(?;g[0i30x)B<=a;˳$ ؆*ӊᾲDz֧H>m3F'|w.Y1ec(M4+̘1cƌ732cƌo4@rx5Zykt%ᩤ0d3[Y2v0$c#)g4Lv.2 ޴pted@HkTʑJ^۩mcF;7S3ͥ_ `Xa9/Zr:[m8/$^ q$+_ ?VwCE5J Œ ;.ciߠW=Q3f̘1̹̘1cGC"d2k%qtBM!kRYꇔZQ_-6IP`$Ixz[%p!f6DZڨ+ph^8y#b/YY$Q.x"){D1B.\NZ)mLo1b2F(+< ~/#k=# |G<_ n|:]RI߅*q U3ݱznc6I`A8$ bᲈ]-`%Uz5eb 1WEXr1IV2DF~AFO X.%zHFf|kJd4RWkBrN1`V]DasCX05aoQ8|(V4.5q*$mowhg{d0Mcmw( pP4Qhs1cƌ/s1cƌc@h]Oa1G_^,CX[NcdBX +j ;vجV- E8{(Ct$- Be̼$cP?xqוjtI})ĝ9֑ i"pzˣ\Rn{v."<&Q aptuցU3.ew_L&tY=?]ұk"h%hg?XtF, C_Bёյs`o,v3b+AdO(va@(͎aEvI;Y¬gjYc@)!`"i[Hg?ݩ(À=َ4dޏ8,+\#[ۧO3WC)T ]M*Ġ(I\ 0-<"<#z~3]3f̘132cƌo:rbX=s|R` ȃc6 [jځ- QE#CDGvД& Ɍ]ł@Cdm D4#U4@C)xwqTkV,ȸXqɧK͖#ogx djfԇ;G*P_K#mi(dz=jchV"Vߕr%|B @xO]7`," XhL*b \..>NgͫjbWOd$0!":Q /RDx7fr!ZS23RkyN}GqTeOwR۝.KZu$,.4`)ZaoH1{:$Fo^\~jw.?ޯc$ *YŊDFZ *lJIUYX֐͗Hv},fs$A#'C9/S## O2dL)Rf, j XH.ٴD^8N(]st:9֡YSWM~t<9+-!H*ƱGRZܖ0Gzl|Z'k359<,3A*A菥=/?dhJm7H#-ϧx[ȩI-9H`^3%)F@Ҧ戨"X \[(-|_چ7DB?'(_G߬ݙuS;ӌpO 5A#2h$)ܪ[;hib̽Hۦm1Rv|> 5v݈ja$铧%9תNd5 %X0nAC;_2Yk/˴$=[$^hX_~fK8$p+&`Nch[fr(k=!tuuc5NO~ti劼 %wN|9]st:m?aUC$6g:t7@1kX.dz-\@ICwJ3lXW '02j4ma4sHSԸʔec4]a{FX &&uoW u_Ai-vCp@T,=*=JFG{K8HҷZMLH[jB zgY~Q4UB||aJn//34a5̯;t:k.N {QBoKvu(ͥ?/fhLH< X3[k}.u`WkjE*uk!֬TzF,0[װv9\dvm=-#%s0P f֞Z)`P99ϣ-To ^)~k>J˷o~fWI:p.2fԯV[ kMYyv_& q#%ix~4cONߎqEϼRl>86 ` PGJ3[VxKPxyi+ kJ(/Lj—@œu /H0Ab5G2"w'>T \(QqzwC* Kt^t:K<3=gpI"+xo|x(n8͍sK@2bPc6Ef|trM L[8y?%,"- GD;-i>8I>`L4b +V=4Pn56f%8=܀|=ڠ>yprZtT/䫐KaP.Ȅ G$)̗8rt:ߐt:Nkj̜@pk`̔ `>cDnS "C96ᶫlѼ9Ű%oah f NNpO%zͩ3K 3)M ""3z8s6L̎'`6OD2*"h#-;z(3V^[!JA5N8 vFٰPN/an6- 76=.!Pb֭%A+(@'qjB&M͝xΫ5|%t# sXlM6(nnBRZc^ʤlLnmAJXsP,#Պ(!ɼ)7@kMp[PnJfk"D wR;o]KTN0]st:-f#% @ˡA0l/=/xR)dHΣÿ],nn~00Mcմf L`Lpr\OU[4h: %fIe'Cf@kjR$]28QOOzQ~9}ڊɿ LBHFbWV.>.jY)#x<wkgX|l oPC)Il9GvIA`U>9IVˏmش1M&7@š Rk n*lճ8(MD2Y#C- Y,?" @1M5 PDzߧf%Lg=!E)Cٲ+Ɗ'$;9 EN8?}NcASg >Z~ڂvL_'DZ{HXSi6D_AN!dڜ%fYaHֺW@"FX:ܧ0}V 3'||/U[{q3 Q:ENsKoGR!DGo^U(t./>2X8:|x`tyv|%RH )@UKjM$)0D&>&pZ0 S}sjoѧL,( /vМp2aZɴԐ;kܚ`xz{UMk50n̙2lo֜u$T7eNݳR|rғG548_}H$@|!t:\:N%/(£)Eq#|p0 Y-RQM*&7[r ED)64EN%'?d>XxYo 9qh1yH7LRyG(cULuK12CL{)&$Ej"SntSx.OʞVo)2˃7!'忓aZôF$`MjRߦG Քж[~`gHjq-Z 5/#^-iz[J(k$9|_duOufZa 2^-X$d~.?,? ,w﷪CDfUwH硧FU8q.<;;}7=k+9sS|R(vX5" Ğ>{0+x!`wחβ9ZgL9}\R9Pf wdR-G,Z nF3שRDfV2YΘ1cƌ7̹̘1cƻ)0z~z^+P^Lf8׽ݿ4 Kb>G*wWȥAXU(pxZANwm 1뾣4`ʔ){-^q."`WfƯc+V#a%쯆wԴ-$"Ug>zv s^_U)n1-[kk (!-43q>!$sa6d,hkb{cDb Ȍ5H 䑴2ћK-I u?Tg&a%k:g"l|ƇHo| I {{_GO t3*8FTBHH*LY}PpG5?3f̘10s.3f̘b"6^ kDZBΉPZq-X.wtP-vAd_ IDAT0)Z Ve"/[Rg@<ׇ7C쾪E]rO`,>糮ϢO5V3~ 7k}<5,˗'Z@͏{۴o#] CI=o$f+@O]6Y$4%,Wk# -ap.ץ 5Gj}t@"yxZ`O7;۠4;b / bQA@yvrQ"DkHvr @dj(<= CFէP7iȐ@Ȗ-C)|pfM26:3f̘f93fxDZ[EH̦Qg-BB\8J\6lP82C.63hy>nGwe ώ$]B_g00Be*HO$ZzCP֡-ZwT 4wFU_͛P"*bu 9КaYuST%V{j `m#hBo[=lc{Lh#k?i[5νwvD#d綬Dύ VD=vݯ MRyy5!^AzehrYoO. $ jtU6ws+Ȍ[vKyb-Q2 -4<&omkCf**Ʃ3f̘F93fxWj)Nk'i֋k 7lWFo^;IE.5қ@r%"Ȉr`7`v#k!Nҗ@"X{HƄ`i [MXhx+;ɤx(4^@Bk `3gC|cIۿY-ȅ2+V0gڍGABOɽT|8o%h*h 뙶jSܔ@}yPg@&A#Y@HJvc=RrGYz`5= *ˡO435 F:ƌ$Y!Q V&ҡ$k\Uqvj0GE4Ȗf)C&0dи&4[Kosf̘1cƻs1cƌw~ ŹX6׋H/nM/+}|Brڠwf& 4\]R->UA8 [ ,?<[3fZ{ҶVy֤s40pqR$͈%^kT1cƌ3^s1cƌw6opJe>lnݿfXp~y]_:BZ,2DkJue$ec0>tqstcV/ų+ !a1$ڿv7$<jL BRNAm0[n2" P BGG^a:IUzv.zxl"Nք%ͬ[:b`&pn,lqGbɛ}cL k#һĽZd1:gi?'#3Sm"i ni/a'(%V Gߡ}P̼Ņ˓Z?y?=>=}yrkqybYG,"d3f̘1 0s.3f̘.Vj&T-+RÇZi29+܈RJĆ=ő;qXd $/3<{a?N7aF}e8K}~F8A&ʐSipbM\4⫀&si8 ȊݽQ=A3ˬ@d۝?7T5?Xe#aJ9S Uenlh[Zh$:Hv]յ> $J,!HK$y{^Ph0_!Fmm٫I-XFo :I"6ŖF):32"\ Hk\󳋋[ŇU1{ wv{qO^P$لOz5ZB 5eRrݣf&&bȦ<E\LSY!afZZJdju7+/%IPҝqu d!SniHxf̘1cƌ̹̘1c_#"IAztI4f$a{7pj@`eŰ89 /.Ꭱs 4gg:}x f_ Rp;ޮZfOɚKGU nͯg?-{?e MѲKjcޘrC8؂*)njK!c|9 X|t"~C)4x0}򅡩7s,g 4ڮ+97m@*͞=u[Ɗcai̐0InR6%i|rQg捫3證hN2a48=0׾k͘1cƌ̹̘1c=9pH\Nk/7k  alTpoV$8Fd$:m<h_(Ȧ+_s{KSE̽`G)WZ~si-4\WߺU}Ezc78<ݚkJ(V)\jHt;10!D #3bj0_x9 Ul^ Rn&CJ(bkFK/iKn^njƌ3fy93fx)+Cf27./?RQv EU2 Ȉ119dXfZ#!w*{V: -KPЌfrɮ{@SBjnX+?9..?GVO5} $h@JM!Ԋ[@-mǦu UlvfB3@9DJYTnhu}kIdLmO_XJ̕q)6A ]^"~CgAK6Kekގ72)2NO?]>Hz^>$u4ZH wj}$'-r1 M "SI@/^@=/|oN2@ebLr++2B1z?}zW݅.mJr?K?)&()z"D:ਁ (@#uT B&ԓ)B<}C۳D+ BL*]}\gG<;; /zɤ^ a}= &qUJeztd˷gƌ3f̸̹̘1cƌ]$w ʄ =?WLZ8bHd4݇SB *'_~bM__#*zne&S6"TwY^m P Jf,$dM$/\=}]jO-k`l@.e&mfgJf$ rpnbc\ sޙ@6P~ܣ"Ez׆; -ĭ R_p?W~:IkIS4[LvhF@g,v3&ce\6?vw1U"nd}7@6`"pL0Bϼh)ݑ7Eo6cR5э)ԊȷPo`)db2?~[BMX.~cfa,J} ٮ7QD$; fX۰1),o//>5vj g̘1cƛs1cƌ7-1DO%X(u[tDJ.85F h0f\ͭUt( Xkf& NCtE I΄|Np0E0+_67%pˌ S"բpm^ÚKf0 B e{Ot2%%C!C/q*9Ժ0BH ad&٦h S;;)Ov,AjKG$1!Ʒ$J%q3k~.֚v7_h, bHtЦ"!Dػ;X33$mgd6 Ag(e%$]H`8*sޙ!R] .}N%znJPa mBw--=.Ho ޓWmgeDg>kU0Fe^FzVm{ݫө)iʁIHH9(|V "Mbaڈ:zz( {JbhMF#91" `"xh@ZH^2m@leL8MGR6qAp^r%5ol ,x e S ˻!ȯ9chn ^)0ټ͑1`zG*;dUᶀX& p8!!*SOeos歐3 #I,3ϮB%ʮ|t=aX&J\MyVkɜ šg@R[GEE" pV":߹Ud(e6WYaSBTkx:M@M H˩9ɋ_Wf5ЈRtEd#N,]%"i{µy0h%x:mf[>M۽S;["U> Ȑ$$>d*Jg͠a nzo_ۺ 9GrdJ[Ee)K!wɜ6y |p. ,XM6ufH"D~c( Q(Z(Q @qqGߑ58!j3dWD4 ڵ}6NN"D @-a$" =sAxã_d+$@9>RP+b[gp֐5 2=-OgU>#p.!lLm.;ί6YvoM!llKz $J3X@9:9 :=FNN?q8㣟o!Ma&H ]Pk?Ζ[y+osLRlzk[RLSˆX t4^+44asna:gÌ&ab DP & QK O>`j d+*.)|:APܔ᜾,(YYǛwg)h vY[|6CoĖļ>[I0 "B$~BlRύJ.I^¥h |U,˂ |C1^.~׈{?6؈y휈b<' lAiX@pviosr5\>q1(Nk\"Vjp'>d70n2=wI97%{Zg_"V"p6ǚ8{y*j4MJoBڰk_$Oj c,_7c` (b"Z+V{/3Ğa:gY}mUlj$h >/t=* tf298qȕul J2` /k9}$xj AcZ }g X첊:%v\v[Od q)2-hq|#)2@l[~,޻(–˥}&p#%6GI rf {hJDN}vIJ iBӿD|Q "an$7==kVA Q,42xr[jX_jl ,e ؾn@ 2>>z(gAG7?{y!fYJ a0~?)K~o~1 dj*<]ޅ/%=-X`_ ` lo)m{<%㲇 ^M/nXq,f0txDc`<ͣß (sUQ5M9a aҮkP0ba+":Yqv/&A$p]L{r,Ϙ^Ya'Q Vs0aSΧ-*앷Guס1MCZA2{r=˽9:i0 0o|bnك璊EX7B fɰ 2QRY@X17X#d^SX %Xɘsdr虾v\k 8m %~L}^ύ[%T^nUQƽ eʍ!קgu5Ty9Ir_KK8NؘT5Nu0y"by1R&!Q>ˍPŽȞmCbΦaQq;BJٷ(_s1YD=Y`  `T:;Muխ_jE:}LEK%5'WvRW($7GF"Ө@biz+u}ډ6IgE2:PBD%c(}'zL$k/+",K[ᠼLj9 `62Q駆eaiҦa~qđJ(F[<(ps2 &'Cp ˼frVp+!Z"[ ̱/3@X*3B<yZ4Gݶ|zz6{FTE&XߏIDM%Jx?RO..~D%Ee*c) O#Nc]k$E֣fl`d Y#,6lįef<X~#2~5mf6G~Td<(=y\|v kǸhPB;[4{ƌ3fØ93f̘`oS)뷛.KƬh03%p' )FYxI)7%o9kCn{QH$) KidJǨl;qd4rY(MŶb54$/U4Br; JbJEąLNE':= P SF;ܞ;Bvۀ\:'4z[Q(ë_vdD`BN)(ƾFG):K{R:2V#_1 mCVָJ+_"*)Lꀽsik aL䈈#0H21q(=fo&GN_U40KyQUKJSH&8q 2/HGB^0VV ͅ'ab jk!$U/LD&8vw>}I)`t!hUD;͘1cƌw32cƌ*vfUU&z[N6eI&AJ 2@"ȰDۀ`Ȁǧ`֧̬>>K"dO`>߯n]ʀΥ؛B} bENLI*߳S3g LDH׫'_30R$.e Lt :mh,_Khg!($PI ]h[,ֱ l ę%i$HZm @J$(!ͥmy*dٷ+sZ{|kJ[ 1чBpͰ={hSV;Cn`DMIRl J1~KZlAX=@yĈ@Hq<;!uJ]V($V*Tܭd"í*BgiGV ^=qP 'kXe,֎/>a+k3q;>\f̘1c`\f̘1`]F?xW%&DMdmn(Œ>A *!АaQo qn/"h jSI/*U32[IJa?Bp ڷ4P%AMR0 q7$Sto8|+L}R&FFԜ~/54U#ܹA/i̽O4ĹHl $cYLIE&qRm=fY#S< 5 )lKdv 0%:h1ƻ5~]Ƒ,z PҩrLmYuHpmn )ƨz 1%VEWDN&4nF:2[WʫrI$3J 7@fGFbV:L-Љִ^eҊ?]Ll7x2 PfX:sE7ܬ8L[[NtL{ ӌ3fx1s.3f̘1aT u JaTOAFDr T~11a@l ZdWW~SRZI@ D$ٖhfc@UcP&}v*yqIk]^$߁yfD9RpA+7Ym&ԴT%%roɖJ B# `\2ߦ'Cc52d&#$lHұJjܨ&! t3Rf1L5"1.L'SK#0FF,!P\d)I hFxQwKjE>"ÌzIG4eV'9*Wu CLdTJTEMb xaHKHiٖLf^u^v2GĺX]l4:Gie~qi;IL!5(c/?v4Ha2=So]J婩g79hcԞ@2:3X-T߹իa D6W7VzLEg]?9)ڀҕdX2b̠L[j=`/瘰!97i BKW#K`7nD=2Ll#7˼;'<ˌ3fxK̜ˌ3f͐%>aOǨW0 se1Z,J)\&͈E|sfmY甋bNdDY %Y ʞ:eB;/uы&ʥܝ>p:'L?_~|~cI |%2G_VNb(43<\vaT^jgy(H{_TtE ԭ;풆 3ш&$M)-}t[տ  =u Im (AWxOĔ3qumgZGc8 LHCVYyw_ӓXY>n B"FT{nĺ{{l ʝ`hs֤?{X|q__;z 2EYbKmQFƈ*^]ҿ;Q+,Ih6-=&Lɾ]]|}GQ54#hcIH* `FtEz3ֳ^Cˌ3fx̜ˌ3fx[KO~ 0@q69y'sY@CCh螩nJD$lc (yEvרYaKS c鿹:e E7[/U>ǁ31(s،(țo#4HdwhHX}8Ҁ 6ڢu B3F*cv@A#{? ˗G>ԤV]E"Lgt+ ξ|TƋaMN=[bY V1" VGu {bxz}~q1nʊ&kʠEuI(~G82kޕX^s^f햅 Ʋqc^ `o$l<5A@ʱ2ŽeVU ^lr}'O0(q!`8!̜ˌ3fxNqwdF}*.d[Hfb83Y JcQD\wӧ?M1SWo(=1;S_6g˽ﶶ5שro@E4."qp툁X>w lg,X<8q̭Mo?^Dݽ)&TBv "2k||v/L =i3FU^l yc}kH{+TtYĘmCjWI) ӈgh$]` -\M{nh鞒]|چxT3I`JVuQC2@@$Gxx6 2&c\`&0V&)ѽpY$G coRp28T Jfn^1H$Q;_Myŭ<-o0 !$ s͈1L ZIql=30D=dȨM'pp/˷ooѼ]9/闔b3f̘1c+a\f̘15GY>т5$(#3V1J~bpAltzyiOVj/ah'?4 Tƻ-1RB#)qN}bEF@GeAk{%TnEh1l܁vC# rMaS!t&Vw+@G#Rn`[W ms'/?%suJp5_M0\y;7>Ȭ|*Ha|N-DvI )CHh$ $\$v< ALjn_LVߊx0Eʩf9e.ONf`>%UOU`#¡*F!P$$t n\b$Ol)YBR+k̍5=V)m蒷ٴ(] ͔V\Y1&]K=(+!)=wR>rr}UқG1;H|ס M7cƌ3fs1cƌϙ Ve$o^DP̜Zޞ* D`qӣlx͓S0R88=Ckg{-I3=p\QSzJx|?↞+#azNioW`igxD E.w_=;iK𶼩"GU)ݹD_x|+K6)'%[^PR9J .aRo #[go2(6R1vQI^գGߋ5]i\fD%{_xCy!tԇHpJP>{HX& C:6]TxnaO)Hрۦ1֪;Z}6)hU,"0\;>>;W:[RUN |֨V"ۘ@fm6)Qi% (!v2`7ȯgttR܊ڞ3/}f93f̘1 32cƌ3pLB$HfٵA9&ue[ }}_4c A'0k(}170ևsMIHZjGEČݡ69(m9dedd@H>3RXu׹?s]f@WG4hTM*2Y8ޣdMY2{[Fuڋ1Od$2QqD !}(314Moz0uԓ_l nJ!3FT VwN.~ʲҟ~8#K,dj[jwjz 'pT̨.ep< :7%[&"Ј=_{uw#K;}?3;]Ep z1o&v94+F.-wo-&rRZU1֙HD%H,D<`(ir쾒z,DBrMF0MJ4F$ |$#)b'[ i*ޒv21A /`j!MwH#)qÓӟsVCcZ LkDlX+\}3u+C*c0$].:;OR?dDbWMIR:H үWpzOySlnWyh9clOg\%x(,b "sǧOމig3cƌ3~0s.3f̘Þ{A4L1eԀU"pk*lX f vG 66GH* B#V_Yr. ]jqw(ƒA` ؍_̔!QC̤3a&@(٤qz#n% mG"0##Nf~Џ$*`Z\{|zPJ+ʩCj具48%2/{o{-6,=qB3Vkǧ?Pw#2v[{3(y 088X۞Vu5޷ݐXd>:e(ԭ >1_ #nqxpOYLbc.Ok n0C_՗8ޤ5b&'G3`Ɍggg?71 dr"k%@6cm\b1Fr:o.I)M%HR iuRDs)sd*nYy̐6] /SX+lKG0Uw3f̘:c\f̘1ms%I23[AfgjQ]b. 4 Yyz!sw]+~NIb[wٻKַw3tDZ)B2\K(""!1x왾ΥO[<@\ IDAT|NXzKuvՑ›]?;Czω!n`,yM@FI95(SuK1YɃa k @8_}p qI-JCkkM (#3CPU#mh5x̚dDH#fC)h_hK1 x~oh A0o*ɣtښ%x) x*]A H7ELkkA]mE|؝qd`, RPj aDc8V,ssS8aBL+UU ,@lRD+4 8>E*7RqX.%`G7{:9O+S,Y'-09n Sch,ve]hhӳIUgɵ9eƌ3f|a̜ˌ3fl +8M R"iҁ3@Z<{fmw׿_0*Uևo)QIZy? ɔr=̼d$L,7kn$u.MÅVRR8ɞC@ 1@RD!]>"Wݤ ջJDPio E׏Ha 3HrL5BU #BDUf G P <<*0abe0H'AXkѯNaȖ(5bEx`1{>ۥȯkn-6mu+~򔼁^I Π2Xa 4?Fj Rn@p.p6G*ۡ.i}!X X,cVjjkJOBʵy\&&\m!6Es)qWstkT1d64E1A>8 ԧ쓕V=,r1cƌ_32cƌ3M< .>5ŠXCqoH_{kPbwdžłr#A{zzIx{AkFOE+476Jidf01 ӈ'4@JXNE 9PA ;aKtcc*HRX@qz؋%P5m:Ql@D8KEW-ffݕ=pBA,rkPC?/la*R*$V$ҡĭDbjR`U1G*F aRlkWlF||q'-M+ơXsǗuNovc 7jFī]r)@]W󇋴q?ȧ:%rdP աYw9{;)z"2԰Z1^&)F-@cD[b$ˏ7#o@ $#6fJAq" Б&v+f̘1c˅s1cƌ+N3+O~L3aq_cuoEZK%[\F׉ F V[>i;t-ģq<{s+p{{$;o9dyG{Ww.Y59HX ÔۅHi] ӳ CV48/o _k 8:z7CP+4O)2 PB+iX`fwG?S\CH czI&U}nD@8wBqr=:#V~vev|R7 KףLY0Gh)a:_HWg4?LJ+'/u罌 Hfۊr5cƌ3f|Q̜ˌ3f]o2u ˈb'gO>4r$ ەn ftD@Pv˛׏Vx>J4\_OE8`cwD,Ev/mwidӈ%{o^Լܠ-$RB&Ԍ!.EYprQpyQ k:p-Lk~v Xeu e {LH(S1DoI(5`Xr]E@kQ3[vd$!%aN%u5mǼC=2yl3bv+=n+ YLIJ8mTq!&NnПu;at: Z*DY2M2<:i-(RN`# #q ݁,QiRe/ɓӳ=GV(ڜ5! YjcC) d{G-Z#%cf.%"z-c\,I4VXPZMi$L꯬;4+r/jvg̘1cƌ߄s1cƌ2}P+={HCky2:PEQ9˄x!w@kmf4NN? wW˅M$$@ >N}PoW-qKqIZ;n쒝~/3o,qzLJ9ܘV)`I2Z=Ā\Wo8n6ѽ7}<Z̊W1_IWbtsYm+p6!L0Ykg_M[`ᇡ R`1Z)y@R'='wC-'܅4$ebՠ+3|P+J-,q}=|V/^. 2cZ+-6u{ F\5(H6YUGL)/ſNB;Cvl}؊]wClj "3V3f̘1cWs1cƌ/NLJ1C,Z 33*l&Hl }A%hQ#p K̆ieIw Cl.ĸQŬ"oؔҌ*4Ȥ(JM骆kgI"x|Rl_!1MMR0|jZDK)2HMoh:w҇\:*Ej&jifWiOicLL ɞy}n׿髂V&Ӌr(qh C!4f2FBPŒSѬz[e͘K/{#əUϹzffUuy $alFX`/56cXʬWVwEfVW{EqQݪʈJuOBN#zE)EpmKpԀ9=Fh |-&L2}Z9PZ%&'j֚ Ei4w>cOTit~\kUx2=j&L0a„׉s0a„ lqt}Dx竏2u[r?l~8#% `};;8;X,ާI"//+Ie^!јThh&}9 B ^Q!RMsmˣ1h^%|v݋/t_,f nvC a=Z~|y3i@ΫP' 5x-&Q6T^ӊa-#3b[mPՠo86;FJBRʗjVN?p{ K$<4F@DN\Cdfj Pw*PV;#6pZ[%)pD *9nH;e60}1VQW)OW"@D0F=miu'rMpΗ7U˹G&L0akĹL0a̤̝y#j8ËO`<wk>ϯ?T[-#[cf8ƠU)::أr ~:tqY1t%=r XePEo-yrAvrgBDM9lJ۝BYZ:H+PQb@F/n>DOj]L1](Ej1.ȃrZ}"GiơCѶEmꩄ;,} Ayc8PZ7]\~N-B-ۺ2 gC{ڙÖ*; ҃>GU@񦔛!4MԖEZp`!щJX] ^jvn025v76l@p\Pn+@ ]_UZQ:둡iW$̢ϟ$8_;h#F鉙QHOhMf3P}j&L0a¯2a„ !'"Dt xXKCe,lgII`?,/~~<c8zeWˏuP ,-{'Ռ_!iuhn :APNOgozܓ07}v ȎZ=pܗث )dgtu|BfKA@;أuy%;r" WU5cv( ߰N# c|0 G~;19F1؟}O?Ify;~?VġqOΩTx)\T\^_= %HHX@~!X+jĀAI'36]n(I_-ku/aa t2m O[ 0'SCQ1\?{ejdH{Df!"}򠼟_O@P2a„ &.L˄ &%@Ԅ %Lla[tMkG]7Ի[i_Azb QHT 72*3A!c9~fM!ؙRG'g)gwon?%EkF9[@8(Hw !^:.?}uM{U pCӨaL͏y/eJmWc1 H(9(&Rkh+i#ﯹTKBeX h*u_Ǧؗ6H! Ɓ F 5[?7$K um&c3X|2|ZQڝvNM9)Ԍڷ2 ؜IճGA"zIK5T٠}ZP3AbZ6Nn.,]BhD%XX^rDR]ф &L0q.&L";ZPFm'IًvW>6$rJ2kMB@{N,0*B+*Gno-AKB.qJ,uO 3 b+$ɫ!|ȼ<AFo8wt‹"0_Dqvؓ6-!D-xߺw?Z5H,_>ܨHGiD]0{Ec}$m GџJ]_ +UYJiBn V5KWWO0Gf! kG)T=y4iuy1 gY5|Pe\;$VBҺ7E =#=pmcC L/ҷmsp\Rs7k!րa6r537a߃3 u؜<ʸ53a„ &L˄ &hYcƔ.ik y)0™o;8: Pdq\[F 80fҞoO >*XksPn {s("с4QA6$̈mAl ϫhWy`^A \>\0Tqb '#{ %㈎;#bmZ]}Z '"vIgj3Cfh,i}a(A@vBdFM @*DET@,>B@=efee-i\=$CA FI wPG!p [o:P=b0+ЖMKуghleo9j`hg^@5lg?$:G R9 ̢DFk,ݐ "1DD>Wl0#R >8]`ORdk0&L0aĹL0a„norI$F?[_[FO]ߥg;)T:tY=-vU̩}OGN `kih S@kA+=GAB(l/R$E޾KPi|pz7GC%`H!Kr'{X\,n&T*@Rea/XybN\&B`FmGIUTb}rO&}D-F\\.P: +][Dc#i0`DK 0_i@j&4,j3OO? O{]5C&fqf.$ TYjPȪ5C8={[s"_^g[cѤ-tÁ$kVM &LĹL0a›1y%6,@;ЏTVnphkwu=]Wuϭqb; D^ E l^H6I@B<{c{pέc)A]Tjnͭs9ճ]{&@s&LS0[0}Fd88l+* ) 3IՍ =~`ٽeZp hi&VCT,wt9dt1W/f"=zzN4:Du]~<&dZ&RlŮ( G)i&U5eFJd8"P&j[0"*yv^ 7dHBpvhFl62>uuw%7^;]4$ĨRJ+jV Ѩ1.Қ0FwEߕl[0%r_YhAY14?wc|hQ! oIuf }R]ANigijƌ3fxU3f̘1AfZDƪ8q&_"͍q$j}`V Wfв]7?ohU̝6cm7YМ<: ]J"7Oi(Zz@~.>Pݼ`t/ͤhxzp.|1\@*A@{j[5$¤dVkzrYef6h>&,jki^c+k}/ #!Pf K90<럺w^9T]mgB;fLǏ߽wZKbB` R"^_|bx1ܶƵ}3&n/.)4>U )cVu퉣캒2qɏ ̠4T3Eox@7kmPUBO%Ljp;89HDloϬ32cƌ30\f̘1w.;,SP7#@A(C}r3+H2ZHszg@̍nV3{tU 6b;XH`mjv -xZ ])DsH ޢ[-d>~ߝSsYK47Z FGiu{dku} HsK׀@v\U!N- "\*K!pn..~ĦY[X FC&tB}@h۵mT&ܑdb@V IDAT|7s Ma(k݉ vK]^^|bݠ܉$@"CJZ8 n9e2m,%LmOaaУ$S412uys`'JjEz82+FPJf{ Lrʶ;dpddZ J 2+fbI3)sr1. 3eiig3f̘1c/s1cƌW/G(+V؝p MFfy/%D}(Rllԛ)qOY`z}#2z ef6?{i T v?xVGuoSe+=IB@HꡕH PB*3JHwce `#Jo\e^qG]]}Xe^kJUr/g?6==d:o&K7È@mߺ:%L(T kxyqa@1XA5ѺȾb,$d˖61+XWA)"ϧ414YPY]X,!íU ,xk2ӥ0`h_Z5 iuĦKBm(b{12="ܼe$L8;F 3ӳw.Q ܜ̘1cƌL̜ˌ3fxzPXus4K(@@ Д,;."˫_<ԓx$o1۶%SK~F)HD"i-SIfYf TD.)NW?zaXr{ `CQ7zH Os;? D1pB@nFMj;CHBh;dWJH$dnĵi~wq;(6dsFh)Hw5wSo |jv}}Q[R nɩvmm;IF蓐DDחxAsVUN1ϯ/!#)$(EZD]щ!i 2 `e~Aꥤ]6< H;\ { /^՟?x`ȄiϘ1cƌ|̜ˌ3fxASN'o! f9ۺL۟W7d=R1 l/J/CVd@yQ@*$M7[m9 w ,>՞H̏:Z}%Mb1(f'P3IҚp-Gh@A a@^|p,qW,#K* {4?μy}z̫۟D`k/|n%|3;4ohxtT]:J ܙ QF5xO!/.+D!4z2i{ˠ2ˤ$fPe^Dj)Q2 ܺ8ڮDtb ;DJ(:px~Q -+^{œ4#Ğ y_ &Ѐz_,aejڝ>sBBtZfz$Z߷[]ǶKe$. ɏ$( w=]߷xTWLdWS}S̷dMgnBl0QR5d+;|K}vEyh .PY.̇Ϳ=8ױG!wBɻ3f̘1`\f̘1cCuCUD4i$]گ%-TeVoh&m?j4qSʸ{D)GzFre803%3$u"Q#{TpcB^cZ&|()yh\džcMVڗLpFhh2;PX!vI›Av1u tST*q67%">o^(%Z}S]ڀM{~̜4VbX>HE:S'ErHSdi e@gca:g^g '(`Cv3DD.@f㼄duԙfW/>-,&OHpēŏF(q joS X./W_kBlv9evWAQaXU,3#ff<49=Sԁl"{Q3f̘1s1cƌ)&PNy%D&IdyAtύuz!*8 )IxZL/KrvB[i73E &f=;$ݎUԮj9UdŬ%V8PPD V%C4Q#vq42'I"ێB}5N&@@1%` Hļs;;[RBX*vTq ~yݘvv/yd{i 7>6HcdNy+r0SζepVɀsOH]T(^vq GMB ,9VIf]C:<U3~${  ZD 0D*I)0pi& 3s# 04/ nq" ,R b;: ST)Tɘ4HH4IS8BVCeNYI JDnbu1T U$Śr;pH?HUUmMrƌ3fR̜ˌ3f|꫿%ݖaLd631 pe2DBʔ7^~Z\}D p) $_H0PjS|g]:6^zy_3@Zk&j=})VƒnSy5}{Hf%mʤunú_Pm Hm>i '^fE9(KhD']ejJxus@1vRvdf1}\kΎ)Da/.x((ؿǯ>_Cʤ~v T&HCT6*lShPjD)2Vdr}! A[as\j^Ӂ.}YqZ]2-!0w>_&:h%rr5Y{?b}ԸV{s_%Eغu>BtOa*jFlƖv!fC886}`}Ti D@[l7WfZpA #%[\\<X6@ւ*肫 &jj5Ҕ32cƌ3feƌ3R 2 $"%ęz4}D\\/ggg)*ʼnrV rInQ V`4p{׭ jOg4Wן#E[58>؜P zQ4Ŝ\Qq5 ,]0xB R8?yv!J-M9*)+,>&Q['@%h16Qc (CGn.p~ʑeU6T-s,GvwKy],"tm T/(늧c= E:f:D Dz:jð T \}fIx$sHdca U#"Y4r^\jfHfIߙq}Ժp5sl$ٳvZtDVj/W.k.fX0IJ]O^-FC&ʀNjo:LoPxow(@ Ieg?rBB WsJ顿2Tߕނ+_D4^dѿ5Ɋ2kHDV틏^j USw>O} 3}G[O/JN\p{z/ڻfeƌ3f|U̜ˌ3f|B*!u]_`Q$9zuf-2A`X 8ER08CƹHXʣy[<¼y"WfH]ѢIN.V.{qyb.I3Yca[6кmE'Y}j*jfCjd1iG&wPoXS#^eg6IX[ԝPK190H[ƈtw<=8dΩc;$D5@C$cCX ?Y.yq,b\\}VO]ÚD=HLA[IֱU9(͈aD;wx<3O D[UM&-OB Є@ $o<"c{|^<|^n$s֋zf~>Q]2HsvRnF\/O ^adAh&6P>k: wb{WML6!0!I0?~ <8  XT٦ٰab%5W6h`iwXCrí܎|JD G!D.!#ҭ狹 ]h +7& 5xt#fkJɄD`:XifV''e2|yóc|["&ſ_&-s$60QN?K2z’0EW\_XD"-ߔ^V0^ToD]dG 4a-,w>TYN._C4jԨQF=O2jԨQ_Q=?%#..e|85UޚX<kmɘ [Hh:!y)PtQ_k8Ҵr='iԁXA*:ɿjcr9OǙ<1^,0[T՝X\D@SX.qREAiAD7 RFRRjt*=ژKZIFZCɻΒ{([BL4w"%C}U/Y'@&NF9W(B.e*PavXA/֟E<`͐{goBOI{PgmKvD0 ]l ȨS%,5% 67َAT !vD*6g2-w[) 9hqO8 [}ٿ֍7LQj}!D"rJLa[ӃfQ3%(B7@ь(Ci@#hf~YVIJaf-O;¤Hbn{)yNk 8@4)EXpED Zz8A;5/xfs%p"UANZЏs8w^)>}ؿv=}/5jԨQOq1jԨQ_Mh&O}޼mb:w/Ks'9 Nׁlxc\ö)xvX. hBAnhg_R8exyLne'[㈄u `Ǐ'\05MhtZa;b+۵9IƃPE_^ 'BX[p"^J̅:pk$֗?'PKM.}X쇋wAF:/}WLP5+gwfZgO-bj:fH Qcը}$-;bKBdG\P /_24p8>=BP&$cP+ ,R)0k#ɇfʝQqc{~-MXoO1ͤklؕ~3DKm (u3$byftұafsu q~{'ȉH=[9+盫&v#]&=n &*-Oiۗmu/Cٛ]I'$;/_\]l:װJ@*FfNVFD:J [:/Z܁[8D5Fx ~ <|y7F>‹$5g*,wf95jԨQOk\F5+{.j`!7VW-~S,5ɳ?/(QۋZ=xja ^z<|zG= 1Fz׏~R쥮; PԢR|gOUw I"*:c,b6sBdOBLFv\g^7ISjLȼ:?V//.7rl 00 \xYc 4 bbdZ3}uT n'}o6o/Y43ØuCҩn٘U e-%8W Heu懶`"H!i]qߔV i 0_|Se=4̩P3 斁,}@ʝak]lSsVـfw_PF~Z=g=2i/՜H4$=[j @9'M/~rhOL aX,~pH%n۫O@6qZa~Mp8To}_>uϿ]aUA,g3D -~amеdKD6`Ho =-➜ -2O|S4Xc%;F5js4z.F๴<|f89~s`$50qj8Π eÇXmJ\}|T&hv?&ʨgO7 KGIPLv#(cL 0ƨf<^nR[AUcGd)d}Jr\D;Ƭ)E#БYvo5 IDATvsN#Glq:n~S̊ԺN<2[{&M<k#Dr#mi;&)ܽEzjv`gؘA_^MN}3px0Y5̽Ϥ5 I` ,fx@,+ QI@ͼYF$lda3*Uח?mxA$t歵hD3v `vbWz% (UiQq|f5&=;nBj!?]ߝH|Fg_^jN^ݡIxry'`Q{_vX,^5ap`%"no&ZJF"Q''?8 I̾IRAP}TnRF93jV%١$)ǰٷPA^=}eٛd2ڒ~9>jԨQF}X_A2*$%ACr^H`3`0uZ3>O2:oZٰ`AXG)t+Rm)njHa4>Ѫr,ýG""}캯=;_Ӵ[4%x<7,gQ3Z^!+2/"ZQ/M \GOy̫|"/(S0YX` bf*dX,3*C(dsis{$J9\b)fT܏n.ϜI2: Kv2c6\ڝn=֋$A֟)E-Z{\-Zܘ3dv!P+ a"x廿?s$iR#~Y0jɍD+3/ z<<=$$8crN|PpvM2A3 VݯBwkVd&HtFtƀJ& 0)͜ZMD9MmNG؝Ph,LI}ނ/Cki9mLvR}3;3`+021VJ4b#p6IpE8ZzW!NYvnw0hI괖 Q&"ZMn?%+rb)_[Q1FUwf)x$v/~T 6Cdl鑙#9əHuтXd]qD P:ކ f=Ch)Gؗ77$t?_NKz+`~n7iUL@2q5pb2iI2$\g;s^n 18`tR_2,MgpC Љ"[Z -UV&`#,$;+ooDq(Q  hѢE-N-ˢE}>K;9 O?|xkܴ4 5H2{LJj0<7n;ڎP xsCey~FfYx_[8/LKBzm^q+ t zpuI@fYEO2rq*N54EhSkH=Lr`uX} Q8z0Vp4f};4G8&}Ǽ^d~Վ ,mL7WΡ 33DcLeܻ߸47p"dJ$8pD0)$OKNA1pw8JLЁ&sawfc(@kL9 k<2(f$` ) tDHh!Oq$*u*;H$zv,UD{q7 )+V5`-&)n`PPZXJ3Wtw_Ic$斺e(3 A1ϻov ɐ "quІ o֣LY "<ڂC$ Fm@Խ/9sg|V 0Gd8eѢEx.-Zꘛڐ jEt*`3e0X…lP % gmtn_B쇻ier4y%W3&vJVmm؎ Ȫ@khjl6b@G)q;f2 @=IMMh uꡅS~HL ɺ!VbHvenB"*&8bF)V6[e={N='g8=B`vh4F5rusf(&ۢ Q6`lg;Zs{p_Ujgt$Nca#VkHp`$hEnAD;g^bYyѢE-^-ˢE}VR "- F!*.]+ψ`U h(9/KT2R83usWaͭF L*I[6y4vn!ȹmyDoґDsn_7Ymycb)6twt(8uza{3h:dj@ki*@{%LU$ P‡#EVRraS!WgHzuZZOsb&p1p"P'ҙ,IӊQ{af5 !C+iƹ064n'#dw%w~5ۜLA"3eHj',MX|93K"W׿Lmy<@FZʡt=lZNJ0Zݟ=ȕt81Nm;Ȳ늯%JUhcǐ@B< ?@0!$$$`L1N{qG޶/;ЉD,:r +#evOy}Of0S.f͚5j\f͚5+sIfe;#Δkײ'WhROC@@;GaOyoTiHQWbL9h)1 Q0h2mN.R / b;U4Ki@޲@M`AGCB&dJւsƊFm!uZKYԠ3*1%! YUR0 ̝JZm+@!̎a}=/Ѵ4rmswMfǼpCVQD 2Sj4فnaWߩyV H[`:S򂚂Rusd~zx4?)# oK:RZfGP@H7,';+m o޼ߝ#"VyhVT|f nOww?-s|[L lo N@ǵ{1,B&ݑ\|;ay7LEsuk2qy̼5 n l!7( ՅdB?m'z1ڕe2fuh,00>i̚5k֬/s5k֬w7V?L]%NSO8dvE}֠>>6pom}.}4Z>e$Eh/ACM(pyԒLpw{Çf0!$wӞRTLǓgEƿl'Λd`(MqDL%F0";MBS3|#k%T3Ld+PGjEy}l2cֲb}ȻR&ܼ<#!y $PЈӒ6BRaN3O7}'av^ h}תj&-j~?~`6qEZpufs,n$xL88( F?#7J;dn}KXp[VF#@f?qKpXfֈB Q:\j}BX1GG7}%mgVhB|q9 22$ j15+͘|Ġ QMRJ[A&0oSjմ@# to5{5 mIӇIb=WF @*ZSso7Ƭe.T1/2^瀩aS]o-t yDdo`܃v7ʳ5%(T4+ (P`L94[M[Ʉ`hg W**#/2_)Am_H`$D䆬 YNz PHB@K,! /RQF0"Wu(& E R̊B JDF?WCeflޕ.׆liD_/f͚5k֬Q2k֬Y_QYV\\p }sڂm{`&Ѣ~b[ؐ.ev>4NnxhNd"BFOXf; ;@a3pJ^c[-ۏ BFsƧ.RVliN!fClx ^N^z3Xf%ݗ$wyu=27`};٘vI!Gꅖ^Rdɐ9QJi('و!D ? O""J9j1V@_^\-}\ n =/}ކj='X4pavTC h` "¾>sg|`QBN{W~шh-X#8!gD޹Xv]Ux9>u;nb.!#FDc qH$"WRKX1 HB%sꪳלNuX"㵺>gwc~_?j_,^4;+^PatGAaX%X #}O"QckKyI#@/&u!ץ 7-V_g,'i)`Ldxt>+vo`!O͝i Hl?^,^!6{z[`q;#޷ΗpE Z5֡tz`&n{ʠ!57;MQy05V* C,><~h£0W*f~nƀ;2ъj, F5+12w G+ :uܺ|\tٍQKjm`m8Dݛ1w^ G" ~PLav~ǽ5@;HV9nОF.|><-D5.euG_1k ?AbFO2ITwۚ4e{/f,$x`C)F_hjR ~AvOJ,毙vPH%ctJşO?q9wY#3voPxvPJMM^y1BYcٌf 4P*鮼'rP߁jtշ. v,W_q3dOw. IDAT)3fGg5@ۖʇNӁCxݾ\8΀jC"`p;d=ٽp6ƾ%j.]N4$yׁߊr Vu(3P6@ljp:,`r;ݍqݶJ9D͖mLv^֙? m9IMnQc&=nk_Js09kmGRnoZ!k{7@O^.,͑ p3NonF ڌGBDǃCwfkh{l$L2eʔ4s2eʔ/hL~J;q+A.034Ahlg!p6l7?:{`vKH_釓Nf?(!rΡ$Zɬڢ7n+-pq纜_Vf^)TQP`,FKٯlN\>[0 8T5-z70 V@~<5d=!`| @7ཚ`H؟{1H!IPIXA9~L)߾ 8"pJJ9'撀 'c=\ޭbDڈ+Q2a撙 {˟`; %q{dL\^NDi,>n:sti0gfYQSy>m Cx& !SOe37 gfE˸ 3BH'Sm^w(IP+Y3:kIBfRjȣe&=U;{]~McsPH3ٓՀj8"!{{cBRsn6;4  Rl]^2XJ"37'eBPeʔ)Sڙf.SLH/O U=mnN`A>%ova`ȚJ"nh 8XdVDŽ"̙[PlZ XDIe33gwf=I?'UV^#&!Khd3gxG@Bbg2,6^x4ؾ׵RCdu_{,wyhdYݾm~'CGN/@F19R,gE;z!12ywtABHzc= fbؤ0!D2V9=FX03`NYdkIsx&)Yea$Zh=1>x $8jĐbbF%+:GDl6@STŝ8E}Ysa@(2a@&MHH7 gevegY_ZhaP"dC _)L FcH]kqK Zڶ9kjƄlfkVw,K2ICr6ƌ60v $zhCxF{8S0ߏv gW$(=mEWrMk$iA+m?@4]>At5[q@Q0}3aV* wOhȤې9'.cA8|<5R"% iF9AJ~pm# lc SChwQGuQ_rQG VZ|܄똚q w@f4c\2şHD2Pa{i 8D[4S$C'%ǏyY9AfT28T;;^hVtC1lBJr"WfX߼m3{!dXENk}\D1k98#7lnߋ8ϑg98!}dm0>]oL <@Uʃz`[M&:pdn5)X9 me rLph̽mI,o_yO"ʈTwv曧݀WfMb 53DQ LXsPfWsAbyg32_\.t_>]}}/.8u;Hp3't4cM- qkX!ʬ-gN0B$_'5RQ{.T2EopRDdYTHd-?\o~>H%a^P$}d4̄LE2xDihF,HP}k{WIݣXL#"_n05dt9ꨣ:uQG}CUEF-^l-C")9~4 '`)1\034g8@6({Z$W7WHfA!؟{{/D޺aי" )pNf#m̙ ݨ-h¡:fkhy痯__ՌUG`z2f$k`Y%uGf0Dbc=CA Irz9._N"GͿ2ꅙ i82ʗq"($f@$9 <~Fi,l3d@? FV'2H5ؔ/^/ٳ/hTz̕ˮ_e7j/18Ʉ \,^<SM^mHzA ՏzLD>)9f2c O>L牦8Cxm6\EnY|(( >?g}>x3.6e7HBb2Ydj-yN|3L+nV^QGuQG} =:oVE ֫X,_NÀ 8MHԖd@9#̐H Cs8&j8n?(.:=nķ3x:k˃Yt,c e l*ҧ]*teLМݸ'dܙpެvK6/.~βyZ^v!+m8̈́joPK5 wd`"s ?I㬞}Y=E6 ƀ, ! -D dy1B a[3ӗUwY=32!+ 0ݕUߩsrE^JFNHhCw iKvf04Zh ,pAU)N)]%Xs ]#F1a\F1 A&ZuY.Gw^,ﻷ(4C3ܧw|xr]3>d6Ϧ760{H X C0(YB@;7a3wKJFka"*^M 8[5+cz! nb}q }0=x6I"%bR#A˓諾Ҵef̈́( |-pdOC 'Ik[  MO53rsz! mqO W%>q!heB Ayˈ77sO>d>FSa{SpΩ&j7El'ᷟVk}SMshu'0-h% 瞮XUTMSW%U2MJWZy^ H;wჵE) n*Pe m7Çtx7-;00vN a( r3׿Bn+~(!Gu0^] Gաf!͏k p  JѽׄcGei\Zp &hy.ڤQD]X=u+Lӟ'K8 |:$Eo]bbHkJf,?I7D^-r\F1bħȹ1b5b(h4'."&J6ֶ RKrIdHfxdC%J6 a6*-Gn`~Zr@hS%E.Wč){0@MyAVf_+(쇡J%PSvP,%\vw([ Qg@sr{oV%\ТNU!Dus4ԏ%w#Pr =a UiwDx\g/]#J*d-fT, .`|`|b f90v0&^!yZ@ГD-nN؎7H?[D؜0 ,g28FĹtҝ `n3lZahɸ77:!o*U?q" ,e<]s9 a~ Ռgze")͆G,Q +Yqqe4%)QJNWȍ9tA U:-Z PWxmĈ#F_PSF1buږ@dZa,L jZnp4}lO#\-2{%KQf`W#q~f/5=拗JRA٩?>Yd4IT§ac<= ˊ>yL fS<]>Vt[9bСԎmd2?e,=H- =ћNk.ըE֜an)³T:@^ZVJ傽_@w=8{] E(= r ՏjUlbɲCS!2y| ]j[ B׋b%RݟЕ I5x˼lKRIK`ׯWIԆt0Bʡ8\$3K%ΫEri}|j0f$s)%rȣs[o+o Ϳ1bĈeĈ#x"$ 7~+4N{K|Ҥ ,rAs.Ɏ@rr)O j^h}1V~$QS3!.jaNΊFvc1J rO!r;FȖ5QF2i;A[V#X@U `uTb'y9v 5bСx?0:`YdB 0n^|`:K)=Z- YH'v%b s5;N3mJ@Ȃ/U'DIb%yFMGd}{jЪ Źd:BFYRBa2y r(1D s=F$C!Vw-yFDrg#RT%8PbA4(цl|·.SΥ £n{@$Kqњч\X%dG9-azPJӑ@FH8%EJ 5FL$.89TYC>yĈ#Fȹ1bVk\!,%-~l%$KYP 7(` GBFkG' GIAX=2MM3XO ,O˖NzFbzZ+>TEgZ'/ ֫@_@*FM7KpxSpMr IDAT GtD:'4bʼnRKdtxtG_/a]x:nwVuu|_vd=/^K[.GP`E9ԕ#~xt|HMC"Q2{!r9=,A,]"‰=M2[ `ؕ F.O޻(8eXJ~ZaqI+rEtox 0$ҷJ+4h3 3Gil' 5f#JxeT]{'oMS92⚾W,Rׂ?&<#Ԇy DA %<|{gE8]iĈ#FL9#F-sr.M9 ~:@i`n:#:CԞaV/. M!ӳWhVlCX-NM'~eܴG-Fd7IpQd~D{`PER`z~iԤʈZmHEWJR$ӈ!1 FvQURe}FD6sf0-YJRӫHC$zD:Alڦ6$0}ADap ꙴv{NwEbk OItoOݪIzeY#Qp\ y1 嵈]} n[qmA4!qB.׊曳ɤSXZ/e%H ,P|RE&E}ޫx|1c+|OAIRT).).)3݉ҽibcla.TI yΑϘ1cƌ/s1cƌ' mغ?)I?;p;Rڅ5q٣'x8R\B͘1cƌ3tg̘1kzimh'$,z5AGd.g3e?rtSwl̠nzD@~>ΑxlSQI"vss9eNSqKaJ¹c:H^v5X[ 0C%!ՓWdzs@ /~$)H`>Ը#ӧ?2y|TuXjkz9&oE+G@صojEmMv8vo  V~G8%Mx|: _ޕׁ s?("a̧E)nZQӷe.b'@fYDa2Z>I ] _RnR$1IE&W43$'n .  h<7gurphLkSN:/=zR;.'56M-b=)a]\͵il'L eRljoECP `Oen]ۤms~3fxA:3f̘ pq'-f!/@"44<1#'AJ)D6i7".[a %Ra BkYj6xTfN}I$A2 %w)2bq~A\.`*AS# A!^m?2C$*[0Vgo"/%ddc1ͨGEz^`nQWAŵ[fB8tHF<:~D:T2͎sOύ jж L ŧ|n)mK3`Yqvo+WGUR[݇c%^hx9J)P1NWo_Q/5C6ݎ2Ch  ,FXW dLV#I֪ dً;|D$قl(iǐ}ϗŖOQٲWZ%LPRL]V?0| ޞ_H3o9h٨Çg<}wLЌ3f̘%1s.3f̘5Esezh/D# )8-@1BhF 4px<괋Mލ}>$ $YBN܊vǠZ쏅JHt 0aid)RfaQT붱~h*,~aR'-G mvT!LZku&?k8F #V*[غ gG 4v!~}o,auߐRMԎd**̛%%M(3" J0TZ$$<6V~su0ݬzݖ=1T =8]xtHl$<{˜=MeBtU.dT˸Ix3HsdC&e8hDDnCogW{w4Ps3O5>h"C`sXYJ $ !"dUr!)bCF28Mh 1&q<2bp͖E,͘FRrڝ#xDY T4Żlc1$:"I;P&2 0o#j1#3*-k$kIEK@|rmieg#]2cƌ3^32cƌ_Wh*:BDeLrPZzp;"*t"7!'b&2<@D&(A  :I|fv"%4|{_(z8|hD i<A ߲:bv -Y(D)CF %@(%W> RF5@\cS&6O.*DFΏ 5 D֊ip?ܻI[/k0B wR8%=U7GGPq<&_]qs2#`H MyCۀ޵Hv]յ>_53~">!$H(m ~D28Տ:{/>skf,!` .iJ=oguUؙcFm$ gfqOauT}3٣w맙ՒۏOO~||<n=S^ۏZ,Ks snZ#vk|uh0 %!Y"p*,; F˜G2VWPdUߩ\*li^eYQ_&P,%?sb^]$ig2;JcF'>)a,'Of9`kPpLCǙCB ~Z;p„ &L8 &LxE Pkni5Y玷#O[T&(J!8:SP 5+4jcv⯬o 6<Mhc/HdGVǿmpHتiIz3z=v#I0DJ[4kDUoͰ$ק?vfןZ5,=KRJym؅YM"+o\>Y,'l۫˧ғ\k"<8غ3a# iKhP 3)(6KQp_W?A0utedoΗC'05ʈ%naWqt,|}@ȓh]"ۧ1%[ӗZ k:d6&xRïg L#hTIbԄl_J -0p7񞼾}Ǵ%{S%`lK,ۛZdLnOEAG߇/sޫvviL`"{ ]TN3ZnNRayoD.&L0+c\&L05^b!8֣}Qș-(HR%46@W=Rv4UQ7mɈ$wf[NvB"-{i1d8hE:X,m@8XbNxW:a=АS80TfS02i6liҌ3.27 Xs`z0l :b1 H)0vpPJ4H҂vn3fo7J* "(i0C&ɄW&ȣ Y .PþVHuZQ7yeuK|-ݶV&LhPzsr6h:L N_fث.Dc )49x߾$P 8b^q+jkfO) ^|F jp(}- &LSW &HLF&%6,Q7cA)eMm܁AKFZilʇJ\}  2DP@!Rzyd_z  u'|IV?Pgg2B7(L9kB\iNYH$MvA ;jkh h19>;ds]%f,kv]ٷ-`G;.fc܈?)2c N^=`J_?>m܆%NWGbe3/!*}K>bg 1-p.dz(jW !g[WWwP1JAP~nǸgN0a„e„ ^[`aQʶognI%Ye$X[\KΛOZHI\hlI8{c+o%Jn $@dC ۧvL^LD##Bs\"Pb0DIF ^N94BE{UviM$D*OX$V4ܫ*C(^'4wFt`peS@y6#[z !2^vunQ+9nj9-WyU`{…:=v sy|}zSCI ^DV旰~2;6wkg E̐Cs;XK;˜IT~(f HFq!/ %y#<Ȉ@!)g-<_MR.ޑ< {"r#\HiqOxDYkaدe樦2̦E{!Y`3uќ JW;,@DX./ٓL3 z̕;Pe[02A{۸[_8a„ OcҹL0ak䑑mٗs5b;_zN)8Fd(h_<{39La0xY:3Z2Şs ztUpJ́Mb\f0zS}[ͬ9wVC,kKKC7׷Oa9H@ V [7Oo"&(HZ0E)h[Y~'rFIs$Doѥ [  %N(ě'i xF.F!l EK"r_+CΥ326I*zDטa z`ۼNA%PwoFC{ Z ?VO})H?x+{x:q.&L0`\&L05!v2qvȷ.Ĝ(Kd$v/.o~<[@b"uƼ ĉPyx" T="dE `;𞼿mq A6qD+u!5kW aX.fZF7/]j I{p92![+f⠔'d[/-s^|d-~ُEmK$gprp2{;TqL)fh{_vIOwd uGƈĄ耣ϥCyH0iHa]c7n׿ ^NR)= !x&ny"|nRƅ@l\nz+VYxau՘dzv 2h!{gxJ؍O;T#D!3reRcP#] A$ ; GLiK$a~g)tj|V7j4/d`:}ګv5@mƀFh4iKhHG^G5iAV/Ln8}:!axTUمs$ IDATV ɶ#4G]I'?Xf4[ Lц$Ҋ\ї^.. rWjpzUA(5x}}ɞ02h-l51cB [%!!  7 F|Kq* R++]~ucUN&hLrCTo#ÊϿQ䔜ǩi=R4ԑ^,{rwF@P3؛[$̺S_qMs m}UzVm1ܹh4KCh4&)@wgGGLD*R0"$Z(cD*=Hh4נ4ƫIU Qp±UE@`hzQ ӣ"@1@Rd2!}vg p:{_q#A0?,d'P~ w;IL І"^IܩLZ@$f7#3+۟Z6A!EK2c8weU{ٿ%Ƣ$ܶPU&#]Cײe+@`>9˜g>H!8rW ȪxHҰZGD;YqVN؃R2V0P1 "Yi.>z=A"cXo`2Fh|S4ͥh46H!2l2 nAY0VqIi|9) rZMf٢lۈ-P fuFԮi~(r*͠p  Ҁp;]f!`nC7?8KL R{ÍlYbcB!QtZܜ} #om<ߩ0׏.U6=)78}1th젎R&n\.?-(`UG/%N(2:Q4SpQbQnzRa,F+p1`(;S0(gUժ!FV]bk6F;Msi4WG*xmY::o K4䒌i m&BTn:^rV5DrC3 d?ty`A&i^LR;re\W[|~O?7± nHBxedY\^>ZLncڋ4_~B50A9撈~(ծAnͿ褩y<"yoreeE,/.?pw6=f?M̼FoNG@-[b#t>L)^>Y,?V@ɨ!3pw,B5>tKS룆WʰBi[ؖ\FM4FxUGAj0YxYa@XxaXT4/&s8JѰushPjHm] i[W ~H~?çzX|\o_r[PqZqvTpv`뙰'"R78=(5y*Őqءo^_?4FM˙0"叠Df‘@Ub# eLpDBޏLI#JYh;C I$܁\J,3 )PbaTl $iHI a$ЈhLPTi>dR@\㾔.ח -*I}s.Yş]ww:NYxt~W6 ۳-_grd=N{VMp# `&0nzEoM)0ӶpZ i>vXOJ԰…Pa9uxb(qَq09n0cLI wYA ik7&n@.%|ZҰI Zp[ړUbc$HRdSJmGDEat+8g;pC(IH&b`،2㈁`[yH=/r'<m\:N5Nแy7y![ u+xб:;_n"kuIZ`Gh\썛[zEy(j FҊCV+X_}'f Ȫ`f(~ f!Ma$33Y}T,Wd1/2Zj0 Ք dQǬ̠LI[g^6oWFM265$%9OHԴ B%E"q9߬WhMN L8pzӳTb(Ȅ+IE@f_C͠/6/MMfҀ6;t:tͥt:}k˽-<"6g>t7R_?0vaOi"IiQZ5M%&/%i]+l D"*:Z x5~z6sdS[!',)w{4X6 ݚU˫{\yW˦Ou:N}.Ny;ߞ_*Hj#kEOG&%?tSIi"S̼q#1ˏF^\&Sqz.7c%. L4<}-î[34,<,KdJ˜rl=i܏#yd>D@Vl}z]3+l?FԨʍnhG ++j*U*v:NLt:NZ@Ν8Kz#  VV>]O~^DPt2qz'nZXV-MqjVlb7X¼@fSI,` "f`ɩz֜k0C&`SMkv8C/Ilw )s-ys:Jd"GGoJ{4~Nt^8G(&hr<[HmR0r(t'.2H[(b㢔˳KP&{i`ܙ$\~AȽ/w 6elc'+D೼"iJs${ZOMf51@)jm!sJRPf^ǙR7h*U|Wa/h6O"GB`&wp30fVt:o! t:l1I+l(0~"$ cSI~:wkpj)we'ƃLH5QFa@B3wS8:|oOLd&q$M鱴&Sqg&`&ƒ02H_I÷(#!36ŞW[x1H]rOH3cٞhH;Q DQH=8eS]pt:NJt:N%TKICͫJx2Yl+mʰES!TF|jvU @Α:ݘVt:o]st:N祁>!x9C 5] Ѵ3cEbWO?:6ܐ /HXJAZSn 4!F(Ac@X Sq|V3gh0o!sKl xnPs:0 S4Z C7hO'!>ilT]U wr HP+q)̇aS bwevgНN|[NlILRuDM$gHn״'ecE (QB1fRI^IIM}h9Stts؞VXOacvn/iXOI;B/ ٻȮ TMMR0Ke<" Y&;bيEi$l~N5ɑۙHMQթ ڰ#`76!Z3\%t\HGp16,_kЫ 1oՇ!Ow=} etUL1ӓ 6kUӡKO[̖5q$Fa[ʧW?2GT5Dڹm[3v0n6(CzDMzWk0|4P W~ƕbQ V}^3),I)&wRJ)F EhgaCk2iWV's^\]tp J hSaflm<ށS@͛ٶ P(n6^+IwuD*u@@6ܷ}?jUJG1/.jCo%!JQ@/CnLP"evxf/7Q駏Gg%RJRJ/Q  $NV -hnv(0 Jޘ显>ؿ& P d@Xw=vpŵ"am!kpNH z.3b~nD htB8>~xD̰+hEP5fsT}|p?Mf.)Rz$3RJ%q Ij &rVGҡҦ̪Ž6BռBv L(1M2@A @m騲bz84ʴ[i`Smm]m" ީuI;g܀@kg<C~*ػI |7OmK0HHXb@@/`B/XlfɌ c #$FݏrUW{#2Wu;ՙYYQS~&{⚙i\6T9UE^-2&2q| %^zue@$@@`)}h10q(f[IS*hdxbԻHQO@K.Z𒔐*^Jc^,2ߗh3BrZS.ffffx `fffY33b i(|\T% Qe=b9/bPV#B@Zi@ w]ɳC/P"LQUke/- i]Zr{;TR;ĀTPf<"[;C<A23-᪚&YZr[dfffpFJPY @j A%+Zq_u/1cw ؇%#h[oG@$2XB2jE+m,RhQ'ER6ه#wi"$TZ*I/T] ck!T*"1ΝXQ@˿;.fff8s133H˱:Z{W?S"-hܸp9sWyI"o$)BA#8HplU-rS @&!D8W(^6s!+(\Dl-Z_5$E PjDhO*'p\ʡQ'Ľ۷~h̀{ `JL`HBv)Câ333뜹mErLaOC*:_~cݓ]hx{BmߕB*dg9PnK26B*i1ɧqW=q@DA YU. TCb$ VՑ1RLjo}J%Z]$P1^31׭ H1(z!"jBb(w2Ղb& P(`,[ARI0#TAa,,R QGe@(!ʘwn[%00:.3ؚ̈ˬv2-fffƙFZ6eteQ'YE2TBP/!k AZ[퐥uZ Nb_$EP5ZaZJqOQr,o~!R-(5 DH9}9#:azzPk=9s133HY&B6:٣$ف Q 5j DF#ܼ+ׂ{cE+~ح.ԂfP ً($)$DG8&+C%3KA[ZaLZ`[Bc1sb(2FkoI Yٺ/133U ^9Rny  @LU1Gֈ Ҳ6$@EO29JDpxvv.8Jr AqH $8.;w1ueId  *nȔAYZBa^{߬VNh꠵n5offfu.fffH DhÈڤ<V*.J`^BevSQVU#>u8@_\"3e EhB)M?Νo [W(mdSd]j54Lg:g.fffvaI?[SM -3Y̕7giyϚ=C\. _.333333339s13333333x\.333333339s13333333x\.333333339s13333333x\.333333337<033'@l<N_xykl{,y+7W?qާq.nݏ\̶/̞Joxmgff)iqlk7.sOU˃633{8ιԻHb; xn>9%*23"-(GӮ#v$U'%z"N6ٖYY03{8[wq^Ƥ)t!==]l_oaedB}!i.28OM߾Nlڏ-w3mEu.VsiOEl_I/n ooffZ3q$ ʅg6l?Ԃ=UkVbf(si$b.94c੫\N%j\jVw4cj£@sN;I>F2]/}Emӹ$1A l>³aҴ]?L})oi7%NSsyn\bjU8 GGҥ  CYKW/n6P1#=Mݔ*vO:Pk^(p _8ֆ|'ݲN@ %?ѫl|ͯo~iƉv^ED{vכmsNۉ)؝"g18v{?&__7oOt.% (won (샌?s0׹$dk'.iM{ {"j+UJoXeY$DU|x%.~?xwλ˭[wH7_~7(zy~!Uc J{7LG39JCSXB({ eqp?oٟ.[?7_up:IHD 5qt7`(Ux}-MRN).ছ3c:oESd[-hVdxYzٻh}s}νIȠP$Cю AE*PpP: Z;+` D%Km*T < k󸹹(ƀcGr9{579ך'yn1]4,YfߛyAaCVZ>(ݽy"bRtlތnk>̊U<{mEeR E;>SKa'#Q"֨Q$\z8\\:-N$ܽjW[Gwp{ߏ%b z&ψFt,w%/;ep$=`<'v5p[g{};?CK"#f՜j(j] (@0a6L^%ՎHw/)9\Υ~֜o Ԩ+ p[v͚ȰT ;#O\\zlv7FB<&fk\|=Ԍ1we9QU1h/ ZYVf6w̻>Cs^oGFDvx2fsةo210:%W)oqm9\aX48@3{9{E!t ~饗^;z&e K,fܔ]_qٵOcpE@A ;$f\)(D BPcl[s̑w7"d QjSGތ+[v;n_奖@4d -ږC^qςAX-p9(FWܰd=%.7rcϝCρ9zߞf[/z#^+@_q1:ל˫sZK[ǑrI0#df&k49+w̷_jΥFSap.ݢ^y@WMIFC0,;[(t!8 4IeTep|W9aMm`ec(M~zȌ<\(΢XXϽxUE{@4s [>/4KCgCDsiSpg~܏]8DjXiW)Cm);hC;-+Iٌ8c%++Sl"Ȝ8)3KR$ҾRN"Ql 10;Y#bܽK= BԨ 1g` Kf\/Θ>a,+{ǰn啷rwM P{`X#YE~?S6#Uo#]Fk8O7Q}ʮ(@I ,Xpyi i u!Kv?J.Mf#)Y^RKI ]ER.5`$"p GYEJ~I FuzIg BVvi?!KބK.Ƶj M/g`3<+? '2B-{|PDe Υk5R7}s z[x8ۀo?qKt y;<+?2q.x]ҎzےTO]#ѱyg};~<>6 4Z@dPD#c[EHRu.pUZ,( DeVEd&w@L o IDAT6ZsysOnzsQA$v璠q.#(<w7]M2e$Q9@J#ITV&7D@a6<8sϭhVΞ5&G원YJsٹ\=I9p5/6nZȣ#Y&g٠E YپQb<&N"KH-I|Zȝe[b(_7$,4@s,k6ݗ-]߾(]˿t0K#HP ~ׅ`Ξz Y?5jv=&p.}X?`d7ݴtQ5ͻ3W=1zft9H E-8͍1uo 2(e$BFgQxl9ԀY>=g>O9L*m#-\uyݺAZ3 dd h[ \y,Y)SZo$u)GtoVW Z5^%٫srq -YٻKJBiM/<ƸKY4Jٓ֞"EmMBbW~(DD2e$V|p pt-³>te[o+81.`iDMUӃFd ENկFJ.ЭU6ډmL'T.c?%(noc<ÈiBTD}4b.XNn D3]B!4 qMHhD< CIf&4H1 ^y~jDQ2Ԣ4i"bf KMV 0xl4\9o?kQUCXj27O2Gݦe|%7|kro. gdJ w^ΙdNZ޲= #i$w!*3`9H2) & ByL)?iY=,ӂᘣ?̧+Ng=* C++6~_fj qYM8 &>ʊ.Y|]`%Z_m=ↇ.j SAK,ReFK: $ՍHB$fN'l$!`X膱00*G/&P*pqkh6Z/L8,ޅ6~6saS5u hyUuQGΫ}={j\VxX~Z^RV̗gYҰq/ &wcG`8(GD+3l{{w,|R[dkAf?S?Kn0;qZC{5D,tEM".Ⱥ}/fNaX?&D ATSAZSfakOb+ eOh*VC$u=xG6s<UZRu/.voMвr cNl+W^ga}DB~6#MqD@-"}Cmj[9BEHF7)~lY.Kœ}EGW+ѭ[0kDR?A qξ,OVj@!E2.Ѓ^&\0w+±c 'n-)+^ի9d?ډpu ks6:%e̓^xRh^wvZ!x`R_M0 R-<Á.T4;Q_)Ecшzkּ5?Tߛ׳sO=3|C "!eLDx SrsɅQN$Z 4KYgt3}*#p3swAʼ4 j؝:WK&T,7Wr-)Ò9 )Eqm2\&ؓ`ɻ1""LDTbMz v<"jN}M#?oU+@꪿=g<# bU?er.eǶ1#־dTfPif"x{; ; p)p\@1, 2rUȽ<`(0&K@ʒ:&6/ K8y޹W< a2G\_+(لkX>D#kd.[2<@ZqLs4ōCƘ1"芊6`¹hY2Q71뿹ڣ)R y&.Uaި"`\mvƻe-~(nJK~3^@S +V.Ah9[= r#4Ds{l"gK0"r7_7* 5}IM5//9kÜ"aMW>VDLW޹ M BMMۯ-Gq;߹uJ$D>ܿλƯ=n6MΘ0xFU VNAo5FQ( J6-e`jYlH42́9i2j>yi+Rz-ETD]s@3*EKep4N9F,?onKr) M2hš,9vng_y×of{PTѐ:\ kD")`fzϻZz/nu۶cj}u_9+-9p#Xz gdÚ7'#b.T9JY$E3R#0h݄,"..۫XQ@Sd՘1R ׾n-7]CZkxP{%=q@2 }(_7@Џ##eJ%t!0}ǍeYE{l|j8GX פmy׮=D@WLGtIF_AzxZ, Nzbݺs>:`UỲjt1iƽvuؿu$ңA8;*u4RpM U†~=gג tPO}W5 . {YbaJU#nM e*ZaQk1OUL03WWbƺ=fǥܴ+ELy2鎢0%yMà =ߺjZSK8J)lxl񯮽fOp PUv6Ag*QX lR:#I Y!4@` D>?n6 R Aƒa9&b1:d][I0^bsÑx-o0wG1O2$=Rlh|s[/ػ Kz߽==0*QBAJ+ BRRKA+Q+)Dbh2"j\A $!Ʋ,cX\RQĸ8 qI^s=Idbr[.9{w/8 @S(5eĀ @Ep0IHmҮ;_QWYr,QjXbނz Bw"ro$1[بcvRLof"DE}MRt 4;f ,֭g=븟krYNuU1L>h0N ük2T3qb@t. .MT f| ) t>p[\]JC['nkF&@ƱJ~UTu}k1@ưMs2+%IU@`{^/14H1,"[ILHpܩĔAR KpW#ʆnoD$a4dIIs43{_7lFXs5^~+1n׽{V"39WIʥhْ. R?Q`fY)Y$b,Y[BU3nb 3EأODC>d .i>YhO݉‰JsDtY6-Ȇ&R\9D%&KyjC !$QSc](A&e"Fh$4RWD aҤI򧧜g7: ؽG{ GK\LwtD;*}1ACrl)l 30à ?05h Z 1& {"хl_]zu`=v !J$<0$P6FO~KKxw>VD&OIf%X+!0+k !G6}Թ<(MgѨ&5xI!CM ZD*/ÎVnۙo8 =H֗>ŒZ3ClF]R ANs9LfxlQ-Ecq}G/=i:gVnM;Z*jA%`b٥l %. ) Fh0'D &m?¦5􂷝s헾<1A(}ҶD!h4I$!$e}9K^Z HY(Ps:y $#[7ᕔxN:|ˍo<7;db]8|c ESLRi]R\,ЃlSd,E:FeFY"\1fa,< ^X}]>3=u,)&l__*lKMYV~A,QhC0XKK^x}\ͰQ b^8Rd ծS IMhqhlL.%Y<'uK{R-%.O9 !({_^}߸cC8cWi[[N[}稣 )>?RE"4 v`Vǂ Z!KDR vǗosŻv퇻.)FE`irZe3FDt&yeMNF7$$ZڞN8*W˩GeybzAm 'aFuw ˆ6s;nl:4i޽ZX4&G=xlPV Q$EtbGڼ[j:S+`8qI9&vsV!8 RIC 6i5yi{ORo 5Hd kBHÁ[ Wn;] wӌzDwܷ\Q`CN:Iei3_sqGͯ"XXXݾ}Won?vMWF 9d&E(`X&y3=Iak "&no9-/xe;铟-{-MꫝE|{x;ox+A-;P5)Ƭ4M37nPȝuJ0 3O8_'# ?Ѷs:2Im-ZY=Ywa/U `f5&A2PًTӒR֭xN|cǂqШ4㜬w@F=jW72s'DI@f8L[nlrsO8m~8s+MKhp7~ຏ|fMºNrӟ'&Љ0NRVB@8z㻿oɛN>_zΐksfa%_4H 'l}.3<ؗXiY/pvv__u_uB `D2g5d1Y:k!Q2p H@TGJ&K7=#cx?)¦y[UB"yQ"HK̺=9_{3KlF3{' {sO ~{i1Fʑ־d6ja yχ2.KظcǼ{m،v^n7mn@)#,%@vŠTh>)Xk@>`  O8=i'{WlWYes}/6 BWw!E ̔-إ-cwa T"A0`͐ : bu $o?s{/ * Jܪw9߷^#Z:Y0im4`ut b쾇V~ٸakB<ZcPoO\L3ka? E .8Ӧfet(;00EW7^x~嫞XUnscFF iJT38_LB*pjG R.?iӮ~Nx^ GxѼɇV=ALl{@П{>|[ O;WI+'[%#CFPG2e Q.WoL7npff:;qp3[^9ᇟ4uIvR$5;y3sȭ3ytcL!QߵR!N҃UI ;C:w%sSc-/SM@ Q RT^ w}QbÝL<%)`):0)ȝ }gXCrs1TKl(W\~> HxS09y]~ag}пL+qjxj 3yQ>(7<ܦ߽hůoVjpjfd̙pBdf;) `QC/Yʙs6A_\ΉܜWt.)Khl)OSG3l܈.pnB#`QOǮɵ]ŵ?5đF Եtd)=܁ hDFefL>Io^z? ΍65=2;fK4Ѩ;5 Su<+ }pwnhxiBfAM8m 6_S=b/BewO;N\nN '3ɓ;&M:P_|y6Ijȝ $58#N>{S֬Y3}朾nbླq{Qأϼ):,YfCA6CɏF'429(2Qjܢa٣i"Ñvݒ믻-*AEZuJ) B-˶yߨ,5 IlxA#Bwb* \s7}vAM]J'(, :hQ@&uG~sep`fZVxj͚޼8 'LI_d"bAZ2C >k֬Us"5 G"g6TgY~dOwȨ >:HC͟3 #{aX^u9_rː=Zh=-2nDN}c_ܼ9#Tg}YōLkoτhĈnId+wY<.<6Ʊ `s_7zͽLpMjJi4RY%uGh"Z_tW/rRV: \1tw*wLwbg۲pTYŜn Qb%I.Wn{Ygt$Z6846'wr 08r(5v3+f,#!dBUɱg5{y- j2`qQjۋٳ~6cƼ^&5) T۷mxsir-ΥllJQ` nqԫo0½ƔIh )$Ȳ"gkҹ,je.7!b7!OB֢5Sɶ~ǿp4o EY3wT7v֮E>l. 砺H}N=4)-y?m"d X.iSw6T)8G !YNO:FdTEHz!#c2eYM, h6pÆ駟[79O-1v|dM#Oۣ;F[?%[1(u(Su w~{[@[Ș*AHWf&1o{>6bO(ကPMrڴkN17oW >JD}{)V}8䎭]xa˫}/楼^Waۇmcr}&SL|$$/\zS9$y>[l{(YMԝ?sŗ\Zh ;Cw(ri׶: bJR%@p UDmql)mJwȽ~_Xkܐt;wνw߽9{Ӈ~)uFzZSvA+"R0PCO鉿:T^ U1Lf@q+? ٘KhpŎD]I{`tOF%5j,4co$/˳aN>hAΣ햖6h$C&PSfSc}ϼ܂GTY0"&<>ş=i6$G`0K):$GUwcUkFFS'c֬I)4Ow!x=;eD'!ʜ<فlb2ݟ=̲QkC7Ql+ˏuz$NT̠kyjqGw;Ws#P퓍j, [ǻpU:gU+CYC3.뮕0.Bٵ Q$^͂|pv-V,'5 dɭ,(gCIdY'WE x?qE}OPGf4J.y}!6DSp p]krϕW]ҋ5mL Y,l ߰!6/Z%Hpa |gŷ>qiIU HC![fa|˯ Q t^ fPHu28{ie0ˆW"@H)f6vw*7G=5UW֩n45rPt{$Y:-`kUxv;IZ 'r@ctez-!gP#5%5[0njݴ^&{&@jTe+$p7;1VuRJ&^r]?rUq̅$-`֧9$9cq Mw'I!|t[ {moO[e"B$~7ny/^ޑu]wS06#|S"!8Cf[o==~x1b!ѱf͚`R$jl%PB ֓gXA(<8("'c?RvR&!E^OKP?ѭk{w[~m OYD(Lڠ2df1o86O|Z1<`i9)Y$*KL`iy~hSc#7ylL6 spE% (Y< o]pg6 V7| ?给8jH-spRҶ\H˿%, |b$`&GG'wGoB $T(3V3XQNp_5M^³qtӝ1 3mIC=: 7x}!&㚯yŗ (1F<"$0)b{)jj&C ۇRJ $8ms,%f~`zI4!g@=ɊzV}?Oi]&21B4u՚ ӬxxfruqGO7s \ϟtר +l`}j >/:#@ Y#ܒ=[W0㔞N9$YU(c0h9Rg+iy'`D,߀#Xv]'!yVź-YO_86= p/Z:E 2K.t(ej$iQU\n2@- taYW;L%]` 1.'x㈰Z[h) b`bC>O<-ٺ!6%.쩁GG;իqӶKq˖HsYR f:)%t*8(A ӫG~ !Z$~u%n9}mI= )ቧqw /b!6;螋ga0m'AU)Yw%Hݪ5jhW7Gyw\26 TfLr0.iqrg]{4UJ@^Apgzڅ8bfR::OZc@)yhUU ̅ܯpܱgҬ*ir"D,4ht鉧*x,fA1IZm^uc&V?K/o+r23ЯF)5 T ) eWr\՗}& !^UT$~DN^cN.+.ClFHI `tTO"XZg6:HCN`E5wܵG}}-w'Q#P3PrņL0woC=Ʀ_II!RryU> .9z晇>3+V8dΏ$ 1i{>0Q'Fw|КvY;̌0@y*$5ƪР gEvK$Cy/BuJW^n>蘇~rvLTZpX#SFpk8l;W|ÏXa ݆vІM1Ц$ZHƔRhYG :0+CW6/k\^~ׅYM~"e__&g Ϯ(} UɉcQGpp %P֯ 62&&ܡ\bWPz?\ȇP򠑽XB[:(ъ>Md8hx61u`|F-TUøzsp%#5b kr!b3c3\9wz҆NyIJN;`Tl*{~'sI fo?$qj,^|.>J(M/qN.~7rw* d/4S 5uY+hM 'SsM/pX:@ $` a51Y8RD'*oG3`F:)/ѝ)y00{n˗\tɒg?{'i덍Ξ=wN@}+bͲ}x; FZo$$Y)StUu]v;)3Sk.yln +V__ H 1%'|Mp'' d $m$@蘫B ??k:eV!p7 pLJ;rV9*k枑g-tM9mff{UܠX~hxBȿ!$bט55ʢHDHOx?&;ʻk\  $ )A&Z^-:O8Z#! J [ڒʂM i6O(P_yW?#al}ߣڠ v`[ZIєse{L LRձPGGL)*)ĵ;/GFAe<;.޵Uy;@L"NKPZ)qDFl80TR*-Stu(2Վ#1DORqL\Z rsZksΗ)SH̙9''{Zyw9L'5Pmj.AP0 %.sz HliT ߟ9W߿v_~ޙ `H%O &-Ïm۠K2VJ`pbe0y,J̀/;g玿_ܸwyu}%#pA!g_`Ƅ1b{׮%YaqY 1  [`{˗#&0+Q2j -glFT헡{v;ӴP3T6 g{! >SJVy" FT^, C. 6n0 aF|KC6FCE\ Yi0+fugv89#%80Aʭ*fC#yK5Zq<ػuUA9AElۓ䟹DE<.$fag!+DK` Hz۶o3YkQz,ѓh'NT9/ShT'|ؙB0c2D_X+P W^:jeW6@p8 ,B;Ic9H2, 9a7Y Q,& Ea~񾫯 ?%,L%*GRJ\% seK T*BlxVҋ@_LTI2N֓{~ɒRr*L6+$޸'{ &ثxv+M<90== N{6k^t{|BJ>uk.Z{qlX;Pe=w~I"hV[wN 23wg@U ?Cׯ#~}F.K}$ IDAT=B,Elފ~k䋠1 MeNf啫qm^ UjiTVfgP m:"T"Ô><6@,[dmh8pJy'جT <0½%:n &mS U(eA&sw& US=^uPyn.X}yic={xQpH4__{tBp`̂+G-_> n7@T9O!Ur@aK##-i1 @꘦ßd!hǷ5n9此XXR #Rd9HRϳJŮɽqtoD*j9 uLwW~&iƽ$B]גR1؀+:}>OaE !xd"cssyxAshJ~vo[?' !9[L iRlB5_H/o-L;**Mu0|Lי)lo%oZRR,tbv۵I<L'mi.ģrK @ ^"uQ\/hNXկ:}`ꥴG?zS?13s?{j!1Wu`` Z+K R):Qw_kxkkÎ*oY w, 8,Eɬʒ<7>gÆ6͌rc`J\Ugd'gy7 *B^XGW PNX1Z f9e@()gU-qD1ʒ9ˀ`jO!2N"D! #ocbcOR=!W bT 4 JRfmTdHH5J fm@8a=q׎%qepF֬=Z rp22@J`t=UtW4tV{Jme3M`7`L:Ջ,*oݜ(Z,_UѠ˝GTx &d|& $CeS5T)A 7='kL6XH6t[G7݇?tTg $B/hm³<19^w@;[m7QN:iv떙K/eٲO՟̷|p/6aD "ADx R[+kVV Fk"6o%\cII~MmbiZtT7VſZur &-rY 8MĄ+d PoH D;껣&aQcV_Y9 5s?M*R{Cɸck>@:D&˺'J'5`}o߻}'񑧩R l̕jҀTo`y7w:'? 6pڭ`PFث){W&ՉKc[ e[3!1 n{b":L՝fR8ϰcV@(21;i/.?KB.?gK/}]r :@7 mU..oҥK;ᇎq [^nKET8{!m}6; 0<L07;^q~JΉu$~wPωGUMso9/Oh ȌϽs3mK\H^-lg_w6~) FL*̗aIEI$'w INV "R|2ypBX&/pB2(l%NL0=6s?zq{p1do15 )`n}3"D\;qj& AAMM7}'qYkړObBr&GbBcO[b 5%L krJJ`P'}LTFFX Z5]eY2tA҆G-ttJ\宒waKKmv]'83^Shy}b– B+K?bj 7*JЁYnB.3\A_y9?,Uff M VwEhT>32%M@Qh׾Q%$c.qǞ<_ CH!Zf!rXT)|k.^wYh!BV[}/vF;$ nU.6A6*gD$rz$9UiȴfEUOEI[GfU#6+&"ыp_IY I3 h{KHA,q>S<\_<Ĕ0opsW\y\" "YZ!(QL@bL13d 'NU2||x͹lPlPݬ:)͋@`tt[ez0d= P E y(!"BDb夅(TO?W-˲,Β1s貁c.uߕ:o|_\E3JcO;[䂞b h!B6)řP,#YP A=?W ?7_g*kē{z‰~@hP߇$ڷ"xpn77nU 3K0f?|;ƽFU44;n19cs!t "vBuȡ^ap&@J* 3J@uj Ab獁hk}5^Ӏ%nܻ)$/4D#ƷKB;$0bԼ:IUXȑ!]cL7^$[lFmE!5#TLhKWץs W٥۟QmnT W yf=5NX SFNS2Wy-N@ˉHZĦ^ i6 r Ww묵1GMI ZqJKUL#bS|XdRy<6JN1=?㳊)8 Sׇ\Ȑ2zvC-Y 0'W:7_rɯqI@i6 ,$*If3XDFe+MHmt6QRm_+SgZ#D#({<.4D)gp)g_I }>+]Y`9|U+@H`J 9rh4RtHtoXõ|@%W+zѨc1vH.h5⬑ APzx!ٵםn{?|Y1}xz2͋% z.7/jѕ!`"N~ D*H;L֑$KcZK{ m͹W'joSw&mٚmZr=b2U7 OHRZ[]lf7'do`. y*J[l ut6Tw gb2:Y,}3wL3띋l8-U[D> z箽z*˫^uMu~}/OM B !d9[n|"ǧyIDdDigy5i5I;?phHAKq\F`iJ=qYuJiXkVؑ8Iww," cČt:m6> aBK@?G2Zu'۸t%uENvlPdUEVGf^{xӷeۏ7!EAȉmӷK(2 h(ÙMǞxg\XXٹG~Cm҈dXׯOޱX]:./HxkG2_}f:"UׯC`>=q ZNF '5_#㼩[t"zYë5mi N &j<[",@"I3닅1Ubޓ޹čX).U4Włమp V%Fzj/{{K)9K?93cܿ5k*655q|qo;صGw\2ĩ [$"8P9\bnE_SSI0 s~>hC4,:m**Oq)F Ac|&%WF Wz5#@hRzՋ#XPhu^*HeUY=ݽjG oTlDA =[{6똟toG&uM"ߴ N UQJ=QH3 DQ53u| i;޷0#Wi~c41. H=uaVO6ѐznt2]_|DG `͚5>RpĄ64'on5v$nɤ(=ܘLCеKV:JaU)KN!b8:[ RIFN8mf- Uٰ(3Ja,(j#¨̉&b3wgj+8K/9̳߳>p)./]B5ֶ*ߘk} 7Қ"VF*iiL`[ T5*jj#_?4%jn[X۠u/ǜs/xouds^k9ךs1R>FKGYbhd('0g5Qss|QT͘\;:Vڨ c0.4p8 yG1F;Vsdi'J˷TeM>oײy IDATv68 T[ͫ RتSLXYCo\`6E1t,<m_ 5.=*Dfцpi̿ ׽tHl;2jH ;VşWCFy[I/e%nV34jύyou'dp_!q afRlη$#6>tӯ~Ϗ]~^pR)!DK=IH3xLN3wu.ibYF<1y)|/ 0⾻~` b=z 킊rJb$9~U[8 pNEɪx%ᄙt/>yMlnXAQ]&H!2yM SRFJqh@i,%%M;`򥴕nC=|' 4ZJYݭwRU%lv[[u WڬOw6V%j'7Zejݪ-&*ZTD\ژL[\vj02x[nQx1 呒6]kѷh_k];a:K/gmg)hTT&+IJ.DeIY1J9 tSP=ݍY hr_G釤 ۵ssG.hyg/|Ù$}HM7 eN!؀hҡd/]`,`wGyY+D3i[4ٙ <5Īka7WHw鑶łHcPC]"ߨZITAsVDȅ~wC۠^n!4Rf~ N@O1t$)hr h287z )OB3!αiPR ch?ZrC=H +|!߾Oms׮;lMLDd0/Kkg?};&RN ( MhwqС$pujċ-ApZc{M.0#1&B;%`)vat:Yr=-yW.T-X-)$% (tņBgk1:T m8[%h %ĭ$ހ %1},+UCm;dݣ%@'ЙUZ\Dcg?;n"a+=LuDFd{#T^(8I?}a o-2y6I˳{t~4AY]Jf5ψl \: HP*[aCXaL;Ƥވp"hv_rECec,geD|;<,-p).B pIۜ#y B1aPt8!U xrVʳw3,u~\wFhna/v;aiPy4:, n{555J@^[ h$= m:۲,hIǨ 2f(= 4wVʥ3~Ӧ,nW,Vpo}"2@h桱~(cū \p OxRqQ t_,o扪V\22:? 5T$gx᧢C\a'2훤EZZԆ O?'P4@Aoa[n͟ziD^լ]RtisMJ^Yf萛<t<)3uPPjN4??M"?+,%.+(ւXWZ=;sRKi#5`[iLS *)Ɣ(%&H) :/4E4&I)1Nhu#eJ3w{wc;w:N[fs~c{g=k-C}sUmOnRQu&$d\&Y^7(vE_L?~y~p/>Fs$jp/@GȜۚAqO+I!fl.-`^`&~͈&2ܬ5Tnj>fmrFg\$BeBsO>_M346ljTZ(F`xMax\)T̯ӄ¥BYI~Fkpw8*}Bl@a`p\Hi!t3_| %*`Yg ˹><+~+[R'ʩZuvЙou'/ƞ MxU dr44nIG_ק򳿴Vm~;=+Rs*IDd x]ƹ]F^[G|Qz ߆P!l(!1HBOI:5]ZZ>3lv5˧נ)HbN Gn[?p?OGySGgFDP^C)i}w+HA1*&w)dSNZnqd %@=(wlL+ǎ;(C!uW7ԶṨ#Bw+"'$3mb伿hz05U[Y6!u@@z9O/*P gB0" h=`&,u^qЗS:໹ 8w04+#JD w'K=6b- ɭDUf^ jCAIagLPgf"讲6N ]DŜ)JbhrqW-NXv@\u!1>$RUz 0;Ě1#%@Bx`Lh!hy8&Q4dPbhLJ<4-~!W ]Ezxp6^.^ ??%瘒@ӱkcyeyOJQxw)3]'\ Z)K"Ixo[s;b&vcZf?W"j@I$ *P,yٱ7!zֽ{cۗh nl; X (:wE Es.υ/ܡ<,$e)5 /J/h"9 gl;S݋;g#$O7\H%`^6`\V^Hl"DuC4Ӡ趆Ra_3^+ hѫYh\DR!JH`Fs 4"gieQ EF(G)Oђ[jV) -B5 LlN+8ݡpuW1gD^[1y8F~;@)u ]n@%mȸMђ}ƻ,[d4-N6ZBZ%2QSɧs|o+7]w駞p]}F6YlX"B Za#&"oXҸ_QE&3\bnxx vwzaQI,4AƔT*Q$U#j2ooTQk' j3кNb]J? ?` &609)5e-+[IwZf~7D.HB8BDEksezf o{Vww"Yd)PŇ\EU{.t-}5N!)3]׽xKSYntSXZ>^xGL5#mK߻ޫW2@f&-3UugJ(% sd^ \͉*R^qkEypCvXŇ??1K<ij^a>gVL/[Z=T-`'P`,G])#hr$$5G |y3t ,vK%ӏԘCkV/LۈiBϲF[6O@`rV Dgxa[i}UyG5pa"\ԘUDHŇjTgUv=|3c]*bY=FF#6st8DM,!%#)brR3x8HrIrO ph2,ć ٣Dš3O>|t7[ 1cne897gy$iȒsHxh"C\K5 ѳȚ+(@Md#@K #,wΐlG1e'9^ }gSJD`{ꑺ{ަƻ9 H'0ץB# u=wBDّ& 1+(G~o0bb8j,m -2ҼxAqQh xS p z$<4E ]E$:Ejhn`)Q^2{J|Ŭյ; % NFLz;E# b9 x)[tf&R;Ĩj|H}%t޽{'B{FD:Si"ym A&fO]wW$!i  Mk.ǝw?_W 9bdL0uB݄H6D'"~YkƔg&|u ͨLQyAh@vá05SDۖvw}G_zM/~&eR1zmgP 7Iu , P8w'N$.ʪ E!YMM1]jM*jZX jSM%QdU4gD(U( 4ڀq@j* fx3Ǿ5 IDAT70& .<Z3}{>{ovҹc[1:Wm3K/?z9\!D,Š>jÁpLs|[0ajTSŴn9o(>Z5bbQ]scETu֯՚{~@wwR;H5SL9sWSǟrDl'`5[fN)pTbُK˧6ܾc:(\C9ђjD "L_|ԉ_SU"{ߝzF%REa}F5wfFD h2 @# ڀ1AKf'?sV\݌@D)ن /ZLvդ?Z /,1"ېHIR)98Of!5@r1ACtn5b{IAdvMQ 5KPŝdA4R"E$,sW^>~q'}e˖X|֮}+̌LQ̹T#j )CXRWWQ;ѧ>h׎.؛7 Pf@DLDHl(0cUsw'A o=qD jaf@"H)^°Mݭ7z}c#0% FB2?ǖ=T$PP,6!)yu)4e„s̒o?d5NJLflf;b^[9LK*HHpfx|ig_bT-)wyncn~\n+U= @("֯ԩϘ1+'}ԗ 3"e ~kҿL1F";ZdѨ"缛H"0DhxɕNG fy̕ttIT.(Ni[ʆX'N<FVT[m832dJx饷'M׌?vy9fhY^-[Ģ(چọf/O8a]>+2rHI n~o?OQYh yW;F*׺r^d 5fg@|9P~KG[`W,a_hu2eCp点r -y"z fYJWR˰” X*iZj[b)ˠ&B 733M!;## ! piwzXS,!y gDZT#hؕLi%XVŒ H78j``زJO9'.%mK3PE)3g36pM.a3N>0`f2BNu LseSbl{ EcHUP0#V÷Rې2@h[ JlFsi 7=ʞ{ڑ @ E&.,~%zhYƊp{R"ddJދ \LJ~{,X09dCa|K N^'Fd}Y! ̃rǎPboS*o/^2sI28 lB4 #AޥXpu (Op?PFx}A fU?,Ti{Y)Srk6)snֻ;-Z2!MXKYCZR*evL$^=Zi^ɲ4Ж2^IWB(s%o̅ J﫠=9뮿W{L;UNKQ2~GҬۧvn gYRCpjRr%E)>w]y|] !5a;sŸǺ6(+|:l{A<Pߟ舂٥x𫇸)R WϞ8Y@nrMKجٟ1ej ,0Xzyzn97jgY>f] kk%-UcNFd}ΗX xW.€_g,vQkߜs}ν7A1 TZ*JI1JR:*446i $H@nxE,BArby 1*s^kXk{. 5aqws^{7O;qԨr'_30 K >;x>fFTWdz⋦_f "?;d֬/G8d$(q`i\扗N=̾:3[~ &^x(N ɅXkK.1wѢ^%&,ՙ}g#:#?"0D,EC9J>g^>{atNG?0/KoVPZ@ P1XF#0ˠ]!TA\/?"ĹY2Pxp˖.a!Hu>BIB`j0m袳)Y'rmӶ62?C0hs޵C|R$-{j.d^x `3oK[l}vI䍼Z0;>XKۯH5mdDM`=o޴IUEș` RheIմ:Y) sԪ$h-]B-o]|gewܱJ@͎S\!-ۚgfXIߙhQEU jf\̛s7O;!8?W q]skސ+XLB_8ti'jG"BM'HMڶSw/U@Lؠ _ 9`MqmϢz2 CB._Zr<`؁S/77ql:L4 CkW͝ 1B< w Wo6Mynz +BY2ȑ޶|L;u;ıMe-1bM|of֥\ޥ}`w D᫦s05DG9FؽJYfܺs kU<_g M~~RћJi`eQhBD#%r4$"fF8Ff/(4 ĹAX`aX{Ϗ%07eEBy_hʠB,> !nLc}$ yCcel/9)̚=wK0$dyʸ͝ޑG7ٚ"nB0̹:oy (J+;ive~ƌlC6+ng-]C_ .? yS8# h(cЬT#tc=j+ܪW *lي<؊ǫ,@߯|̈́l/M4$^{Aϒnob#n q7͹bC[Qݱa.ɗ\mͧ`dr kf3\4ˢ&kąZW]}׫juϸp_uSO 1~/z.ejCgFcLt}I@dЊozdd f! SOdH!4l`_< {#?У~z~5a LjF ƘQB&)fs1ݸP3x"i.FL3F +Es&砢MoAuz/k{Sp'Ξy&B1ݎ,A}"R(ʙLƄx,Zt'd( 61c(|qUZ L7wYY]s; EFLK$*] [쉢Fc$ ň6A)*ދ: ̝<{93h>?7&=̝=){ڣd@d+}2BT"b&_bX~bJNU'KOOSTL:09V. k_nDwv}h]l8/&VBX7ZIpÏzkUWEDDF:'>-!!pǎ;Q;TZp1 E|YDNSX^V* H)H:g * R% IDATF/}L$@H9@P ar鼃m>}RLӯɏ?s='Ha8d,mЙN,okMF_\ʑQphCײB^5%ŬO)}1ǞzхWV:|QduX[]΂-W꣛=;}L=R>;&Ĭ#psƣp-h|+ۍ,`AEq5*@H׭ݥx̔~9],_T%Xš1hfo{BG(79snN>lzf~)F ! qHf MnV%]BI]O4q,a`dv1=(0 fT""␮@`:LL˨@zSUD cN`E_Rv`b?.Uvzf'-+TsyOtW՝wz<53?.$g҄$B+)P~s!KI5'RU;g>?^A8t|K0Az8H&Iv`b*sτ5|]qa??ouhѠM-}8k/}k>ZzB.L\VAzՉom(v>˯H!X P8#6>;h",G F-;xt uW[4Pj(|^o*aL<['u6FtJUeT:ɉ±Rjzpýzdh[WF1:)i3\(:򘧜۟v:-P%1J0tQKls+4lq"nsٶ~v*1h;?8B kн ա܅Lbw"?<[ȣcJ5A;_ DR q6w}ϖaad> -v;mM/l"S4d}TJj A87U5Y;8EV{5g#m@(µgjҪS;oھZvHM9t LydlbJG8sd%:ܫ NSgUȝ``f8ŸxN9{2!CKTVe)0z,3Ĕ |t+ {,Po>27  lc¤o(I4ciր/e" MK.3=oib{ )Bkf1EyceTev}ӟ4 `uAIx7 HA ^uP}1Jq~ᡰ\Oh""P'v0jiXzGQ$`b;hfUbѪ_G#/ϸ+_ҋoE, T`@]jm̪ÚH! *y N>BsPˊod&6NG!U fSAkcj_ Uc<Ռ,Mi)"@_꒠G\Kd ο#8Esː=̪\U`rˏxA™'wg_1t5XFEYyb\3WcnOnf)ڙtw\W] Ѻ~?? ,ҽ$46v48dG9z7Y hAPMjp 2:/kQG~b3^5bH$/{S l)(#yr+(,w{XܺA p I7?:" (!Ykh/jOhe;|ABRzőG\u#1]w?l(D0G,~O+c.W2"LhG-T1;Kp7޵ŋ^lKw3ϸuFif|^RbVvYQ[z0/ǿ\PhOX5֖dѯ~睸GaR鷔\@K'*EϸO<ؓ DG*!c*zfH7PzٱWT-o H.KhKSC ZQc|s=AĊrQ^ Eh3K/;G{Vft8 .Xc^x TVIWͧ?RY)g-,9޻GOZGt G,#>#OPhYPQr3 RxQ']wm9:"1_2z\[ ub(%*(#C { =à&.#;?tI*@*pTWFdP>B:AF^qM>[ԱBC6}Ix@D+Y?_Z>ܾq}!@ L^_V(Z@QO|c׿X;n9TB.u\o yaJu6wŭX)1[O;1pY b4p']+*$apQ=t?E/|k Sn˺-GUz]y.@x:قIPE"Ax[(-hBI'ڕJ? ]ʣ:V(+ !2V޼^EοMIV\cŅĸXoWGdrj 2٘y!XC?T ?06o) uۨ7&!?PTQ}!;DOgXbQ:CqHArI6iL呱6{]wPVT tP˸/Oy~pW{THTR1 Yrz<ȕ Ҩ~o7_k-cAS~qkDLjzyUi'x|9<dTOSRǢ." #MJ?|%)JŢvEҼ C.ߜsiu7V=D@R2aVZ6BHkA4*DD4CZ`{尴58{>]…s6{ Z0=ǹ;={;HM=QaQt!0@DiI=O&*;pwjr~|\( d ⇛lnj4Jp h9dv5zQ00ҀR!q\8Xa!`N5:Db<»7i^X0VFFR 3N2#)a*S>NAș'<W]ykʆ; ./iU 횭RD3;Eg,e}i鉧zbF.-.BR<.x}d"cK˾_ 4N"L~7M.i.\wڙlk@f{*^rp]K_Ԣ 9c^q LF (T ư\j)U-rk 1H ĬC( `,[ ~R8+WVr^cX$îAP:kSo`S"g S)PAQhcqgI.D'N:._>;V ̝7VYU@1)UQ%/#NR<y_t!,f,nMD="e=Λs܈Ƌ5b3` eYHq( ^Tt"0ˁԶX:.‹.?\y Y ֈA4PPށ\ u2!- =Sh`en{g]`i)͊M4^%R̘KD=CBf=+K[%PD-*B0@{iB2R+iБd E]V5fqH.Ij*xڗ!F ~ۛGv^,LJx ͖VTBaOn/ %YҔF,'9[%Z91zL΂ }(a]A$چuhT8!TCRykuO.b?\P8!F hմw:sk@(#ȨR+-^:UtPv\w ƯyW\Z T>n{fpj[Mge18TAH55;?鄝mgM2ocsЗ'Ql; x!\p]xN R% (TEFH+3 JEZ*aI<}߰b] 7{D6A*Z%i2"("]^5b>ȳl"<|[5/;'f [h>r_72EP3{DUWp*͔JKGh)H h8PZT-rQH^ 15\c.ͦ s~[s\xg~${-@Vg4tڌrK!s#T*A;9Z3o?/ B k-MvhK7Q⎻mvgkLY"J`(0g>+ۊ@]~'>%3Q>8PpJm1 _8=* 'ƢCot_/"1o}%]u/ϺT3IY砙8;?r!^tSqgVP(WyM ]CTըD'P쓻;)W [n?gˮ^>@p mUUE(@]0{ $`.s[8˿WnN*B-@ +§`."446ɸ\uB}[Q-bE&x\)@G056?uk>p[ i$z +^WKʟn$ՙ7T@Zf8\RHT0WJ40h;**A*D/uxG6!M񺒧<n?Y/|sګ. @Tktp /c<묋E*o!tԅ)h@!=;C'CD"I5X[b Hu.;oϽV px{+s16jĐZaS2hSBE/v6+x59+Cz8TFbw>n98Yyl~{qz^@}lw^',)RSZ|ÏN=ȓ&pL Zpr,Uh\%BZ2Sf}y\#*QJZ FSJ"D$FEU&A4V=zۙgKKGN`%t*ӱV-t!Bie3@L!^f 2Xm8)(=/;-"t)B;-׿,,[on;w_wˣK3 #TPR"!]2tMV8d9L P5p5WYΟϾ2H?sP` IHl,>pas-fgt;[`t IDATo{[WDB, Ii0TASH:*:d)MF)d^y#C0d$!EJQ5mC+ĔHT!lK] EO]P*ێK=m0X+MrOl<+LL\ .*P⣟U_?V0署{aۈE! 绘 Ԯ)sڢy`.{?c0ɘ<$^+M^v8IScb3OJäćlM%j6U3llr|VԾ7wMXi;B4fKдH ,y?[ .[̆ EAHUd(E{9F+,hfɖC_O)8Lk^y&%rHO^%2rBQ5ij$%Zw3\}a;2C gׁbB-.ѽ>䘣O ʣSHUh0E[JKȼ/K kP]\x%?Nҥ!ݻ +(Bz5h2kT ZKP X+l,[nnʫY)#D{[۠u>\+ÎS8tD7=~H%^˷|ItPN(H0@ڌKpמ=.jf4j`E=vu<μY M}ɋ!D`I Ay-SO; ZeJQsUNc]lUηf+̘E;AO}:j9+e*`L0c(DԪ6e;O=N>yHNk& á QG@;L&Lj g!hB.&0:~ֹ袟uC.|_]Xk tR:;}CܿݹRCTC`Рk1ё24UAb4G;|e: C2]LN sm'sVIaDV aJq  oLB2MVBSS3;`#ptcmwYk5._9&}'E6k}}>wim""* Lv&Mlt+J+"IQ]l!NMi0K6$H.r$Pp25hv˽Zĩ^}wk$RAk@&2 ͑ 30birYN5XE5wN=YE *t믿 O{G!L1jvB2-X]4Vv;2y\clA M /XcǝuaS9SKń}t-<2b]x 7?[EdYc)@U=;z7 Y( ODR*F;X*5iF  4["F"fi`@2:M/IPmPyL4c=:WGyXZ&=tZ)Im2rS T+2h@= mMԂRрn! 2ηm2"oAWwIlYBGO>7˔}=}`" :b@U23""ECOة4(̾TY{}jo@BV@AH4TW97Q`U0@`5: U*lDDcjFjG$T7ngu*Vuqwp7_o}eOf(tXEJr:s ÓU>NAEC0>뀥.;vl+LiIEoR:T"Vmw~]$6!EbL.n\v{ytiU55Al9@UB6e$Y$3֙OL4Skp]HRCdoJIU%xE+1qǭ?Rg.aN:v^h,7M#vmw/[noe3MR8pTفP U<9wyC.i) ң9'ڊ:i6\:ݛ}3O~_&DŽaȰi#CUs}]UE@X p ”܎|nvw@TUHQEq!|{> 1 VbU%LsyIcrx$Mj[ Cr]>Ǎp)nyZ}oÃC1@њW_CߞW]y\yɥW}σDN F$D @b~9)*2,X8PDQg 6>"Kr{8{μDwݍ<\,8ٚ (ab5@,=7Dz)RMA`)qDDtَ_BtZJӒm6PA$*Bu^oټ0T~>zB`mTS[Qm\sOZr)`$1PL4c*EHH Ur孪b+Jl$ &cѥ۞Wh1`q3fa۬F D$wqwb%o`A(uέXE/U-86[xO;WyH4 j<.502*1>eLr|=b+b%/Ӡ=.l򾦙$ \uPuUЎH)y#E3L;BGMhND4TD[…߱vEԃ܎u l THEZ4٣4xd'TƗ=aO)A|{hi3Pd黹춰QGgY*Xi =@E˷P| NPLw;oq_&E[1X/fJ8 *7/wn]UYe+1\PH .#:UdQ*3:ZHO~cMZM Qf6яm}?]I}Ozev& -Y &IbHLX26 H֤GdBfC] O{çf";I.4z-մF3 9t J+rsUCU4/wv;iY mVAM@VoT /um AKeoZBU``[$njmPmnt8HcDVTV6m)*VON88yRXC,mGYZK*lY.TH" FH5+ofg! Xg*2$%!9Y:rW?ݟ83c (F=4o`s@5j D1^RnRh+2hkO'^še@˖er՚F͆PB9,$c45ٝފ$H U?έCEEU"\X^մfh3W{O΃D5bn4m`a'QeVPu=!~o`t9)Beq;XUmE}`ɿ[M$|O<#"g9iQ:g!Y ( Z~QyE0J tV["C@`#[^%)poJ{DG0d1ʊf!xxEDA#7, 9眳&QD3};BH)M5G1{=_{iȠR4$Ṳ@FfFHd)BqeSU w~jU׿\Js"NeTSJ4^6}OA:NVr@rFU"Δ4#H&eq'{М:zGoGyO*NPpnܶ5*9pL3] 67fI*Qi+;יs)\9jjiC=N>ivptMx@IReH/Fͅ<b<ӂR`boxPh[)`&Գ#"}j~y,Z.Ko[RJHmقipSJD@>U'ޔ~beHy,$Xf\_s+_w,D(HpʐSDbes$;{QxcܽidUވȬ(dAE@QT@@AAAƂyAbd(yFEAPTDQPlԆvxZEeF=gY~w꫌n{^{w͘Z>_=[nb}FH@"ܮbђ*Yn}ݛz"84m^-N"^1_]eϪNKFƺ&s;'KzQ\{yv~[YA$x<^9E߾M]R. ul3=0{SRTTGМ&EK5`WpOQyԝgnΛj޻8s)V2^R)af=P/ݐ|j4Ҽ1F8W䛖/i̲8TtS-F/uG;;G}ɄjcPnuhТJW+"%ޘY7܄2u['SUz[n=kXsI~&1cŗ6WC/LKX52Z/n@r}߿0H%W_m/}ʝgՋ=VN+* kՙ"AcBvwyڔGZk>_%*Y]~/Dqd\DkZ(g↻P8|RSc'x̱|toUP-('O=AR5Y ,Dxf܀1:#W_Mgy\U4WYޱ̷)dl1W, pi;n;@ԧj$c5Z|Fn0zn:-ph]4GO4X|wݽ ˹iv99d%XtQl]=?ޡ*a Ң#ypB l|O#BT[*jJ}@VBR•>Bmuƾt[l`FlqB6U5&8sΙu|'^ s Ԍ: ({y}sW'ԧ%%} ^T}Ej[D =!TwѬ fv鬀[ﳞ8eK,<-f ؒADH&Rjx}-E-XUǜ99dҢQ;~N]ͦ7^+)ŕx]Իb>2csڮӪC&]s|-9G Pbw~ \ u,w'0(tE_~[n92€;<=L![P*T 9e<Ʈ;:n^rփ޶ HZ[&8 +oN+ۛMPh飌L 7F;W]w܊X*F[YV0gP$X =EP*;5?I'p3uq:O_|$̰,آs禼*(-P X5%48D|d/]@[/m̗uHʝYAzd x<K3)\`WdIW7%4Q2TŦ#88o9cGw*z!?;_*3⮯p)g_v5߬Y{h~ugw_bMS[K\*S~@r̝[vy_^"u\nYRՆOyqg~\&>LRB 3"}۞`=A"ԓjR7ZH"4ui4џ/XHUm+225hEbCn];~Ixcf%*q": V͈Xk-9 K=Qk\+x/_E% 'H& rwf/u6˥*XP(AG[ҹָV"HezƻyP#&E.)MyѧwX!Y< .;լuT "=D`sw]ҭ fyWC%-& ^+10R^*e`KaɥO_u,̓`H4bT%b䉗_M}8Bxg:|\u\䅢⦛qW=ugoS{E 8کZ$ʬ4KuQ[&T}X^}~7N޺T)k-9(PL 7#rL;I}n//ӭٔ7D)~xDP˲HEUH WRAגw)s}=܁a> ))TоIdܤW/yDƃ@=ShfvҫP p"6"݊\vM}MPwjoYY]ote;oc?!-4&; c55IFh痿zj> =G fF1 -hV3[w L6f- p73zFm@w>t.5pSR`sEYW&Ҽ ͺUI-?,ا$aHXV2@ĻcP-"wy~SO~gEHX_9η}k 6 M!gfy$}oMӫ)w|`h6Qw fnvqGDZ/suOH"Ay2iUIb}>+\jͭiyra+ٳ>X4QZkw i`~0"'/c׬zTRF<C0ުo^/^qMKV?c:t*=ou <=;L`-SGϾ3kmT!Ȥt~eRghZ`͝7AK/;rʭܲwq$NZCԆ agnorN9tI.ɥrV`2::a>ad//vutq}h9 uQX R-=^oN_=ƻ,BQ{ۿ|ܟ[n9c]j?EJUtF:Bj3CP_"R*GLd#wvo:@%B-W}~{oX( )\_QXS}ؔkP'sq)S[Uk5/=LDg궪nA }ձw|_5k%xܢfo=?E9׵ƴ 1@77ɏ}6@;('S@@CA^}D9f_mF%}V]a6:ZP`ܓeO] ~֒ƼVjSXD>Iu}fԲ$snklOkM.: Է~Kut].=g嬌$Bi~7¥=s5[! {Ѓ>u{E:/R"D"Pji居ضT VpwX!\-V *J67̃mЈ<[~TkJ}:KA.ZũCk `Ǥ9hF'Y`feJ咘JyxG 0c@PBUWQN2(T @FbH-{e+-d-E2غD~Xk3 LН&Td&̑n-u^XiMKS}ܛÿx+wqFY`ً#`ڷԣN춫^U{m!Jb_,"]Osϯ|ˢ| % b# NIcT4x~뗞/IR:$1K2q/UX:RҪYI%tW 0r2:RQjLn'%.u}cT+%o0ywIlY \'%@Od9gdmA]$ZfIHa$Cv/>#߿ۦ$<˅+GiLňT&_wѯ|~(T] q C' r$52:WWc=qmG3WJ)p槏z{~pw qN G|b_=~,6N}zCBՌm7'ԬN(2=s|*Z6(C[o{WB5=8܃HVW޹ZflpF+ OIN#9e!?d @>Qɮ^fq4X\mD-X5|jJov͗n>>amj*KmcsVTj>-xqN|EɡNfY+oP‰[o3ccnpMHL zrOk~?j-R<닄ڸ,K"I!n \-Mݔ3K`U%9A_q>6VJhh"nHm#">wV|޴NLx0u*>{3af7"FJ PJ!mf8g_0RT]0J2kOD 8bOԩ !ڴ L<WFԃ_R^z~pґ[LbbRJ +tBsRS$K1U"&4xb_ƫ 9#s~cw~҃?TNF$ 0iKuqi{?;wK}KPsjaOO:E{6ҭp1-)3w]J 9_iKN_~{L0fSL}1e\Cؕr<*t _k~׻W;C>BBCHg*t7QRUH>%-uwi?r[ !s lh"fd)4ber{_7(\   WLw;ݺ=XD& R&%ԭ-nqAT:>‹>wȶu9Q1ڗ.Vek\<ڝw=3$bsw %c#瞋̹ܳ'5+!iSqb,z+&nzkmfe V> 9krAw;rTkШV4p*$_ff5d,)yQyp9MY"ۘIJg P1[#]~}'9w'=kA ;Xknɶ{j HљmglɫuP&A6d/=Nbʑbg/ۭjg(d= IDAT>BW0%QHLJdMVjJ.M ~ɓ'0R BCR{.;pт+]0HX*Q)fr:'|]tCrYw!?w{\]AD H 6ØdX$="8 ϧyQa,Xυ@JhfȢXĮJ3.rᅷM_tɣJ(K$-D|o|OY/ȾG.PH!7*cyK/3eY嗧g`{Yp̃.O< --\};4cXd%ΦSDD@Yӟp}G-[Ntu@qڈh~',Uo=ջ&Q*m Z/^.{>CѮJDI/ޢ&Pd}7zUK.1Ǵr՟g_*dJI~A J\=kxQkbTrDs8^,d1eEBZUryلRdz@jZ,-:Kv]͐7ӑr~"kcTO‹f)H${GqБ]*41NJT+Bs g $_qm%JK}~d~)F7K/@yۚ0-sN_]߸/:!U zʊ<]b\zRjDZQXfZ$bc 3) Zmow '}X=HqPix쥖hT*BT 2S`=qk,{}hteĽSJhbqr <a0)(h#7=SC:8gK/cfAN)Hf reP ;cÍpd?P,Ոne nkZrKf˰Eh!E#̒P5r#Do_:/Sd-޿[nj`GxZ_y'<]w;mbI-ݴ7Wt̨̻-('~96v9Ӽ 랡6`R4խWaU,0[ sgF.@ ,OyEW::ʬt/@=J{\o+aPU nuQ * Gmv[ ?SDX#&TSAѢH F[|n҇@c{rJ]DyR@ B3W=iLL XXB :_ n0eyQ$Z{wE-Va(PBp ulu랄ܿ:sӓ=H6 9]*RC;=XpW)79c,MFS B[u*[kae>N"k9ܡsӼ NI=e1T#0̣k}+nW\~4w咩:p37dziL t.C'` $bMۼHqu q6k޳Ehdгi*j^ΘFٹ)YnÀlUe}P:^{$}.eP~WZ7gr0GPlr:=}W_}Q sD#̑DX UǺv沈߉cmOa4֡h%]iJSe=1a"Vk{ %˽r7'Ct&e|)^*F[SE{\Z/sFvFcw;^qm;| bB[[n;O6"hHX.dtkKn~Vswss=)VO~dr0߱0^A^RՆvJ" [ȉ׌h3s~U2ЅFIxsFͅR׀IVZ |Dj g nnAm,X Tj]~>"N GFO?Kd D՝ r%hx5!!l !Bc+K0fIEAT <7Ӓ v2'1WGϞ# _Zl-)'d#ZOD#b\xz; "Jo|amV#שh@' y,nlJ7zkEK~)Ҧ"-"!" AԒ8o7X33 "QgwMIY 둭VsS׾$QRD! Fs( ڲN3:aX7':͙a~ SQROD.w^Oo;-[Y~5Ld) %Zm,4s-7H‘KyBҁd} ۘ+Ĉ#R33vI+Ωe}BxqPo5zN8ēKS9欟<,{7EZlI{&y1"ShHAՋ-GG0@zozy`VE\MdKQHc1ȣιlh2q+@2*a}wZELeBfsdzS,ڿ}7XoVY;$SFx%@"L bPaPYfgk G'3{ͫ"C\5_4JV^SgZsE^~Ӌ"wX,6KM\@_p,fN;_|E;j"Jhy\iui$0OU+T> +jæHh?{۩ki%^tgtm˵;'c޾B& 2„YΓͧU/yWlWuk}}//@ MBБĶfaTj([F$L ~Rj *RF2 ֡v@޽ޗq޽sX2&ACCP+x;%%~x`L hLzU*̂H2Wc^ /RiAJmQr/^ "ہҠD$$C<9 Qb, #AJ1M{scmB,I)W?^fNIE>~=lj'ib  ^{ho*P!k2% 7ܔRX ֫W-nn[W )Ģb# Qi ^qBCQ"ϊd2ĥu-{'^'9 o:*Pg^_r.>u3ؼ~_HD6F5V BD*$"&)ڍYVL2W+mOe|fHrC*SCK5  *+i괻Ir˽z7lӦ<]&F~n;Orȣ_gN ^"bC< u8#Mjض +I j@JIC3'cs=1d2]{(abA[67B)ϔʲ#'2$1=\kcN lz'ɧ~nݻwk={ݻAU1fffffӋ.]YjˎXZzOAo:yMC0B3 =Yҷ CziPd:572"29hک, ~UjxQ7zwRAe.: JО>Ԏ߸3D@2zT`PMMFE+W8Q"k#UsH8!KR $E)tWhe fpA7.׌y+74`ӈ%1 5y4$`A!LE8a[fGS\m@WpPL$xb ոŵ=!-@USMҙ0A/kc2vơv<0A577ŐVCUQ=|vŊW,[l/~pecp' Ut>.%ZQ1 kh%yx.O %]SӑyF K}ى'y"hl)QBa6wi!jz`P*='NC!e7 Cpf/qN$h+<M *cxk]}E6n)`xfQKP$ Nt5WA@h@`lB?!LU3CBc 7\t[׽F[ (T"!`8D''/HOI1x&^_۴z&[ d_˵9R9qG+ NIpr.5#닟uGEPҶ-_M{{=c{_l`}GV_A$ &5S`1!A,R³T->AI,"ZdWP* QC?R$M`TdD]kԵzIWFbՑ>]8k%jE5 A! <3TBh6l8]Ƈi\JmXK4':2\8oQȌ}p4AXQmŸ~gW|KI!R(m%57~?cRhhE?^0c5g6D(Lp3;f[Ŝzа\B#ҽtvWn<~VmΉKyXݝxF\X[GJ CO_wlO`E_g F4!Wlpf99Ęa9@w"Rtr˸cd`v`2S|t &r.";ŵ Tf=s9 49&$GtQ @BY:s?218Pc]1lm"b `MrDB-j1UZh9ttH6ҥseBBDCcծ=X_³Ú1Ս'XaysIk4TB%G5kv݇?tW\ D Zyv;c#u4!ms.m}%Su[:ʥG /%S4xlP}lDŽB> ⚑^\u‰7 ezoj";> A w#1a @3e2dj+͎S*0E(Kqa~<~^7cBaG!DXDpJs[ѶY1$=I*YT$&Uy5[q TQ{< 50xMGڲ֕+%O,bATD:`EDHD(xɢdvuԸ{CP@2zU"uG>S~盔ZG@@WCVTxrc{1#;ǪH-)ֵ%2f0bh.z_N3ےt++}@Ap:&Ujp,;Oqݤ uigkhIb3;XкA_7}KFCvky1ff"z6~6AMǪ>*U8L=XJ?~EeqM<؄L97GR &sx2+8Ly}o<74CԒ٥%ҷF`>+rk.Խ Pݺ|GN@O6#8%E{54_GLtebϔ_M:υDY/w˺uرUJ, )`/ ,5wAVu}wyP< F›`ʼnH*UM@%J#a #,$8,1E5$U<RQ1 L;?90S -[SӷokPh^ڮ#yo[`X!S@qE8]5Md40`XpYdi3Bo@8{MVM,<\79Hrfio00\\'iPͰH2@M Xt[ׯ=s{ݾCi7ݦ%-МMwwUm/δ!#~g.l h )v ̵0` IUBrHn+zڦf*"BS?-SJC'GmGT$PY2YXP 'wӎc֫((y;  ?iB ٮʧ4a~?c1FEe*N9b R]4 Sզi8m@JКhbTDqǾg> i7 !3lo*^Dt:RY#U D!*Ana_iu͚>Ⱥy֬9㧽Co!&6ޑJ5 Bwz1HYS%or5R D5 ;o9mg>LcvE( p1bxgX*Eӿˈa"\| W_uݹGJqm$^;.o,y8PP33DNp)JLG O떘EGE5m&"^-L`-Ġu𮢅Dj>&NXiiLtGݰp,nDt.`QՊ")c#t~ DlT+v|WSV/n_| o~l($"V"1F(l([16OLK3_)5}&fR=l%%-5 @ DG?5dۢms"T9ISq'r^0 {xbh}^5I1ϬITmoO B!|MW}OU[;I/_~% -uw.TS2,Fwe}/da'G̚n ;7n.]"j Kn"BP &3^~ED193_yf[^%)˘bzwP ЪXzȑ#a'MxGzx7{PCEzhr ٱHgRht^M\J>6Ч-< IJS/gN8Q4Sr N3o0Zq 8 cR)d4gqx,5f:R 0yG2?kKaj {w}+? 418²^Oڗ>:Wͫ /SFr}Z6w7|rpQ#H 58rx E;?$El$Qt_1WۜK /-;C^gဴm(hPę :MjJI\, >'br ,ARē vl4j1׺g^}Պ/)pN}>%~ˎ_yגw#9ͽ=0iUHhf FD_#`[Pgu'Lk~/^O9Y2nC=gyHXsQ~W9)KDaM˅s(}&>KĩZ* z0͔]}&c;G:SD)&'v|Kh$+l7]X >dG~wjɈPq-d0r02 Š ĭMUdaJ9Py \P‹鋷U1D/RֲgsgR1x_ewSVj֙Ҭةݨŝgx B%iQQ Yz_I̹'0pLsL3U28ž?wop5b$~y~t}~ҝR脚7qT9h 1Cwދ6.8 g$|9A(`P~Jޝw~OzJw:i~:hF&ϙQkQ_{,%ˬ͈*c=jśp8Әj7c-_v'|5gv:T@M3ŝxUP0ĀW_}[E@`JIDƠM x %& 90~x!03'yrש#%83_;4U1F @#٥4j ]/#"VU51֙XpnuocSn7SSSHZ1F#SQ41 L} 22{D6v}_tիGUZ>ZޞAqtSE'!Q5֯W^ԓ=Ū5] JEHXӏ/Vnƽ'x͢0RPɃl6{wLsO@Rxߏn_73gb$ MS]\{W[*آhUafAhvne{;/%[U5KYq9I=~gNlp2Y:@4dd)RŤ}CdN*"EK߱HWyU5/B !yM4s)3/1ܮ)]key]yosi(r"Xi> 2NeP.ShCA &Bhgj20 p"\(S"%[Fc r䜽>O9IF8Y{/YZ3?]~-T|G}kviju0HT%+\wÍZ\\b`Tm3NzlPСE6g1{l<,P+ETBͳHJJ]"IBJ1ygE uiP<`0t>G%;eZ5쩾S6/|eZ !!yBlu@DL`2 ЫR2- &jh7xD%;;r< /KO&Ѹv›ɝS|{Kd09PdcѰvշzےM!TYS3\Sa7ݳgZ`.P,_rwrf`!(3{s_d3˟wNrRa)7)'"Z Y)ycЁmE,%J 8X)$> {㮓p?nw}ˆںr~m4X^{m+/Z_x^xe͚n GjWeS<* 1|рGV!y?xiCzG S0Qby3vzy@I17=z׼:xX@jغ#ej[ԍ9O?=DK Hg `Pw,Ղ90 wvykn~NJ 7GXp\[DD""%!up#F̰~ο{EM֕5pQT=^վ}:gUBnH.^2O$Yֆ[8/BZTmNi?yj=UY}3  VL/j."y4E U:ZJ>ih i ȦY n߾)'`;)J>_C'[]$Ĺdeկ6]9o|g;WM*i-5=ysf8a(>n,u_߉AzN1cpE2Ò94D. epBʗ,6k ]k*஦Ѡ݀sFe Jln\*.@#n!?CJh% J2pX#$)~ǫ_.yQ""1&)vn5˗g7fg"ԭ:;&lek?q2aƿ߽+Yykv4|"JRAK;课{ |al/~ڨ\R#\{%w/ Vlu+us0kk0DB<ȏ^ty=I&E3>$&]jk?c$(7IG"!R~QƢ {͞ 4JzA'|]5{M&2ɰ-XGOjj^DÓD5og|uva!B&]v, THl6{.+WBhrHR$O8』a1ul.Dp `4~a cV{ڲܼ[ @$Xv(&MV}:R }U:6 cwG4O o|X2 L!] !T{mC!sV$%X{c4uO |ܾY}|ڥn5t' pSL gE[ZU ]֊r&HvMR4E #~g- \ :Iݡr`ÅFvD0b»,q:I9(J! ͛D[o9cڌSǏ e)>yxƶCnvԓ y&[67fd;N+N.pjhTvDP*r nva>^HofuG^^^{O53<$Icn[$TӁW^ٰ[6dqЉ: I7$mZQTc9^wTKVK4ERjRsG$2GZ: IDAT#&;_ Yl!H6s1a/;ɒDӈ*=V$yj}ִ3ϟy !kN;P]itvgh Mgn(:s떃C~@ a]򭛿/gvN>:kfj@v%*Q#qء=9_8xze?yVKܺnXCJ`hM0RU* :̳Y @ ȕϽxT3{MIzs;- ,Oz^{6ػ >j$ S E`cˎD "@3f Y "&CcLʦĸlH W  {W>}CZFbCK^瞻*rRnTMp{HW3D*.gDPf _|O~Ag@RSIDF ա谔1H03pJ;\n?<[= rH^{UȎdG'"T4WE-]z;!{Cu@VBV B&1;IYVU&^?S#Սeyx . %]1Mi#"P<7(ۛ+Z#"b,l$U{P 0x=t$nnZ(,%JB,Hih+~/'r3R"A' EM†]lsC8IJrB{$|ڛnVX7DT`Ah82s_x윙EȁKv^e'oBLLywh20඿嗍4Y%Qi-=?i+YIGWiPOAG-D5w QwZH+O!1щZ'd"NuQ%t5@ H9~1@YwNaѭ%4-O]5c1\9$@)<3V]o?Rb,<-FJҥs 9DUE f.?R`vT; X<&ĭl*晭Z P[*V^F߮r58-YpBȶꆝvo|/b{n k*߅O8e|rY_z)Gҭֳ[ֲQ4  X:}/"u @#K 6啹G9Еsz1]9QuKPd[!XD#O*4(BPA=+5|8š5ϟzҗ֏C 3m|?DͯYכ)tՆphN^nÂ!$ v}ҥK/8vxʻMȱн/&-&[vƃyvݖA] I^mI~"-'h.1;N<%O_uLV!Q#$p q0"(M׾G @3Bg!Ddx}lL夊RA )ho/ZGPZf:)!ʲ)$aJuS`C+gKlAR1P*.yɢeUaBTEIo 1_^#wCbTH)9CK]u@ů]S%j2U)M{D-"]ˡ( VFRKbДEȗ ۚ[K5 @T$<ߟe4(zfRPe w|O]|hyp€.}'b ;EsJ;oP2҂WsFc;-; :C(Q f[uYg.Ki1D:lC6嫷~ʧPto;"F%f2x!G_pfxr_oi)*GoZ;Uq@&RQwcGN"pĕWIJjaE4B D6:ógȲBhnD7En^D*CkVސv@ ,j9)"ky .P8x}y5O+lN[:7 B )` Hpjp]v- N->PusF}!iiug+ @ih^R0P$n]5\|3}5?`;K(Vs] ƶyCtjܓ;u$"cdx$RPBK'^q @} (㏠ҙ6ZL< ^A򴎦7Y99EU5"3Vc<!P @bTJ#@I#M57ϓHmcucW> Z*L6(ٔ.H36U_]Y,e|1A}"{pf͍D!':d e̞2FI1&K#Eao%ٿ(T+DcDy"WkqL^$&񎂎eF-{;g/Kz 1.fԝhOom_OhBЩf[ZlSȴGL?g|;H IduD& !*D#_ 0APcfϺtł~e81WMބ]4IL覯,G[TlDK·I6Є~٧\x@hNj55%@Z}M+na~0J=sARԔ$E%,2?>yG\3;nAͺ˳,.aqD:rvBcf?SqD'6=̷tzs:}1Ԇ7c2fqKgĚ@XF[WAM%doe,R™g\DK2+-)sϝpr+,(:yeP3O.ڪ:,7F섅7}Wrݟ$iѠ8qzHth>Pŋ/˝уHbpd 6iC^g/?mFvf&⎓S73Kxj6Kv@p&IeQvrS(LÆY|y낐(c n+s["ݰ kYj0ɤ6U9bŊ}!dK}s3we% Tq P˝]my$ޱck {UջHIRuh]ש';_B~oBW-dHRZr Y͍j#9^u|ws?+)ob4WRE(P\2 BWMSwѲ%rY%\HRURJy0cOL&}R?z';:AYx9;P w?lvsQQ5;@eiaoJظ\% tTck4Eyߟ(Ai:zT9gֻf1kKk%3]K8vvYD5Ҳ:?k @VHlH%AiTij( #ֶj@hC Dk%ZBk&6VК4TJQTj)s鏵>gI3g{/[NX=]gvo,CEAA4%gTVnV^% ga r0G\}h=%OU4wd"fx6g}?^l}g0!I xe$r}K-J.V*:89 拄<}Gſ&PZ L 33>?= r٘Nߙ uz.҄^ Q1kT{B0IHp qYg^ȷ:&ŲQLBTv`uC^g#Le)Mtw}'4Jc .%t\FUuFK1Rln놾TRp(r/h3MB^|_,e?Rm@oܧf}Zf> f1O]!2YmzlPB<>Cߨ]3"md^Y-i){J}cv`| Yh<ԟ:aYD EG|etU9RdִR]޳=ܺ@:t:)mk,{hCwϏCYk_<x~=l0mؔ%ikK)l7ܩr#X rBB M|#o~v[5H96n aҕ[ %HV2U%3"Cm^E9{>z{ͪ X17٭ɧ3~|bx/}S14ƄYڤ- ,,+Mj&6ShQ.5thwO0Q'ڲBH 8w`#^w(pQU37iZª3df+>r׸$Q\a:_O,-^s :6Z*\uC`nʸ mtY%c0TBK> "$7Ba(w]La&fHjy頧쯍} DIճvo @``&`gK6LM^%T"M8Ɛ>uY0@msS-lg."7ZZCJvahd :J0scw48=m&|n(h`1[y2soRna,'+&JH̉ƼU&l (}Wpƾ<d^f(,vE$(^ PO Tn+>HY[f@k ^Nh&V`#Ŧ]ŦMh"'n\uG4]\tz>d(lD3ƣ/Y]Obnݳ~H.ewin򋸩Oǂ;,@j\H) K%dA[6=|%EA3Bͼ^u{7N|m~gP)]_y!\fhi,pӱs{[T1:q 4.Rf ӹ6nXqzeE&u;i^SPg/bK}tKӲXv D@2N3@"JՔx1^{y>F#S B@븈g64^V7*= SϕBB'Fjbo2쬽a%K*?}ϞFTUN<<$ʡ8qݰX}w^*u_۳ +ݭp.S7J A ۪Ie5IΩPȰvN'-GS$*lJ\v]r\^T5`# ˿>uE.*3ISL{ HP(Ƭ lD,ʈ.?LhE#Q^5J X]Mƹ7dje9CBZ-pŸهFC>> !l udVEXF2h˂Mwqkn$1[Uz8BLȑs3Ѫ7l8Y f.HX_Uqg nq5R*&|4̮XX:_=`'}DK_O-r$OzB%Å?8:aoPTɕTMKKU׍<t-@2s\΋P|[ar)1wC~sp&$?9-0)< ՝Pl{?S `іuZ|gHsoZaS>SS&B z3YﲤH.4 G?wi=YKȕi*aav"ԒDFlSΫ[N"zAs7*GE3% Un`R={.{2hWi7ɣB"Py(Вes~j/!J_P7ab nKa8:Uڪ: uO1zk!03(*Hth~Fk*4s-%m!}dq_BPD"^I9ٲmVx3ry$;S˹pS<!MG# SϜv} Ox7L6#wHPhshuG;:`uBP٩nJuOy>!∔8K«nB|x{E990߽w{f5hP$"urq ]'/6R%SCi"fyl+΋_|p033K 2RY ؈QsHTӪ5d^sKH:XL CkVM/RθMǾ_G?x$SYM)TԔUi[0hUz IDATF㥺^V0#vI`&Q^09~Bш$:.z `hnPgcj \U# G5`?zfa?.a4*MQo;li*08ⴗT2|BEqu3=), \|;oG:(DR4䷽7^C?g\f ;5{?`f[N2 QR$âT]7 7?߼*?[MLiPB0A9'18cF(xVlEEiM}iJF-w&2h"\(GV0TAvj8^g#Q9Kjuir,Yo+hmf wꎼϖ#&M4s"nq-42pJx7 .k (ƭ6nlљ1Z|E#y!/|^w_j%$URg: p v3jbrJ<3^%ft8eQl6Zշ꿾Ju$& ꇾ_6μdzYqTo[YYyqçV5 ѥaIGPK=ԣ5~6cfZXpy,Yݖʞ, m:G!õ`Ϣ2:U%1p,# K_zo<[O۷o:n_xw~m6C\H|DJ(0o.j֭_ڽni.9V9ȝs|b^)r?sz' 2l;٨ayGIJ` `q.xqX7@돹uqVzÂjBWxI֬(M=Q}Oon[Xqcvz'Oy^42X}ªȼ.)tm3.> >dM-!yL`#CYNkQk;kN"j TYmCN)x-C,nV }(mE֬nɴ[PXT 94^Uπ o/|G=ȤF^a*#Ґ,pEpJ˚sLdlBftv @J]y׮{vzvvKxOޏ$pLU[fJ{PPh%%SK~w1m;*#2S/1}Y:lBt&uXo]|OZ7Ac8R;&A- |+XZ,, #9stL50\=oba&Y֧Y?ۦH3{q]E4Ёd_g)M"@<I&9gNZ%pyqs~Fn]QR{q)໐U%rՄ@(X@[[L/+h݆ . CzuJ6TZS@niBK?6Dv#2;riG^+ˇ@*g $st% "®AW~QLBh#"$@n4g*(nee%B4`DiE&!<c NR{XMR oHҕ1*Fu+P^ 1ω9}FARea~sDFF8&"_VPR͈,v2J o!{"(!'D@{~~#5J暑Hf S^dY/)"/FFo;q,%YJ \b`)9"S#;iwZgFebJ5\#f8i̿ vdV,aQғ ^ X$rO 1nwcsj=J TfBX5fYZC$̔kiHP${(B*`nnxhm4?{|w\y/8~ O<*Iw rUR~Wod'ȞmH0J~ܽ{Ν")D O)Oz.|&bTCϑvp1Ɣh9&E&9]G ![@Iըؽ;P; iNk}gjx)œAEÅRxw[Yҗ{MnUn @mn(sկo\ŸW`tB1Z]L"[K(xr9n5vQ#+((P)„bȑIN(ەn&3n)Ʊ‚Ca!-NQ" hbWbdbZr,+3q&7V\% =(A!@ {,MzЁaBу0_\g|P-=[/tQ>!ĥn%pnԵs|rءHy#Hk62H*rb֙ʷǶUMi_ `xz;~-_0QˑG)Uzfs̯^\röN _]taRN&&$]^;a F$ rFLa;1O;f엳Q bTz;X^BZ2#5{L~! Ĝ2 )_Wō?gf}/]Di./TEV1C]DMPb0vDJ"S$Ъ`J@dTV0j`@}(k"$--/ǃ'__{l"GCo3T :``'>quzX;;H! dhbӮSfԥ$ݑwWEF$B[L)YVJ2̤loO{_so~yM"6fh0e`fD2N?{v(vI/꽿s%S )wuIO|ٟ|3_"sRͦʒe4Hcl=|AxaWЄ~Nebz8}N]PEF6GoYML=vUK{衇AhΒoŢ(5ȉ{`[Vd' =VH#i..|dY fH!Zn5fQB yCKP`iS~~E]X=tQ5a+&P}XG"{1үPKF*jȊn.q:V(Y߸32Yh3Prva8War,Kk꿵9{0c_}xٌ J4AUB T;6a:(TT)Y+Z7VcL~ FV2`{j菜Կ.SK4e\[2漏n+PT(PXJsR+oX{o={hr$%K'=ps" PHIt*_T]\I0_q" @!hcHO"rC*N"H$".GlX*HN=OܹPyy bqLƾVL(zWކ/fD`N;oa+ ԤeǯYz=E8$CJ0>+~PDg\*SVg)1EwkW}N 29GV=Z|nV8FҖ3oIMmRlsruM{:~!vLO(j}c,W)B(wBA20E궖'una.tuD9(5i 0RϦ`, J+h`b> 8Mu8#MI#<so|Wxvo LmgL6h($c^w'v) ͨT+jF*gFmDG:h$I{hIu%8ǐOߧt4_sHLN 04H $bbA+v'k "^.6փ:z?˿z"Q\=[ 6!- YȻ:w $m1 7+lj^Ɋ>!Q4#hמ~ܱ9 u~Һ22 e:N*4^4=^'`muLv&&B] "jV",£À7Ǵ8YFvu:a'Ϲ? $#pzuAJ~}S$c Z"{M!YԤ%VlA m-c`q|klHE ~>w PX\-:Temh0+J`B#RTo\ĝzHaa+-G~R@ԻKٳs۳&$#<UmO "&b W(cl&YF-0Arڮfĕo|c {g\G4kbek=ַQV-aAt24,AH6dL dFH1I6Pr۳0H4.FH#҈ K9}}un C!t>xÌfu7~ͧ]~=/8^$<A Jdt&U5~oB_ S>G$ҼL;8NNs_(J黛H4Ag"5P%/;J$~ /Ǿ8jK$1&jYbR[Qh)wKpwr Θz OLu^ E᡿G~:z~8oSZB=fBjgfe)1_`LeS.-#nm *BG^nK Z򕐗^2a9|Vl| ŷ_*Gz=t'wU0 7}jUW={):]$[aE7Vdg(.}akorSO-y~< ۄBu1 $ so&1z@!csJK"T-ZZ>9} BϼRv(xx쯬އT5G,#}l7?uJ髟sF䊙c ]1R,o [ª覈&ݧ9-0Hf#!!0mTJN |w7"mFVAWu nW sX=Sz1':n2 Ս ԭCR95 ѕ6r'S{S[ GvYGڵk~>YJM!zU=+UM@b!*+Y,X RkZ%JtRTDzLPCHBe2¢Fl sAB*Uj<~o<yn#RLjD=E~Uj~>E2P!JXݯ?hn'WBH"qb%Xs-᧪{;1(3 Aà"Y$u$J؍ 9c@@@ 8(Ah FErs^?nfӹ֪zCc©sŪ`rPn9uPx $>/v˭'EL,|qz'k0Vq:ŘIJV̽O^4*hi3#4B l=?|hQJMS8A+M ܜRzI, 0s|o_'z+;;~O=^4CZjU0:>BDePT ˖bM}%ɠd\K4) "CF$~j@̝J.8ߺ?ߕW_ԠA ފ*pfpH5{zьqǝtii:XtG}Ʊ]n u- Am&m? j[W&B8ā P'w~{=ù)wTt!1msClxշ]}ݡF.l s-DҤy%BѠ:!&$swޏ>wBh0a0˧ɛ#! V\ d]D\q[FտUvY%tWiۀ/ ݌jtq7 7?}m= )AMsyf[MBzv ƙWViMO;tW@S#.G< HX NJ ]=9*@8\9POuta0iھdn0,lwnSi4W9'yzP 㮁Sy0}Oxi"iS m ɄPdx۾ʯ+ab>o=kqDL|rvM-`If|-?qِ9X b(q cJ+Hz}4>G2JԘ 6otQ)GF${ˉw[VJfd-1؟pAjӰ41U\V,I&#|*fD7ߺ4N]5:?_<5\<0+s4e›lnňM{R=l5jS~~>C+ZI tZD#gVq|o:B3sOtȼ 2"AU)ݦ̳TǷ!V&[K ?DD4~̻߽| 2%Kc99@R(P%E㋖3Ϗ/\bKWQE($9GErST@HUXt&̙z, .W8b`N&Pn;5!0D 3SL/eg]!=pF>׿yr0+Tu1?)ۘNDp>GG?u4C^eKlZ?4?:'̈\29=OI`qUժ~\S-hk[ֻrCHa1ar\t-'|}SvB2o"RM^=np){Voݨ%I{eC𓻗mm0WULAͥ[U@ۭz;') EHVw>?_#n 'y"U^g 9:7nZ;_z,D#Л93Gݔ)F1<|JpV_nBZCel-93( .dǝs}`J2"ʺc @<O]Q 1H~;ӧfj8x 7 >o^rɑS nYP8}_stN]v#IߑZL. hMu-ݤaAGC3gn>lU( i ?l_ҹ_q}Ҏ&&;3* ;}sfv ?f;/q.D:+aC͌8! HSYmȾU{ ~5"dŝ̉!jq<' 1n^۸(^Wow|胛O P &PgUoNyꙅ) *z,/NB2%EY $ݾypmG^z*bpb\sߝJ'H{MVuGl1V_܌xR;ք8>k!>:cPdJ``BUtUTWlkk;!gI5;r͝K㈣^ͫiޟ^ a@GB O$\j3n5f_xzw(臷=Gn'O=x#S3-^Wlnッd+s/}yOL1fg"JɈ.g>w|iδRh&rZ[]O2E2P YSb 7Æu`A`x[^ &i2Ӊ¥߼nW}, s '~">dH7gc=/"VL,{r5+f0Y˾(hÀB) 6er4%&cL\B&1B.3>䋖")1D[YL &o~̙;~rt(:8Ǭqɜ|8,]+nrNH!Ewn#pꦺZ@i49\IH1r&Ie?e8K5LI#B3 5W`ĭZZt=TIzhjCvgO8n#_?YWCDCơ"Z4o{QKF&sD:F^rL zۭ|߹>Xc @1s|%č=8C olZo8($PVfˏo x ov-<?F\ JDI}p%M^?-C]RLcn#A 7mtJc"ުۤ8Sfjڍ.dK޸3){3=~uNhtEtXa4 '8;$2exZ I)1l(nvS353F#ۀpϛw/^qr 8,8ĔyD!W,_8+nf $MՍ*@3 h/49HiZԝNu![us{d9S8ܯwcˋ[H* 2-!ûFaf@K7\ӎllf`CB|?w9!c9<ordEa@"ѰhNb3q2]+S_YοkWW  qrZ2Q;3QB8UP RWyfSZ%Sf&03 \aتNꕅKcCã>w0Nm@ W\q;e>sqĶ*BiJ5sq,>a<,~f܉$?#JR<riHCfv gZR"3gu|0UЌ7H3xZ/4G\^:B--?&D*̟WNƒ%Q'ȔbQd:&ˑ؝2\̉ٛLt&ilG d&21 qqHDN YdK*g{^ c4%F$P'̪4Ao];U fyp,;K/IށP g4clj6Hnsвľ{f=11o=3/;]"Q)(E\4d IDAT,ꈓ>"%YS Zu}==6Zl^Z#<KW /╯y:0ʮJS0de9\JPh~={;@~b0?a[ *Z*f1ؐ!s3ōG"93)Xë@(݉~]|^wia&L^=yG `SW?_>Гod]5a2j*Q?`2Wpqh$ }EY{3fsfeᤀp}I.\02Lao]q1Ǟç8:jBX^;qm9ZU[ cyc.C(-Zc‰P mP毀kI'_άt+ÜJQV釿;z=jV;C)"n52"r޴tO"5̾fԳ9ytܓ_ݛj R6\lo>3ۚɑ(qrYoֿ+3qryyqa<܋λ~?9DuZ"՛md!/u -6ظh8*H%:pgKh +?dF̵?9w,;Qz0)o77+sw $WyЁ>(|k,9pQI XJNZ'Y)1ZLLhOrI-l5  N$m:fx QnΔ /]k" C堃2_yW2:ʆa@(pEzXӏ?GAk?L>&:XO luIqu>r`!3јC  LJ2f+c,2Sǚ4K !_pY1ej7:xի?|TRaZWn\ xU -!sE"Qo7fo}zO?k3oLuhļ/U!r 1eL<˩b%olK 0@ A_b537*6OLȒCfow;D̨!&<,R nFnLnjH@a$g(9>"_^=Z' +gr@}ml13zu)v\d'6|y+aLoXI'\sqVWDo Zt{\5HoĝY] YAZT}@K2X RY.>50Cd[ݕ|@U1FAU{B Sh&ª J&eNwTE=꘽=x&oBHc8+N?ku] 38 3Bu;>y 7%<(V1$y_HDy+( lnZ߽9s瓕pǍ3`T*jq*hh&7pK ³7@"RbsW3bLu ޴M̥YMB$$ R'QU73>2T".6KYcK>MqٱExi9ʬ+z~1N0b@씨̖ ?"ҶҜrD\ҁ}~9+E$0<A;eu ‰"b"I^ʗdX'j MZIF')1!9ԯ}&iW.t#ɸQSVՅ݈܈`#ԡ\`.+]R'#A pٷr?uwII cQ*J6\3@X EsK8&Vf ;+!PangpDQ3M׽n枟^{- m[?1K8ǂ0k!%9.bfU;$L[Z ́=WUS 2L? f_ #$QQ"f[]ۦKM,LE/S(ajˆF03.dN R"I܊ˏ8KEeS{Y!䞻{Fk!'f[d%^wWWovVjhJ6 ] Hm*"؄gp~Hu2vL_o;&ԧO h Juu`tƤ\:!C@Apι)NR# ϥ?J,?ٻ|zR&Y0̰d ͽډ5 PP339##f!Ne:i8nB4.5yȔ5D U̱5M~e쌆Gw4d9'cQEZ@MY2鞃 ͙L&r $ )y,Jv*Fu!.JHsw{y.ğ Mf#7HŽ;w$9CYu7M@Vijdf6Ef"8~Ms"Y ,BHW}'QnF? ?"&8yTNo1}J0dUkUX4jFy*[ɘ \̜RE wSJ$Y݄ *3[mɧrӏn.cLEQP:,{~~)%7Zh Ä6D߼Zqˏ; t+suG\  OQt4{sq.GNV ̥^%?cf w$%̟ǝыө@ל0BȣTU)b%^m&z7 z뮃P4C}~qc 1 LX?z'n['|g3A F`00IBUJުc8e> "Q(kCG`!'-TJwCe=8tZA#&S.o^11F{>eQa%V}o:o]=k]ml1ƬYUnh&ךiIe>`P(N5^(d{R[3/K#s9l( ȆA l -TU.v ĥ"yJ9[/R2 E(vJ6z{X=Ӓto4Um* b(A˂LVP)qIDa@CcӼ 1&d3BtR`^]27)KBU{ܰ@Cŀ+{5=EЁ.Y&u^Uz @n )+N~<]w=j:  nVb@v7hRs/#ч͙sb6X)',s,$ZrJBD-[Ҥ葔l!5'L% 18ղKr'X G>zͫמ) @8dm?]w?u|f Ұ.̢I]<`f9[)U#2PnȤ,ꨈԽ.,5H@8Fc=E r)KSP!jnj5FsLWh 0RMܘj DΨio?u?Ԃ2@oP?o ˟P<)UhkU>8 :'݈dɒ^ P'ikjA7y}fp q=33,+^{항ld~/v)OKi:pY60377!DfZ'@l1KN &oG"JtRTz;f4m-fLQ 6C7rh@V\%-rBV6D# `(&'a՚1FwVgԴdvX;B*f ;!5Jm {ޘU IJ,)ժ[n;KҖ[~Af@ze-᧪ԹIDQ$I4AdinrAP "( TTĄ( è8"(Hj=콪c}i`76s+T=$b*2u#GigD9i>(3"RsP"cO'ٔ$@#'[Y`6m;O~0dɝ//5E+jiHeHf7H8Q_1G3K 4sq"r5bq IDATDMV'-ͷ~܍HƄRc%"[ȓ&pPQ-{*w+$ƥ\y)s{IC#ˮyoSZrzcTw38R@ /s䞚#I`vcdf.G"Z_NN0=60^笚NH \;n ̀ ìV#C 1 B]d%L6_M1ܝ)wЛF c%!mB>A4jw/`n`BÝzta@BU>0 Kϼ[<c POTĮɖܲN^CX. Ov$5J3G'l9ڳ &* p*" қ2]4o}COF#-1a[]Woy4 vđ})ǩNM vܼ*ꙃņo^C86[u*LPjLUo-8j]T̼Z=d1tʼnu"$e@D@ْHH:+j%KN>7.NȌ}S.fwBQ7}0w[ک[ h)2gY$NeeR}\ WqZ;yO[p~-6 (9 ,d%rR  &E EV^)x؜=1\ᑸp@]Aܸ&GDb)"TBDeYbx{xk_;v:#ZeN_ &NpW:6VK|B$sqf2U.4n0@ݕSq؜(tD(*lkWCmB)!'`; FYI=UčԊB;/uʲ{9\aY5 BgbH@_St pwkL"AN[n[U06\6sO e \ZqI:a,D\X'j:VE{"S b+Vw]-=\$dnjo+><> 8d@, Cn/T=dFDL9۷HDI)(fߐ?*Y3.<qG'e DMfxMD "hS_ihYeS'>^$ԘY6$v@<suɑX<Gέ9u`-܌r&EY`6prF@Y0eltuh ]wS_u]{u֞1s8uRf3Sl[X1p*(2JLD`"ܑxJި6w?]1LE &^{ gmgwp}O꫄i1 .9oD/j,EԊ7Z {2ܟi K` lu|w ӈ+<2;>:kNEhr3ZtM<"r$&4 n/]~-Uo(tB&om+A9Tv|[y.kX/\5 GO*OA)'P7?piVOK@򙎄jzHL(KS,M:4ր*P-I )[t- ¥cSMZM(Ѹ2hHJCKaV; PJ̚5m7m馛L>zkYf̜!P9RI07KG_:r M7y7-_.1N3k 87[19B1ԦQ(J }Z23MD\E>XXH;,Ƙz,uB==>pՙf(ad*@y4OFNDLupЇ>QidRP(i/4̕!#j,}@-Jn”ܔ sg nEKDH^'KR%jS%!Pq wX{R$#͎Hԡ> 08Vsx~20}]۽^ڠE^uS_[-(Q^58~/ "fZ#sLӞ,8Pw{ZlfsDB숓sE2'!X<#C '/( u*:].=e(14NNC7¼yGs5ԶWk//*J"[DL;,-j":0*PkZ^׉I'LS 9q%vM,y^{>ըL]:W Ybn8"IS .Ce܈؃Z o"ū>󍛼~׽fu^]oiS˱)(JAܦ!g q:^6r1Kڧ$("ZCDѼ'aw%A\Fv pvTΡlnZԈn}yДTA ֑‹oTM8i%O%D '=brWHh^m7 )VI$g3hL<bS)խbVhu9nBQW0TH!Ij; ՚XD&Beuis%Qz2.Xy\k]p3-hD.Ͱ;Kȇo5&opi'm;~7_HPc`"DDZ+s`8z6>(fNp+ĈN_8'宐`H s| gQx 5. h!E!!$&vJo֧uOf/DHU. "݂ɬט;ll. f(!d <Ѝ@ՋfFLdU ߰;|{_]+WtYJU#FXB-&.ԪA\-VEs].6rzH`Yd<ŻM)oKW'D?x;YL5HblR(y/;WǷoYd g ;3\x_{cT5j!Xb{;?B`2Ju&0@I(. g}7}ImbDbd!*F6U2{z,+x[} ec;Qze `a+ۚ%?=~ c5r {׈g~q{Ϗw/FՂ @Ds7CLAqmP!Ѓ>Y"%TPߚd-Vs۝ܝY5DQv?l+?pN}t-Z5IN wT58z lQ 5#RDbX*y=R!r,zWMZe/ 8xȕ`.RVLGC4s$C`|suFG)jRjY4eTMς]Vr!`Cd-Cu'F('9z .<}ę6ĎhpG>Ͼ0=j PeUCZ% s*ª"v (42sUzKkrAVOz?\mchwI#RS+ IˢO3rjJS i DH a\:{l ٍ>s~RuA"l5ﴇzo~w}/}}D܂;AʅԠZ2@ f^mV +wƋVuA-Yrf[Lc%9߿\osw#f40GvMy.O?W??'4YV).@#2YR7|HPS[{lJ&I @vPt%al7[޲֛i)SQ94ܳU $diSP]Sis`LȈy77-;DzEC=Gm@Àqf֪t%$oьkl֓"5ܔzzN"W._Vm5 dJrn)|Q%a+ *HA9D+s"^; EZhMIUISGskrlh/0W| }w?DF:Ү6Do@WaÊⅧشU&&>)e+XQ/?~۾.2;!)Ns]wm?{lؼg I0.xB6q,]7N̄P1<JX 5#~s6w UK'*Qw&fGn+p9r;fW^yTa5 Cơkcq "Pg# xYkA^,fSnUG{ࢅǿn8# >v jBGpNF4S;![VqjbؕXidB7\;AYlٶnv[n D|lGͷΚ7aMU3)ދf, 8=sjSIlfNY015qUE uw=vk[,WB8ul_{ͅ,Vzo{nckD ԑ۱fT+'a# B n )2b}6 ܪq7y5Y⹐kq$Nh*~':%)]/'ƀaK\u\shw}޸_'\!<  /[*wd2 BJbkƭkC2`Л9\ysN >g |d2R)K!6_t;&="⋯o1*ŕ)$fVO`9D⮤&暼;;s@ZJ$yg؀OϽD-$c!4I`Sw$ "nDnB@DGS: MJѧ"= $p;MاMw={v|-A\Qȗ0/Pg+ǻꫝr㎙3kf)?Dڏ= DM-9:@00cQ!`R~챇ϟkO|gE.7Qz| @rNlؾY&|8R,_yϏ3R]9$ks(3+yk̙sˆg`Gr{|LhHѬ,)í/-\7@fMA',X:o p!* n U,6![{=wL pCzgLq4(Kˢ;'ͻw]gf@n,5|=ngN9zuߗ?%jУV B$nF`(r9b^H:NsEsǦ , bƪyyLm b]vx=~® f&C[#l;(^tNV 0bQgM˶j0&}g0ß3}{Oƴx>u:đȡQ_q͵O9MP!v2?Zu'00Q u˶z ֚HWҜG;p8sMoAH+ykWvem~5ѽ<5C3,HN-@EXIR0J8%fvZk-2Y@a~O'ON|e%-RD((Nۺ&̊^& Hc@Bg}kb?Ą90A&WGb -"G 111S[{$#* ,<}hCH&?n $ IOG8gu5 oW@,YܬR'*y4SìnRl6 jT xc )2CHm[ƫ>xі[w㜚D^LޙW\c ;ܹ8j *5sԸ: v-`%K1pl#~/կ5"lņN?CpsH@5Ӏv߲o~oۨSA!$= p@a, .=܅Uլ#=7u ѾL69~{ѲRp"SUd]=v V1qdNlEZkwmo(J4ȥU'FoxhI5}3@ g~+nJL""-=!:l*n%;be X82?}u_h 5W^Gs+K8CbY[~WJs#̑b׽~ΟQB[ U}od nen7ܰobU5k;U IDAT𼫞!vڂ[o3UBDP* -0PS8:+(QS#@UĚ IQǪ*Ư_g'9|V$`$d m7736 &fU-Nm#SO=Ok.S%a -_k Ck⠪$LDF3 T'u BdK]v~_NmԠ cepVJW\uӇ9z.Z)Y'.234{Qu]%;Np5ng\4G1j6dNJ^n#zqs6tkfR&#>wơi nfhlwQ$6[ss> Ia[8O3(t8F7fbŊPϞ5vc-8yd䁃ȑ;xՔؗ`.i4 -:hNLN9{}g)sݣ[ 7R訅|fv ^ \}WvN7DcDTV,vFp!ׁNZiI ,ug1B Ie$aM7?9(LpMaia[pk7 Ġfh@9 EA?IEuvQWH^yMիZm$)A=O+_ݿ'̆[nsɗͽŠ!TCjG43sv!Bcpp$Zl^vYGCQI-ݙ$G@FQ`>iJq m%gCOn NJq˭ =מգ-hd`":ƈA#k-,v5fuÍoj4S!7-EQE꓉o5^$ IQQYjbMNƐj6 T'z٧N&x/ӘY>IuN۔0"u nE캫0wk/ é##pݝP7}ŋtFGEs6g"|W_}˃}v#0'0qERE۪U1!I:Յ[xB FO+1pm>K>3IfANJxo?񉯘89\!$r'-ĮgʄZ?ﴃI/Bv630YrmGȍ遳μs}Ňj`,fx};#LwDH--":zL"e.*<w&sQ$(Q~a}-GFT,jt2$aBf UIĐ#?=lJ?r ?og}̼pTruv1'|HֈPq|wG4-dJKCS꒨XMx'c{m6EB^t I,]5u?cY7Rq 3!M`Nmq+[]vjɒwi$ӬhUu0&#/wڢO>.[%IV; 6Tg%~Sut"0{D43wWA׽n^x^{%ՄhM 9Rq,FI1mw(M W<O2K1ClfQ^AFT%gw-wbpx=םJ789^; Z3G BRtr5t9liBfV*EAC m5hjUhɱ9qox!1H,K n03aLm Qa {߶ŗ,aY)כI翎&efԧyըӘi:=oykֵe+IPc>>'|vo2sad\(Sɚ4K<2{+w[Yg|S1ٟp?LRӝTLàv}y覛o8-E sO4) %Kq$E*3Eji(XD#{ & bRА^tn'SD'bM3oX 0G 7ܿ+܇j3j J,(ŭ@PPR.C209qu)FBݛGl }q}֯c-"RDp n3ћRϞ9lYݯzkQBժ?^Գ:f -$-K?Ug«|j.QTeAI zag# OTMOdG+^VqZh]Gt‹~_CjE:*3҃52L6tƯ_k'}vxE܅p7TgiџQHJ YoYe/>@ńO`v=S`QZv4΢*S5y LܼG `'y {ϘޤsjQDfUMmIr2$ʼns/;3q|>ԃ,$%o>@k~͇n}Esr*[ܥ'@Z 6Hɦ~˶vv fxTJAj?_ecsr, )0:oOlȩ-'jKU$?7)r@s4T)Ds gz=gQ Βl ?FlXV@l$#L0M+/8٭J]-ʏ晃6LX&zb$6A`wE!*⪫|79e I5]۽so~ywls ]/bd4%T Ts&Sx'.vjl. u.c-$ޒP3U;ҥ'f`4 .PQ?+ؤ󫜰WP2a VOҔ>/FjFZ㭷^ԧ>C(Uҩ}:2;/<pB(3NxYV%nԈZ^1s`HF0C_O-ZLmdpne}OpvcbFӃmR;r?%U#x/5@ŀl2cYZ`RD)* 1,8:%Ozkp'*&{VnMƛ\W@‰OXt׍'8+`N=D"uDnw*RT%""WQ;w \YZR@){1K23At'}8)ZI0%dv?mF a@Ug>ϿyxZڃq'3)Ś@.u7mycFxr;$yIeē.<ޮf ʿH Ȅ_3poz,]2/AI I!1)bʂfg[is5C/&9;x%%Oy4 xs1= 駏0ip+݊D܌ɘek|,=jthg薸< ~CL)uD Cr>{>Xì r X`d̥\^WaY1LB(eT+ᆏ]?>Aw 쨥$^gtx!Pp1/Zt6M=܍V9P`Q1 2tMc:112f*I]xI q/-C%%@bfnLy;(VVU2HZMf132U)̎LDVĥrPT/ˋ܍'֥f3?Vj6xIF"6" #xx9?~+{URu[kH4Z7N{ IDAT'Oِ .]|JPM!aS(R6cl~G9F1Ÿ,̱Iz->|ʕPXT{mPJBxoj/wqȓP`:>eԪUNbI?Sf/? ЊĬb]` '%#G 5{?38n' - sQաoSЖRBw/gwUQ7$uf=/{1q.p8EKoxz*]sPYt {&O;oݹlkX|'$D0K\ ~_87pF Ha3?hsi\hV}>/:jLMK\zW$Y5 &bFTaWIN8ua"x]ҔK<|e ;KL~JD cr~E_]O>[wjF81FŪZCD4`W*[nמ{^;Ρ./ \Yz,ָ@ 1{4-/=\T b1e ߾jx-WSzqXpAS<FJYb'5ƛnh!"QƬv!CaÀܚf-> {|y|UW}g>&6XȩQHB &Deg⾎!rrZLR޴k"/ %Z|'Z[[e q={fw9Ƿ|Ԁ)IeJ }^?Jó_8 }=m*TImYs!5sI&xܫ}9X:G0Y^堞(>O_u Z"dVt7dZsN)|[zҙZFUbݦoYۡptM1{]F?ؕnӍ~_*ʈ#;vvn!:R5~Q T\8 T4hm~oY {bo9*e|(m2>֧?5:ԊGN0IE"Ƥ5[m/vѪko8o=CpXr6B d Μ+[|\44iWm#b) B?Qώ;}kAX "j{[湄Fy KhӍLeW~˯)EH ɮq49KJqQ-Σ NVRf>}铫w7/"m<ү\u/~jS2AkUs||S!-~ZQz5ܧᬔLnRҥyK,e(Q#wNIysAT~Z[*&DK Zһ{z!*KdEAP+@D1G#Glwя'ƎƸڲdEi|zHm]').s/EEQZZ;u/YVb4v>I'ʱGs?06g !{6zLYsm%4d]U$lX ]wAT.)G$%f cɓpICVwq(؋KoZAo`4oby? "C\u߰`"S|R>sQ\6[]I:\}˟^z“I0&DNtY]FiE 3g_0K]]9m`(׆PiX`P"u\v} ^#HUImgM8yR6!3Kvi 7k\D>\&+5Hn4zfN4yZ &XQ2̝8%Gw:V2ZS^FĒœO9售W,sJ"(S7\G؀ &'@Ŵ-sֆd-3߇Kii&@N%mU7·V@i[5_}m+D&Xbڶ`A׸?YøJF͍c\D]3~knm;qc1ZP3f̦guM;jpT0Ԯ[*#߹rE!k7ܧbLIi}Z,IxbvK/Z|[e"%h &҄  6: d9sy0Z`y?ѯTʐZsO10mQ?$8K@ra.R|ݒ? !$-so3ӭt+Ab4M+"pq3 F !C+uQqfD&?CUm< O{ ViJ :jS25uO v0ՍҢ5D-~?e hA\H]S`R6c|О l,n` {nG* f6ؠ ЈK3WP  ㉧8O3gz۾; ϽAhULYX 0i\W#H-9wRL~S'}n~x-SK Lŝ<; W]}C_ˠ8b"E'VUB%*hXM7dm=zԶl=v6ÇuTk޵wKȠ-yDY4Y5&ELsIP W!&&j3gL?2`(2Jl#/wk5CVၖPAL|y;*ϜTS%Gf>~;Y,0[NƯF] B -{5]o!"5`ֈYRL߶~Mvis{'+_F>ٖ[pYkQj 1?8GV>f6.^x+@j(L|r7krlV!GX\+WS0E z;g9u0> ^GBJ"Aq#AvD_xs%&NNыKp 6//Ȃ֤gSDKA )XdO}bC:@reiKɑ8ɸ ޓ'{i5CѾ"`GE΁b/ZxɦXYc]^Q)>;Vu:U@ }xMZ۾k?fJ8r-&aٷٕܴ |5^& ehIx9 AOͿOK>֛ͽ`Z{yJLZ"\FuޮkO0 J ',x/};nX 96D4u+B F{|d?aV#pj⺩A֕pafrIK#m=v_ꌩSqLL VZsU+)LfPyn^ƪѣ7VN?m MA\eO@?t*e|FxqRP&@W^]ɦ``pw d1;ZLQ䎀:jSoAlп$7F ͩǹ_@-थ2JP)"mYA:kQCWtJs)B5 ߶"ts&$łEv=\(@ Tb5r1~x;;l7hQG Yd\̗< " (`u2H.x::OE%zWt0bfTm?$2kniq~p[zELqFu N*aZrq~/R $ĩD=M7Q:וt&uPPe`d ʼ? [*G~ hP*9 6s>$8M(Oe)+sj&梮ΖG 3DK(l \$Ȣ V {CAQٖTא fcm5Hg_=lSFI U5+(s)7& .3M!p9]Mt6#P\ ߵ^9K+Djg`eRP[| \p~j0*!щ3\j %)hQQ@24t,rћ7͒( rKǹ?\$s֔*&.ߚ>S-V*nOBz 5~6&Z3g䳺T+K~&˻%(* Άq1 ;3r =9˳0#V4Tַ~m:+TK\X\ XjSY=c1,>D0^" U P9;4TAϼ[|cf`o~l -$Oז?)^+>VBg9¯ iVgήEo@ l?( yJx B(&X{xxHa{ /pi˘j(5jO@y%j^D/.5Խ +yԱT K5d5J- X4GܜD!?j|v"4Cp676{U!׸N5W,M+lfPv$eT\8 % sHA>_t*Fߥ's (_Y< Nr^PQYZO|t&JrX3j$v56* $ӄAhLQ֭wMבQ @wŰM:K}xcpkEs h+)R+p!v !fD8Z?h V(kE!/puAp O+@H(럜 Ʉ|Y?/ \i$4si.5%옼7F"g?ndNq""ػ ˪Ͻy@T(1&$Jƈ DC!L! J"j蠈eIHE4QHT <FR)| >{XkϹ63~L{9{z|녜'y%//ʐhP |%| h~Z@:.h 5H x`#:>rU!ΩMt!VXU!By t[rQ5:- ]i)J\v̋)i]Z )]$%Mt=5LD&E*^ dNg x[h%DٹyBX̞ g#^21fmo7&݌ʮofo v8BU. -g,-X>ZzOGe=SlH#~W<#D^E+WO;O|#RTP=i}GDTcIJ8PsԠ'fIjl+P]zԑϷg%yT3wvc#l X6y5`Y[qq x3` <];.̋.y] TAШwcٕ1=MWHvAn%Yse~Z-+ T73@]:CAm2ո5'@f⌰Xe?6+np  ؇?T 'Y c"Z212Ͳ IDAT&)us`.YzpvvR!Y췤yu JȾY"j>fy6SN=8Pi0fxB+j7+@jf .ss!|kQ$ZƳ#.@džc.4:U ؙ1CH8:ZM{Hʈtr;ognCj!ǿx:ⲿWa4O4sȡ>s%fذTw37_U&3bhiG͕ٸ±طE,ƀ{2ﮥ ٗC) `\~{7j l}R=mV#eu峴Aޑu/4eNU%$*Hs0[xF &i0ۘKݵK##0!w /}:q8p00ZV Uش:F^b6廷.)K60|C!-M#=G RuE7߼ڳz1~M E]ZJRm8R,s*/}0򱀧9,.㦧'%NMNT-GʠJkX6?9Pa"O?b9()3Yˋ׊?92s48m$&r6/]P95Foв?-x@]!PƔD$'OsCRa.D(H!)iFC0m.a>@JE6jѦKm5J%_3hͼ*4*Է4cP+nje*㘶fj_ Jq~bˍ&ٿoX:)`\YU;yI)9w#XJ{َ9(ZjMJ_͛ 4G@ք~潗缊>`X,Zk&юyT([b bo)*5Cj1b|M Q?e,~+,K4'_dN,LTaQVA\$PDž 1W&a'*+Bc+gWjR[ .e8x8&,[U9A>Zm̀Un%u/1 ɶosrp>G| EJ+z;V[O[ }d  AҬNQښ|v vqVwpR6ܹLmZ?kţ5z!nX0.@} of6S%rPsβ̯ +% 1uwN=ˑF0<.jͩ#.& SU~Q1Wlr@8>$d2Ņq eMM 6?=KGtO Cݿ#ȇJȖ>],cFQj cX1(T$2|b(w{MXڥ؛enZ?am[@TEU~s~.gu+ !ts )9 .)=m<P[oUs~F<^޻(+Psa2VaբVIW:YS̡/Z]j*j4>EAS!fTxRӌ@ Kk{x^$<<0iIꖲaR59н(NDDbFsXR*"F6_rL1-,] ZjEl.D(QRh-W.ZGpiU蒁Uj<ŕquIp" ^wL B/s?h>)u]WU߃=7F5w[w3===33#:99bП\5ָ=0Hؾow) Xu!8uNaDL~έ {@wNN`&jc믿sbfnhugR`<כy/}󛎮݊2͇ID(Sk} Ja"a(lZzV(ʑ)nBP`yK!{MR0T6zTjiM-6}7r bEBE3"n@L.R()SfFX*BP1c8(zQ<ǥ,64uUU.q9)Q,"DTk VX$af;j+H^ФqZl(Jư!ޚm@J]K;5MXXaSAfHĿA#`"OrMkւ)׶2LJaA JZR*)6fsuD1߲|\4wDmfy%8.b@TIR(`=9 EX _tPx~yy}hZ|ШLOt Y BU$xE<ߠ\h8Kh5K^ڞe8ؓI$F?X+F bRMW"Anv_Z$wq]vI; !:·\|ɕ@TEm}x瑿?>\t_D,! Aոv/]eIDlG}T3tzJ\#HMT+hb]SP(Dy䗿tͪUi9KS3h솶`1)&v#^;.8^1BwkO!`fkPm"FKm?$cMXalQ:x:En@KXy n9qU_Qln6[Um}q:rl^vC;% Y5>9;hEgkť}+L40^;́{]gbc^"P ?(x-[y]w}[=n}' 1 T)*(F(4V=n~űzoȊQe5OQ%*b՚0_ 8_PGŕ֎)ۖI2;p]|`vٵ?.WPrx;׬k?rܫ_Hn0`=4w.}3܎ӘƴȺI1iLcӖ9zۦTW+X(2MòIpD6ycӘ~jZ(c.aQ,./DAI&Hk g~m_[@hBޚXr8JEasq{>OJ2Je j&byNDIJ@A/??! P^( <: ?xh-{6[^UVcEevdbP-UPo՟_vTPV<5QjdDmp2y+X!= ^5_A)_ѱma=ER1 䚺$U]:hgWի{)uܘ'iLcӘ$*"|}۶}JM#q}٧M-USӘS"+TY XB`| > VCXK4ISaAq9kM7x |׻_{ {.Ky^S6~ٲQպ HDrdHOƍNOk#j XSk,*`y="Ccc-+3q$1)~snwz[/:O#4T*'q:8 nypv&5܍6n* H}͛7sw{(;H`DI%L(~@{1/ >/?{nvA:L@}]c(!KO(K@8~l?a[U9d͙l{k߾f˄‹CaRIi;Us>_pM9V*J򛎈cۄ̤ Ek/IX*QciS wV&N2fg͟-6[DLcFzͩ*f#2) 9i:M"O/YVT~p񳷙Չ-}B-6笢ֶ]|ngnH[7gȉNT@"4u;CeHYJݒA,PEz̨r@ HH"2=a ihicG[zJRT|vz pLOH7cWT Aƽ05 0H[d?rp4fS^z#[GjӒQS-Ҕ)<;׮^zUV.^<5h0մ$Gs{쏶?cǎ;v<<؏w Gpoæ҆7޴),rePgt`>72ҋ^gǔ24)ݙO/E*.|R5r$ MܜDvOdC 0#IAT`N F!"JHI@υ|SD00w2 Ѧ:|%0ƮIWcᆻ^=MG/PU}}S>nu-^p{=-BpUcIל_$R/̑2\Rf ]T*'#7l#"dbcg`wRȼNg"0"sљ|駾A 1Eme[Ⱥbb[vn" g2P#*~"Vfcҁ;R (!mۊl #f4|!z_/Yמ !YW%(GTW*'>@C2#zpaDHjL枛pP.d7Q GMӘ ) {B`@/>um:])[S[]lR%ٙj(Ձ ڵIAR"#Iyms twk2ĴCZf"B`vJ;?u5ׯ@$JVlJra|݆V*JGD0 W+q33\6T*'#L{ ٗRJ4az| >G 4Dp4% !"d<7dcAP]RTP&eW]d2 !HO"Ģ8Gny96I鱤{9a@eA&S@h,ġ%J(Ll$[2aCY]O{}7߲O;jQX VBru]T~iHqL #-+.6~Y^.14+wycc+ַϹ3=cl` 44!I! RhI@*j %%rTihKmBT&((`)yƀ?q{sMUU1{gܗ<^ZR5UR]6#ڵ e` J RK"\tW.9cdpb읣"@>rI$axe]F 0{K/{Ch+IDATݝ@K$ HQZ'4jXƁ7 SWZ=׷ӿظa=TSty&JP[0c52sNݼsXr S04y9vۈ0L5*8#EɄLW/Ň>ޝ7#=V?U1CtxʠhseY )92TK@g}d?t#'FEcT6Bnve?N4cW,;xɥwCY@藦dҚ1cZrI#' NRՎڵ{tt o\Konn{J\}QS i } k_\d:Bg@*͓Gw "!-%D0Ġ&YgT5Tʲu33SRc"x?Q?g{ی.2#4@L!Q@{[}om۽yk_zlZ{ٳonqenʔ)CCCC&O|f,TT1&Ue0qՖ($, Mb @hQ@!b&_뷯^0O))k . Bo("ZfT+NfϞv?so,]zCYh6f&B3s~9',.0@SxQ}Yyy9!(|u՜ jYO@4oVpD(ẗ 3X4tDڒFFf/<˜%b#fcg~ WMCL\D"qOݾVj\EZm<ܽPp"H/U[?k.jU͇Bmu$Vf@RA")0SJXCJ ZF`aLp>$z֙2`1~bsZރYZ3+__;f@YM t&& `N|smD20`B)I`egΘeЁ 1֒5<>1H$;'|~,tfe-' DO$E^u XLpGo=_N҇RD@ؔ P*D87V1!YYmj!Շ%*.X"ԗ==}5iGH|t'*`i)[jhuak>ϞZ-ooQEh|ppҌ9f3g͚qI'͝{QGMa38 ZO=8Iu1F(O>g~ m0kv..{h*oM=oݕW]L` FѺ> p ,Zh! KqE~+hɒbD@5O}IX񱚊Qa?LK"H$Gԗp"U?1{`پO~|1iϫ tM$44V7jA5 Eƾ.NƯv/!_z~M m (xwe=5N"x#E{h'J:_s]f?#hB|Pj wVc\9`/P.[v?~ԳZ2;Vx٥Lgf@Qoox Y@SU&R > СkF͸K.A85dmD"HaZ>}dgD+̙+ng9>PyNBT0BL,դQD"q:_k]`ݠXJЕJ*tLTrwOT>mFÚ׿qM_/MDĴȥ ԛ89мAohn[v Q0^FxNUIM@я-?xy3. 'D"K+n)}FSdXR-3Qah _?DiQ ]lVQCƴ" SCPSkH 6{FzxOD"8UʅH5o9Cf@DTS2Sajy]dXj@ ] NZ}N$D"8qu:[T_?ndi {'?Y3' FgqD5F$&SΝ{^|a /M?͛^j)=t$p ]~E-d]&=#KܫЬ HP5qc~U(ę(3_ԛD"H$Pu ! %X}wрed\u,.BSO{Vo\;ICMh:q&ФPX6eޤoK Ve"$$$$Ԋ"!6R'4I3sac{}3 )@F b#-Bw/5O88R JZx>1Fj^+&''&^>{a3Nggsfd0F* jBRQDek~?vSR!"ɞ/!)@)n $q@?"dҒT2T);81G( ]ڝ͵Đ^FPԌF0BL4T2衆8<"s.,.ry¹tq9)0';7 C 8T eyP)TkF%EcO R`Y 6=5>x5/7HJE|A:2 -yX$$!AePPI~w985qn[hfԬaFGGN7g sVsy՚a| A h1qqAD&1[h. VfB(+l7$9J4˜lT0B޽ч7Ϗ a6C'8:)i.բ\he>d)}P *,Gj]{88dS}a 7R/DK{}QBQ@Td&G +&+<U`)88sr IFH7~֣NP J>!i*B2|}i;o_Y\l5ЪDb5/:_*7Hz7cYsȹ\bUmͳKY3q99T X`TkOX{VUDD5$88sZԣ#h[?ظno<)̬VRmKP##CF՚m4fN^^̔j@!Fa h}HL?=Q{!IENDB`  Oh+'0x   ( 4 @ LX`hpssNJDHSSJDHJDHNormalNJDHSS2DHMicrosoft Word 8.0@@n @W@W ՜.+,D՜.+,0 hp  NJDHSSl1  Title 6> _PID_GUIDAN{63A74CE1-EDD2-11D3-B42E-00C04F136AD3}~:W5L[X7< t׮ͦ<ם?8:&%Ɣn >w{>ELuRR ;2#Z2K>$#뇹hUXDL7,,)RDuǻOLiX5jԠ'kګ6[&Dcl\T΍ko.zPYvMRϣ`uϢ:Vٕ!Jn:祥OvAgg_+>#U#MY~WPt13,u,anl!!Ɖ# Pd_41*{@ew-#vnq%(WnEQtQe+>aÓl 6ߟ۽*ՒZ ]Y{=YORSLW$&qqȋ3w\>N.fuNHm$Yمo.INѽD9V7d4[R8TI E%{y]1eCSCt9\6:o{T٢؄Ȭd*L;jlk%qiI [rtViV2ej)93|*>&>Ѫ*@zt"Zmrr5RyLІZ } 6~4 IӉe?ϳl^lP Zze::|]%Z'ݻf4 U5tEQEc,\(vGbj5k ϩ6@b*h*je1 Opexj-8G53bxՅNko1΁2+(`],(11xA)/FX".3DJMþ&3G06:63#P/jǶo{$f<MV3@J}s>[N- !@Tջ5`+\ƉK?Z :BJSѭSkeb O}Vhg8f ?i' J@ *ΛB ɁP+U8+*[(CDQEXʲ35V"dx"P %RC 6ny[@X TcTRCPSd`漪uG^hdλi@gtJwAQxAނPJ0Ȍ 'ҝxN$-Cevp `x ʻY}EX "MO|t urgvg5c,gyYV $l۬EjJJy.sf\"B勱P3Ye* w[tUy((b%(%~#R"AAty'{Wj#ƠO7{ 03`pŗoe߭Bh@MNX0[<͘fwSA?{OOtu',,6sڣ:A̶߿x_ƍn|IX0+U~ vBL wמ>3w7q|=X4Rb5 F8c&*>;*׮IQa?K̍WOIj.nÙY:eQEQ؋1(bc)_ݪd1Va!DJBKWG;Z(1ƞol rdxXՃ|Й¦O>ig(ԁLM~GOofľv/W=!"l TJjqx@r}3^緰}PLnb4tw2'')_:*\yKFuK@*Nv:/{qGÿF/e%2110 h D*ιTSƜԹsrF%ߋWv9UI6$yy!!vVB-!Z56$ ~&Đ_%YfI BK3F3]u9yFɲ)$UWnig$ӥ"{iTށG <^"!/+cBsb+3;^l=u(~)Ldգ1t&*\U)p|x ӿUBC LaȂ&Vk׋j]-Z+8Brk4ºBJy;HKSY$,a<qA9vg,iïW{ͺk PbgyI6\׻Ftri"t\c8\yԓD,?L* 71 Y= Hrf|$^`jAc?vyvjU-f!J 8{R'M43f[n|v$iL6v4*R5{OdVJ!^y7R"mհ{o+K,IݴDĢ~Lvӹ!?ddNDQ{cspP rv|5xN&ZԪQd _EQE!\(n7j*8C TPU;Ɗ h41q zT-S dch6'0ySI*sjb+* __{`v+5-;̼ߵk?:}׻Uµ ^6̟yn*ikQ;to'Ȳ /He͇a6֩>)(<^ +3x_97 1U%um_jѬ{gKLDA7"0 %ٳ&'lYt:gE- գ}M7aAs!T jd_v:6@3(c.QE^Yf Q ÛT_Ր:3 @'Ujж(0o 8MD3Umz5e/ 4"bt Ƥ^) A`^V.zF-zXO SA]T[|ׯۃUY3Dğ<yKb f~2Q]dNWJ\`DVpGM|MLM49 ü?;jbj˙f^3le"30k,׃'#ejeUJbvgzy`apֹ8OO:@3)2M ]# sCQ8()WIW4(LDQE'Үu{ ƐDF!-Pl1dB3삝YUe3]# g '`3` dJ[ޙHڇ=v{$H a| OLpqtG IDAT+T%(;?;J{ Q+HZj@ `7GaL,7!b1f]G3d^MbaD9i1WUfbU=qt-Mdުղ^[@((:b%(:,j642tm2FpP~@',%QW8씣I(yq| D˞utcMuN~Q)+@E᠆4d)ˏ6m5 iqa4x FrwVLo  d$ { "eXZI0 E !. r;`)$#9%Cz3ݯrAr.$9 ӯ UժT­L6G lmU39eqUhIArIL|%\u63y0yof׎!cx^U]`8.Ek;r^*`Ҧ}4Һ6|jD_Pk SrFwVT;^cclxy P E dl8$vB:nWy!kS֔%I$ɯsI$I9cS[ѝzL&+Z\poXNDU UHD`a_T7ɮM'wUyQf+Jޘ\[Bē@sey8 O˘fY@gH󗓴vqqg ѝ"e[^cgYl%&p[DAf4[ELNpF)ĶU<wnR$I䱖b.I$#'jA cT[ga۹+qkspp#frw@E-6M4FþxYn0~(]&Io (! f"f6u 'tUs<9fyX_{kԊmUM6L~haM=©Z療)e@Cg-5sw,.|)d'꺕$I$sI$I-UקL pQxCy`@8CC[[O@&62/dwBWqwx{f "Gք\!;)gϘeW'{Fĭb3h3\ZUGѮ9"y`ߎy,=S Ǹ Er^ Gtcճ|n2'w\̈2w!^u,#Lf7,(Z$I$.R%I$U --{F-b65:udPmӺ7(7_̓Or8H כOR} ڛ\fU-#/C)} #"p4!n1vZLwָ'aWebgAآ:l96RX`V1*2E W ĝɝ EUnŹE3ٓMpNlZׇ~3xR6*O=2`d+{:ә6\p(/7M=G6 DMfVO>`sۍD:M !NOOS_&D|hbC;[KMh Xc^@g[~чEGrkyȲ˜9B)!艹EhbVBlL댎`DhۂZ?s 欉_?ԍN)Ƚ@z7k! `h*iVOh0?u%`6`] 8;A6q{zi0!nq$lioދN5ۺJtp=ۗ?Swœ`@ bZ1y\ hmiovƟe\I$#"\$IOVEiαwu]a{To[,:N^;Ǻ!΄No6  N998kFWSUEw:?5ܫ^q)Cy[W7o$uƿsνU>Y$'0 AdK ""@XXRr Dz9VHNƫBM9|tw{ɂ3M`F~{HԇsO nSL2Ep_&):V):3ca;w#4aBl)SV(7\cYDKM/ fbd~'i 5/B$,co4+ua$1ƃ>&p0>-5ԙ|]fw0i$K'vBy`xV7kFG/]uPt_!0]54 3& FD%xio$+j m>Si.eE.$#B\#3bM b"23(iEť:O!1 4z_{Yi|"q4&05c4 7Vdd 6DL#IFÁ]ld±Ex6/朔yC y0DF$!ܗŚ`#˙+R٧G (Oehd0\Ue!^,e~HG5X.T0fLńpޠ3C9$3 z3)aG0Up$pZ+oi![" {"IM:l؝6Ɣ[>XcIEEEEEųPi.ϙ M ȌdrxhI$O23;7%23%c"Ũ,be@%aB+=`J .~zN q-F),cHfDz6~o{|IvlrcSJ{{ĈQBla1M32wfq-\|=KڽkB(r8eLCʺϚ!S 0^$O >DսJNh>p(X7[v<u{a Ҏar}ntR%z7ft 4w0I; nߦW_GkTOEs ȌD<'"zYӢ_z3#XʕRQQQQ\*****'WDs8fW L-n1eDKHwLRKK vdpV|bxz/'s9`3߿ğUt~Eu}6ߜN3Uª%&fyv8QjDXo15j*@\t C E a(m:,3lz8̔~4gI-iRj30 Gtsނ1L(+1IA!n{`Yv5dX̫:G Q4jHYg 2 ɼyB;X*O nN.ZLY4 5$9vr|!ʐ%`J[N$to1gQ vC3"BsOMyw#eSM F'UTTTTT|MTKEEEED!\sxmae,I(:WCZ6 ?ۨG,&%C cBb fK [_Y<_=մ^az (F3,K$j"`='{eiTe;?UuJA9Sn/! ˒2yI#'fD_t*I P@{LDWc8ٹO0O1Le98~:Hq dIѾI.nVr67B9QP]h?Ln¶Ӕst[+^4y0GԟnOƣhVJ›K)BDfĀ(aC9j`N;lK+ DY.E2}̓^3۹T'*{rjTh.]VQQQQQ5Si.χx@Ls 鼧 Vt`aMYxc8Z({,?,ØyddR&m3?+yt{בMW6A?_t:ףgfwHcR&(adg0 [M†%gpiw+Fs4CY.hfɱx52 q/AlLxY$U58q>mթɁ G⥞/R !@:,@Sq{ m["P3Ѣr`8-USz{Y3ۣ_.7[ 1'򄚃k:%( X)Hku i+\dKJf!0/,kkdv‹Xǂ @\$,979v9},wITTTTT<z`̌Qs8a.PxX_E<+iHinI )0:o ^w&!@1iuLӭg}quc7`~<'+瀳@R3$"͐j,^YXaڈ9NJ HjSg!:fuQ%+edbτfēwknF(kr7y!;+n[F4R̎ĵchĐ` ,(WZ!rZe qYi!PN`dDbEIXt{ohhB5Kk.N]g IDAT=)ORjx_Ha jMvlwZ{,@vଦ!Fp rͫܺ?TD;^btfBSwVqKCQ_UF'*ͥzbX%ԉD͈($Aw.T>!+Us2p墔n纥ڕnĹyه:Qɖ#42B-E U8ꂦ{SwV6;/^ ôV:_j<?t5)R"2u%;wGݼz#iĕvl=Gw H~^2PW%Mvmagz`r,YN܈.#HĚ K۠jTXXm8DQgHH4`0QzwXܢt; q{::gZ=+&rOCD1$^@I!ȲaI%ߓo @IKp`ˁر!ų%ܝ>*CR$wvw\]ܺw0nTKNYԇ>hg[emm6d:]TI!F%:#`E.(%v!(8EQ.HyrwG_?_~VES񖱩:e`8}Ʀ 0ˮN&'?ʲd^(.OŝtioJ/=W'@Ո^EQE_Xs(f4PCpP6~vWӽV{{ΎOXK<;uX#rG$R2 l)ʗ6X7Q{["NU7D  hjA:E+_=ٔ6LN`̆J7.ϯFNSr6+~[6` blQÇU@쇃S6?<4U"'|||R%"fx)(EQM % wjU;$ 9RֺH©{ `jT Og ~ChLS[!xg*TV ,2q@Ѳ>%jg;g˼ ë;3eW_] FͽO7%Tݽقk<2:`1[$ϯ8uuЙ;ɏ?$5&+n'@ Ӣ|I%:Mx0xbJE\*+"%9U-˙w!EQEѹ5(U1lTEb=)ƭX* )* v>Pfծ*DUE6ptl<|(YɳVٮ/Mxr"!+A tJv߸O2喗rx2+C,1w~,/uԴ|X)wUcBg:ph-7uͶ%Jm݂~y--%ܢU3,yfE2E6}vb闀9:3<2OlP^WZV }~Vu8h8TqDVIL#ymYԐFAD3 L R3ч_<4/<NTWNUzՑH]>kV:9[D0Eőҋ#3DQEѹ5(o*" ≠A@l!6o0yj0~kGM{M gL+g}cێwr]B꥕WN/π DѿCU!v'7}rbgxU?H^SIbEajɋW$J4a߁@NE: 6 9"#2U%ojsY_V$:zt$^%w; *+чU hi65a!PKiI-JY bJ$H)hDML\Xkk9d>0vBV^UJAD9}|;V+nwF{3UI^MMf2|"U4*;V (#QEQ5(oFABӣCY~Q!>QѼ{3IoX8?g>sr~^SAw?+ݢq48vSuwh[m0ip֘{:mNhcqHfucA`հI0Ft_'\7}+acfv'#. NDLOsB Ad/4>_^M~VTD""  bȆ05f=8X} "[Ë!X!(ʗ -Pbf$&4Pwof]WYo6 :N4+$tAŐQfY:X >Uydm5dc{-Z{{c=PzB* R(b%蛩~%-k'_ku5s]mZ/{ך3̍oMwT'w":h'%eiM+4*^Ф ̪,>?: @mpwq_3B1G潿٬߳޷*r'nB^QUVUOl4۬>( uG]c=<77˿1j4@߰W!8u lk냄k2HeMikEv#`]@XvPCM@j'{";ȖeαO5Z8ÿP:+?Hl[7(*CQEP$~U&t]e;yi3]-_o|7n~ (_wۋ#TRmfa jmbh*ס)pp3e:!,DzqL)mf&:q|eS;.+w"mdey{D c$̘";~+=Òuf(,%y.WQo)6ɚK &΋Nb8 ?>ٻHsQ=U՞`]QdvdIL ZVB= <A !/H?ۙ_9O2{l';mGnM:u~l^^dlQݔ"9.4 І^(_dth7gf2ˆ* 4=rQOD"zۍv@h?(*I$I..\$I7e howVIO9pq~#d+oNFLUUycıFÏY#͘Ẻ,輸hJzwD{y@|c:?V#6S 1*yS9ZXqzUU׈S7됅z491/r. Gj5qlx `:@UA0h:nOr> @Q$dfpjn>uZ#"rсϛ3,{Ǫጯ1LAFvx˕Y2v;if<!zf96氍wb-e#RXV/F$I$#\$I7Dku~F6 Ǟn[&})ޏ&^1;٧Xh̲ߒMgxOAe{4]- Pk6ˆ+1PpfATí)]؋u ^r\9^J@а{/>e5d9 D(n~>l=*k#"{ɡu dd 3wÿPY1|tl(_붲؝S tdF!7R{X|Dl)'=w[s%BL6 o-f:nD~Ĝ,B@F$8gIN/XOD.~LYD!,7䢉zL͎=1I$I)$I\)zo2(mFjW=9ȼ1.%*Oޝ >zo58yIn:<~\oENbcQnMA3c y"p?(<,ԩ5s粼i'zM,5$*9g2snSטUMS#Z c#L[]P4-lk K"WMG3ۃØ=`{HS &6x]lͯQ<T@10jfXOY](: QvBkeoӰ1HVSwޞUy-JeVyXC.~1 ?z kzD`3xE%_}%bD`=5S,Na?s[$I\\$I<_lQhhPL%T C2G`LLXlnFd\x)LFWWiֆ¼-UlbbZ9M>D9ZԑMC/Z@]6aɠz+c)=Âs8D\]ȋDĴ5LF[fZ m9G^yѲZ ",Dm*`g*tCUÿa~mM 0+M{Zjp{[[Oѿ旃V|ky[FV:QfZjVyԡñ! G~B֋5Wn=uLҥ n] #[hQH@~Jc5jsd Lm(Xȱ9t:1Sہ5\hp_ڊj9_Tfۓ' 5ى3{5OK™φ G}46wb|e|g\!9?$IҥK$si9;kF:WĴ= EY F7uh6q7 dcWK9~^Ǒ- 1'w֡Oحkb66@4j J9 0T3pǗK&6<)8u윔~];Fq6E|+;(λC=z҈Q(UL_n΋袡LK]F9DsNblu`{ \?_:v]k#&9 ѣ'o?dcG~]X|jO\1VwtCJn_ nV ROfΨ/ߨK>T|&Zӗ"2cOv_0ʣ9^Mb8 $f1|fEQE/ŘKE3̈IĒ:Ry eCY퀭秿|'!03@>n~!e_q寃a$<{;Y:Nj %_vLj+c}ٹV՘)KK_fv{^*!kr~g\ l'&y-i0Ћ% ĉyLzд8Pn _woRP)#,Ҥ:)zRws{ۧ_o0ZH\͇*8"{!wǪ\ʰ^k0ٛ+Ï^t83#m; O>vƦҭ$UN뻎;̭Jԉ?jhp3CJ]5%9]U5‰$!T8RW۾3jf@4oa^cBB/x4)x2>$deh.qsޗʃbwf6X{Ž< ʊA)P7@ `aD,Ƅ+3,(х. Mɬ 0ikky߬ATVχkttu'-[_P Jr=;B! yvxpO]R_xQEQ1(׆Yq.vUܱ0,A)' Q!uTF̪ ޷ y)@`b)a$'2фh ,sDbp.@YkLR}#2W.w{,up]Ҽ4-')2 k>4(@j8U XxtESxl;!Ly% <,\,sY;99yfLW l@r(~tAUU͛r9X_EQ}ab%3@g2| z07Z'3zlQnC@:7e?0$_S$lvMִ58FWYAgfZ;E&ۣчJ r Rs59Ǘ:_RKz&O(UDGjjˇNVWN:wQվ S S8%9RA9X AFPLOUZFPNkF>wtCejMDjI%( cOy;Li#""wR5[4EQE_s(z qG&CD>cٝ]ڝS^0Lv~|#Tu*u[̞]Q4ϟ7zW1amʮ*h}]UR;d.@ RB~֋,[@tos/4χ} ֪[uZ.rFhnUt8MEB+N0QElOX}W25pŘ'Jp9b3u?޼,HD 3&Yv3aU DH}jfCfIV?p8`G+I`\B(Qo?ʶ|iߨZZZZa|5FW\嫰 \1!')EHFOdX&r5'+Fd!\  O@Q|( hjR]g^H3Pl>V$5x} ,҉7vYz8s98{"qr OuL77nj)坫=ի`PIAH B]Dbm"wr! kq@DH'i@M$ D6s:}PPCL"_NÌo~( \!5H_{~A}srpsf=dUDBT`tg>߿?'K})yg+\Q4*wh@y8zAJ OH$Nj(y$<|;KKKK˳JYhh$;g%DAAu:*%1kQ_p\KH"DXR91LЇ(DA(g HMtA$r@Rs=M$Ua!\6!F?^/^%&:̟:xEVwӮ_eAUެrlin5+`cVK?.|E8GN; ! ?O_G_js *3W ɓ<B $D4Ec"HR쩞}EOAS!d47xwZUB 8O}l|9qMXc JU6~JPR\rGoD<(G(:";ۿ .N[@ _gK>|ѐJ|(#zd@i*IHUz8EHHUd6MKKKKK7L<,A2QnR'­9!0@0Rd"d+[sɺN h@"sp>' DQ:qi $ "B$$6 #\ k˷FTdwRꅰR0t +Ǧ%-j ?VӖJ 9chƠ;Z!:4G 3Bv֫?7_L=9GDz&3ښS7~;ae)];^8 i"pp6GmmX!A=p(I@ PC$O) bJJ\ r.-vk7VI!ţ͗s@ndYW[K GlU݁/5p9H  H}"L=u B2 Da  i"<ݢ5?c1C-----h5goHԗhF+=cvaR .>]@tD&@zglB=$ßu9)Ryt p'cl3PE~ ){ a$XmQ\C9`X4_bʂ<1Knu`$qh~qN zHUMZꣵ| 3WH@O[LB e"\T,UE7 ͉!]\H@I8 p@'/\ {).#]L QgϽw3xIH*`"xxv`VL $="(LCĎ&I"f"?gQhP@\D$ K΂ _BƋdE, f9ѐ{nr,Km$^}7N{ 0 ÷zrzrJli~AP@$heE7v{b<}JXm'Arx Y ;gVa%&G`fX"6[_O+1QNխvЭ/Q 2L<2;۝^^wmf ҍ\R53;{NO:eS%l%6--"-߸vb$#äOpe6ɋ2ϣI /޶-;h'̳UΣ½δwWz%WjD?PAHV8ӑ|{M[ѬB TqڙL^YSR%` sXz6zǮ6#Uӝ&OlWJBDСB:i&oFSP*)ϭ[̊9Vsm3/-h#GOZnꈸR@XҬ.?E(qj#c%[?z@Bd6${Y5f;" "]K(@c Jk"Cw s+P{\T=5>[yVJ:EAbwR2InVCK*e`zBȷKyXM˜-- tb^h .a`uKx] }F-GGGGGItttt|H ut|4~eN*9.$D0TSq] xZ./G1s)y X#bf0‰ ؈"vVtmB R Upλ27zWJLjNS+;;?o_GVWB߽ R0d08sYBX)F?4;.!}F&W{jaBrUnkMTNe[L;9mzt:\sp(xJ> <" bI %Z-XQ?zD$s 5mY Jݟȱ(}                          ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~  kY uR"2UOr&I)}<9/ָ}w6r}i*-< aPܠYSʃ^&* |DCdmD6Ve1җ\&%$DrʔK ؀'QKЃA %17'v_::ͥ+x^/g/9e*U>-NOivT:ͥF6WyǿMŶЃE2֚Y,_g{{{ E/Yhoz0l|!{K5Zo#K5^C `o~41Ոi@-6jh,4D<fn6>@R!iwvrƙ2}XlmJ@Ш* 4g- [UB$"37;S P& e Ny83?AMw~4IsZ>U`98G8i?{ Fu÷p^X6QIFv2KQ!#p8Pp@p t=ED5(.$ƙHFPlQV3>`ću mRCT14L7?y+2fu/P; 썆N:8=} 2F,ga[tݙ \` -lt3~A`%Lx#~"4YIrupzX%phZ!ޥ4ѣʃ*=x)J= K MkҼrAh c^=$Χ7,"3v\άtGbǒ,@uLa`AAA ``1F Hn>tٙmWegf{럫ՍZΎ/#CNy@V34 C;AC1{Z  oK  04P=Nd%q]) YS~朌^nKO9NܢDA/6{F{vSHDm4)7r\i@P.ZzJNiVonXH%! B){:#奧gBrf̷D̠ ")F5$YO"T94`KYh!,J1 "*b(Amto6?oGmEEjl=YѸ3=)L22h!lR j( \oa `>ܑVLߏ6U2TJsݟ޸f(rG"։) Y=xT}\ Jۍ+-~zxF|h—I.(f)B@k:Dln fVJc*?8`}c!"[>1g6PQr=*w Ce0"PG+9W{ۓwƐã} ȅɇ>ݫ_bù`4=n\WU nV+j:06 W4MZڈ4 Tƛ7W`Ӕ۬D* Ɠ#jo7*&eS;wlf.*)fʅnv;/?bm. 7V<"Bʐ'·gkj/ߌ&'\%%Q6$0Qkd̎R׊P&n2RPh( qta:]t9(W^C򾟛i"{BjcOO.QhYsqJ:q_,#`2(׻K6C8?o7任{kj1_UVӌ /y8*}Ġee Qj30ZJ.Ao&݊| #R e̴J^A&x).F0/}^tq`y} wr )L)] ha9?|N35y?:!NOrraC`fZ*'Rz8^;5h\…0btJvEtttttt|et:!qFiSfMws~]HN&E(-fuNKl&lI}a7wp$"XA#.Go%B)Ênǩ?ky 'ɻ(7[Ef "zޮzu;fcxN l:8Zd4$AR:5.. [1)K(rFo6{י E/K7rkQr v2DL }rebĒ|0-#>0NkЃg@X#RĆQVfWv#U5VEL+ dheʪ_is^<8:t:~/M494FfoN()G}[UlGϟ.M& \6Q~x۴';=Z\"|ƣ^RHB 9і*_RCVx;nU.DD~Kw_[`q-ęqn׹z:IZ;A`M6_ ]ͥksr쥝&H( D'fO<ҍ>/SPrW o^ aflqB>Fl*l|gdqۈahsi OlBl-;qŒg2$Q UPl BRquE #3+CNU!=kbnPbf=eE,%;P X'ˇw Ώ <G*.zh崗b?2l Idb3s8ݛtE[6/]hC4L(N& '|y^>wv=μY:,o6dZl;<[U{;[{OzMfF_ȶQ޾ cfwYǿΔu:as)ד ƻ !tpu9u 1@IV"mU}O'J~ЄD"!J7=VlpKP:N}m------PKKKKˋGWV7B& " +iY3,UKbqFM': 1-垐H$5 6 YVMvn|+ؠv_L'Ud"1h D,blӣ_^Lݯ[Ҧxh{ q޽N1ȭ7ͫA&%2twV\]N0iӭBwj`/PKk<, @id)M~<}W'=3l\n9m Lp3/>P -d 8o@:?|73L9D"@# Y=NY,]yA J.pg<~t|GtZ@˷`LDHx^ .2UӲpD& 9ͳ6'f]E (h8jA>jw_ nFA2t"6 JК@@`>KkB;xujc2 :r #HVF ,p U,@`QȕJq{~Yݜ驿0+!RzK wĆGܫJ 75D7P{I.s]Jc@,jSnz9aX%CDw)%:?G57z ^Y3R[ZZZZZK*T L'hVb?݆Yl2 gT֔h$$ @W: ͻxt%sҝ?juV)]jDV]OvtAptugDzDOl"toӧpUڥ[UUB4ϝkW=^ d=YZ nENw6niMr_7/$ +._mYĕNMln^&,1dKIsd"CȡuVXG;0O%9b?xvP/}bǃ6 d{FxP})}K)j4z^h+;[F%:ts)H9+ЃXOsBqL˖5-+ Q\ĝmۿ _7)ʢvoPŷuuWi> m.ϥVsiiiiys$ 'X&HG,CU̬dQQfM9.MK$׌`@~*tQ)/+9煗[UF:HL"S)Dg9MkpXŝG;Oa% 1, a9oK;GAպ ^h{+ ߰t5{Hn5(!ŽVZ"Bd(!.LyeD#J8=$PJf PTC?0Ty+)O?A7_=fc,dT}7[;0Oi1;^$E,z;M˳thn&]1HMs苁_Rt#Ǟ]09uMPJ8W T碋ƖVsiiiiyIΕ$gEH a ԈnDTـ'ݿUJVȀj>XD p NIM~#`gsu@^r 堁Ld'ƿՔT$+Qt,O>zZxk!8p{5zUA A/% nO"|01:SP74!A zbE&iuv뾘\R bSBdltȜdT\`6Kli>~*\ ߱1}rNqiJsXWt5{^ɣ7|l})DwJsHV=cyvlj_Z$Ir\w=)WNSfYhdvG?UUu[.7#* Y+ZͥDEBO p>;k, M>-C[["X{ZØLDfuMX|J|*i _7 &zhf1n,^J&]U pr L䯇7"fb;Ʈk})29$gii꠶'=h ;AчK/)8j.Ц ܢO>bj.$쵾>J4Ҍ4q3=i}2KH&*|"AH";H8rXܢANGՆ ha7Mg4t^tnxn>l#XuWَJiw(?>6R׼`w2<2C|zޚN]Y~އo^{>T-7+El-yPUکIRIRsNo7TGtEўq k  1&!ab0 ?;J4ĂsPQ#<zMMMMM͗OԼx<QC D#w$ 2>qIJk"=;fyc:s.D/-A| D:@*F ݘDI0 x‹!yiCLI@'@%(o,c)!j:??QLU*ٙ2SUC<diSNQbrFgt{hqiH 'OآO^ WR2zeo'D + Z \ AZ %jjjjjj~5мvJQXua63cgZ ) $,th|OşF;*,Y^t^9xtTt>:} [4Qi< tQ:ŷjg4LV[EevtWhrvvhB\5*1$t4 fFreySn{՞?6D!D  XV w\V V(@^ ?=v9Ed 1< n&m.b0TONAZ5[L^)>?2_h(fE$ t`ta7n2[1cVݘn@' 膆//fg יuIYNh&>cB@>vyh﯎F oj4{G-c[ƞq> )u[l଻{W3du<!Bཽ0Ay.S7Q7c3gF\5//E3~:}Ee@jhhhh4KCCCWxcRjwRZc[`weE%r "j|ǣX59aqKtxe9-I7=תY Pm`: >C8ߩ5k:ushI1|MV) !R =|;def'OŻkO''QK=.$BtL|fuqө׫47.bKANL"In;pH<hl^wyŒ΁r!u=I|;9D-/6PR dsrTM=0O[@rVVvlqh oz"T@iYyFp_P^,dK3 df)^Yٳ2NkUz<λɆo(L4z z`Hib# M0wT<H ^%$01\2Xw9-{<^r#_6{?:ah:w?lݮ ToyY]wEIrc\AUg {! E|=Pކ?)u6 Ј HҲ'x>=I]yW2t%+}b0R(b+Bat#mn֬bZqjﮘ`9ylr <"ZR[ ga@4{-Wrz#;B^hrfG`RIUR8#u !!<T <]c2.qDYK&G"s90 |"s)5 G{~\3eRI$$q« )zcrf[1"\3١pe3Q5MagVHtK".s ˀ O -rPL,y9s;5.6 _ ͥEdv?nV&u0^`Ʋu$xUgX|0N2:I4*D_rz%vG\Ԟv{VUe\wq]`hJzBb״`ġVKKf3077|v%@kI.')2>9J1R^U+S2k{*qХ^!XA@B1ԙ!HXJ 3x'O( */+"㿾d* 3r*`+b~ݝ񩀤16xq2Mh8;8ǟ6_E[k}vV0 AGL;!imy.( C`Kj[VÐ?vfw,[JhӂaOHkhhhhi4 k ŵ!8?<%'PU/J ? f̬X8[Iw']6٪;HIpɀ@J.W&Q^.H&ڝppcТx7Mr f /\bJv&nVn<M̺INT#7?[Fljr+ 7o<۰ `TBӑ')/Y>ng:IQ"662'U b`*S] Njŷv &(h* ]qY=]CCCC×FsihhhZ0< Nj^l BSWəx1upw2+e=xv'KH+bn!^xb5d]ٶ$Ab 1vɍ~{fYE&uNf.=aXY&M~MEp*+JxR%di k@tYwa^@7$=;Ԓh#QqrttW 4\Qz ;% [r4QNs+fÌ*\`VU: a|Bwf](@GУ5x׻ƓSJ`~ow$wn]i_>UN퉿P4Q@4:ѐ@4 oH!xD!HDjtۮx8e.:V:]uΩZͦ!ގqqUΙZ>٫]Dt~d Mrx>p拽ox8NTo-)/cX Z%aSv$8:}j( of;-,y] kgЁr3ԆADkoiii@a|T }%Z2q>`Ṁ>'?+f 'c)H2iJMd_/\hV3!Գk3hq.$R?6|aZ0#5}% W_~ r8Btxh@bo۞ͬ\&Kb )]f$ivΥ7`@4)a>Q|)r! $E brp?a8 T.~z|m}Јwag> fu^[{w:zq˟B_N37UmrSY֣_.^cӽH;P_~^4W Ϛ{7,twͬ"Lp2L,a ?#Wjo<vf& GIJirByR68 Š,ˬR`xIKox)a~%EpqYڬ7W}U%9†gn+9$ zrJ*T>^tBw Z5+S҃Ӥyְ2x˞J 23*gj qBmpE'-z*v/#ɍVXKkY&G#($AS 0~(GMiJY"$|_NfLW1ڲ[ZZZZ8Zͥyy&cA@àz+kWx_?oڪ{BNHdf37 ڸާhRތpRE@$sw4I,bU񒲡rKbuյ"Eqo8\k{B{B!W7s.׳n̓Xf(a/iq:yQ'I>xd ] ǰ\=&9K@xÅFgR4-!xXO ʀ7C15zV Ii8ȹ(bp*H;I&ꛠN@='Ǔr48>OSC@ fpx!lW=勣\ZZZZ[W P IDAT=}{7C>4p5 hXL0ɦ;N]T.ű&T(N[٤TF4?P#I Ӣ<@ jCI:ݝ÷@ʜIVWǣzf3_*kslDkX;o $Λ>*rݻTBݗixEM -L.1Z4oH(@At-;5d!#IXu: @,OD  03`h"!75it@ou!9-~=̝a%XW~J˽[+aKKKKB,a)2^J rv+Orm  <1b bS-2JfD@;ٍ憧 8 y͗ ϑ\-J Nc`+dKr4caRK]ڝ\Q\:BNmzRTurc9\!EN ?ڍև13وo,;$AA !0 {Y!&PT>!Ws:U ?Tm]^i鲳xH`lݝןg1#ks`edI, Av–}vuP{†KeZ G2.K2 0#`Q鶝KX09LٳXxlvyR޻n׌e͢{![O)/k9AY2+!-S}Gϲ2ab>p/‘ M { !QR! k'|y> 'hҜNb)\|RU/P.>(9x>w6=r>oUtw)ZO*P" @E ?Y %"o?‹ H Y"dq39U'jRQnX]]SS6n=,Aҡ6y5y5ht% ]2D" !AaswL 3SQ @6:@DH%XsJn ^2<%/?+j872)f滻;WVİ6*ޞ<6:g4~lIp 쾈.r L2~^Ubu,4, K * ,W(/LMih̆wLdG$T^S_;詏UuN}8@gD: 1g!=/<5[J `t+埻 !v'(*Xn:AUs~ٹ|񖖖/|B]1[1f=Vzme^TH϶M0,oMgM1LQCMB&g6 jXwDU68*1e[?Q$e=Ó'5YB|'׏F%,zEeUh}`4D77 胹"9 + +(B)`-KH0l!9"*!cܽ"iV҅](B-pл{/r S*qk.Gyfe5AX0sEr:́9bT\<_=`_qfVțUCDhf&cuL9 2ADE) ~s!f"("1{\KIX@eɑ=iH,e*F$4һ3hn{^hdE@81BjJPe5K]-----Nr`TaO # t29j Od.u 5gFVdY(vO*b%37X="%"hDZG^Xe%!G*v2X%X#(_xU)!ycF1\V54akL'xXgu.51,A# ra6iGy6 =~'\-----Bxjku'Bɜ.PlXL@47PINS B@,$ _h8|ümrj@1"ȃ<_OUvD֙.D zX={u59vv?*ǯ( A;EՐtUAѭZ|: HhE%nJx~oo\b&jם*ED ; ѣkn;t'P""A+c+ͨlEe@f5)!oȁ v,*Rg^?4G7c }W-----_%\!쑙 ]E' X[/=h3t"3"At:D"Tn}5EG}r" A L!Q;پ[#_8ro.a4z-RՁO)5}^{{{,xX+jiREg|>y'L.{ \E)NY`k@( at 4@NRZ,q 01_\J_(ag29-3|Jzbľ6hVH~Gq - !½f|k_ύg-z"e*lhu+\rj5HhZ5HhRtUܘ D"YH9tz> dOLQ=aMBGݙ^ *mO>H<hsc1`)鍘"Dj~Gk!&z\ZZZZ+ 'zz^ի>> 0M2@ԈC%Jr:oz}8l n o#WvϽY`K-Ѭ1*1 6Odlx10e& 6  *[$5Tw`ջdAJnQ_mucoEU=id 0QIN*RgC, !mb؛TIU{A4nЦuq}CnAcQl>% -EJD &i$@! B 5"[TC^SR]6 '7ֱoXGjdc-ݎTr4JU\%cOeZjaUKuLe`hq%[S Sρ7~XLAd>~>(hOTM&N]eG9drrVBO_Q@LoAtHV[fr5'*Ĉ{74444<ͥ'BxCD'辭Z\T"s)ų$,ȞsTT5LnGuj "$E\E. H"3D3 ֍1 ]ϥj5Yb~e

z$"咢+'i)Bn[w%DA(8xaythG f8NO+I@!z !a mdtVQbe 22(dU84Ē{dBvx(wL6]MVTl sҦbm=?=5sJ} /;i$<*R (@{&%g>Cr0&x;(íԴTly{'դa}Õ{qEӃ!q^g|.1?>&IJ-z?#"HMQTJJ7Uoc/y{+k8]Pu/'`{7Wt=y̏˞JBjv)3n;N7ѶȫKIqŖWCpqkFƟ5~P09c.w☒Э{FF\#_GZNae'+,3+|7qqv@C/jaGzھ^;cf{Tߨ!#]ڝkͽz Z:A7əME)Ձ̜wFF ZI'tw?{eM.NkAO J ) vHJȒ@B94$ 7[CQ^ gBN:%"25͵_%D )?K}ij;d G4 dbdDAu%ܙYA]-y)WYk0T+f P ==aA;Եt{H+}W0Rs{y Jt?@ IOM~(-!30 iDtOq0TT[5;sq!lml<|'".186iz{cwks7V@E{M)(|izyqsr{fxWw/f{DAw!'[V=x&3,0DL^昇q6s2]ƅ]>u*9 2O3;G: %Rg&^{4CDZ%0')Ly u"ԂyIiײ:|oLR1z3-m켃هϒ,?W>ֶo ߋJ-.Lt ՔsӶ-M) )d8G֖ D2y!9AznND0 ̏l] F "BJWJ5?/S(<@A‚P2=I#‘[L ml 1N÷Y89ȿ`{u{|cq2p#'Ww!8jr*_GyK +#`ON99a ƭ%5 @!:J3U 7V)S* Tw+G4XhoO,}Pq0 LS2qɉ 10~1jF15܏|t4cMmv#bbnG]4,-k2_%BOnFO{%fY[gzPA#O%>$JǬH}HD1|"J@~z&$'-JGrKnΓXYvWH*$ض#8B';qF ܁pv giw{GC;[5t \gJZ*{wdfp򉼂/.-c)<[a&S74koٱ{J?ZR ]p:s)l|hBUW  5%9.4~@XZA~~ 4񓝆x3mWj[{u"ϞTU7jEv>;=x2TS^OY<11f j+i>, v>1N^KZϘJ  '%ekhVҵv#'uM^kRE# An"!~ocmu}xwՌ*"c>2:Tї&g{k:V>uS?w8ޘ CAwmYUmR!"H HwH " "H (("!twwnz"{\90s9c-UorL݂1YwE+㝒sÝ/’NsV iYݽM7nwE>J|9ޮiSQ\Vhx0qix;Y /ePnj{71O"b|=j_kREQa@_zVEMUm˗ӟDon=xZ\8.vBxR]^'/pƆ]85~nX'<9C'ˈrz(37UMIdutN7   U&hk_儔6(*H,_ouilimpnerCMVr0v`^F#wUՇjv-Wc*W_024R˱42PSUjBcGq .@Ay33>CsSUdC-@_X=PAN'999ihi:;zGKK(*r `3Sˆ狫ЌD>.WhT'$={|aX/;oƧWߗ=̌ *+M]RI3yѳLB#:n,{''b $AOa P:,^T0uKՌ*\ˆf:i#nCBKM Z;]Cðe&U&FVN6ѕ6NweY ǧMc wը[ َ/.3%s_p8?90v0͛N:'<^R#<ǬDŽS3:Z j_#$' {2Q~Nw+Am=M= \l"~fv1&N1Cdi9i.j:S d$]kA𱒜vHTq:ƷP|z y6&ax,t||,5$!|}] >S!C#nOv1\!b =TBؽ ҤHM$!3LsCFЍ/%y:9yy%cpqZz'/V+X8DT+\={22,}|(}y!'GMd瘴Ǔ ;ηq )DWMĥ$nYDT4WVԇ2"f-ig";^b3_=|bs¬E^Vqwy(#=XWc`J_RᚓBEq%#WW뺪r:57, Mn1W$>Ϟ%#[*<捦Vs{8@^ZNQ\3侥sؘگӳd$[wz[8l}APi7lahY.\W'K}kHFFA6 XPV.!&9=312  ;qq ,C Dd(UC؄4S`nasW]@mljdEnڹNxG[{YG׮߲ OMs^=<> 25APOCai3 >-s=aiΧ UfFTu@PM^5 Vf^"?KZJ C_F0€grE1\C]Y_nhk`eZV`jicUequ ' TQr=O[èG0WrWՕՒwxěz2E47&W?LHY]N^Z}n[Qx\YXP>pt_ZT3M^Pnpl|-3ϙ#qm_0ֵ0?ӧ*_ӚiaVYsxD?1_kٹ>K&Y/ngF$zݑhm1EūD16Z8ɁQޤGp؆{ػ &΋Lz@N}6`;9[ޡecGGYEW5LG# Kz88IJ}u߶awa㊻m1M Ӎ3c<_WS *J"&mHIF^1p s/vllo¦$/~#$Ӑ*B'%~CyU)JW7e` n|wch ƒ'D:mN! {  |j<.1! BF>u壧 l >.쪊̲1raC0$D}xk`8(qpMﬣhnITo"%]߅FK }hiâPKw) k" /OlOJֆgҟxh^VjL'Nfjgljq^𘖮}鱵!7>whk$j׾+qs͓KPs;"!{~Oяhh+j.L6~]PVc }X- $]4D$EFV7==(^jr2ݯ;h@ sHɀA!s[Cx$J3Bw6{ftdϑ,b1ȊY!xH`pDQxWE.u7@NLu?q:ED꧇l tCR4EE|¢JtN 0}\%0$ަ}hi\UHc"Tc_dž (?5x?-'* ;FV?= Nr5yјσy G໷ŇYͮ`e6Zص"& ݇gHpৣq ӓcUMkzli/Z7E>JhR453Rҽ10ؑVZ]FMU=c=;T:ѹQKG_\iqkʇ7Bo ,y/\xR{Jvfwk#C~Ae]m~jv6J-=-]moU)i9:9qK?O&# aAP@_[×A6> 'A~Κ҆q1.>J/2w'Ha|9o/MP+R IDATI|Z[A8qQJ͋f;mQ.{D'Z |qJ-z7l+ E#[ 6c$)AS6 DcDSQS'(IHE4xE89ΑW78pE=r2zVr2rmA:PQ,B;9}̈F(p5JD.:䢆Lb:i͑ LlOj(k4㾥™ z$!!H8|#D2A ɔ8`ЈY}F4 Z H )bAmB %bB{^Fp)O;6Hq~zG~ 262밅j2zbzJ9dft.~ P)2/"9pp099«r'K =D*̆#(a'I1HYzY.54IlcB1!GW SYK>m:sTo;ID%Lçx|,>Vr }趸rF Ϳ-uЯHК}yəyoUT|ݵ9J6嶎GGmQջmv^^\,ٻg@][?RF\K.Jlϝg𩮜" ˡ!5Jkt%TLT5֋j?qQ7VZX\:후m_1ц΂`w1nLiBBȁ/f05T\OGm}l[P:F󊒔u >vqz3:HUP)GF_aܔiw|j|J6q';+7WzwVU:VFF߂cFtVWZ8>c`__ 6⚾Vv} ~gkȐġ60w3Ҭoo(lǍw>_+l ߨ ʆA 3m/J?떕w3vkX^xXOݺ"D/.XGd522|^\~xHyݨ(ߑa sG( >ʖr\\jS=Q3si/ĢSS;OE#~] پ\KA)3?M\PYC/0'g?o3~|Os!O?WO̶;;[_v1P助xLpAʷlt TR#ӛ^ka .*_eTnΌn.vd$Rtyzs-`/~Y;^?UwWׇY?|,&.<[ƩeWEsc "v)g 4]t59/ba/΁3"-_Xi|<|=ݢC^g rwe=,z`gK@7'oeGOzƭ/"B"B\M6]c4dz[u6 @ !OSw~)B:]ۄ@@q q)I'x  2<%%2.!1=5;5;)%9tE1ꘚpo*HBEyW0+MOCrl{MP pDHT"3󹅞 "[suua +]ۇn];2"=u[Ѻc|\e}% ]qA<<X'O~3^6\4!~~a5&b#C3=#!g1qe|`\_^Z9A Pt7QrbjhzVIqfhLPɱS.jܮq< gn!bG] ՝~N]ՏDg,/K-t5w2HfDxK2-;<?ǧ$O,KC~R;mK*OT$h a)Z>(*O{jN#-hvR%74%/=> uegqG>fDEІE)_ }zvP^uAĦᴗɗt-դn^(͛ix,'- b7 \ͯ^\UT!^J,w(M| 6DN]ַ Oڿ'k g&ìWk8VV>}4oh{-'Eޕy7&K>޴X w>3g[{}K7ԚGJ?+j/AaA!˦JMC#EJ0Xm}4ʏ2>>ζk{"5=]eUN\vvij H ..)I/mnJ,koR\=9mk{ 0K~r~csjm ;3] Jtq! sZDĤHLDHBjaQENnFTSY#a!q fCKsGOז%Z{>)@!wnyPheoDw`1!7wd|WV\<B54R^N*Lf'%+^w5jTDCWK_mػwoDdT>E"8xeX} ol{76 s qs~n‚iT³SM`juK}::Yy1l| -]ì" &4"Ts.o܅x9APLJ!%={rMB=O%u$"$zgeS`~m1:8P5xzNLF{9}` Bј ׏0$c[?Ap`NA,qAP+S~j"kx{581tcnOv5m68uN7rFNG&e.K[6|Tlw |p^ҷFvF{wI]wϵguۅDҿ0T]1*e& u^qyIƢW#ħVZƤH ӵ,Ix81=0Ob񾟧&'綣Bt8>C7b^}O3aG J/i(|vlaMRg*7vaOLc[s,;00t`/[3@DGv؎{YH2id ^Đ0/wa'6W6IOWv`f$ oӐNNG5Omw2;tc^ ޿nQ31R ͐pI:LuC3IĊ8[$AZXg`b?8:#ܣdAL=6)p}p{cT. p[ KG#{kVx\痺AQí`Es[P 4D 7!pB7ie1E 1.\771===79yKj_xDf~[G5^ICς,Ži?;M\}.?  vLizf'+fn[)]Zp48+S` 9H)P|9! >v@.@>=$e\JN 쭡x5fAseh+bޚ 9\J|&O(hHv&:-f_ABhY֡;m%ω+>}k'A'Llo,BF#=]M[%kġ 4vg,/ K5 /L3v AY:ٙKVV|e}7n2off:A~x%0Nf`ญ3ǰGQvjFVV67Lgg p;%e4wt3,b\mJ'O tl^Ր.wͮ] f cZ|^qsA 8:7o5OKg;( pf,"a8]㽹3f ũqQCB`f]̡Zi\\rV蘌 8V5^ħf)QDJN V{y#])7O3EՉ*ǞFLEKPY^o3 [6&zyٟcoj_$>OIyVP#.}xDR"}ݢT%M}]U07^\^b(-gIGvvo-oc?5y4;KI5aEMte\M4u Tf[JJNIu헳ɈIcfiɗbyyݐ炬WouO ?;WY^]V^E-)Bota5MqUE֏/2>5^f䧢_Ny sv ehG&*REbUs洷O츝 W^B-s /MXrPDQ}G -[q-[OXI6 Oν7A#w`H,}k<1qSQUKz y]looA? AnV>Na,Z0weeY[mCAA,; O\`7u [w`++dwM]jtni DAɧɹAfFսG*g ()$hxobu1iD ij03 7gj{BkrRqɣ , }O=xBa:*GfkE[vffNN>EU-Dwm̓@fNJZ Q;f~kEU)ݤ^uİkaʺQIk%+3/kM\1NNk/]tXm=|E2uWjm-^mj/r Krt5[Z"\>^|󾲡DWѺ?̳򚍝G۴_&̤q9w@<_{0qt6M._$ ­ 0+_+'$Z@M aD]r\:*3cBã#^13n6U3>Tgb[29Z,"R| (08"'$~][4t;Ԑ-m*GA[;pQF~fyeTgˆO<;!.YZҕ)"HWy]GvjlⳊj’qQ]5>Q yzj?&VSS]hvCĔ5ÍW&Ů_)}X\WJxҒ+cagf&0CBucXHlͤy8O6O7;qAL3dyBG;ҊZģlmQc )'']Gώl!,'0f{NC oCN=+ >ntg ,B/05άOL 1Se{:r ﳾ &\X`&ڿUQ-.)@Y 8&gP:@32`Ġ?yEښ`UMuҞs3а_`誌V覃e|s,dKEY#4D'Z>ykmvO~TZGvn蔝NUTxX|Cw}\oіfqǷ23գ]o݄m?N̉w:B ?wK[A^sULɈmッ(ҽǢT޾ʟC˨L{%DߴH ~m,xgqD,K656 I.l܋s`%-/]VQق#<ޞ?_vlTYJor. B*%>_>BjMy-!up>ux )t㪡hw󧑱DַhS҄Ī߿\""b18n}$'}B-o uz_3#ya35lɆ{Bm>sVI{`f""УRB/3a4TwM;GcpA=JI={@")쩮ۓgBmyG4 6:* [/215z%ՂoqS#7oۻ_vfXwkCO}S]]Uɻ/k^SVyp|3({6W,@A~eu2a_u @E&|zOwq[sIM3: %Qim詀ۇ|N@.?у$zmgPr9M&5\P%.J Z9DHWlqZV\4!猎Y?X 8D5 OX7*h**"._䏏! df]oNz]Nwv'<yܲǏ6W]^{=y&= s3db!6iJL> hU|6H8U/ ;mgr/()O|KSDݗ 򬲕Gٳ{[ IDATh]_smfgIռ;1<}{\FϦ<,fp{kjBVWVV7 ?dBs֞8;5}{!'#ޚ^=هhL6*(}{V,"jޣO6 x;f64sj;í0J $lso GgCH$ ߘpq3"ϳ.1,a0H8L |g<څڧFx}$ 3њxӪ! U4tuu(Y~l/y,񺂖vZfdΧqNV6]En }eYhLG 59}SoIYU%i8[}H,d.6fCΨX3^x4PbwջqHLUWd';IiF~2ޞ {~eMV0W3Ckk3[fNkZ%rPE=\ƥL{P=]I56-NAmZ0#/SÝ uǔ([>6mU9K'8m"D  +(X<<[{+j=54nNػݏlJ_mo,|WTlpݴ ᴶ&);6VZENZ}y?dSj/h엓SGށ1 w`Pi)o_ńV7g<Ãҗ7_zd$aHX@C7;m(TBDk煭}Va(쥜M][;_T]Z_U}2<*+wx[KKvdEe'@AqqQ^ޚ~񫬨σUyC5w\&W*i(kVTXm(j~=n<"e-$+.nԪl~a-͹}Cn^VewUԗG1b/0.fe_*>72\{>ʼgV~Ս̜g}:g;߄y''U6-΀ xTKd~!&dfm!* 28\Q9iXWwG(p}{rҟ`BGƂcghg=q3};h=eGħK >9jSbω4LJ< ɯt/PdzU764Ω2IH }m`Kfr2V84+3 lSC4/ Y&9f7}ۘoV s%-.IIQ2|jνeLዓM- ̴sWyrqIX|\H)t^Ap8\{&fw>8<$UN)">Әc>1'^GB!G|Ǜo5O-hzaN8t<81G`@Ɩ(ϚX9ϱ o0Bf&i様Xӑh3אַ 9ܻ|?)(ȈOI@uVnukbb Ⱥ;%i/]'%ڿk) +7?e)+Sut?32)/38G48UOfmiohh d@C0sK}2WamȬc2n#Ԃ9 QQRR ✰skN`8|4/%5>3`DjN9<9uʼn*s$̌U3*hiVW0fvjj| z\)0>6w9?ֺ"vlW>[S,Pɻ~[O5&N'uRUE*&m]76[&â,EE49R8࠰=3 )n9 PQ$iDF+´4O/ nݿy?ꁛy@P0[e m]F4P1/p2 TM.|yQڠmA)ܲO*bm3ˈU i +Ñ!qvΛG{z>di <5y'YGߍ3:%ujkd[y/#OecғgXyzWG3_PPPq]m8Ģ@|%,a]T^.,$} ֆ7||NExE>T77| ,1Oã,<[Ѓw O3q>0oLU+-( ! »-/=A-yGicvv޵ƺz~!SttptŞs ~Ă೤$K J I-/-qgO˪SI!v6Y7ǀgZQIHQ?~t'ҒM $6yNx K[߿xz@J*|,]KN%e@De6h+jA/*igBHE1΁O P4nȽ8LVH㛜ᑏiliTRcη=Wפ%:6/o];@JH}(lmmE0aW/ml V5twKÎ"CC/"d=y60ԯ!  ֞^\IKLщKZPVAQmvpζTkgѫ<9Um[>!{{Po 552J[w|<Gj*}rKQaaFPK)Y=cCSObc]7oX[eW[U]cfuM/L.ܶwOZZ40kl)-׼a0h91hҾxO'~ }].4#%RSRz;kLo2< k{^eak{9&򮄼׻G0D~NrlRGzO &G4/ff!wo; }{0fr2#VZU/6>ڷ)I3yi/YxZs1FZu+꺊})jy LMEMUzZ:d$DDlc |;j<#alhd1O5ip&Tzܼ 9v>|w-!'NiL>y.B˫oCw9eErkc+č1賮N/#TN&?t(|yY.*+/QS̫o3?NJCW6诣H9/ YIuҲd>}qOgX=Fi*6w:;xG+;pC0$ݛwT|X[5 -?Ȝ>3P-ֵ4iS LXBM";97Ab/yy`TMe9%eMd?< a^-$\AJA}(zgh`B+wXG"ycbdE\-^yG5M8[YQ1)AdV=BIQSSz@Gàmhp~qVVV'xkku¤fA2 ~D/#^;Z +-Cs޺qBbDE'܀lK*k[ZmaȨЈe(WGWY#Cs|j no[U]o @WU75#1!۰}}a]}~.*UlblU^00ث=v=B43i^X5]݆޺~7DDt~SP411eDfI841=jlo~( 77!V_ʫ~S} w;y#=sabb;85^SYmm#?xF-̝:F[[[L]Xtr WSoESmks7{nXַqe}q[^xz K@G'}[[~/7*9{ST5?4;ohr=)AUNye}n…vGT66zPO-e[2|]= ͬ(uT'H<*$膮TBlDZxKL%?N5ՄIhlHNM7vʼ@ p:<&`JԽ|~Qq&3L=+l=-=<3t@_ky uAh_lP)3'yq{;.?:y)]RTv wΞJ (|IZ]^?']Tz$tmRڢ:I%+Wivwvq$ HOWT:]XYY\6: ?v_SۀHXkhK+#4c6Gqv\Z2c3eЬHČ,}cNZ0:PU]UwS:,`X@E&Dc/攔:xw㷇*DRk_zGupGqnǩ u2@Cm{U?@kK]۸ oi0wp >8>͠2:O RQ>46|om[{5i)gF,=(( lij\ <,6oiX@Vf v^A1~q.^a*)&A"A|xy1{ UE1n> Q'Nc| ANvn.>8eX462!.(,)"B`>tGŚj8B */DӒWݧD6tMploۙlEDE-lx7"Ӫf{ks~^~ǧ,6?K 5\:eҎ:9VJԩ G1qþR<$2mZvff ,kW p?uKLܺ:9Ix3o~[q= 7n\O=4|BA%_Nڙ?s.JԵVcs_MU_>23;-_znܠ܏ `s/;;:b\]x9ֽ' &SQam]# ag[^Z166wQV`@`ڽ/P맆 θy7g݅W7#4fgF~x Vҥ0ig/?5EE`= lkjnKkL/OUWFExe%.uEM ve#' 4JSK蠢r0(ͭ={*H}<<$ #+kqDEyeƲTq %]?~-&:z5m;m5E-*<̼q{6lSFRL: {E.z"籋 _Kd* xO%W\o-XH¢3"6"G![ Mj` i"XwfTK E]O 2VV65]cJGAF>نM/э 4,nL~;b܎}&`m+rr19:yt}PǠWkYcSnfk**Z LVWobîHdk %޶vk)Eυ.T3; 12s]_~n^CI/Տ?aSg:RX>"tl|B̝ {؈ss?-=:< /1r1[ۧO^R 8oQ/ 2/"goo֮[YɎ3>tIWMʊYݞ>V~1Q`Ö;"ϛh-~%}}y8s 瘭W+ щdX9.=HKOϢs<R+ZR#b$ފꯈKW_Ź{VU(C]mr_;yO#$.#>.X}EGon'_V p@wG$ 3Yɘ记.X9Tj[XH_\GH][]nZ64NkeODU@0eoKX]:ll IDAT b=H$ Rx d.]C> sȃY6L.QJ^O260Bb;~Nn΃ȩun%n:CV] =(\\f `RM2pICONM_/irѨ 'B&W׆"}\ę/=}&" rٕ?Y^ : jy7~5_ߘ jokX6~/TqlM9,4`vETL2[rVs=8B\dsW@S¨ :!M,h OvF璧"A(옹~!Q0 ¨#.l:?~wc;`)λϼ=CvщO_z18lyopȅԻwFL =ܜ/-Fg˘Y52thZQ1G6$::uMQ3aSbp=mmZfN`ښSj 4x?4@#u5.R07{P4ZFBi}mj +x=I6t2sl޿!Ҙs `%&t8u64ƻ'T&/&*茏v7)ɩ0fr^d&[he&+@sߗڛde͟D ޳W%Ϟ'YŵvueU< XèWE،" EGFLIye|# CjkԖU%]1OKK4}/L\36X۞)nXolG>~hu_Gd`bk ;r9aM$h6b|=%$H щ֞ <&cf&.Bhobh]K'e?bj+VLqB$ġk`E=z288gcR YB09޾;pKGw_mlh?y |Sf`dሓziiɠ^ssb/oî\R\QZSzᑜw){GO<3 8Y!>Bnؘ 3W/\(Q9t҅s>?u5:śe5aag~]sK#'6s38MmhгLk+GCV0|bt!29^Wp\QEO_SBqw-MT]c)2RpŅN9~o_TDʮ}P߀czu.l^Ҕ[^[ 0p aaD*07APbeTIgҔ+xM H(aI=#)p%PsJ$u`aaAy-V< A9i9RFt;6(O MM2 䡃KIJP&n&+#4&['(9?koX3LKgOu`0XShK6" ·SoO`ԈjRH _\OJ.vvJ|{WV9~4MߋkfidUޱnߌL 45{~ŭ=M {Ô]kYo> v-n4il󡪢䋓q'.Ζ 5GaAg]^4zmYOu :!%ؤ}K]Nin<4(Le4]5ܧ(:KIJ9 uT5֍NO*H)Bī1>gpL׆A%YU$od&Ҟ<[[[޼RTֆƺFK.Ql@6rS_?Bu>w6FUUnolUQѩA^qID:EYVmjtvzR]]+CHLzCOƲB2riuY)% |YW+S? T: KJ ,p6՛7;<4Я#^AiU.))jhѱ>x:E{XEZb288C Α?8zw[jZ+{^e{zL7;ĸL_Uqk|3G$ ~y=;i7:Ӯo CD_9 C"u7wv5uv# qnpbyNs] @M]mmUc_G;6nkkm[YM>eDaN\>7m`ؙښWf VM-~Z8{vCE߼ki[mS@XLv6N.鳽]׮E$D@nlmx2DT̅;Y7f=φ}Z;t\L\GW/BBj˪j?'Kr,..^{w¥`Wcov;9w[_߶|`l Q@{ys))W5 ,>^Mh)K}#+jn%?{ys!Ws %]:iz.54v?%GouuxBwW8?݋>uY\ڳkۺ\qn&wslM~x3494ygߒR-5U@ h.Ցh?(ç&y&8GGEDQ,u숌 4 ; Mv%&|m?8JaJ TnAhBZ,4>ASImEgGom*r kT60^P Vq:&4MvQFX[ R~s; 568{xFU=t匧A?Y~  VZC%3Mr~xXj蟻x*!aA??jCX,-OGx[ /m1i`['h: ąٜǹi(+K bB6"o:تKYV"qΎ˒$aNC"mXDUxp^I^:~} .( o`q+A< %F+IqpLښ!;VaCV 㳲c/!Pz>U2Xhv<;3nX;VHjI{!腉%-Obғ_؜z : e`Пr.zkuv%>97U䰡sqZ)XҍB&4}lCPۤkOu7w {0j!]KY5ŪǏ.h8 CKE{xHKUO_ 9N=-_+%Օ}dvv6O/.I)!0y|.(ނ_#,> 4)3ɷ3xҏR%0N;{"(.&tT(pZ ;[r:zZ8Y9={DѸ79L7|&$bgK>!DDUXV ϜHXE9ٿ$?叨V[Q賡\C!U5%ߌMmHgʭ{08\[`bnlS@8|jt{[SW]m`._91i665hj W&c}ʆ}K=Op$g]Đ*tfrXd q5гAc|p]\gn궱nksմz S/l[XY^9|B[Z*Qೇڏ:ٟUP_r3v͇0[Uãn.ƞg?Ha%,(XP64*7B /ee?% LN˸?߲:5egt8z\ba8RΡc.ANGm]4v{}k^H|ol4oܙ01~a~9_Gjss[G^Ro&}o9^u>#UlǎGEi=`0X.>:uE TwOJru!w-~)'- 4YUSiqrnrif9TYp;[p:IOz@UVZm4;?8:jf (V6CA۠UڼA.@ܛ:ҏT֗ioYeAVl,{ed @ld`ku ]eTRmVw??_[-LG08goEh[GHdkA1ICS 6& `Z\7??dh +/\ܲ[Zd6pV8xbe݂a栽]! iA !5bA!9 {Xq5&A$qAPcx%U>Hh҂,T=)*ML,"Ic? "jJH&-lqoƊʜ\$~N u:xPֵl*..ҿ~H `t-ťڧ|ll 7Qs  c,vbuJppذA+'Ozlz eog%OQ}3wc/|/?jY\|B/efU܎I}H+831ojzpz*ػX_cwaдw&&5\;;F8q9~::33u<4֍8iWzv\NL 8Z`ddGNUS&Qie?!@]Ecbryt~BIJFc>}n*ZÓ:<~/-WTMO}fo!`-o%-ﭪOM }qQ NG^>x> j,4[ْ׍4hib984\3'RabԕG $GPHxdm\WWH޽hhwN,N6U? :zk{i~Aaa~A䴻rs 5߾4wM,525{n|b~ܐG7W2o.CZkBQ\݉ssdxe'.1ŋC.N K[z nzrҹх!'JʊV5e>~Fb•SjFG ^=V?]^Ӑglh@Kc|XQ{ ϟ/g7ִjzb #Um?x0mU=g|3r{ߖ}zv[BL`g,~_o& ڜ~7T2wҗ"(0EK(2utVwc'ayqmVCj:+>kfvx,6d@O<0&(̖ IPR'֧9{sM(R|@8'i5GАg|2}!h I4h'm _߆s`hVatUL %v)$>鰖%(HRWD,S&h6_C+TTF^af]#@W}$oU'̄#vdYIaS]*jik ;egQR6]faeGWRSiqTaA$Nߺ˗o}oq?&XANtTF2uvNfdqVM^oIlJLu!m5C,ph.,7u8ϹKT\ĬN:|wQQo묮oUFc“COtEYUCH^;AGA~+CGǧWJxp/km<{ IDAT}XBgacjmm!q%d׷f|.73.MC4*#]lPtwנI PYݜl+R"PQkh_TU'L0--60,{HM DE<ѷxֻOu48r,,~ 5W|NNZM&:9??/`qO5EyjZBY9|i.|b}KS!nN%z;>x]+*4RESĩc ˋ&63'UDG\S <8}k S{O>GnqI&'E}*)}(yȑWΈ?yZR2 pwNSѻwÇC]#3Ms/UUTV}|ӧ܏iI>5238x-)΍D[ yiCvЕ%G9m D^Lj3g{'&V|C~15m`w|i~a}{Ŋ MVRs6 ѷ1)ö:N.6 /ߞX _'[u%I#'yxْnzzjm:SsQZ``ϳ^'|ea\p*0\]M*16/80e"({~ɏ\ pxٳl4v|JmW;:WwRc*bb$ܑܼBqn7#߻joN yϯ.άkۼFU^]CV}BFJEQ@\Ćf6I$DF,)*k*gT^ f'Xev0F a٠l 5I1`һC%b ie 2C'ByqL#/Qx.QZJ_kkg",y`y琍$~?+ێ8,4}AbAd[&7LXl>gW=D-M/SH?ȿӳ],ΊˈxZVec ѽsx>7GS+`H Y[mD5. v,DHZD(yJR: c2sP ac15x:e(ژSY$48Ȕ }{3( 1=,VPkkHآaoONXrq"bO1yE ;֨itλ̷vaJD벾f[qv[qmUP޼;{*etULtO`7YO/1_nf .Q.Fۚ$=_c*4e3/{S~"w7s߯?vgϠQ!>qw371huYՊ* d)/SP4wcEUI FKèȩ6,W0/`,Y%sXdDDѩjjjmR)ɞ'iwTpteSm+4y/'o'-.Ea212)Am)ɨnIe?~kSp?'G+(z:-xpH,FQFyry) WHtz”&Hq4L ?WUP&6dΏM誢J+/ T ]XRP֤gN<^K/Nh gY^x*r^ƴ1Gx챵Q$cc√^gOmENLMɄnkNy9փNNW~hlD"S\r.ncd{·zǠճN_X3+-Vk4>xKDw*uLx/.~k iB=ӱV#~92Ƨi(3tho}#hgm'(A롦?<Y :0ftd^nni דN]is /QZ9HGɗߙl GI"_MM M7z1:%Y/c>}BC ~?ֽeaEZ{xX]i,il1Rz72嵔(KOw61ć·;u{F=g}^L**2!zGӾ?p&I^5{>pwK>tJD&f6,9m]E!bNk ֯>Q?Gq'B$yrX4m흃_.];-0q5'e=y+@+זk 1렧t̨kxVM^9$ '$GGY\˝Æ|kkVr)"DS+?C= [ 2?[awE+uI'LP =|)( ~}-hz۵ξ}@QlMJ{ULﮂϟ/]$Di[p/{m{:(q٬7 r{'d> :v3xu14w7N>~d1,z-8BlpDp.Vƣ*;;ZbFƞg'f#WS<?0;2ӝ/cW v'<\zʣ;WZWWcwX/aĈk6*a':+}CE#Su_ `cMɈ=fsa2b{LNP9w>.N뽻q$*(<%cAnLBv懻/>G3S^ ?vփ x]7_8ً^xyѨqw#J KЧ#%>Б-x$mmf]E^U5qXض}UڈxFҵ-l&uLj+,Ma\ |B8tO M2lmbY8sûwkIp54 Hl\)~>;-Y*vu()-Mms-]zwg4- "p"X⪊?APѤ! ¢b2ʇ9~)C< v>iI.2 8#/,2 _1083479128&@ok@`=?&dK&dKOle ObjInfo CorelDRAW RIFFz CDR7vrsnsummWLIST doc mcfg *4 @ @?88 8c1LISTXfnttfont @CommonBulletsfont#@ AvantGarde Bk BTLISTfiltLIST0filcfild$z+d@<LIST0filcfild$X5d@<LISTdfilcfildX@<2ddLISTtfilcfildh0@<?W2f2fdLIST0filcfild$\f@<LISTfilcfildLISTTotltoutl|d??d@<outl<"d??d@doutld??d@<outl??f@<LIST] stlt PX50< |5J@@@H 5@B@B@B' -D c9 V? c5  ncd9} .0H`x p`Q A2J@@@!J@;0DT!X5J@;0$4!tJ@;060J@;0?\,H, t, ,$$lpBullet1HBullet2t(Bullet3Special Bullet1HSpecial Bullet2tHpSpecial Bullet3HDefault Paragraph TextP05H 5D 9}2,lDefault Artistic TextP05H 5D XDefault Graphic< LISTuil LISTpageflgsLISTgobjLIST^layrflgsLISTFlgobloda99 (49U ddGridLIST`layrflgs LISTHlgobloda;; (4;U ddGuidesLIST`layrflgsLISTHlgobloda<< (4<dDesktopLIST`layrflgsLISTHlgobloda<< (4< WdLayer 1LISTlpageflgs@LISTTgobjLISTPlayrflgsLIST8lgobloda,, ,U ddLISTPlayrflgs LIST8lgobloda,, ,U ddLISTPlayrflgsLIST8lgobloda,, ,dLIST@ layrflgs@LIST8lgobloda,, , WdLIST grp flgsusdnLISTlgobloda$$ $d+LIST\trfltrfdPPP| -=_9V@-쉐@LISTobj flgsusdnLISTlgobloda4PTX\` d.kEX؊+jrL{T{җ{L_TQH8"XM1fDfDfDhr>n2 ؊ DDTDDXz+<LIST\trfltrfdPPPY-=_9V@-쉐@LISTobj flgsusdnLISTlgobloda4PTX\` d.kEXJ4AH_~HޙޙޙhtР;>.6җ6l6җ6<ҟ>jJ DDTDDXz+<LIST\trfltrfdPPPY-=_9V@-쉐@LISTobj flgsusdnLISTlgobloda4PTX\` d.kEXh52lb6"66VԐFxX$.3!v:Nv:v:VLQ07&f2l TDDTDHz+<LIST\trfltrfdPPPY-=_9V@-쉐@LISTLobj flgsusdn LIST(lgobloda4PTX\` d.kEX5$ wĚtGړH[!4e(z@XQ `'N+ҋh\K(bpGb&bv ('̢>P9>PV>P4ڑڑyڑwhrH w DDDDHz+<LIST\trfltrfdPPPY-=_9V@-쉐@LISTLobj flgsusdn LIST(lgobloda4PTX\` d.kEXL$TSܔ0ZV$P ~@yܖ`bRؖ|6Ƨ)̦:lҥ<2.N3~:V<ȜEbpWƙl҉#/Rrz\d\] <ޝv v3o >*d$TSܔ DDDDHz+<LIST\trfltrfdPPPY-=_9V@-쉐@LISTLobj flgsusdn LIST(lgobloda4PTX\` d.kEX5$:fdQ;dQdQ`OFʛ,40pEFd4Fd&Fd vNfb.t.\& t:t?|QC;CCp.nLfZBh8< DDDDHz+<LIST\trfltrfdPPPY-=_9V@-쉐@DRAWBITMAPS&dK&dKSTREAMSLISTSTREAMSLISTDRAWPATTERNS&dK&dKSTREAMSLISTSummaryInformation(_1083480955 FE)dKE)dK1Table  Oh+'Oh+'0 $ 0 < H T`hpxNJDHSS CORELDRWNJDHSS1@@@`@`CDR7 [$@$NormalmH <A@<Default Paragraph Font  l,b$Q \s _  @n( N 6   AB S  ?^ 4@D `@GTimes New Roman5Symbol3& Arial"heFeF!r0NJDHSSNJDHSSCompObjhObjInfoObjectPoolE)dKE)dKWordDocument }  FMicrosoft Word Picture MSWordDocWord.Picture.89q  FMicrosoft Word Picture MSWordDocWord.Picture.89q  FMicrosoft Word Picture MSWordDocWord.Picture.89qq bjbjt+t+ }AA] UUUikkkkkk$ZNBU3"UUUiMiiiU iUiiiii E'_ i  jUmHN N!!"!##$#%nW Q \s PNG  IHDR_xP0MgAMAPLTEٟ pHYs.2.C҅ IDATxMlGYuՐ KU/HUOHTY\*Q[+H\!7KHB9p"Vp&HAHjUFm߆o=gcvwc_sspc{3]!hTzzzz.bcr~+6dߒG./!8U y%2/;?z E,l Al<Lv4BgV_'hDoeK;-;6 F(=Ҍ1ڧW*拋hmE2(c{v,?!ǞAkkG_M7'(դͱЃ O,=0φ 3jj3)9DXȰ?0aW;dW?A|!ƪ&igot87`ڴUbNuU3g!-l\C/='Jvlqߞc\?J NSrX[5Fc76ʱ~X ֧>3{L#=Ik{S:cͬ,b&kYj&2;kfՖXdKc S)a! e_|xEaY0tb VMZLc6EE%tF@1}lpd71 zc8`b}CGS\ -Vh2̀:.a0#@E}wB0;2cgx1:xnD)8g@dD;36`cf30BEV!}M3kc^g Y<;N154Yp 0&mCx: |' e IXt= üt*F%srL1"r,9Zl,6H"#ݱ<2XNydFq43ςLtn鳰jαrҖ%igM:,PaIYLSb&Ot׳"f&g9f%X Fsa0h9AY|05ouXlիB c3tP;Y-v' ouEfP[Elb?5|[- G˶9 B Rp seǺȇIO\h3m &)RbTS. D:KKd2Cso݋bl~&D뱻ysb3wJ,yWR29;٢ٓX z \ qGT†DKcA Ca Οw8!C<6W qG$\` ܢ?JbO`RK0 6D8(nS n/y xЋ,àwWS zX`DVRw"(5b)0~Gj,rUW06væfқ} 1}%zUC1Rd]tcp {0yqlI Ű0lԈ6m ۄMs2f5ag1<ڤq3(f9V]UȰ=MjhmL3(s, Mg(LS7 <Ðm Fy{940S`v,n^̱>ۍ, v!hB?\`@aVY"aF046|:@Ḯ>`Nr8 n'H#)bs%: lzkfKXSjTX`EL+$LnS,REJd]Y]όT0+eq'Sa*51Z9Yj dXrJD`#>sga|u&>g ϱ)0lgʺ:pL:AâB zuXk1;m7E4<,1 4>3,Vw?0`سYvyx ;- #Zݛ?~χ̆)w=2ϰ3a4̤T30CY303ì5i0+l2f0YFvΤmG52G`+F+0Gs9fHo sëF`fPV/G&׶`m-FرAYf4CY541w؁Xw pn`i0gl7vX'pn#;L5eֻSՔQϡ~vm4͆BϿks5=a?gNj(j9 cOo񳷋/)4Ie. 08{] y _8̴jb?nxtiq}IUUU#6sNhn#c۶ 3uֿ]afVFؤðjjc'dDy ? @ A B C D E F G H J K L M N O P Z S T U V W X Y s \ ] ^ _ ` a b d e f g h i j l m n o p q r ~ v w x y z { | }  ՜.+,D՜.+,0 hp  NJDHSSl1  Title 6> _PID_GUIDAN{252222E5-4491-4B86-8CD4-604478772746}J>u~N%i4(#yPA!,\ZJ*k҇dl-HIR:,ocb/(@zL [u[h '4tYVRcUQꦦsK|ζ6mǜ]XZ/_Ydg?PeĤم嘘+ZYjzy/#SSqrZYNSS׃{w޾UPRvMJw.=2?~wcG峱98<عwc,1Ȟe 3ƚ%.IE #%ZmTDPZ,P!:}cf̘Ŭ۹suz}>\=2=1*21b;ĝ&QÖ֎8uvVEug 8vϭ,Gt&-2*&:>wnSF>ܼ{Fv.Y|Y]tJVOB3S/4:9~n^ ]ܻ62u&pSs{ѡA[wϝJl w05>{)q5m=Iq1ϊ^~2,}Uӵ谰 ŕ5{>7Oi~',-v}4/\N⍂[Ř\wzNtToTCEE+D{ u=COT *I_Nv@ssbrrdPz?ʟpEc|ҍhp K)A(h n]x68VAC\Z?,~LVK>{ڭ%ܿQ'Դ47qͫպ:啕'w+Y5w̎pɽ`Yx(SA3kVC7NxwE^QǎIW c3,fx\ /ĹMNOʪ4<*{bp/!4pUg毺nLKfC2euנ nh[^e@Ѵ0ã]ڱH dOBv5׵ ګ|n#{YW+k8sۘYb-KMSp]~ycy~8dOK*͍v~npH8jKd haC "*9>mT^^ @r9 }6y1X39Ger؇v`qF o_:~&!O_00uŇM0gjq^O54 xBQ$]Ir% Lb0%ӓ?ubHă{c-S!Ņy9w$;84D\|N\?;ڭ;7j?qx\/}ٍۗX_amez;lzwsL({#£:յfNY9c Oy+ `ӻ>0b*sct* zSK0~ljnƵF%'; $~ Eg[!GG'le.L`fhz> LA%C\URWܾ[|Vi/FԱL#:Zd޳4ԕ^RT\*Y~nV(?Z6m\!֣kke׬AktMZtf0j$ǥq{UE%᪳sD9Ω !'H@$ۻ "ʢ0qE&LXcфD*F)q0y:V{ `ii#~}1.7:YU[ "?@Ewo34ٯ\p4GzXzc"#^aH3AJЩdUq\PGK VDE4aPmC$\&I8جWEcՔ:{ul[\A\\2KDL;d8Bil\^&'01<ԡC;lqijM&:v )k_CگXoVY#`MqueqGTv۽!\ϼiY*DD7#>yӻnw67gU0s`jky2<U͒Rd5N]M(!OLR~vt*g|w{2|&}CCj S >twu5MH :s-`t[CZh|`ρ}c`t >6}Rӥ0Y).Ξ< 陔@gӑp}~>sSkZ\ZFk.Y׮[,sYL]$z}_Yijf pstO㡵Up&6"@A}GLc8Փq6@ _ @hnj=SSK]K2eOKiU>.y=jy-!ﵷ4Z?Ж]6{z^HK\^\}HM4(߀=F?|(<<opx6Cwod^|(~x=9咤Lr>!'OTQ8yIo,p=xk*xBR m5bs!AE9IU5mC9WOGŦyx945DwcS]7 Tr*"lM:77ںgW>^(!Y;_$6t[j^'5IBBD2пw%'JGmI =H>TKyYL#{Ҧۧ_4^ͥAl6ՏӞv_ 1|-ԷzƤ}—3A8R20E(sE~" BIIHC&0|1I :YYRr *N'`rP"qVP $R~dx –%FZ K{ z;`*tK_* X칦ZL\ QeQA*mn<5I(jkȓgq"lIʕ *S&yP8q~(8cf,}Gk.S-5(W0sbx3_7=8S[35Msv,t#V\Ktܷ&L_).+u]iF>V&O<2:;>|xWZrM+#,XmwǢEyܬ*/j_6zCaʹ[}&VOI4*S|7Kghu\ZK3vfB 陴t|g Zut f3C## N~}_o_QMek PB Մt ]@;P.(;(6 ("cCK -$!>ӽsܛY=)g;6edz#4:%{8a7瀢#S%x?7/ *(syEuܛ.+Fmʣ=܂*Ӯ~xxPgcC=wTTn}f1qkCŸ}YnWcXi[LǕ ??ŀůC#[S'(a)Nqɗw=[9Xڃ-A=e=GoξuNK](B{!4ۧ{y50x- Gz~Mˍ ~/$7eaևwqaXOJ^[n'Y_FJ˶X`1awyV)[Ε@#[:m>~CUfIZ_yA樺:ayqyq2Na1U4մUXQV Y_Ur|2A8>#omldpTl9ϥ/CC}umq> ߂vq4u(BK2AnBx::O[MDQHycK Q]Am pj85$ZdI{gB ++}L\\m̭Lim=D"E||r]"w (+*x>ϳ7em6 _hcobnqQJsǞ<}a^Y7v38RJuI \rի&tl2ۋ̿~7ݤV~k"윒i5Uu-4]$[#$FyEY^[P<3j\,b0ʪZ(K|ֹϟrDDrDR_HL_B4p%>o߽->s?#둽O+7Ȍξޒc #y挎P Zz*iT#ˎ7껽'} O$ih!pՉ%eose9agxhP੟ΏMMp=Ύ΋o ؼioOOOMa[·b^}$[h9Ķ]1I ;4UCY">/Б}WXHtThdă6e^ >~ aסxssS_>plnvinf)+H$ tg{&g*"]eSGoD5o)hh[e0rXR73EGL9&w0S2,,894"-36(h$bR^dI Z"C0d6IXᜩa9#G7hǓTG&RʔQ4&&JcB[GZS)4Z s?XۃG$g 枉K9zeOAv)L?(?@ /7ۋ6g yŏ1bh_`5(DOՍt"C _p]ŇW$F-HMg8FbPC%]B 9M-s%Sz*nŪ`XٞGxa`Ԝn_@%̳W9MuekZ*k[:#ϴٸ:UoӮҧ&o}c5ط͛[6&ښdz :89sejc3SfUUS]6)iWQqQ}=E4&=l/2r__D >WRF|Gx&4܂Wl0 &GZ4 $4Z3# @c -,]pR2659?wpWsG;;4Z)1;`}' pҳ SǨjDq0|cS~cvt@DhnS'p oE_"BvVũY~QR*\$Hx/ST э"Wz0b1 0x]  H:`K$%Il A[ >_ %Il A[ -At H:`K$%Il A[ -At H:`K$%Il A[ ?g(۾IENDB`$$If!vh#v#v :V l055 / / / 4T$$If!vh#v#v :V l055 / / / 4T$$If!vh#v#v :V l055 / / / 4T9$$If!vh#v#v#v#v#v:V l t2&&,&&0  55555/ 4p2&&,&&Ti&Dd 0  # A2%BYzL.(I%`!%BYzL.(I>?H@%x{xWG@p )PJKq(%KqEjP(}ϯޛg=;4iDFL8o{J L}S[)6wOFoǏ7*,ZSrh}ɭ%M h)L )_H^&9udc^K . '^Fr!7 -DBpaw =缎%K,Y]J*(]j :d妍 &[/sl|gd~vD: ijg$K$GjW$D p;E9[yPO帥t륗FH/MtRAJ '^a?"LH/>Ewo~+,Ҟc%^%MѤn2NOZh~W{\6 qH5{vr<pjm9Vt5mpw Fcέ9>'zű6Xv[hmVzȠլx@{񓎰s:vAtE"nᐡ!0QLlEygkЮ0@ Ř7':U}:Q-.LTv*q }8.BU 5G4ҵ3mz6z6#ڂ(8f5qzq 'XJíV B7Í d6ٛRҜ• ;wpY+\Oޚnn1Wś+Z#+k3N4TpE99x+Į8{6zk'w8+k8N6+z@GBDS/^T'7 ԆsWet!Ί>gq/qt[d>dv|&x )kפ&8Qs(] 2~I_YieDNZ\r׾'6D^X_yo]ĹЅI WIһI.U>wN%ECey=}r_9{s.$uE% sS.m\ara";l}Km̲2ѶP-};—&v\j)  p ϖ:gϪI%mzj 1Vwtd`.Gmt1k)|r9=p W0gNYJO5\$ 1RY p`g^[Z?b w5|ZMjUp|B!|t>GsTU*HI)&4\rH$$_ג@2Yb1Y&*E$ AOIl˔{ 3%e؜`z`kQ\`Ni,&= rZ7x)vD8?}[O~2;-$CďH)%U4&ґ[H?n##`Ye#dp{mWn%b!bċ33!#NZHzi,Y{ U$V R qYFK | Ƽl9tG-}Q"CU_]Uqr1|H>r|i)p' WGO^O < $L2 ߬DB_ܖXs^ PQ&EUXTCLQx `_N+s* oHߜ決jWޥZ* *iJΦY9ZU XƦ-o݀ciLrK5!|Ĩ  ?s?S]<{`ƻsz+w]BO1[x6n64Z3i0\?=Ҥ\AcqZcwgiS}8e8.Gm:;`i@m/-H <\l+-z6<X< < <Nu .]AtMHߙy6Lw&F{'u-]Uz[5cбCwE|him{|>@ˁ G9u{F-f_Y>q]^`>|yS].{obzc\&{s` X/ݿmB_I '8lĴMK'S] /Rޱ?݄ゴp\jqUz[|O K3<`15`;vp&C 3 5XwR8` :j@>۴={^k$w3yU#pb-Ě )cn8/x%́M+v]tU>Na|ŒD^P:!.o*."ٸ|>fkZKBpI~.rv?&+b2/ TP)~{*HW\[wvҟ'Znp[ि`w- . 1L27f? 14E߳1woY7[NU¯TTů:P9`ڒ4RUfAT2:håea0ˢ ,fYMna¯8YJoTpG}5KxIj=*`5 XU *`M$Tԇ {'xI6 YW>]Χt1_:fqRYl@~ Ml.wm5ϵҶ60|.ɿO~G9'\bKnK )HiWCʹRuꮷrC%}+iVJCX @uMIrJL.r~w8ۊw(~lu]Mx VYO<2pOK-,#.7AIz}!\`bt5M4PGP;E55j0䐑H>:#Yi!})ħGY 8Yi<秞jP D[Pd`s!d*~ h\ Պ],ȈȈ+:̌.ҝJ"_b&T yW*Bd?)dktq Q>/I2*+ץߐfh?s'e+_D&yʫ/B5 UwFJNT]^3qx***o#:Kii)bⰖOZJs hOv$GԍoQ7v8/ׁ .~菄]`R:[<=yye9l؉?3*.0 {_A>JO #QU~jrd éOC4 IlS|@ժ盷2`I^V]l$$$Uй"++3q2f/]ʏ4gNoVަ;yzFGMs[}M4iRҨ-Ձw{QQBeasxmX=̖r_IGMQ Uyg6'!ԦqS}g f$p~2mGZ}|֎Sv=`Z K:@4KWHJ qՀ k_{ۿO{'k[w/I}3G7O}pK z s1k#scϗn]$-}s1ǧ#.*F=FO)=ܨKqMT-5lȕxVX>h;6޿Źq8;ęetIprHUW#nl||iSߖF^-epW;sXt7gCWjZ8eY3KGUh)$ǨLyxv۴{CoP% 9sxULm7[&E^ko +kKxx͉i鐏rj% +IN%mtN /UӡUSINa::R#{MԳѳu4Véڏk{* (V!RH iɅ g3~g ̮f>;1oxppoǜ\=rj]Js%LF8\K/ l+=߼u?ecc䴦ŒIn*VXZRH9)lTdQk?[e-Y-aZ*i!~ZsZd5$6M"3of==q&k{[/jt9ZO7hIݧzXc)Mg56\Gr|)RgOz僧z-4L8 ?Iq9圆a͖rv zxCy펳l-=FA٫%JSM ke'O{rW _=>}]ٛSwpt;[B}oNL@>Ql}VWYy)lRH6s^r NFφ_=NipF#iI2cRB$@OHo ՠ:bFuC4׷:YFi|ɭ4U@ӂ[X-nq'k8lI ߅C!~uyunֱ QG00`7':=ت%x9wi&v}inteъp5Ŵ -!xŵ8孝G[vqy.vC B ͉Nǧ_g}XggX; ךK~P_] =~R DH\[Y "ޚt d&ddd1d9ۣ 2ze fD7?o~B{AIM*GOmYZ ۘޣNBa<޺=Noĥ~za~B x7'uTWqWsWq̂̆̕ζP<ֱX< ́ wo3{L#=Ik{S:cͬ,b&kYj&2;kfՖXdKc S)a! e_|xEaY0tb VMZLc6EE%tF@1}lpd71 zc8`b}CGS\ -Vh2̀:.a0#@E}wB0;2cgx1:xnD)8g@dD;36`cf30BEV!}M3kc^g Y<;N154Yp 0&mCx: |' e IXt= üt*F%srL1"r,9Zl,6H"#ݱ<2XNydFq43ςLtn鳰jαrҖ%igM:,PaIYLSb&Ot׳"f&g9f%X Fsa0h9AY|05ouXlիB c3tP;Y-v' ouEfP[Elb?5|[- G˶9 B Rp seǺȇIO\h3m &)RbTS. D:KKd2Cso݋bl~&D뱻ysb3wJ,yWR29;٢ٓX z \ qGT†DKcA Ca Οw8!C<6W qG$\` ܢ?JbO`RK0 6D8(nS n/y xЋ,àwWS zX`DVRw"(5b)0~Gj,rUW06væfқ} 1}%zUC1Rd]tcp {0yqlI Ű0lԈ6m ۄMs2f5ag1<ڤq3(f9V]UȰ=MjhmL3(s, Mg(LS7 <Ðm Fy{940S`v,n^̱>ۍ, v!hB?\`@aVY"aF046|:@Ḯ>`Nr8 n'H#)bs%: lzkfKXSjTX`EL+$LnS,REJd]Y]όT0+eq'Sa*51Z9Yj dXrJD`#>sga|u&>g ϱ)0lgʺ:pL:AâB zuXk1;m7E4<,1 4>3,Vw?0`سYvyx ;- #Zݛ?~χ̆)w=2ϰ3a4̤T30CY303ì5i0+l2f0YFvΤmG52G`+F+0Gs9fHo sëF`fPV/G&׶`m-FرAYf4CY541w؁Xw pn`i0gl7vX'pn#;L5eֻSՔQϡ~vm4͆BϿks5=a?gNj(j9 cOo񳷋/)4Ie. 08{] y _8̴jb?nxtiq}IUUU#6sNhn#c۶ 3uֿ]afVFؤðjjc'dDy3{L#=Ik{S:cͬ,b&kYj&2;kfՖXdKc S)a! e_|xEaY0tb VMZLc6EE%tF@1}lpd71 zc8`b}CGS\ -Vh2̀:.a0#@E}wB0;2cgx1:xnD)8g@dD;36`cf30BEV!}M3kc^g Y<;N154Yp 0&mCx: |' e IXt= üt*F%srL1"r,9Zl,6H"#ݱ<2XNydFq43ςLtn鳰jαrҖ%igM:,PaIYLSb&Ot׳"f&g9f%X Fsa0h9AY|05ouXlիB c3tP;Y-v' ouEfP[Elb?5|[- G˶9 B Rp seǺȇIO\h3m &)RbTS. D:KKd2Cso݋bl~&D뱻ysb3wJ,yWR29;٢ٓX z \ qGT†DKcA Ca Οw8!C<6W qG$\` ܢ?JbO`RK0 6D8(nS n/y xЋ,àwWS zX`DVRw"(5b)0~Gj,rUW06væfқ} 1}%zUC1Rd]tcp {0yqlI Ű0lԈ6m ۄMs2f5ag1<ڤq3(f9V]UȰ=MjhmL3(s, Mg(LS7 <Ðm Fy{940S`v,n^̱>ۍ, v!hB?\`@aVY"aF046|:@Ḯ>`Nr8 n'H#)bs%: lzkfKXSjTX`EL+$LnS,REJd]Y]όT0+eq'Sa*51Z9Yj dXrJD`#>sga|u&>g ϱ)0lgʺ:pL:AâB zuXk1;m7E4<,1 4>3,Vw?0`سYvyx ;- #Zݛ?~χ̆)w=2ϰ3a4̤T30CY303ì5i0+l2f0YFvΤmG52G`+F+0Gs9fHo sëF`fPV/G&׶`m-FرAYf4CY541w؁Xw pn`i0gl7vX'pn#;L5eֻSՔQϡ~vm4͆BϿks5=a?gNj(j9 cOo񳷋/)4Ie. 08{] y _8̴jb?nxtiq}IUUU#6sNhn#c۶ 3uֿ]afVFؤðjjc'dDy3{L#=Ik{S:cͬ,b&kYj&2;kfՖXdKc S)a! e_|xEaY0tb VMZLc6EE%tF@1}lpd71 zc8`b}CGS\ -Vh2̀:.a0#@E}wB0;2cgx1:xnD)8g@dD;36`cf30BEV!}M3kc^g Y<;N154Yp 0&mCx: |' e IXt= üt*F%srL1"r,9Zl,6H"#ݱ<2XNydFq43ςLtn鳰jαrҖ%igM:,PaIYLSb&Ot׳"f&g9f%X Fsa0h9AY|05ouXlիB c3tP;Y-v' ouEfP[Elb?5|[- G˶9 B Rp seǺȇIO\h3m &)RbTS. D:KKd2Cso݋bl~&D뱻ysb3wJ,yWR29;٢ٓX z \ qGT†DKcA Ca Οw8!C<6W qG$\` ܢ?JbO`RK0 6D8(nS n/y xЋ,àwWS zX`DVRw"(5b)0~Gj,rUW06væfқ} 1}%zUC1Rd]tcp {0yqlI Ű0lԈ6m ۄMs2f5ag1<ڤq3(f9V]UȰ=MjhmL3(s, Mg(LS7 <Ðm Fy{940S`v,n^̱>ۍ, v!hB?\`@aVY"aF046|:@Ḯ>`Nr8 n'H#)bs%: lzkfKXSjTX`EL+$LnS,REJd]Y]όT0+eq'Sa*51Z9Yj dXrJD`#>sga|u&>g ϱ)0lgʺ:pL:AâB zuXk1;m7E4<,1 4>3,Vw?0`سYvyx ;- #Zݛ?~χ̆)w=2ϰ3a4̤T30CY303ì5i0+l2f0YFvΤmG52G`+F+0Gs9fHo sëF`fPV/G&׶`m-FرAYf4CY541w؁Xw pn`i0gl7vX'pn#;L5eֻSՔQϡ~vm4͆BϿks5=a?gNj(j9 cOo񳷋/)4Ie. 08{] y _8̴jb?nxtiq}IUUU#6sNhn#c۶ 3uֿ]afVFؤðjjc'dDy3{L#=Ik{S:cͬ,b&kYj&2;kfՖXdKc S)a! e_|xEaY0tb VMZLc6EE%tF@1}lpd71 zc8`b}CGS\ -Vh2̀:.a0#@E}wB0;2cgx1:xnD)8g@dD;36`cf30BEV!}M3kc^g Y<;N154Yp 0&mCx: |' e IXt= üt*F%srL1"r,9Zl,6H"#ݱ<2XNydFq43ςLtn鳰jαrҖ%igM:,PaIYLSb&Ot׳"f&g9f%X Fsa0h9AY|05ouXlիB c3tP;Y-v' ouEfP[Elb?5|[- G˶9 B Rp seǺȇIO\h3m &)RbTS. D:KKd2Cso݋bl~&D뱻ysb3wJ,yWR29;٢ٓX z \ qGT†DKcA Ca Οw8!C<6W qG$\` ܢ?JbO`RK0 6D8(nS n/y xЋ,àwWS zX`DVRw"(5b)0~Gj,rUW06væfқ} 1}%zUC1Rd]tcp {0yqlI Ű0lԈ6m ۄMs2f5ag1<ڤq3(f9V]UȰ=MjhmL3(s, Mg(LS7 <Ðm Fy{940S`v,n^̱>ۍ, v!hB?\`@aVY"aF046|:@Ḯ>`Nr8 n'H#)bs%: lzkfKXSjTX`EL+$LnS,REJd]Y]όT0+eq'Sa*51Z9Yj dXrJD`#>sga|u&>g ϱ)0lgʺ:pL:AâB zuXk1;m7E4<,1 4>3,Vw?0`سYvyx ;- #Zݛ?~χ̆)w=2ϰ3a4̤T30CY303ì5i0+l2f0YFvΤmG52G`+F+0Gs9fHo sëF`fPV/G&׶`m-FرAYf4CY541w؁Xw pn`i0gl7vX'pn#;L5eֻSՔQϡ~vm4͆BϿks5=a?gNj(j9 cOo񳷋/)4Ie. 08{] y _8̴jb?nxtiq}IUUU#6sNhn#c۶ 3uֿ]afVFؤðjjc'dDy3{L#=Ik{S:cͬ,b&kYj&2;kfՖXdKc S)a! e_|xEaY0tb VMZLc6EE%tF@1}lpd71 zc8`b}CGS\ -Vh2̀:.a0#@E}wB0;2cgx1:xnD)8g@dD;36`cf30BEV!}M3kc^g Y<;N154Yp 0&mCx: |' e IXt= üt*F%srL1"r,9Zl,6H"#ݱ<2XNydFq43ςLtn鳰jαrҖ%igM:,PaIYLSb&Ot׳"f&g9f%X Fsa0h9AY|05ouXlիB c3tP;Y-v' ouEfP[Elb?5|[- G˶9 B Rp seǺȇIO\h3m &)RbTS. D:KKd2Cso݋bl~&D뱻ysb3wJ,yWR29;٢ٓX z \ qGT†DKcA Ca Οw8!C<6W qG$\` ܢ?JbO`RK0 6D8(nS n/y xЋ,àwWS zX`DVRw"(5b)0~Gj,rUW06væfқ} 1}%zUC1Rd]tcp {0yqlI Ű0lԈ6m ۄMs2f5ag1<ڤq3(f9V]UȰ=MjhmL3(s, Mg(LS7 <Ðm Fy{940S`v,n^̱>ۍ, v!hB?\`@aVY"aF046|:@Ḯ>`Nr8 n'H#)bs%: lzkfKXSjTX`EL+$LnS, [$@$NormalmH <A@<Default Paragraph Font  l,b$qzg}Π @n( $ 6   AB S  ?4@̆3@GTimes New Roman5Symbol3& Arial"hf&f&!r0 NJDHSSNJDHSSCompObj"hObjInfoObjectPool!$E)dKE)dKWordDocumentR q bjbjt+t+ AA] UUUikkkkkk$ZNBU3"UUUiMiiiU iUiiiii d7_ i  jUmHN N!%"%#%$%%nqzg}ΠPNG  IHDR_a?^gAMA pHYs.0r<[IDATxQ@]S$(@TePP!Qf]3ϴYw|zƹde ĤxxzRUf~cJ#[b!$ܪ/R=(;Qt׳Q?P27k | uKw ;3i~q!eBGti=RhI#N>^&B頶u[aWFc*!L%qkV"DԱ]}Bԁu D^>WԄig,|k7zRYD1ząLKrMOR޾AS}%o0wPa+Aw,1u hޣIENDB`SummaryInformation(#%[ DocumentSummaryInformation8c _1084964154( FE)dKE)dK1Tablek  Oh+'0h  $ 0 <HPX`ssNJDHSSJDHJDH Normal.dotNJDHSSd2DHMicrosoft Word 8.0@@Gw7@Gw7 ՜.+,D՜.+,0 hp  NJDHSSl1  Title 6> _PID_GUIDAN{A1264434-26CF-48C4-AF55-FF5CD2E017EF} [$@$NormalmH <A@<Default Paragraph Font  l,b$T9rFÿės @n(  6   AB S  ?(4@H@GTimes New Roman5Symbol3& Arial"h;f;f!r0 NJDHSSNJDHSSCompObj'*hObjInfoObjectPool),E)dKE)dKWordDocumentu Oh+'0<x   $,4NJDHSS Normal.dotmJaimini D. Patel2Microsoft Office Word@@rQ`@@tEK@@tEKN՜.+,D՜.+,q bjbjt+t+ AA] UUUikkkkkk$ZNBU3"UUUiMiiiU iUiiiii @SN_ i  jUmHN N!%"%#L$$L$%nT9rFÿėsPNG  IHDRNgAMAPLTEٟ pHYs%%& IDATx?D b >hH|L 8H 'ER*>JD(Q>Br@BsZgos尴80Z&j7 o' $P>C-@*$9[=C K LG|+2ԌM+٢bV7|vɼoJXt>AN:ZEwQEG]O ;JL7 ƺd _>7QS0=̕媖jՑ*]U6xȆ:"{YSӓyQ?$"\J%<ԹO{L%,T*[JS}#j3$h$0L:Vqђ n [MNr ~פܸ CvF%i"L *G;EIFMNh}w#a=MSQ~?&~G5s#.^6ʧݎJg4MT4q;Ah4]Mn;1⸸>~I> h:I|?<0^/Caa~IENDB`SummaryInformation(+- DocumentSummaryInformation8 1Table SummaryInformation(0l  Oh+'0h  $ 0 <HPX`ssNJDHSSJDHJDH Normal.dotNJDHSSd2DHMicrosoft Word 8.0@@(BN@(BN ՜.+,D՜.+,0 hp  NJDHSSl1  Title 6> _PID_GUIDAN{8129FF10-5210-4B35-A10C-5470BDA79CF2}REJd]Y]όT0+eq'Sa*51Z9Yj dXrJD`#>sga|u&>g ϱ)0lgʺ:pL:AâB zuXk1;m7E4<,1 4>3,Vw?0`سYvyx ;- #Zݛ?~χ̆)w=2ϰ3a4̤T30CY303ì5i0+l2f0YFvΤmG52G`+F+0Gs9fHo sëF`fPV/G&׶`m-FرAYf4CY541w؁Xw pn`i0gl7vX'pn#;L5eֻSՔQϡ~vm4͆BϿks5=a?gNj(j9 cOo񳷋/)4Ie. 08{] y _8̴jb?nxtiq}IUUU#6sNhn#c۶ 3uֿ]afVFؤðjjc'dDy3{L#=Ik{S:cͬ,b&kYj&2;kfՖXdKc S)a! e_|xEaY0tb VMZLc6EE%tF@1}lpd71 zc8`b}CGS\ -Vh2̀:.a0#@E}wB0;2cgx1:xnD)8g@dD;36`cf30BEV!}M3kc^g Y<;N154Yp 0&mCx: |' e IXt= üt*F%srL1"r,9Zl,6H"#ݱ<2XNydFq43ςLtn鳰jαrҖ%igM:,PaIYLSb&Ot׳"f&g9f%X Fsa0h9AY|05ouXlիB c3tP;Y-v' ouEfP[Elb?5|[- G˶9 B Rp seǺȇIO\h3m &)RbTS. D:KKd2Cso݋bl~&D뱻ysb3wJ,yWR29;٢ٓX z \ qGT†DKcA Ca Οw8!C<6W qG$\` ܢ?JbO`RK0 6D8(nS n/y xЋ,àwWS zX`DVRw"(5b)0~Gj,rUW06væfқ} 1}%zUC1Rd]tcp {0yqlI Ű0lԈ6m ۄMs2f5ag1<ڤq3(f9V]UȰ=MjhmL3(s, Mg(LS7 <Ðm Fy{940S`v,n^̱>ۍ, v!hB?\`@aVY"aF046|:@Ḯ>`Nr8 n'H#)bs%: lzkfKXSjTX`EL+$LnS,REJd]Y]όT0+eq'Sa*51Z9Yj dXrJD`#>sga|u&>g ϱ)0lgʺ:pL:AâB zuXk1;m7E4<,1 4>3,Vw?0`سYvyx ;- #Zݛ?~χ̆)w=2ϰ3a4̤T30CY303ì5i0+l2f0YFvΤmG52G`+F+0Gs9fHo sëF`fPV/G&׶`m-FرAYf4CY541w؁Xw pn`i0gl7vX'pn#;L5eֻSՔQϡ~vm4͆BϿks5=a?gNj(j9 cOo񳷋/)4Ie. 08{] y _8̴jb?nxtiq}IUUU#6sNhn#c۶ 3uֿ]afVFؤðjjc'dDyYw|zƹde ĤxxzRUf~cJ#[b!$ܪ/R=(;Qt׳Q?P27k | uKw ;3i~q!eBGti=RhI#N>^&B頶u[aWFc*!L%qkV"DԱ]}Bԁu D^>WԄig,|k7zRYD1ząLKrMOR޾AS}%o0wPa+Aw,1u hޣIENDB`zDd_a 0   # Abd7:nd7:PNG  IHDR_a?^gAMA pHYs-1[IDATxQ@]S$(@TePP!Qf]3ϴYw|zƹde ĤxxzRUf~cJ#[b!$ܪ/R=(;Qt׳Q?P27k | uKw ;3i~q!eBGti=RhI#N>^&B頶u[aWFc*!L%qkV"DԱ]}Bԁu D^>WԄig,|k7zRYD1ząLKrMOR޾AS}%o0wPa+Aw,1u hޣIENDB`@Dd (0   # A b۽*WᛦS4 n۽*WᛦS4PNG  IHDRNgAMAPLTEٟ pHYs%%rB@IDATx?D b >hH|L 8H 'ER*>JD(Q>Br@BsZgos尴80Z&j7 o' $P>C-@*$9[=C K LG|+2ԌM+٢bV7|vɼoJXt>AN:ZEwQEG]O ;JL7 ƺd _>7QS0=̕媖jՑ*]U6xȆ:"{YSӓyQ?$"\J%<ԹO{L%,T*[JS}#j3$h$0L:Vqђ n [MNr ~פܸ CvF%i"L *G;EIFMNh}w#a=MSQ~?&~G5s#.^6ʧݎJg4MT4q;Ah4]Mn;1⸸>~I> h:I|?<0^/Caa~IENDB`@Dd (660  # A b۽*WᛦS4 n۽*WᛦS4PNG  IHDRNgAMAPLTEٟ pHYs%%rB@IDATx?D b >hH|L 8H 'ER*>JD(Q>Br@BsZgos尴80Z&j7 o' $P>C-@*$9[=C K LG|+2ԌM+٢bV7|vɼoJXt>AN:ZEwQEG]O ;JL7 ƺd _>7QS0=̕媖jՑ*]U6xȆ:"{YSӓyQ?$"\J%<ԹO{L%,T*[JS}#j3$h$0L:Vqђ n [MNr ~פܸ CvF%i"L *G;EIFMNh}w#a=MSQ~?&~G5s#.^6ʧݎJg4MT4q;Ah4]Mn;1⸸>~I> h:I|?<0^/Caa~IENDB`@Dd (660  # A b۽*WᛦS4 #n۽*WᛦS4PNG  IHDRNgAMAPLTEٟ pHYs%%rB@IDATx?D b >hH|L 8H 'ER*>JD(Q>Br@BsZgos尴80Z&j7 o' $P>C-@*$9[=C K LG|+2ԌM+٢bV7|vɼoJXt>AN:ZEwQEG]O ;JL7 ƺd _>7QS0=̕媖jՑ*]U6xȆ:"{YSӓyQ?$"\J%<ԹO{L%,T*[JS}#j3$h$0L:Vqђ n [MNr ~פܸ CvF%i"L *G;EIFMNh}w#a=MSQ~?&~G5s#.^6ʧݎJg4MT4q;Ah4]Mn;1⸸>~I> h:I|?<0^/Caa~IENDB`@Dd (660  # A b۽*WᛦS4 K(n۽*WᛦS4PNG  IHDRNgAMAPLTEٟ pHYs%%rB@IDATx?D b >hH|L 8H 'ER*>JD(Q>Br@BsZgos尴80Z&j7 o' $P>C-@*$9[=C K LG|+2ԌM+٢bV7|vɼoJXt>AN:ZEwQEG]O ;JL7 ƺd _>7QS0=̕媖jՑ*]U6xȆ:"{YSӓyQ?$"\J%<ԹO{L%,T*[JS}#j3$h$0L:Vqђ n [MNr ~פܸ CvF%i"L *G;EIFMNh}w#a=MSQ~?&~G5s#.^6ʧݎJg4MT4q;Ah4]Mn;1⸸>~I> h:I|?<0^/Caa~IENDB`@Dd (660  # A b۽*WᛦS4 -n۽*WᛦS4PNG  IHDRNgAMAPLTEٟ pHYs%%rB@IDATx?D b >hH|L 8H 'ER*>JD(Q>Br@BsZgos尴80Z&j7 o' $P>C-@*$9[=C K LG|+2ԌM+٢bV7|vɼoJXt>AN:ZEwQEG]O ;JL7 ƺd _>7QS0=̕媖jՑ*]U6xȆ:"{YSӓyQ?$"\J%<ԹO{L%,T*[JS}#j3$h$0L:Vqђ n [MNr ~פܸ CvF%i"L *G;EIFMNh}w#a=MSQ~?&~G5s#.^6ʧݎJg4MT4q;Ah4]Mn;1⸸>~I> h:I|?<0^/Caa~IENDB`@Dd (660  # Ab۽*WᛦS4 2n۽*WᛦS4PNG  IHDRNgAMAPLTEٟ pHYs%%rB@IDATx?D b >hH|L 8H 'ER*>JD(Q>Br@BsZgos尴80Z&j7 o' $P>C-@*$9[=C K LG|+2ԌM+٢bV7|vɼoJXt>AN:ZEwQEG]O ;JL7 ƺd _>7QS0=̕媖jՑ*]U6xȆ:"{YSӓyQ?$"\J%<ԹO{L%,T*[JS}#j3$h$0L:Vqђ n [MNr ~פܸ CvF%i"L *G;EIFMNh}w#a=MSQ~?&~G5s#.^6ʧݎJg4MT4q;Ah4]Mn;1⸸>~I> h:I|?<0^/Caa~IENDB`@Dd (660  # Ab۽*WᛦS4 8n۽*WᛦS4PNG  IHDRNgAMAPLTEٟ pHYs%%rB@IDATx?D b >hH|L 8H 'ER*>JD(Q>Br@BsZgos尴80Z&j7 o' $P>C-@*$9[=C K LG|+2ԌM+٢bV7|vɼoJXt>AN:ZEwQEG]O ;JL7 ƺd _>7QS0=̕媖jՑ*]U6xȆ:"{YSӓyQ?$"\J%<ԹO{L%,T*[JS}#j3$h$0L:Vqђ n [MNr ~פܸ CvF%i"L *G;EIFMNh}w#a=MSQ~?&~G5s#.^6ʧݎJg4MT4q;Ah4]Mn;1⸸>~I> h:I|?<0^/Caa~IENDB`@Dd (660  # Ab۽*WᛦS4 K=n۽*WᛦS4PNG  IHDRNgAMAPLTEٟ pHYs%%rB@IDATx?D b >hH|L 8H 'ER*>JD(Q>Br@BsZgos尴80Z&j7 o' $P>C-@*$9[=C K LG|+2ԌM+٢bV7|vɼoJXt>AN:ZEwQEG]O ;JL7 ƺd _>7QS0=̕媖jՑ*]U6xȆ:"{YSӓyQ?$"\J%<ԹO{L%,T*[JS}#j3$h$0L:Vqђ n [MNr ~פܸ CvF%i"L *G;EIFMNh}w#a=MSQ~?&~G5s#.^6ʧݎJg4MT4q;Ah4]Mn;1⸸>~I> h:I|?<0^/Caa~IENDB`@Dd (660  # Ab۽*WᛦS4 Bn۽*WᛦS4PNG  IHDRNgAMAPLTEٟ pHYs%%rB@IDATx?D b >hH|L 8H 'ER*>JD(Q>Br@BsZgos尴80Z&j7 o' $P>C-@*$9[=C K LG|+2ԌM+٢bV7|vɼoJXt>AN:ZEwQEG]O ;JL7 ƺd _>7QS0=̕媖jՑ*]U6xȆ:"{YSӓyQ?$"\J%<ԹO{L%,T*[JS}#j3$h$0L:Vqђ n [MNr ~פܸ CvF%i"L *G;EIFMNh}w#a=MSQ~?&~G5s#.^6ʧݎJg4MT4q;Ah4]Mn;1⸸>~I> h:I|?<0^/Caa~IENDB`^ 666666666vvvvvvvvv66666686666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH H`H Normal1$OJQJ_HhmH sH tH J@J  Heading 1$1$d@& @CJ@@@  Heading 2 $1$@&5CJh@h  Heading 3,$$ 8@@81$@&^8`a$5CJOJQJR@R  Heading 4$1$@&  AA5CJOJQJH@H  Heading 5 $1$@&5CJOJQJH@H  Heading 6 $1$@&5CJOJQJN@N  Heading 7$$1$@&a$5CJOJQJN@N  Heading 8$$1$@&a$5CJOJQJN @N  Heading 9 $$1$@&a$5CJ0OJQJDA`D Default Paragraph FontVi@V 0 Table Normal :V 44 la (k`( 0No List FB@F  Body Text1$d @@CJ4 @4 Footer  !.)@.  Page Number4@"4 Header  !HP@2H  Body Text 2 $1$a$ CJOJQJjC@Bj Body Text Indent#$ @1$^`a$ CJOJQJpR@Rp Body Text Indent 2&$ v8@@81$^8`a$ CJOJQJjS@bj Body Text Indent 3  8@@81$^8` CJOJQJFQ@rF  Body Text 3 1$ CJOJQJp"@p Caption4&#$u $d%d&d'd/+D5@CJ OJQJ>>@> Title$d1$a$5CJ66@6  Footnote Text@&@@ Footnote ReferenceH*0U@0  Hyperlink>*B*PT@P  Block Text `'@@]^CJPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] ex9<AD5FN- F pu_*sc a#l####$X$u$$$"%?%\%%%%&h&&&&&&'5'R'o''''x !&-47;>FKJTV]_acegwy}~AD5FN- F pu_*sc a#l####$X$u$$$"%?%\%%%%&h&&&&&&'5'R'o'''''  !"#$%&'()*+,-./0: r] #(),H/L;M?DGIQWfZ[ad+nnqtyW{|u{iЛn14GH-z`;>g^yN#55R@S@}FNcwd:!;!]-  X`L()B)+,w@%(`#a#08E4T[=dkvvx}M̙x. J. . . -/ s/ / / E0 0 0 1 ]1 1 1 32 y2 2 3 K3 3 3 4 c4 4 4 55 {5 5 6 M6 6 6 7 e7 7 7 E8 8 8 9 R9 9 9 ,: y: : ; F; ; ; -< z< < = p= = > b> > > 6? ? ? !@ u@ @ A SA A A &B lB B C MC C C 'D qD D E PF G H I FK L M N .P dQ R S U BFJNRVZ^bfjnrvz~*.T7<a$:losx[^agcpjv<_> $N+5=GlHHHHIUII KK+LfL~LLLLLL'M9McMuMMMMN-N6NkNtNxN{N}NNR*STUHV`]jk/l4l9l>lClHlMlRlWl\lalflklplullGMt]2!H<s Q!;)A(_hwRaۖ֙hBķܿi:e]]=SwPh( W#(901w233 558@NvSY^eiBr{cx@-ݺ% tL> 7  M!&''''(( ((((%(+(1(7(=(C(a+15S:%>A=FyJdMMfNQ(SVW:YZq\audej?@ABCEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcefghijklmnopqrstuvwxyz{|~     !"$&()*+,-./0123456789:;<=>@ABCDEFHIJKLMOPQRSTUVWYZ[\]^_`abdefghijklnopqrstuvwy{|~߽#ٺ x:XXX  6=?KRTpwy  /68<CFJQTbilpwz ;BEIPSelosz}4;>BILbik$&LSUy "$6=?^egy$'9@BX_bi!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!l####### $ $X$p$r$$$$"%:%<%?%W%Y%%%%%&&&&&&&&&'''0'2'5'M'O'R'j'l'o''''''''''::::::::::::::::::q42$BYzL.(I%J\ b$/)kٞX-1J_  b$zZQo;*cj b$۽*WᛦS4 *P b$d7:T b$!:Ɉ۾+|^0X b$=& -?mЗ}  0e0e     @  5% 8c8c     ?A)BCD|E|| @ 6q5(  ^  $$  s"*?f  s *jJ? $$`  C  `(#J$ d 0+   # /s"*?f  s *jJ?0+ `   C +  bB   C D3"?bB   C D3"?bB   C D3"?bB  C D3"? d 0+  # /s"*? f  s *jJ?0+ `  C +  j 0+  # /s"*? f  s *jJ?0+ f  S +  d 0+  # /s"*? f  s *jJ?0+ `  C +  d 0+  # /s"*? f  s *jJ?0+ `  C  +   d 0+  # /s"*?f  s *jJ?0+ `  C  +   d 0+  # /s"*?f   s *jJ?0+ ` ! C  +   hB " S D 3"?hB # S D 3"?d 0+  $# /s"*?f % s *jJ?0+ ` & C  +   hB ) S D 3"?hB * S D 3"?^ p + . / s"*?f , s *jJ?p + .` - C  P+, hB 0 S D 3"?hB 1 S D 3"?d 0+  2# /s"*?f 3 s *jJ?0+ ` 4 C +  ^  `'0! 8 s"*?f 6 s *jJ? `'0!` 7 C  &M  d 0+  9# /s"*?f : s *jJ?0+ ` ; C +  ^  )P+ ? s"*?f = s *jJ? )P+` > C @ 0(* hB @ S D 3"? hB A S D 3"?!hB B S D 3"?hB C S D 3"?d K' G s"*?"f E s *jJ?K'f F S FNP& b J S JA ?#" ?$t K c $  ?#" ?#  +0 [ s"*?%r T 6TA ? ? lB U 0 DjJ?P+r V s *V  ?` +0  +0 \ s"*?&r ] 6]A ? ? lB ^ 0 DjJ?P+r _ s *_  ?` +0  +0 ` s"*?'r a 6aA ? ? lB b 0 DjJ?P+r c s *c  ?` +0  +0 d s"*?(r e 6eA ? ? lB f 0 DjJ?P+r g s *g  ?` +0 z p c 6ACDC Logo#" ?*z q c 6ACDC Logo#" ?+ +0 v s"*?,r w 6wA  ? ? lB x 0 DjJ?P+r y s *!y  ?` +0 !z } s *'  ?#" ?4 'z ~ s *(  ?#" ?5 (h  c $A )? #" ?6h  c $A *? #" ?7h  c $A +? #" ?8h  c $A ,? #" ?9h  c $A -? #" ?:h  c $A .? #" ?;h  c $A /? #" ?<h  c $A 0? #" ?=h  c $A 1? #" ?>^ p + .  s"*?f  s *jJ?p + .`  C  P+, n  s *A #? #" ?.h  C "#" ?- "  jA $? ?. `>>R`TR`T>#" ?/  s X%?.@`T`T`T`T#" ?0 %  c R&. `RTRT#" ?1 &  c TA0Biohazard Legend Symbol#" ?2  c TA0Biohazard Legend Symbol#" ?3v P+   s"*?)r  6A      !"#$%&' ? ?n lB  0 DjJ? P+ t  c $  ?#" ?   B pppp?3"?  h  C #" ? t  c $#" ? P  # A#" ?B S  ?kl ")L)* ***{+,DGGIzYZZabccnopp1w|w˛u2;<g{|#5S@}FNwdxd  ,* 4T[tdlv}-x#,:4+ kt+-kt`p4 R"*2 +(R p+R p+R p+Rp+Rp&0*2pm0*-2 'X 2 '2 (2 &2#-`'-R" `' R$ @&c2) `' R0*2*=`'=R/pGP+'20 `' R1=`'=R)>22 Q(28 `'29p#2? )$2B `' RC=`'=R@ `' RA=`'=RGK'2K8 )p,4J@$$4[4'4\' 4`'p4dH8(p4H'H4pxp'tqxp'tvH8( 4 '4o4&z$ 4 4X 4}4h7&t~x:tH0T#['kT#^'nT#^'nT#^'nT#^'nT(#X'hT(#X'hT#^'nT _1013243583 _1013243660 _1013244203 _1013244692 _1013245276 _1013246415 _1057059007 _Hlt10883872 _1083480946 _1083492455 _1085833919 _1084964154 _1084968575 OLE_LINK1 _1084968576 _1084968578HVVy@@@@@@@@ @ @ @ @ @@HVVy==pd|d%2Wb@F ou^dJM^gp8|8 ==A>L>{>>? ?@@[RkRYYww{{|+|,|2|a|h|G~U~[iÎIL wמڞǠ֠ڠѩܩVa(+6*5157E09fs-6AKMWel&/\d3<BI V ]           o w   M S $ , A G ,23;y|"*2=CV\dks{X^zzx} ")CPT^ H K   T![!!!%"0"##Y$`$j&t&&& '''('"(,(((((((56S6a666667777O9]999997:=:V:b:::::;;D;R;\;_;<$<a<o<z<}<<<m={=>>>>Y>g>????@@@@PA^AAArByBBCC CCCCCDEEEEEF%FFFGGYG\GHH_HmHHHlJsJKKLLML[LcLfLP PPPHPOPPPPPQQ_RfRRRBSISuSSSSSSTT(T/TnTxTJUQUVVWW(W/Wv\\\]aaccYd`dhh~kkllppDqMqqqqq(r/rrr ssJsQsTtbt)u0uvvvv1w=www| |||||8}B}]~f~q~{~}~~~~w~ƒ#߅V],3ˏΏ&(FM%,NUqxŖlsgnɝ-0P]ÞajHJx|U^ek ͩѩ*57@׭ޭ!(0ľϾ%2E P   ----67[BeB9CBCHHKKPPQQ0R1R?R@RRRSSUUQW\WWW`XjXXXo^x^:`C`3c4cddhhJjKjppzz||u~@I,-ST@A͕̕  23ST^_!klջֻyzJKBCPQ  JKYZ  hiXYr~;(G())++CCOORR6[:[m[t[hhwzzzkr|ͺԺIKLNOQRTUvy  _b2*2 6688;;;;;;4<><<<<<==5><>>>>>"?*?0?9?Q?\??@@@AAJBSB'E2E5KKLnL]]]]"^)^Z^]^^^eeHsIsssssssttxx~zz~~~~vxߓ6;>dglnuzΣӣDEbcۯܯ=>"."(;@R_CJ8A !&  B!$""t#w#$$4575;;====>>?'???NNaakcncklllImRmmmxnnnn6t8tjwmw2x8xxxy|{|$*XnILe>A!~_ϪҪ[EǬ/F COU?tpMHux    ))I/W/N6a6EEHHIINNFXHXWXXXXY5Y6Y[Y]YdYfYYY Z ZkZZZ[\_]q]s]]]]]]]^^X___G``````aabb[ccxxXyZy||||}~~NVҏ :ܛ<}eӝf pw#(-0åƥץ3HJ %">@T^r^`ejm$),izŬҬVZ38ciFL28216 1 6  K-$A$,--...6688m?p?HHHHJJ"J$JKKLLMMTNXN]OaOPPPPQQ+R-R?R@RRRRTZT~UUUUVVWWYY[[^^``.c0cddKfMfhhiiJjKjNjXjm"mooRqVqXq{q,r.r@rWrrrttXv_vww0xTxzz{||:|}}ہ݁0`uy,-֌ST;=imo/$,0:>ǕɕߖƘʘO236YSUNP^_ƲȲI_V\kl̻ջֻNPhj{yzKOJK"$"$BCPQ(79+-RVhjY?  y{  JKIYZ   /hiXY0kK M  X  )    _    $D^@J X  l"s"&&\'c'((**2+;+++v,{,--..//0000)1.1T2b2225%5;;<<==??AABBCCDDDDSS]]``eehhhhKiQiimnmnn)o,o]pbpzqq!r,rrrssssss t$t xxzzzz!&Z``fGQцنz).ytz^a^h6?&ҕՕ&+fnӗחty  Өި#.IKLNOQRTUGI N[FRvy3333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333ٺ Iû)3LVxļ "?JMX[fǽʽսؽ &:EZe}Ӿݾ >Hfp¿̿ݿ.8ISdn",0:fqy3AF_H SH(U5t^S jMc (U} 1 h4ʋ$D t;d(U1HjOt{dl<8#Ov"4u!Hq/O  L!tc""4u<-&"4u` *t +tJ)X5(U5t=7(Uhi;?t=,5Bt5vD"4uj HtzH;LtMt ]Mj/Q(U-?Qt0N\?!5\"4u"m_ήBqPeteh4ʋghit+n(UYn^mFpn?0vtt}ttY uH&7muHv(U]:xH{ܲ[}thh^h`B*CJOJQJo(hh^h`B*CJOJQJo( hh^h`OJ QJ o(<hh^h`CJOJ QJ o(< hh^h`OJQJo( hh^h`OJ QJ o(<hh^h`B*CJOJQJo(hh^h`CJOJ QJ o(< hh^h`OJ QJ o(< hh^h`OJQJo(hh^h`CJOJ QJ o(< hh^h`OJ QJ o($hh^h`B*CJOJQJo(hh^h`B*CJOJQJo( hh^h`OJ QJ o(<hh^h`CJOJ QJ o(<hh^h`B*CJOJQJo(hh^h`B*CJOJQJo(hh^h`CJOJ QJ o(<hh^h`CJOJ QJ o(< hh^h`OJ QJ o(<hh^h`CJOJ QJ o(< hh^h`OJ QJ o(<hh^h`CJOJ QJ o(hh^h`CJOJ QJ o(<hh^h`CJOJ QJ o(<hh^h`B*CJOJQJo(hh^h`CJOJ QJ o(< hh^h`OJ QJ o(<hh^h`CJOJ QJ o(<hh^h`CJOJ QJ o(< hh^h`OJQJo( hh^h`OJ QJ o(<hh^h`CJOJ QJ o(<hh^h`CJOJ QJ o(hh^h`B*CJOJQJo( hh^h`OJQJo(ghh^h`CJOJ QJ o(<hh^h`B*CJOJQJo(hh^h`CJOJ QJ o(< hh^h`OJ QJ o(< hh^h`OJQJo(-DocumentSummaryInformation8CompObj+r0 hp  NJDHSSj  Title 8@ _PID_HLINKSAhMv mailto:info@tdict.org *http://www.cdc.gov/mmwr/PDF/rr/rr5011.pdf.0#http://www.hrsa.dhhs.gov/bhpr/vicp  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89qhh^h`CJOJ QJ o(hh^h`CJOJ QJ o(<hh^h`CJOJ QJ o(<hh^h`B*CJOJQJo(hh^h`B*CJOJQJo( hh^h`OJ QJ o(<hh^h`B*CJOJQJo( hh^h`OJ QJ o(<hh^h`CJOJ QJ o(<3^S Yn{1HMc /Q=7v;d+nJ)X5"m_ ]Mq/O zH{d}tghi$D ;LO5` * L!j H5B +5BqPe-?Q0vtM[}hi;pn0N\t=<-&!5\#Ov5vDc"} 1 eAF_Y u! S&7mu]:x33Sm@x@UnknownG*Ax Times New Roman5Symbol3. *Cx Arial9& CG OmegaE. Britannic Bold;Wingdings]PressWriter SymbolsSymbol?. Arial BlackS.Arial Rounded MT Bold?Wingdings 3G WP MathASymbol[" AvantGardeCentury Gothic  Times New Roman MT Extra BoldCatholicSchoolGirls Intl BBkWP TypographicSymbolsCourier NewYWP IconicSymbolsASymbolA$BCambria Math"@h0Bg0BgwqFNjNj!2KHX  $PSm23!xx  NJDHSSJaimini D. Patel3                           ! " # $ % & ' ( ) * + , - . / 0 1 2

<`6!)|f.VDbxy|{+enBDDĬn}VA*Ydp3<5kb+vL iC8Q<+bmDr DVU. epH:`@P%H}ѿwZBxVcZ :a!1!Ne)64444h4ko,?ًoo$OrEB jX0h\Tkn&Ml@ѽbyk\ @Ÿ7>9|Erx+ m7'͒i=ӎԌ~.|Ʋ6Do6 ;? | q ZĊ~v*M(ѯi\7gl .Z ^X rwfwHR@@E SU~s=~k6~3|ܙV-FAOs^N+qj blhhhh8Sq ʍ?!.8sJFAb=QQe\QW7{0~Z#R;;GQ|4#B9wT!LSú1><! HyQܞ6 `P'u7_M^,HvfadCXO\/hx/Zw?]xۧLEͥ_]mE7Gf]oNYynTyl_įE皍+kejX Kdr$,)wϏU5Ļg>}n˖HF/XMr+{𥬵;<&_Fko8U֫d+̴ ,z D B:耺Tn XY~Žbg8znP\![dP!  H"&cNAJ5%r&v;pJ{6SsdT7Fsihhhz"۽Q\U\vۿZ~ Y"|_Z]t XEh7_(WY=@aE @ܣaN˲{Su}*ҥhِ :Iܰ:e9Q&lۭ6#mi{Kϝ9l)8界l[v_~ /&,<9?M S$@XI {A^Oj]@r/Aw (﷑sΝ!)rH %/"Mk^[xz' C[mm!q8m@ PtE,%rF IDATs@ID'6$!w~ t4Rs `lѪˠlf Kr`eCZh@xBoMn=Z߱Yp*!S]'=px3C)LLp2+Q@SSU"2sH-"]ڽ_*HCz5J2Š3"cS+ ldfFP"ȥZsTi /chzO%M#B -]w@0&Wi4X`W 4Nsqm@@ӅT(W641-BfFpP5~g.J/eiƋ;AS(時7oǦ"-G8Vaz~X#"P3LoMK*Sb9uI Krޱ~y1/GTx"yt+N|J vrvtq1* DVa_b' `Њ. V0"1Bd44FT \ a*4)`Y:@gDV*?55555_>RSSSPC WĹBO+^8jAj@ eg}Ȳ[irdz(߳BKDr9RP$ݛZr3nN ZT—`?d?KoxC[;2^/YG۔r'uPӰ$yBsSP=3Y4B0j$#W`=:DY&k^hHP^-1'l B j;`đ<v%M.+.Hh* cIf|$U55555Qk.5555_h2*Ns 5Eh!pn P{t\nȋReHk\5'!1je';iH06jYh Q %mf4" Mvu!lojǀ4kJ;!(u?}: Mo6ofzf />P̦qTSm4# [h15)x(Ȇ f^k^*@D+)7!MENwOVD^@p"3UU:ڼH{cF5_lE'1ag LwE|׼_fϙ4uۄ ^iI=TXsAC1./,^jD4Lk6==O`mՠˆ"3@fJ@L O`c᱓|S Sˬd~ |Ba"M'Dc>pE˖|ԚKMMMi97Jf :~JU2/ 2N"umgg[Upۻ3Bɍ7*NSp" 3,BӴ^ҪO^_6D@(6]!nExkt6~6`\],U)9EfQ(,}G9{< [Tb!0 /c#\ML-''g$AEZt4k(!KqɋZPzɇЀ<ͳNu +˰HqRcbq~wc.ٔ{UZ"nz;7(XV2+.v]W,tM'vOzHwb4<KLM)p+mAlxljlT5X0!P`LaX,`OdOŲ,N1&2XĘ7J2"Z}bΥ8T_J0: ?"LqQSSSSeRk.5555_yx{.f$ 8B *"::Hh몘7I 7Fg3 ~v7A%<ʯf .Y.*岐VmfgKdi4CX)}#[Y0^;c³Ilb*TV]wLpOeyje~Ʌwկ(*a%7f*`,z1@\ϗe)~=#Kn#d 3`,Nb'GoY"5~\S[Q@c@DzvU mn0ۀH,,a] 9_RV$msygHQe̐6v~& ,xخ7"EsCEQ`6@4(m-Ћ%4ȶ>y^v$l10?@r83$A}<G̜tƸֺK?tn\CiVЋ‚s%bK\ڦ@ u5N .-RXl0'1lҚ#GEsNR,im8aS"uQSCJ@r;W/K&Y4sgLJ> v]rҸ/b~r0 h!Y9Qנglq@@`  %R>VQQQQ \****^z YdPFxP}D*0QHZi2K4lomM9?w+kFov\1neYBf7EAwflE ̋+\tB&eWO†5.x57e¨o[`Na!x'yGX !9 SL^<PSSH-"R;`rxР(wUfζ߉4xY8qAw@E$jM LӂC d s14@)jg/H]2mT%7/Wb<ǑY~<\ZݨL\NΧmZV_38fvg77~Bvql8 iMG47֐҄AL~]`ٍʯYMȔi;5 MC 0\;>=k'WEEEE RQQQĘ`s.&bK^\#[r͏Kєx"syI:zxk6<]ś6{S{Lś 5X ȳDff .ƕ&),'d0, (Wnoy_F'0M܁$QR]8X+&$ndeEЈQ`í b]TvI $dS# uDa#M]bvnq;߽trࣀfԸ}#+(*/ !o>#!mv?xy?AR_X?!4cZ=Pk?6-˯7 t'$>z>bT"! ),ޠwvEg1$P|꙯ <(P쟰hi}+J)K nʇiMzJZ7t%"n>wsެNenxT0^MD01#>H`eYW0<>̾UTTTT|4[dTyehR̪f8S |Xv٦j.ycf~,`1%"kh5o5fIuh;}Xޅ qCqa&xN~š(>Q#^8Njέ&jqQYg@;ʞXe Թǟ-W@>~]c 5K'1#ΝՍޜVΥ(cQw/Odk@F Z-舙|ּ _WEZ A{͠ QQV`ٱ;bX6euPvFT7C2.DښTurzvq]ÊfvǶެOdkAfa=:R^,C)0ڬ' 90?ijN4q}â=u1in$2TKEEEDTTTTĐ-5T/Zwk1wI hegk0"gӳPqRq^w򪆓!tG q؛V/-0K`x8ؚcU~SmuW9 kEq9)D!GNbez:sxh5q~ jlhN˜Ff&x8"w"Y~5HD,rZpg7o5'Qϲ.?V;w>QpɩbԘe7h׻B\****^b)dk(y߀%O{11Fբ*dL#g_S\aQ5i祉vZI&hZl~߬cHcvO":o~gw"xnfvBweOyv0/XVfv159;sL`s$q`0"bOiewU_!4:WF=H\=}&nl~z>rxu{je^߼tw )Lu|dLQssYboTD}2#med5%0$<O~B^3Aa٢3 HA쁓/gO>VnQXRkNTOɋh-2$xxٓi-tW<+D{'"eMyRg0`d q)o̹zyUŠJsx'! ɮ ^ Qs JdLrORgބ)!F:r[zLonN]][Fz h78JίIhpG{}[UVgvgfA{Xvˈ]CZؒ8OAr?!(B $Nrr<=侹_U0rm e䍷RaL{$B{.@/ߴ|9ommvZ7 If/dOVΩRr4?}7;yWAzwAQ"HUȣ3Ӄ[?m* ;n3AN14~o\pM$JFo4o|,U$%DءCg3otKb WCSy~ `Fd!8{?;nMW a? q)jeKT*eͥT*17@$GG;oE\Ü0JD Q$VTQ. ?d}%@y-_q$$*rg48`HIɤpfvGO;R g&/e]/@"^fY,UvS-~,_0W 3 @Xa'3~zͫtf\U_eg>-!aY\RZoSyVwv{T}<y`SVA\u;CT6 wxp 8MUd uXZ޺^ jmh;{'l85)~%k|?h2܌<7Ef N^ӓ==y5-G nf`Ub2YvsɨT*JϚR*J睓ck/IdC4{Ϭ[HD]촢q-ǁܖBrmI4.B%8THs%&D3ͷX@rz=>O|LI$1'"MaTһ xDUPaTh( އVH85v 0M[ق)$?"$q0.PUMqs0A/@# L'VU/Z2q C<ҕhO .B$)ߝ8Yv-9NYGOɉD-Wg*J3JG >JYl=\@,f|lc0+t-A^h9Ίl-Ϲ IDAT^OsO;~`{geHQW/4 bE S%67 a5qiD`ͳa^J.n}3Yʿ̽khnCDG6EF$A`zר;DlyXȢ4=kjX%ɱWJ1]H^@Ş,zs&Sr0-L4o !ae7 [GwĤ'~ .c$ܡLz+R"6s0A,&?uL@MX}PݝXxHzVթәU?{}d/ZIbHRsB*w>f3#FvTGO4XeT L˰mpJg0Wő33ٻbܴA1ЖF>KU$lcMpc$/͘)UAo[N|a4 \NLIR*JϲR*J3@yK'ѫDKw0xOCJH *"rڡcUzf ~3 ['̺3.`5ކ.ft-y7[(R1cIm 0G_~~)iߡ?vJ3ﺖ_t>k^bOsbropDyef9iox_zp,Re`L݁AfZ h+˿=xr<"{G %Ѣ;Q "sTvX$+N>EF u̯""*'DnoV3F-̇ivLp07y7RT5RT:ȄL }^po0VdȲcƉͦEP11oBė˕ jFP!6UZ{>_ןt nnZq(xOI+{ q'xKB<Bɕjk)ps#*(1/_BPyn6Y6=n8GyfTi^g CrQ`7s kVE8?dN3LS8 KjZt%ޢ@SG nG,JJ^ubDn5E$8=r#n-:D1[$xm,.fscT*G, h8%t83pw' ҁ3fr|tg{ZoQB?~KkpVu3DDU@3 HvUեh6ȰѴgS.Nt{WOs'kyw;r6oW$ _'xn;5XMɴQLEg ]p,J9P\JRcWv<2ݸQ؊z}_ALjOog.\HտOhSEHUߨ@NF3P;+zky-ƒ|G)~ŗg6WYQW {>5^Sm71O~(2g~~;HJF'j]eQMAֱ ;uh)_UpnAR)vۅO5s~Q{gI$Yϊޏ'8E'V}Y4Ҍy~)4f''1, ^lÈ dcwGB 3}74$Is,o$I#c(#3p˝}th郣Φ;/UAޟgP['Ѹ>fA~Ҿ`7fjw"ٴQ IiP*dUi .2J1gd- @𡝷L72`( JAɯJOCl PʼK%sU:XT V`TuF<*Պxr/iTlZ xw4w#o2lN$II1$IeoĐr3$Gщ;qM5xJP.aC|Tw/᪖G pwUUM3t0|Y94U`s:(Y puee[ޏ>Qڊc{_$|QkH;sR; bkqpKĚ.hED@#`f0 @[uQ#Hj5oX5'Zt'cgIz9}l,#̣zMsOƄQxUbVb!8w0#Y@$Ir>R%IdMrl^[>y^T44ZȦ-?BKgXC0"g_x;8*NJ)@wS idшLxyRN:;]{NCNd{O8c'W~- 3SO[U Iu6˝ژrh og͍._*tùˡ ^DztZu7MuBTq#D-Թ֟e4 @xl޾׆Za[!StC\qZ4s#Q.E9PT3?K$I%b.I$Kp(nCM ]kPV. f pf QvgZa>)ԇj9zw@s۰ue hSPRTxx jP84l쳙G{h~V fxNƌYcZw1EFY6bD]mmJ$fj t ,Nďaް;Ddju0ȍO ԭ+?N'pB9\=ڨל˫ Apn-sػ~ZW^45f,.I$K*\$IH D)3 Pfv 2b= Zg#"Zx};)Bzx}\[f&^A'V6&n-Vay#N2V i;v;eW;-6CpHG5mJZz!S!R"Ncp7JMC9\f<&Cakn8ƊAk) *$c 'oIWi0Z Nnٝ^΃4ހ4r j5$I$G$I,=5%-lqn7T֬]/QOv1T)˅ a0Y` $-]v}|#⊠azHRX3^N1T$Hݽ;j;Eb^ a:( Խk3no?M06`ga Jjt{h_zY*6ߏZ^kXiU"33A}.٧ +a@Uc ѮhTs9ڍ{8pO;SG8OiHx/2NJ$INb.I$K/T@Y`V]8OIx9 Vv_%N:5.0+ /_Ee>BDY t5VI0Oovŷ,^Ciqww>mLs`W1 Us"jp:l~עzvn)FD=rSt`#&U9Oc" BQE x!WI~wwb?:[4I$YR)$IX/z?_`GҰL:3X6E2CЂ_ۭ75n17Iv16loMULPSd@I9¢Jݽ͵/S֟5E^[,HEZW!Ǵ u uyP!`+C տg_Z7 M"@e",c$F%i\on00٣[נ-`ܨ:&Ij3Y׳~O.fBԆ'>'ܗB P۔:B[t@)Rn8xo>+ur;$I .\$IL4j v,d U=g[ ڱ"CGga2f{oBEBb޽Xkۇ 6}| W7[߽1-{5}quN,HT}术ƷQt:;;ctJ `0Ԯh-b N2\\ !"в!E#3ݙ㗙zsN=㞱V쩪:xQNkfCZ%  oFDLU5U3B4Eqt:ιu5NyF<>u=-Z`yҨ䢛*0]" W@ [,y~>ŖǸX5_\H^PfӲnxrU_C,>]SM+rDtbM\ 3F4Jh'PW"k[ QLJ >_fo'uz)N] _L>_[)^YY#ڮ%yv3 ׀hhwv\#UVI~>h@$8 LiU'tg |zx})5kT0pZEDZ mo2]DA59]X|wt:KWst:gM%g)#224ot|nQ:UjRSi.?TYӒxy+HvOGWZDݡAo:A#ERDbng, `!; ՌaA$ܮE=xATDDhrW^UJ2Ĵ;ff+KE.gU E+ˆǻ1eJ/qS9ռ}xH𹫖Dz `[A#LAZC=>_~Q}F+,#f?qo }sO~1 1~@9("_l׿$?rJF kR&ALqoNY^Wst:gD,сnxD\ P剛 Zh͒H"<&BmhEx! =ཐ{'h??xc̡!&KA"bqOQcѠ㉉=ݟ)\^$H_m a6XG|vG}MU]%h;yѳVk 2vzVIOL?[UW=̽7q\^3ЊO*>Znu]U׀l<4kDP!9otĜ ;TQWdN6dn5^ Dn[k@a "D@У`^g]qs =۠Nv[mƣ?ʥ:Nj.N6b\GgtȡE@DHX]xҚ D@wΟ֟~Q6 \FiҠf?Ӑ7CDiG,˖9!lÙ%+Trz rGb|ۼ]k$U:n3\ư^85N mӶ1Ơq#h<h4!7m (M!")]N~Q⌊;ÈߧHpXoB[sF(ɑ.ZYԁ~ҘŌudPD{(?;NTLt:3d%*/}|Tf7;ɿ>x֥?D[3H8<'J ,ɟ-}ӠR!AQ(6)$"q!Kid ;8Q[*\Da^$,_LGC J_^0nɉcE.s낟O!6As^W t&':bt:WWst:gJyY]z\/AE*!d1,<+fh"@a-8S|XK䜑 4 śj'Ma !ɗ.?UWosU(mY}X!P"ҽ8UಥoYk[8%#u(@6DVr<=,DwƋןFsdAll%ƒB,iPK9NƋYo2r",#Ut?K7b JJclL?X0\iX]U]4ǐǔHB'F:5Uh+F)rA5% !7K#pePhoOزL3H ڠ|' &IAp{2Y_ Y%{ĺB@CdtZLRt=]ͥt)^&U--Lˁw7TgW ͖"vW6t ?JHM %CT3 {G `}ń ި L!yfRL; BH 3㰜 [ouV'%!)tQ$H:Z=p0qyoˏ>]g<{ojݥ_# PBe`{X!ٓ'}gvDqs=|2խq]0N63{Cɭ5lY7h@^Kjrr2΋I=Cqh̚PU 0a,@G^"ETulgVOV{of.أ-}m_~J62A6 A A"I)!j@!!i ,RUP h3-iɉGtF(TFi kh|a.ãen')7-  Ͱd .r*a2E6haH ) NBRP)#/ZDj  $e $H)1d{iQ3R-;'?P~c~X[ Mm͗=:XohЩ [ EclS\ܾcl|4覀-җY̮qgH!jdddd+g\FFFF^MD~r#{ŶZjdq^_~pD w _`dDN$;OUu"5w-)?w̷xUifmb tzYA@ p!! / MC=r3%NV%?PB21` A8ԟ 'dj"fMxCb"2 W2?^W/S4`+ҔH.HaQ\A*L٪(öfL9(yuPH8PK[BLHҨH 0@RH6N4=l]n+o>q~ݙ||Z?]'_ Z`y&L5he-w>9\@ z| ,fwL/c2/.2222j#ȫ_j.`6HڤO#[ӯ.)6?i.nkx ɩ@٥O&,GބtcswN]d(nlHH8|GCh%R FR#%p?YJh`sLϪ/?u4Hf$dL"(TRN0j1|z`wM捨;4*S$&ƲI FA7a 5ȁm*ki! T& ɈJ:1k'*}Rh s]符3 IjT/mǬH ,Tɐ>_zʗ˷4=@7@j J TB_t_Z.uLjxLERCKXyҶ??T, nv\OIKxH+KE-˸$!s7od6}͍Yb%$3fH- /i> eVAZqw5zDDS\׺aB%cE7!ٍ|GLG W`)@ 8OKpg5奏RjFt: 1ԉЪ2'^@L08HͯG>%$]L5 -AF#l MT o`3+Ӕd ).A%3T=Heds\vP@$c¬ɀ4#@51+v%hM!ouD Ӱdf}ڋڦYuJzѭ0{T}~1^>.?̛54M£O f#####/22222"Z1|'o *L"48ɎH%Ky\ Q(h(WhS2Ij3g-;`W &d$SSRGGOH"%v$"JvVAIlڔKtj{h Xyޟ"AԡD(IO c{+s榗Ua')SDHFIq*tIJ?x@22ISәS/ܝNPd* L~ {ΪNoB2 Ud"z3Lj!9d#sbNL^tvfR pOpp/К 1#Nm jw.?Y?/"^]̬5B+l-3 l  X BbH ĚKܕSzd"Uno/"*#KQSr`j4}htZD&$.gLEhq"tXgx3=====_fzͥ-u&WU8 p$(. 9>0A/*Igݚ(Ymf[h%99-#EФvwmJ JUJ7ۆo%6N3#`v 9!Tݜ*>=5e tޔ•ur%8(9OJcRsnL܎8uU2'KΈBv-1=pA܈чBwS'gN. VRR1bPӽ36$ $PW*SLҒ%U2D3XZʡcCԜ u]FTUultN,Yp(UG\tnD^7狿8xd~V/O`wM N|0H N^#o5ӯ MR-V$AR`nI9Bw̻Ds# T7JB vTr TUk)UZ_UOdflj}t{oxZDC&y+{ `2zؐ(p03rkեE4%',߽pE$b7 ۋ=t2yTxQ"=vF߆w^%Yd>w(XX !`9ր3kNOLM $[4]^S[z/AMOOOOK`\~ o-[q}~p9|- M~P|:&JT8t=t@*M` Ze$AC,c,W^@ dR4BtfmPx7'*Vѧ0Ĵ?c4y7PRA2`P-xY2=1]JB< hUe]Lˈc5.'aޕGo&Ï2+d{^&ƑǡI3% VozjK AKijH<$5jp 8d3ԱjYnmhT K -K'3 rԈX xgW1z8lk^\^%^,i^syymx1}elo 3[DP@MlI)'QLWGƻo8֋J;-դ)`ɣO{BM>=I2d1~׊#2P97z3#Ժ/nQqx)K, N/l/ci IR(,Vϵ٢\~-;a@zK`5I’Z'm "ZBJevb\[ЊGvv>)j*h&xD@M(E *\Y FDaB $(Ê 򩁏5E8LJ3HGnVRFjck r +iQVJ:=2Rv0 A(4U=====ciCwy'LcVJDJ3$&Z.x$fj& '?s67>,S`=S`^[6%4fe+%*g<(<#wj̥嗒I.bnvM?kBRZ4}QN$ZRku3/ ma $O,,222ZrE;J@8(-0H{Mgo<$Kb8=5@ 4s8*[MܠV$ t6o4㧍:#SNc{sktn:^V:3״sK։:I IDAT(f_mr{leXm`kW;l|C0f3JK n8|,-Hhl;oo߹d-iЌ&FBB(D,l5Ӈ) @ N4V$?PV@x hV1#f;M~A T3y+5Sp_j0p0aJ@sg{{4'LX_q㲑cjpg1`8|gMA77_=~7 ,?py%/ϼ_h[;Lr/ h_ު TUU] 1{Ïw&^ r zvwFb?bJ<>~b ꐔhA)`-r2ޭޯXZ/[p8|;j[6qZݵ XBqHlҧӔo G˙F6^K6(so>ykZlMv4mf=ޢBcˠ\.[GJ՜G1sHshͯc18,E@X%zn= T(j!a `L,x\|[D!<wvoz_0m?ikm9jϩImLdEB5}6>qcchSCWq=\7?#v5y}Fwy`ޫ{LA.s,3ut{<+\||}&"ZD+q `tFKizơҐMp$Z FI?:/k%&Ԧ#=sw0k(YD Xz4v'>}B_ \.{gˈHi r%s_90݃nd{O|'??:fK -E9#BRtfݴO\w.`Rfdw~ߪ:7k<rAXȤf)'g6VUoƕuMyosy+LMӂ]oSsfN;.,1#MvK+ jw;o!ߢH>Z`47lϸKyw-D_7{}oHJ$%hf(veWF7q]EcE6@jZI[Hk)q]43(yo$R4);,wgޙsϩΰKZ<ǁwJ HϨR~Gk0&&nimdP|YG^nnM+9YmVcRNl[v{m3v~w:}Ye5[ݽAŵMf0$ %c{zqn,yat0뼾,p09m'ޝOYYS+1ddTBEI,,*(+y.EQ/hӜ Aj/6q+?~zCA3O-*na&`Pem=Fܵ"- 8uİ6-cB p`WweaGBMFjJn!iP=^Y7gIMB^wh:|% X8~skϤ5w}Qc Z4i $oҜ%"{ѩRsPLv,\(xAKQŋEp f$ u 9;wS# 򼱾33Lpɻ`ich;ށ9``$ggL$ڋiyƒ˺.`Cnb=oFv^4q0dba3R!9Gßo9]^ 4"RO/`rM\ڜoZL|pR ~9# 2n#/RC>?Ͱ/9 Wؔ.(J̥(O YK"]q (WEQXO:A5] lߝ*e恳轍 &.7V?5`@-N::e#iՕ^[R% ݷ=w y'ԓLQEUb.EQ/V롩U")rn6>v~mez ,%$-t>pw<ψ&϶B)}ϊ+IZXYkl.9$w "sX7n @a<8Lz[? p03V& 3X3b% tx!4V] +9 sam4ZvLVrxoOs`gW`sU|Iّݔo5I{3,&~zUUBm`g<ل.nNag9Ic۽Y c`SEQJ̥(vqg^XuR׀6`+:r0ri Ҫhd~k⢕إ( }s'j._t:%`@ x<'z.KjL2 0p:S) DB?;ɿ[0utOG4>Bt8e~X%o3^hz[V-?iqб0ԫwF?_9͔) ov߭k@oR& {~z;:6֑w~nb+%N2*,vaxL`Ci qu q?hxp!y,dvƒ?dx2=޼@FkrH){7)nQ;D$1K@ ܧs v$( ?p? y4rkxڠaUDx\g=[BSF}SI7o xlveKn--#p<o/'`\ޘZ5;t?ئ㏉DZ‰U'p;J=)lb e8CpXjfW -e8`[gf:]"y5J笁yL+(yJ̥(,,إ N{:ol. IɬEkC r'4:Lw~;jir.[KMHx6!ݧE @kz-ɪTѪ]) !80I:O7C(SZyJ`F"pogm 7tܸ3y'-v(Z}S)K s>mU;ith `4П\:@ A!<;uǓ$x=tI>+h]>#]E8BpWeMste) Dh@%e&yj U]*( KQEqIovw$]Lno1]-CMTvnޝ;ӈkУ[O&Xז9 x&'Dڴ`*`rtxF9 IDATOAYHNA{oIMFV5@{YgN )K2sJ亘n-y>kl=8g72D&O2\-5a! :~dsI Ƙ=Ux&_ zqZƳ =:wxV{# I(\G 2b?p{OWRDF۝l~ugHSQչgD3aAFƖ^[QE+1(jΑ`ۅ,IPxPHirz{O}ON~(}<$vۓSiiQݓp?*bu(/s)(. w_y*4 iOMI^w ռ&'[|DBŋAvRiQYk:Sɕ;ά {Nvc$"$!1!(@hHYhH\ BH&];n8FVwk){ $bBF(KȀ0+-CO6\ 㹼  jV" F0!iC D# C21nI5իN.unD6I"owZ  -U=|@0&1M52Iă2SS!H='﷓-cΫ˄awP-hbRŖєRPCx-b\FFFFFs($0LaײQvWL4*k¯('D(lo=׺EQ1E4Z0i2dL [,~MZv͍iԠWdw߯m9IY˃6+ 8`yj94EE-_5Zl-US. `g-.v{`PaHJ m* 3LI`J Z*Ik% ƤXÀОF*ٜpXV\ŊP]וvM>{rQ*Ǜɇe]Mj$R|//'J Y_B":M %=J8<`nL$t=aCzqpQsܭ@S_XV%#@mjROWb2w tV'|5,p z"@Jt9 tV&YG]@ՎŶ?aASa\̇3v `s/U`* sx(($wQlO#ZVPаr& 3E.TL^QY$2d!hHgS"jHbhّMB2j֛vNS T`EFYSKni?g M+Gn7f"yM_#dkVj`"`^EG9R3 ˧O6o}"qag{9FwrυH,b)GKo@'׵ڑ 2~!PExbPdUxXQ@ 7v?FҔ%QL)qҪO3IAESg~rvvFe][p=3yՕXq4_DB-PηK";VRB6r]87"mP(%" !%4JPDID`D"≋2@ \jyay/ :d쀒 'l?=5+YT{m@x,KͶo;mi_;*$JreDn{=p}WU3S$Ryep›F2%CWђyJWBzWkJc:^LJ@šZ[ `w$vgc*"FzNiژf)#J3/BV҇@0QXD WbJOpnpA~Tj#+ JlYOS}6P<>d#Ut׎ )-㣔 {־nwztļ"p(!`$1ͅU=_}nEwpO6>BR38"ZfThNͿݷmdddd䗜Qs߫M\QxR*+,,[t; kk&̶1p8_ւ,g?=M3 n/h?}{緡TC`}/;)?ihXMd{} j){{nHf|ϗI4DI aϽ1B,83]$0QIFl9ݸ@l3Pv,"s8_6,nP@X]ml~S`W-$I>4*4>W=kGSt9e2x0x} !^Yy+1X~'IvƉ11mN^Iyޢ=OzgREQJͥ(8˘XNjhu# ~m3 Wy&7`gxe1xv͆`ul=I=΍&mzM duig3%h2\!1.J^MСnIv  pA&s1ꗰO!7Xg5&w<-CfP`"~;~d4$OEQJͥ(xBÜ"Xx4 h x@$*>qì荪Eb>X SN)Xoҥ {CM'= y_"M`cs2>9tU͏+K.7#qv:=swu?U:!LȄ5,ʮ&0e=;{G<'Át)4n] ήКs _?F>'F[ԇҀ6S3r{GkGF& G< j'jcEQE/(oQjfO?Fݗҁ /УhX{bpRXYյ7}㏦?>ږva읽'fK~%Us}`=Glo^ D8RBG?!|.}6+FH*>pOb_=pw%M\^0 T.9->9_6.ݾ>ў^0cޗ!\MO4Og?1_FZܧ=nxojpEQo/g(⋁ܥ1 <{]z' /}}ϑ[DС lnx0xWGU"Jn+`?2V._־ 3jC =*[?ۉB l1n^PtatcPtsX`寅H ĭ9~+z؏qR?@&Q-YF7y۬)XQ$D2 q1xu tlR)RAAlʰzJLEQT\(cB!M&:"[_?}kkʾ' .7}mr;1>&w- <{[%7# D@ G km5ovݵ,0 [~ 2 ;vy`292Zcg"M7Oe33 '7&ӗ]p9lfw]8PJ"h9)jk|!}Ow1yX >pͿq+ۓY@Tzsr7g7 lAW{:^UAB ̞OZ}k.( KQEqޯtZY $wX^Fko{{1|~c]cb3bz}{GJwH{U. ܓUka ̱tVO@LHBJ⮛Otf5dfZq\:>&uvע&9l=N\|2s!RJhp]w`|ppv^n[Kh4^4FX/( &5k_M(4η.CRDLJyV;J{eMTs.UTJ8mf!# Qf#*5+U6 f:`ZI# `$g4<ݖH:볠5lrX +]oo4 @&S(T!&&8 IDATs# O9|&ӯ~+s@$@ o?ף,CT` Tf_vXh4_4FhOvY͚iݙ81: F7<8;gkN zm|u:=;]ܵdrPudGhXwK9;TR $"d.lnz@|x0" М J0"T[g Q'E}D{Wa+-PgR004!4d.B D]_ʵ8)t|ԋgcAr.]@𓧜f[#M4sdT2UZTHrFTkSg3W#9ʼ?HmЊR(k7"'&e 3R>ΜXX.7KfFK\Fq>4W&$!yP;wk\wjv$kG޽0^u=/zw;[;XGG IL1ƒlUҠã?-N5ڵa xD4`({YʗʱU4Ӈ%RiVV,TIQI@² !xpGO$u:U!%I2L2"2:^ːwXu(SJY=fk (e_|ZHw`"N&]>:#F}I*\N~Q;`C91U@*ìd /ƉdLw{ﯞ@ٚ~ŜG߾MRΏO|g7_':UPh4/E\Fq>˸Xn}ۻeNFKLؙTh%0U-s!9\(Cwf($"9n8_B8aT[{gG,%5#Dڠ, Kס;9 ֧~Ys.{ݿ?&aRAlϾ/ˍFh8oKcCkg;X$/}tg骍+W]qtǛoNϪˉq-mh0{7~i{ݷ|o{tn~|M D!% J~N%09js_|\#Gi͠w<~|L\YD,%( '3<fL&4(+{)_؊20zLyz]V=4;><_lnVz$*]d>s)E  x0;pkwk5;:W{ŽUt[* YLAs wR Md!MC8`9{3z2>ݭFdgkݰf<'eh4i.F8K-h:I5uGZ;5.-%f݇Ot打ntͮg4(^֝Fē_Zv׽#.אfb24 ieXW^E^ c_ً ȔcLʀ2qV#@ Kh=L0!<"1U)ЪpFL>kyRZ\)//}\&$eyV=G`f<GO, y(TYF^/4Q•Å*2) BmhTy,k< FB?o7q1I$h4?4ͥh4gPnR-!*{{ƍߣMFC'G{gӈFqd<ݽvk ;uy"F$̅6~z $|Wxs+G5M͸$M$8K ]JMx;s!=Ze}HcWhB 3U.xz˹K)_S\b 99zbH¸` PJ'{K 0[C<UB8rY؝= JXDʼH<@gF֗vv<UX+-*ZTH)Bn&) K.ӐEQEQ'E"!AƒI3\FB$RxԹzL82ٍ@6vQ<PU)G^(Xe` $:|7{Bewr]Z^u'8̵*)˰/[5k%3h ox\1:1v=#Y|y)hzo+.Uso/N@?\qC7c5[ \16!3Ru4հ*蔆ual4z&S{(ςEQ .R7?!R  D IhiMm ~ ڙ mHk0BP7iTv-|-ɏlބ6IL >/ _Ŏ$]lj%sml۬m \J Do0x}-ԅ@h]) \Jlݕ_d)\hZj6ĘR=ց&P%! ctg狳z#6ݯ1.zd1h$o@+B[(l*KQEPt7|soppjFh_@ 6i"8/ Ok `{ w|(- hhBa۩}[ Uݐ_>Kv'+Rmg#uu{ u_]2^e<.QDRah!ݮvw;2{9ݻ@MYEdĜiVuN*@2XgE:('T}$N],:77ޱE@l)"'kLQ[`U<_1<_ ULSX]EQ|f̥(xh2ՍJs(05|SHF Z y"hdɶ~jvG?9+Km^*"PKʚy]*? o/HvA ¢ԅ, m"CDgR6YEdW:K #,L3vr-fB  YSꆯnn~zm&aсi z8i6 W#2Y3[Ṷ)l;9rk`w{K,6FƊk`6>muZQEQd.EQ#mvz"CCx2HT^dhVC݈[&:"ݸxm'D`-ȈkGҹK]4".?cc]'ZKYW5UʊCY)tDuV ;m7˲u~QEV2(f3=J,Mn109-l2uhE' e%gi26x.B[w'K1֭S]9iЉKOYWˡxetx'Z<;íodq/֩pF˻DCΠd' 㞤s4J$Q+bU\"b `;ӲeKĚG^DN~fUQEqi\_EQ7N rP*`XQ..V/AH$I~<$I$=YNTwѸy]pռSbZTMn{kxݿ&#n^ztZ_2zw DP4w4QLaf(1gVo[>dk0ieXW`Y6Ϩd_a4~A4se^i'yw/gNQjy5Q9wFuҍ7Yo_f?If' l[N`/Ff(CfN"2`\9#\8ff3тȐZ%I$sIy.I$i]}3, %i3+xk_ F JN ;^bAwtqݣl\^vUHyzs3mX,cʹzm !iZ Dzx9 5'{;۳.,4i\A\] ^i+gΰz] 9zo\yzMCT.zP+kPm[u?]a`Sjy"Nn(Mo%K'a#q#b55צG O_xG2Cĸ45_-7 E&a!` Pi\lme"1G婭7ֽ,$2#6:W*8>;p\2=@=jJH5zbQ &a2rN\KQ+6t.74mhz@ScØpo>:j qh3 hBHJaxqy.<vv2z#24ZON^u(\)ɇ*QruJ z Ml0yBWN|jK&ѸdVn$m]UK}JW:wDeeNNܾ n~rv7O4̦xWX̀@3b@ jGy. fwy;$I$GR%I$05/8"Q-":ɕ+͟>zv{lv(6c><[hJM(A\2ԚkV;[Dŝeab U#,ɲs6z-X HaP`ؙy΢1"ޠNf>] v?@oqEZk!b8fUzW>xwzI`c[U+&=>n4߃dv!nІpYgA $I$b.U& IDATI$dԪK3 œj \gq㧧o<pD#]W %Ui^nR_*cI;1. zvۗGu:bъq9gqq?~,Ѫ:^(o8ODUC߽of` ۦP ?` n\CZGDE0E gC0s3JHF-n~lmY|<㩵<;e.5I/NtR l_ #a^AYEyVqN$I3K$I2]֢ΪBQNu[[Ǜ7{!}of.W:ޡ˅f6Wo}|Mj`먰"[_{PVLbUl\UˉLi QZ_}˯/QHX -BU@ j!Ѝo?\{C cbghUC98չ m^#;W7b\WT(p 5,4\Djaf@VD7;LYFˡ<}_q,̄ ^Mi!C3>PC%8$=[OڍB(@VO$I~K$I2Hd6o&`) iX% Gf^6: 'kjܸZg|m!=W_}RՀ5+5D~Zomr4o@zMKW[V.dF*0Xt#RYKY,*7' Il yDA#2-\]6ّG_DZ/HNMjz\NJxwխ!hHH`A$E#,c8VEk0uM!K;r3.n+JR&UsT*R:<=.t2s0 ]xY'xƊ f{{}Ej&$:ݽ,d&=,"vƯ:< Ѹxi0N Z4'lzLgޥeȍG_3BAr@s(4s_qW4Rt$ȐNs0$ IJ2H ɐ 'u/ q !qJsoBY * ,@ A t ⯳pw ErC ىCI_!]@pe0ymɃp'Ff#0fOwWp>%Hsy+=1X/nʲzFmNh3ku)-9`l!xW6<fEMo]ܺRT*穚KRTVy>K6g4@TUu;ۿoF}_?:aH4agw; lgk\nb67D,b햶+YsF[XF1l42|̝&2j'IG`~,zAc~r2&0"y4FT 8ֶdvx(Q9EGtDCDJBqv =V9; b@ )m > dBT \17V2BI*t+9`>M:F)iDp?z~=B'~͝;|[Z<6MR;iHd23dqfK.Y#K25ҥRT*j.JRY (HJR1%%/rd؝ܙ_-X4 .0'x*֡l]rG;ˆhV\30?EH\/!;R 2~V6^Hn0 KiY`E2@t"9͒>8!HH$0 .v+D6`:b?BFiѡA*vs̿&c'-H" 1 <(!%Ri:YKd5hX<06ǂL߆%ot~(Zi*\0$ K?Ikk^3:v.3o,Z E>7}QfG̫5.Й `vcQHDt,564vRW*JrRT*gظ|O';Ѳpqರ==I̿\9 ٞ?bc֜EPft.A)5qizkο7J{Uiih-m3!wPN"<^Y40\d2f@XdQt]E2&ɍ L&) SOә6_Bɪgtb[b N3NPs&p@A$@qj4))A X$~iJ bY;7RYVyp{<W=Ok.C?8q dM/uy4ͣv/z^oףenn\3w]ǩ( kE> FDBƳfa]4O XV*J全KRTD1e{~4Y"yf8^(ދc2]== NEɮ\ 䝃> OQ26\:o@(S=*<{Wa'whSo7w`E`F O9ED"0P8W.8Pp)|{{-J٘oq.8UN7 : t Ӟn#iJ 8Dv K\ w&iYbpv"R)I7?9d;D1y`nXp}\Ks)g^K~|lyy}P` DY~S -2tߍsmIBb:W*Jr+RT*MxJ=ytzrC֦T9'o,PXJC]E ̬.i0v~)=SKPKbR( oG\ BЏ;MVou % C(͛T鴭/tD^jCg.)%WZf9StOC5SݤyrfjAGUzR?k`P[a(FFPEԎa]7́lDtPeƅbWt,L_׿Ly0~&` wG: juM\FE,k @ Ԡ6"H FuR:iJܓS-g6boF9{_:wsk)5W\хw˳*$:R%a+#iϓ[oYRP( }ͥP( + puIHf@@J6 Vೣ-ZƓ%FqOk^(-8K*EW8~? PKke #t]/!8 Y#N7oo4)xmYq"H( lfQ53I ^0A)"FbA Ra4P9ͤNABb \~;SEmqd%@zce Kt:d:fRCȫU[Ii7pLUHF^9_̶€F,Jl[ F]BP(Q4BP("I2}uABCNaGXzs~ɍk,% ӫt%/F ipVO`GPV@A2}>]GlՐR7 |bTzǂo,g (2l,ċT&`8@8H%!9̠Nr~$`j )YއUZ y%Gɟ/Uh=z'\mÞwGLʵ䓜wI}"H׷eIj+Ωxw B[A\ BKb@Dqx]VIҪYc$Wo* Jkjλ \CQ@μu`Av_|߽6l8Ms*uӃ,OgBIM,e|>b=b'.3 K'TrZؾV=?UfPIKι03ϐf"jنb#E f/'.:Ml $"z=Mh;ȌXrPOBúz:=գa .qЀUuH#Zn2\( oG BD@z1>{ÈIn4],^|Kh[юhĮǀ D8:C"Z懏]YsVbhbE Aɴ HEYJs䭽?OriХegZ%8ȁ!j,V*ӷH$.נ!)WmK9 gy@ ȱjK8BP(h.BPXqgY z]T/mxP[Ś!Ƒ]W{Vwk41`/L#8Œ `8@M|d{U< #Pz,IJd7%JGo!@z~=E~홫s[-8LNo9% Vgit磣ע\v IPF{+y?&aAd OR.VZ2{I{?Vb$]OԀ @`" :<:(;@2@3S*#}Es7(Pmop3c+=G?N +?4{NߖX"mڶaVp]JdjJW IDAT8I8NSOOOOOzͥ";w1QDTd3k*#p E Gnev~fܳjXx"U'K'\ؑ>'!$[I;̄O~+2$gTXXIBW7!tv<$;u 2C&I_NYm"=MuoE6'Aݮki@bx G%GʪVۇ"J8%SmBS罹ml3K0p3۝onV iufFlqj䝈l\WJ"V=M<])V~======/\zzzzz3o, ʛ@]0Ւ{+L ҠzVӋI@W/ܾG?o#z~m[JV/wOv>F܈@UΚ"J5H9sP$k+*B=޾^OUHj+HGO>W^t?OmDwf)x/J3CBkoރEGVb<۫TEuxk:c+?A ZI8,ROך+?6p7LXV}*$3GX#j%E[ԀD^Ik$:>y뾢8Cp>B^ss|^5JDāc]>pGU:S8^B_/֮Jݕu6-)qQJ ?0x*yUe<]:m`:I|7zb @v*ZwFTX ҁ{"< '$ѓ,d 5$P1isc{YjE4rX15f*B$bP|rg`Qzs(%o%;;_Z' `H5`ph1$!:(<`x՜#&°ZjbE5zY* ݟ-BmPgLRfϋSLwc3V4}ys?Dk`ȡ^syԽ袎ׇ{5@ IHyDѣoFpyw{;=緗O4ui[$"$e/oKZ$K?$  &p/v+ΘR놁 3xIBMM`hTfL}0 J,D"Q:bPiA|׈%*j u* "$|ac|:F &t JH䷢k9vHk!Ah6C磠y9 @scpՕL>(L" |n)ס0(#(yw~y]ɇĺpE@ri;K+ z-Ix#-D׉Z2Ty|\n>ؠ0sA)ХAI@t7gORJYm@T`P XgNBS]LTޔ8W(l$GWԐ:)]慈`H%+`t(yۄ-E2TV3iq=a@fVOS;2'jߍFW25LRkАƍfgܹNCa6yLK0LM|"yf#/lSրVV)0Rd؛_{F‰mQ(IK5tNL! R0!f@WF`˘"9,1g]FK@,N,fV@ . Hanv|,o;{w|V+bCWBT?e/9]QlhH  j쪫s==x4Di4_E+bc3 ' J1̉=QV[~}UEQ(1(b)g_j0\-rn[Ikd6HpoG77FR,f|FϔIi>"6t`^0L#](1{,ec8d#(q  b2r1~O8=J\6z LJ:OO9۾4~Ou2LΉdfgA\W߫d= e""Y'R`%Wa9;e1tckvyd8ueN}Q.IN!^_aYF_zO[9<[U#թv0=Dȫ!bۋB\Pn;f[^{^DNCv7R~pIe\`7\VIOKش(xᔘKQE1kIR֒j}XІ+޵ O[erтSN[!v< abol{fEjNkiX+a] 0Fx-W+z q֒g%G/wj9~|ʣrCU54;I/ k$8* 8m7ȸ(^^EQ!$%Aj [GM 5b դ3G8{ʞ/ 2s~/{X N}ڃ̟6{z|˻hr1%ewYUyN_}ecWn$?$Xs$#uyY]dbQEQ+1(b:74$z?;QJ lHi1ެRn&ߊrƬ>&c.6#UQ H-^۝?qz Z3#H.?tdސZ_iw<ޠ0$vނWs`)͡t;k s HO[@s&dý9;ܽ_&ȣ^oB3lhFu/+!+|~f9BKi6@oQEQLTb.EQ,1Kҥ޽ LNw3}5)~ \V-G!OB!rͪ0=n=ШΜ䢼}CX@XZNqR @iREQKQE1BאH\\m HaI|wF7RnL^6V {>zmΡG#)M|UY:INaNm`@up=/c{2W%|H3Q)uab@Fe߽޶~WU6Cl*Oafb!κ$ >=mb0$!ol>0^\n2р:6Fy9 %~ZEQXEQdqe)z |+@i9 ;RhT}{x9N^8 l~jP)ڤsn wWu13.Cz5i+k"P|B;ۛZ-}/hwTA "% rpxզi̴("IwQ[&6v^5k!\#CS͖ޯ.޶y lM}N +ՎE5a¬EФYIM=XCB\і3sώeEQD%REQnDN *n&¹AV4 X=ߋ(KEQ@fGTN ,رYEu_&>=hD[h׀ڳkRSN5TAJ22ePz;PX|4N, K.~q_6"#"ڊ(s)Yo#u9VZZݒ8,{$x'=ij~ #bAdyS>@EٛZȺ@uRހnVJ`ódp~ޅo9B40Ins b,DyjrVc",37t8P$"G5>¾b:+Wotfބ4Pӣ~l*#]!,iPv9\C8vM$]Dѽ_Z鼟FXPq]*XSÞߙǪ\PO?W-͛@$plQվr!eqzReY)\,˲Y.r\  y U*W+ڼ==eP)LP0' ;HdeOmvd4@^4ߟp٨)Mr˹TtPp7Cn979|JVBe<(flzJlx]LU kWE뢱/h CRQJ`w"9K2DXl4]7DWSEA1(Kf7"J*HNYL% EW@%H <2x@Lբ9py \2SWr9E|=ֆov͹>l4hrLbQSKTk'@:.Jg5I&L&dD,˲,;GdYe3+P ֯iq{n; =ڤ΍op]5,Us~&"$1)8N*Gs{TZownoqѩn%k- %>gl}vrTH Ȏ^cwovi"'$<5 P,677 s^9uHrg v _Kف: j@eFlIxv k `q eYecNȲ,˾Q=HP(:M0exvѓ̨,uf>>evϳ.+ԉ*`k릳mJ /4{O @VUrd' AՏZ6@Q|zNc07eIF{{^V[B4<TTɗ~_ެtt(_چ'l.YDDUCN\+ mz-9_Hڗexŕ'!HQ&2 ب!рM!$A-b]4As )2)˲,&1,˲l* IDATrВ cmYmVMwz8խW^jК؅[T/Cw 眉<;:A}s(9uf-U*%x^v#zGu-e\~ª-uѽ-T.%Nty)5c)ߟ}:!aeYY;,d ^#KAZ()p9eY]JdYeS,ׅ.ă=< t}ƢI৭{>ZJ%p n ZɌ^dވ,XP[[7rC`ۛ,Щc$Z@u_veqYx$RzcmZ RƝ{N*tirIN(V\ a5{q}jщ"c "bPҢ],˲l,:gYeE}`E@^Ibt"*I95]T0u 7O W+k"Mh^($O Bc..tAN%4 I!)_Dj^̕'~_uO[5ђ3O+_2ѡ|r7Ǫ;}'H;9˲,^eYMUD"r>,G$ޕ :{)+=j]o9vOv4uQyGh0TQ@,U좆B0^oœv Ie[4{WL 8z8E\i\$E]qH <ߍ\ށ#&tށ/[gwrv3r?PUjGzY`NHT &eYeX-ʲ,˦1#O2S9kibUYG*{ oyb &J$iRJr}hTQN㨈w}Uo&D!80{V]7;Q%ox" @TN'0~]"# uEY٪pПR:$.<7I["FUw{V?԰F_8'_& M"(‘s,˲K1,˲<""RM BYz}alEN)!75wbׯRև_f砀is *I%:M/hW7BXpx6LCLԱ )UR(w<֓Ai{;m(ї1E}@Ht% q*ypX4ul'}ĩ@^_:x yf8E&?Gbߥwαd'H x!b>BSYeWGdYeS&zyCkQqsAt@4P4߹_%˗,3(\ 7S8Xz!+fKF=At`9j9qX(0Y F]U|}*=nd$RF@2Qf&%D e@H7 EQ"!!@BW4m{^R5c_ÕXY6fO3 |l^ѤjJgǸ,b܇-*r7m^*fuT8, RrGwsjA_7`u70sy{H <*k332>Gܟ]4N'/vŻ]6p|Q4)[~4I`.[[6BP(I\ Bp.!LM[$3~Lrd+):N3qO!~4]`$.E^X2. D_ @f#CaHXDAҼN2rl?! 7#8ɢb6硄h&On唧T\m+3HM]:9X[?w;SiՑ%fnd:TL6G7Q[VEV=Tv\e.7ݘu}RîVmx૩ZvCξtP( +Q4BP(,Bo#uЕȱ|DUo{H&[<ևlR'tj 9OwfOFqjBP(ZR( `m) J+zӹe90<^IF//.uTϚ{ "<"HzS]hW`RVfU_Sq89i]Mb,rq!ҋZH $J `CKx툀LJ8a:2 %ɉ$:?GQ):ɆM*TGWwWJ0<&MO΍ьդ9cheua5kf<Fs[ R[H2*sq\B㿹tx%|LrZBq\/~\o~&< Bp BlD1r_!rd?|>쬯iM}ZĵKRiz-P]"NQBg#UuI6J&򡘂Hpc (slC]G腋Xis$Hs!) otH2`.n h)O;rEP,<,&fU,+p 1uwxwBVGv.4L ^=ڏp =O"4CqLH,+fik,ۚ&'L.3B?\}ڿ_l&Ojwk^( ™ͥP( ḥM o}06sdKҷ-ln~x@v+<%+,࣮'\|s}f?KYxn0i!7G+H^Sr` p%GK$m @z(^ijC^A"',#?aTYG /:a[_‰f4CHR@((ٛDx!D2 @/D ?w+PHj`1=zfp~S u%b%+߁̪GkŇR􉞝Y|'(br#\`˓Y]u,Q( U)KP(\.@"0 1p :9{48/J8W%رK0\GL{ITNh?3߁zh" VrIFҡêfP;g%65L9I20j:SfAm8vHSwndY^knJ /1݌J]hAB_/@Gख़h3C##?]vf9]78g/"]KδTv9ǑNʽ"[Ff!{\JˑIgt# If1PUXم#+Rʩb%~! u<! 꾰C["6/\H[Wy\WZ筅:bv# NZg +u+brf?nmUBPjS4BP(LgRm.!g7 mwƃh2!2C9.mj}  0άn#⎬ʎ`qÿN[~)ML8'}GG5v37 !ʝlK:cA&%=<%I!HcS,:״'Ctr]5#iݮ.s0@M2k&zEqOr܍^vd$T kHtM5-(y-E\Mh 7HJPp>p-&ϤÁxsvr'?c$L7U3H1G {U|z-ՁkYsw|q/b]klVeY$,vIwؔez>#M ؎a8`rh #]camxNY϶gN/ Ba.܄BP(|eD))jߵ'ֻkB1L8AP[Hy#0Hz3|hƬ"rxjX×­;)%Anl3kڽ\ < w~pNqiÿ@oIpRkȸ ^P52ma3ƭ?G|j7-i"jxMxl ZvRAoO\6z̃ӣKODJXm` ` BPΥP( oNcHmN2rBҋ: Ƴ?A I%ܳ{fS0phR!,c am1P+n!N9v8Δvjcg5{9w>vڟxc{{{)Wڏt_*9 k}pt.˒0k@mB$uf=P"zE{ @ا 2A !bҵ7ayV_ph iCQY]n:S2P4.j{x5t_W; |nٗGWĴ"T1A31nlƢBP(\R( %(2wdFTtRnRãۓ_1ۻ% ݟ_c K2i )z?wv~tϹ 1/յf*e:@@E$i%Tޭ{w_gfɛ5q\$S2v?!W 0Qj^57t#"h̞p0b&XDZ#().-2,հǴI"PN; 9)\ݞϾw9dnJ!KT'u&ݭ!Qq=AdxP( H\ BT`!; `<5^' An`ry1Z0;[ }-]ē%"ΈIΰDdTW HZFrOⅲ5x?ToxR&`#7-fǪB??U6DB$)`tojE0ve):r`냭cdqpg;֪Fֺ{"@)Hriu5nFUFv 4AWFu i ӳ~Goש/ܠE":,\LǗE`E9rD=_伴o{}tE3,!~v t2R{fO,Mx/h^zUY7~[^Pb'_37~_* VGK .f9ςgK^%>ɤ-BPxuͥP( &928@?LNvl0h1^%*Ae3]Ҡ$V9 ң/Mp@2ƶ t~U}$WHT"MR AG.sW TB+!3T<470)5I{T.\Ā+3 Mɠddm @ӑ MJ}۞%dʂKp9Wp>^6C 0P5YM1u#w=*g Fo[ػs)SdO'Xxvov#, GeUZRٔ=0kչ6VSe 'MKyKP(^-Es) )KZRn?` kI:p#\f0'=yliD#4 L?D $DtR?x09/*2 ym+10:"8r.PȘ܁V39jarMT2s9f)[&39Djp,ʴ(e>)ezeUa5xM_gPp~߀9:9y 3o׼yZ#;ϖqFߝf{w=\[PUŕ3[F/Ma?wbv.9g,s|`8+}}Aׯ BF\ B_ЂŝɒI̧@1 WwۿN`9.wR^>_n{b>L&?~]g*YIq#NNK3|Hf e;v{ pIH8@(/t")G#@No攛k4c^NpthDt?l9!d$$4KuG"Ծ1h4O.^G9u<+JqtggO|GXN `|R s?Nl*QKx_tNjY8 Nj:]Uc 2EL'ӠP( _OR( S aU+^K8>44]mߔn&FI+>& {x2?βv;[ .Q +/w~E[H`gM"ÜnmҡryిX&I<|({ZkC()χ5 PͳCG 88\rxIDrԔR8Zxhx+i8"DY49J=d9˨+iZfu)C8wwƗ\n\g{˞;qqnO)*f,+?,mth,@RaI BP}3 vjO{/|lksr"psU3bu $Bv~ӭoe5ER` wCt8a꯽3C1TKQ ͌ױ-̈3ioOn /ܕHDG&6qlm `c/okWO8sO ?yœp4k"{ҎӜlgݠI"ɜ..d~OGrEQRs)(7פ°J\a(ٓS[y`/z 2>!\ۓhxAE~3\^FB#%mN `&˓X )G]raתxrx͍ja_KVm)hxpX4K0  ?ld|ZUOۼp %%̂ ӪӸ{`2;ظ֮ȞP7p\yKJܣM6D0v]|KպYHAcr8'^6(((nBEQ ’&߾n%xWPGuܝ-2A2X̗ ަ8 OZo+t?l1K472 ю2"ѡ:/N&߾α]?=vN0&LXxE#O i; ; G/?w7`mp'?>ZM(uڲK!x Ow2l*]n武9gfrdVY((\( L)aϪ5uݦ}fָm><}mSneϞ&6`<-2QsMߺYGd @%C׬}YڜLjqz/?J*"\jq53.ŧ6EvCurǐr/{\8\'0[2DXN:WȞXޢ(#Pj.EQ9XO6 aHfddpYO$Xigi9p r{<^sAϕ.myP]?gI+IKY0`vکC|C;)ӂK;]p?|]xX%a30UK˩?dN31ڇo{WUJ9KQE(5(hA;$\v8\F:NP\c-rwH2A/O\sTmP4D  Yٜ\nNqkb@aj{DFב^I.sVnsag:9:}6UV]D2-±4v6ՈYKSEQ?REQo4+9?;9SX toB8Ot%gJ)+x} cp"i?r69Y|yw,G%CN{F䒛>. {ԓԕ2'1x;߉ Be"[?t=S3 Z@*Qـu{kwL iwD":Zxdb:i8x;Uw3ٷ<:7_qAIV S?.rRN;6٣^;9jpXlt2CX x(:(,)GAvcI܃YruvmF X<}В>~?O<"ڟ߽8"HJ0Fb o72>j _{_J; uNw\'']\pN+,tSzY\ h=`{`ƛ'#Q.if1"?]˝RS (ѣ>c:'4,(( lƎBEQ)5(L t*5C?/a\Y}T!2koLUC؄h~xm.AE)-> n~vn]"Y@JΏ\g2+o K9眍`~XFt٬Z}أM`9rxPݏ=ARgய~A/c=n_(x^EQgIm V8f.Ɠ_tԉGx\q퇰cgxs<r2&1Gv{4?q V䅡f@l8a4mCݓ]| Ó4B"t1z5[r.EQ?REQj4x| a75l{_S@9 ̺Ik}w0*$o{Ϭ>bt_p_'W8 w(pf8g ^od {R[w6{S#}4ދO gB8+VB_8g774C_l/eG)F]WxN]cT_gZQEQ\(3,KKBκk}YS$A9=S !&Ps8x<+#(D 76N6m:<9Dސ|MQdU@яE׵ $;i -(tQtSYEQڢAQhH9X#i$sާ j%ͷgߊy} ? ۳f 5熷#ڲ'cSyۜy8=gOY}([ID\%]I2\mO5agGV><ڋ UzD7=xEp@ {;6ך:2>`MZ^²e5i A7SG'[[e(xʜKQEq6&'GD!3h9i'CO3N205 >ב|MY:59O4W`  ѺQL[I ۚߌW+r__b e˗kX6#gR<v4UPGI)\тб_hH٠ Y,*(ӕ9(T -#;Yݻ~ BXqG":N?G}ћ!)­˔g{`xk=4P6 f粛d}ٵۭgOs2Xe O0 mڬ=Z%҂/wD𻝸y CUD'À-+ˆ`|8 t"i"_G=v/yH|%DZF:RM5}؃(J[lzɀT7Kǘ5Q6/Aжd[pz "YOO>„(y`"qꢿ9BqRGꓔ4۷@d⬢(8(x`Gė}Jh72*BG{\Om,urgf4q9޷p&گ@˰=7gx # cd:¼),m,}9C{ ;;w2~Sy#utxFJU詛3i^F A@2TUBO?Ww=#ѷcێkUN yNE.H+f; ӓz< }UWMZ2EuC"3iRkȰ}-"ܘ>z{ ƯZ&@{=n.OwV!*G2p +tCs %) ɞ{,]Vr^M&{`=]!M zV/@4Q}Ey=xY#ux_<­(7{f:e 0vt{QQEQܧԹEQgNãH7c؝]׎GoKx`pX϶oیނ7J`OIWDn̦?0\1Wlw:l߱ ?0x8ri7؂ Pv$cS q{:r$aR|qNhAĝ/?#׮yN5D˩6 U 3mXe!Z0ѲqAN/>e46˅B)w?h!0C@K #Ox#p2hϋFZ5 0Ÿ;dsO5xcΚ1ܮl{6;j<~屦̚%-5ll%I"k~нCHln$ԑր$$#'("?Ų4kGfdխNpfUPZB#8p?""8QGLN832FF={98'zd֣+78K:kxp}z}K F@JFigG/.Œȋx|d 5ӳ].C^2jo|wv[0])'8x7kvF4@)uJ`R:]Ҷ$_gl+]c"J?fb]/0YJ.lrnA"-2/Ã?v@=[``ԛs)tsz 'wkbw㶛wV&3$4BY[ecG_Ť ȩD_g@ ddJAv *7'{X*9Mw s{$߆oSܒ~zz},P6yiRe/R 6Z.kfa04FB"}G7$ HC &d% dl[| 8N 㞜 8~<ȗa\FFFFF^^߬yhoYMv2,%ptv=8M?}Ko.o=buwi;H2s"SuvD2Ep"L 1TA'L i ~ ), ePEKOCS@DW"\D[ƬR}CDT/:y?xbӚr^|%[5nj\ABrs A($@( y/H3N"qҴo,$@@[ǫyX#?@>1eddddE8')6DkvщD&u)7fSXʡҜIk:yaFEhŠK!ɬZ"I9& [ Q$H e0r"8`,AZ#gB(C 6LhpwdHP)66 Dc[D(R+]L%PɌӐDP" $Rɬ`J#KydI[#Edš;E@}6=$uZev$~֨~ao,sR*;f;P~6Cb%_YMX,dV0D41ٝ!RS!PHi>L<CfeXf<\Ntא#####?~FȋXNn=@A ي?7Y. ̓.Uˈ:Wo vs3\k1$8)(8FHN"2%/x" )` >)?)L ݽfA3u04+*/!!$ $G`FA$̴bzSn՜9v3nSPhKtwށNY΋_DGeN-w]2;Νu_ n'/iyݑ-C͠EH0 @ؓ]?J<}C>9=F~NҼҟ~zb=N1$.J0[N kO 0ؤ֘ftIfG{KnJpV(@'ɀ2NgVVIeqą5j82222QsT.X2f? ?@n77+Lפ `¹Wiӣ{o~ʦM+$͚z~bx|SfTJ%+gT _d[bӧ{R&90[ÄN6MyeV֑.>"˷]FҚ 3Τ]]^)Zfn /g./sX~[@Dv'u:-AUW_fivȇmq&e?%C,'P )]fV إk5j&)` 3)Cѯ'MdV@IԨS@3^JwP OUiXr ZDAPe@Y[^p˷jngQen8xz@A.w@[ĔSE{zE4hu4ƛ' ^0Le5XPVbP CyτGGc=:ѓ .3[6Wc?s,IFd2SKo>ȼ4w3 <]!d``aHAJّh\BDVZH~:y]NaWeG2Yf k/DWX.VgZ.FWڶ&Фw<$tg@0Z5|9>z+Y2/GT3s|Nȓ j1(-r8dZDiZ\GHJMcYӌY^BEY)\<1w0@oNUJ뇿u n`KtVcI%AaRg]:kj''B722223j.#####w2ۑvyǦ$<.2L V誔Z;ΏW^8X9wv- 0.ӓ|t{dFBRMFw#Gc>a7g$oH,dcɀ;Pb6$) x# lN,l5ÏLwջdQ="E1"E"moU{݃u9`+[_K2f0 ~D%Gؾ }K-h(KI2P $%B*F㺾8]P  &@o20֖Ι "S_<5ocJ> wVn,DP B;iʮa6֡upmY& Bjf? %2U5 GNɣw ^AI4 Ǿu]w{zzzzz+}ͥL M{%X603椡 5X V'HDb62v_Ň md:{&pZ3ptT;A8];JUDr8ФMg K2Th y88f7QpduI@`ҝt%0*pZYJcfe_CcqW 䰄۪DL8~oy01R 0LU,$C6'D"%s^=`/4j A`@"MnK̅s|/%󷡡MX$ NigƓɗlH5c5ycpŀJb IH25ZD #5X@+%KycHU5h F v5ItDpѬ(P00Ӝo3wz=5ڊXtf &7ۘΡ_8b* "YSBڬ-\u_'vJܐv;Jh ʺtvJ4]aSRA'>Ah%٥<pzފKSLAT:Cnl`⪮}=====e5̧&8Ri hmw*1K&ȁ.&`,[g1JւA"}m`JwW?|}ssyuŃ]Ģ/?1uq1[LjIUrL+Pj !7lM֯^&7~8%d(9rg ӈ96܋ـElE=e+q pZbqDL"v @:䠠f3DPkLfTl;')'N"U( hwmJH&ɫLw ,Ճ*ѷ_CԊV!XTVk:+ꪪ)xB6*M.m֗_LG!l.?======_x]Xa ȠpC6Px.gwj@Ľm$"(\ [=G ]+nF0"@?rti+`4A1hBtw鈝N] LM^spk( !!3E'ܗu[8dÃQB&G] ɐ9(hXZ%@o)L4XU Z*@QE̽-rrO?i< x4VRג'P bj ,.۶!U<|VU!@Eӥte,SiC?ry몬rm՝6FQUȺ2i# nj=====5# pĚ,{fZ?@B^ Q-ݯҝ'J:^ GLsDv br)qr9/m+,/pk)aG #*jkI;twu+;9WUFQ`kB_x8mg6fqQ)r 3ad-hRg%9j[ Hp34k} ^cWhF#ZR8XD@@&nKiy\UFPQ%Z4 jA$ΐs邜֊.kh}JSM>4H Ng70A,ȔRGR kv]Ճ֘5ZA.V{Z~D2=T$ "Q1=wt>BQ@%=L%5;ؕg+;_-]nȧ=nDBzzzzzz76){WY0񜼗ӽ1/\?a$# VuqO8^>YRn:n[P)J́IH@fWP/`1e)+dCEM9o3zoqǰ)YrR[$S>?|tl/!4nNV{\V_ ӿvJK ^,UР4E0NC0\}skLxalPDH$0I$:3nv!\|~xWlN}# @P`hBMZhl]bϞٸ}}y2$F@Bx@V#'ٻ:HJXr,'VNB$3@jRd;O]fԝ-7 *$g2홍Cؘ'EDU%U-p35`O|ϖUgI蒺{zzzzz>}ͥkM40h}zB0j6lDHL̰msg9GZjrd tO4fmS Hh %0T1ե|UjZ*x:\y Eʈ~[l)-A"{QNF,TvSL2L,\7Au=:mKRȮ IDATȱuʡL?ċW-r[^wcz#*ֻ9*U !7p""&DLef( 5_ w$H\D@"R.H]5Umﻸ(v 1*}U{rIuB-,B("dPc8bm ThDkLq6U?r;0|t7Xg+ȐjQb{s6{5bU74tOᗫj?7:8??95 )?m]ƞ_)+Ncig|lO͢tr:;^!\|4wBkU3Y_hnI yO lc`":Ď\::::>1"Of ."jT[W%ˌeO/TB -3\|j^ LJjfTLv0^$ ԩCk^on(K8k:tL0CX2FZ5=:~SEtˇ;x)`b0ERuɸN[w/f)Jcͷz㈃^sC&,_oznP!|&Zz,-&~l?W*T!%RHl6KJ, ֹ/z /X8a(޲S k)"`s_$[G:n}<-G_Iy/`w/Rxk5ILM<`~L+)\aLĶJ|u0oS<͞l̵ w+9 8(9ٮ\NLY$KбV;K:ͥcM}uy-(,̮W/z,Hz02\:gr>Y݂zhUrA-!Ԭ E9RoWyviqSQiX>5 &\'U`{j9嶔ă/ML;}EbgG÷~ V7dtZ);mI@ pmrih{{|D,Kl/_6!ˀ䟯؇᫁U7^x&+."(1/t\o}Q=!{]dwOL.={",NwX3F(zA/F2$ t(ýHr3L^wUW `2gHwĵƝVPrVC&~']}GGGGKi.k"7+7kH tҶ4)hOᷡ5- @fYrvIΩmD r2{^HdA5*k AH暓h'ݪ7H$2ثzewͦ}B@Z bql>~-G \>/ m[*aU&VT-`|\? 6ڲ枌 II.D"C'L TF:̀P <%6|'rWї֠Ms|i!B*69A' ,B5YY, CxsR 2j=ѠtC epKr"ò~nn.ǯ3mxa'ttttt4с"\\A][HAÕ^uT2xZhL& y2Lk^?3(IzKsN;Mf6PHRTȓu+$Xv^+'fB\*߽dgt8 +*l2!V[he^ЙLN 6_Jի|>kg#̿#:<.dЂ-$P_D_a j m@ UU3:E Z,~]ENΥ^lXH@r4e?.Ouh0Td(tY՜,,mHeQfY1+Vמ ;{#ZtF7iıP<4Vs9›Ptvm;Id$2ӈ&ږ̎JwGxIFBDNڞS尗.$8tV(7X:B) Pɣ" (XxɡC XzAGd_GD]OKٚ n WHgIIP\ ZmU -tQmVU=ZTixX)Q uE4W_W"AXi ˏ/ 锳iL]Rr/IDW% Q}/l:DȞNMK8ZkvQC"!xxöKuJM[:\:::::0?|8z-Jŝv2wi#şV|pr<9~oXzRSdA(ZHo “:ElYK y*7fW lcgcE vy27{o2fok>xNFD1PKaHisnJ%q~V1'}x Go m^ CA/I[^o`oWObKdp:oot6G[/龞l=lf?ct*`]Cb= [-Vi[-F"zAE `xRt䱳ChB%%mlkhMDdOt]@sUϮBxuS-2 %pl^.ck3Ԛ{|41C<{T%V=,~?֟We([Tj-d1,=|^^ Qb <=tw[ہJΔ7'G_y/b\ :#Ɵs*9WDI?'Ya ӪwA9M 2lIVzϩ=ġ`J* oo^pal2] B#JJ$IW)$IeiO]gNǧm3ԭތ+n-8z{:9~IXhiRO 4ّl[mcxg B`cMk,n| )Wݟ8~7/" f τ#<9q[_h~qe:'eZ&qx|_$ID)$Iގwj D;;BwGt_$&,:T hƬ}T#޸s0D!!X%@-|Ӕrw"rx ")3_BIc"[=>ⵐ_Vɯwڕ[罺#bpÙ&Y~)^2t!5X,0'D[%u2_I] \6᫪9@_Tn__b0&j;jv/^BUU//1 Nd}B;gD@'0;˿ 2=މ6lqlybWwшw$v2{uOpmo4>aF;;ĶpNָo'OoLw8ٞJm?gL,pw9ʯMjJ$IӤK$Irhue;nWNr[--St q 9m6`f GO{S7ܿtAG4i7}"rV6%#mgEP ]tnqE9TVϙ?GXн|e8YUoݮr8Eg '_2x'!<hY3{ ly:we4#8 8ȭ(~y}4:R kVgz h<A`hO5&b=-`Oa`ԃ ̺}0aRuo卶]=etI$n6/I$IUKN&astQ|ôR'23& Yojb'*WChps\Yjj&(ƣZ薯>z (#bȶp?|Ԯ< y.yrC*l[1!#Y;9(-2Ѽqvm\T>xF5gѾ䀲h"GGS )chux,Whw"wW\+a4A##iv5T'[WLmk8Pd(Tr{/+I$Jy.I$1u7]xZ!dBMҹ*_R1o"!m얿z]hs <;1` _6Ȁ6sX]4k[[w>׆Axe`rbNylB=^4Iof 6&x;~}[DޮƜC  wij`Vk(bvˎp Ya`E$#sgzƸs~h[mG]{[J$I~<<$I~UMI}U7Us{n9"EBdHܐ䓐 G;S Z D^Zs5VpLG_Jl;X (`\ϒ3sCYv{FzT[ yrdRЌ&!돏X.(,  k ^uZ66p"{K%yo$I$y|<$I~Avz nLt_;mBPM2Xf &2wUϡq@fCPYv#Dfy WFu)w@"vӂѼ*9!e(hSuϯ_,u(Jt̂/F$OnȈy~_i3ȄC&N^< &D$IXI_$IY@U罗?]nN;,1kAÔN]fa\mKѧ`N[p"ZZQmnEGKN s`0A+AnѼ65e##wBiSx4Ee"x.Mhx6jYw@\$2#ᄷh^=D^V/37vG/PPQRCI @ p| 03P jz7n|/\0I$RKEI$Kj̲ᣟl2Ss c:|kvpmȳhlbA(9L ?:=)33.EpmV-XWĄ럚}{!Z';;õXUVOu,cO^tūiGysVreh8%۰E`P%R4o;HjD4:}a)7mT#FdǙ!?)3pw̩㇜/0g"cw!=;jsQ`'I$MsI$IN6Ug{7j}0⦣հg!=#q7W+yG63r wK]ё3 u6yk0m۠@nADLJ0D"R"jW?|(glta@"͵\~6AdAvEםZ1t, -xmpBsY,= ~@|'r&GpuZ}u DeLpq]7@cAl5>);c v( ET>WKzFD 4ـy؊պ'c%ws4" ̀cz#ˮ2Zm5Uv "7QDHLP(B$~7H\!@(BDD@=(3ݮqm\grqgCdse9UۮtY!;GH4(d@$*COW4%ěɻca\ܹݝ?Ⱥ\ij1iR,%6;]tȄ R Q$̞$)|%.Dg9)CЕb./ |VBd nZ?KjLt `&%e*lo9XЄ vR/;O Zp+κt> Ƥ 'E憼1Tyǀn б۩aaOi=5|@2|j'DP(J QB~Kt HOrgLtd:VdAI3 ̑C8,rոK2L_AX=tPE4g(ud @3sR5u9:r4MӼsii.:ō +nvvހ:󗣎I%aguCm(ͻ!f8B@MR{CKZoZ vQ•j8\/ 1|#5fsC@ &vQ=pQ$)ӭJ9AVU@f{{WOJ}g)BXݻ3 Cv8<OX %2">2T!ֈIGڕ#UrNh˗wgg7jʋ4wntmB cJL0@X a޿N32 SXnkQ4M4ϫ\i1ɑŸ1FE 9iapc!pyI b($2<1;=4<,]d: HV[>s;Lѫd^n' -7HWm%A Jɕ }%L PnOs -hj;:g=:!Cٛ-zMf?rݚuڜTsW:}~1b72nL'o/|x F{?~} 0J{q%[?D#$i_0FBGN+Û!Ȫaf^X!8ܮ"޿.3~x r Őq `EYj, d/Z 2tjD[еQ,Ѩ4M4/Y4M4r} c͡ ُ Rs#An% IDATS X*Xڤ%7 1͋2.-/fg5{f0|pS#Da,A*$Hyd6 Ip 5^0@VKhk,'ɳO\O${O"nE%NK97^:ŵntW}p7؛lit|_lO,,aZZ9޿(@s\kkQ7 Hxf`:2J%ς#W, dJ=-0n pwϷ|igM~950*5&sdAE2 점:UJM4M3h1iYf;ܭp+1&U!%}o'_4NFljN Zٹs?Ǎ+99CC9co3rY۰ذb A\d 7 @@AkK$MG|}Nye$-\}TAf+ڗ `װcx1{'CZӯRS} m A!r9{@ a89'f4~zll:{.D[[9BT JR6H!Tg%Z=jârܶqN] dLL^U}^Y<4Ic ePR^ɺ%T 8/2cNn2\u@ۀZG&*lYzfÔ:N?zzLv ![\B!f\W*U+)UfGyvk !+\B! i2z[u32 þfl%㽏xǹ=BGَti9ů6}W?95֫կoC2{ X#tw%O\M<.Y_!Fs !.KHWP%[Zt8x]"ۥ`.NF5'o z d`6{.Z# @rt$,EB!/r.!³cҽUk6p' ^*NdGfGzF̝u'\ H'o[d~kۍ_%FE[BEXT=< )hGmwuL^:to$2KDT!a/:BOȹBϚ=~wd^AņU\{B $L0O81mr8hNwc0[UFfJ@%O;LfqzV׽^}bj>O~_q#ׁņh$3F-"@LLN|qB!|D%BxLvu:Y@OHT3a1s{ -תwU:yC= !)R ;9JLgw{-% H%'B戸={PbެD/NW]ϩ^6lVT'+!V*`@-p_=B!<"B!;cԨ{WE@uoa){XEYlod\+4p`B* $I ;-eG!qCk2yH\JkJ]$AAd (0]Kw/}d7k@FH$!̱&d -!BD%BxFLoV|w9tX1U7Vg hr0KH+w)cW`OT9= 1<6NLP`6sf }N{ş>cwnv@#\*F7[s{|#k;nB!'+?!.]OCoz_m9RSez 8hۃ3ôrREdm-Dy6tȘ]j7!7k.(` 0"*i* Kp@$J+J'fL?c̶BB>ZK'a3#Vc\=BϒȹBdrPs>l>m +JN}˭gb'fCh2 FreސY: HWdW"]%'Iy=3]6J'gnr/  ǝλ-~YL/ !"B!\l]z_rʣ\菼 r=znlC-F眫h՝L@@8L'ƕ%+TJNqwoq=zrU]ܮ>ˠ%Rݻ_B!pD?BLnD|NA'o-჌?z 'Qװ??\H$da}螌wT% vhiO8L !Z3/&ToTϿɫҦ|ӱ n NJJ˯hlB!gOԹBXcL v'O? U85xX{'+Z׽v ɚ,Ӧ.wRcr>o QWs6ɧ`5ґZm OMT *m4Qf3 4i9Z& B%jOVt%R&o}ڠ̕Ov[O/W+"SfEox'B!9Bb+t̙*"Ig螹jm% rпe-E/t!Xa{>.tUN' !kq(B^vu&qa5piw]6y]ĜF㿦G=}'D\6{j9>ۯOyA0W"bloFΛ[9md~[eARخbj4ϪN!"B!\N=3JeD3Ѝ:/D̈́OsrOezꞈn~i Ȓ=hRd{zzSJ$Mk!q,XAv{B!\>s !.F p(Pk$'t7O?؝5JZ C:uْGnNAU·\rkL}9 rm5"G']z (= (Ǔ:B!+zBhnڐu JJ Ŋ\Lgyhev]w*,|2؀l.5zN'w7W3V2MiMLNg0Cvם@N@T+0dB!"B!\f7R}սKv!- .RBETF_mLUw&xۆ2|'\bпF/.^9"2@VN[)USi3L!N'BϥȹBpNdh4XTcC)'3n{WF@:힮d4zۓWA䆃ׁmȆ-=;*UCWf蝧wT!.ȹBϋV*ڊj@$bY:=L-[v֗HO _\j֤E(Bcu1d&BϹȹBϝddzJ4I\$rkPɎt7Y _UYK@6oV %I `Ԇ:cU-!B8ȹBϩuZ]@CDI&V5X%-{S9y hT)\SĜ-@ĵ ? @ A B C D E F G H J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~   ^1[)q:@T!IdA*N4C@SKB0 C!H @PxhUgw}ι7 fPDd)aAԂfp2(ө-Pbe:N|D1P,B4)BKa!{{O8Aۄיsά럵sۭ-AR½# dX FX/FME1lڼ 3mCĮ̇ ׿pX̓/S""""7?1Uet74o X44ݻ:"afDfD;2:fٜdΑ;Rںq1UDDDc^ IDAT]rCP )5"TE1>WV' sH sChyk#@`V턡PDDD7>yp 5RDҩ"$lH $symǶl]EDDDDDDD7EDDDDDDDDv2S""""""""{\DDDDDDDDzOH)s=e.""""""""EDDDDDDD2S""""""""{\DDDDDDDDzOH)s=e.""""""""EDDDDDDD2S""""""""{\DDDDDDDDzOH)s=e.""""""""EDDDDDDD2S""""""""{\DDDDDDDDzOH)s=e."""Ʋ/^Ԙ""fM.q ""X"|pyчvlҶm Fanef'L9pSMz|7 _Ŀ_Wms~ez&WXlw?a6C_ FihAl0:23KRX, }G~șg}~cڤȯ~˗Xӵ`­@0'D .˚}~83N=io1#^n`ީn}͜9y38t,ϟ?{p[+N7f$"PxA9 HQTͲ~<ē&~IO[9<\_y\{7ܰdppk]#Zff=y~"F/d.w߽o,ΊG(dH4fQ#_onfp3 òED2-0:Գgp[z⛞d^*"" ~6O?!rCA^ 2讀4nօ؁3Ufi䘣ey̱6O][V>F ,@?\ykk^z)-v1c,`w 2.d~kd94^ H 3: ͝@ @(+/Qtgx'OکzyK}EKlkG]@tЉ;2[hԑҼ`dp+O?mʮΙޜ\yܲn}9[Ψa rf0w Td@2$ @-Yհ&>wiA|g >MDDm$.h7}ʭ[(7#6n]<G&`0 H^F1Ri5/sYGihO~C `A` FBN>7vuثrnX&)ƏԚsk"9z d$_~N K,eGf2ILfCшvZGy '#GOg+wϺGmx:>C0@2spG4҆WkpfOPW>XiHf^G3a+W-z}{pEde.[`eK/_nuV09RA9ŒEJ2D dX { 8[Qu#E$pd ɃeOf~ĝS.^ͻN^l.HƟ~Ü2*0k N*Ⱥ( t2a37RHe HV RB`??>Mgѳ'_sOofE{{@.`Iޞ0)& 4m۷?̺M_N("% MZ4h>?oޜg;Mاbͷ|',[Hsm 'F+sÜfQ}$0 Hfư ̆`M$c"D0{Bh)!ɜ2 F(/FP<_}ڥלo[܂5 ,<5"װjxl?uwهMm=1o‡z1@ $aVHL氈*[:ڌ60ڸ%`n9j twDX!{@ лg`̌:u؁}̙{ps4he0'Nx̋LN=϶lO"0jǺ=ng.>rᰀV -4 8r{6Lх/5̒:h;P̻e`׾?o/ܹWot̎7j/+otD9#Yw03'@90FpOǍ_SǶe޺7mND^2jZXV'XŪt z-^gw{ xmSMMC/i 8BC 2HE"B&A,Z:\DTiJ mS.8m`9zwfeLe_'V˳zVȌ0ZEjQP^4 JsI+AsuJ_}dB0#)B>Ը֯Vp2ݐi}\Çr { \nG?5 x/*VC* e@)R NG L#{ .2s: Ԃt 4%fsO^4g> n%b6Յt@+`NlOOOs?@`$䦛/|μG8]*TZC!R4I 5 PSō"Ii旼tk/kZckr4B˃ɞ>EWL eQh˫yv*њϾ?u(+DP%WMjX Vb`Qa$=* ),+I1[f$ڤ`bFgoUY#QxT+3֙Kb&/z/>obG~eʼ4 "ŪZP3rm>/,70 Iكy/)`%ת#Wvk?v;1s+|]wm1 VTkd&X(!}.!:a[v.Nl`g^f 1Qdɕ`|e PA(M|$lu8BHUoB$t)a@(Vi[[tO3G_rӆo<1y͠K{k -TM#nV# =Sd3N"ji H2I#1WWu?z12jxysy#P8\x;ij.ߏ_2 v,]))Gh_}_ykwqan47 ./m~rw{n-є !h`AS);*zN4MxN` khjIe $"K6~klmEh '( ,8]tYwv_{zzzD6nGyc'i!D09yC/!Ihl?Yw?vۏ9OCמsZ)lmNà͘n҂:O`\F]HFX˜ !FE1D*pڋ?zJq-Oxٛ.4,ڲy׹x;dvu d!b"{Y Ð( w{gOϮczAh8Xsgp&R<Et'#h*uZk;}خۇIju= خuF*2&h6:'?8眝o|!|D5xX*(Sp& ˏ'Th|Ͻig=Qs9ZEඛ$BaZ--8;la~MO\w`\(̬"2Z-mE6`L!ddaK:%fʵ#C[AJVhFmr==ksnňa@Ӊ0@ ICƋ zĚ5nڴW_B @hR%Kx}ݽNps&kZenI"0 Rn*B 0ܣB>/32h"{tD+/^~ÃX"7]/<0h -G.+]eyMl/D#"A b~L“S2>o\?+z_|XXm=&pD@0%`ìrY5dQu*"K'lÄ tUm0-’%UcN`WTƥ`e'[4wO_OE .ezN9%$===?q|'W ړBfiWgCq?zϣ-8 4MB($!u-1CAh-m9.E P1#X{٥oqs7ymyL^Hb*a`|NMh vmQnÛ7_{:>{Z*w[mgaJ@Du0V$:#Es@@5聊'<"1Zsy, j?v~%E^|ನ{ikui3,lC\g”VO>u!?xK7E4媖,W$8SeӦkP{zv=_{o;;?k}y!QH;C2ڴN41uR3SvZjmVcbѪ1VQR(Jm4xE,}{=>%U۔s3{yֳNq{7`@l$ 1B&WIԘe"qQ#™F đ1 I-Uڞo(SJ",M2߹NT^Xx3T>J4(V6=Ie[]፲/4Mz~~\u\욚]Ksn2hx]EeY.!fb@k̾z~eVv^\V{L9I lk^iQi${TFm7{;()!U4e+x P;?S*}!~wuY{WMMM. ֞>ߌU.E$Kje^ka𘥖 -ˎtt,fs-=ďvt~𡗓2X5UtJjy^H̝@oB5j%چĄJc_#tzm`\R&ꥱIU5yoN=Omy 9WL)iI2BR$XBD2 `PՌAZٖ07s?@mMΧ?5[݀ # ŔG fD`=DҨFj̃T$%;$8*eob.`A{i&2AD<{gڊ{?zÆ&9ݤXS,%D]p[֙>ne;:yI?8Q-KL"V9;߼༃8 h:e15 ci‚QvFB@ncAD%e\CBQFeĝ(5ft~ESQ&þ𡒯ɸ?uUQB I,KK)VAf@BbYZ (b" ˘*  OlM:{1c-b b1R"Qbdo DPI hH4:`ޢBYY1 nv#"' h vŖeΛz[>n Hr(JԔX&)` &J}J0Y)Hܥ*+ @.*{地}@|X>k(PS6Sof) 1Tg2O!swTp2A!%H**t  TwGѵuZkwnW<#nP4uRFV 4HѤ 4|555;KϧjF$()eR) ':eʁ:i:JHNE+ZR:c&A^|󈠨J)y@lT"x$*l {~xnq7߼KyWGl?(0]ƃl }wͼ \˓9"7LҵWMAEx쌷S ]- 6햓ҧ?- ;:Mpa>ل6V,bS|AUᥠMϲv#cv=fnjW==o[u}D69X$fYrŠIE̍.eJ5 rδSLHe`$f ]Mg'Ol7 Mz@jr IHHo[$̩%NDǎ P:S AJR"NW*$gӎ>cۋ{Z+][3cj20F>3fy?ߐ!{/_O=3 ^9NQd.PE#"TƎ` J';4r$L|+?-/x{־{Ƹg@)M%ZJp)T8F(g=\rCk΢\t}=}$RX@_L&L^f1}__Z"rUh5< P$ "VŤ*ȪJSKQ`2Csk6M- lRLs3B$#^Y6kk\vٽwv uckz΅ZKݾc̙׼lt "!3U/ˁZ( %@5&RSetPs&)A RC{.\» IDAT&}O\"XT"jÿ?3{*a=;:e}^oX⊘$K !5-*"ЂJk4qd0h&`"ͲMA  }ǟt܎N}L#+WTn@ RD[ W?g3qc1q'N8pXW|`֬xez ¬0U!sn$@H ""6ګ&3>Lw[ÉNH3wȣ T"ƅ>̴闿r̈ 0YH @TK`唫D%;“j絭Ȳz?قW^YCI 2̀<2˄Jxmuޝ* wdtӁc\#đw{}hmw/yiSwȺbes;@!.#ԀNétw3ǟrzD#r4%0谲LZ?^1CoMDҌRϱ7Wػl1;EU{Uuƿo>K^Jj|4%iUlMv 1* :ZX  E(J EA0j#-:X3ԚFTTpZss! ;c\qZs}o et`Vi#Î "jN/x-\ŒF-LK _5,pp1&4:kN9u@7b snQ&S84BC3xz2ĴK>@S[_1~3 >{9Jykjٶq]W{+3>[g,0O&  0W$t`QXp`p0W"Y)p0EN&"w+BAoFk' ZR&q/s&}Xax5uCX͢5-IX$R[X`đG&Db3Y5SP:ׯ#߰kVfS?[A(zJH޻XFǬ1:v^{ԑ Q]h6Jֶ0 vlϼ; t_)HCDXe{&4 41aOۺ%#RbJ A 9|؞}FǍך̪& )JZJJk'GԦ..rjSm/4C/_9oR*ZQs]9y!L@Զ$&˾yh|e,̬BT [qA|0Kt54[xjKo5h[}GP7kf]MԘ1I(Ԭ& f ̪*.*KZWB5:z1_vC3"Im-9r8 6ȇ4T9W_1{X͸+*0# >+|rΜ D'"E-2 ,gYۿ]9C~0,H_ hdJQҬm^_ի>_f;SbRa0QrЀ36: z'-[;2a%DRyQ9ADpTv'Go[{58C_zusԣpogmx7~?V1ӧ_C>czG8#iC+Ct; iEԐ'IsǞr%W4\Jd5s>aBÖA=~Z5$Jn b O1Ь%Zj0I"Hk*Aar_̽;g@y˗{1Sm1&$%|JA>bجƍ3ɬY.AjD;?4JöCg?kwl&lV0<)j{!̒h;.  7FHF0h$ߑKfDAI(B"@o{ۄ "1*9όxňÇ`ţW>:nxo+ZJ ;;3(43G1k㘓ֲ /YYUcUfP+ji;w{=r9b 0~OdN > ooe~fϾu͚i?jOT1̨к[iA5-X})~<>ʼe4$/ cܟ0z7o{ftߣEptNb 3O+yB& ٷތb(n:~H?] 4h]zff4J%L a֭5W"fVNu_5&( D[L8cΜbƬ=,AQhTޞAlk{(SJEWw`gӋ>d1ɳh&HgzZ٢Ese0Һm3̨laF*դ*p UaK^?Nu粢(Ӵ9K՟ۧvJtPҺ% bj@QW:+u^H V%X$@4r =_zPTt_ZVg1Fl;psi̔!qϟl[Ok[cLM:JTg]j@Y_J.'orv'FxCo/K(&)v) ;cmQC-B",!M+Jǎ%Zq_8EbΛ R@FYZP 9syUZo)iA]F +S.VG'X4zyHU- mEHPGV]ZRh$?bMupTDԢYDjΦj9kԩSi?21 h(%Z*`K}G_}7ZjY4}H1 p 附Zpj8M-pH# L 8S@. `~CVAbt`!0@J"?zVgϷo} ;c`iPނ@DLsW )(>KFDCDt,U Ѩ ¤[uG8)fA|͹tݼ- P[2ny$ּsU߰M&@uUĈ(7u>?OFj?$9:ESn&LG_[Y?1C$bQKXŌje%+'MMy*T 4z?AEPWNj#V|Q+HysSyޤKO8p, _,VVѢ50>ٽO:+WSi6EWۼEZM\Avi.ӓUnԼ;yBV0B𹯈H҃4664sƍ[AX3,!Yy;a7Ӡ~O]N ,), Vw6h%غtg~Z΢ iUR:)Ƃvc?/'6qN,Z؇pF!+]iL*%vԽ/4P 384ʶ\ҋ,}^'4E)=gyLC 1ZSO-bYUuǿk}ν}EcSM5hԦ6"*iFc奨#HlMQ!GS$ՒV iKvA85ڌN(q9gǹАD^xg9w{g~yW,~!FJȈ`| "q<8#/:֬P`*0"V~dͦsf5MƦ4H L@q(PM3]6 do7~]pDm{dۣ& ZL5~T=Y`&֐rT41GXzgl^bAL=K>B 7zܷTAOo J0<(>Zz̈HT96AKZL`?kótU-e#MΔك./((N̽C0`D#!n05:̾#yA[@J&23䜙ؒ?vŦ$ėGA$Ge˵_3@ߴhCsF`B߸9a/-KWW7QIAbjCU|j ݏ}uľ;Si_^߼ZS-'E%_X`IȺ ehI̱jJ Q~θƳR{ ^(7Ǐs?E}Ȳ}LaF1SM=+q?͓<߷@pPeFĕ͗G u! FlRreR\g`1#[;RWq33sX` wP~LYAVN-?=v„]h Qb2B]ޟJ N1 Q*8ڣ?~og 0B>|.Z)֩ZR"wqH dwqޞ=\l5O=s۔#z̵+W>5pfw藋:{_;e@ Q.L`$cH"1$"`oɓ!U!e2JP<HA(C?2[T9O!u82B- x f0i$ QMYrG4`Z]O-Q3 R8c_pƍg7F18gcGipjRz 6_6]+|"ǃ@`.ĺn͙wų/7n~g 5j GFdbN;4Ԃ Js&MB((AfF#H b!9zgc|О3`ͪ0!3L-R##(xPf.$Bvcɉ}O c%l;4 (9X"du~MOlxlY%CqjyPvdžbШtuTJ [?[;MDT˭V]vo^scVʐ .b_Ki"(N[K61{qo{fjh=J@%Kʕ? DqglϘ1RlfSw_;/[*92) @% PGP_i.׽qqH9׬M^ 1\ppbbo%BI EPF?>+N|.Ҳ {yqI r0RS"1 gGM=jbj@0Uaghn.#ggcS A~Oȶ"@`۝s( !uݮpu|DqB G ˗z_~S6{i>m`8fO=)h"(%΢ ,IFEluR]fD j'1(5,T =}{U!CQYjVukz(rp̪ =9!&z.McUPPPZ9LO kwkOy8=8h0Ks  'B@ܩ%@0e>/м+o߯#u/ؚ)nλ2-ع0zK F H gD!""rn{ͺmQ{ qӥWEm;\Oƅ<; ;#@D$ @RNPd1@ 2P`9Ęͩ8N%I!6&EaY!Y{/{% IDATE#Г"WUMLgpKti KWc-d*5 )> ZDpokDfd̚yV ]L(5X~)wdb,\xڵw^޽d#8imEH*HMK_g>@)(\L"yFFD8'&>XWxHe(yڂozC708&ZӮ,V8I:.d5UV,M@,jߐ$ UNohC2"դ;ڤ,]z[1LgWݭOv֙bS]b4QO=N8a4FF6,:;J'(e|K)&1F8H֑:.Adݑ*c\cnxR( ϩ8"c,uT'XwS6a@ NE'%K+jTi t<+|`G`pa|Mw̃[<j3 zIa#In^r_=bguG]\|řSwb yIKuj!{ԍjd_ܐhc[y㭷 gb(>7ցT KP!BZL٥` &Iq_RRrZ^r-׬ͨ[%gyuɿ9wv m#.aR)%T,i "˜:="C͘Ϳ%ۍz}xyVz~O=yxyV)6Ia4e2eQIIΤ>o\|GVQ%*#q+~ Y=78WecmB"4ˑꝪ [ `JSW sS\l,۩uv'x̑Gqd g|Dē.E ( SE@ 3o~A\WL}b$ A' ].i!]=蛇ylcpCL.))5heh?cdO >MEHT 4{߿^tJvD >uƬ;4ih"s h8x8Lb53ףB(Ht&;c8;`=&pw蹋ο1]+bo?=BΠ[ȉ],-}"R*L{N^V@ierosz+#Ϥ¬Mk:8Gfi3p܄ V&`Jtlxvιs~{/}O=o!hY~pߝw7T!*B2e[XzwqlB|I=ĺ:&!4i;]϶+))) >E~D4 AkC-S)?m+,[=B^i9$Cl@PpR$f*FrI`eD}4TZ#iucԞ}1dn9k?7?3@nLC l%{d*WARdZؒ@z#"tAg2^U-]"Ѳ8p&/lL'{oΌa`mjED щnLڀ4c3(HF]_vOl'}k~x=G?1yHYM`e||[9! >Fut+ZD,o*`#+=wVxo^tY76մD=J1!#s9R[9#Q 1d!df 4zE*Hi4lݺWV,AjL:w}s;{=rwLt ) =Cm݉v6w97F(VX'% ˨PMRVx}Ml8JaVAòMcsқnhm>ff"D fa^Kڒ2ZL,( Sꍧg q(A\m={g̘~3cݓ&vUsBgzݍV\+W^ac̣giш$m ~\Lͪ ღÁfpaWQGreqIӴY[`"E%%%% 򹼼! A|&* DEL?/}ޜmnyE'!\ eLTDSͨB#CHE *Q ✨aVwiH@ճͥ-@""R3CLHXey\RK?'T]=+zU "N-;[ܫEg!VHWEZWhWl.oV&&FWH_(d*KJv-FeMuQxtA{ƒ׮?o DjctUT *e@A9Ȩ..HqbRQ!ϝ<"tF}B9pq"FāIJs"g1-4Kss s{f #c1`!)CLR q0JH$M (_`*6  `Qe,;e iW;;3z@+@Ts=0GR#)]BAJ(?~ީoo=b̢$baVhd*A[I\Pʼn'<՚~^X;|-0iR =Ly;x^uX F,*H솒EKFMaNZ6Zl  IC]9A-PR#2$x/ߴ? 0ټv "1m^MjpyUl/#_wb7w?DŽz{@cU뗻k .**$zn1Gj۶.xYg$- Z,3u:]KW@ȋr0àH3p1 Duyý_$`)S]Y6-զMSj>l)i)>`[ hZY; n,@ԑ -ĝ`[A>lb0W}z= bmrHdy^nI$ e5+zZ> 5tn$b#B& ۲dw}=C$$iJ)zV:$ no0 3}C~nhw\>wM/8׎nvx1qpe? o#[ :cws(%ܕda9W~c]QXHr(01ý{kIdNx*vz178>hpV 1 lFD5$% /% "Caʀ@Fl-27fb C0$D-1j tCA#[+\ sl'u X44Ԝw^F>\ pviC!-PEiVZ׬az44" ΁aܑ;J9d٪y߾`s裟}=8WGSu`"8;vw.:u A}yM]f#M"wڕś+ywF6q(ᑠӛYI"d!";[NpGId3D ᰶgbk-UoؽA[@&l*OrVTTTTT/ 2Y#'jFitR`:SK]7Xk;}j;I60 3/&X{R1PE^֡u'2`F2L1NyRF޵8:4nZBBM/3nqzLc _@nUs)1h+w-߅KWaqϯ=p9܋}3 "Q|Y:;pcy, fw?}Vѓ[b9s.{G[pgq# [El39Ÿve=!?ЌEmڳ-'Ǒû çoZ0^dV֬daL c;*9D 9Nd߼r`ʅ LmB&[*Kbu0qi! toc}i/ AIV]duI'Bq(ȢF vJ@h@+-hSQQQgr6v* 9u}A(A)6R~䔿:n1ڼ`Q̽gp=R̅(k!dq@Mf6GAĮBe<) ᆬ5(%=ؑ'-ap| Pqt" D幓LXW|q޼֬f^xᜏ{_[ߚ2 }@$[TsvX1Q/Oz,B bT<‡>h/up;gvWAYu{&>8^{Нp{ϸ㮯1/y☣;וFxzoK/5 LfP Թb'b-z-p4"ֽ셗׮)Ndb.`Z0OW?xmxr?}{98uw/ v3.W3&zɓ\{Y*bJbp"D5jӮc]7S6u͙PEH!;HoԺ,x´"=s}}^\^["ĶBͥ {i,QmR F( 9D ZGbV8OhѺŋ\ٕ+W[YHcT2$2N1cQGv8[ I"(Ǯ fʏgWnt̄3HC1"; .[٦޸s ߝ=O-Yۗwq{vsDp&^? !W_s :{{?hq***vh>`HZ©RZ@ 5 9C4k3'%|pŝw޳gUutv\ r)^R""b.% Rví>cbP߁ p3HDJdFd)e4/28("' g|_2]~ώ:I@4WD1-Y3sNp 8E;`7n1H'PV"mJANL0V5Y)uIح$Zߨz_gZ.^!,#o{cLU/暛2ᐡ[zuQ?ʽ)N/i]t@'&SKtB#K8&zpQxf@L -#P;Curι;ye_|h_zk Ei^:lp6 [iJ⁏_kr?[T=rFfԭFH܅-˛ZK(!j|?~ڤmZ0+W.800p衇MN k?{dUu>}A ƚNęc3biAR Lр1F"4hTQQTߏ!>FFL۷y8Z@w3>uzs{o-v)O^! A0 ޲9|"; |^jkm-|ys}! ШUEc"#Jc\@Cj/u>u23 '}ŋ!WZ3Ql[b\9 ZnB\J*(/ʩt{;ZP})k#emۋ?O'|G^jT1mj2uI LޫV5Ͷs' ~@qٺK'_QVa$#F0s{9[W\ 2꣬R!JB*1{"L*EAy mj6ۥ=[xʊzBĬ"`zCFjm }ɑGte#ۆ IE!q뫯.*h;8Ӏωƪ30*$A&QRR)AcP'NғqlyXhsWjC &'65 ;a|quO_m@\/ ic[|g.kRP̀jl@ (Tf-j ,Ԥ> ΆuL UOJjPAmf]a^Hcmm8yXYS<B=ꉋE*`{Y rآ\s-אBհ+i.!PHU IDATb2T ظYnC?KNO$~=ƍR+ D+RݶsP#DjԨ652j !]euBbFF[nH}ix}F(R\ӏ_y݁Zt-Kzja,Z&9V?ac(?壱b/#N/>" &c?uu .ysm 8&1n'˅w̾vA.|r9?G#O=i._!(u房ٯψU0o=3gqlCo^̮0 ;eC8:uC<835 ?@Q2ΞӓfccU9֯1ྕ{"Wqz\>*kʼezO |*S;%,PlIC%j{TO9aBpJ2 `$j/U:IQI !` Ȫ j+vPesb-ӎ; 0O=MeT{%"UU.0T@ pmC;pU6nLTz DeOaMVXU}qu q!-֐ju={e-J' PRH~85kIgl\s"Xv\H0q`WZR1aҗǟwHVzJ{_0)CBHCFp1٠څMM]ϲg<6wZ7aX %Sb/S?n|q#&OZКлM,~ Rf&JVΙtʩ=PNKDLmeΥxJ>K˲\q֭)N䕁6AIlX>ug"Aӗ,9j ;"u-[<|H'^:s*"!4즖G~-K/RiĐͱ~cY#'U˫=B I,nOdв)f2aG򭫧H]N-۪^W*X%MǜËAOiK,% lm|`XG6ZvKo:h?v@ D*z@&aڲ=qymsfGjj6z+_h =zwLZ[[nQh j\c B,>MB_5YŤV)YȋYKchL>&D>{lEUիxL27Uኘ6[JdQ`g!z[eQ6o, jLQ2'8 ^T#&@0Ǚr禤&j\z LQ9pR_=Xk嫇;}^"D><(Du6U|7j7o?|bțș(U)ʢ2wrOZ1+&gqs((8s,{ ]XTy=Nܾ\:}kD FԎ攞Ӈ;|~W_0 __3t߯ݚުe)8 qF)}E9%b(,>οjlۼl2:0| \rls o .p4Ǎ~xo32; KR )L!1Tu7tع^s5>·?ZCT/JDfg3Vv޳|'ݔK*H@sYԠV=䳾| N\3/}?kǟq~BBcxSWuVI3J KIw_~8;oݥV1  d%7tvmnm]9(%y\kG55>D˒xpVp.n^*HBRbMf(I`xq=bإ߿O>ZL{@3vf( D,Pn` H 1q^)j6Uޫ+n Ap`Z6 e 8(ӺAS*PsICF6fԑ;FFN}&Y 3kR, jƤDlem0b fFMLAXkDw~cm!_nm,Q׸!1#Q3&#'2usN`)lXmPwϙs}M .-|J v@&uW<6~;=q㮪6O|٩>^O~߉&yZcWbYÅRr jP jDiؔ3ȌDM˼6&&s0O7H 0hG3絃xY47eC0#+sFN!  =<4Iq?h .Ì_W1gX"As>(5~kzKnƌhk~ΙNp6 <7YB(*bl iJ+čφ612ASA d$Paj;mUE7,zxʡDs;F7޻Ui Pɰ`hP*`10$]' [oI 'W@ߝVjDEܲ (gD֭z%포^V@^b\RsLV8{{ةGNOt*b^̕Fjjy3cgjuO/졻 豓,ǡi%!㏾麶]ߌ Ds 1k8^{C]P94rZ5cjҧ Zv d<F0xr=(VC(vߣA<ÿylʕXت폭xכ6ubDXZdč. `@K1|$oI jTRvuHKVR93[OnT(J#ANxBGۘ3ǶN@Q&TjpU8ԩPԌ02O\l 3k>5QlNiV: b8_n*{QwSK)Wk#8*6{jR @>:AW.rA[ܹŢՐ*|r)ԹP'"Ӑw9HȠѬwK=P.Y~K_{*Hv{u?`:Z!w$Zn[ U*ΔJ˹0*L@]<IQ0349X(&ؼMwOkē]Ypl Vh ,( ,}I0W+YL8StCv>X <=;~ܚ[zEixH yԈ XK*rH%fRc+dw&L{m!L)P=ģN^W.+g~awQins-Aj&v ZsxF#jα&ӎ8jez+z#m5;l~s;VQ<|" X({^ E.JOX)?,w%Ȓ S!6}9ӧ=ub}(RZ|]Q4{MMd̒!֫N G6>-{:҉'ݰ}~9z}'R,͛X0#^Ɩ;㨣km)fy Krgp r(eaĴ;2uTZkO'goVȹ;M#[w|xy͆5k^رMUBI5TruV'CHk`sO<2kon+ZgdD^TX5 H{+= ]iGnw  _9Q,-ћ&#1i)'3Gc˞$hr.`cI4_UX-f=ʺ28HltkFԌR2%fjf̬jiT"$J3y'_y*nvYwm-fB䙸(#C)) &S#悴sW|T 0[`6A@R./ ]zW͂"#"b2 ±F,qNyw]?k7ҚUas.ܳjW~cCw#"e2YY2,̜1 yf>Z2ȡ_9vGqwX«agKϺo$̭pjAKK2r d4\RE! +X, WN4fs%EM\@IY` Cj;G>⋷wTPkENR7+9P2 4ɠ?As &2@V_#Iם3{Z7\k}IBG5X"t <e6UQ2,OiKP!5($<@{9g5}% ` `3s^֚kɓV㦛<m$NrR|9Zz/9J`NBH ) ZBPKxoM97Y}OV]5{9qKCt%bv@BH`DPrQްz=JJ!w4q@O߷wNꁯу9޻1e6e~U=prL- 4 &W#@D=(6M1q`&g1Y%DIsv /t!O/_qV=:v0;qaڑ6kB:b.99mĚc˚b 90zb$N*̃ hr߸x`-@ޚ1>W~7FUt%/<#R,䒉\5s.PL%m ~,n)\3oY+p+[c5z >ށ\7ߺ{W;(;2BܼJ Јk\V,ükκlκGݸ[4L72ᖅ2S[ 3g;#yan&V?ŘS h/=cALM#[S{Oϧ<:d=oޤ@i4U~M>-͎7>pŕs.ktTefwor {e #\ܛR`q7vNff3{ [ʴg|>($͔Ytr3.O՛1{m&ofc7q^)(0سj_&u>KO u6bћoL-1/A/JvzSLĸj1g_U?#p;.yۋ8;uDPi^Cr5 #" 7"6['c}2tIe!t:C˽O~j߽>b{,^6|߯z,:*P 0w51sӒCX FlaV4/S6}wYl[;Q;BɈ ?6uwo;YnېTfcy:il]3I`, _ygx*ٕL'3b0l7{7I3o:{նU7HڦA93Me sʩ킝Ӯ~uA-? yNtg8g+S0 ]G)7gi;5 hD7vW'|E) &0Up&7ӎ1/!Ͻ~뻝"\CC2jg;1E1@]0(nkCR)Dk ƪb4nckpǂܸtpgKhe(3gצc E˹&P   Y8?ڔ)ޖΎ;Wg ,~JBKL5Kk~cBI4Vc\;o9pfKcfc0&2:i">Î쁻u|g>9݉'^Fcuǂz,4EE1ԙRC{:e)Hb6C=,g6m@"6%06)u'bx{Θ1m~\[Ewܥ_rNmX9D {Hh 梀h= >'֘Üb(qF ez&x&ґ8A{P IDATg8zGs8/\pܫjY HW"i&ww7g.zp() ö{qk)&GR(A1rZ!o$J"/x=3.ZӦT՝;&mkſ|ߔs a|vvA_8{ \&t_<:OrȑGT /,apײuR!0T]䏷~|eEsK%Yd霫yj-Pvd̑L!P$,ƍ&Ѱ^JJ]w2DNDt 1s.ϖ$!ژ6jx%6 GxywÝK3P20!icRT 3^!7!Ƣ̽|ߵx|ԯ ~D5&p^)Y, BC_/"rB G翉97}zR"1(YQ̩{;;yԳx]D+E;O/_s~PS` o;`Q?amى@5b5NّI "8Y䬀xpXETT D3S樻 Ȼ~Ͼ;FGhf^4oED3GhD A/pEp4F&6 P3c8rD!iE"x.ᅪQh3q|f5Un];X̼ ^ܞ3kc Ay|_nN UXȱoch`jK޿ygs˩f93-'vcs0al(eb=/k_/\pϗ-_̃[.ٽCq%('ĢDn$p&+[ùS b'3xuݑ2ET2# sm&F)?vް20?;̒hsI$*( *TE% HVA$K?@JQ@ETrˆNU8wf|_=nݧzC vA$0!sݦbS 6sb8QӈH04ta. Ty-?Kzo<{y]=;sNR37P2p%Pqp (+GNáR7Ξ0YN3$g}Rǘ,z>ԓOO]w}O=5dVH~$$,/F)`TyP2+(t<;3 ; +n܉[ּ`j4T Q$Fj̽Mrif"Xj-`k Ya&yi-@\%N "DԔs9i{Ɲ-օ #$ ;*iˇ68w`͗\ arT r9 P6֑85>/ ǻx~ym&rb8;y n L0^s:CQEĭeC:Xfx70tu/{`߹>8У8#͈3v+[t.O>vǜ3osϹ\S(a 3b\4*ƹq4 w2?xWҎeҒɄgr͉:‹;ꨓ~j&% <DZtD\+HjshR).l+$hY% p4 gSk"x檫O_Ͽjt$68M %0T=|f PX$d"\Ka[ϯ<;ˎ >;xy_摇$Mm"k*Y$ѝ=A&((W E 7 k)Ym<ṎEWCQhD:Μ^*'E@Bl:ZJ}کGE_M7Ə֩ 3gD&HRʅg?ADf6Ep_S۽qj3_⦟_vǜ^e/̉9B0w%"3Df[HDn-7T+?ǤAKܦ Bd4F:qauh~|뮹Ԣ䋮?g.`$1$mbIwFv(.И7c9$La y~#ۜx'w;h U!,ǩ)®Hp#WwRːYI.)%TA)Zk 6 0#OJ:ڽκw&.Ye_]on[ް:o}vğ5?n5q3K@Kn^9qFOMOX(pR)L)J`ԉ@4Zk[:Iv7`U?:&KGf!:L2?*@\` dFh@[K@ǫ'4DoR\UDM-(Rj?8M1Y|L]SRu0w2rnb14$\aܑ %h{p DM˄ 9$3J0ZuOp \[ݖB &_f LZtY taby 3sWXS\pYcĶ|gm\P-Ln " D/.F9<75\=ǁN3byv퀕V:- wq=ӦM'F[w71'sœ <*&dtf$١I5%J"@,3 z47ӥզvG$Iq:IP!' \P?>_( B3{K!LngꎯQ p#pPM}oȘwG/\AeNLN=p*ܒJ$/)r_)vryAza~xkB<詵:Dpl'aĎ' ~M6>E(_+Fɂ Y,xA@(s9pBɽu'VmN42(C*sNZBCue3=pNhIu癪pf/,8y9E[&w^#'\~\eoov睏h;{'"ZSw4Mh))@͘cV@]M\*.%_ Bl#sRqI7ɳg]ၜgNhLSS84<c-bM( v1 FnD5r4i?rEqI5JIk[ Q,(q2k9{P\>}AC1UKTA͐BY9{6 Tɭjf`qZV&v"pkj "̼4Ͼ݇]saK?gcNE 4e{.< &Cr]#OLZ$ek*MSI]yi&" w@Z󠙛#OE_cIǞ|jƳLݔCu/[R諸(J5ueaVC(0oHr Ҷmf>2FFGSp3XҦ/٨ bl)/\\zѿw}wOsjSDUdPMP!soR ox#<1m&y@~̹fVY#l=w,ɹ5+ޢծQn,)iu$DpՌXBSSM2KWsM~?3c5/R(cѦ$\y 8K`fnRT|A^>vµ j3Bd"X2H@q q&'!$E.Zu6KA; 64,קkbk6pu^^W]1z5 "qИ5"+?<|-ror#E:n0:Zk! ;QR_ Pl P`O pȀt]aH].l>{?2;@f%FĉI 5F!<HH 6~مIYeyzK2mk !4wtD"ຣSʕܙC< ` 17u*€e&~AD1{StaHaN ИGs[Nu|mypyq19yX$l8yF{X"Ƽ!ʲA nKd?7M=utJr>h QX$,\!)\ |e,w+~J[yщ\U@ēq ׄX`#n̝m>^mեA/ƫ^]]Q_fP!ϫ?wsN\) 'ʩʠ=Z@QFOJTy>?YxE$#i"uQvڦV;8\@= c(cPM_ř=~ML%S@`Eb>$}S~6Cs! 8}]'D:Fa$`Dʑs{aeAT$ IF2 Ifqss_]>U9z0֢5q 48H1M/y}+Ku=xE<'Y;-BKV'BœUz/CB D-8L1SbhbVGͼ:#s|up߽,w-|f]&vi[BY TF%vR woz_wYuIɅ ,p*,f9{iښX0PA b "wg MQr4KN /:ߕ4L,BI6J গu.)"P:'@}){ra8yJT^z$`bwZP ѬNg䰯}a].xϥ/R8Ns XEepkvsc> }{l`??{N붬uABl1, fڠ$U׆( Vemx%+#L6D9À)8#6ƨf"G[6m7䡦dE1S$Q7L!!6*OjT1L6 Xs_]w}> /K$E*UU[ !(2{o!bWs O5sSr~a9|Ʉ!KVKS$Βļ9j B2 ]% $e5*;k3cI.D5DsϬ{﹊Ï 2^m7m2u N #0ښ/`1W&ct-z&CKA!རNm0fME; & Cfk EjSq d}'O&wUP"Q "EM mMvi<;_xD7:H] HC ]xNM3RPk<+(B(M nV(1j@Z*Lt nM BXDuS*$OmPG 0]F'm Exr"zS`7@K4"2|"vMon1+D в4^޴_WN8ZQdoN4>ӝky [#1;߾[o )9:ng^ExՁ[|_jd3#Øxɿ/>n۟G:@$D kS@1h23mm |<CԂ LĎd-ox;4wG>ɷ{NyzԵMՒ+˳3|T.Phղ`hڴlo~HÿvPLZÙ@<931$)x6H2G9MUͻnB%|p2x A6 zMNѵ%s$'ӄ1A0$G;Geܝ!=Iq7MI FTTĂ@%,Lp"$tz$?4LaGb/GCf]'m蘣aI r(YCΩ r.c bQ0%he& Hނ8xH(Hl90-SZu]v}ul$Cإ(`-jOB6Z9p\| ]L>IDM`Jm 'l#$fݏMBWy̭|x}nϊM-܅#q yop2]/ 'Nd#i͜wj?v4:RmǑEMc, SJ ;n!; zƹ RD",jIyj7 q~N5L2q5x]2Mr)Y9VZE=bRLg sh9PRcn B/^ayGGoU* R=; {m[V2=?\Rt,J2kx曾m~툣ĝH"!cB9sB.$@Kܳ$`=up4!VˆFRD),Ed^i7Ԍ3VY*,# w"ZgyĻ=XƳ<3g5@%e#ɨ׿}PCFSCϋw _mT(t0GJ m͜pe[OhҴK/u7gu*/]4W\oۯ_2o>RxP"yi#ֵn9'OBD쀑+N&hGV/  rL뮙Bw[4 }?-0 IDATN4Jxz7Y)Tw+_V,I 0\E.ZxjA;@pQ,fpPf }N,'Ne  H+`$F-ED2$M+^ ;^wE{wP_sW2ɜ̞{n'u3NlRn8Ĩ>3ț$DX楹mƟpeq\2ܝH0V-O$epYێWцw,`"QGk$Cmd N'yzp*^= '[}ׅl!Z,BL@T‰%h$j啇޷c{#'xȈA@ͭnZ TT") H} VPe!$A[VD9;|lNaq :gO<#8\W]uڋ2yȅ4 hCXKd"/6 sW9#\MnE5 2ky  D^7R*nSN _x;DĈє))I-w@b0aXsۉJvv~t_z JpIyX=1 @9V sUK<{w?Y*={_M{JUwغFQqK%9$+h[2HB[Yv#0J0Cb tM\ 6xon3ЅE41iJ&i؄s_$y vb8Q]YoNT+0kWn;MSB4$Y nJL W˹ g7gs;G%q3gY;&E nXRfpqRZ)0氻P ~[mL@ Q  iX 'A"!DL;7[Xkm|6}hHGeeRRf)HJ4 |kVyɪ{Ge=Ew#"Ҫ}5kgn%h$)rwEL D&3G/wo7~ʴ]iS@ >XTOM]mc e]r|=bO𝛼_-"*5`)Py0$!|ۼo>ؓS#52YdyoN 4+4V[m8Cv~Vf2Kxu>yxW7D%(B}\8H{/0(r/'Y沐w ;}r ;vmr=Ya`rp2v ^lQs?ˎ=[;nS~ÏUwLD1oꞀ@؍H scuW&Bٚ"X].B{[CjJЉDl'4iZQLd㗿 +3zYBkiFxWp_rΐJZPbj .;grO:+0exFj}' p]Lv؞$3{@ha2IPhQvhJ PN VtZ)+Q=q;vs ,Y<|KϘ2;<裶r˕sG9⋎_* |&I7Zږ샂S}֮i 2j!L]ۦi G#< zf/wg/2O.x5yt/ͣ;F[)Wn\|B RmO*h^кJ6":t8è lE.‰qܱ#4-R( .0Вe'yܒSaiaz-Aqa{ꮖZL*A94F=Tƥ1Ec4G= n3* Z"He3Ħ4.p4g"TtQs-]#!~,g}f !${i.D5,=♅ > ӟq.3PEƶ)T BIJ4dz{g';|Tdyzy[w|믎Sk>c0 3;tGpк ,c]wbwijTiׄ"f5'r}D\u5q0aQa/)Z$M,\2)O ^8yJY E+~zR]~V|˟t!!ai 6mD* &3U^ˈ nnEe9s'߹?]okf{~޹ٛWCy"^dLQc ޵f1@Ԍ٘L8y]' ;@ާ>o7 ^ \r(Q lJc'y6!F4kl-]c4DTj*2Z%$V#eD`cE#جe^w{ii`[ӟxߧwyM \-CƶUcYhަo\ВVe" !QJ.$DF$ɸ6;:{.?omrQEj a,O=gCcBc6']zӚ'O$$y W{?N:-7~o#0zA*a7_=}nXJ:%C H*[.^~%svXMf P;P6#7A!O]x3<+Oy],)H~:E]ԥqndèYsrbRO& SwePkPrK0F0R.5W߽'Ϋ'wKEXrˉgÓO~禛N aq<`S6$i!`sW E"iIwޕKگ}59t{Osc ]5UO77yF #hb;R4s:ez"fvzA6@-|N!#r҉:;W] ?;؝%- ziқhgmi]9N+urg>a%?cO}E|/-c>991(iu3 PI57='$1ظ1+)C#E;^v߭h; BP*Z5mÏE0c]߶pE FZ[]k]8zKR97΍Qk|l!}æ;l ~;']w;Y{eg1 13,IK]MP!0fgrQYv3z/^}pE/?dQ؝qlcO[?&n,DԱ4Zx3@NDA aBA"MfhTdMx;;0!#+0cZW $H}{T`5q۴@.PdYɑxMXaXW CLu@y_ 0G!3f+|^'g )9yS6!t 1gGFpw$r)q2z2uh]w⾻]e~/hM?m߯lijxյj5.g(,L_($"Dqf3*5a鿞q9vAMvV[6#| MUzS̔ SҶj`1O_n9_z+_=g4]`J$f"'c,oTx6kH4iiIDμS9."C޽k&&h`@ VuJNuO {9L*3mݫ:x' @]j3d$¥.@EkޚfrO,y?[#<Ι\|ds51䭀R'kg_լ)vY\u`m N);AER#asE Ͳἳ52flwq> yGsds. ^p VoN=nA%ŘeT*興Rފ˕[wGsw۩r*Rye7v;B 0%1QLbbþ\DfmE6QT(K/o_Ѯ[N>(@ oD4O|zoՃCU6@\VZ6yQ]qҚͧ\ݶwoײTQ{6~x\GA0ڔ^~~jE?e5~ IY @VVKB="*) Dٻ. S3f_] w(ZP jrޥrQ\FG$ҩnS b;5 q  2M422ӫ}>kv{ ŝZkGn.'n0f(Ќr kAnNIp%n\Z9E{tiyħwlqN d]=Ɨ+6xD+; o;ҧ0fhf8KYrں. _z7ħ?v\'o3*2x[x/6$`'cq]i@*HbZ)|~EUe[kjOX v3L_xq;ʫ&3{L'j6 ] σ[D%~˳:aQ2c4ڒ!Drfg qІnP9k>N}ɟDxX o@ t%4f3G?3]SFa5zixܨo̡svābϧzm}ΖK4|.Ic\;ҖI' 랧Z <A*t3π06xLƬ+FwTKqb?~;a"Fٌ}PgNq,cč qک_Me9ZUsb žֿl=cXf DDlfcsgwSB,M:;W|rV[ōU:hM&IkV<؄8e$DTFfl.Nu~MZ?ru1KLzgrؽSW^t%g\twyg}?~잫ӿ.whU 8-^p\2qk_$k Z{sݍ &8gĈ3 h&hdRC|E@AD /6>8:1Q!5N%U%ytZc{ndVQP=g{gc By:0)L5蒋Ɯ2SdI,yU@ŘLs/G]Î8gHd_Uxdīiҽ*w/:|iNԪj.bR%ʬG :_uYli%J$Ԉ`DHF$)6 =Nr/?g)ٟ;<_S1 PH͖aꄂ"2Ú^{%K޷hLO,[/!dW6Ъ 睗~k[o5_3PXT  v0vI4Ljw}ÿl^+%(+OA U/!q%Wl+`Q1}iW?` ~ Z9+G(BëX QxK麭b=/?.=z 8WdQؕB$?(\{)G_uq;zl CP֪E.Ӣ-E@.X5!ش8'7z]r?}פG~z/Ņ>;n\ࢩS߮}[W[@BP[ =JAӄ8iX:@(焢FP믽?s=tz;;>c|lb3Z ۀL;??b4ĄN2b:H!$V*\$ >0(Jm1-z_76.aѢ ;"is[D,GMo,  A8ýs~8 ?~)CenA>B>""iYϯvڡ/tgq<K\7ﶛe jCAɕBjJ5U7(;d2kD #'d4+jJ5'yRtsl}kmP)H%Ӽjk4@ԉ{f|YscGÆl3 2 A* ~uþ}-kO+9O%قL1qnQ] <8x~$KFisVJ^) su\yO=S w!/Ո-;oZ*Y̒:AB&鐓zOϸԘ'#xf,QZX]H/-b}נ7rA{-ny=ˮL%&8ˎ,4cR/@XAfhNNvӣO]o3 43i0%:ͤ 2-(0qI;9',`@Zc\8nۯ?=fDe k¤!rQsPc6_D֩{/hȿcؚlZ %CϐAӂK$mRZH>@0 IDAT>O1WIw> vLЋ6W 6NYSQ*))-) WĖ).ST7|\SPD"!3;rw?C7uV+Аìg^uȑ'YhSsJ+C,s 8~D5E0++tM7ao oh;L)!xz !: _fɃ9fG}Ux1 ! ZB1l@^M뢂jTzsc7;q=O 'r`"*Uk.Hһ;|7]f4s ^7eJ)wٹP iQ#QB] ږ gGxr! 9^1RlLΝ~ֵ3N9!sd|0 4KF6qП>2͕ ׬yh]H4s7 =kf\*432!l#cLyJr D&zzͽŋWt(*>uY $WA0K=w)c#JH&->/ުzACCoN}}f_עc 2xQQ"6`1'jNnDb*Ĝc$N[MBd$i!L1ba*Eh|^%F5v"2 "ִomumnpԱ{jeeBm)>#d6)3P`n'OuxcXkeg -LDbȑƏ;뱇;|k,{tY[1JΤ3DfP1(nGwL%% αa)R{˜l,"* o=ოH<|'NzrQspG0\dHԳ b1>JN:O<}w>9hRցbEl;Oo⥩D%CƂ9=u^̌#gRh*D$gI[bJU!%VTXO H;{6J4*->F쳿M(8@;M`HIg3v(PPɄDB΁H&ޙP dLroB2,ɉRx""peؠ[2W/+zb=eZ^U6UqXkA3bŭK9t"&xveq"5*Ϧ)b[Ѧt6D?W95uϤWzT0sJP*oλF` @F8Mf\~鱇|/(! Ψ3V&rQ1+{4~Զ* J8U2!CfkL8p@8ϧcQjCDPg) ]Ǝum948*j4GR&5 ULz ukH0`k y8!ZC=!Zg<񊫶ɭshp K`UɲPz=aݺzg8TJֵEȊ }BB&Umg akL7Pv1=W{C.!L?9*LDޕQ}vf 0`8TRQ(D%`H$v !qQr%aM\9vlH0)1*QHd&F3uoFOqj~LM{s$bcBw!HӊF(-Yp$\iΛAfElߘ/\K]i0)Tjc/n(SN?矹_|tG~sؿol{}>|U<=;go5 *NZTqZ3ù]wC(3F@6Ŀ,{S? ""Dj1[w('.ү_{aQҡOu,SU>/CF( 4E]jc'5ZsYmR76X?2%4BDn%ى`iVx-:`߇޻︦Mȫc"G ʨxFZKXŋ#k?M6&t4 2!8w"h41s4.I2AւUr㛠Kou;輐eCiH-" &@E,2q7T>cq< cHXo1ԛ#@*STw1Z/<hJJtfwR.ś6PfՁù}/gp4Aat@CDkӟׯ_ֺ6l޴iSYY{Fcp```??k}{_8lTu\( :+54Lj2UuRUńq#Ңu:Wo5u[A_b~@(ɱn[ ~7=8@x-1o5b::ATcX:Q#]DnEg܊9 m!qb: $kVtj@J$c"ujD !B{@)BD &]CAQU [,B kDZy=C?w_3gΜoa_EJ73V6>uܷvR{-]-4x1T )]7Ϭ]3*t,ZN hm)ij,;>k2y@{Pt*o]+ .;gxUb`>Ej$h鿹mXhEgxb=X:/HܟJ'I .Zu {g<;BXCbtn2;e;1#g"3^3T31vig|lL{t@IVT*kwɈEhoFV,sƢm`kt)GxQc2_NѤctkcx[ ^wl؈=gq8"2'IH4+( 2 Ĵ'`EaXw2Z 8DGs^'t1JefNJf\9|%-'n}×s ,[IM+iF! "ļZ ܫ/w;'mE3&XNqg1+"I dsp]g/R11 ԉCyWݚŴLmΆw"u S)8sӚ=[EU:]@y,Yr+鿂bd9Ч0@͑1oE "o)o`*:ogNJD)!* 8 2nAE*΄d-?J&eAF`HX~XBI;>jncfk&)Dڀ?zS0QzY;fwWz䕴sɵļ^>qļ#-Xu~+"t~u1POnI-}bSlt\[nd%[v' "Vixuz9{ї~3ǟցC`0kVR;HUxQEɣY,(;SHՐрjMb)h&T|4@LHBK_HPDWha('X?`"]-MM֢)xc LTE+e .͏,buUˁ͐~d {qƄ1 QM+UK$]ub[RKz=y]0<"AJ_gx4kt>*lKw%IA™T+U "z!\v'DR*:>yR/BQ1fñ}uBLYzm;Zz^cu\R6'0W|柹i4:hTpZ09KYz&4Q"p @ My6jxN4d3'rU]|z-!"IV@o$Us^Zۚsbh>}SU%?|߿вU?yS0OёA&Q:gVϜ:dP1 ESqͱYQ*IQ*1nʱ*Nb ,CDL͚k֌_ՓOt,\ꥑh, H(تy obqŸ-?7pEGϝ{9^>2Z΂堐 8'14|^xn@ryd/gl.!DK/R0;L-K'>w:|'(ÒuBl\jw-22ژr!fXBD(Q'`3dTmBdO?B!815KT`@*8(#D,[ƊNhի_z꩗Qf۰THJ QRٍi+"h4m3^.}lyu޼݀j)T5֤u1'?_^=Lrv,:3aLHжX# vU.w%tb݅l1=C$jxMXOeGWDr:R|oii[[lVca6dq3˿~I7:6DƆ!|,3(`NsvhzR$b\8Rz'®?U1Ur&Hx(Cr3^jiga85DNI'sWK vcUū`Ob$ѢlA95ǣ8~J.Fd>? S?ƓR:?[=gĹ ;! M;Iit96{ry?߿ .6YsYŇKN|kZv|]4?=;Fj SS4)Gd-+qYe]!em,XZX,,ehx`lQ-`aB DIRu)Bԕ*h T;zeo?MT) E7Sm-XGY"%U__+f6/O<6듻J K;!i؞uqZc7&)l=[hMl̙;c޼m-ay嗏^0s<uF42#o_I8ڤvi`Ҥ[ujJάО13YZUԔ Q¸`-LI.戉 8@E` F@U C"Z6hMI%hrqܻVsl)F豯'ǔM= JPoiޝX6e(5#/-7ijSEEԱ²_Vގ]i{4F:2离̻ɬ\yt.0'qwes+.iXR_o^g~K0u5S|HY4Z B Ti̔i3#BOg_:tc Lbp2HgݛOήV,~Շ_}5oM{\QJ.ؙțyoqڌm6Y #`0%*9s+4i5$qF^~ [&Lf\"*D]ĹZFΨގ+$I֖;r,,jV*.U8NL#(zw!e.4Oz:"Qh0,xGxϜ1;cG <ޔ)3\ҭ2Rd(Ɉ`d S2h9wߕW_0f?Ml2 Qo1*#Fna YH +n6B,ix;OD=Vr&2~'繽퀺nlj0uOUKT& IDAT& dvneRz^d9 QfC/E#bEpM@]\wsR;}s{]uŇSZ^"!$TC\ca8Q'4Gϼ2?|PxG# EĚFR01I@Q1A= Njhj818%CT:B鞻;q:{':"qHc]AO}ri v7|gœiQo*w= wkSCW_3 FHdJA.u=fϜ2vlE&Mr")`݅ߵ1c>g:xx@Lc_7fY蹗^4-)Z+H@`vT6'_C•@ڂ sLLsJ"`Zr=+ k=w{jKQ[)C%X=mڬeVvR DΌ@d"wâ}e:gndcM^1Z%[OFNfFGq_⊹bl5-+ ( .US8g"Uﺽ?̩ӎfRd-UқsxL ͝'S&0BƒeQ`\,ATlDL6Ov.bh3<.\_4==e)zrQv{,B4{"ѼG1ʋޭmPCz@,k;\IPQ7\g (<,(ĔHaH'`*^"UYG/GJƆJF֩{Ofc[A7u*fhVZ]-\2g_lYqpP7 ,-~%O=yCGVmrcObS)2xffV%Ήj!qǍ9v&4i`3 8nOvF%=8P<C{ѷp"WbJD(I "nֶ^1529z[R̂!q:ԉ.[5oq?)E\]c3a|˄,8wΫ׭UHjyb5dnV0Y߾E_uwN 1B&[_`/}Tz{b-Ronu| d\w7:M&b ޜ_re,Z*8DDX (1Hae(|ey&!8 Ĝ".o:딯wLo!D߄Ws^0b0%L?w.=jӏ܎S:uO`*',+\^g*dZ(CkTP0!d 5PY2S'rB*_Gpw"m *3aH~´%+V|9zy qp*sG{ׁn G2DU̜\v;wZy >Wott,HZ%9DNz򌦯c&;43w'/?b)vVc׺3Dd^& QT*fa'ĤIF; }uF)Ag Vw.Ydf掲T':zE簅gO`OIw1d /‹.UW-+NG )$l@o<x`ocO?׋A2S l2@#l"F(+/k{"Vh2ϲ{RW)DN"j #FKgsD&̋$Bd& Bh} %Ov͚e-B*pMY5fI{$C F{]x_=, 1HӺ37S {KH]ȕ {k63gZѦ&@dP5<<3{(sc~c ^}ejNnC"^c瞻cǾhҤɛ C ɖtuo7&ǂӗ]=C[@QɩQ0`۰$beYUP)҈SNkwzs/)8Ы4B y"ݕ܆(pv` }I?M= 4i}h 3E7J*w)3- `!vR8 ]쫣o=>5مgNID%X6^lepR".B$SgլH5Dgy XS[ Dz]ͫ*5Z:οx]+URʜR'yׇϛ}ďmmM_zA5/)E1 D3yRYY{L|pn鑛zx8[!By@/8ufc.d̻(*̙yzXQSlٕ:\{osITP"Y%םNLz>[e/Q?<GG^T!`-}uzƎ&eM6:y\pg\n}F_yĉ;\V&Ce`pF<0g^q/ N91SxmPC%ղa1磌U[Myi YOghW:xFdž낭6-D.<ƈ2)g(UfsAvBYM#^GZ0WBPw#)ulIP&2IJF zweVJDI+Dc ,T-;am4-e`9&% C?15Cd^Owf0IpM %YcƼaL;iடƕ}'x="bI)zZ_sƷ3I Tˉ+ʱVz\x̻Áq}'^cZQ. jm+.l)YyWǬ?t)TqO!oKI}@-X8 ND $B'd٬74Jw=v;&#TՒ y}k11Ì H`7I"^wWGiH  QfWwxDQ:»J(=ν1?|䥗L6CoҤ;?AFLQ0D: U[usf  }_({H(P }ewq s ٻ 9so̮ 0NlCY`'aP`dxŠʈNJ-#p )`QP&@ Eb0.W~`*L0bT2Bݙ{ϗ=;+ ̪@o>v7oYYT-;Jى@G3#z#OyX 1RQQh4T>hB15jk\s:(ήR -ට%N8cguozE@B3U mn=iQ?_s2_4FuM )  ,X0? c_NăTьh@6sצ8n<փ]̯G*.YFcb Jt~Go㖛OW/"?&\ ZQxH#$*2uέ?&\1)A jPG[tWD7 tjȴ]0 !UgD6f{lh缙a Zi2"^47ƢHսS{ϝn42=TPuDˆEiFU@DAbE~nW_c .{w%-s.#cl$b"Ex uJQ&y9H@DūD/:oYT*d"Bg3`hb:S>)-!*^ މwfZZX߮{oL@,Mx (;F\"U%[N9+>ԽKX~wk )S^(1~,Y7($}:8$L5U>HUƒ^7;3x__p3m+N Kjf!X"m;3gr /گd[7o_hHI2!vi(F%E˵f#L5%\7UͧZm%D[>dW-&=!yG 4O:pŊ% b`jќd>ihN%&3[4/R˲xU Eqμst9P%QUAĉY'YOͮˏ@ٛj`ӭWsD@N ?67"/,V` G|7n#MN ibPnhw8twUDBh9Ec,(D;ߘ{@ߚk֜zTIϋd>vhtnq!p`=" y:(BB@+Jh)`#BxIixŅKTFg*N (c0"&h 褴Zh8UF*hE:X~')=%Bm1P#}XRmĹVc;﮻.x`#WF@t`AD aK~ScfBӨSxV0|25AwPwY'tぱ^(QoQlZDҴCL":EtcXn^|~aMׯWFapp0K%[w1sG2oG1olY\Iۇ1xZO߿c>H%H+n"^ ^}λxܛLQ#**ێ==w6½ʿ|=똊?ȋ:J13!@AKh}w_*cO$&&&ݒ{iep DohI.k9|ׇktٹN,9fGVz1mY$-> 2Fr'f$CL,cQD*B!:$4ZyS?qӏ¢q (;RK~Y* EC޹ך5W|~!pX,;PFPă0P*K.y |A x#n<5YbBP$j"@`>WG]{tR)-2V/or=J)z˼ 3ElV~GSJٜʱjډ{P'-T͝w`=G%'D k"p;: Ϟ6l ):35 9G8RH)ur3<<;73JӾDÌ${ߜ[ۺ U T "k…8o넳p4[xwﻴ Q!Բy6 m>e_8ST ih53e084*T{]v=Y,+uyw7yaG +i T+kJZm%0qnJq˴2ƕ5\CAsg}iMiy\hE ٛm);u-smyW5@D݁YL q 2oɧۿ{3\%P*Q4خ*!f=7Joh fp 3I>]~y_x cĉ IDATi!i^ C;~&DH4Nf*9ȸDˡڜ)Hr+ER!=R;KeĵН(JSyk #jmgs7. y hKכrEJ?Ib:—^YOTDD*j=3GG_QQ3Th*ZT5R!8U`FO 0BD@PJ#Y0 "Grzѳ6e+h4f'"fD',ua׽ tSI@T%'rݕhoFbhq6l/bU  LՋy@<윥 !S_5 Ž +`ՊEw9Cr5# H>o42-eoZQa8.ڷ,T3=ի.{cH"R ^L1T$(s2{-J6ӑ& O"np`vd*.-~KkwFK渊5H1wk.!jy;ex[S۶͛lٲR̨U}9eê61-פV-1@Sr1T+9Sp)`4"^$#c?>^`N<}ֆKzB%gO㶐܈ؓQGlv`H$bhѵK >ZDub!K[x-5H:=3+e q 8Hr\r<qY1BA2".x"S2@I!i5=3;3ΌV|*i=޹}992Ѹ1(xƧp.{io3ȩ0& T#U fP U"PVn,8U@#rD'·c> /%K~>)=W^}=C}6hT!83)8\obX&g"( .Xz啟 ظSXtnQ]pݻbÀSW+Fք01s+ pfA D"IkA4J?2J 8 k[D&u{׺K}26-M'u@T"ާP%RWd "C UzhEhF& $(phe~աΚK;U*X<[CZy"0QӤw.2ײP68 Ш080s[AFD^ 4ٻ1ZX{ni=.{T!dJ$jf0j;QtBR Ȧu|o*3Cqe,V\|>Uim1Ěf'YDМMQg@mK lBT|H@# =6[.Ң[^? Cئ t 2JvM|ފD"0"pR/fӄ$DLBg5/qs2;k(;'k<4NQ{syh{^LҒj_a <"(&X2Q~Ly0јT33 ӐhF,?|K33i,@ĩ&l ܶ+顇t'{n׎1廷l1Q A@`\X{ ݋PV0S$R5h&"j#U#}ۭBM/ɍ 9X_Z-Cj R)Wμ1N}HK!XL])mFD |;rP] jp^M"]?=7(g F67heCu2Q-?R*Qaȓ+'a~ \x9W΄Q ĸǾh~_ܹ0p!"24gqMpJiEܥMiT-B-,H$:),LjX74tuw⿛:%G͛_:XC:Y!TPZFʃ5׷G*\SQDU#OԍZK$N8rTxX*]GGy`n^xQ. f)1Jj%ixתUw-:㎻a;:BkLL ,#ow?C4 fH%ד_tOi ,yk!,F*;:6&ٚaU+jG^~'[^S).=sz/I;P C`05ǫ/n Ƒa'@$`` ϔ}?*Ҭ1,sKI:CF*ad Bn\2 E8_ZQߌ&舭>6Ӏ`wg{Sn8ӗ-f۶=yglb@jqPR?e5U%!(%WPSM J2$*܈@îTx]QUByR_dĨQ^9R:f_]K˖~*͇6q00QX?x|*"!΍FNW_ݻ1S"OrQ&n W%BGRޣ " \Sdfd5d@%2FdJwuo'6G_;v)qEhJ`.C>87N&= f00og7q'Fw[ 4Ʒ-*jJũqn0Ξў..<-6n ]Hz87ܰqK}w5S Hb5B̈5NR&~f&l˚LRwέZzkޚIueSCmUZ/ )qW\`#O05#2pF5p Dfs wSb+ 4Lب`>\Xz5~ѓgbPKq*(ap"@0P+.]sםҽK ve+\V>ȿQбR A]$hx~wqG~]j/jkf`fR7|21 嫯:ؚcxhMcP@²۹k8wg 6c{ p`g?7ўeޝY^F SL3c&5^xN_g_}{A L d ) +Ο֭b*X=Cy,V` `a]rL.PUHL)+0;QۇWڕ*v!s?vW; u0ufFK1 Dr8/]@#1:,3l]ZCv[n-D`dnue6m0bZx_>[d:aO\{]i&CV\|: D"A@#810ի&y\;X@T-"#*|?nJk<3W5IG.Z؋L4]P˝BGnG}fH쬐 -  )Dラ;/f/@@1@̅(OʝPHSCo;?SOn7j&IWXb0t{=U8 YIzݳV:ujoh35]HIT(H~{C+\ %!X 䴸 Mm U #P|Ҋt?v_$uc J;K8Ac,D~{As3ϜΝXKK)ݡDKJ2KZlqXUrپXBl$EH $V ԈP !lAuUAy  hy\S-sR`JE$֠NFA{BxoEee7w.r9.p{| YGd V`T&x2m6t`wI*rpJ 1*&%*<3lhiYCfG7l^#C$ʪfR%& ,d\R-3 3+0~Jos~ @؂*j$[=(tɈT\V1bʇfeʍ;bY4go<> ~nLql-fAک|)  vwYCgZ7c澰~Mܰ! ^AbM/Hv1 30 W2Y,{́_G?㷺= _E@( gђ PUb؇&CH~旃ݲt.ȯhb;ܸ[gztA@·l:;vx Jt…/]{CNc.pШjUt/š9.޹^xuuk'\1'-QM@%Fu=n}δ3yO<` ,\ZXPu)G5RIvWE~<IS*Ad a]6i~{_0֬ ^8;"}Ҵ#=ǟF1,,L(TQ[3Th϶rqi_>DB M ꭉ곇`l E;/r)y\;⒅]U*!["BP:dKKS- ?ޛ?A?i% Y\r;Ae5UpUM *$3%E)hl&mG(xbn$0LDFHsͱ͗9#v-_"n N91h'o3Q2WzNEsn秊;zYsG^p>"vcܻqnvmSDK`W|pǺ _}}9L3EF[0ܳNr#K!M=6 +; Vw^$sO:jwg0ol5xbms"&AQ"˰  lT'"` p_UOT'ZVkMNfL7V䓼Qx'QU%cQw*m^@ge6GKjBhmkUBNfl|!#G]pݔ4Q?ߙͨD>uDG㛮k;V:-gﭷ.%Alָ!-`놅JY|ԘuhgqđPgglj]$qT)!/X. !r1$$FX=m'u0˞=X(ty.q [. V5@3Ђ$bd%XHqTn|W/ǨQW-Y2.|6; b I-nHaZ"P RW- Ia\M:zD&ySJ`L:웧9tf޼Ep(ԒbFp ]SoՕ\-OTl; *fݞ{G!/XLԨUJJfxӕcN]?NVU$_1J!ej! &EF$qMML zOC @)np9Ql0 8! FM]8!cF?YAQQRzU ,%F$fYjdq4];~L-NB 6է:#aҷҋz X%  FE DQMAĤ !Ҁ6ol^%Ǝr'YhI cl ;2ۏ>^;_v-P-z[DP%KTC)uk?r?YU2%* q)c-!f}ZԒ$*&CsR3N߻3| ,~KDB"jUR hZm>wءoW},QcYLj@ $j@DjU € .!+@!"8 rECf:3Xn3`ڽ0YVx ߜ2yM$S5T@(b[P#Ҁ+BB`k<䥢C%* $/`@ X3|THx0L IDATr y+DP>Shs;ԣOVB1H#X Wr%CnqW6`)^BOAD;=2gկ#Ev'1q Y89oeT؁vPEj5$Y%zP`M{! N{/ΗnaniJB0 68iUUWA5*zv)"q0Hھtƭ30?k+/ZR=HHo"ʋ\V(vQTa:x,O @# u(VΘ,SljåߞgVQ{guuXM}!)(ݛRUgZks^@PQQF38y@D! "&.Cd'Ш(2Qh N(SZN_pDuw:kg=:CHufQZDVn;< =7(V7 :t/||O~2q,cԑnqR~Hڢ6^r- OBUd"i>kw~!|z+\U>]V T!t $dX[*'uWxago/ nh DZLk!LRF^kfIQ&PS'#=MO|⊻||%F{!!Pd5IX)kr^}ѻSS.;ֲAE8 ϏfK`-\1Ƭm'  (fV,;Qosc+ɬ '*|Go햿+~ .cg/vm--d\9(" )tWHBBDè,i1'>1yq~-|.7}Re=DpI>e}@hYaRs9WιFNz5i$+Dīcxb(J$Jbi'qϮ{̿{jՉ$}FTBY4Y|UЇGcb@[3EF.rȇb!%\TRZ(DQfk'bh49}_G{7֮n:l)q$6B@$Q8;'V-# 1gsW<.@f!-r-B'1!fXVk$heg=/o;GB*tͨN={-e@O}C;=֪/xi2Pfn\=[U|2 mc5?z1o~s[)2`)Cm1)'s6`.ĵ{!o=no}%x]28C dQG y\)!4Z. IoX.!҈jR%FLJ,k۾`yɟ?A9Vэ&25jt֘K$>]?5:O_P [bBP1P>ɨ2i|YwgM+I`$ǞhI͘ 휱8Cwxm߿My'OY#b>E4`1,>^;s9?:]w]>'RNzɥi,G@k-A Cr9:DQe  R DE0,x."k!R*Mw5ӳ Ok0ְR } HUEZ4Hu>rAOYߵ:lՅ9"AiLJDLTV|.{v;n]p5pM"Fc$\4w*QnTB#T'HJ2o [_sspÂm $ut/? ([3wɐH",EE6Z&b;v|-ɉ7}cF io8`Hh6s&GUAw$ RX̩t>W^y9B 1lۨM$:CtfU0ycyȪ=웡:o}h 9}/ \@Z[oduwO|1[hݐVk-w]{҆\h@c4 BT$bRl<꠽v[K/+W_3rK3ig%L/IAbYb *ēW=l8真| k2|@աXߌ]uJ#d[Ea.{ᇞ|1b:bA% lNM0Tа~RQG@ST=(=i=w \sԑ'WcrF8 ϔ"da^__p_+|7 !f Hh5wL zĒwFZbDFk} &LL&;8A|9=т#ՙ!fI[rk!=P!DTSI$((m.n^r‰pgKy.ILa u !"JJ XtjE677t]b>;ajMIc6 sב4Ib||Ôj7V+W.䧧V?papͷ[a.W1XǓ9E+2'7ٿod2M񬾢OQfSZkzdkU Ko*["h&%mNNl8=v[wܭ͚ȃ8V9/eMo&&.R97zޕS;-}󻚃8BET!I&*"EF_r^mobdj섑ēt{v1wm_,&2Wh%6s+'y.;ޛ].Hdyp6V#BH< A% m]L7s@z׌:&@߈f @F`U]{VO;eNJgmI#'&^7A[qN2"W3"@XZ#~'r>u+eVd#()iy}QS u1(>tڙL&(%&T*(etr(|VWW5Ʈ;O}S6W[.o+Zdy)BKSSOtdIto,y1R.*<&P2L*`  C5MMsUs֜|.42 6ap2 PZHXBEdISb%r1T i.= & T>oƇ倗{ᩧ|aGD$4zJ,Lǟ=>?;ɰ3ERqM Uc@E$3u,8]`.'|W}A.i M쑆=(%!hX!hY RT\ѫAOme9_z4O|eda@PsTU;ڄP%@ UDJV%`9ꨟ("J\(k~?)'Ј$a@2l@K6$uD">1MPҡʨ)16&vw3/g?O޴9-+ceҐ֋՜⁞$cXd л2*tW6{}=cg\\ڒ2~ܣ 1[l%n? g\WՅ&?~;ϝ/x] KC:qP,ZpDcMJʫ]޴zgZ_t__`%I"u~!GKkwawrrWO8lacD -!uQ:p äS-@$&*i׵)/_l|gL61}HTð J/R*+^?.G>qb߫h["bO65U-6B hV31./G޸.p 0h(}Qw)~irX'u^_֪)T*)*68:f;Tգ# Q69{:7-Zh,Gz-m,#$ a\6^}fZXu>OዑŴFzG3(15  )yTF *"C GmOwIo?b"31 FR!YM"weC?/ňS! = vUGz6{~ ˄s[ηû~:V,.:&3sjDui[("θNHZ̩nlGlȇooʍ7^rʜB777vܚ5s߰~r啿4I20K*jdRqZ$(pN]m\߾R6`o+JRR Ǭ&"JLr+Wǟt_zWZa?0\ 8d.kO8ͯ}zbݴ;t_w9HӋ Lm䶄N =̉Ê q2j$:4QU 4ZRT;ȍouxIrXm vnvP $,Lڪ0'DJbZT'9"t zO,&9iWm7~s. ҤYNk ju4e{O<D`CE)]]N={wj׵)D@fBܨ[jeІMЀ[a"w3 }T.?#P|߰>G^㫊7tAP@jӅ̛H`e8}*f-Qyp:d.PTEEłQ#D9pc hU{rկÎG?a-c6RaD;D2좠=cJ H9F.(Z11;H֭\ׯ4`F$:ܾA&S@U8#YVIݔ/~s֮kw:K_k#ujщ<eERUoOy3"U᭗XH$REԧ_PSDQ̩^W==w~S>2^E=f́"BQ5LBDEc +SS.Bw>' L$YhI& 8d~Q']aYp3-" '&")?9Yru{)+!4]; T` CF,VK-^{!'\uM1}d:Cb6DUm!. .]t`h xz5 )+hcpɅAB$NP AsoV:HO aۧ# JTF3D $RRf5\͸J&AuҤC`A*bхNY6Lnf*Mlko < WDnP9h((P="ArQ5A>K7%׿FڅBg<٠ %i&:aV,MFX\&a/n7}'  \d f1S]V$R{տ}g/\xͫ^q8eCH]Nx.k\j9mz;P;ǟQߩlPMZ'5iSh=רТR VL(:"!L ؚPz PFd:5U0cbɉrQGV޲u+61*,>Bta"DR"Ch*Q}U&}L pA'vg|Лʋm~.H Ts۶]^0ͬ:dZ8DĠ%eɿfxqٸkUԄ[mn}cc!$`ubS^Bd<\t<Pw4Xҵ݌LURRJ >AkԪxRAx0v35yѡ_6D}_!="DݤMo>{vS]&6-l7XD7xfKgܳnmm*FN}%Z2inۯ1Pg;vƃ#L)K)e2.臜 Qs 6FOzғ|坰Zn_k__O5= 3;G R6KD@T bSmȰbjd ^iܴ\UI,+uo9Whb ۛ ,LN^⧞[Ծ{}\c9q]\sQ#zZ&LN` 4%hc$>̤&v-sSx&Nso4py |\Ci2Y@1BY : k- ~M./? HK l)30%DEfOYL"*:떯X~xA-\IjA.97I>^JHRC~]%Qb}RMfjXrIq}Wsuww -@h0}A)5)jhQz r%~ؔ7u`&)j;鬓IF lPjVÔ Uԅ(ʭM IDATvv??7pևO^m%6=1Fu$6̽P @/15Y氒Z{ jסheViB4CQ: NL{"d;^;n}+?JpHQA))JD ,R 0#FdxDJA@Kek;^Ȃq9TNtJqDɮIz1rr"@P%`* h@QSk."EX-B')AfpUVg@\I&BE@PX\z$1Yb`mGK,$u٭ 5:)ޤ믿~Y֭ pM2*p"eq]fua"KYlSTHۋ6UCT,nw;\N;o9Εl6)̦_w`\0My, ^C&0 JUD#ƳOd!,rTg@hDr[ܞw'}:˥fJMZkg J ADDNKamMEQSJCA ̤1LjDy?}6Q/|ZBAeU${Uɕ$.*֐ nu ù(ِYkAIpcO@6}sc3:ď~ƙCL5^;MMblREŝ:5FMj]6Ϯo{ӂ2+"6Mv%'<j?緊}}N@N$ []B@֤Vܸ t7jՑDL=Hn'̔".Ό. >, AQāR/$DU EMnv;4ίxj] "b7(ZjX A6ޭ;)Ub峬dK#P\'xk^{;\7 y҅_9+DUmHtbR T;R{ha4Ƌux&Yv*B.yͺ[nPA[K,A06MAah0:il7ê`.sl/}ro7bT`-0hH&>BE8aBAj b]JK41QTlo}_pRJ f PiY׋hʣ@E )Y>DNB"d"}QQB N";pHS<+:.O#k+h&|!!P ¥2EjZ> N5U 0#*QYJ% р[0tK{ˈ@q5'ӫ-RVUmRʣ6=聛msvId?ߟK!*BTjG̵+_#as~ρ/F`&a>3t#!"AS$ k:. :}AXaX{foϊgpO|0WbMXq@pX @DJF2dVOup0i%EOdZJ&#< &TT$VXobˇ=![l-}mBfj%a24HU%)!)a(Js@Z]D<)ZtB?-ޯ9̕?5{Dfx'&IjwϽ?Y>q{BuvIL舢ڷ#;\>8LH(k=A,yjy~˷zmW _m5D$p -w؃."U$CYL`I,”huI@8܀@RM0SZL%ZT1N٠(थD97/<1H$J;%5R8l FXuԅzq 2YxfmHwEt$ J)3w,Pnkoyn/W_{جT9@> L\EP<~o 4#iKU;2!(;l3<\u ՁNB{Nqޯ n{ϋV%*kq\RD*`|͑viLʙ\=$*;lٽ>|>KC&T Py͓uqRkͩhY*7 Qi/Ee|e-YMˡ][l1hMs6v~_^^RAhz|!0ĦK՘O ⺤Ws|m"' p `jY_^#$9l8gFܹ~ПK/am$L)}o+k6ۛ!C쨖A3fW_{_<'x~~7y?8Z>!t_g]<Т/?FC9 l \JL;b.H̫U&94{H >vҤq+>OkpAj$Zg 9#/:~m/n;[nO\˚>ޫ'Īa& YE\mfhBjش]Rfuu?kWx8NǢlA֞*FIЌI>twO[5퐃/}gvE./5eWWYSR!YY[kϿ0%{.#Y>4ЩF#.?юQ~ 7ԅ_‹K[ΌBP >fB-"'I p$eЂh.^X@dn\o|6+9hOWYK2oiȐW]XAEq„ɿyi\i")9w,*dC{( NIsd+'L3y2>;^f25 >U($91(2Q2)rRwFB pX{U8=w1vV6y~[l?|WOaf`)& R;S3gKp;Z^X3T," Dj\c&@{rYquҸUO}cܙ?s\vΠ`fN*sD,ddCwA]}rBYRZ3uD00ml0Ծ&\ƌSsDY=`(*J0a2"58 rH;Un1RJ"Scm7_Yuak췮'.$j)us@+\DW%eGI h; LMzƌUg_t}mI<TĐ \INDsl6͈!2(96p#)>w?p_?2(. ~ض{n%~w7Eec&E.Ԁ3PR@]]LAyb&QwNo|ۭH7p3OWWlps|Ǭ( Ⱦ AT $fТ6!5Y[:Ա'ngќ9ϻ)w$pgO cK1;Yܑ$G}sDsf\O Yn .ERޥ,NöuW? i]6Oꢶ4bėGŅZ`ͼ(Y,V*vKgk;~u֟?CBe&>Ii]hf*yj*]ogrdٱL]Cg=&M:WAP@ y'_R s>Vditt:cfOzۼ-w)3jB@7`p~ZֵliO].Z׿y?鯯՘9:Lk/`VSOw*׻\}q/!33"8O (U@7?3I\tr'&#n_[[+u ꛟyN40gVRi *hbDzfeJ@cxhRHe@rq$Z`ʳVر(Ehs>yVgϚ{_Ԫ/qalp\UlH!E3rU Sdl7}Wɼ~;uף%K,GţGO{ܑ#W}Y^t:2XWFޗF 3!R8ɛf!5 ` x6ˇA3O/ݸF1s٩g{⡣u.$ 45"|tM4j3YYfԜs `Cs׆n_/w=٬Zf(?ԱX~Z;?fN@u"BBL`ԌHN{ ._udW._~Ŭ\:3#,bR8%(P Ј`ZFOD C&4iA2 m TT졦,IS}UG{6ĺg.+T]Y.a{ZCCOkyM.h4<ITXt45TM<(5]fOq]S鉯%%xUyq$V[[c$K $qO^~.+S!Z{Ъc 曋EQ' <)#33B$sۛ?3Q-fϹJ) LcT4,9d3ƌ(.}v4J8V|C:M.6^šKow5v1VV3j1<u пOGJ/y7ZhP%c/sӖ㞩U;Q09z5HY,O}bgLiX _Gg:Y7r'rڊN0y!ཪBk/@H7Nuhz?quW_{Qf&-sJĀ Z ,mf|`Uu@+oRHlpƎ>a_qe&>'Ts05a|ey} #]>*S Rnђw[NZ͟%^⋋mf 3gJj%f9X:ZT͹XC+0Ḧ#VTs[Vc]*d7q":P3%b1u)EgDLBё.hȑ|+~ȣ&um"쀈P9/c!)2*z{ =̇.@?:=yMh=+u;ba,;reg:~+rY=)!3+de^43U*G"L#~PTC t`BQL7df,1;hС͚}mm~CG>{iU;SGͿ랟\kUsuN@QXT@#Sk5I'~1c^xԘ8msϞV?̘Rv  4Uu8iz)Ŵ]/|7OCzkjFT@/]٨s:)ϲf5+~ 4S"䓀99%bfU+$o섂9"1dw&1!f1@ly#(]sOo:~{`Y >%R&mͥH=p3闁N `5O)2̧n!d d0+nm7g1=0С~wՌi^q:- UTA@.Dmuv ,WG1{uݴO|*I Stf@$3.Ff1@.G3v-rs&ҺӉ8}9>K.Pǩ άLsa7-μe{D@-6*}9 y%l MYO^!tk.2>eѳ!˻nw\j讻^;KZU_\8Vfx.nj;duk).3[~wm0vlM`cn;Ma6]p{mw ϽʫnIU^Uݘ L@\!(RkBT3RnU*FK %}0F0K/]ݏ9o ,cpd:=;tE>:+٭[U83M' R]"cEFȗpQSN^ok+ 2&CD%C΂&Vfo͚ucx(k[V<XQsy@*]eLMɈznQ 7^A3h?ZN=B#iTZ_M3'Ob|[2v߱)("R tcǟ];?{놯\4al*ŠD)lf;]Yk,611H4| t~ I){?w .Dymeu(AJUgU׊Gxg~T2t, $U%" Uze3f"+lEvR +Bx,q>Y]\Br&sY\#Z4[1Z!=tKzKx6=VT͢1;6"V s@UP‘sƙ+zk5ǍMANbR{3=i{4jaΜ[FpH.gN9n~njuSN[ĺWqeR\3tI8^~x-^z5;/n2++36kYR,>U̘}5Utv. q@`Jn؛VY-f IdHr_s\=`Fæv .ѳÚcjK)J>nh={Z+IG'e Fp}ۉ/z&alI|+6Qwt+K~_0|oB@`D֕]/lbu} C$ 5 B%I 웆 %¶? ɤA a3@&R BJ%WNv_+Joid%2e) gʣR>%uY() ^;ᓽ1p0>5mW]u>왚vY4Ē{n\A>@Sܰ% +^wQ}fmݺDֺkVOWWTw=xH$ҬYN;uUluh?n׮>#B0,dX|I7m!kиkC8,HCбJpR1̀x1{Bd(Ix[Un77D҈wKHUꂟkIkՏe;vfaxUb>RСJ)V+&gbٲ)gvQp;rA2)̡zx~BOiiӂc.O޹+HYkR\VT'(ꖷw7CG% O?pvm@ Y:5.,bd֘^.5ƾ¦'/~H%G/\8~-$yvPJz#:3iڵmղ9ڞ޲Zsi|lȒ U1`5i2XlWw|.\?3C*:e+W LiѢ0 cFo3C"NkuSؠ&kױySgϜ;{߽3Q"G`KK߷vvݭ]J(ym:h$}zO7-/m{FA7uE}%uMy˹k?? +mp'vK˗ݽaƵX~Nzطh\EDO~w5ک2K/Rq ֚aκ+=ҭ=45v: 6e8"M .1VKe53gM8v~mۯVWw4}O}h Q&8DȲjBpKrN>giuڡm R_sޤyV'qKhd Qu6̙t;Gkq)+˭jKhRı՗ WV֯ p%lXl Y$o< feyy{^0`xu3 '<69dEi"IDATfСזgZkEDo(IuMy-ܼe*\DPİ 5uFkF^_XFpDBR>w14.묳sATbUg? 5dbĉ0['bXS-VB"5촏Yx%]q>?i(v#BhK}OޱG4Gx!.I[2**22un}sCj_;3umWm!R$IH0"$@"4Q1tFSƪUo%>o[À9Wyy_w] Զs8 1};^o=}ΜO *!`D2DqlٰNy͈&hq"U!j$7u/d|򥢭SF IP%&OMXaQT$Ld 8pt)֮ۢ .jŽ9lؠFHU{t˪ŵʷͣ)cOՀ忤Zk~)EJL;9~yyN<ݓKJbQ S(}ߘ`}{/ЉaQdٶaSM=bhkhQO3ҝ.eS۱ZYWP*18;UH*I!q'8gئyk"%$SP@c!Թv -xG<}(jJolԨ^nݵJ4UQ}7?g y}u<.:B`Մ[`[tOSᅇyṫcPw{{K6uwrV R*,%L՝Wʻϩ'-ZSA +3qbPL.`2#zvxuM2/%"\$w6~;EP}tee:Q-LR:u<-$11G=i L1U,|QoͯptMJD%UHAYPMTPcNuyy_l[U^H;Q+`P]PP~Ny7O|MJU[(Y Q0Uܳ;~VԾD !fhۼ7hΰO|;R-V-P @6?p\ݦMggt߳s=ys$*qIc?]I4%əBgL \j"rBZѾYg?󚩾~wGL(1Gۭ:+UT%E~vsn)op( q*c6ly'絹 =? .i9mۈZCbtMus\H<<-]ƹU%J) .5ÿ~ݦcLӄ(0p5w>f-J5M)SMe[0YQ N IL!h!+Hw^2Onyye Ô+Wc۷-m߶mQ! ifQ[[a-[lݺuUWlse]"$)'|R0 lD q,9YF*Teڷ fLwpQ&Ւe"c@T+\@+HTTcǡQXq`H\*fkaذ%AT':vA}цH"uȆI,'?vPİ  T$С}CY[g 2~@"U7%,WaŘt>{"y5+mdc)%5E-:y޿|1qک7.[8)2T$ENd ].'; Ϲe"eNH aHCEf([*BVꦘA@@P[L"+eHCB3tBCC޻Z"A!`]]]9%ffHr`svǝg?;=E4 %4R) f DSv:SB'r uR),0朵lS+ÄYMIEi{9ē9ss:/. B:eg 9uc%hIiQNsN[elL~yH@F)` bJ+_q=o>T0 1+}.փKϜw/z>1aj *`mWՋ.] sιO*PPC%^}m`soi ,+8e&K1 h-aX !QTPc&Q0 XfCCQdE΃hB"6-,JЈ$;.}TqȮV$u!k@K@sA(#7,j)YLaR {@X%" `@%AEs AίP Y:в쪪Z%?,\/Ӽ~"cG KafhSBm59(6m+!Fsæ~i{fU("]@WΠD3Ԡ<u^Y) +L7ڿ_ک@Ȧ*PlV+MC93>~|GBI E:%Ub!i bf*!td "j˚@#)TB=bɓ'O4i̘1}wiJ 1)5ʢ]d /?I!z3sϙ..͒qz.@iZPJU#HLAjblEcEsιޑ2rP$S"]9oaMsm ~k[q= 4 cVPs-!h`P a 5;5H0M%,$*6>5/]f5,ݧ0SQ9g#bYePfB0`PER@ @4ojQTST9FN4vΜY[O:gYc~yƠvUww5riF@g4@ _{^w.U Zvw,ު=,U8, iMQ"G޹x6s`FYqDO6fo;b]vh9n3nSO><55:d,\aЈU%`(bNUQĺLmOGd'=_rmB!)3Ƙ5C$"YU(5 Ubu]S C0I1ˁ$F1gٳvmN νiɧ5]Dl_ӎ=4׬TdKBsQ3dȞVW~葧Yj%RL c7BEutd1 Z~a^{p509>֌gȑ#߮j}yCԢ"4`$@DPU3I L"4%9"ժFw}=v63BFmu꾥wˢM(FA Sh -&(1 !i "b6EZhNjW3u{s9qُ}<`\λ]DS>ոo酃s9 k+.b/~9ŗR3DBNI"YP5@Ww9yv;ܜ {BA QZS'cԒ?v{a(3 bֵs,U!Ĕ% S &T L3% ְĢġәm9GU1)R @-cwuރs9܇BeXpےߵGx~媪ʹ,a68~M2eM'͘1}w_Xt@R4Lu s˹,^Tx1ȜH aDP`=Qg':ĺ,WNw'[sι g1ug`@˸Cvo v9snθ[ȆFz7_i]K֞zE=lTP$S$DU#ΒHl 5K4#M@C)7u뉧rAl9Ț}`" Lte7kvcct9;I v&AiUHcY]^pDH'W8` /}Ĭ9s{?j?)ٕ4fE |?/ouțs.oǞx:UBN 2)$,4!=lesA3G{gs?' D%LXBwa3}Vg˗'VxO=O>kT+hbO/;C s9u]uϽZ4@/50'ϿW^Zroo cƍ0=*Ls}\wO$먜 ife*5X!C]]]eY [͔e-,!VdN37]p?s9>/׮XFAXklow/9s}`~;-6DaV ,BӖ$@=5ugs`f0IF"Djkm9s>+V̛wóϭʐ$KjVQEq~ϝyPR~6L1$QFBp„PcX +6&ĵQk(iS  ? @ A B C D E F G H I J L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~  $$If!vh#v(#vX :V l05(5X / 4$$If!vh#v(#vX :V l05(5X / 4$$If!vh#v(#vX :V l05(5X / 4$$If!vh#v(#vX :V l05(5X / 4$$If!vh#v(#vX :V l05(5X / 4$$If!vh#v(:V l405(/ 4f4$$If!vh#v(#vX :V l05(5X / 4$$If!vh#v(#vX :V l05(5X /  / 4$$If!vh#v(:V l405(/ 4f4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4E$$If!vh#v8(:V l458(4f4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4[$$If!vh#v(#v :V l5(5 / 4E$$If!vh#v8(:V l458(4f4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4[$$If!vh#v(#v :V l5(5 / 4E$$If!vh#v8(:V l458(4f4Q$$If!vh#v(#v :V lz5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4M$$If!vh#v(#v :V l5(5 4[$$If!vh#v(#v :V l5(5 / 4E$$If!vh#v8(:V l458(4f4DDd[N ^  c :AOSHA Labelb J+ jO5;4n ɐnf J+ jO5;4PNG  IHDR[gAMA pHYs.%.%{ IDATx[(abבU:,A6Q*݂ǝ{h$B8 ^ gv@D %"""")H)Wgvd;;~RJ9_/?~O{<%9'ψP%wv^3Qwf.79{ݬ8N@%Nq+1C]|(Fp1b.F,_!Dv!A\c &K`DD3NpoE0F4{DpFBpю`MGlr ?a` ^^hx)ƈ)u^V~ Xت1v)f PzM8lޡ?2-0֍&c;ƢR3=u&c@Z)Yt4SN| M ,L.N`%)hJGE+~+<>V@P"7V!(]?7EAf9_u.*lAaKoH8CEM~ \B;VtEkdMf\KӉQLY֫yFm |].a cX=./RJz522wP y(+/,`+EM,B232rE;fJ^ ЉC~ζ&.GDPV Aыga)m6_Pr8qQ[d[_s\ʚ:MV1bNqKC],^WxA"bC̢է~zMj`"ʚw5 ۥŷ$W˱/|5܏g SaPg8m2OVP>/ +v ?Hs0sUhUt&iĥc>=jxl.{u%:<|Z:Cs\>EAD|C"8 DAQOyߣ+eQRIwG87=;-:u0F̧6:9}z(˒#t+:-4tz[I5 U/}׶!m- s!]Y,4FQl) ]BA`Qz(F"N;'m"о([JmP"~HSpc;kiJ@);%Q$'Ѫ~B.ŊYQ]sOopY夅֬GqwW&s,RMC}0$v㦇0gMpA/Ғ/-1 ӌl/TDoV>n aGjr7Nx!Uag:x{s+~_}!/<$i9m"ɐs^o87Ϛ~]-P@2 H]ޚ ո<(jӘB_,k(X!~PQ0"&_Sh޵[dzUZ9]id%c| x\ԮAw1C{7:>ώ#lULw2ZHa}sOUwJb8o}.M<fM?)xnMƲt# a1-.`k5䴌c: G'Lπ]~WgMg_rOYjӧH=5JRV.?C9%?8P7`Ys0#;#b*oqx-&P24 5+;7AzZ¡!Mj* _#qx>.܉M _AQNPXD#ʚ9t}qv+9d"*e5^Lj9SU7aKk^O+GV0W]47/p2TP<]0Ϛ>C2Pat4="b,C{<7 x*xվPRV5x:yWΎ:@T|-4xHhš/x3y=Wư)b/皦7?Y>|x2h} oj3fu'AɦDD,Y{@֚6bh1FdHn  ?F;!@DL=l!Fwv!GKC@JDį"h|}Hhs=E!i+!@k^l?X$@o~mG(`Z5߶IENDB`$$Ifl!vh#v$ :V l   05$ 4alp DyK *http://www.cdc.gov/mmwr/PDF/rr/rr5011.pdfyK Thttp://www.cdc.gov/mmwr/PDF/rr/rr5011.pdf$$If!vh#v#v#v #v#vp#v:V l0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p54$$If!vh#v#v#v #v#vp#v:V lH0555 55p542$$Ifl!vh#vB#v#v:V l  05B55/  / / /  /  / 4alp$$Ifl!vh#vB#v#v:V l05B55/  / /  4al$$Ifl!vh#v(:V l405(/  /  4alf4DdU `  c <AHealth Logob l`lnr[hnl`lnr[hPNG  IHDRUT WgAMA pHYsnu> IDATxgPٚ&& M9(**`B$(`1pEAP(*(A Ari:Dvv;;^2VsS-A B/J@Y@%sI y%d~@Y@>3YA} ,+:P d :B⾘,I, e P e P e P e P*xW@!%d~@Y@q|*`0ػV ~t&`[%B<ԅ^Wv ~jMK\]{shTѧ 5-K>*()udUO$KEj -y<0ُÅ pwpɼ]i752̝;ʜL[Xsyn| D;g tY("M@/eo?"Y-俁􏉁C TG> O'ViNF*_U{1ٜ̋>>TrKY$꤫ocGs7nx׾7@[^gg#O>kZ::ݲ-'\- +?ęO@9L#i,YލGJ o0ĔԴ|!Ң{O_8*?)J=x"?=KGSTTjxd~YBcDIM!ne G,WlÆ*յG,m++MNpât6H32b1|HUEIIY ZD|KD"\AII*s**p"\y}DW$)gU4%R,#L*@#Q(@΂HDu[|Fg&^7 Ākii,t;1  " ξU>tvX[ړqI?4¾n᫆:k sobtXJq,Πdg21 afbܘq3en @;zʼN ~vsbr9>A1*aSk 5̠"[\`Ĥ]k~~g3$oWo&p$&ƹͽUv6&g&C7O-sRZx)ޕtBLųfnpbh;6L_0(I2>Bf֨q%Vλ>ckWsqa|!qG[_=􈨽hwtpxYyn nfܬ7~ܜX$t/>innvcWΓxU'N?ξ:r(-/$dXRnViW5eX/o~I'v^mhTlGzvމC.˗Kkw߻ov O~X@IتOZʎS5 1͆}A9 \Mlo+b-_6|P~H9/0tu]~͠yLkw }!qeSwJR`&6r!#"%~ -9|OJM %#E qʊ2 9,_y&,oaH]FLR⎊e@L()!h۩rN:cfv4V WXX3-!1ԪdE"6ʡAG&E§'Vj6FOTYAO[XdnN [&g (olkp"1{dMpA^u^7y3y[wd +Bʟ{v99' XPWC4w 6+;c=i8ӳgd{38\7ÈnUذamo||~"-ϧ܇Owgp1sO>Uz@"%TN\d &_+9i -)g.OfٶDؑ9)|}sG8YsH=cțǷ} ʪOrNGG(϶{?P]=PuX|g ^8,ULYv,XZG`|$M#0mH}aH̓LK+RU}WUÚf;&;o\#%a Q`T6cCuU/+/+m+dw"\Օ% ]W[UKAF/'.OSѲ+Ҋƪ*T2SPiiKKX5Iy Ҭ}%Sc 2E KʩldIӥ*fZ"O,3S6Cjʻ }j{x [ pxӻUȱYJסut4jk"(R1ƭnϞQz.>/b0]YΚM.wn,F | AyOA˷ݳCU!L?zmʾ kstug6hXp8|ji88]jq7q`mnjoD! >9eӺ{{EXSc1Еܠ9 t,m33xO`kˇf;E^>B vD^>27\SEOlP,?p]SB,֭]uh# tƮ(!vM3+y81na_W \w1=c`c#L;wӗ]{/j|fm[Tqpٳ17ݱgϟ#YhS]c}MckoBݰrsJ &_ e\ΌMvۅo<{z"L;6M.|^QY5{@^"-'ޡQ?o.o #3Yr}s+2*6jL^zkS]M_y{x,SYUo_Aow^۽;'EujefN:~[[T\L\®ng\r0h@OO߄='霢/-/H"qMsgO6Fy&tj*,y;&w>*ek]^\*D3F^Nvk[=~MERGE<]#[fNd~=_  Q'MMr=^ FIR,klrBomit|lL^GM(5}4C*. tt_E楮Q- 쬛doPY_ohhWM{("nԄH 3l n&)aH73.(˛eҤ22|&9CS1]̛ O ZzzibUxwk+"o`dHhJEo[l;\LϠ&҄M`mߴp< [7mI뀈Џdbঐ%5"5)Ue>kgƚm_Z|^EQk?Hmmn +dSki@wnB~ёܛ)<ٹ~7;9~ d.g[ʟN_&8Vl<\{£_Dۺ߷wwqًY|ؑwuNn\18+aohK^-] 8z qwf6kFpHCk@/aQ2ktusb)rJtʠ0@w2Hdjh#sXXNR w =.q7+l zI@B T)(qAdž (DQp)M:HR I FzHgGh\sWBG5 }4JqqkYZCݻ &;i0%( 8c>}Eve<C)+!w 8k# Q ʕ1V# O_~R[lZxllύcC#?W?sw_+^|yq& ʆ6@g،s B~%ۦ{:щCجؠUw|!%č}~`kgVճwhq0clewf6Z^ҏv92Tk먜B`Z$#II* W3\g%U&`C>sUR8b!KJ>D2Z1In]?},t@> 잚WSݎ4_˂-C]pb \WeU$VpWn#)@ime˘nWT۬0.aEu=i6c;X[IFI(b&Ǘ6rxi&@idYBed5MA,D]A> ڶk%6-/ [%X4hY)ȁ(d)Sf'R3(ɂ>F)0,QIfȚZ"aM:&BLHF%,W;8h ?9=㿝5$kc819c+~طh?_.g7zZټTmCtzZfV֞|Yq15?zJ5tu! F򑣇V.PǕ=}c(#+%pUb7cc%pRRZm6>ԏI&ztVzj:ї)pE=.3-}s ,K\ޗ -f5uVd&+Rޣu5uMB-p_|ÎҸ #h۷L)9O!0d^ѻ92 l`Je  `"&Yj<)- a(}),ؤ7]Geo+jˋ"HOu맙ۯ:+,O%`޽_/*m~}(s/̜ϟ .+^H 9ZVXIKR->awGv޺u<{@pRVbT x˲>{{%6$>;fg0xzȟGъ9$st5vf*sO,3&9ܩ 祆ut?.oYeo8mR5-uG2r/ ӄYZv &* o-Oʏ%t-羧~eMnV:ie0ex\mEe22ǵԕ8x2Na _,őRjJ7 uwA wѥՕֿ sU5 L6Ͳ$UkSL,ԵKE۷ $6tpq%V޾]Levioʺձv,rwbίnSуZ "qUi'BV0Vv"Jg +~Y6O%X;LNT|ȂQQG5L[tqj.y r~OW3?@2׳n%K ]'R LM{[0S߾??T8bw@K[ccG+mN_z8([b2ap虷;>(\ tLWn=owH&3zFT&=op}--Zb&_íQL $ c}#w4ғ#^pa714TK% 3=y:[(4oxSSeej\9đ8*تi‘ ?1DBX;={oi;Ÿ1+&}33q\r9:8D#8_ _2sz!,~i|T$nѤbGyi=}:lDPdU{{CKH@BFfa>+XoWQmwsa'w_[s$~l6F1qQܼ}r2i);>UMl4r9<6cvU:YR۪M&k4Q(<lbAjikmJ&Nh△3Q3JM{14=5ln[({#7ԇƎA`> |vήmImlR^ij@_8==mtqY!^Zqz?2?(H-*5f05GeƮ]{ť5e0S󙙥VwkRӸB'.@5l&Fק.Z+ ګXmj-=pk=U;Swe!iE|-Κ$y; -퇨/ W@(Ý"& =J]دE6*ig6XǷ |];7H DgHQw.,X8S4a"gAF=6Ot{zhO{X#+5£wwqGLrz/p bGaE), `&U?/ ;q$zbîCJ geCcݳ-%s?@`r3f/CL }1th~ڠg翂iJM!M~\V?3!)O`p&7"1_P_'$\M#Y{kjgwy%Yy(C梙Ȑ Sda6خ50%}ꈆɤiiEtKmIM-ٰ,> ȩMFzr :[d(﻾t弜~VRQx7]o,9y|kS=BZj跩ũJt*}ҌpueH]%.= ZWÔ= оΎ^yU|Cܾ 2Т쨄;ǕՎ$Ť,fГ$C=C4.'ӶDE;ښ5evl/p,q :k f\_{ E$${id^UYNGW5˛[/r$Mm˔UeE'O.nf6nqAsr02AX5/[&}UHwr @dCV}Ԇ2<>T\R] Ӥ0!AnLDӧA7;[-CfM]Um[ D!GݼIb)!-eřlKdʨM@@! Triu=J{ig=ɺۗSZgH>Kx~.Ht@:1WCY 9(4:Y:Ԩ^Wch~5&6!&Ga\7k؊9hOL;__dn٘J}^^Unk&8w~_@`anh΃mS1wܺGGDE ތM03S:ym`?ȓ MU0AI?knPy/% w]aW= t~썋K&U׶[^vv?aU'7-g}0<:uGZz۷ t󴮁7!NAٍ-}ˋ >w^DѝX<>8#{e¯xWu$}ATʍ(Us։ubĘkd}:ɞzs?d(?IPB͈mWF # ("ئxK`kCOxVTt؉WȒENS0MT;۟{fY<.P k琧g-9-(]G cCS 'VZ2:]70aGR/y|ܓxPggk r l.y~3ro&+ٱݵ `{[ u,<[ wB~Vtn,Pf16kwj́};wsEևˣ cg CнG"m#Hav`Ϫ;fک a9m]ӂO;ytw(pn/w(=r(Zg myQu*GI>ϗٱ;DRR:c‡"s~#|AL}']}G'bucGw+`iKeaGCCGT)ȟ wl;kgN ޳]{&%.%(]g#3:rPh(y=qCMWз%cEщK*uҫ0(,2jr9,#1CGp8Kyow6C#5A/,Qf+Oor GLPv ֤ݾ⼤F̗9 KK 귷.FXmgwq pSIUdXwwWe;w^J_35ssӍݔ9|ݫ4?FFIZ{5&*}VS]ۏ>uJD{LY^RRI]oHe6*+YMm=($qJ}]xNlzxXti Sߛ;de k`PVJЈ(ksc@ hEE*I9:S Ep[&,/~Zs{Yޛ"iqqJWs?KP <[|`D\PQTآM,O+) tWթ(-᝜|C\ENbEǼdET+'1vt6[I^=unnQJ\074XHI^A *'-?2"@_SD@ r2T Pck]tBnѣ%"XNMI%\Jal:܍{0eDCsC:}m-v%4o€m_kP2c3ƍ%nnj"kGp@=SgehRWG.$\1Z"Q u.f.! M9%*">1vb>R_Km|z;hJ:G{fb/4azVЬמ'-Sov58/P/m"B~qwp%cE#U K_Qh^{|oo-x +geg鰫][{d<1YG6Hnomuhb +KI8:45|Œ|}4ꪩu[윮ߺR2=oIwsf$"RZ1t#11obr]`@lvN򡃇,A{D,=CQ1"Q%眣 (P1"PDE"(P 9s`"3׍׽}s愪>UU]uHst[{Mo_gJFFGO!rdnC]%h$m q-[ӰEi1Cj[#a1\u[{r9e!g *8 7$EQJ3h>BAAap#q,(9%Ė'p?(#Eŏ/]" ?E>ʏޛw׍nې@ICBlqikMiC M`% $TӸz=B7I~!HzĢuV dZb;N#-jVT#gI3kuJʤ$/ AaYqcUÎ>n,sz8Ng2eWv,$#$C 8(1>!pFL~00ݳl2 X!dJ*HHӐ0ed"i/ŶLTqiGQ&:!)ke,\ƉDbfUlƺG j_Vif%f9hu ++U~_g8mŸ5Yb"".3pCZKOnN]NXm"*ğ~ o*fUsG Ɇd kޣCxRԥ,ݞd~WZ֭=rRԾm^Eݭ;?} ;t1F'9?z:wΣ#Cv0qAoKssڊ} m*9vd&CEN]y*jD&S.3!TWPIIVVTiχ:8l$(ť㳨UKȐ}RΝ .f¯EM΢dYo DMO)Ȯ+,(ևJdЕUJ+ԔX9|}(Y^^ așsv!z3^dV{VYf{n~#\.7pMrQ~K_͆Ȑi9yO_hvNMb>@`xfǎ=8̜&}-=&O_6j*k6nr݉&, -յhk` )I֛$;눻qS(}M/ I 3:֨d|(xB[txrn}ɩI=}'tq$/ENZ/r?kh ؽKc:f>YLc ;v]$).Sk մ oڴ r:`h!1##Wbzz􌬪^?K[c >{>么 kgƎb[GG_<~.E9>;fWoGGHؕqu=_g洷47:2$x܌߉{Ru[RSm;8=5}7jehON}nkɯRYhߩ;Vj_T]{L .Jw^HauEaJu 5  ˶zf%>kDg=cy>57|7e!+׬jPh䥓žgbr-=`(ާ_y lOTw]>}Brj sq6(o,g}sc͢v !.1),άhdH.~Qܨjb1ƷZkzZ8Z :fPKV #lFS3r*%wIJV?Xu%fJr<5:`PKBg5^W讦53NZ+Ǧffg4W!X=jz&hܖ{e8İVYRЁGA(rln#Gnss2XT4!@e7Ԛ,I~]((;ǯޞr˪js#v=|6ƋWBg  L|6W6oܐٛvWc>_W8jǙ- :®\5Ukq26{gBYqfɵ|<&)-v>WtZhiV%%hjt`;8GܸM}RA@RS5%y#,M7bM%ՒEiIl1m'p85J o}PWEG7v$)k}չFFs[wPQfI(VEAu0cPtLnƧcѲ+djF_zilh !ܿuKX2irLEepd%*,6çOkh؁;P ZfzvjZ4B5bu,TV^d9 'hes:g-A9.-sl&p PƆ^e|kcaE1?~rrzR_/=cS{ H:x CO M-ڽ;xDW]AaKW6fnӮ.ۈu|ʓF uq^ĵ[j:=|`hdC'{n 3СFsxmmSYS\[vȑNIoO|߬jPVY89nv<oox'7p\QvE3AgB.GP3ok(.11wϡv=BǚmPTCّ+` (KS簨}m{$7&r~YQCemՃػ[q({sO^h9;ܤCynE_U3NJホ=. 0Dk*H%%&UQ[rdJ]K'4Vkz')µ}ہe$ IDATgwZY#bSYmqrL\VAi^A˙kTz,#)+&Kwg͎ ,ߕd7ߏ(*tT2:MO18"ދz[oYg{')jj`܏N՛&ZNQsHǮ}({ < w΍/g!\ !'f~FGΗd~mulsV6fZܼS0;*Ѫ5rv*}8M;1'rhoo7O '?.{Xi<,_D] eR֛Ҋr˙U5ke~Ļ.sݣcl;v$ ixn=_o4cR$ K&fWylbǗ~/7;r 6•෯LN:{ʆ-D8^οxԫG/P}v݈uvx:(40ūɃGvH51@/ٱǽ~]"X8خ^ 5O5ںZ NSS?PTXڳRvij)U4rs U]1Rn)516յ/-A`O?VXfP\*G'99Dvu pr"!j(.Og"$Ř(zf H /eұlN~Q1z '1O%K#P"bT&OhHR$ R|H44lwo~sC ) S/Eǧ'0fVmuE$xyݝ-:##CZ}]52bB|/SeTW.:OGɑEݾI1Y١ᷳs^8t80SAP`pPҊSg.>OK;xҕ3A! MM{VhݿrXu]1aa]C㫌\at)&g ]ݝqO ݯk!jp> B{~SS;L{O@(iuDb  OSz[W&Ň^qX0vp"5erz"J)̔S :h<(,tBmmr46ި9<621==GB鬟!|/v_7_~}@N^:ł_d.Ԓ: 2~+mʄ$Ć 6,I f$<`e]~NAD 9t8=-wxNϧ|xxjAuQ7ovVNMqrx4YMKmlxh,Be3B#c#+Br!iiY2#,[[%"#".@ ㋤VyD^LXN}: M6,%oؾk?[Ya#UrҪZo50uEshcee]:_cX] cCQ ERc]uk5yX$yEd:#9{V*S(*-B5/$.$&1.%L ~N`9/77KN&`gKt~zxxi3%X ƋhIq~*QH@NȆL:FGrr0J-!0lnM"3B$OlѴzwqgJb jn5zQvO_ͦ[a׻&m'FpٸBhm1?K#ZvuPdfdς4]4VW嗖iSD'g@3B}m֖:Me=:xڝ}^Bmmpz+l !4p|tLPv󞅁%i۹Ad4J}kk!ܴeg{Buu%eEB]/@5k*J'Օ!1R<6Cm\r޼*kLNPRX8޽AeeG?W(04|Yw4Aܼ{Lmܺ[j>l 1ǃG\%4um>>~oǍ<.\!q;yttxKBXP֐Bxޓ!,j}-06>Ȇ^CfS$a֖6*.Pٰo?T4@o&∤ѩ;q‡ / o3-#woB~ȆFtlkW8|6w,IoꟜbW6}ń…Ți<8=N<»wUWa(A'Q%Il3 >aK7:;߉'aڋ_ͱa۱slXXT;MꚆwoO&A=D_Ҋ+꒓PY/?}.A<}8N(^a}Ymsەx_;KK!%탆 ?/gkf{?!ߦf_Q.jH5j%9C[:|f޵/!,-9&w<ȟ.ȆWbX'Ӡv6tƂe]nse6?Ѷp< pa@& >! l @ ^!@i< $EHt #x*1 C`Ybt \ltuZ ~N1N0$1gjh4N2!"ƨ":bǭ\ Ϸy0eҝmqUҳ|:[襤^9cŅ,@>FӨ`?ScD"f 9y2G$p03=F`2Y{y:G@px, D"@$YL",`C&2!TJl6? $@Hd/G0h6dq 8!nN:|@~B E6L&@&DDD`a>@ /@0U1!KJ0W@f:K˻  Fc㇢֊ џU%;՜+0̓W #ܜ n&{,/5Ƀs<<̩q~fD"h/32MgqbH1 (ёqO x22711!Lb CdoE#p ,0?Ge2qtƣYމ"gss0LufQMMC84JZ`cئ.@Ku~8%6 ImD@&{foӋ(f@scHɦ1)tWK']V<@^f!` *+|X^5ZX +ݣ~ \r^a1Ӥb\\ oHJy023ilh<"t !tvry, 3?gfbRҞ890!{N;1Ȳjm**pqqbB3g".!a]KocqUGaBuFP3S.w/YN˪\x&۶յ֒M]\F aЙyu?[t!^'3ՍOKOzn10601ܺB*͹6=5ͭqɇa '&?mrdݓn-þDFE4lt!2K:a7+>~z_k/jc3O7wlqa{ŲOu5Ϟnan}=q7zR,X:okaO+aMf>M5ֽw^}{rGYgcr5tvbnŠgxࡦ٣ʫսw{{IEDŽTu>>J_g~HaQ7{lQ78x%8rpD#ΎNvq5$g%|ƞ]G9wT{LxTTUY_py&215EtF k W8z&^ҷNx 9u7t%DsHH54_&,-M{::dۤTkip2jZLXkë#Ԧz#uÁ!rIn^2m 7tu'#QwE5 ys[ޙZ{(iS`%/ 8u"rR~~Q;}φGZ&-$n.qԗnGD/Nww:E~3ݻ^#{S}QQO5eǽgY.’e^..e\HA2Ÿru}zG'7)R^-)"5Xiuu9뇒RUeE51 Y ;q2 j(6@I -l&ɄR"K#rKHqJAH_j]#*ROW^_Nࢩ+f^& $x,A>>N)!Es*,.*)ϥ )9Tjk <{I9 9S5  jֆ՝kWI-_DEᵝ, Bi]^>$y gŒ&C*CΨ^g"^gƉf뺷%Tרnʯغmv?WѪjE'ۇ,]zD 6%z9֥*?|@Om#8MyFI U$ dQf³> ַD PW߼g4%}k]F̢j /da A6GeQ /Q4˿JjQv0n.痖J8XK_*Tӷ@@@@)s#^!oL\^y>8:.13.*byʉ0r+0BHqhnCQn ဗ3/?Vbы=lٮstԥWO_̅=c%䥼~խ[m6onr5vOSwTԝ{i АqU{ SQŎyVU*7PWuJ-uߗu:r34~',L<]= FOugz:..aC8¡>7_q6yWlnR:{6g|DscCNn-L>72 Z_GCgS#vx0"̺"=㵅Bcx|B[Yqz S}ʅ+wNg~(]Zetz*$Ƕ]hN设>eȨM뷐TsUU:*:CiIɾ QgBeC/< ! !)/˵u@gg'IѾw2@njik갳ci=Ɇ KSk7+u M01zxI&FV<1,./emlb͛ Uں&%% ?۴vwqZo"鑙f,~~3:ڦ{]GFnFDnLּye]W{ĩY&'7ᮿdĀu%?LJFvwՕ%5v>y^7?r^xrdpv iQ^TlvL1;i>|QYGCe1OO'6PcϤ< ǖ,  E-(pCJF,2ΞA4(Hc  yC /7]߇__2,! ~.bc;_p|+3"ϯXMN>M}ax(ܩ}v\z$&ҍufHˬ}{<{y=#n=QQ%M]<~ P6ٛ>zZF'nNUIUgNߖ5vo/P9!*JNVi)CTW]NHH\C]A^nRin>$ǂ݊D|-ؿR"97/?_X_Dt"I>Qq1%KxUt #&VɭNf'iPg"[X @}@$pώ4,ֶjuLk XKW.RV9_`@EH.,YU.\cؐ)"(!%[DLxHI+ GLkjZĮ͇2 IDATRojxȭX㝍_1YAyHtlz,VWTw—OxlB-#85X"YdBE3Jh5@؜UJjF1V"\i8+GdK,gj9)4.DHLG=WPb!މ;^PUV,}b;:)$Sq7i+]}JiR66[,.^SYnn#j ?85+W~en|< 0h,._< &ܿbs;Š.܏ju?ד~l)ڝ[/**KN8tϷ޻}WSI#C׮MA>:Za!Jc=ɏm/u61y'qASiɫ; ߿v67|\brj v6ul_jh8㥹勼B+@LXZ]G&9pbxIUMmk{dKKY##LL~06@M۷8jĢ2S=c{ϱggh}}79rjhu ] sw12>cyJ}Cn@4u**hjb#={ !,))ő!xܿ_{Ärm}$ W6Qpn;Z%:q ?g˰ڄBO]8!} eilNDn؞WT6>=nKmk{û[|f CݹaԛW=w%Γuo=}O·O^6v$>z@!/4qr:YomlK)[WeibY_ EO}=O׵Tڱ]nar ?u^>}{.9{5&''l[\j_=V7*6oiui'Mo]21t!LPfw3O]lp=&[VqfC7gh_x_-m*c ?Hx}J0;U[X!&▩wzvqhfJO2mmbtWffoo%a1]ӺN:CrՒJjZ+W7Y|ɖYDYnUTD!.2Va[9 |WPDarHͶNa7+)]>251S?jtԏyo''G]:贙[Ĕ*+Q=SIw#"}[tZ􍇷;nFq0uED^wwpϓ±**kyQ$& t&]x н}%%^nl߱uZťRܒ"Z˳XtEPY^**&d*+X4A.8)XEfhTiY 1IJ`+\я62u43f$1rCFYQ?e?/-8 ylGd:Ke5*d/rTҠ@C󐆦2M˗LkvMMiv=<25+4^ //])9 WHa&z L5 { jy6>auK,UUV Ծ_ E`M4v? ˭zokz!hמW4n`2MevbڽVXkiSqScݻEG˫V48|kdU* :XXinvlҫiM}n^kͭ-MJOC,˯-oDU8쨋s̽۱]C[Zk l7bw] E9U=~gi@}vԵiuuƤ&.c[<9a5-K>d16#c!.Ơ_ c`|Sq{O%ҿx/], !(((陜13o~fܾl)<]OqZF#}־蘣q4{c[mMLzN%Q\6lzBנ/Vٙ;|tY/|aʱ}-yfaV gVV:ai ׯݍ kj+uҲEu#QAm;vR]w>TEASYnkǪKq^R]}x:4 w!i~+w|H_ Il$`@Aۡ7[{WCByy5ŷ XG0` sq|YZ=E5NN,U0nyD|`Z;v7 W);Ud'hs/8WI N9pIwnbTOfH#gZ+"*[LG J,RuQ\X'~lօR_M;wqrDd~͐̒W(ؙw޳͉g7#&z?{qlC0=9mH m,) :y=n} !Qw tw!x/Б ,/O3 `m+'V$A|m_N(` 58茟B`i(ɷDP\hEALI'v\=$]%~rYOWa˜6eOXk11.^vzcwTuZab1޹uR#s- gS__{S6L8P}3dMReRJJ_S 9b>AI,U6|y,N1"hP۾q{DSE-:/OO:v`3Cyq_\_]{rO,r0u&-~~Ӟ1ik܉ s`IjN%E<6'sj`YQSCeܣ$3[gFǴtL{3 32r# 6΄_"68[b։} y?毮̂&0?C&wryZzj{7`ǎeuGzܳa`q:Gfz7w':{WXpЊƇ;n~(2.Ap!<_Mxlcb~MS*,UdVxciY2䩂{N牺ieBO JgNi@CG(" zOX&rd0m9 &"eY fXʊ:l-4S 9g7glۺs䘯ڲϡ"^d=??nqܾ#' ew <}əAE\u/zzk-6ηC|&/rQ$6HuH/Ҙ5K0@ ddu"s#~hvŊe2j I/E/V0l]$~JxfswuǧrukEJ2+V.`Nff7zu;vGyCoS F&Ƨ?3,dk7EAr9KA`FE *HF$ 3s94 003LtwNUsN"]Z\WAb20@,MFJJs$dG3PnsGO/LRӝQg99*/8 wwg}#)<\AZbo}5dietVA'7զvn)<ҷS2Q# :ٻ|]Y]67ŀ`zzj 9]_bfF{>.,*[,^61XUW?/)B`m5 ehjvj A;s?_R~ jkd^d:8{kțuםDED^w=8>}QNAܤQuSsNneѹ_p]R"c/G]*j|ΫiT^_nilqK.WUD|l,9p#!.DzW:m-9^GHȽOOFv={ն7=K _7Ӿ#% &b_V kjvyum=#C>Q.sFOc%ƿzSUM3'(^ ;h]U%冾Õ5%.C_c\,]Ռ 7r5l]n:!%/EŔ~̾q8+{7+++Jror QZ=ʀ'{H%9/ WzeO-J*,d~tumusdID|ki1Tfsa?^R v@eH6wH>HFNAJX^^B3La(r~~4eH`6yWb?s799^Q&8m0k U9nOJ 8"kى 5EWgQyxџ# & _ 1>yrj>m(1A&>ѮvC'96p_p}b]H éHH0ǙX)(؀q0͉SG(c&]%"Dض(x1-$(%t  \fwOА10gV'$mxjgibGXҴO̮&\Cf[Od$!iOO=J=wfGmSS))HdJΫ5Ԑas3u}"<ژSjj[Bܶyds ]S~ rwMeyȟook $` _4Vg^v+wTRsSUW?阸fƼ5Zhqˣ鋊EOR'~BC3N 51o"p&'-G#g˻-!q-<ýꫝbʑacC,,c"546$E'@ IP*:.m, D!w[^Y:±<;񩨘4Ʋǫ]Ʒf;ߺ}# ;_S^>2ʎ;߼kc#yE*;G8Q+6 tR x 2`@]o;(A>e3 JI*M.͝b> ݆ħ|B`jSR1X.ٹŬ|1!i/>E<KY%rgd>~G_'k@[zc]onlCTm;ϯ,MG_ YQ2LKYmJHY[MP 5051&((;2=;}l--g+[V k.^nЂMu"+u# Ww8A!~5(0W{E&/PqnfΗj>.8KT%&(2>7$,N[Aeq}CKK7さuiqn8m9.BW=K}w5p DޞQZ&.9dai֍51R]ym%;7砰J)ɉuۼ^޹rie29>D Appl"#>A4t?31KQ]Oo;[GfkkO_v@{ISE7oVjTE%z:.ݼY@BJF)CHCxH_ڬBIi'^tΊ w|YCJ{xyv="z&iIqƆK0M+䊺a;oUG> Ll 񌉖TZSyh$℘8d! M[#sJ&ޚS٥X#>xNzvSw>-MmtDſ!- $!e (W'cUC&NҨc~vACd|g:P|ZP IDAT~LJF9_m%b>ƼҒâj59L "Ui xb ߑ%8 |qf)=mtu<O@PQ2^_mAd$hwu0!H)pͳDǨHH5}2 @޾@~ fcv(+{{?J9h*yI؀G7W~l|o '"X*όr=S}Ǟ|"Jz3/]wo_鳹AJB/QՅfPR)d)*PRd<;c䇨V{:{[FzYxdm$iO/U.IϠgfPND;$:1 z@vbCvzen8by8+5v;*++w1b#TSM#*b縇Q**Aq<2U%5u\ ol>CdY*%.ƣ toCOάLdfJI@PYB\\. 7 ,' d vPUρ6^..Ѻ>^n~> 70Ѕy JV;l#/#tu4q8 Q\!哬,$H y`㪮egae|Ru20M. r -1v-$y%4̓l\0YGM$4?]„&)#gtA?,CUt"&\FКjF1qãJC Coc5wP{fg;; %i4c䫑s@jխ-i Ĥ/_ą%Vo_|xm *%)]X[Y^ZnnyׄJ*Jjj%E$ 0cv0JKM#0_BLri"[Z,}#W,۸yYwoc׷am.?}rtj^OGcp|2%[s}Cݹuɳ-¦s:W!annL-^ut(()oUWS^^}:'%OvvՍm¯9^NH1)){;w\prC{gM}ݫAwA4ť޹ŭǏF%$V>ooϣI)==+j^E<|;4epxTd{׈gׯxV6ܻ^RN?Kk A8\486b`ddnWa/%ΨN<򛘞z@CSK^FSΧO9M r̭ܺQZRڷDGñ&ڣyArq>qK )^XiYZ\|VRQv髷1q xq9_pYpJ\jdZbfċ |Cߝ<<$+x4h o97Dw\., "|CYQ'Gۚ^*!&7qU9+sПyX03AX+TͫHP$c%Pkh55L}AhcgtԨ4}L!;Hj'쐰8:UiO>IENA:81#IN=g8Dlpsk2"xp~MLAzj}usWPj'?L1A:6v&a!4zykQH%.ͪV02s\N8Q^ePe|Yt#(*Wf{.7ZFn;g xp[Y[lkzɓ24֋V<װuT8 |nounqlsDCg^YDnz"ޓۀouy14#cLH '$?; Hb0V'yv<\<$>IE)&Q6J** !m] LGчh9騨)Pdl4%%55 ~yBikf]EGw1')Ilt@ɶC/bnG liĒ[ikr.t-,n,,0bd(i1fUR"ؘY5@1=~iɓV!% T8j_{R?~k[z6#LLJ'8O)h@EI{77069oa'Es:no]TW]O`ӼtzVfìmJ{|׍?>X2 Z,(M__4q]^~*-qswGwVg?;D%֌ (g=}roāE![emMi1q*˻-Ʒ7$c?唗p n8Z=bRqy9 h#]ULO4!-iKChcc]SJJHX߃y{Zmde&&D]EsRRz~nc}j}#GQQ9S;;yup(+?[XPrҖWr{A!dE `is/ $pjbGx`$ErK '}m\@Q|4:ʏb޿ن)IȄ'|Bl\yBFFںwN[ٮ` ή...wVWPWK46;!C쇇*^APYE3*>B/傂,dQ'I/^ggkM }i{nuck95|?2&{hƧ܂ay%i335O^P^B5"0)Ii=دꅆGonH IIol\.;?؂ 5ʪAa0ۋ9YƮ a-xqXI֎NQIM7w+7wp9‚bAaɹOS?99-:6[RZaqy>UY:}萐xl\9}𨄥)9%陗AOUw1_i{^QM twav쬡yOŅ9fK 3!ς}B§'}jiձ4q11 *Zړ-oώ7 y=6ԫѩ3]y+ǩ koV݆U5tƒ`ǜ`χu< _cu~?>-%*:6ymĨ/5eJ!qo9dG?'EGfU蝹qA^_MJ2KE6O ׌h<@Aעpu9~3?vN\{VI $Qzk+y0sKpP(aPl8/+b?7^_7we2*2L/c* mCkW$r_."C 4R ( PV[j]F@uqJ LuxFy#dl`jtUZ"b6QoRpqSHGNB4nz'{ 8ur2?gP9 UT 1ۂ#g8plQC좈}#l\؉6r>E ۙ7oM%9!0VrZʤf?{a {'+)sljZ7B2҂IiE\J=}Ʃ(hfb4m˗MVvNbEubzdcn,YEEsHTsNRgvb TvҧFNY°'&g)qK##3DDB'X"Zj՝=EMS ѡ93:tGӷiO-.ԔRe=prv8 ikmR7IPPV)LP7X\iu}ɔ|U7w_./c~e6KyM}"=CKk'+.")gODPr@_9c#S3 x9DE j+(F&fKLVVǁaۻ{ldTA> ޮv>N!$`cg`qppu Jva!.ɍ Ӽ[HS+{=z d"0iE@T ]\?>1[h*"u&6WZN'~7ֱǝN ʈJ'Bx8 2/#H.}TEeC"bp Y?8TtHe{;p## ߀'[s :%$V#,77T%ħ HK(Ψo.\xꔰL@_z6o?,mC^ADez dea㇁;b EeEJ;>>/XL]k[eM&sT|}{KQNklrhbHRP {F$DV<:]O[[-o_O0>ch^TWh|A77NZYP֜U_ۆ:Z_|"dhof>Tk۫ΩAV9\ۺlu9#HӠsl,*:,t!)%n𘁬^P%syq,z&F/_t ~A]srkS+?P 䴬7O/HqfcGIiͽ]nCi7wOO{fvxU$$%<4'gd?=3HEEF4U }:8[!)2TX[ZWBghAӮܺjE9˗^4>'40=.MKog}GE b%2=UuGۋjvEEhǓ;]?_XE]ς9A rS3yo%qqˠ/!p~6Vo ]IR~ PUQw'$Z]iu-%#94E 2S1vԄOPH@Ms/x$9C]:'6!?tHQTȚ<+=Ej̝5rܬ]P d9=mZeSC5ޏo֕)^X>MH9ʺWRSҕUV|nhh*{;0@B@~wm8ޟ\۵v.Ů .>酑:e+wS |i \&Xlpr֖d~)څ]1.ܤڞv~!U3+$Ғ:OlcqV9_ye5$ľz6213.-"ơAv,prJ~0(',`}*),ʱ޽r9z[k;FDxmޮ7@,ȩhdg倣>~ JDD&c) rXtċK(~L|p W iJ2 nlod!`~kK Jʔv e6 uh &t-򳲔Ǽ \Y/ŁSOO~xoN~,/0/Vd Kz76rB(|lT!O&XZoC$/4TMB6eG߼RّQ637{' >7i) .X\73\ y]i5O^=pzkd'o|.{edfinj? A_N{tY O{@-F$%.MYޱ!OߐҔu2J$\ΆgGc&65pu5WS6ċ eoﱱp!bSt50x-6&U(M5M7!Y^YLUIJ㱲nv/5|<"< ^^\56Ap||~rbC] ݃<01G<`%#A|} Z{<ȭbPLB.1=M|yA,?㇟VI~C̖6Uegj]zx l)'[#% VӁ#t uwF(H*L-.~RJECB2gW%eZ:Jkjń7-yzmee2r+mlî:>yQRQ-/%>@|Ur +Wo,r65WN&Fz ttz?$9;;-ٚG4th O'_߀}346sXgw# yKgn=]͡ɹ/z5Ń5M؟@! Wz{dolzА!~Y/'n|CJZIESMmщ~/C(,iz6+(*:,&$yȢWy~ )R=u ;Z^==>2)۝["RV M+%EΝQsTV˜_{]^^^I|܇ Ԫ"!J i1eظF͌C# X{6&@ƒ>$dDf6w߸wknzMDGa/20| :%ٵ JKN4/<FO0?]Z!a;<4:uN&+É$剪J]}{ j=Dyc賌Vŗ/p0ODq:ޞR% c3/ #$edUXiUO0l&k"= BD WKN24Op/*ZXܙ>FWCF *h_>01O[&õPa9atYw1NzaA崛?pww?5Z/ l9UW-:V|\B"" }-/X"I1c:hhDxG֧v[*ct4GHiF _EN %ffe> -!-pG#,v8?i3 OwyKJt@g$?Fv%5%035B@C0 iZu4%a@8 qI' (#Q̾GK`8:rq!%ѳ:p>PQ.b>+5\:$oo9p1EIEl.|"\RP@D/ F";?AM4|_U4-l> p~ejxL+,-bed;:/|2mܬ^gmle<3-gm0y|97:(ly*'#'X8<<6(&6䆞M˧!&zucVˋ΋d޿}ͳ{cFϳ++4/hl* {=;+Q-ȯxÙ;\ҥtյ4 xzȄ¤ D:GkEA>%R^:#.(.] ,-v1 SK ߜH`@POH(92>9Y\V?#s[;{O1)IXP |sN]'?&7oOC*]4tvv H֗P8xMksOW?2vttkO RSD$e0 A[\Lb BfedJH)!5ο ?x}/-0C|. @Lz CM$8Z[ãGh=]V E9{-J*ʾ|HL+2225415IJɯjRQ%f@_C[VQb*JEy7d=|+5=#<yCۻwg#k>$& 5-$;<Ļ2,#++ cGyV6HR^I/BeynS3Q?"4wёx" b$D] Nx;ZU7#سqy:gtN1Ҧ~i1Qjl b8pV9xol|\IGL?~Q]2V]1UAɱ]#| g7"&~yHp'~,$k+:B_47U21~㢄byKX[蘖U9uMKHi^|ѥ]48;QElTk M]>w{ "di󥺡ov[V8`$dP=BBAS܉Sl=j3JNDc<K-,xzbJY;+uWSPV />^Diw1HϮvS.'|sbrz6o_&/~C_GKI ?%ly-48'riEI wI$xH0 bޞG\h&|}kw{u~q~2<%:H+)u,;・R@_@4&,N9ݹ%T\qZἦQE1]F{p^^e^If]cեY*Z3!$(iY6L} ?Ӽ?m^W6HJ~z' Cs33o5-LBuQ;C-5M f<Ξ&w2_.SPEA},<*eebT%`7LV 0TSe-a&wOy5߄h:ݖb;]v躞xz2o:$~)-,+wD˧zHW?h?Uyg7o7X_2:OKـG{=rs>4rܸkbύ; WcR ʌ;z{ŸFǥ uL''Y 4_GwˈK4&%hmU\qRcI'? xxF}j61<4LI'ݹ10 {SXJLԋq4?ݍCiV؂*%9 a4| F^^\94=7\zb 9ՏҲdd>K;: sqZ\ v{wBG}6 k\]- rPQEP{B^^|dh0@j\y٩iN}eS'Zz⨩9-ZlOydD_j>[[m/P)! ?v[opP`Yc3mC\;kePk()mߦzFa}Ϫ+z[.Ylj*\j'3QBB Rh8Eo493ͳ ` REeę7&9Ig8طxcG  &%m98@A`pX2~8=:=RS@9̂Ch)z$e$(08 -:dr E ұqWחRb@P{1^EJ<:4&szfi_@fgiO0XcF"RB %Q $ (#TtE.Rt4Ф#b0Xάw߷dI}v3;elXԙٙ_ӵ~WU/1!g1$i+O{: )#ؠcݝbRr]V6#zt)nx@YJyCh޸ VRST}t/w˰()og|XٖW77#`\ji T0 SX*dzv+t`JMu_FEYX%+[j?"`|,LZnJMM1AQ,fY3r2rCw>}Qx- _scT_<X=vWt鑸H({E}٭NB</V݄ܲ@|njluiW%]%ٺ#7k۞1BY^q8~]Ҟ$/͍Z6B/\$rm^?B8)#}3J_ko^ւwTAVlћ^XhGW7 c`Q-)%2D*HIt 3RWcJ-uW[cg{ 5U6?5@8bp~Qi4j]WUc|:o^2?]?Oz{p:N0$uYU_w?( &wiԋyz%7uA }O7,|m<\ H~A'N;ueDo^҄yv/83H#{+Ӱt[軹U4Tۆi_I 5sQLKmNly2nAZA4O iu:}Qs}^HQ kv }ąfv5J )y%[7nŢMG8$r޼]Pz7:uO_% Wii&]RrEciWKeկsֽä` /(_eo()4 >TՄ'_w<}$JCM!hT g IDATG"Ohh8VfcA\9nzvb\(3awc[&ӖQڶI#a\禦4@{HaTVJyh;82 Cij-3˱㷽oLj?KvNw^!ӷܺSVWw'4 y`ns8ӯEQc[r.*s\IMًؔڲ͏:3ͯ,ILH+/K:b~哪O+}*s)YhιV`b[65~5U*8-EdRĺmPeZCؘ)7! Byh7ԾnݥP`xya0<Ьeӎ +u .9%:.>Qn_ZWW%eQTVHԡj%5+*0ףep{f>I~ld[&(eFN psmg]qS..؆ -UԅN2E6έNIk߿G儵 [TILp{XMn+غS==;`*-w rCjy^zpf3-[K' /TL LCT&%mZVHf P~iz^N'.E%a^C(aAZ 3BPx? %2 ̦Û}x^Jjw_gdfa+g~R;k?{i7dA iUZ0y'7+ kfU7(4,E=wrsmZHyh4PW00! x ^&.ߋ`ɿt,6MfNS ^&V!,(;drCF6Kf,wB$¿GpV9!";]TEkB3S`"._޵URWPmbK] 4PLmkVф֔by兿pBYu7̍`WjMgA8!Vҿ7p P3.طO>D%>q08q1k]S#Vz._MjTll΍3פ_l0y4zUQa_#bGEIa0=t<,:=CC*{W(4o;6vNm䔌p*c8G<'.**#GGkkjH:T& S7*A\i(@&_/es ?m$Jf޾- bb +k{]hxP_\jp}KMsr1X7ZQ=0>B9IA<88 cd<:1Op¸L˂$Kёb;U,uTO]QN @IeSUI~qǬں2=U [K[ZU Me@ _3е/(X}?<骘'Ÿ}|]Yz.粽g]Ny ?WUuEhg zRPY'L@t}p<?gx?:L>u~1(1LRBTOE[a}Ρr*ݺF$JOs cSmk!p `kdt o)ddxf$dCGRsO vGWF2*_Pr{uUhkp{Y`?8H E5A@@+9οՍȸ4-ݥ]R^%EE$?'OyDQ}~fޥ}~FőZ4@w=+'  =+lOHE^95􂼊7-ů_~*ܚUVE0Gx (h2ݳ1sSS<[puaY_?F"" t <݈pvR+ʊo()?zxF }Ց~#ݨ+}s'EYuΪȈoNt)s͵5Z}.mZZURm{ERys#_o> .﨧?(OQ b? $r缝}rp':FM˫UxEnvYYeu"Y9W FOIW\Hwb:cSm4洡m<“[h5%} ،9!G=;4| v_bqa7?o,ApyfbnaGVKd"ɭ?t_g XVV5 `Mm۟|~LDeGז2⣄dx5}JGw\@HA{c ($(?=U_),>8|7`_B@"lke NՅlJ$L-F)#1{Ҿ/ϏyOzT__| пi:mLy[;OK*oa!EA0.g*+B?06pڊҎ(kcswĬ*ʋ?e7~aꬥ-]^U!6rpp#C;vF߇[7M" U8@; @aPbnaݾ~#yscLPqԵ끧]ϊݸUWe Џxo`j@KU8;75zKE 3'0O2?7_ RƆFG'GƧJuUwח6TAu%c= \\٥*!u[h7ԕ&٘(z$SSSK[ǘI0[xR B Al-W"zaq\׺;]5-_ , m4DT Z >g}L.hlRֲ;頫nZWY)ȐK˪2i٩MU{h1r ijrra8&s|F@~I# ãOqj` 0,3 K=P=!B^-s?D}HMLnJSeP]C? "~ t Q *%ؠ ?|RPT! ɑXbF6fwsuOF5ں#%A$f'*91N  !XA lhY;~~iΪ:Ҥd*)9 $E?\m]^[`YHҢ #sr?SXSBor|jyyQTLhzv779_\[52Goq [^XT&攵WVIaBܳs4$0b$ O/9F %D 6'C0vx@ pF<<26ϑ٩Ez&K##K3 v'(HIIhl#HAtv~ Kr039ofm^YQ/&y~j~nsiقLb%Q4~~ޯFM<1R Bc{sWZ_vr^t::3HJTAM $'+̭Է 3ҁ0uـ\e&3vN4YXB+sA^<\)v촤䘝e07gWo+']3r>w5 E'EyuUTP;f`afd7E|vE);mc7_g[$$7AYŹbp;rUI:=e~J94=i&*%듢ZGg۹ |.MDWj\Đz˗UR#_y`c$paX T Y])AnK~;,#ە3;&@CA<]X]"Yw"|b 55m݂Ԟ˶&k+Ң bqx/]5APRJ(/obs.$PITe}.*"^k EJOZPSh~0;:!ZV\SPTz/ƃu4&, @ z|] ZYau++L HJ*vMOɀ x$ IOMtI(@ޮXV:3), B?"`eJfwօ7v#Muv&:(iѹ阴r?]x #Kw<}s\Y/j&Ƅ.Uen40`ue丗\ מKO߾4: )+ҐΈ1'n66V7>1o7c^p5|<eAB~:X:=JO RnQU]c~v@tqms+kC=ۓlNElLx'#ݞ)ʠgۘdطCRݽam~")-k'#iP{=z68E`@L仈8r<׬4tJioctLJF.xƅS+NM8{7>e).'"13[MZfVssdD2_˫DKC]-u 2R’ى >75>xxB ;o %EGIm(#+%w֕J(,hzUq/; HSHw'Wh.,W"J5t$ m8 _X(_;Ûl2T_s4t02iM4\SZ``niY򩪭^[Ygo9c\X#ӪsEG7um࡯|U7y*/}[]p͝3<uP(,b#u3ٟK{ӷxx>|~ZkU_'RF'Q^A9gO|>\\p#K/US7K24I~zi侴_6w`շ<F':Z$etoqHw'|OFxCD:KG,D-vaIZva~v=351GOL EHH9YvA&:2<)}CT7ryy~>$4beX{ Ȋ o"  R('+C' () ў 4 ȋgK3ҳ]Vg؄T'e8X9Ue& ,YJIQVg\Gyvvi˹?ʗd'zusc{' r;ƶ <S#V KcU)G&zŕk**XXG6 |a#-xGdBt{ 0(.,} EKIFkC< wvPh% ;U_]à|㢇m"07 JcpYSshb)Hs2 -V 455(q.Iq9PJJd:ڪMnxGD屳SrF}:78;t1) oR M4IH@Ud )Go/AhR_  {n!55݋CC.LY{uK+u6{’6zqDSQrEcc3lu`LR[ SqQo_Y[ݸHEJ{viyZ4336rJJ.;%&6k+wM S:f_z8ebwupyGFJG:?_ąߗ} )ə5c٥aw^,m-kIMR3ؚq򔌴YYq^ai۹/ RFymۋBMQrJONYbK38f!-8>1qesKDPre}:#HJTv -#]49&841$X|Ap vJHA©>WH.v² a)WRaQ>}Ag@>0# /"\]A-?ڡ6gvʪ[d$) D;z>$eJK׵[}W6lßKx6\mmp (/PT'Ïb>;{u w H`P~ԵxwXi>/a@I႒ZS=}8ioTÁiNQqI]k"|Mdr_LDsxLRHlee>L˽ WK; | FB~Vv0?fyx~iu[--CpC{hIB(= {ĩАw𕙰Xs]^gD*ޥ{~M Qiki?gui.p(?g}i攧onl8'@W}yf:`lD 3+aV 7gftOW||PMte>>ԠcZ[' PUQDR AWZzN -똞h.:)u)u7ґ (u5屲(T[ι8JJB؆_جiAj.wwixvWP{4$^p ())59-h# xqs di03- n"lcu3% x͖+XW.]?ْLNV]JSLKseȫRuEM7gg9C;ÚM-- M݌TcSU0y{j"*o4/>)Mq @``mx+-K?g'-M}1{, AhONeE{x`!ip~JSMi + S s~R'8kP\[T&ʩZ44, լ*yƆڣlkH\raGjJIjKg02$$/o)$zq)`g!j|aadsakW7Z.k'̏fIP,~a}sytcmsp WU-loT3Naז9Hrӛ`J*[{ [Xnv#;;noCX&9NMC_ ˲0[UB_ff#z*(N0oKsLAQƆR9YM$Qii6!w9B$_K௄?&ǂ`MmzZxltxkg() /.io΢;:c_x89WƔtvVA-wA:*b|i~nSK/}.%([{mv:<I %%Hk'Ii Z_F30}k#BR>#} ?*!-"'b{y[Oy=(-/nXκ7ut\p<*>#/jx8arUzco̫x|)yx|gwTԮzܭ(MHpə˲Z>dWY44u79Y17 H{N?x_ $$cZʩK,=\._䳌+Kk|i,.X8xE5 ª*I~e]sSs8%'lhqFGltnE[suMTrzB֗J3niաICS睼@UK[E ofKKbѪlc ew1hQظ]#>=w۝D`%$d Kw=~vJIMnPԨyW/QI5msG}|@_Wo^9uVVc3R2kol uO[myޔ)Zw߆?ʗHxzȚ`0yLFAٓ.7$}yVVWqvﺟyh ٓkwkk܄E9|670DF/oc ?I}S뀔M+Dy؄褄]|UD dfdXY؝x|~*}l-B\<=ݯ^{xzsss~~ia~*Q2R(aoTgf JC? &"u{W8[@X>S + ɉ4ܡcf:L (>xESN3d}]܆v rpr zH kV).e44BNA n% e%a L(%䬍 եə)qv޹}""b@IڦxXhi VFXBjE BW'ȅ 4}G@)H0dpx(7<> 5ʹ~9=/͔t~spx G2?eiE&)(X4VI-*P7tt33k.+-RV\IC3'OYf E~U[Sd}SL~Oy4]e]5g3W$ıLuM2&[]_u&"{(C&xڣAOo }*~Yx 3}~nfZ=hok\Tik?:wsoyX'656*ZymZ\%]ǵ6ۄ%։aVz&qc+:b3K1 Y)Iuq 4Mazq)7okMGRF2X:m 9yw%6EPpYZ]L4\LLխevJIC+H#(# r|'b/DA\ڝ7VVmGDQВ3JMiIDmۇ}EKŖ^Nv2:ںtqS-62^C-v~H|TDa aJVlG[J̴>m2G:??Kc>}E&|~|M)QqzrLdQ鹯."6EEI>GWpmk\Dz6#@Ɨ&[-qfb2RQ&mM9ޑE$JGBh|%̩ʮ>FC qLNL-PͣsP"J*.j5emz 'vN(Hˌ^:f_;#4ٹrLA|uyF{5ue&1 /'f#_MCP1hZT!1:?󄜎9cl\Mm^etՕ9jYr)9;:K+Ow<)hn "wJ8 ckt†/^vܻ$SYaBGmNc2 ?nl/츜<:ylZEgvKC\sܴb}wq],}=9%q֮A)-"ab;{66{y۞tA0cΏ&} {?:3a$` %>})0MIM[G"T%_$,|OMKPD2ob?`<+99YBR:}msgu`cF \t+**]z |**d_قz_47s ?`UgWME)&jsOApe'`ib!1miQ餂59;CQUA mO^"hN6֡<>m䞋 ζpmo?6jm}AMy6Hh}/q&DJ+{O_oorO,.ɪ#6&g/nut՗ cܼazƋp/kߘ _aksSKVf?ai=xO Ϊq`x8zo-*$KC5mPc 'AA 1ꆷ_]Kw[~̃c(!K^7*#BڦR='$noWSU91%GG!g/K~869Sznǒ [W''' u&gĸ:yP;y>==;)E11f/''>$#pڳ{7Ka>޽yљOaf`C`׽o> wY +Wϝn& ]:tӅ ,𹌨$WTVI[[wˏdTj"Y_f\ *:hh4H 9.&=#+Hx~M ?0oM׳'-q8]_*Sa;(Q^U>f >v Ub$#P MxXwf4&1 -MEJ Г-` ڀ!l`ffgA*:}EEiYivs!YZ8c񍪆 ii7okoh+˨o(W>{񼥾MgOcZےں|C+- -oeeiͭ6tԬon9$&HyzMN 3ַ$|䢛C݁?%H[6Wܸxc̫o>\9gwg>:6c9m${򜿻;7 ^Z1;{۫zcmٞ ="# r‚+?-Tb;J|9J3&JG$.$0Kmp[X055gKÓPRQ4Hل+sG4sRL SDd+ c_Y9KglSC}-gFu FR%ESß#Kyx &!fe(PzFN,[7 e$vr4VY8BIF7j.; #{Vf $ /#C(WXRR %>'@ABPP`1$4dУt#;3BF).0Yd)tTGw&وHa$6I݅ 2rK#6U mv搛{*f;rh)wgMκB )1u xI)&{[ ,e<ld-".Мfwhbmխ&냠2 omndz#m(wA/Lݗk}_5~dgU}y~~jFPdt|dvu=g/[+{{_]UHOO )sRP/G/Cinmt+ 2?00㔹 'f:&Y}q*_|% /\+/'nj&ŸLpq}3rٹ Ib>rrpWIXR*,$~҅+c˲R)%uMBbc w=0Z[Mlx B_-XY0o qJ؛w{h..ށl1QYdp 'h|j"m>\^<58>^ZQ))>ncwڽ@ N $^-N.|APWxPWςO@P\XgM`}cK3+ * ܼΏ ZjaowvvѨ$) E "t`pop03.j@(Yc3]mZ&a׷֚T4 q(+-~#!7KHϐ3 ~>n 2gNzbxE@bh,+ g/] sٹ+ӓxuCÝ.;HK2Nw즦043.JȐRkuʊ~-(@L :=lT G'8[kd4tG"r:ZꕵEv '$@LK'" Llnmo×`){@ ;@Aax (   ŰCعxMd%DɈI7on3> |i?urR( !mjhPqb Ltri /z{aDv'“d(IҊ^ui*'%,y厦'OxwIﰲ(s>gM8">:j"*I / [{{C}f6Sc#sc²-l\܌,,=FMh4NMOFA>CBQucyemuuvl".Rb,L/,RӐ1R AJ R.NcS 2bİm, bFTSpm.RB}j>?7#'#uT^FrqaebqERg sq}:¸^57XYY/21'"&ɗ:,g惰 oW}[;[]<*U IDATμ~( DOqCC]' *89.6)la!~W܎vXF[od=;FpUIQ!:${BgmZT׌ ^ni|k ^W3S^Ơ:OSRRݸx'"wݝ㎛:p:9#3-68괍q=wUmy%%E^Η%ݽ.Fܾ|]bi)L6NrhhPRliTV&'\p˳+m_JĔW!q1 榆rFp3A? Inl]gk{}IKhH ͦCwHgo_ ͔a>^řg/C4AdZj.?"*$G(ʨDFEm;ARB~ẉ7VُE'& !腵ows(<AG77  t`Aʕ(#:4>&#øy o{'l8dht̳s @K ?S+/.75ǁ鉀H,NTHbdf!=7_AVAWGgOWPsk=]*rXp=V^BKJHr ;}nmwG(lamSKEkju]=8mihً_/m,ooZj[|hyAʻCkOB_hEF ķ.|.9#^PA\R>ٽKP`|q62)Tu. )jJ?~.bm|#U9볳OÞ9}usS:]C- -%>> IOO}GGC xwwgcƝFV'HR#_ Nx+>ꕬ2%%meQ>5M %HW(Iɠ0:த-%pѿvʁ 6M_JXXx67Y Qhp}cm `9"R;>yճ7UI9rgN׷?x*>#H𖯷^ms]υ%:*g4U|*Mko6?LJmf6|N_WKFKWQqiIU% P¿x3Qӟ8 7lmEO8\,ɮywb]`qzߓ;(]7/[[a`CKԔCnPꥵ8K[':<AqYy >KTlnSS "P]Bc// ߜ'",+LvUTB}T<Ԥd?]&IE','DO!&rrr ?`:BEzgz`l`LF-)'##dtt H-%;:;Q^Ҥ-;6:,:(ja)vKN?Y47B, fb%%cfd!@ 8/;vGDF `@'@{TTu4؎h)CM48َ$.vckr*Jj l)ii&,5XYY{%IifGWϚHȈ )<ɉMKښJjs{wwMm-qI13baKtή :2k7h 1 "<}ggy8AQD$iv FWO#s_=Š!Q#\7նY^X{Y[^v:Nj:Z+ +2,O9u:eoYTih`*=5™{;WA%y* @4H-JO:-CyC 7*|ҥ{Ƿ1HanN޹۷O840x,$PܞAps˗9 hcݮ:c 1q yqՕn}5__st4uq !sn]]XTMs}Qi%. }mޡ ]5=TIQ5+;A?op$!M##vw6wK+45 HKd}46? \tr'/001<:9o`೗( VI^zbfNFZvsg7*Ꝼ:|GKIo`DSYmze53'︹?T?/GƧ]W^hk|\":qUP`ms[Ǩ= 4 ߽7 ;xI ^{H,ʘ7oLubr9YەԔa'ϞۘYc!o,R&lJ 9s9$ If@D D1 (Q@3sΙ L9?X]w{}9OW>U]U3Wo%;$rs߼WV85:a5UI ~ AV@s[\sc'~UIwE0d}ͧK'qzxx']wpuZ_ih.))##Xܽdkg–*dٷ9, !#y? 7h TB"5yi`a`2470J FQ8 <'3#$..>19F(ˆ (%3 '-# H:&aqn6fvQ Annea6y9(  Ύ RB(w[[+L̦6jr@D(-!y*:6t݈N+,/46;w\]Eͣ0 ݫf$xv-(ZUTZVU}MFN_{Fݻ&,-N8q΁s^] 8/CW}{Iaхcn[\% dvm&@m&9X jkp23(;V -  )- G@!AA( D$lB"w5(((zr2r;[R,\k`ۏcsS]]C2 Ÿ~ :eokxĹIxRKS |uwiiV8;;ۧCsOSӇ-YY2Rm0T+[I鹪($gyL,Ʀbt!Q)p>luwo[ć3>lmm[YwuB^ю ]䬦~_7^\cc!18"NZNnhp$-PQBp; 3t <~in^PDHnlmC!D9=$8 &f KMK7;?'-#@`WD2<% #("@?=~Hh>_ (Tٹ8d$e$FOx(9}oIA萹ޗVST $KIN'G@].<4! eU/r%]FtE+cX܏/K#cbHydnr]oθygb233& :PFPOIMQYuڛp픔[߂KX:D1 ies Ao;˪*}}>vBTP\^G^te-+^<65.!*@c\r(ʩ~󶡩QBLDĹ@12ޗu K.on\칍@HK?|򲺺R[dyk+.HRQ|j}k@MY?<K{ /Y˪6ٙ{;7o' ,P.E8LONȠf`uY@:=kkԌlC0 iui!Q[Q"+/77>"*-I8 l[ !R1mR1,,R0q!Vp$+*5;@" 9IDBGP!>yd[A4939%%AP,%Ajz>v _ţqƆrCH@C 0w6#VQٕoMCLԞvnm/2_V~~.@]Ĺ@A1~-Miҫ*oxxꐸg^{^`!!W_({6:ZZrZNqOO{Si{hhQ!QYcnW9T>CixO~,}~/OY™XY?C g_t?@ 5=&hjaSVW/WB&1ߞ<;?6y)"l\\Z8ji5eeMF;+ե쌏V9IKC:i+ӔC-o+L>zFIA ܼvXwdt{PHlg<[_eu}"_S]]Z] #}cqϛ).fAAWuu!DuMN@}}iM4xA`nT(((ad 15\\Rno{`%i *;5g$CRcaltt,m$-+-%墣Q(@%!Ȋi~V*1e&$+ oRr0T@ t8IKY5;mWVսHHv!YYIl}ksi~2Ž?~¿~,rΌ,ئ)Sc37cn&9y>35CCOG TH vlx]Qa]y1/WI5Ҟ <9W^E1$PCE_MA~cw^rsdTUV>{Shhj`"{2ӛ.o3@ BStM-+,,?:d|I$=xmpnPMwb8`}y?`epBKclyjKΦڶzDV(ax{iXQHk_>-oO_Z$m*i;7V>"E.ͻwc|>8qᅋ~r BJ*?]J ]Mp43'gL~u)tX@\Uը= ԘKo?}{̬SƊWϝNJ{TXT4𔽳~S}|W:cx+u#fU66[H@[I=lTBǍ$7lgoS ROM@q 7'-oPRPU&L#}U k;|d4_;HJ ;=& 9Pu~V@BaeČݥB%bK1PoΉ>5M5>ECLe.ضW aIQ}𨡞 F #d JYYc D@SRó__̺|.\IE@9161 >0͸uf.Qq'4m-3j?|. ~*0@Q歉ܧ*[mM<}BMI?y_Dҕ[ g|E#c.X߿GEW _ni[bfe쒓oled㪪V}ˇT&g,䧃=E D p[I!"w '!) ,m/^^I[v H ~ 㲜yKeY<͌L}=66fe+8dceao`WYE=UVN~'L4M>L -_nkuf`H}TSMzjަϷsutIAu5%?k55;bjfnalZUY_R&i IDAT\bA][}i^GO۬설9"/Gị$gJ}O??) V$3W ,MIj ~Q3A#*6fQyG:{]KHDi چNY 9 p,cgCBB`{H!AίRXp:'&(:1$* UǁVɅEn.ј7a|۷k)a]ʤiرY|$|@Y^ 4`꽔Mlaa=MM twjя{;?W;&J ?Ph]Mk7W::#sӹŒ"2;价vII²OE%*;HS~{:zۻFdeWwQYn 1ZZHZ Kw-o!OJII//STRhn/<굴7ܦ~eCӫWv'/Ψ(+ey52x`ФיO ,z]BgWd_OT"BJ洏w(1L 녨pַ݆">/ ]`mwE yG),,)(hmhI}zfبJJps'Μ `xӗos^]xčޝ!AG&:;:%=esANA>Ջj]$B??ڝ0R]}MEEIXN622`lt6-H 75:" ",)$RVVmdgca)MFN|%zƍuv=+% ^g㠀@X , -=@ np@Д 9 'ã@jF .BFǶPTtPG9 %QR# d, +(zeᅯ"83/lAHBc 3tR4 L2}_t T4T%_{v߄50vo[ Td*n):+jrq+![*S38baUP-59SG}=d]{oO5qS??atV,/#ѦΔK;EyYVƆrT aq gK5{5 bBf$0FUXNR@qn I! #4P^Z--Haᢢc`)J rvI!z,5&"zO@s{xKFJHLlkPXHXa!y)Iɉ}C3vZh1Rkϫ?w|nt {l((I ?(c7n>K Oo=а1Ⱏr?\LMh+._[݊xxG?GlD㩣oޏNiYwB`=V7y9!?s}2Ԟdq3NHǖ,񳇖#3Gw|yol};d\Z378t#vuku/;GۆjOK+QIUqW# M!6WߎR~jmu$YsT=L;4楙əK*r.?d.Re/-%)*+<~_ s $ā ڗ&GSAws29K *IOfɑ[Crz|OJTswׯX(by×^qAɭ=h Iȗ44vK+@sQNDKC6t \KrXl[ {iQ²eC=*'/TW7^&2* om)*,V@ 'E$\$$;Hl]"(rM{@o?>u Apti~7;Apvn> :"c_Bv%%utv(l-&AMckH_>*4Eq}_4k8@<e|{UUdcm$|u/0n~E=֦OM\Sx,#CTx볬 w3*zʨ*D[F3Мx{ycvr]\B0'o] gq53<= ν=RݑSWD@ߍ}(cu~H %m ߭:=p-$"U};ɏQ'|ikJ[WG/yVk{<gsq|n9d;6<سa[KAN"ʓ!*2HEk铬wJrOy;P+ pw *0@ti(zCH?sZ^ؚۜ) lq33`-=l^@>6LGM(6-A$! 3)!"nnXذH"G\fg A! t;{ ? lcb $4EIfkR"ΎPs22̷IHs55b<0?lO耱7kkA <@ɀW\QQk+^O-|`h`q`@/Mo?4T5޿v|YME_ߐ|k{L`N o^Xݒp'+ݨga.,3 ~ ]8'I$'"@ADksh'~#'yjY9.M  gtSڑW_&V7:\T\(>Ѭo <\Ybm92812:ZP+j3>뀛GuC!E9+ïn&k)Nl`OdDǂป71rsZFrcn'sׂ< <|Co%?-x|)# /zk^Dx/:0X\ ?>^఩3.NTR^ۘWUrPP@+m啣maAqU-uG#P7 H&!nir^X&@K^Ӈr"N';]TXRT_cڊ*Zs+۾Xب>`hUeM'Sksn}ns)^Ju=tH( e_x^a#ioӏ9y]AL t.:3!N': S^ѓ'=XxӢn^n rsq2J}eAʱWYq}D[Aݹ5 ْJ"S-G3I[}_dQ{:;;ؙ% 4I꫑pym{wP*M |Ҕ-r @HN֥BSC=y3ݮz^ &Z |iKX['-.Y\P31&YYSA Pzf:. ^$23oom=4eBAp`dF9hi(="#چư1 șA405:@GIEnmkn%2:Xi8+75 RRHrI'/?;~]~!g$o -ҏuI%e'~qU/4|Ju\o{/LT7vvS5ӹsbZqAbW_p>{D=D>F[^BD|[HщQ8LOC$d@#JϬLҐ'$8̼m^द+;Y7Q8,&mo|&p%z&Q:ge{,uSzC/m("0&Aec?zqv :jCs cSW>Ejj*^Rm}bM|/)Jdדprz;3"-5htoO8چE]3UebF]ek5:Z{BxNh䵐Gs yFF1<xyQ@(׵$wn d4(?o^oMP/+4\;k nG%~*EJj6ArVE؝I܀.538fD[aB )pH+nG%3e`mqI4ttPC5uP'ظNmJ PC5Xgu! U4%eڤypd LΧ߾6}&.egnZ_lFi6͇ŽQ1v1I|YvPHV _mT W^]o$4մ?i(fnm||Rѳ;V`=/t77Е>yxx.NBc~YP0fhmFbfSMΉG4T)w# ̎NވMk MOLxwՔ1U_*.. >M*.\XSAˑٟh+!SOu4Mߗ\;4xp+,&yy`EIA4N'vR)~"0喹!/+ȸ:#SOKcۮWO;L,}n_>h`et,9ڧF8lkt4*qlM I xI*6=vٕ ar2h􎅓׵p8!*&Mi<G$1Q֚#"˓b}9pUEU"ܢ,lI4BJ\u|TJHCĞcod*_YX|RbrkSLH%=2PTEpfOn^_{@PW ۫ZA"AZT SS.ҮA!ǼP *3DI"]USP]zvCh>wz^MFzw9=qmU卸O#A{)v3zv9dw% ~kmw"{.B%h9<Cʴwl<(?Z>SIIq# 1; 6OwOnY\ps񊓱Q­pO򒣮𰃞B]l.]O\B{'""8?>6~dͯ#ܧ'^u=9,) _AXYm)zI5}5X̂C<*vZg^Z&>ݐeucY)--\GM@A(-zEkijaܔ18^qSIS]m}-*PCIDŢ8JR9-+ }&bhT 5vd|s$yY=ripKHnj@^Ri *FF**b W7O spqOEwfkZctt^qzffc fd@7\퓓eL| u)fm>bbenH HyMJf!}~V/ݚLqAUԌ^> F6ZjoTHļ+[oDzV<=EQ7^l}xyau7BT缤[{Z@pIgn<-**[p J~$VЀKգ0Д S5t,4r^WVE[~%Ɛхκ"< N r@LՍ `Hل?ŋZ~-q*B A$VIT"\t տ57"}0cSz SIIKiW9]Ԑ[~o<Yظ.ązy ,q